Page last updated: 2024-08-01 17:42:11
ramipril
Description
Ramipril: A long-acting angiotensin-converting enzyme inhibitor. It is a prodrug that is transformed in the liver to its active metabolite ramiprilat. [MeSH]
ramipril : A dipeptide that is the prodrug for ramiprilat, the active metabolite obtained by hydrolysis of the ethyl ester group. An angiotensin-converting enzyme (ACE) inhibitor, used to treat high blood pressure and congestive heart failure. [CHeBI]
Cross-References
| ID Source | ID |
|---|
| PubMed CID | 5362129 |
| CHEMBL ID | 1168 |
| SCHEMBL ID | 16059 |
| CHEBI ID | 8774 |
| MeSH ID | M0026184 |
Synonyms (149)
| Synonym |
|---|
| AC-1347 |
| BIDD:GT0803 |
| AB00698339-07 |
| AB00698339-08 |
| CHEBI:8774 , |
| (2s-(1(r*(r*)),2alpha,3abeta,6abeta))-1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid |
| (2s,3as,6as)-1-[(2s)-2-{[(1s)-1-ethoxycarbonyl-3-phenylpropyl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid |
| ramiprilum |
| SPECTRUM5_001721 |
| n-(1s-carboethoxy-3-phenylpropyl)-s-alanyl-cis,endo-2-azabicyclo[3.3.0]octane-3s-carboxylic acid |
| ramipril, >=98% (hplc) |
| triatec |
| hytren |
| pramace |
| lostapres |
| quark |
| (2s,3as,6as)-1-((s)-n-((s)-1-ethoxycarbonyl-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrol-2-carbonsaeure |
| vesdil |
| ramiprilum [latin] |
| delix |
| acovil |
| unipril |
| ramace |
| cardace |
| tritace |
| hoe-498 |
| SPECTRUM_001958 |
| hoe 498 |
| cyclopenta(b)pyrrole-2-carboxylic acid, 1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-, (2s-(1(r*(r*)),2alpha,3abeta,6abeta))- |
| altace |
| carasel |
| (2s,3as,6as)-1-((s)-n-((s)-1-carboxy-3-phenylpropyl)alanyl)octahydrocyclopenta(b)pyrrole-2-carboxylic acid, 1-ethyl ester |
| NCGC00016955-01 |
| cas-87333-19-5 |
| hoe498 |
| BSPBIO_003347 |
| MLS001423965 |
| ramipril |
| smr000466386 |
| MLS000759523 |
| DB00178 |
| ramipril (usp/inn) |
| 87333-19-5 |
| altace (tn) |
| D00421 |
| KBIOSS_002512 |
| KBIO2_007640 |
| KBIO2_002504 |
| KBIO2_005072 |
| KBIO3_002849 |
| KBIOGR_001858 |
| SPECTRUM3_001794 |
| SPECTRUM4_001269 |
| SPECTRUM1505214 |
| NCGC00178127-01 |
| MLS001216547 |
| HMS2093M10 |
| HMS2090L11 |
| HMS2051E04 |
| 1-[2-(1-ethoxycarbonyl-3-phenyl-propylamino)-propionyl]-octahydro-cyclopenta[b]pyrrole-2-carboxylic acid(ramipril) |
| bdbm50084681 |
| corpril |
| CHEMBL1168 , |
| hopace |
| c09aa05 |
| ramipres |
| nsc-758933 |
| ecator |
| (2s,3as,6as)-1-[(2s)-2-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[b]pyrrole-2-carboxylic acid |
| STK801937 |
| (2s,3as,6as)-1-[(2s)-2-{[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid (non-preferred name) |
| (2s,3as,6as)-1-[(2s)-2-{[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}propanoyl]-octahydrocyclopenta[b]pyrrole-2-carboxylic acid |
| AKOS005622534 |
| HMS3259J07 |
| unii-l35jn3i7sj |
| ramipril [usan:usp:inn:ban] |
| l35jn3i7sj , |
| hsdb 8393 |
| nsc 758933 |
| ramipro |
| naprix |
| pharmakon1600-01505214 |
| nsc758933 |
| dtxsid8023551 , |
| tox21_110708 |
| dtxcid203551 |
| (2s,3as,6as)-1-((s)-2-(((s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)amino)propanoyl)octahydrocyclopenta[b]pyrrole-2-carboxylic acid |
| (2s,3as,6as)-1-((s)-2-((s)-1-ethoxy-1-oxo-4-phenylbutan-2-ylamino)propanoyl) octahydrocyclopenta[b]pyrrole-2-carboxylic acid |
| HMS2231M05 |
| CCG-100833 |
| ramipril [usp-rs] |
| ramipril [orange book] |
| cyclopenta(b)pyrrole-2-carboxylic acid, 1-(2-((1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-, (2s-(1(r*(r*)),2.alpha.,3a.beta.,6a.beta.))- |
| ramipril [who-dd] |
| ramipril [mart.] |
| ramipril [ep monograph] |
| ramipril [jan] |
| (2s,3as,6as)-1-[(s)-n-[(s)-1-carboxy-3-phenylpropyl]alanyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid, 1-ethyl ester |
| ramipril [vandf] |
| cyclopenta(b)pyrrole-2-carboxylic acid, 1-((2s)-2-(((1s)-1-(ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)octahydro-, (2s,3as,6as)- |
| ramipril [inn] |
| ramipril [usp monograph] |
| ramipril [usan] |
| ramipril [mi] |
| ramipril, (+)- |
| S1793 |
| gtpl6339 |
| (2s,3as,6as)-1-[(2s)-2-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[d]pyrrole-2-carboxylic acid |
| HDACQVRGBOVJII-JBDAPHQKSA-N |
| BBL033964 |
| HY-B0279 |
| NC00627 |
| NC00083 |
| SCHEMBL16059 |
| NCGC00178127-02 |
| tox21_110708_1 |
| KS-1103 |
| (2s,3as,6as)-1-[(2s)-2-[[(1s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydrocyclopenta[b]pyrrole-2-carboxylic acid |
| ramipril, british pharmacopoeia (bp) reference standard |
| (2s,3as,6as)-1-(((s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl)-l-alanyl)octahydrocyclopenta[b]pyrrole-2-carboxylic acid |
| AB00698339_10 |
| AB00698339_09 |
| cyclopenta[b]pyrrole-2-carboxylic acid, 1-[(2s)-2-[[(1s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-, (2s,3as,6as)- |
| mfcd00865775 |
| SR-05000001908-2 |
| sr-05000001908 |
| ramipril, united states pharmacopeia (usp) reference standard |
| SR-05000001908-1 |
| ramipril, pharmaceutical secondary standard; certified reference material |
| ramipril, european pharmacopoeia (ep) reference standard |
| npd2431 |
| SBI-0206728.P001 |
| HMS3715M16 |
| Q412666 |
| (2s,3as,6as)-1-[(2s)-2-[[(2s)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]azaniumyl]propanoyl]-3,3a,4,5,6,6a-hexahydro-2h-cyclopenta[b]pyrrole-2-carboxylate |
| (2s,3as,6as)-1-[(2s)-2-[[(1s)-1-(ethoxycarbonyl)-3-phenylpropyl]amino]-1-oxopropyl]octahydro-cyclopenta[b]pyrrole-2-carboxylic acid |
| ramipril (altace) |
| 1028843-43-7 |
| 1-[2-(1-ethoxycarbonyl-3-phenylpropylamino)propionyl]octahydrocyclopenta[b]- pyrrole-2-carboxylic acid |
| BR164319 |
| R0219 |
| EN300-118695 |
| Z1515381509 |
| ramipril (ep monograph) |
| ramipril (usp-rs) |
| ramipril (mart.) |
| ramiprilum (latin) |
| ramipril (usan:usp:inn:ban) |
| ramipril (usp monograph) |
Roles (5)
Drug Classes (5)
Pathways (3)
ramipril is involved in 3 pathway(s), involving a total of 4 unique proteins and 17 unique compounds
Protein Targets (10)
Potency Measurements
Inhibition Measurements
Bioassays (100)
| Assay ID | Title | Year | Journal | Article |
|---|
| AID1347106 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347107 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347098 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347407 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1347086 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173ISSN: 1872-9096 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1296008 | Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening | 2020 | SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
ISSN: 2472-5560 | Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening. |
| AID1347083 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen | 2020 | Antiviral research, 01, Volume: 173ISSN: 1872-9096 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1347425 | Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
ISSN: 1083-351X | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347089 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347093 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347154 | Primary screen GU AMC qHTS for Zika virus inhibitors | 2020 | Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
ISSN: 1091-6490 | Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors. |
| AID1347099 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347424 | RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1) | 2019 | The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
ISSN: 1083-351X | Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens. |
| AID1347091 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347105 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | 2022 | The Journal of biological chemistry, 08, Volume: 298, Issue:8
ISSN: 1083-351X | |
| AID1347102 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347101 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347103 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | 2022 | The Journal of biological chemistry, 08, Volume: 298, Issue:8
ISSN: 1083-351X | |
| AID1347095 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347097 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347104 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1508630 | Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay | 2021 | Cell reports, 04-27, Volume: 35, Issue:4
ISSN: 2211-1247 | A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome. |
| AID1347090 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347092 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347094 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347100 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347096 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347108 | qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells | 2018 | Oncotarget, Jan-12, Volume: 9, Issue:4
ISSN: 1949-2553 | Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing. |
| AID1347082 | qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal | 2020 | Antiviral research, 01, Volume: 173ISSN: 1872-9096 | A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity. |
| AID1079944 | Benign tumor, proven histopathologically. Value is number of references indexed. [column 'T.BEN' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID625284 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic failure | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1782319 | Inhibition of ACE (unknown origin) | 2021 | Journal of medicinal chemistry, 11-25, Volume: 64, Issue:22
ISSN: 1520-4804 | N-Terminus to Arginine Side-Chain Cyclization of Linear Peptidic Neuropeptide Y Y |
| AID588219 | FDA HLAED, gamma-glutamyl transferase (GGT) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4
ISSN: 1570-1638 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID1474166 | Liver toxicity in human assessed as induction of drug-induced liver injury by measuring severity class index | 2016 | Drug discovery today, Apr, Volume: 21, Issue:4
ISSN: 1878-5832 | DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. |
| AID625290 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver fatty | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1079941 | Liver damage due to vascular disease: peliosis hepatitis, hepatic veno-occlusive disease, Budd-Chiari syndrome. Value is number of references indexed. [column 'VASC' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID763533 | Cytotoxicity against human A549 cells assessed as cell survival after 24 hrs by MTT assay | 2013 | Bioorganic & medicinal chemistry, Aug-01, Volume: 21, Issue:15
ISSN: 1464-3391 | Design, synthesis and evaluation of novel 2-hydroxypyrrolobenzodiazepine-5,11-dione analogues as potent angiotensin converting enzyme (ACE) inhibitors. |
| AID588216 | FDA HLAED, serum glutamic oxaloacetic transaminase (SGOT) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4
ISSN: 1570-1638 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID1079940 | Granulomatous liver disease, proven histopathologically. Value is number of references indexed. [column 'GRAN' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID1079934 | Highest frequency of acute liver toxicity observed during clinical trials, expressed as a percentage. [column '% AIGUE' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID1079937 | Severe hepatitis, defined as possibly life-threatening liver failure or through clinical observations. Value is number of references indexed. [column 'MASS' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID1079945 | Animal toxicity known. [column 'TOXIC' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID1473739 | Inhibition of human MRP2 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
ISSN: 1096-0929 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID1079947 | Comments (NB not yet translated). [column 'COMMENTAIRES' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID1079943 | Malignant tumor, proven histopathologically. Value is number of references indexed. [column 'T.MAL' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID588214 | FDA HLAED, liver enzyme composite activity | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4
ISSN: 1570-1638 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID763532 | Cytotoxicity against HEK293 cells assessed as cell survival after 24 hrs by MTT assay | 2013 | Bioorganic & medicinal chemistry, Aug-01, Volume: 21, Issue:15
ISSN: 1464-3391 | Design, synthesis and evaluation of novel 2-hydroxypyrrolobenzodiazepine-5,11-dione analogues as potent angiotensin converting enzyme (ACE) inhibitors. |
| AID1473741 | Inhibition of human MRP4 overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
ISSN: 1096-0929 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID588215 | FDA HLAED, alkaline phosphatase increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4
ISSN: 1570-1638 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID1473740 | Inhibition of human MRP3 overexpressed in Sf9 insect cell membrane vesicles assessed as uptake of [3H]-estradiol-17beta-D-glucuronide in presence of ATP and GSH measured after 10 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
ISSN: 1096-0929 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID625288 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for jaundice | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID599064 | Plasma protein binding in human | 2011 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
ISSN: 1464-3405 | Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design. |
| AID588218 | FDA HLAED, lactate dehydrogenase (LDH) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4
ISSN: 1570-1638 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID625289 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver disease | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID625280 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholecystitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1079949 | Proposed mechanism(s) of liver damage. [column 'MEC' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID625287 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatomegaly | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID625291 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for liver function tests abnormal | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID625285 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatic necrosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID640615 | Clearance in human liver microsomes at 1 uM measured after 60 mins by HPLC analysis | 2012 | Bioorganic & medicinal chemistry letters, Jan-15, Volume: 22, Issue:2
ISSN: 1464-3405 | Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism. |
| AID588217 | FDA HLAED, serum glutamic pyruvic transaminase (SGPT) increase | 2004 | Current drug discovery technologies, Dec, Volume: 1, Issue:4
ISSN: 1570-1638 | Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. |
| AID588211 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1
ISSN: 1520-5010 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID598527 | 1-Octanol-sodium citrate buffer distribution coefficient, log D of the compound at pH 5.5 by shake-flask method | 2011 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
ISSN: 1464-3405 | Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design. |
| AID763534 | Inhibition of rabbit lung ACE assessed as hydrolysis of hippuryl-histidyl-leucine to hippuric acid and histidyl-leucine after 30 mins | 2013 | Bioorganic & medicinal chemistry, Aug-01, Volume: 21, Issue:15
ISSN: 1464-3391 | Design, synthesis and evaluation of novel 2-hydroxypyrrolobenzodiazepine-5,11-dione analogues as potent angiotensin converting enzyme (ACE) inhibitors. |
| AID625286 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for hepatitis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID625292 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) combined score | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID625282 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cirrhosis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID39767 | Inhibitory activity against angiotensin I converting enzyme (ACE) | 2000 | Journal of medicinal chemistry, Feb-10, Volume: 43, Issue:3
ISSN: 0022-2623 | Protease inhibitors: current status and future prospects. |
| AID1079939 | Cirrhosis, proven histopathologically. Value is number of references indexed. [column 'CIRRH' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID409954 | Inhibition of mouse brain MAOA | 2008 | Journal of medicinal chemistry, Nov-13, Volume: 51, Issue:21
ISSN: 1520-4804 | Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors. |
| AID598526 | 1-Octanol-water distribution coefficient, log D of the compound at pH 7.4 by shake-flask method | 2011 | Bioorganic & medicinal chemistry letters, Jun-15, Volume: 21, Issue:12
ISSN: 1464-3405 | Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design. |
| AID625283 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for elevated liver function tests | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1079946 | Presence of at least one case with successful reintroduction. [column 'REINT' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID1079936 | Choleostatic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is < 2 (see ACUTE). Value is number of references indexed. [column 'CHOLE' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID588213 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1
ISSN: 1520-5010 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID1315906 | Decrease in albumin level in ZSF-1 obese rat urine at 1 mg/kg administered through oral gavage for 42 days measured on day 14, 28, 42 of compound dosing | 2016 | Journal of medicinal chemistry, 09-08, Volume: 59, Issue:17
ISSN: 1520-4804 | Discovery and Preclinical Characterization of 6-Chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1H-indole-3-carboxylic Acid (PF-06409577), a Direct Activator of Adenosine Monophosphate-activated Protein Kinase (AMPK), for the Potential Treatment of Diabetic Neph |
| AID1079935 | Cytolytic liver toxicity, either proven histopathologically or where the ratio of maximal ALT or AST activity above normal to that of Alkaline Phosphatase is > 5 (see ACUTE). Value is number of references indexed. [column 'CYTOL' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID1079938 | Chronic liver disease either proven histopathologically, or through a chonic elevation of serum amino-transferase activity after 6 months. Value is number of references indexed. [column 'CHRON' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID588212 | Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents | 2010 | Chemical research in toxicology, Jan, Volume: 23, Issue:1
ISSN: 1520-5010 | Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. |
| AID625281 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for cholelithiasis | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID567091 | Drug absorption in human assessed as human intestinal absorption rate | 2011 | European journal of medicinal chemistry, Jan, Volume: 46, Issue:1
ISSN: 1768-3254 | Prediction of drug intestinal absorption by new linear and non-linear QSPR. |
| AID1473738 | Inhibition of human BSEP overexpressed in Sf9 cell membrane vesicles assessed as uptake of [3H]-taurocholate in presence of ATP measured after 15 to 20 mins by membrane vesicle transport assay | 2013 | Toxicological sciences : an official journal of the Society of Toxicology, Nov, Volume: 136, Issue:1
ISSN: 1096-0929 | A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development. |
| AID1079931 | Moderate liver toxicity, defined via clinical-chemistry results: ALT or AST serum activity 6 times the normal upper limit (N) or alkaline phosphatase serum activity of 1.7 N. Value is number of references indexed. [column 'BIOL' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID625279 | Drug Induced Liver Injury Prediction System (DILIps) training set; hepatic side effect (HepSE) score for bilirubinemia | 2011 | PLoS computational biology, Dec, Volume: 7, Issue:12
ISSN: 1553-7358 | Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps). |
| AID1079942 | Steatosis, proven histopathologically. Value is number of references indexed. [column 'STEAT' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID1079933 | Acute liver toxicity defined via clinical observations and clear clinical-chemistry results: serum ALT or AST activity > 6 N or serum alkaline phosphatases activity > 1.7 N. This category includes cytolytic, choleostatic and mixed liver toxicity. Value is | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID1474167 | Liver toxicity in human assessed as induction of drug-induced liver injury by measuring verified drug-induced liver injury concern status | 2016 | Drug discovery today, Apr, Volume: 21, Issue:4
ISSN: 1878-5832 | DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. |
| AID1079932 | Highest frequency of moderate liver toxicity observed during clinical trials, expressed as a percentage. [column '% BIOL' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID1079948 | Times to onset, minimal and maximal, observed in the indexed observations. [column 'DELAI' in source] | | Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
ISSN: 0399-8320 | [Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs]. |
| AID1231572 | Inhibition of rabbit lung ACE assessed as hippuryl-histidyl-leucine hydrolysis after 30 mins by colorimetric method | 2015 | Bioorganic & medicinal chemistry, Jul-01, Volume: 23, Issue:13
ISSN: 1464-3391 | Design, synthesis and evaluation of novel 2-butyl-4-chloroimidazole derived peptidomimetics as Angiotensin Converting Enzyme (ACE) inhibitors. |
| AID1346986 | P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID1346987 | P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen | 2019 | Molecular pharmacology, 11, Volume: 96, Issue:5
ISSN: 1521-0111 | A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
ISSN: 1552-4922 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
ISSN: 1557-8127 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
ISSN: 1552-4922 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
ISSN: 1557-8127 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13ISSN: 1934-9300 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
ISSN: 1552-4922 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1
ISSN: 1557-8127 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID1347411 | qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary | 2020 | ACS chemical biology, 07-17, Volume: 15, Issue:7
ISSN: 1554-8937 | High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle. |
| AID1345457 | Human Angiotensin-converting enzyme (M2: Angiotensin-converting (ACE and ACE2)) | 1984 | Arzneimittel-Forschung, , Volume: 34, Issue:10B
ISSN: 0004-4172 | 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S) -2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498)--a new and highly effective angiotensin I converting enzyme inhibitor. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6
ISSN: 1552-454X | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
Research
Studies (2,016)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 141 (6.99) | 18.7374 |
| 1990's | 493 (24.45) | 18.2507 |
| 2000's | 802 (39.78) | 29.6817 |
| 2010's | 486 (24.11) | 24.3611 |
| 2020's | 94 (4.66) | 2.80 |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 606 (28.17%) | 5.53% |
| Reviews | 143 (6.65%) | 6.00% |
| Case Studies | 132 (6.14%) | 4.05% |
| Observational | 8 (0.37%) | 0.25% |
| Other | 1,262 (58.67%) | 84.16% |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| captopril | | alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 1984 | 2021 | 25.9 | low | 18 | 26 | 38 | 25 | 14 | 1 |
| ci 906 | | hydrochloride | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| quinapril | | dicarboxylic acid monoester;
ethyl ester;
isoquinolines;
tertiary carboxamide | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 1991 | 2015 | 20.5 | low | 0 | 0 | 3 | 5 | 3 | 0 |
| cilazapril, anhydrous | | dicarboxylic acid monoester;
ethyl ester;
pyridazinodiazepine | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 1985 | 2011 | 28.1 | low | 1 | 1 | 4 | 1 | 1 | 0 |
| fosinoprilat | | L-proline derivative;
phosphinic acids | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| telmisartan | | benzimidazoles;
biphenyls;
carboxybiphenyl | angiotensin receptor antagonist;
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
environmental contaminant;
xenobiotic | 2001 | 2022 | 14.2 | low | 57 | 0 | 0 | 101 | 54 | 4 |
| alacepril | | dipeptide;
thioacetate ester | EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| perindoprilat | | dicarboxylic acid;
dipeptide;
L-alanine derivative;
organic heterobicyclic compound | antihypertensive agent;
drug metabolite;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| corilagin | | ellagitannin;
gallate ester | antihypertensive agent;
antioxidant;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
non-steroidal anti-inflammatory drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| zofenopril | | aryl sulfide;
L-proline derivative;
N-acyl-L-amino acid;
thioester | anticonvulsant;
apoptosis inhibitor;
cardioprotective agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| perindopril | | alpha-amino acid ester;
dicarboxylic acid monoester;
ethyl ester;
organic heterobicyclic compound | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 1985 | 2022 | 20.7 | low | 0 | 5 | 7 | 21 | 9 | 1 |
| quinaprilat | | dicarboxylic acid;
isoquinolines;
tertiary carboxamide | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| perindopril erbumine | | addition compound | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| spiraprilat | | azaspiro compound;
dicarboxylic acid;
dipeptide;
dithioketal;
pyrrolidinecarboxylic acid;
secondary amino compound;
tertiary carboxamide | antihypertensive agent;
drug metabolite;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| zofenoprilate | | aryl sulfide;
L-proline derivative;
N-acyl-L-amino acid;
thiol | anticonvulsant;
apoptosis inhibitor;
cardioprotective agent;
drug metabolite;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| spirapril | | azaspiro compound;
dicarboxylic acid monoester;
dipeptide;
dithioketal;
ethyl ester;
pyrrolidinecarboxylic acid;
secondary amino compound;
tertiary carboxamide | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lisinopril | | dipeptide | EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 1985 | 2022 | 18.9 | low | 0 | 2 | 15 | 16 | 14 | 2 |
| lotensin | | hydrochloride | EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| benazepril | | benzazepine;
dicarboxylic acid monoester;
ethyl ester;
lactam | EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| enalapril maleate | | maleate salt | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| enalapril | | dicarboxylic acid monoester;
dipeptide | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
geroprotector;
prodrug | 1984 | 2021 | 24.8 | low | 15 | 20 | 27 | 33 | 11 | 1 |
| enalaprilat anhydrous | | dicarboxylic acid;
dipeptide | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 1984 | 1999 | 31.1 | low | 1 | 3 | 14 | 0 | 0 | 0 |
| benazeprilat | | benzazepine;
dicarboxylic acid;
lactam | EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ramiprilat | | azabicycloalkane;
cyclopentapyrrole;
dicarboxylic acid;
dipeptide | bradykinin receptor B2 agonist;
cardioprotective agent;
drug metabolite;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
matrix metalloproteinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| trandolaprilat | | dicarboxylic acid;
dipeptide;
organic heterobicyclic compound;
secondary amino compound;
tertiary carboxamide | antihypertensive agent;
drug metabolite;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
human xenobiotic metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| imidapril | | dicarboxylic acid monoester;
dipeptide;
ethyl ester;
imidazolidines;
N-acylurea;
secondary amino compound | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| imidaprilat | | dicarboxylic acid;
dipeptide;
imidazolidines;
N-acylurea;
secondary amino compound | antihypertensive agent;
drug metabolite;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| trandolapril | | dicarboxylic acid monoester;
dipeptide;
ethyl ester;
organic heterobicyclic compound;
secondary amino compound;
tertiary carboxamide | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nicotianamine | | amino acid zwitterion;
nicotianamine | chelator;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aminolevulinic acid | | 4-oxo monocarboxylic acid;
amino acid zwitterion;
delta-amino acid | antineoplastic agent;
dermatologic drug;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite;
prodrug;
Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pyrazinamide | | monocarboxylic acid amide;
N-acylammonia;
pyrazines | antitubercular agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| uracil | | pyrimidine nucleobase;
pyrimidone | allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| acemetacin | | carboxylic ester;
indol-3-yl carboxylic acid;
monocarboxylic acid;
monochlorobenzenes;
N-acylindole | EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| amifostine anhydrous | | diamine;
organic thiophosphate | antioxidant;
prodrug;
radiation protective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| amodiaquine | | aminoquinoline;
organochlorine compound;
phenols;
secondary amino compound;
tertiary amino compound | anticoronaviral agent;
antimalarial;
drug allergen;
EC 2.1.1.8 (histamine N-methyltransferase) inhibitor;
non-steroidal anti-inflammatory drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ampiroxicam | | acetal;
aminopyridine;
benzothiazine;
etabonate ester;
monocarboxylic acid amide;
sulfonamide | analgesic;
antirheumatic drug;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azathioprine | | aryl sulfide;
C-nitro compound;
imidazoles;
thiopurine | antimetabolite;
antineoplastic agent;
carcinogenic agent;
DNA synthesis inhibitor;
hepatotoxic agent;
immunosuppressive agent;
prodrug | 2010 | 2014 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| chlorazepate | | 1,4-benzodiazepinone | anticonvulsant;
anxiolytic drug;
GABA modulator;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dacarbazine | | imidazoles;
monocarboxylic acid amide;
triazene derivative | alkylating agent;
antineoplastic agent;
carcinogenic agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dipivefrin | | ethanolamines;
pivalate ester | adrenergic agonist;
antiglaucoma drug;
ophthalmology drug;
prodrug;
sympathomimetic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dipyrone | | amino sulfonic acid;
pyrazoles | anti-inflammatory agent;
antipyretic;
antirheumatic drug;
cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| etanidazole | | C-nitro compound;
imidazoles;
monocarboxylic acid amide | alkylating agent;
antineoplastic agent;
prodrug;
radiosensitizing agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| brl 42810 | | 2-aminopurines;
acetate ester | antiviral drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| flucytosine | | aminopyrimidine;
nucleoside analogue;
organofluorine compound;
pyrimidine antifungal drug;
pyrimidone | prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluphenazine depot | | decanoate ester;
N-alkylpiperazine;
organofluorine compound;
phenothiazines | dopaminergic antagonist;
phenothiazine antipsychotic drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| leflunomide | | (trifluoromethyl)benzenes;
isoxazoles;
monocarboxylic acid amide | antineoplastic agent;
antiparasitic agent;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
hepatotoxic agent;
immunosuppressive agent;
non-steroidal anti-inflammatory drug;
prodrug;
pyrimidine synthesis inhibitor;
tyrosine kinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| loxoprofen | | cyclopentanones;
monocarboxylic acid | antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| metronidazole | | C-nitro compound;
imidazoles;
primary alcohol | antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| midodrine | | amino acid amide;
aromatic ether;
secondary alcohol | alpha-adrenergic agonist;
prodrug;
sympathomimetic agent;
vasoconstrictor agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nabumetone | | methoxynaphthalene;
methyl ketone | cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nitroglycerin | | nitroglycerol | explosive;
muscle relaxant;
nitric oxide donor;
prodrug;
tocolytic agent;
vasodilator agent;
xenobiotic | 1993 | 2006 | 25.8 | low | 0 | 0 | 4 | 1 | 0 | 0 |
| 4-phenylbutyric acid | | monocarboxylic acid | antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| proglumetacin | | aromatic ether;
benzamides;
carboxylic ester;
monochlorobenzenes;
N-acylindole;
N-alkylpiperazine | antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
lipoxygenase inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| salicylsalicylic acid | | benzoate ester;
benzoic acids;
phenols;
salicylates | antineoplastic agent;
antirheumatic drug;
EC 3.5.2.6 (beta-lactamase) inhibitor;
hypoglycemic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 4-phenylbutyric acid, sodium salt | | organic sodium salt | EC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector;
neuroprotective agent;
orphan drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| suxibuzone | | hemisuccinate;
monocarboxylic acid;
pyrazolidines | antirheumatic drug;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tazarotene | | acetylenic compound;
ethyl ester;
pyridines;
retinoid;
thiochromane | keratolytic drug;
prodrug;
teratogenic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| temozolomide | | imidazotetrazine;
monocarboxylic acid amide;
triazene derivative | alkylating agent;
antineoplastic agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| prednisone | | 11-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug | 1993 | 2019 | 16.3 | low | 2 | 0 | 1 | 4 | 1 | 0 |
| levodopa | | amino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid | allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tributyrin | | butyrate ester;
triglyceride | antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor;
prodrug;
protective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mestranol | | 17beta-hydroxy steroid;
aromatic ether;
terminal acetylenic compound | prodrug;
xenoestrogen | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 1,4-butanediol | | butanediol;
glycol | neurotoxin;
prodrug;
protic solvent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lucanthone | | thioxanthenes | adjuvant;
antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
mutagen;
photosensitizing agent;
prodrug;
schistosomicide drug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| psilocybin | | organic phosphate;
tertiary amino compound;
tryptamine alkaloid | fungal metabolite;
hallucinogen;
prodrug;
serotonergic agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azaribine | | acetate ester;
N-glycosyl-1,2,4-triazine | antipsoriatic;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| doxifluridine | | organofluorine compound;
pyrimidine 5'-deoxyribonucleoside | antimetabolite;
antineoplastic agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diloxanide furoate | | carboxylic ester;
furans;
organochlorine compound;
tertiary carboxamide | antiamoebic agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pn 401 | | acetate ester;
uridines | neuroprotective agent;
orphan drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| beclomethasone dipropionate | | 11beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
corticosteroid;
enone;
glucocorticoid;
propanoate ester;
steroid ester | anti-arrhythmia drug;
anti-asthmatic drug;
anti-inflammatory drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| olsalazine | | azobenzenes;
dicarboxylic acid | non-steroidal anti-inflammatory drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ancitabine | | diol;
organic heterotricyclic compound | antimetabolite;
antineoplastic agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fludarabine phosphate | | nucleoside analogue;
organofluorine compound;
purine arabinonucleoside monophosphate | antimetabolite;
antineoplastic agent;
antiviral agent;
DNA synthesis inhibitor;
immunosuppressive agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| carbimazole | | 1,3-dihydroimidazole-2-thiones;
carbamate ester | antithyroid drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pivampicillin | | penicillanic acid ester;
pivaloyloxymethyl ester | prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bitolterol | | carboxylic ester;
diester;
ethanolamines;
secondary alcohol;
secondary amino compound | anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lovastatin | | delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring) | anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug | 1994 | 1994 | 30.0 | low | 1 | 0 | 1 | 0 | 0 | 0 |
| simvastatin | | delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic) | EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug | 1994 | 2022 | 14.1 | low | 13 | 0 | 3 | 12 | 15 | 1 |
| bambuterol hydrochloride | | carbamate ester;
hydrochloride;
phenylethanolamines | anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
prodrug;
sympathomimetic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bambuterol | | carbamate ester;
phenylethanolamines | anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
prodrug;
sympathomimetic agent;
tocolytic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gemcitabine | | organofluorine compound;
pyrimidine 2'-deoxyribonucleoside | antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lamivudine | | monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol | allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| irinotecan | | carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound | antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| adefovir dipivoxil | | 6-aminopurines;
carbonate ester;
ether;
organic phosphonate | antiviral drug;
DNA synthesis inhibitor;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| capecitabine | | carbamate ester;
cytidines;
organofluorine compound | antimetabolite;
antineoplastic agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| baicalin | | dihydroxyflavone;
glucosiduronic acid;
glycosyloxyflavone;
monosaccharide derivative | antiatherosclerotic agent;
antibacterial agent;
anticoronaviral agent;
antineoplastic agent;
antioxidant;
cardioprotective agent;
EC 2.7.7.48 (RNA-directed RNA polymerase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
ferroptosis inhibitor;
neuroprotective agent;
non-steroidal anti-inflammatory drug;
plant metabolite;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| oseltamivir | | acetamides;
amino acid ester;
cyclohexenecarboxylate ester;
primary amino compound | antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
environmental contaminant;
prodrug;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lenampicillin | | ketene acetal;
penicillanic acid ester | prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| droxicam | | organic heterotricyclic compound;
pyridines | cyclooxygenase 1 inhibitor;
hepatotoxic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
platelet aggregation inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| talampicillin | | penicillanic acid ester | prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| prednisolone phosphate | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
glucocorticoid;
steroid phosphate;
tertiary alpha-hydroxy ketone | anti-inflammatory agent;
antineoplastic agent;
glucocorticoid receptor agonist;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| irinotecan hydrochloride | | hydrochloride | antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| benzoylmetronidazole | | benzoate ester | antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| droxidopa | | catechols;
L-tyrosine derivative | antihypertensive agent;
prodrug;
vasoconstrictor agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fingolimod hydrochloride | | hydrochloride | immunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fingolimod | | aminodiol;
primary amino compound | antineoplastic agent;
CB1 receptor antagonist;
immunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| amdinocillin pivoxil | | penicillanic acid ester;
penicillin;
pivaloyloxymethyl ester | antibacterial drug;
antiinfective agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| parecoxib | | isoxazoles;
N-sulfonylcarboxamide | cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aminolevulinic acid hydrochloride | | hydrochloride | antineoplastic agent;
dermatologic drug;
photosensitizing agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cefotiam hexetil | | carboxylic ester | prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fosamprenavir | | sulfonamide | prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nepafenac | | monocarboxylic acid amide | cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cyc 682 | | nitrile;
nucleoside analogue;
secondary carboxamide | antimetabolite;
antineoplastic agent;
DNA synthesis inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methyl 5-aminolevulinate hydrochloride | | hydrochloride | antineoplastic agent;
dermatologic drug;
photosensitizing agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methyl 5-aminolevulinate | | delta-amino acid ester | antineoplastic agent;
dermatologic drug;
photosensitizing agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| clorazepate dipotassium | | potassium salt | anticonvulsant;
anxiolytic drug;
GABA modulator;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dabigatran etexilate | | aromatic amide;
benzimidazoles;
beta-alanine derivative;
carboxamidine;
carboxylic ester;
pyridines | anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fosfluconazole | | conazole antifungal drug;
triazole antifungal drug;
triazoles | prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 2-hydroxyestradiol | | 17beta-hydroxy steroid;
2-hydroxy steroid | carcinogenic agent;
human metabolite;
metabolite;
mouse metabolite;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| salicin | | aromatic primary alcohol;
aryl beta-D-glucoside;
benzyl alcohols | antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bacampicillin | | penicillanic acid ester | prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tiazofurin | | 1,3-thiazoles;
C-glycosyl compound;
monocarboxylic acid amide | antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rubitecan | | C-nitro compound;
delta-lactone;
pyranoindolizinoquinoline;
semisynthetic derivative;
tertiary alcohol | antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dipyrone | | organic sodium salt | anti-inflammatory agent;
antipyretic;
antirheumatic drug;
cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sulindac | | monocarboxylic acid;
organofluorine compound;
sulfoxide | analgesic;
antineoplastic agent;
antipyretic;
apoptosis inducer;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug;
tocolytic agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ethionamide | | pyridines;
thiocarboxamide | antilipemic drug;
antitubercular agent;
fatty acid synthesis inhibitor;
leprostatic drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nelarabine | | beta-D-arabinoside;
monosaccharide derivative;
purine nucleoside | antineoplastic agent;
DNA synthesis inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| amrubicin | | anthracycline antibiotic;
methyl ketone;
primary amino compound;
quinone;
tetracenes | antineoplastic agent;
prodrug;
topoisomerase II inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mycophenolate mofetil | | carboxylic ester;
ether;
gamma-lactone;
phenols;
tertiary amino compound | anticoronaviral agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
immunosuppressive agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| uf 021 | | isopropyl ester;
ketone;
prostaglandins Falpha | antiglaucoma drug;
antihypertensive agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| travoprost | | (trifluoromethyl)benzenes;
isopropyl ester;
prostaglandins Falpha | antiglaucoma drug;
antihypertensive agent;
ophthalmology drug;
prodrug;
prostaglandin receptor agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| codeine | | morphinane alkaloid;
organic heteropentacyclic compound | antitussive;
drug allergen;
environmental contaminant;
opioid analgesic;
opioid receptor agonist;
prodrug;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| latanoprost | | isopropyl ester;
prostaglandins Falpha;
triol | antiglaucoma drug;
antihypertensive agent;
EC 4.2.1.1 (carbonic anhydrase) inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dextromethorphan | | 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene | antitussive;
environmental contaminant;
neurotoxin;
NMDA receptor antagonist;
oneirogen;
prodrug;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| heroin | | morphinane alkaloid | mu-opioid receptor agonist;
opioid analgesic;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ximelagatran | | amidoxime;
azetidines;
carboxamide;
ethyl ester;
hydroxylamines;
secondary amino compound;
secondary carboxamide;
tertiary carboxamide | anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor;
prodrug;
serine protease inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tenofovir disoproxil fumarate | | fumarate salt | antiviral drug;
HIV-1 reverse transcriptase inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cefditoren pivoxil | | 1,3-thiazoles;
cephams;
oxime O-ether;
pivaloyloxymethyl ester | antibacterial drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dirithromycin | | macrolide antibiotic | prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cefpodoxime proxetil | | carboxylic acid;
carboxylic ester;
cephalosporin | antibacterial drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| gs-7340 | | 6-aminopurines;
ether;
isopropyl ester;
L-alanine derivative;
phosphoramidate ester | antiviral drug;
HIV-1 reverse transcriptase inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| abiraterone acetate | | pyridines;
sterol ester | antineoplastic agent;
EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ppi-0903 | | 1,3-thiazoles;
cephalosporin;
iminium betaine;
organic phosphoramidate;
oxime O-ether;
thiadiazoles | antibacterial drug;
antimicrobial agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fluticasone furoate | | 11beta-hydroxy steroid;
2-furoate ester;
3-oxo-Delta(1),Delta(4)-steroid;
corticosteroid;
fluorinated steroid;
steroid ester;
thioester | anti-allergic agent;
anti-asthmatic drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| naproxen-n-butyl nitrate | | carboxylic ester;
methoxynaphthalene;
nitrate ester | EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
nitric oxide donor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| varespladib methyl | | aromatic ether;
benzenes;
indoles;
methyl ester;
primary carboxamide | anti-inflammatory drug;
antidote;
EC 3.1.1.4 (phospholipase A2) inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| selexipag | | aromatic amine;
ether;
monocarboxylic acid amide;
N-sulfonylcarboxamide;
pyrazines;
tertiary amino compound | orphan drug;
platelet aggregation inhibitor;
prodrug;
prostacyclin receptor agonist;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| jte 607 | | hydrochloride | anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
cardioprotective agent;
CPSF3 inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| penamecillin | | penicillanic acid ester;
semisynthetic derivative | antibacterial drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| etc-1002 | | alpha,omega-dicarboxylic acid | antilipemic drug;
EC 2.3.3.8 (ATP citrate synthase) inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rx-3117 | | organofluorine compound;
primary allylic alcohol;
triol | antimetabolite;
antineoplastic agent;
apoptosis inducer;
DNA synthesis inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tedizolid phosphate | | carbamate ester;
organofluorine compound;
oxazolidinone;
phosphate monoester;
pyridines;
tetrazoles | antimicrobial agent;
prodrug;
protein synthesis inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| azd 1152 | | anilide;
monoalkyl phosphate;
monofluorobenzenes;
pyrazoles;
quinazolines;
secondary amino compound;
secondary carboxamide;
tertiary amino compound | antineoplastic agent;
Aurora kinase inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| brl 15572 | | hydrochloride | prodrug;
serotonergic antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| N-methyl-6-chloro-1-(3-methylphenyl)-2,3,4,5-tetrahydro-3-benzazepine-7,8-diol hydrobromide | | hydrobromide | dopamine agonist;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sk&f 77434 | | hydrobromide | dopamine agonist;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methylprednisolone suleptanate | | organic sodium salt | anti-asthmatic drug;
anti-inflammatory agent;
glucocorticoid receptor agonist;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cefamandole nafate | | organic sodium salt | antibacterial drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| sofosbuvir | | isopropyl ester;
L-alanyl ester;
nucleotide conjugate;
organofluorine compound;
phosphoramidate ester | antiviral drug;
hepatitis C protease inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ML-210 | | C-nitro compound;
diarylmethane;
isoxazoles;
monochlorobenzenes;
N-acylpiperazine;
N-alkylpiperazine;
tertiary carboxamide | antineoplastic agent;
EC 1.11.1.9 (glutathione peroxidase) inhibitor;
ferroptosis inducer;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aripiprazole lauroxil | | aromatic ether;
delta-lactam;
dichlorobenzene;
dodecanoate ester;
N-alkylpiperazine;
N-arylpiperazine;
quinolone | H1-receptor antagonist;
prodrug;
second generation antipsychotic;
serotonergic agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| cgs 12066b | | maleate salt | prodrug;
serotonergic agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| s 8932 | | aromatic amine;
C-nucleoside;
carboxylic ester;
nitrile;
phosphoramidate ester;
pyrrolotriazine | anticoronaviral agent;
antiviral drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| tak 491 | | 1,2,4-oxadiazole;
aromatic ether;
benzimidazoles;
carboxylic ester;
cyclic carbonate ester;
dioxolane | angiotensin receptor antagonist;
antihypertensive agent;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| valganciclovir | | L-valyl ester;
purines | antiviral drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| fosaprepitant | | (trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
phosphoramide;
triazoles | antiemetic;
neurokinin-1 receptor antagonist;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dabigatran etexilate | | aromatic amide;
benzimidazoles;
beta-alanine derivative;
carboxamidine;
carboxylic ester;
pyridines | anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| molnupiravir | | isopropyl ester;
ketoxime;
nucleoside analogue | anticoronaviral agent;
antiviral drug;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| PF-07304814 | | aromatic ether;
indolecarboxamide;
L-leucine derivative;
phosphate monoester;
pyrrolidin-2-ones;
secondary carboxamide | anticoronaviral agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
prodrug | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 5-methoxytryptamine | | aromatic ether;
primary amino compound;
tryptamines | 5-hydroxytryptamine 2A receptor agonist;
5-hydroxytryptamine 2B receptor agonist;
5-hydroxytryptamine 2C receptor agonist;
antioxidant;
cardioprotective agent;
human metabolite;
mouse metabolite;
neuroprotective agent;
radiation protective agent;
serotonergic agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| dilazep | | benzoate ester;
diazepane;
diester;
methoxybenzenes | cardioprotective agent;
platelet aggregation inhibitor;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| nsc 664704 | | indolobenzazepine;
lactam;
organobromine compound | cardioprotective agent;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
EC 2.7.11.26 (tau-protein kinase) inhibitor;
geroprotector | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| molsidomine | | ethyl ester;
morpholines;
oxadiazole;
zwitterion | antioxidant;
apoptosis inhibitor;
cardioprotective agent;
nitric oxide donor;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| pioglitazone | | aromatic ether;
pyridines;
thiazolidinediones | antidepressant;
cardioprotective agent;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hypoglycemic agent;
insulin-sensitizing drug;
PPARgamma agonist;
xenobiotic | 2008 | 2014 | 13.8 | low | 2 | 0 | 0 | 2 | 2 | 0 |
| pj-34 | | phenanthridines;
secondary carboxamide;
tertiary amino compound | angiogenesis inhibitor;
anti-inflammatory agent;
antiatherosclerotic agent;
antineoplastic agent;
apoptosis inducer;
cardioprotective agent;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| methylene blue | | organic chloride salt | acid-base indicator;
antidepressant;
antimalarial;
antimicrobial agent;
antioxidant;
cardioprotective agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 4.6.1.2 (guanylate cyclase) inhibitor;
fluorochrome;
histological dye;
neuroprotective agent;
physical tracer | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| thymoquinone | | 1,4-benzoquinones | adjuvant;
anti-inflammatory agent;
antidepressant;
antineoplastic agent;
antioxidant;
cardioprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mor-14 | | hydroxypiperidine;
piperidine alkaloid;
tertiary amino compound | anti-HIV agent;
cardioprotective agent;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ginsenoside rh2 | | 12beta-hydroxy steroid;
20-hydroxy steroid;
beta-D-glucoside;
ginsenoside;
tetracyclic triterpenoid | antineoplastic agent;
apoptosis inducer;
bone density conservation agent;
cardioprotective agent;
hepatoprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| 3-(2,2,2-trimethylhydrazine)propionate | | ammonium betaine | cardioprotective agent;
EC 1.14.11.1 (gamma-butyrobetaine dioxygenase) inhibitor;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| lasofoxifene | | aromatic ether;
N-alkylpyrrolidine;
naphthols;
tetralins | antineoplastic agent;
bone density conservation agent;
cardioprotective agent;
estrogen receptor agonist;
estrogen receptor antagonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ferulic acid | | ferulic acids | anti-inflammatory agent;
antioxidant;
apoptosis inhibitor;
cardioprotective agent;
MALDI matrix material;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rosuvastatin | | dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrimidines;
statin (synthetic);
sulfonamide | anti-inflammatory agent;
antilipemic drug;
cardioprotective agent;
CETP inhibitor;
environmental contaminant;
xenobiotic | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| diosmetin | | 3'-hydroxyflavonoid;
monomethoxyflavone;
trihydroxyflavone | angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
bone density conservation agent;
cardioprotective agent;
plant metabolite;
tropomyosin-related kinase B receptor agonist;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| rosuvastatin calcium | | N-acyl-15-methylhexadecasphinganine-1-phosphoethanolamine;
organic calcium salt | anti-inflammatory agent;
cardioprotective agent;
CETP inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| (E)-2,3,5,4'-tetrahydroxystilbene-2-O-beta-D-glucoside | | beta-D-glucoside;
resorcinols;
stilbenoid | anti-inflammatory agent;
antioxidant;
apoptosis inhibitor;
cardioprotective agent;
cyclooxygenase 2 inhibitor;
platelet aggregation inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| molsidomine | | ethyl ester;
morpholines;
oxadiazole;
zwitterion | antioxidant;
apoptosis inhibitor;
cardioprotective agent;
nitric oxide donor;
vasodilator agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| salvianolic acid B | | 1-benzofurans;
catechols;
dicarboxylic acid;
enoate ester;
polyphenol | anti-inflammatory agent;
antidepressant;
antineoplastic agent;
antioxidant;
apoptosis inducer;
autophagy inhibitor;
cardioprotective agent;
hepatoprotective agent;
hypoglycemic agent;
neuroprotective agent;
osteogenesis regulator;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ursodoxicoltaurine | | bile acid taurine conjugate | anti-inflammatory agent;
apoptosis inhibitor;
bone density conservation agent;
cardioprotective agent;
human metabolite;
neuroprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| mocetinostat | | aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline | antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent | 1992 | 2006 | 26.7 | low | 0 | 0 | 2 | 1 | 0 | 0 |
| bay 60-6583 | | aminopyridine;
aromatic ether;
aryl sulfide;
cyanopyridine;
cyclopropanes;
monocarboxylic acid amide | adenosine A2B receptor agonist;
anti-inflammatory agent;
cardioprotective agent | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ginsenoside rb3 | | 12beta-hydroxy steroid;
beta-D-glucoside;
disaccharide derivative;
ginsenoside;
tetracyclic triterpenoid | antidepressant;
antioxidant;
cardioprotective agent;
neuroprotective agent;
NMDA receptor antagonist;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ginsenoside rg2 | | 12beta-hydroxy steroid;
20-hydroxy steroid;
3beta-hydroxy-4,4-dimethylsteroid;
3beta-hydroxy steroid;
beta-D-glucoside;
disaccharide derivative;
ginsenoside;
tetracyclic triterpenoid | anticoagulant;
cardioprotective agent;
plant metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| jq1 compound | | carboxylic ester;
organochlorine compound;
tert-butyl ester;
thienotriazolodiazepine | angiogenesis inhibitor;
anti-inflammatory agent;
antineoplastic agent;
apoptosis inducer;
bromodomain-containing protein 4 inhibitor;
cardioprotective agent;
ferroptosis inducer | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| angiotensin i | | angiotensin;
peptide zwitterion | antihypertensive agent;
cardioprotective agent;
human metabolite;
rat metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| liproxstatin-1 | | azaspiro compound;
monochlorobenzenes;
organic heterotricyclic compound;
secondary amino compound | antioxidant;
cardioprotective agent;
ferroptosis inhibitor;
radical scavenger | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| marimastat | | hydroxamic acid;
secondary carboxamide | antineoplastic agent;
matrix metalloproteinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| prinomastat | | aromatic ether;
hydroxamic acid;
pyridines;
sulfonamide;
thiomorpholines | antineoplastic agent;
EC 3.4.24.35 (gelatinase B) inhibitor;
matrix metalloproteinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| aurapten | | coumarins;
monoterpenoid | antihypertensive agent;
antineoplastic agent;
antioxidant;
apoptosis inducer;
dopaminergic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor;
gamma-secretase modulator;
gastrointestinal drug;
hepatoprotective agent;
matrix metalloproteinase inhibitor;
neuroprotective agent;
plant metabolite;
PPARalpha agonist;
vulnerary | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| batimastat | | hydroxamic acid;
L-phenylalanine derivative;
organic sulfide;
secondary carboxamide;
thiophenes;
triamide | angiogenesis inhibitor;
antineoplastic agent;
matrix metalloproteinase inhibitor | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| ageladine a | | alkaloid;
aromatic amine;
imidazopyridine;
organobromine compound;
pyrroles | angiogenesis inhibitor;
antineoplastic agent;
matrix metalloproteinase inhibitor;
metabolite | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| bradykinin, des-arg(9)- | | oligopeptide | bradykinin receptor B2 agonist | 0 | 0 | | low | 0 | 0 | 0 | 0 | 0 | 0 |
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| acetic acid | | monocarboxylic acid | antimicrobial food preservative;
Daphnia magna metabolite;
food acidity regulator;
protic solvent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| acetamide | | acetamides;
carboximidic acid;
monocarboxylic acid amide;
N-acylammonia | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| adenine | | 6-aminopurines;
purine nucleobase | Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| allantoin | | imidazolidine-2,4-dione;
ureas | Escherichia coli metabolite;
human metabolite;
Saccharomyces cerevisiae metabolite;
vulnerary | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| quinacrine | | acridines;
aromatic ether;
organochlorine compound;
tertiary amino compound | antimalarial;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| betaine | | amino-acid betaine;
glycine derivative | fundamental metabolite | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| carnitine | | amino-acid betaine | human metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chlordecone | | cyclic ketone;
organochlorine compound | insecticide;
persistent organic pollutant | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| citric acid, anhydrous | | tricarboxylic acid | antimicrobial agent;
chelator;
food acidity regulator;
fundamental metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| salicylic acid | | monohydroxybenzoic acid | algal metabolite;
antifungal agent;
antiinfective agent;
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor;
keratolytic drug;
plant hormone;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bupropion | | aromatic ketone;
monochlorobenzenes;
secondary amino compound | antidepressant;
environmental contaminant;
xenobiotic | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| aminocaproic acid | | amino acid zwitterion;
epsilon-amino acid;
omega-amino fatty acid | antifibrinolytic drug;
hematologic agent;
metabolite | 2004 | 2016 | 14.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| fosmidomycin | | hydroxamic acid;
phosphonic acids | antimicrobial agent;
bacterial metabolite;
EC 1.1.1.267 (1-deoxy-D-xylulose-5-phosphate reductoisomerase) inhibitor | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| creatine | | glycine derivative;
guanidines;
zwitterion | geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent;
nutraceutical | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lactic acid | | 2-hydroxy monocarboxylic acid | algal metabolite;
Daphnia magna metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 5,6-dimethylbenzimidazole | | dimethylbenzimidazole | Escherichia coli metabolite;
human metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dimethyl sulfoxide | | sulfoxide;
volatile organic compound | alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| formaldehyde | | aldehyde;
one-carbon compound | allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hexachlorocyclohexane | | chlorocyclohexane | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| glycine | | alpha-amino acid;
amino acid zwitterion;
proteinogenic amino acid;
serine family amino acid | EC 2.1.2.1 (glycine hydroxymethyltransferase) inhibitor;
fundamental metabolite;
hepatoprotective agent;
micronutrient;
neurotransmitter;
NMDA receptor agonist;
nutraceutical | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| glycerol | | alditol;
triol | algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hydroquinone | | benzenediol;
hydroquinones | antioxidant;
carcinogenic agent;
cofactor;
Escherichia coli metabolite;
human xenobiotic metabolite;
mouse metabolite;
skin lightening agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| inositol | | cyclitol;
hexol | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| melatonin | | acetamides;
tryptamines | anticonvulsant;
central nervous system depressant;
geroprotector;
hormone;
human metabolite;
immunological adjuvant;
mouse metabolite;
radical scavenger | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| niacinamide | | pyridine alkaloid;
pyridinecarboxamide;
vitamin B3 | anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| niacin | | pyridine alkaloid;
pyridinemonocarboxylic acid;
vitamin B3 | antidote;
antilipemic drug;
EC 3.5.1.19 (nicotinamidase) inhibitor;
Escherichia coli metabolite;
human urinary metabolite;
metabolite;
mouse metabolite;
plant metabolite;
vasodilator agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| orotic acid | | pyrimidinemonocarboxylic acid | Escherichia coli metabolite;
metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 4-aminobenzoic acid | | aminobenzoic acid;
aromatic amino-acid zwitterion | allergen;
Escherichia coli metabolite;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| parathion | | C-nitro compound;
organic thiophosphate;
organothiophosphate insecticide | acaricide;
agrochemical;
avicide;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
mouse metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pentachlorophenol | | aromatic fungicide;
chlorophenol;
organochlorine pesticide;
pentachlorobenzenes | human xenobiotic metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenol | | phenols | antiseptic drug;
disinfectant;
human xenobiotic metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenylacetic acid | | benzenes;
monocarboxylic acid;
phenylacetic acids | allergen;
Aspergillus metabolite;
auxin;
EC 6.4.1.1 (pyruvate carboxylase) inhibitor;
Escherichia coli metabolite;
human metabolite;
plant growth retardant;
plant metabolite;
Saccharomyces cerevisiae metabolite;
toxin | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pyrazinamide | | monocarboxylic acid amide;
N-acylammonia;
pyrazines | antitubercular agent;
prodrug | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| pyridoxal phosphate | | methylpyridines;
monohydroxypyridine;
pyridinecarbaldehyde;
vitamin B6 phosphate | coenzyme;
cofactor;
EC 2.7.7.7 (DNA-directed DNA polymerase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pyridoxine | | hydroxymethylpyridine;
methylpyridines;
monohydroxypyridine;
vitamin B6 | cofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| thiamine | | primary alcohol;
vitamin B1 | Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| uracil | | pyrimidine nucleobase;
pyrimidone | allergen;
Daphnia magna metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
prodrug;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| urea | | isourea;
monocarboxylic acid amide;
one-carbon compound | Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| catechin | | hydroxyflavan | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| menthol | | p-menthane monoterpenoid;
secondary alcohol | volatile oil component | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 1-(3-chlorophenyl)piperazine | | monochlorobenzenes;
N-arylpiperazine | drug metabolite;
environmental contaminant;
serotonergic agonist;
xenobiotic | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| amitrole | | aromatic amine;
triazoles | carotenoid biosynthesis inhibitor;
EC 1.11.1.6 (catalase) inhibitor;
herbicide | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenytoin | | imidazolidine-2,4-dione | anticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent | 2004 | 2016 | 14.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| tacrine | | acridines;
aromatic amine | EC 3.1.1.7 (acetylcholinesterase) inhibitor | 2004 | 2013 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| acebutolol | | aromatic amide;
ethanolamines;
ether;
monocarboxylic acid amide;
propanolamine;
secondary amino compound | anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympathomimetic agent | 2004 | 2016 | 14.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| acetaminophen | | acetamides;
phenols | antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic | 2004 | 2016 | 13.7 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| acetazolamide | | monocarboxylic acid amide;
sulfonamide;
thiadiazoles | anticonvulsant;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| acetohexamide | | acetophenones;
N-sulfonylurea | hypoglycemic agent;
insulin secretagogue | 2008 | 2011 | 14.3 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| acetohydroxamic acid | | acetohydroxamic acids;
carbohydroximic acid | algal metabolite;
EC 3.5.1.5 (urease) inhibitor | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| alaproclate | | alpha-amino acid ester | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| albendazole | | aryl sulfide;
benzimidazoles;
benzimidazolylcarbamate fungicide;
carbamate ester | anthelminthic drug;
microtubule-destabilising agent;
tubulin modulator | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| albuterol | | phenols;
phenylethanolamines;
secondary amino compound | beta-adrenergic agonist;
bronchodilator agent;
environmental contaminant;
xenobiotic | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| alendronate | | 1,1-bis(phosphonic acid);
primary amino compound | bone density conservation agent;
EC 2.5.1.1 (dimethylallyltranstransferase) inhibitor | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| alfuzosin | | monocarboxylic acid amide;
quinazolines;
tetrahydrofuranol | alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| alosetron | | imidazoles;
pyridoindole | antiemetic;
gastrointestinal drug;
serotonergic antagonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| alprazolam | | organochlorine compound;
triazolobenzodiazepine | anticonvulsant;
anxiolytic drug;
GABA agonist;
muscle relaxant;
sedative;
xenobiotic | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| alprenolol | | secondary alcohol;
secondary amino compound | anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent | 2011 | 2013 | 12.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| altretamine | | triamino-1,3,5-triazine | | 2004 | 2016 | 14.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| amantadine | | adamantanes;
primary aliphatic amine | analgesic;
antiparkinson drug;
antiviral drug;
dopaminergic agent;
NMDA receptor antagonist;
non-narcotic analgesic | 2004 | 2016 | 14.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| ambenonium | | quaternary ammonium ion | EC 3.1.1.8 (cholinesterase) inhibitor | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| ambroxol | | aromatic amine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ametantrone | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diatrizoic acid | | acetamides;
benzoic acids;
organoiodine compound | environmental contaminant;
radioopaque medium;
xenobiotic | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| amifostine anhydrous | | diamine;
organic thiophosphate | antioxidant;
prodrug;
radiation protective agent | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| aminoglutethimide | | dicarboximide;
piperidones;
substituted aniline | adrenergic agent;
anticonvulsant;
antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor | 2004 | 2013 | 15.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| pimagedine | | guanidines;
one-carbon compound | EC 1.14.13.39 (nitric oxide synthase) inhibitor;
EC 1.4.3.4 (monoamine oxidase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| p-aminohippuric acid | | N-acylglycine | Daphnia magna metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| theophylline | | dimethylxanthine | adenosine receptor antagonist;
anti-asthmatic drug;
anti-inflammatory agent;
bronchodilator agent;
drug metabolite;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
fungal metabolite;
human blood serum metabolite;
immunomodulator;
muscle relaxant;
vasodilator agent | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| 2-aminothiazole | | 1,3-thiazoles;
primary amino compound | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| amiodarone | | 1-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound | cardiovascular drug | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| dan 2163 | | aromatic amide;
aromatic amine;
benzamides;
pyrrolidines;
sulfone | environmental contaminant;
second generation antipsychotic;
xenobiotic | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| amitriptyline | | carbotricyclic compound;
tertiary amine | adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
tropomyosin-related kinase B receptor agonist;
xenobiotic | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| amlexanox | | monocarboxylic acid;
pyridochromene | anti-allergic agent;
anti-ulcer drug;
non-steroidal anti-inflammatory drug | 2004 | 2013 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| amlodipine | | dihydropyridine;
ethyl ester;
methyl ester;
monochlorobenzenes;
primary amino compound | antihypertensive agent;
calcium channel blocker;
vasodilator agent | 2004 | 2016 | 13.5 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| amobarbital | | barbiturates | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| amoxapine | | dibenzooxazepine | adrenergic uptake inhibitor;
antidepressant;
dopaminergic antagonist;
geroprotector;
serotonin uptake inhibitor | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| amsacrine | | acridines;
aromatic ether;
sulfonamide | antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| anastrozole | | nitrile;
triazoles | antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| anethole trithione | | methoxybenzenes | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| anthralin | | anthracenes | antipsoriatic | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| antipyrine | | pyrazolone | antipyretic;
cyclooxygenase 3 inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic | 2011 | 2013 | 12.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| apraclonidine | | dichlorobenzene;
guanidines;
imidazolines | alpha-adrenergic agonist;
antiglaucoma drug;
beta-adrenergic agonist;
diagnostic agent;
ophthalmology drug | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| aspirin | | benzoic acids;
phenyl acetates;
salicylates | anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent | 2004 | 2016 | 13.7 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| astemizole | | benzimidazoles;
piperidines | anti-allergic agent;
anticoronaviral agent;
H1-receptor antagonist | 2004 | 2013 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| atenolol | | ethanolamines;
monocarboxylic acid amide;
propanolamine | anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
sympatholytic agent;
xenobiotic | 2004 | 2016 | 13.7 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| azathioprine | | aryl sulfide;
C-nitro compound;
imidazoles;
thiopurine | antimetabolite;
antineoplastic agent;
carcinogenic agent;
DNA synthesis inhibitor;
hepatotoxic agent;
immunosuppressive agent;
prodrug | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| azelaic acid | | alpha,omega-dicarboxylic acid;
dicarboxylic fatty acid | antibacterial agent;
antineoplastic agent;
dermatologic drug;
plant metabolite | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| azelastine | | monochlorobenzenes;
phthalazines;
tertiary amino compound | anti-allergic agent;
anti-asthmatic drug;
bronchodilator agent;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
H1-receptor antagonist;
platelet aggregation inhibitor | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| azinphosmethyl | | benzotriazines;
organic thiophosphate;
organothiophosphate insecticide | agrochemical;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| baclofen | | amino acid zwitterion;
gamma-amino acid;
monocarboxylic acid;
monochlorobenzenes;
primary amino compound | central nervous system depressant;
GABA agonist;
muscle relaxant | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| barbital | | barbiturates | drug allergen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bendazac | | indazoles;
monocarboxylic acid | non-steroidal anti-inflammatory drug;
radical scavenger | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| bendroflumethiazide | | benzothiadiazine;
sulfonamide | antihypertensive agent;
diuretic | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| benserazide | | carbohydrazide;
catechols;
primary alcohol;
primary amino compound | antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| benzbromarone | | 1-benzofurans;
aromatic ketone | uricosuric drug | 2010 | 2016 | 11.5 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| benzocaine | | benzoate ester;
substituted aniline | allergen;
antipruritic drug;
sensitiser;
topical anaesthetic | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bepridil | | pyrrolidines;
tertiary amine | anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| betaxolol | | propanolamine | antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent | 2004 | 2016 | 14.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| bethanechol | | carbamate ester;
quaternary ammonium ion | muscarinic agonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bicalutamide | | (trifluoromethyl)benzenes;
monocarboxylic acid amide;
monofluorobenzenes;
nitrile;
sulfone;
tertiary alcohol | | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| bay h 4502 | | biphenyls;
imidazoles | | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| biperiden | | piperidines;
tertiary alcohol;
tertiary amino compound | antidote to sarin poisoning;
antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist;
parasympatholytic | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bisacodyl | | diarylmethane | | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| bisoprolol | | secondary alcohol;
secondary amine | anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent | 2004 | 2016 | 14.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| brimonidine | | imidazoles;
quinoxaline derivative;
secondary amine | adrenergic agonist;
alpha-adrenergic agonist;
antihypertensive agent | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bromhexine | | organobromine compound;
substituted aniline;
tertiary amino compound | mucolytic | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| bromopride | | benzamides | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bromisovalum | | N-acylurea;
organobromine compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bronopol | | nitro compound | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| brotizolam | | organic molecular entity | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bumetanide | | amino acid;
benzoic acids;
sulfonamide | diuretic;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor | 2004 | 2016 | 13.7 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| bupivacaine | | aromatic amide;
piperidinecarboxamide;
tertiary amino compound | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| buspirone | | azaspiro compound;
N-alkylpiperazine;
N-arylpiperazine;
organic heteropolycyclic compound;
piperidones;
pyrimidines | anxiolytic drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
sedative;
serotonergic agonist | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| busulfan | | methanesulfonate ester | alkylating agent;
antineoplastic agent;
carcinogenic agent;
insect sterilant;
teratogenic agent | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| secbutabarbital | | barbiturates | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| butalbital | | barbiturates | analgesic;
sedative | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| butenafine | | naphthalenes;
tertiary amine | antifungal drug;
EC 1.14.13.132 (squalene monooxygenase) inhibitor | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| caffeine | | purine alkaloid;
trimethylxanthine | adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic | 2008 | 2016 | 12.4 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| verapamil | | aromatic ether;
nitrile;
polyether;
tertiary amino compound | | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| candesartan cilexetil | | biphenyls | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| candesartan | | benzimidazolecarboxylic acid;
biphenylyltetrazole | angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| carbamazepine | | dibenzoazepine;
ureas | analgesic;
anticonvulsant;
antimanic drug;
drug allergen;
EC 3.5.1.98 (histone deacetylase) inhibitor;
environmental contaminant;
glutamate transporter activator;
mitogen;
non-narcotic analgesic;
sodium channel blocker;
xenobiotic | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| carbinoxamine | | monochlorobenzenes;
pyridines;
tertiary amino compound | anti-allergic agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| carbazilquinone | | organic molecular entity | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| carisoprodol | | carbamate ester | muscle relaxant | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| carmofur | | organohalogen compound;
pyrimidines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| carmustine | | N-nitrosoureas;
organochlorine compound | alkylating agent;
antineoplastic agent | 2004 | 2013 | 15.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| carprofen | | carbazoles;
organochlorine compound | EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug;
photosensitizing agent | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| carteolol | | quinolone;
secondary alcohol | anti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent | 2004 | 2008 | 18.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| carvedilol | | carbazoles;
secondary alcohol;
secondary amino compound | alpha-adrenergic antagonist;
antihypertensive agent;
beta-adrenergic antagonist;
cardiovascular drug;
vasodilator agent | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| celecoxib | | organofluorine compound;
pyrazoles;
sulfonamide;
toluenes | cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| celiprolol | | aromatic ketone | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cetirizine | | ether;
monocarboxylic acid;
monochlorobenzenes;
piperazines | anti-allergic agent;
environmental contaminant;
H1-receptor antagonist;
xenobiotic | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| chloral hydrate | | aldehyde hydrate;
ethanediol;
organochlorine compound | general anaesthetic;
mouse metabolite;
sedative;
xenobiotic | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| chlorambucil | | aromatic amine;
monocarboxylic acid;
nitrogen mustard;
organochlorine compound;
tertiary amino compound | alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent | 2008 | 2016 | 12.4 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| chlorcyclizine | | diarylmethane | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| chlordiazepoxide | | benzodiazepine | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| chlormezanone | | 1,3-thiazine;
lactam;
monochlorobenzenes;
sulfone | antipsychotic agent;
anxiolytic drug;
muscle relaxant | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| chloroquine | | aminoquinoline;
organochlorine compound;
secondary amino compound;
tertiary amino compound | anticoronaviral agent;
antimalarial;
antirheumatic drug;
autophagy inhibitor;
dermatologic drug | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| chlorothiazide | | benzothiadiazine | antihypertensive agent;
diuretic | 2008 | 2016 | 12.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| chloroxylenol | | monochlorobenzenes;
phenols | antiseptic drug;
disinfectant;
molluscicide | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chlorpheniramine | | monochlorobenzenes;
pyridines;
tertiary amino compound | anti-allergic agent;
antidepressant;
antipruritic drug;
H1-receptor antagonist;
histamine antagonist;
serotonin uptake inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| chlorpromazine | | organochlorine compound;
phenothiazines;
tertiary amine | anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
phenothiazine antipsychotic drug | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| chlorpropamide | | monochlorobenzenes;
N-sulfonylurea | hypoglycemic agent;
insulin secretagogue | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| chlorthalidone | | isoindoles;
monochlorobenzenes;
sulfonamide | | 2008 | 2016 | 11.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| chlorzoxazone | | 1,3-benzoxazoles;
heteroaryl hydroxy compound;
organochlorine compound | muscle relaxant;
sedative | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| cifenline | | diarylmethane | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ciclopirox | | cyclic hydroxamic acid;
hydroxypyridone antifungal drug;
pyridone | antibacterial agent;
antiseborrheic | 2004 | 2013 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| ciglitazone | | aromatic ether;
thiazolidinone | antineoplastic agent;
insulin-sensitizing drug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cilostazol | | lactam;
tetrazoles | anticoagulant;
bronchodilator agent;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
fibrin modulating drug;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| cimetidine | | aliphatic sulfide;
guanidines;
imidazoles;
nitrile | adjuvant;
analgesic;
anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| cinoxacin | | cinnolines;
oxacycle;
oxo carboxylic acid | antibacterial drug;
antiinfective agent | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| ciprofibrate | | cyclopropanes;
monocarboxylic acid;
organochlorine compound | antilipemic drug | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| ciprofloxacin | | aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion | antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| cisapride | | benzamides | | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| citalopram | | 2-benzofurans;
cyclic ether;
nitrile;
organofluorine compound;
tertiary amino compound | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| clenbuterol | | amino alcohol;
dichlorobenzene;
ethanolamines;
primary arylamine;
secondary amino compound;
substituted aniline | beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clioquinol | | monohydroxyquinoline;
organochlorine compound;
organoiodine compound | antibacterial agent;
antifungal agent;
antimicrobial agent;
antineoplastic agent;
antiprotozoal drug;
chelator;
copper chelator | 2008 | 2013 | 13.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| clobazam | | 1,4-benzodiazepinone;
organochlorine compound | anticonvulsant;
anxiolytic drug;
GABA modulator | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| clofazimine | | monochlorobenzenes;
phenazines | dye;
leprostatic drug;
non-steroidal anti-inflammatory drug | 2004 | 2013 | 15.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| clofibrate | | aromatic ether;
ethyl ester;
monochlorobenzenes | anticholesteremic drug;
antilipemic drug;
geroprotector;
PPARalpha agonist | 2010 | 2016 | 11.5 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| clomiphene | | tertiary amine | estrogen antagonist;
estrogen receptor modulator | 2010 | 2016 | 11.0 | medium | 0 | 0 | 0 | 1 | 2 | 0 |
| clomipramine | | dibenzoazepine | anticoronaviral agent;
antidepressant;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
serotonergic antagonist;
serotonergic drug;
serotonin uptake inhibitor | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| clonazepam | | 1,4-benzodiazepinone;
monochlorobenzenes | anticonvulsant;
anxiolytic drug;
GABA modulator | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| clonidine | | clonidine;
imidazoline | | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| 4-chloro-N-(2,6-dimethyl-1-piperidinyl)-3-sulfamoylbenzamide | | sulfonamide | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| chlorazepate | | 1,4-benzodiazepinone | anticonvulsant;
anxiolytic drug;
GABA modulator;
prodrug | 2004 | 2016 | 14.0 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| clotiazepam | | organic molecular entity | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clotrimazole | | conazole antifungal drug;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes | antiinfective agent;
environmental contaminant;
xenobiotic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cromolyn | | chromones;
dicarboxylic acid | anti-asthmatic drug;
calcium channel blocker | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cyclandelate | | carboxylic ester;
secondary alcohol | vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cyclobenzaprine | | carbotricyclic compound | antidepressant;
muscle relaxant;
tranquilizing drug | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cyclofenil | | organic molecular entity | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cycloleucine | | non-proteinogenic alpha-amino acid | EC 2.5.1.6 (methionine adenosyltransferase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cyproheptadine | | piperidines;
tertiary amine | anti-allergic agent;
antipruritic drug;
gastrointestinal drug;
H1-receptor antagonist;
serotonergic antagonist | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| danthron | | dihydroxyanthraquinone | apoptosis inducer;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dapsone | | substituted aniline;
sulfone | anti-inflammatory drug;
antiinfective agent;
antimalarial;
leprostatic drug | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| debrisoquin | | carboxamidine;
isoquinolines | adrenergic agent;
antihypertensive agent;
human metabolite;
sympatholytic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| deferoxamine | | acyclic desferrioxamine | bacterial metabolite;
ferroptosis inhibitor;
iron chelator;
siderophore | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| desipramine | | dibenzoazepine;
secondary amino compound | adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
cholinergic antagonist;
drug allergen;
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
serotonin uptake inhibitor | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| nordazepam | | 1,4-benzodiazepinone;
organochlorine compound | anticonvulsant;
anxiolytic drug;
GABA modulator;
human metabolite;
sedative | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| amphetamine | | primary amine | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| eflornithine | | alpha-amino acid;
fluoroamino acid | trypanocidal drug | 2010 | 2011 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| diazepam | | 1,4-benzodiazepinone;
organochlorine compound | anticonvulsant;
anxiolytic drug;
environmental contaminant;
sedative;
xenobiotic | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| diazoxide | | benzothiadiazine;
organochlorine compound;
sulfone | antihypertensive agent;
beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
diuretic;
K-ATP channel agonist;
sodium channel blocker;
sympathomimetic agent;
vasodilator agent | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| dicamba | | dichlorobenzene;
methoxybenzoic acid | agrochemical;
environmental contaminant;
herbicide;
synthetic auxin;
xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diclofenac | | amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound | antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| ddt | | benzenoid aromatic compound;
chlorophenylethane;
monochlorobenzenes;
organochlorine insecticide | bridged diphenyl acaricide;
carcinogenic agent;
endocrine disruptor;
persistent organic pollutant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dichlorphenamide | | dichlorobenzene;
sulfonamide | antiglaucoma drug;
EC 4.2.1.1 (carbonic anhydrase) inhibitor;
ophthalmology drug | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| dicyclomine | | carboxylic ester;
tertiary amine | antispasmodic drug;
muscarinic antagonist;
parasympatholytic | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| diethylcarbamazine | | N-carbamoylpiperazine;
N-methylpiperazine | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pentetic acid | | pentacarboxylic acid | copper chelator | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| diflunisal | | monohydroxybenzoic acid;
organofluorine compound | non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2004 | 2016 | 14.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| dimercaprol | | dithiol;
primary alcohol | chelator | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| dinitolmide | | dinitrotoluene | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diphenhydramine | | ether;
tertiary amino compound | anti-allergic agent;
antidyskinesia agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
antitussive;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
oneirogen;
sedative | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| dipivefrin | | ethanolamines;
pivalate ester | adrenergic agonist;
antiglaucoma drug;
ophthalmology drug;
prodrug;
sympathomimetic agent | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dipyridamole | | piperidines;
pyrimidopyrimidine;
tertiary amino compound;
tetrol | adenosine phosphodiesterase inhibitor;
EC 3.5.4.4 (adenosine deaminase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent | 2008 | 2016 | 12.4 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| dipyrone | | amino sulfonic acid;
pyrazoles | anti-inflammatory agent;
antipyretic;
antirheumatic drug;
cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug;
prodrug | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| disopyramide | | monocarboxylic acid amide;
pyridines;
tertiary amino compound | anti-arrhythmia drug | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| disulfiram | | organic disulfide;
organosulfur acaricide | angiogenesis inhibitor;
antineoplastic agent;
apoptosis inducer;
EC 1.2.1.3 [aldehyde dehydrogenase (NAD(+))] inhibitor;
EC 3.1.1.1 (carboxylesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
ferroptosis inducer;
fungicide;
NF-kappaB inhibitor | 2004 | 2016 | 13.7 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| valproic acid | | branched-chain fatty acid;
branched-chain saturated fatty acid | anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent | 2004 | 2016 | 14.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| domperidone | | benzimidazoles;
heteroarylpiperidine | antiemetic;
dopaminergic antagonist | 2008 | 2013 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| donepezil | | aromatic ether;
indanones;
piperidines;
racemate | EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
nootropic agent | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| doxapram | | morpholines;
pyrrolidin-2-ones | central nervous system stimulant | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| doxazosin | | aromatic amine;
benzodioxine;
monocarboxylic acid amide;
N-acylpiperazine;
N-arylpiperazine;
quinazolines | alpha-adrenergic antagonist;
antihyperplasia drug;
antihypertensive agent;
antineoplastic agent;
vasodilator agent | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| doxepin | | dibenzooxepine;
tertiary amino compound | antidepressant | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| doxylamine | | pyridines;
tertiary amine | anti-allergic agent;
antiemetic;
antitussive;
cholinergic antagonist;
H1-receptor antagonist;
histamine antagonist;
sedative | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| droperidol | | aromatic ketone;
benzimidazoles;
organofluorine compound | anaesthesia adjuvant;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| dyphylline | | oxopurine;
propane-1,2-diols | bronchodilator agent;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
muscle relaxant;
vasodilator agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ebastine | | organic molecular entity | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| econazole | | dichlorobenzene;
ether;
imidazoles;
monochlorobenzenes | | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| edrophonium | | phenols;
quaternary ammonium ion | antidote;
diagnostic agent;
EC 3.1.1.8 (cholinesterase) inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| enflurane | | ether;
organochlorine compound;
organofluorine compound | anaesthetic | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| enoxacin | | 1,8-naphthyridine derivative;
amino acid;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-arylpiperazine;
quinolone antibiotic | antibacterial drug;
DNA synthesis inhibitor | 2004 | 2013 | 15.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| estazolam | | triazoles;
triazolobenzodiazepine | anticonvulsant;
anxiolytic drug;
GABA modulator | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| ethacrynic acid | | aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid | EC 2.5.1.18 (glutathione transferase) inhibitor;
ion transport inhibitor;
loop diuretic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| ethinamate | | carbamate ester;
terminal acetylenic compound | sedative | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ethosuximide | | dicarboximide;
pyrrolidinone | anticonvulsant;
geroprotector;
T-type calcium channel blocker | 2008 | 2016 | 11.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| ethotoin | | imidazolidine-2,4-dione | anticonvulsant | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ethoxzolamide | | aromatic ether;
benzothiazoles;
sulfonamide | antiglaucoma drug;
diuretic;
EC 4.2.1.1 (carbonic anhydrase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| etidronate | | 1,1-bis(phosphonic acid) | antineoplastic agent;
bone density conservation agent;
chelator | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| etodolac | | monocarboxylic acid;
organic heterotricyclic compound | antipyretic;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2004 | 2016 | 13.6 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| brl 42810 | | 2-aminopurines;
acetate ester | antiviral drug;
prodrug | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| felbamate | | carbamate ester | anticonvulsant;
neuroprotective agent | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| 4-biphenylylacetic acid | | biphenyls;
monocarboxylic acid | non-steroidal anti-inflammatory drug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| felodipine | | dichlorobenzene;
dihydropyridine;
ethyl ester;
methyl ester | anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent | 2004 | 2016 | 13.5 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| fenfluramine | | (trifluoromethyl)benzenes;
secondary amino compound | appetite depressant;
serotonergic agonist;
serotonin uptake inhibitor | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fenofibrate | | aromatic ether;
chlorobenzophenone;
isopropyl ester;
monochlorobenzenes | antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| fenoldopam | | benzazepine | alpha-adrenergic agonist;
antihypertensive agent;
dopamine agonist;
dopaminergic antagonist;
vasodilator agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fenoprofen | | monocarboxylic acid | antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| berotek | | resorcinols;
secondary alcohol;
secondary amino compound | beta-adrenergic agonist;
bronchodilator agent;
sympathomimetic agent;
tocolytic agent | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| fentanyl | | anilide;
monocarboxylic acid amide;
piperidines | adjuvant;
anaesthesia adjuvant;
anaesthetic;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| fexofenadine | | piperidines;
tertiary amine | anti-allergic agent;
H1-receptor antagonist | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| fipexide | | benzodioxoles | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| flavoxate | | carboxylic ester;
flavones;
piperidines;
tertiary amino compound | antispasmodic drug;
muscarinic antagonist;
parasympatholytic | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| flecainide | | aromatic ether;
monocarboxylic acid amide;
organofluorine compound;
piperidines | anti-arrhythmia drug | 2004 | 2016 | 14.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| fleroxacin | | difluorobenzene;
fluoroquinolone antibiotic;
monocarboxylic acid;
N-alkylpiperazine;
quinolines | antibacterial drug;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fluconazole | | conazole antifungal drug;
difluorobenzene;
tertiary alcohol;
triazole antifungal drug | environmental contaminant;
P450 inhibitor;
xenobiotic | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| flucytosine | | aminopyrimidine;
nucleoside analogue;
organofluorine compound;
pyrimidine antifungal drug;
pyrimidone | prodrug | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| flufenamic acid | | aromatic amino acid;
organofluorine compound | antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fluphenazine | | N-alkylpiperazine;
organofluorine compound;
phenothiazines | anticoronaviral agent;
dopaminergic antagonist;
phenothiazine antipsychotic drug | 2004 | 2016 | 14.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| flumazenil | | ethyl ester;
imidazobenzodiazepine;
organofluorine compound | antidote to benzodiazepine poisoning;
GABA antagonist | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| flunitrazepam | | 1,4-benzodiazepinone;
C-nitro compound;
monofluorobenzenes | anxiolytic drug;
GABAA receptor agonist;
sedative | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fluorescite | | benzoic acids;
cyclic ketone;
hydroxy monocarboxylic acid;
organic heterotricyclic compound;
phenols;
xanthene dye | fluorescent dye;
radioopaque medium | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| fluorouracil | | nucleobase analogue;
organofluorine compound | antimetabolite;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
radiosensitizing agent;
xenobiotic | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| fluoxetine | | (trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound | | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| fluphenazine depot | | decanoate ester;
N-alkylpiperazine;
organofluorine compound;
phenothiazines | dopaminergic antagonist;
phenothiazine antipsychotic drug;
prodrug | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fluphenazine enanthate | | phenothiazines | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| flurazepam | | 1,4-benzodiazepinone;
monofluorobenzenes;
organochlorine compound;
tertiary amino compound | anticonvulsant;
anxiolytic drug;
GABAA receptor agonist;
sedative | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| flurbiprofen | | fluorobiphenyl;
monocarboxylic acid | antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| flutamide | | (trifluoromethyl)benzenes;
monocarboxylic acid amide | androgen antagonist;
antineoplastic agent | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| fomepizole | | pyrazoles | antidote;
EC 1.1.1.1 (alcohol dehydrogenase) inhibitor;
protective agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| foscarnet | | carboxylic acid;
one-carbon compound;
phosphonic acids | antiviral drug;
geroprotector;
HIV-1 reverse transcriptase inhibitor;
sodium-dependent Pi-transporter inhibitor | 2004 | 2016 | 13.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| furosemide | | chlorobenzoic acid;
furans;
sulfonamide | environmental contaminant;
loop diuretic;
xenobiotic | 2004 | 2016 | 13.6 | low | 0 | 0 | 0 | 3 | 4 | 0 |
| gabapentin | | gamma-amino acid | anticonvulsant;
calcium channel blocker;
environmental contaminant;
xenobiotic | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| gemfibrozil | | aromatic ether | antilipemic drug | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| glafenine | | aminoquinoline;
carboxylic ester;
glycol;
organochlorine compound;
secondary amino compound | inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| gliclazide | | N-sulfonylurea | hypoglycemic agent;
insulin secretagogue;
radical scavenger | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| glimepiride | | sulfonamide | | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| glipizide | | aromatic amide;
monocarboxylic acid amide;
N-sulfonylurea;
pyrazines | EC 2.7.1.33 (pantothenate kinase) inhibitor;
hypoglycemic agent;
insulin secretagogue | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| glutethimide | | piperidines | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| glyburide | | monochlorobenzenes;
N-sulfonylurea | anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent | 2004 | 2016 | 13.7 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| 2-cyclopentyl-2-hydroxy-2-phenylacetic acid (1,1-dimethyl-3-pyrrolidin-1-iumyl) ester | | benzenes | | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| gossypol | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| granisetron | | aromatic amide;
indazoles | | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| guaiazulene | | sesquiterpene | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| guaifenesin | | methoxybenzenes | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| guanethidine | | azocanes;
guanidines | adrenergic antagonist;
antihypertensive agent;
sympatholytic agent | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| guanfacine | | acetamides | | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| guanidine | | carboxamidine;
guanidines;
one-carbon compound | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fasudil | | isoquinolines;
N-sulfonyldiazepane | antihypertensive agent;
calcium channel blocker;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
geroprotector;
neuroprotective agent;
nootropic agent;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| haloperidol | | aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol | antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| halothane | | haloalkane;
organobromine compound;
organochlorine compound;
organofluorine compound | inhalation anaesthetic | 2004 | 2010 | 16.7 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| hexachlorophene | | bridged diphenyl fungicide;
polyphenol;
trichlorobenzene | acaricide;
antibacterial agent;
antifungal agrochemical;
antiseptic drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| miltefosine | | phosphocholines;
phospholipid | anti-inflammatory agent;
anticoronaviral agent;
antifungal agent;
antineoplastic agent;
antiprotozoal drug;
apoptosis inducer;
immunomodulator;
protein kinase inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hexestrol | | stilbenoid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hexetidine | | organic heteromonocyclic compound;
organonitrogen heterocyclic compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hexobarbital | | barbiturates | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hydralazine | | azaarene;
hydrazines;
ortho-fused heteroarene;
phthalazines | antihypertensive agent;
vasodilator agent | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| hydrochlorothiazide | | benzothiadiazine;
organochlorine compound;
sulfonamide | antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic | 2004 | 2016 | 13.7 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| hydroflumethiazide | | benzothiadiazine;
thiazide | antihypertensive agent;
diuretic | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| hydroxychloroquine | | aminoquinoline;
organochlorine compound;
primary alcohol;
secondary amino compound;
tertiary amino compound | anticoronaviral agent;
antimalarial;
antirheumatic drug;
dermatologic drug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| hydroxyurea | | one-carbon compound;
ureas | antimetabolite;
antimitotic;
antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
genotoxin;
immunomodulator;
radical scavenger;
teratogenic agent | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| hydroxyzine | | hydroxyether;
monochlorobenzenes;
N-alkylpiperazine | anticoronaviral agent;
antipruritic drug;
anxiolytic drug;
dermatologic drug;
H1-receptor antagonist | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| ibuprofen | | monocarboxylic acid | antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic | 2004 | 2016 | 14.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| phenelzine | | primary amine | | 2004 | 2016 | 14.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| lidocaine | | benzenes;
monocarboxylic acid amide;
tertiary amino compound | anti-arrhythmia drug;
drug allergen;
environmental contaminant;
local anaesthetic;
xenobiotic | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| alverine | | tertiary amine | antispasmodic drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| idebenone | | 1,4-benzoquinones;
primary alcohol | antioxidant;
ferroptosis inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ifosfamide | | ifosfamides | alkylating agent;
antineoplastic agent;
environmental contaminant;
immunosuppressive agent;
xenobiotic | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| imipramine | | dibenzoazepine | adrenergic uptake inhibitor;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| amrinone | | bipyridines | EC 3.1.4.* (phosphoric diester hydrolase) inhibitor | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| indapamide | | indoles;
organochlorine compound;
sulfonamide | antihypertensive agent;
diuretic | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| indomethacin | | aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole | analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 4 | 0 |
| iodixanol | | organoiodine compound | radioopaque medium | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| iohexol | | benzenedicarboxamide;
organoiodine compound | environmental contaminant;
radioopaque medium;
xenobiotic | 2004 | 2013 | 14.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| iopromide | | dicarboxylic acid diamide;
organoiodine compound | environmental contaminant;
nephrotoxic agent;
radioopaque medium;
xenobiotic | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| iothalamic acid | | organic molecular entity | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| iodipamide | | benzoic acids;
organoiodine compound;
secondary carboxamide | radioopaque medium | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| iotroxic acid | | organic molecular entity | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ioversol | | amidobenzoic acid | | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| iproniazid | | carbohydrazide;
pyridines | | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| avapro | | azaspiro compound;
biphenylyltetrazole | angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic | 2000 | 2016 | 14.0 | low | 0 | 0 | 1 | 1 | 3 | 0 |
| isocarboxazid | | benzenes | | 2011 | 2016 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| isoflurane | | organofluorine compound | inhalation anaesthetic | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| isoniazid | | carbohydrazide | antitubercular agent;
drug allergen | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| 2-propanol | | secondary alcohol;
secondary fatty alcohol | protic solvent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| isoproterenol | | catechols;
secondary alcohol;
secondary amino compound | beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| isoxsuprine | | alkylbenzene | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| isradipine | | benzoxadiazole;
dihydropyridine;
isopropyl ester;
methyl ester | | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| itraconazole | | piperazines | | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| ketamine | | cyclohexanones;
monochlorobenzenes;
secondary amino compound | analgesic;
environmental contaminant;
intravenous anaesthetic;
neurotoxin;
NMDA receptor antagonist;
xenobiotic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| ketanserin | | aromatic ketone;
organofluorine compound;
piperidines;
quinazolines | alpha-adrenergic antagonist;
antihypertensive agent;
cardiovascular drug;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
serotonergic antagonist | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| ketoconazole | | dichlorobenzene;
dioxolane;
ether;
imidazoles;
N-acylpiperazine;
N-arylpiperazine | | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| ketoprofen | | benzophenones;
oxo monocarboxylic acid | antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| ketorolac | | amino acid;
aromatic ketone;
monocarboxylic acid;
pyrrolizines;
racemate | analgesic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug | 2004 | 2016 | 13.5 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| khellin | | furanochromone;
organic heterotricyclic compound;
oxacycle | anti-asthmatic agent;
bronchodilator agent;
cardiovascular drug;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| labetalol | | benzamides;
benzenes;
phenols;
primary carboxamide;
salicylamides;
secondary alcohol;
secondary amino compound | | 2004 | 2016 | 14.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| lamotrigine | | 1,2,4-triazines;
dichlorobenzene;
primary arylamine | anticonvulsant;
antidepressant;
antimanic drug;
calcium channel blocker;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
excitatory amino acid antagonist;
geroprotector;
non-narcotic analgesic;
xenobiotic | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| lansoprazole | | benzimidazoles;
pyridines;
sulfoxide | anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| beta-lapachone | | benzochromenone;
orthoquinones | anti-inflammatory agent;
antineoplastic agent;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| leflunomide | | (trifluoromethyl)benzenes;
isoxazoles;
monocarboxylic acid amide | antineoplastic agent;
antiparasitic agent;
EC 1.3.98.1 [dihydroorotate oxidase (fumarate)] inhibitor;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
hepatotoxic agent;
immunosuppressive agent;
non-steroidal anti-inflammatory drug;
prodrug;
pyrimidine synthesis inhibitor;
tyrosine kinase inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| letrozole | | nitrile;
triazoles | antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| lofepramine | | aromatic ketone;
dibenzoazepine;
monochlorobenzenes;
tertiary amino compound | antidepressant | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| lomefloxacin | | fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone | antimicrobial agent;
antitubercular agent;
photosensitizing agent | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| lomustine | | N-nitrosoureas;
organochlorine compound | alkylating agent;
antineoplastic agent | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| loperamide | | monocarboxylic acid amide;
monochlorobenzenes;
piperidines;
tertiary alcohol | anticoronaviral agent;
antidiarrhoeal drug;
mu-opioid receptor agonist | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| loratadine | | benzocycloheptapyridine;
ethyl ester;
N-acylpiperidine;
organochlorine compound;
tertiary carboxamide | anti-allergic agent;
cholinergic antagonist;
geroprotector;
H1-receptor antagonist | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| lorazepam | | benzodiazepine | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| losartan | | biphenylyltetrazole;
imidazoles | angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist | 2000 | 2016 | 15.8 | low | 0 | 0 | 1 | 2 | 2 | 0 |
| loxapine | | dibenzooxazepine | antipsychotic agent;
dopaminergic antagonist | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| malathion | | diester;
ethyl ester;
organic thiophosphate | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diisopropyl 1,3-dithiol-2-ylidenemalonate | | isopropyl ester | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| manidipine | | diarylmethane | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| maprotiline | | anthracenes | | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| mazindol | | organic molecular entity | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mebendazole | | aromatic ketone;
benzimidazoles;
carbamate ester | antinematodal drug;
microtubule-destabilising agent;
tubulin modulator | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| mecamylamine | | primary aliphatic amine | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mechlorethamine | | nitrogen mustard;
organochlorine compound | alkylating agent | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| meclizine | | diarylmethane | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| meclofenamic acid | | aminobenzoic acid;
organochlorine compound;
secondary amino compound | analgesic;
anticonvulsant;
antineoplastic agent;
antipyretic;
antirheumatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| meclofenoxate | | monocarboxylic acid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mefenamic acid | | aminobenzoic acid;
secondary amino compound | analgesic;
antipyretic;
antirheumatic drug;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-steroidal anti-inflammatory drug;
xenobiotic | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| mefloquine hydrochloride | | organofluorine compound;
piperidines;
quinolines;
secondary alcohol | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| memantine | | adamantanes;
primary aliphatic amine | antidepressant;
antiparkinson drug;
dopaminergic agent;
neuroprotective agent;
NMDA receptor antagonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| vitamin k 3 | | 1,4-naphthoquinones;
vitamin K | angiogenesis inhibitor;
antineoplastic agent;
EC 3.4.22.69 (SARS coronavirus main proteinase) inhibitor;
human urinary metabolite;
nutraceutical | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mepenzolate | | diarylmethane | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| meperidine | | ethyl ester;
piperidinecarboxylate ester;
tertiary amino compound | antispasmodic drug;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| mephenytoin | | imidazolidine-2,4-dione | anticonvulsant | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| mepivacaine | | piperidinecarboxamide | drug allergen;
local anaesthetic | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| meprobamate | | organic molecular entity | | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| mesalamine | | amino acid;
aromatic amine;
monocarboxylic acid;
monohydroxybenzoic acid;
phenols | non-steroidal anti-inflammatory drug | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| mesoridazine | | phenothiazines;
sulfoxide;
tertiary amino compound | dopaminergic antagonist;
first generation antipsychotic | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| metaproterenol | | aralkylamino compound;
phenylethanolamines;
resorcinols;
secondary alcohol;
secondary amino compound | | 2011 | 2016 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| metformin | | guanidines | environmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| methadone | | benzenes;
diarylmethane;
ketone;
tertiary amino compound | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| methazolamide | | sulfonamide;
thiadiazoles | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methocarbamol | | aromatic ether;
carbamate ester;
secondary alcohol | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methoxsalen | | aromatic ether;
psoralens | antineoplastic agent;
cross-linking reagent;
dermatologic drug;
photosensitizing agent;
plant metabolite | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| methoxyflurane | | ether;
organochlorine compound;
organofluorine compound | hepatotoxic agent;
inhalation anaesthetic;
nephrotoxic agent;
non-narcotic analgesic | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| methyclothiazide | | benzothiadiazine | | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| methyl salicylate | | benzoate ester;
methyl ester;
salicylates | flavouring agent;
insect attractant;
metabolite | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| methylphenidate | | beta-amino acid ester;
methyl ester;
piperidines | | 2008 | 2016 | 12.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| methyprylon | | organic molecular entity | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| metoclopramide | | benzamides;
monochlorobenzenes;
substituted aniline;
tertiary amino compound | antiemetic;
dopaminergic antagonist;
environmental contaminant;
gastrointestinal drug;
xenobiotic | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| metolazone | | organochlorine compound;
quinazolines;
sulfonamide | antihypertensive agent;
diuretic;
ion transport inhibitor | 2011 | 2016 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| metoprolol | | aromatic ether;
propanolamine;
secondary alcohol;
secondary amino compound | antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
geroprotector;
xenobiotic | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| metronidazole | | C-nitro compound;
imidazoles;
primary alcohol | antiamoebic agent;
antibacterial drug;
antimicrobial agent;
antiparasitic agent;
antitrichomonal drug;
environmental contaminant;
prodrug;
radiosensitizing agent;
xenobiotic | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| metyrapone | | aromatic ketone | antimetabolite;
diagnostic agent;
EC 1.14.15.4 (steroid 11beta-monooxygenase) inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| mexiletine | | aromatic ether;
primary amino compound | anti-arrhythmia drug | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| mianserin | | dibenzoazepine | adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
geroprotector;
H1-receptor antagonist;
histamine agonist;
sedative;
serotonergic antagonist | 2010 | 2011 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| miconazole | | dichlorobenzene;
ether;
imidazoles | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| midazolam | | imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound | anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| midodrine | | amino acid amide;
aromatic ether;
secondary alcohol | alpha-adrenergic agonist;
prodrug;
sympathomimetic agent;
vasoconstrictor agent | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| milrinone | | bipyridines;
nitrile;
pyridone | cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
platelet aggregation inhibitor;
vasodilator agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| minoxidil | | dialkylarylamine;
tertiary amino compound | | 2004 | 2016 | 13.7 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| mirtazapine | | benzazepine;
tetracyclic antidepressant | alpha-adrenergic antagonist;
anxiolytic drug;
H1-receptor antagonist;
histamine antagonist;
oneirogen;
serotonergic antagonist | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| mitotane | | diarylmethane | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| mitoxantrone | | dihydroxyanthraquinone | analgesic;
antineoplastic agent | 2004 | 2016 | 14.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| moclobemide | | benzamides;
monochlorobenzenes;
morpholines | antidepressant;
environmental contaminant;
xenobiotic | 2008 | 2013 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| modafinil | | monocarboxylic acid amide;
sulfoxide | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| moxisylyte | | monoterpenoid | | 2010 | 2016 | 11.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| deet | | benzamides;
monocarboxylic acid amide | environmental contaminant;
insect repellent;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fidexaban | | | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| acecainide | | acetamides;
benzamides | anti-arrhythmia drug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| clorgyline | | aromatic ether;
dichlorobenzene;
terminal acetylenic compound;
tertiary amino compound | antidepressant;
EC 1.4.3.4 (monoamine oxidase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nabumetone | | methoxynaphthalene;
methyl ketone | cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| nadolol | | tetralins | | 2013 | 2016 | 9.5 | medium | 0 | 0 | 0 | 0 | 2 | 0 |
| nafamostat | | benzoic acids;
guanidines | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| nalidixic acid | | 1,8-naphthyridine derivative;
monocarboxylic acid;
quinolone antibiotic | antibacterial drug;
antimicrobial agent;
DNA synthesis inhibitor | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| naratriptan | | heteroarylpiperidine;
sulfonamide;
tryptamines | serotonergic agonist;
vasoconstrictor agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nefazodone | | aromatic ether;
monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazoles | alpha-adrenergic antagonist;
analgesic;
antidepressant;
serotonergic antagonist;
serotonin uptake inhibitor | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| nefopam | | benzoxazocine;
tertiary amino compound | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| neostigmine | | quaternary ammonium ion | antidote to curare poisoning;
EC 3.1.1.7 (acetylcholinesterase) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nevirapine | | cyclopropanes;
dipyridodiazepine | antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| nialamide | | organonitrogen compound;
organooxygen compound | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| nicardipine | | benzenes;
C-nitro compound;
diester;
dihydropyridine;
methyl ester;
tertiary amino compound | | 2004 | 2016 | 12.8 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| niceritrol | | organic molecular entity | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nifedipine | | C-nitro compound;
dihydropyridine;
methyl ester | calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent | 2004 | 2016 | 13.5 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| niflumic acid | | aromatic carboxylic acid;
pyridines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nilutamide | | (trifluoromethyl)benzenes;
C-nitro compound;
imidazolidinone | androgen antagonist;
antineoplastic agent | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| nilvadipine | | dihydropyridine;
isopropyl ester;
methyl ester;
nitrile | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nimesulide | | aromatic ether;
C-nitro compound;
sulfonamide | cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| nimodipine | | 2-methoxyethyl ester;
C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
isopropyl ester | antihypertensive agent;
calcium channel blocker;
cardiovascular drug;
vasodilator agent | 2004 | 2016 | 13.5 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| nisoldipine | | C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
methyl ester | | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| nitrazepam | | 1,4-benzodiazepinone;
C-nitro compound | anticonvulsant;
antispasmodic drug;
drug metabolite;
GABA modulator;
sedative | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| nitrendipine | | C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
ethyl ester;
methyl ester | antihypertensive agent;
calcium channel blocker;
geroprotector;
vasodilator agent | 2008 | 2013 | 13.2 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| nitroglycerin | | nitroglycerol | explosive;
muscle relaxant;
nitric oxide donor;
prodrug;
tocolytic agent;
vasodilator agent;
xenobiotic | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| nizatidine | | 1,3-thiazoles;
C-nitro compound;
carboxamidine;
organic sulfide;
tertiary amino compound | anti-ulcer drug;
cholinergic drug;
H2-receptor antagonist | 2004 | 2016 | 14.0 | medium | 0 | 0 | 0 | 2 | 1 | 0 |
| nomifensine | | isoquinolines | dopamine uptake inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| masoprocol | | catechols;
lignan;
tetrol | antioxidant;
ferroptosis inhibitor;
geroprotector;
plant metabolite | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| norfloxacin | | fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone | antibacterial drug;
DNA synthesis inhibitor;
environmental contaminant;
xenobiotic | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| nortriptyline | | organic tricyclic compound;
secondary amine | adrenergic uptake inhibitor;
analgesic;
antidepressant;
antineoplastic agent;
apoptosis inducer;
drug metabolite | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| nylidrin | | alkylbenzene | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ofloxacin | | 3-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline | | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| omeprazole | | aromatic ether;
benzimidazoles;
pyridines;
sulfoxide | | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| ondansetron | | carbazoles | | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| orphenadrine | | ether;
tertiary amino compound | antidyskinesia agent;
antiparkinson drug;
H1-receptor antagonist;
muscarinic antagonist;
muscle relaxant;
NMDA receptor antagonist;
parasympatholytic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| oxamniquine | | aromatic primary alcohol;
C-nitro compound;
quinolines;
secondary amino compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxaprozin | | 1,3-oxazoles;
monocarboxylic acid | analgesic;
non-steroidal anti-inflammatory drug | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| oxazepam | | 1,4-benzodiazepinone;
organochlorine compound | anxiolytic drug;
environmental contaminant;
xenobiotic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| oxethazaine | | amino acid amide | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxprenolol | | aromatic ether | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| oxybenzone | | hydroxybenzophenone;
monomethoxybenzene | dermatologic drug;
environmental contaminant;
protective agent;
ultraviolet filter;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxybutynin | | acetylenic compound;
carboxylic ester;
racemate;
tertiary alcohol;
tertiary amino compound | antispasmodic drug;
calcium channel blocker;
local anaesthetic;
muscarinic antagonist;
muscle relaxant;
parasympatholytic | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| oxyphenbutazone | | phenols;
pyrazolidines | antimicrobial agent;
antineoplastic agent;
antipyretic;
drug metabolite;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| aminosalicylic acid | | aminobenzoic acid;
phenols | antitubercular agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| pamidronate | | phosphonoacetic acid | | 2004 | 2016 | 13.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| pantoprazole | | aromatic ether;
benzimidazoles;
organofluorine compound;
pyridines;
sulfoxide | anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
environmental contaminant;
xenobiotic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| papaverine | | benzylisoquinoline alkaloid;
dimethoxybenzene;
isoquinolines | antispasmodic drug;
vasodilator agent | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| 4-dichlorobenzene | | dichlorobenzene | insecticide | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pemoline | | 1,3-oxazoles | central nervous system stimulant | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| pentamidine | | aromatic ether;
carboxamidine;
diether | anti-inflammatory agent;
antifungal agent;
calmodulin antagonist;
chemokine receptor 5 antagonist;
EC 2.3.1.48 (histone acetyltransferase) inhibitor;
NMDA receptor antagonist;
S100 calcium-binding protein B inhibitor;
trypanocidal drug;
xenobiotic | 2004 | 2016 | 13.6 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| pentobarbital | | barbiturates | GABAA receptor agonist | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| pentoxifylline | | oxopurine | | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| perazine | | N-alkylpiperazine;
N-methylpiperazine;
phenothiazines | dopaminergic antagonist;
phenothiazine antipsychotic drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| perhexiline | | piperidines | cardiovascular drug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| perphenazine | | N-(2-hydroxyethyl)piperazine;
N-alkylpiperazine;
organochlorine compound;
phenothiazines | antiemetic;
dopaminergic antagonist;
phenothiazine antipsychotic drug | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| phenacemide | | acetamides | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenacetin | | acetamides;
aromatic ether | cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug | 2008 | 2013 | 13.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| phenazopyridine | | diaminopyridine;
monoazo compound | anticoronaviral agent;
carcinogenic agent;
local anaesthetic;
non-narcotic analgesic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenobarbital | | barbiturates | anticonvulsant;
drug allergen;
excitatory amino acid antagonist;
sedative | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| phenolphthalein | | phenols | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenoxybenzamine | | aromatic amine | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| phentermine | | primary amine | adrenergic agent;
appetite depressant;
central nervous system drug;
central nervous system stimulant;
dopaminergic agent;
sympathomimetic agent | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| 4-phenylbutyric acid | | monocarboxylic acid | antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor;
prodrug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| phenylbutazone | | pyrazolidines | antirheumatic drug;
EC 1.1.1.184 [carbonyl reductase (NADPH)] inhibitor;
metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phthalylsulfathiazole | | 1,3-thiazoles;
dicarboxylic acid monoamide;
sulfonamide antibiotic;
sulfonamide | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| moxonidine | | organohalogen compound;
pyrimidines | | 2010 | 2011 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| pinacidil | | pyridines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pindolol | | indoles;
secondary amine | antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist;
serotonergic antagonist;
vasodilator agent | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| pioglitazone | | aromatic ether;
pyridines;
thiazolidinediones | antidepressant;
cardioprotective agent;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hypoglycemic agent;
insulin-sensitizing drug;
PPARgamma agonist;
xenobiotic | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| pipemidic acid | | amino acid;
monocarboxylic acid;
N-arylpiperazine;
pyridopyrimidine;
quinolone antibiotic | antibacterial drug;
DNA synthesis inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| piperazine | | azacycloalkane;
piperazines;
saturated organic heteromonocyclic parent | anthelminthic drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pipobroman | | N-acylpiperazine;
organobromine compound;
tertiary carboxamide | alkylating agent;
antineoplastic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| piracetam | | organonitrogen compound;
organooxygen compound | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pirbuterol | | pyridines | | 2004 | 2011 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| piribedil | | N-arylpiperazine | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| polythiazide | | benzothiadiazine | | 2008 | 2016 | 12.0 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| duodote | | pyridinium ion | antidote to organophosphate poisoning;
antidote to sarin poisoning;
cholinergic drug;
cholinesterase reactivator | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ono 1078 | | chromones | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pyranoprofen | | pyridochromene | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| prazepam | | benzodiazepine | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| praziquantel | | isoquinolines | | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| prazosin | | aromatic ether;
furans;
monocarboxylic acid amide;
piperazines;
quinazolines | alpha-adrenergic antagonist;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| prilocaine | | amino acid amide;
monocarboxylic acid amide | anticonvulsant;
local anaesthetic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| primaquine | | aminoquinoline;
aromatic ether;
N-substituted diamine | antimalarial | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| primidone | | pyrimidone | anticonvulsant;
environmental contaminant;
xenobiotic | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| probenecid | | benzoic acids;
sulfonamide | uricosuric drug | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| probucol | | dithioketal;
polyphenol | anti-inflammatory drug;
anticholesteremic drug;
antilipemic drug;
antioxidant;
cardiovascular drug | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| procainamide | | benzamides | anti-arrhythmia drug;
platelet aggregation inhibitor;
sodium channel blocker | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| procaine | | benzoate ester;
substituted aniline;
tertiary amino compound | central nervous system depressant;
drug allergen;
local anaesthetic;
peripheral nervous system drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| procarbazine | | benzamides;
hydrazines | antineoplastic agent | 2004 | 2016 | 14.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| prochlorperazine | | N-alkylpiperazine;
N-methylpiperazine;
organochlorine compound;
phenothiazines | alpha-adrenergic antagonist;
antiemetic;
cholinergic antagonist;
dopamine receptor D2 antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| procyclidine | | pyrrolidines;
tertiary alcohol | antidyskinesia agent;
antiparkinson drug;
muscarinic antagonist | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| promethazine | | phenothiazines;
tertiary amine | anti-allergic agent;
anticoronaviral agent;
antiemetic;
antipruritic drug;
H1-receptor antagonist;
local anaesthetic;
sedative | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| propafenone | | aromatic ketone;
secondary alcohol;
secondary amino compound | anti-arrhythmia drug | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| propantheline | | xanthenes | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| propofol | | phenols | anticonvulsant;
antiemetic;
intravenous anaesthetic;
radical scavenger;
sedative | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| propranolol | | naphthalenes;
propanolamine;
secondary amine | anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic | 2010 | 2016 | 11.5 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| protriptyline | | carbotricyclic compound | antidepressant | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pyridinolcarbamate | | pyridines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pyridostigmine | | pyridinium ion | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pyrimethamine | | aminopyrimidine;
monochlorobenzenes | antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| sch 16134 | | benzodiazepine | | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| quetiapine | | dibenzothiazepine;
N-alkylpiperazine;
N-arylpiperazine | adrenergic antagonist;
dopaminergic antagonist;
histamine antagonist;
second generation antipsychotic;
serotonergic antagonist | 2011 | 2016 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| rabeprazole | | benzimidazoles;
pyridines;
sulfoxide | anti-ulcer drug;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| raloxifene | | 1-benzothiophenes;
aromatic ketone;
N-oxyethylpiperidine;
phenols | bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ranitidine | | aralkylamine | | 2004 | 2013 | 14.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| opc 12759 | | secondary carboxamide | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| resorcinol | | benzenediol;
phenolic donor;
resorcinols | erythropoietin inhibitor;
sensitiser | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| riluzole | | benzothiazoles | | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| rimantadine | | alkylamine | | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| risperidone | | 1,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine | alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
psychotropic drug;
second generation antipsychotic;
serotonergic antagonist | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| rizatriptan | | tryptamines | anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| rofecoxib | | butenolide;
sulfone | analgesic;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| ropinirole | | indolones;
tertiary amine | antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
dopamine agonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| saccharin | | 1,2-benzisothiazole;
N-sulfonylcarboxamide | environmental contaminant;
sweetening agent;
xenobiotic | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| salicylamide | | phenols;
salicylamides | antirheumatic drug;
non-narcotic analgesic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| salmeterol xinafoate | | ether;
phenols;
primary alcohol;
secondary alcohol;
secondary amino compound | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| salicylsalicylic acid | | benzoate ester;
benzoic acids;
phenols;
salicylates | antineoplastic agent;
antirheumatic drug;
EC 3.5.2.6 (beta-lactamase) inhibitor;
hypoglycemic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| secobarbital | | barbiturates | anaesthesia adjuvant;
GABA modulator;
sedative | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| semustine | | N-nitrosoureas;
organochlorine compound | alkylating agent;
antineoplastic agent;
carcinogenic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sevoflurane | | ether;
organofluorine compound | central nervous system depressant;
inhalation anaesthetic;
platelet aggregation inhibitor | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| sibutramine | | organochlorine compound;
tertiary amino compound | anti-obesity agent;
serotonin uptake inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| sulfadiazine | | pyrimidines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide | antiinfective agent;
antimicrobial agent;
antiprotozoal drug;
coccidiostat;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
xenobiotic | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| risedronic acid | | pyridines | | 2011 | 2016 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| sotalol | | ethanolamines;
secondary alcohol;
secondary amino compound;
sulfonamide | anti-arrhythmia drug;
beta-adrenergic antagonist;
environmental contaminant;
xenobiotic | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| 4-phenylbutyric acid, sodium salt | | organic sodium salt | EC 3.5.1.98 (histone deacetylase) inhibitor;
geroprotector;
neuroprotective agent;
orphan drug;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| imatinib | | aromatic amine;
benzamides;
N-methylpiperazine;
pyridines;
pyrimidines | antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| streptonigrin | | pyridines;
quinolone | antimicrobial agent;
antineoplastic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| vorinostat | | dicarboxylic acid diamide;
hydroxamic acid | antineoplastic agent;
apoptosis inducer;
EC 3.5.1.98 (histone deacetylase) inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| succinylcholine | | quaternary ammonium ion;
succinate ester | drug allergen;
muscle relaxant;
neuromuscular agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| succinylsulfathiazole | | 1,3-thiazoles | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sulconazole | | dichlorobenzene;
imidazoles;
monochlorobenzenes;
organic sulfide | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulfacetamide | | N-sulfonylcarboxamide;
substituted aniline | antibacterial drug;
antiinfective agent;
antimicrobial agent;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulfadimethoxine | | aromatic ether;
pyrimidines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide | antiinfective agent;
antimicrobial agent;
drug allergen;
environmental contaminant;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulfaguanidine | | sulfonamide antibiotic | antiinfective agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulfamerazine | | pyrimidines;
sulfonamide antibiotic;
sulfonamide | antiinfective agent;
drug allergen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulfameter | | pyrimidines;
sulfonamide antibiotic;
sulfonamide | antiinfective agent;
leprostatic drug;
renal agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulfamethazine | | pyrimidines;
sulfonamide antibiotic;
sulfonamide | antibacterial drug;
antiinfective agent;
antimicrobial agent;
carcinogenic agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
ligand;
xenobiotic | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| sulfamethizole | | sulfonamide antibiotic;
sulfonamide;
thiadiazoles | antiinfective agent;
antimicrobial agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor | 2010 | 2016 | 11.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| sulfamethoxazole | | isoxazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide | antibacterial agent;
antiinfective agent;
antimicrobial agent;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
epitope;
P450 inhibitor;
xenobiotic | 2008 | 2013 | 13.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| sulfamethoxypyridazine | | pyridazines;
sulfonamide antibiotic;
sulfonamide | antiinfective agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulfanilamide | | substituted aniline;
sulfonamide antibiotic;
sulfonamide | antibacterial agent;
drug allergen;
EC 4.2.1.1 (carbonic anhydrase) inhibitor | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| sulfanitran | | sulfonamide | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sulfaphenazole | | primary amino compound;
pyrazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide | antibacterial drug;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 1.14.13.67 (quinine 3-monooxygenase) inhibitor;
P450 inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulfapyridine | | pyridines;
substituted aniline;
sulfonamide antibiotic;
sulfonamide | antiinfective agent;
dermatologic drug;
drug allergen;
environmental contaminant;
xenobiotic | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| sulfasalazine | | | | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| sulfathiazole | | 1,3-thiazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide | antiinfective agent;
drug allergen;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
xenobiotic | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| sulfinpyrazone | | pyrazolidines;
sulfoxide | uricosuric drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulfisoxazole | | isoxazoles;
sulfonamide antibiotic;
sulfonamide | antibacterial drug;
drug allergen | 2008 | 2013 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| sulfoxone | | sulfonamide | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-(octylamino)-1-[4-(propan-2-ylthio)phenyl]-1-propanol | | alkylbenzene | | 2010 | 2016 | 11.0 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| sulpiride | | benzamides;
N-alkylpyrrolidine;
sulfonamide | antidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist | 2010 | 2011 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| sultopride | | salicylamides | | 2011 | 2011 | 13.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| sumatriptan | | sulfonamide;
tryptamines | serotonergic agonist;
vasoconstrictor agent | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| suprofen | | aromatic ketone;
monocarboxylic acid;
thiophenes | antirheumatic drug;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| suramin | | naphthalenesulfonic acid;
phenylureas;
secondary carboxamide | angiogenesis inhibitor;
antinematodal drug;
antineoplastic agent;
apoptosis inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
GABA antagonist;
GABA-gated chloride channel antagonist;
purinergic receptor P2 antagonist;
ryanodine receptor agonist;
trypanocidal drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| gatifloxacin | | N-arylpiperazine;
organofluorine compound;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone | antiinfective agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| tazarotene | | acetylenic compound;
ethyl ester;
pyridines;
retinoid;
thiochromane | keratolytic drug;
prodrug;
teratogenic agent | 2004 | 2013 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| tegafur | | organohalogen compound;
pyrimidines | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| temazepam | | benzodiazepine | | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| temozolomide | | imidazotetrazine;
monocarboxylic acid amide;
triazene derivative | alkylating agent;
antineoplastic agent;
prodrug | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| terazosin | | furans;
piperazines;
primary amino compound;
quinazolines | alpha-adrenergic antagonist;
antihypertensive agent;
antineoplastic agent | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| terbutaline | | phenylethanolamines;
resorcinols | anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
hypoglycemic agent;
sympathomimetic agent;
tocolytic agent | 2008 | 2016 | 12.4 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| terfenadine | | diarylmethane | | 2004 | 2013 | 15.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| tetracaine | | benzoate ester;
tertiary amino compound | local anaesthetic | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| thalidomide | | phthalimides;
piperidones | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| thiabendazole | | 1,3-thiazoles;
benzimidazole fungicide;
benzimidazoles | antifungal agrochemical;
antinematodal drug | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| 2,2'-thiodiethanol | | aliphatic sulfide;
diol | antineoplastic agent;
antioxidant;
metabolite;
solvent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| thioridazine | | phenothiazines;
piperidines | alpha-adrenergic antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| thiotepa | | aziridines | | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| tiapride | | benzamides | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tiaprofenic acid | | aromatic ketone;
monocarboxylic acid;
thiophenes | drug allergen;
non-steroidal anti-inflammatory drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ticlopidine | | monochlorobenzenes;
thienopyridine | anticoagulant;
fibrin modulating drug;
hematologic agent;
P2Y12 receptor antagonist;
platelet aggregation inhibitor | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| tilorone | | aromatic ether;
diether;
fluoren-9-ones;
tertiary amino compound | anti-inflammatory agent;
antineoplastic agent;
antiviral agent;
interferon inducer;
nicotinic acetylcholine receptor agonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tinidazole | | imidazoles | antiamoebic agent;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| tinoridine | | thienopyridine | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tioconazole | | dichlorobenzene;
ether;
imidazoles;
thiophenes | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tiopronin | | N-acyl-amino acid | | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| tizanidine | | benzothiadiazole;
imidazoles | alpha-adrenergic agonist;
muscle relaxant | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| nikethamide | | pyridinecarboxamide | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tolazamide | | N-sulfonylurea | hypoglycemic agent;
potassium channel blocker | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| tolbutamide | | N-sulfonylurea | human metabolite;
hypoglycemic agent;
insulin secretagogue;
potassium channel blocker | 2008 | 2016 | 12.4 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| tolmetin | | aromatic ketone;
monocarboxylic acid;
pyrroles | EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug | 2011 | 2016 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| tolnaftate | | monothiocarbamic ester | antifungal drug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tolperisone | | aromatic ketone | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ultram | | aromatic ether;
tertiary alcohol;
tertiary amino compound | | 2004 | 2016 | 14.0 | medium | 0 | 0 | 0 | 2 | 1 | 0 |
| tranexamic acid | | amino acid | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| trapidil | | triazolopyrimidines | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| trazodone | | monochlorobenzenes;
N-alkylpiperazine;
N-arylpiperazine;
triazolopyridine | adrenergic antagonist;
antidepressant;
anxiolytic drug;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| triamterene | | pteridines | diuretic;
sodium channel blocker | 2008 | 2016 | 11.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| triazolam | | triazolobenzodiazepine | sedative | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| trichlormethiazide | | benzothiadiazine;
sulfonamide antibiotic | antihypertensive agent;
diuretic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2,2',2''-trichlorotriethylamine | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| triclosan | | aromatic ether;
dichlorobenzene;
monochlorobenzenes;
phenols | antibacterial agent;
antimalarial;
drug allergen;
EC 1.3.1.9 [enoyl-[acyl-carrier-protein] reductase (NADH)] inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
fungicide;
persistent organic pollutant;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trientine | | polyazaalkane;
tetramine | copper chelator | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trifluoperazine | | N-alkylpiperazine;
N-methylpiperazine;
organofluorine compound;
phenothiazines | antiemetic;
calmodulin antagonist;
dopaminergic antagonist;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor;
EC 5.3.3.5 (cholestenol Delta-isomerase) inhibitor;
phenothiazine antipsychotic drug | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| triflupromazine | | organofluorine compound;
phenothiazines;
tertiary amine | anticoronaviral agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trihexyphenidyl | | amine | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| trimethadione | | oxazolidinone | anticonvulsant;
geroprotector | 2004 | 2016 | 14.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| trimethobenzamide | | benzamides;
tertiary amino compound | antiemetic | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| trimethoprim | | aminopyrimidine;
methoxybenzenes | antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic | 2008 | 2016 | 12.4 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| trimetrexate | | | | 2004 | 2016 | 14.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| trimipramine | | dibenzoazepine;
tertiary amino compound | antidepressant;
environmental contaminant;
xenobiotic | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| troglitazone | | chromanes;
thiazolidinone | anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| thenoyltrifluoroacetone | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tyramine | | monoamine molecular messenger;
primary amino compound;
tyramines | EC 3.1.1.8 (cholinesterase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| delavirdine | | aminopyridine;
indolecarboxamide;
N-acylpiperazine;
sulfonamide | antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| undecylenic acid | | undecenoic acid | antifungal drug;
plant metabolite | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| urapidil | | piperazines | | 2011 | 2013 | 12.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| urethane | | carbamate ester | fungal metabolite;
mutagen | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| venlafaxine | | cyclohexanols;
monomethoxybenzene;
tertiary alcohol;
tertiary amino compound | adrenergic uptake inhibitor;
analgesic;
antidepressant;
dopamine uptake inhibitor;
environmental contaminant;
serotonin uptake inhibitor;
xenobiotic | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| vesamicol | | piperidines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| vesnarinone | | organic molecular entity | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| vigabatrin | | gamma-amino acid | anticonvulsant;
EC 2.6.1.19 (4-aminobutyrate--2-oxoglutarate transaminase) inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| pirinixic acid | | aryl sulfide;
organochlorine compound;
pyrimidines | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ici 204,219 | | carbamate ester;
indoles;
N-sulfonylcarboxamide | anti-asthmatic agent;
leukotriene antagonist | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| zaleplon | | nitrile;
pyrazolopyrimidine | anticonvulsant;
anxiolytic drug;
central nervous system depressant;
sedative | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| zolpidem | | imidazopyridine | central nervous system depressant;
GABA agonist;
sedative | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| zomepirac | | aromatic ketone;
monocarboxylic acid;
monochlorobenzenes;
pyrroles | cardiovascular drug;
non-steroidal anti-inflammatory drug | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| zonisamide | | 1,2-benzoxazoles;
sulfonamide | anticonvulsant;
antioxidant;
central nervous system drug;
protective agent;
T-type calcium channel blocker | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| zopiclone | | monochloropyridine;
pyrrolopyrazine | central nervous system depressant;
sedative | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| guanidine hydrochloride | | one-carbon compound;
organic chloride salt | protein denaturant | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| hydrocortisone acetate | | cortisol ester;
tertiary alpha-hydroxy ketone | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cortisone acetate | | corticosteroid hormone | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| mitomycin | | mitomycin | alkylating agent;
antineoplastic agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| prednisolone | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| estriol | | 16alpha-hydroxy steroid;
17beta-hydroxy steroid;
3-hydroxy steroid | estrogen;
human metabolite;
human xenobiotic metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| reserpine | | alkaloid ester;
methyl ester;
yohimban alkaloid | adrenergic uptake inhibitor;
antihypertensive agent;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
first generation antipsychotic;
plant metabolite;
xenobiotic | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| cephaloridine | | beta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative | antibacterial drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phentolamine | | imidazoles;
phenols;
substituted aniline;
tertiary amino compound | alpha-adrenergic antagonist;
vasodilator agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| sorbitol | | glucitol | cathartic;
Escherichia coli metabolite;
food humectant;
human metabolite;
laxative;
metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite;
sweetening agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| floxuridine | | nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside | antimetabolite;
antineoplastic agent;
antiviral drug;
radiosensitizing agent | 2004 | 2010 | 16.7 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| piperonyl butoxide | | benzodioxoles | pesticide synergist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| triethylenemelamine | | 1,3,5-triazines | alkylating agent;
insect sterilant | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bromouracil | | nucleobase analogue;
pyrimidines | mutagen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 3,3',5-triiodothyroacetic acid | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| histamine dihydrochloride | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| thyroxine | | 2-halophenol;
iodophenol;
L-phenylalanine derivative;
non-proteinogenic L-alpha-amino acid;
thyroxine zwitterion;
thyroxine | antithyroid drug;
human metabolite;
mouse metabolite;
thyroid hormone | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| dextroamphetamine | | 1-phenylpropan-2-amine | adrenergic agent;
adrenergic uptake inhibitor;
dopamine uptake inhibitor;
dopaminergic agent;
neurotoxin;
sympathomimetic agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| carbachol | | ammonium salt;
carbamate ester | cardiotonic drug;
miotic;
muscarinic agonist;
nicotinic acetylcholine receptor agonist;
non-narcotic analgesic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| norethindrone acetate | | 3-oxo-Delta(4) steroid;
acetate ester;
terminal acetylenic compound | progestin;
synthetic oral contraceptive | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| spironolactone | | 3-oxo-Delta(4) steroid;
oxaspiro compound;
steroid lactone;
thioester | aldosterone antagonist;
antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| cyclobarbital | | barbiturates | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| allobarbital | | barbiturates | | 2008 | 2010 | 15.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| penicillamine | | non-proteinogenic alpha-amino acid;
penicillamine | antirheumatic drug;
chelator;
copper chelator;
drug allergen | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| trichlorfon | | organic phosphonate;
organochlorine compound;
phosphonic ester | agrochemical;
anthelminthic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
insecticide | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cysteine | | cysteine zwitterion;
cysteine;
L-alpha-amino acid;
proteinogenic amino acid;
serine family amino acid | EC 4.3.1.3 (histidine ammonia-lyase) inhibitor;
flour treatment agent;
human metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| prednisone | | 11-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| estrone | | 17-oxo steroid;
3-hydroxy steroid;
phenolic steroid;
phenols | antineoplastic agent;
bone density conservation agent;
estrogen;
human metabolite;
mouse metabolite | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| paramethasone | | fluorinated steroid | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxandrolone | | 17beta-hydroxy steroid;
3-oxo steroid;
anabolic androgenic steroid;
oxa-steroid | anabolic agent;
androgen | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| dehydroepiandrosterone | | 17-oxo steroid;
3beta-hydroxy-Delta(5)-steroid;
androstanoid | androgen;
human metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nad | | NAD | geroprotector | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| azauridine | | N-glycosyl-1,2,4-triazine | antimetabolite;
antineoplastic agent;
drug metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| penicillin g | | penicillin allergen;
penicillin | antibacterial drug;
drug allergen;
epitope | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| idoxuridine | | organoiodine compound;
pyrimidine 2'-deoxyribonucleoside | antiviral drug;
DNA synthesis inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pilocarpine | | pilocarpine | antiglaucoma drug | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| triiodothyronine | | 2-halophenol;
amino acid zwitterion;
iodophenol;
iodothyronine | human metabolite;
mouse metabolite;
thyroid hormone | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| carbon tetrachloride | | chlorocarbon;
chloromethanes | hepatotoxic agent;
refrigerant | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| chloramphenicol | | C-nitro compound;
carboxamide;
diol;
organochlorine compound | antibacterial drug;
antimicrobial agent;
Escherichia coli metabolite;
geroprotector;
Mycoplasma genitalium metabolite;
protein synthesis inhibitor | 2008 | 2016 | 12.4 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| glutamine | | amino acid zwitterion;
glutamine family amino acid;
glutamine;
L-alpha-amino acid;
polar amino acid zwitterion;
proteinogenic amino acid | EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cetrimonium bromide | | organic bromide salt;
quaternary ammonium salt | detergent;
surfactant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| vincristine | | acetate ester;
formamides;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid | antineoplastic agent;
drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator | 2004 | 2016 | 14.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| physostigmine | | carbamate ester;
indole alkaloid | antidote to curare poisoning;
EC 3.1.1.8 (cholinesterase) inhibitor;
miotic | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| sucrose | | glycosyl glycoside | algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ethinyl estradiol | | 17-hydroxy steroid;
3-hydroxy steroid;
terminal acetylenic compound | xenoestrogen | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| testosterone propionate | | steroid ester | | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| tubocurarine | | bisbenzylisoquinoline alkaloid | drug allergen;
muscle relaxant;
nicotinic antagonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| apomorphine | | aporphine alkaloid | alpha-adrenergic drug;
antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
emetic;
serotonergic drug | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| aminopyrine | | pyrazolone;
tertiary amino compound | antipyretic;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic | 2010 | 2011 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| methyltestosterone | | 17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
enone | anabolic agent;
androgen;
antineoplastic agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| dromostanolone | | 17beta-hydroxy steroid;
3-oxo-5alpha-steroid;
anabolic androgenic steroid | anabolic agent;
antineoplastic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tetrabenazine | | benzoquinolizine;
cyclic ketone;
tertiary amino compound | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cephalothin | | azabicycloalkene;
beta-lactam antibiotic allergen;
carboxylic acid;
cephalosporin;
semisynthetic derivative;
thiophenes | antibacterial drug;
antimicrobial agent | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| uridine | | uridines | drug metabolite;
fundamental metabolite;
human metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| kanamycin a | | kanamycins | bacterial metabolite | 2010 | 2016 | 11.5 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| bromodeoxyuridine | | pyrimidine 2'-deoxyribonucleoside | antimetabolite;
antineoplastic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenylephrine | | phenols;
phenylethanolamines;
secondary amino compound | alpha-adrenergic agonist;
cardiotonic drug;
mydriatic agent;
nasal decongestant;
protective agent;
sympathomimetic agent;
vasoconstrictor agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| thiamine | | organic chloride salt;
vitamin B1 | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| levodopa | | amino acid zwitterion;
dopa;
L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid | allelochemical;
antidyskinesia agent;
antiparkinson drug;
dopaminergic agent;
hapten;
human metabolite;
mouse metabolite;
neurotoxin;
plant growth retardant;
plant metabolite;
prodrug | 2008 | 2013 | 13.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| edetic acid | | ethylenediamine derivative;
polyamino carboxylic acid;
tetracarboxylic acid | anticoagulant;
antidote;
chelator;
copper chelator;
geroprotector | 2011 | 2016 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| cysteamine | | amine;
thiol | geroprotector;
human metabolite;
mouse metabolite;
radiation protective agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| acetylcholine chloride | | quaternary ammonium salt | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mepazine | | phenothiazines | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| adenosine monophosphate | | adenosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate | adenosine A1 receptor agonist;
cofactor;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
EC 3.1.3.11 (fructose-bisphosphatase) inhibitor;
fundamental metabolite;
micronutrient;
nutraceutical | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methicillin | | penicillin allergen;
penicillin | antibacterial drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| niridazole | | 1,3-thiazoles;
C-nitro compound | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| cloxacillin | | penicillin allergen;
penicillin;
semisynthetic derivative | antibacterial agent;
antibacterial drug | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| bretylium tosylate | | organosulfonate salt;
quaternary ammonium salt | adrenergic antagonist;
anti-arrhythmia drug;
antihypertensive agent | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| zoxazolamine | | benzoxazole | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| aniline | | anilines;
primary arylamine | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| calcium acetate | | calcium salt | chelator | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| carbaryl | | carbamate ester;
naphthalenes | acaricide;
agrochemical;
carbamate insecticide;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant growth retardant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lactose | | lactose | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methionine | | aspartate family amino acid;
L-alpha-amino acid;
methionine zwitterion;
methionine;
proteinogenic amino acid | antidote to paracetamol poisoning;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Mebutamate | | organic molecular entity | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| colchicine | | alkaloid;
colchicine | anti-inflammatory agent;
gout suppressant;
mutagen | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| mebanazine | | benzenes | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| uracil mustard | | aminouracil;
nitrogen mustard | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxacillin | | penicillin | antibacterial agent;
antibacterial drug | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cycloheximide | | antibiotic fungicide;
cyclic ketone;
dicarboximide;
piperidine antibiotic;
piperidones;
secondary alcohol | anticoronaviral agent;
bacterial metabolite;
ferroptosis inhibitor;
neuroprotective agent;
protein synthesis inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fluocinolone acetonide | | 11beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic ketal;
fluorinated steroid;
glucocorticoid;
organic heteropentacyclic compound;
primary alpha-hydroxy ketone | anti-inflammatory drug;
antipruritic drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| triamcinolone diacetate | | corticosteroid hormone | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| norethindrone | | 17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound;
tertiary alcohol | progestin;
synthetic oral contraceptive | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| norethynodrel | | oxo steroid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cycloserine | | 4-amino-1,2-oxazolidin-3-one;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic;
zwitterion | antiinfective agent;
antimetabolite;
antitubercular agent;
metabolite;
NMDA receptor agonist | 2011 | 2016 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| triaziquone | | 1,4-benzoquinones;
aziridines | alkylating agent;
antineoplastic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| benziodarone | | aromatic ketone | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| ampicillin | | beta-lactam antibiotic;
penicillin allergen;
penicillin | antibacterial drug | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| mannitol | | mannitol | allergen;
antiglaucoma drug;
compatible osmolytes;
Escherichia coli metabolite;
food anticaking agent;
food bulking agent;
food humectant;
food stabiliser;
food thickening agent;
hapten;
metabolite;
osmotic diuretic;
sweetening agent | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| cytarabine | | beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside | antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| trifluridine | | nucleoside analogue;
organofluorine compound;
pyrimidine 2'-deoxyribonucleoside | antimetabolite;
antineoplastic agent;
antiviral drug;
EC 2.1.1.45 (thymidylate synthase) inhibitor | 2004 | 2008 | 18.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| medroxyprogesterone acetate | | 20-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
corticosteroid;
steroid ester | adjuvant;
androgen;
antineoplastic agent;
antioxidant;
female contraceptive drug;
inhibitor;
progestin;
synthetic oral contraceptive | 2004 | 2013 | 15.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| sulfobromophthalein sodium | | organic sodium salt | dye | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mestranol | | 17beta-hydroxy steroid;
aromatic ether;
terminal acetylenic compound | prodrug;
xenoestrogen | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| methaqualone | | quinazolines | GABA agonist;
sedative | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trypan blue | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| cordycepin | | 3'-deoxyribonucleoside;
adenosines | antimetabolite;
nucleoside antibiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tryptophan | | erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
tryptophan zwitterion;
tryptophan | antidepressant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| arginine | | arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid | biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| dalapon | | carboxylic acid;
organohalogen compound | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trichloroacetic acid | | monocarboxylic acid;
organochlorine compound | carcinogenic agent;
metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| perflutren | | fluoroalkane;
fluorocarbon | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| triamcinolone acetonide | | 11beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
cyclic ketal;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone | anti-allergic agent;
anti-inflammatory drug | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| fluoxymesterone | | 11beta-hydroxy steroid;
17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
anabolic androgenic steroid;
fluorinated steroid | anabolic agent;
antineoplastic agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| allylpropymal | | barbiturates | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ethoheptazine | | azepanes | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| butobarbital | | barbiturates | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methsuximide | | organic molecular entity | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methylpentynol | | ynone | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tromethamine | | primary amino compound;
triol | buffer | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| trichloroethylene | | chloroethenes | inhalation anaesthetic;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dehydrocholic acid | | 12-oxo steroid;
3-oxo-5beta-steroid;
7-oxo steroid;
oxo-5beta-cholanic acid | gastrointestinal drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methylprednisolone | | 6-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| rotenone | | organic heteropentacyclic compound;
rotenones | antineoplastic agent;
metabolite;
mitochondrial NADH:ubiquinone reductase inhibitor;
phytogenic insecticide;
piscicide;
toxin | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| brompheniramine | | organobromine compound;
pyridines | anti-allergic agent;
H1-receptor antagonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| penicillin v | | penicillin allergen;
penicillin | | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| isosorbide dinitrate | | glucitol derivative;
nitrate ester | nitric oxide donor;
vasodilator agent | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| pseudoephedrine | | phenylethanolamines;
secondary alcohol;
secondary amino compound | anti-asthmatic drug;
bronchodilator agent;
central nervous system drug;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| diethylpropion | | aromatic ketone;
tertiary amine | appetite depressant | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fenoprop | | monocarboxylic acid | phenoxy herbicide | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| synephrine | | ethanolamines;
phenethylamine alkaloid;
phenols | alpha-adrenergic agonist;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| benzoyl peroxide | | carbonyl compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-methyl-4-chlorophenoxyacetic acid | | chlorophenoxyacetic acid;
monochlorobenzenes | environmental contaminant;
phenoxy herbicide;
synthetic auxin | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dicloran | | aromatic fungicide;
dichlorobenzene;
nitroaniline | antifungal agrochemical | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenylhydrazine | | phenylhydrazines | xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dyrene | | monochlorobenzenes;
organochlorine pesticide;
secondary amino compound;
triazines | antifungal agrochemical | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| benzonatate | | benzoate ester;
secondary amino compound;
substituted aniline | anaesthetic;
antitussive | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| acrolein | | enal | herbicide;
human xenobiotic metabolite;
toxin | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| furan | | furans;
mancude organic heteromonocyclic parent;
monocyclic heteroarene | carcinogenic agent;
hepatotoxic agent;
Maillard reaction product | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tetraethylenepentamine | | polyazaalkane | copper chelator | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ergotamine | | peptide ergot alkaloid | alpha-adrenergic agonist;
mycotoxin;
non-narcotic analgesic;
oxytocic;
serotonergic agonist;
vasoconstrictor agent | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| estradiol dipropionate | | steroid ester | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methylergonovine | | ergoline alkaloid | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| neostigmine bromide | | bromide salt | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenformin | | biguanides | antineoplastic agent;
geroprotector;
hypoglycemic agent | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| mephobarbital | | barbiturates | anticonvulsant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hexachlorobenzene | | aromatic fungicide;
chlorobenzenes | antifungal agrochemical;
carcinogenic agent;
persistent organic pollutant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chloranil | | 1,4-benzoquinones;
organochlorine compound | EC 2.7.1.33 (pantothenate kinase) inhibitor;
metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trinitrotoluene | | trinitrotoluene | explosive | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| framycetin | | aminoglycoside | allergen;
antibacterial drug;
Escherichia coli metabolite | 2010 | 2011 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| efloxate | | organic molecular entity | | 2012 | 2012 | 12.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| pyrazolanthrone | | anthrapyrazole;
aromatic ketone;
cyclic ketone | antineoplastic agent;
c-Jun N-terminal kinase inhibitor;
geroprotector | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| meglumine | | hexosamine;
secondary amino compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cinchophen | | quinolines | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| amiben | | chlorobenzoic acid | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| monuron | | 3-(3,4-substituted-phenyl)-1,1-dimethylurea;
monochlorobenzenes | environmental contaminant;
herbicide;
xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| iminodiacetic acid | | amino dicarboxylic acid;
glycine derivative;
non-proteinogenic alpha-amino acid | chelator | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| yohimbine | | methyl 17-hydroxy-20xi-yohimban-16-carboxylate | alpha-adrenergic antagonist;
dopamine receptor D2 antagonist;
serotonergic antagonist | 2010 | 2012 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| nafcillin | | penicillin allergen;
penicillin | antibacterial drug | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| mequinol | | methoxybenzenes;
phenols | metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methohexital | | acetylenic compound;
barbiturates | drug allergen;
intravenous anaesthetic | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| quinestrol | | 17-hydroxy steroid;
terminal acetylenic compound | xenoestrogen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dydrogesterone | | 20-oxo steroid;
3-oxo-Delta(4) steroid | progestin | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenetidine | | aromatic ether;
primary amino compound;
substituted aniline | drug metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diazooxonorleucine | | amino acid zwitterion;
diazo compound;
ketone;
non-proteinogenic L-alpha-amino acid | analgesic;
antibacterial agent;
antimetabolite;
antineoplastic agent;
antiviral agent;
apoptosis inducer;
bacterial metabolite;
EC 2.4.2.14 (amidophosphoribosyltransferase) inhibitor;
EC 3.5.1.2 (glutaminase) inhibitor;
EC 6.3.4.2 [CTP synthase (glutamine hydrolyzing)] inhibitor;
EC 6.3.5.1 [NAD(+) synthase (glutamine-hydrolysing)] inhibitor;
EC 6.3.5.2 [GMP synthase (glutamine-hydrolysing)] inhibitor;
EC 6.3.5.3 (phosphoribosylformylglycinamidine synthase) inhibitor;
EC 6.3.5.4 [asparagine synthase (glutamine-hydrolysing)] inhibitor;
EC 6.3.5.5 [carbamoyl-phosphate synthase (glutamine-hydrolysing)] inhibitor;
glutamine antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ephedrine | | phenethylamine alkaloid;
phenylethanolamines | bacterial metabolite;
environmental contaminant;
nasal decongestant;
plant metabolite;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| chlormadinone acetate | | corticosteroid hormone | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methylpentynol carbamate | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mechlorethamine n-oxide | | nitrogen mustard | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| 2,3-dimercaptosuccinic acid | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| estradiol 17 beta-cypionate | | steroid ester | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| evans blue | | organic sodium salt | fluorochrome;
histological dye;
sodium channel blocker;
teratogenic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| testosterone enanthate | | heptanoate ester;
sterol ester | androgen | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| aminophylline | | mixture | bronchodilator agent;
cardiotonic drug | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| azacitidine | | N-glycosyl-1,3,5-triazine;
nucleoside analogue | antineoplastic agent | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| phenyramidol | | aminopyridine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| linuron | | dichlorobenzene;
phenylureas | agrochemical;
environmental contaminant;
herbicide;
xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| carbutamide | | benzenes;
sulfonamide | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| galantamine | | benzazepine alkaloid fundamental parent;
benzazepine alkaloid;
organic heterotetracyclic compound;
tertiary amino compound | antidote to curare poisoning;
cholinergic drug;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
EC 3.1.1.8 (cholinesterase) inhibitor;
plant metabolite | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| nandrolone decanoate | | steroid ester | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| bucladesine | | 3',5'-cyclic purine nucleotide;
butanamides;
butyrate ester | agonist;
cardiotonic drug;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| procarbazine hydrochloride | | hydrochloride | antineoplastic agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| betamethasone | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | anti-asthmatic agent;
anti-inflammatory drug;
immunosuppressive agent | 2004 | 2013 | 15.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| perflubron | | haloalkane;
organobromine compound;
perfluorinated compound | blood substitute;
radioopaque medium | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cyproterone acetate | | 20-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
chlorinated steroid;
steroid ester | androgen antagonist;
geroprotector;
progestin | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hydantoins | | imidazolidine-2,4-dione | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dextropropoxyphene | | 1-benzyl-3-(dimethylamino)-2-methyl-1-phenylpropyl propanoate | mu-opioid receptor agonist;
opioid analgesic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| glycyrrhetinic acid | | cyclic terpene ketone;
hydroxy monocarboxylic acid;
pentacyclic triterpenoid | immunomodulator;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chenodeoxycholic acid | | bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid | human metabolite;
mouse metabolite | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| plumbagin | | hydroxy-1,4-naphthoquinone;
phenols | anticoagulant;
antineoplastic agent;
immunological adjuvant;
metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| emetine | | isoquinoline alkaloid;
pyridoisoquinoline | antiamoebic agent;
anticoronaviral agent;
antiinfective agent;
antimalarial;
antineoplastic agent;
antiprotozoal drug;
antiviral agent;
autophagy inhibitor;
emetic;
expectorant;
plant metabolite;
protein synthesis inhibitor | 2008 | 2013 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| dihydralazine | | phthalazines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pamaquine | | aminoquinoline | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenylpropanolamine | | amphetamines;
phenethylamine alkaloid | plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 4-hydroxybutyric acid | | 4-hydroxy monocarboxylic acid;
hydroxybutyric acid | general anaesthetic;
GHB receptor agonist;
neurotoxin;
sedative | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mustard gas | | ethyl sulfide;
organochlorine compound | alkylating agent;
carcinogenic agent;
vesicant | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dihydroergotamine | | ergot alkaloid;
semisynthetic derivative | dopamine agonist;
non-narcotic analgesic;
serotonergic agonist;
sympatholytic agent;
vasoconstrictor agent | 2010 | 2016 | 11.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| podophyllotoxin | | furonaphthodioxole;
lignan;
organic heterotetracyclic compound | antimitotic;
antineoplastic agent;
keratolytic drug;
microtubule-destabilising agent;
plant metabolite;
tubulin modulator | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| hesperidin | | 3'-hydroxyflavanones;
4'-methoxyflavanones;
dihydroxyflavanone;
disaccharide derivative;
flavanone glycoside;
monomethoxyflavanone;
rutinoside | mutagen | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| medroxyprogesterone | | 17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone | contraceptive drug;
progestin;
synthetic oral contraceptive | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| dimenhydrinate | | diarylmethane | | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| apronalide | | N-acylurea | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chlormethiazole | | thiazoles | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 4,6-dinitro-o-cresol | | dinitrophenol acaricide;
hydroxytoluene;
nitrotoluene | dinitrophenol insecticide;
fungicide;
herbicide | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methamphetamine | | amphetamines;
secondary amine | central nervous system stimulant;
environmental contaminant;
neurotoxin;
psychotropic drug;
xenobiotic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| levocarnitine | | carnitine | antilipemic drug;
nootropic agent;
nutraceutical;
Saccharomyces cerevisiae metabolite;
water-soluble vitamin (role) | 2004 | 2016 | 14.0 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| sulfanilylurea | | benzenes;
sulfonamide | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| gentian violet | | organic chloride salt | anthelminthic drug;
antibacterial agent;
antifungal agent;
antiseptic drug;
histological dye | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 1-naphthylisothiocyanate | | isothiocyanate | insecticide | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| hematoporphyrin | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| metahexamide | | benzenes;
sulfonamide | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lactulose | | glycosylfructose | gastrointestinal drug;
laxative | 2010 | 2016 | 11.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| megestrol acetate | | 20-oxo steroid;
3-oxo-Delta(4) steroid;
acetate ester;
steroid ester | antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive | 2004 | 2013 | 15.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| pamabrom | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| toyocamycin | | antibiotic antifungal agent;
N-glycosylpyrrolopyrimidine;
nitrile;
ribonucleoside | antimetabolite;
antineoplastic agent;
apoptosis inducer;
bacterial metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| acetylcysteine | | acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid | antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| benzydamine | | aromatic ether;
indazoles;
tertiary amino compound | analgesic;
central nervous system stimulant;
hallucinogen;
local anaesthetic;
non-steroidal anti-inflammatory drug | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| erythromycin stearate | | aminoglycoside | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| erythromycin | | cyclic ketone;
erythromycin | | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| chromonar | | coumarins | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| hadacidin | | aldehyde;
monocarboxylic acid;
N-hydroxy-alpha-amino-acid | antimicrobial agent;
antineoplastic agent;
Penicillium metabolite;
teratogenic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hydroxychloroquine sulfate | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| carbophenothion | | organic sulfide | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| levonorgestrel | | 17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound | contraceptive drug;
female contraceptive drug;
progestin;
synthetic oral contraceptive | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| porfiromycin | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| vinblastine | | | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| diphenoxylate | | ethyl ester;
nitrile;
piperidinecarboxylate ester;
tertiary amine | antidiarrhoeal drug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| deoxyuridine | | pyrimidine 2'-deoxyribonucleoside | Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| testolactone | | 3-oxo-Delta(1),Delta(4)-steroid;
seco-androstane | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| estradiol valerate | | steroid ester | | 2004 | 2010 | 17.0 | medium | 0 | 0 | 0 | 2 | 0 | 0 |
| ethambutol hydrochloride | | hydrochloride | antitubercular agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ethambutol | | ethanolamines;
ethylenediamine derivative | antitubercular agent;
environmental contaminant;
xenobiotic | 2004 | 2016 | 14.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| pyrithioxin | | methylpyridines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| antimycin a | | benzamides;
formamides;
macrodiolide;
phenols | antifungal agent;
mitochondrial respiratory-chain inhibitor;
piscicide | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| vancomycin | | glycopeptide | antibacterial drug;
antimicrobial agent;
bacterial metabolite | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| nsc 65346 | | nucleoside analogue | protein kinase inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| d-alpha tocopherol | | alpha-tocopherol | algal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| pregnenolone carbonitrile | | aliphatic nitrile | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| guanazole | | aromatic amine;
triazoles | antineoplastic agent;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ibufenac | | monocarboxylic acid | EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
hepatotoxic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| vincamine | | alkaloid ester;
hemiaminal;
methyl ester;
organic heteropentacyclic compound;
vinca alkaloid | antihypertensive agent;
metabolite;
vasodilator agent | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| metylperon | | aromatic ketone | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| meturedepa | | phosphoramide | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| metaxalone | | aromatic ether | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ioxynil | | iodophenol;
nitrile | environmental contaminant;
herbicide;
xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bromoxynil | | dibromobenzene;
hydroxynitrile;
phenols | environmental contaminant;
herbicide;
xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| spectinomycin | | cyclic acetal;
cyclic hemiketal;
cyclic ketone;
pyranobenzodioxin;
secondary alcohol;
secondary amino compound | antibacterial drug;
antimicrobial agent;
bacterial metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| picloram | | aminopyridine;
chloropyridine;
organochlorine pesticide;
pyridinemonocarboxylic acid | herbicide;
synthetic auxin | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ethoglucid | | epoxide | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dronabinol | | benzochromene;
diterpenoid;
phytocannabinoid;
polyketide | cannabinoid receptor agonist;
epitope;
hallucinogen;
metabolite;
non-narcotic analgesic | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| amiloride | | aromatic amine;
guanidines;
organochlorine compound;
pyrazines | diuretic;
sodium channel blocker | 2010 | 2016 | 11.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| pimozide | | benzimidazoles;
heteroarylpiperidine;
organofluorine compound | antidyskinesia agent;
dopaminergic antagonist;
first generation antipsychotic;
H1-receptor antagonist;
serotonergic antagonist | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| betamethasone valerate | | 11beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
primary alpha-hydroxy ketone;
steroid ester | anti-inflammatory drug | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| guanoxan | | benzodioxine | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| azaribine | | acetate ester;
N-glycosyl-1,2,4-triazine | antipsoriatic;
prodrug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methylprednisolone hemisuccinate | | corticosteroid hormone;
hemisuccinate | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dexbrompheniramine | | brompheniramine | anti-allergic agent;
H1-receptor antagonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sulfadoxine | | pyrimidines;
sulfonamide | antibacterial drug;
antimalarial | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 1,3,5-triglycidyl-s-triazinetrione | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| acadesine | | 1-ribosylimidazolecarboxamide;
aminoimidazole;
nucleoside analogue | antineoplastic agent;
platelet aggregation inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| acetophenazine | | N-(2-hydroxyethyl)piperazine;
N-alkylpiperazine;
phenothiazines | phenothiazine antipsychotic drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| stavudine | | dihydrofuran;
nucleoside analogue;
organic molecular entity | antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| doxifluridine | | organofluorine compound;
pyrimidine 5'-deoxyribonucleoside | antimetabolite;
antineoplastic agent;
prodrug | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| dicloxacillin | | dichlorobenzene;
penicillin | antibacterial drug | 2008 | 2016 | 11.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| improsan | | organosulfonic ester | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cyclacillin | | penicillin | antibacterial drug | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| iproclozide | | aromatic ether | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| megestrol | | 17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(4) steroid;
tertiary alpha-hydroxy ketone | antineoplastic agent;
appetite enhancer;
contraceptive drug;
progestin;
synthetic oral contraceptive | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tranylcypromine | | 2-phenylcyclopropan-1-amine | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| streptomycin | | antibiotic antifungal drug;
antibiotic fungicide;
streptomycins | antibacterial drug;
antifungal agrochemical;
antimicrobial agent;
antimicrobial drug;
bacterial metabolite;
protein synthesis inhibitor | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| piperacetazine | | phenothiazines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cladribine | | organochlorine compound;
purine 2'-deoxyribonucleoside | antineoplastic agent;
immunosuppressive agent | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| beclomethasone | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
corticosteroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | anti-asthmatic drug;
anti-inflammatory drug | 2004 | 2008 | 18.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| carbenicillin | | penicillin allergen;
penicillin | antibacterial drug | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| carbenicillin disodium | | organic sodium salt | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dehydroemetine | | aromatic ether;
isoquinolines;
pyridoisoquinoline | antileishmanial agent;
antimalarial;
antiprotozoal drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| estradiol enanthate | | steroid ester | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| benorilate | | carbonyl compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trimetazidine | | aromatic amine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| metocurine | | isoquinolines | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| floxacillin | | penicillin allergen;
penicillin | antibacterial drug | 2008 | 2011 | 14.3 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| clomacran | | acridines | | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| pentaquine | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| vidarabine | | beta-D-arabinoside;
purine nucleoside | antineoplastic agent;
bacterial metabolite;
nucleoside antibiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| betamethasone-17,21-dipropionate | | 11beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
fluorinated steroid;
propanoate ester;
steroid ester | antipsoriatic | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methenamine hippurate | | N-acylglycine | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| olsalazine | | azobenzenes;
dicarboxylic acid | non-steroidal anti-inflammatory drug;
prodrug | 2004 | 2016 | 13.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| tiadenol | | aliphatic sulfide | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| etidronate disodium | | organic sodium salt | antineoplastic agent;
bone density conservation agent;
chelator | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| zalcitabine | | pyrimidine 2',3'-dideoxyribonucleoside | antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2004 | 2013 | 14.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| camptothecin | | delta-lactone;
pyranoindolizinoquinoline;
quinoline alkaloid;
tertiary alcohol | antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
genotoxin;
plant metabolite | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| isopentenyladenosine | | N-ribosyl-N(6)-isopentenyladenine;
nucleoside analogue | antineoplastic agent;
plant growth regulator;
plant metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sodium thiosulfate | | inorganic sodium salt | antidote to cyanide poisoning;
antifungal drug;
nephroprotective agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ancitabine | | diol;
organic heterotricyclic compound | antimetabolite;
antineoplastic agent;
prodrug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| stanozolol | | 17beta-hydroxy steroid;
anabolic androgenic steroid;
organic heteropentacyclic compound;
tertiary alcohol | anabolic agent;
androgen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phenacid | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clodronic acid | | 1,1-bis(phosphonic acid);
one-carbon compound;
organochlorine compound | antineoplastic agent;
bone density conservation agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mafenide acetate | | carboxylic acid | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| reproterol | | oxopurine | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| diacerein | | anthraquinone | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| xipamide | | benzamides | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| selegiline | | selegiline;
terminal acetylenic compound | geroprotector | 2004 | 2016 | 14.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| selegiline hydrochloride, (r)-isomer | | hydrochloride;
terminal acetylenic compound | antiparkinson drug;
dopaminergic agent;
EC 1.4.3.4 (monoamine oxidase) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| levamisole | | 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b][1,3]thiazole | antinematodal drug;
antirheumatic drug;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
immunological adjuvant;
immunomodulator | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| clemastine | | monochlorobenzenes;
N-alkylpyrrolidine | anti-allergic agent;
antipruritic drug;
H1-receptor antagonist;
muscarinic antagonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thiamphenicol | | monocarboxylic acid amide;
sulfone | antimicrobial agent;
immunosuppressive agent | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| pancuronium bromide | | bromide salt | cholinergic antagonist;
muscle relaxant;
nicotinic antagonist | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| pizotyline | | benzocycloheptathiophene | histamine antagonist;
muscarinic antagonist;
serotonergic antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cephalexin | | beta-lactam antibiotic allergen;
cephalosporin;
semisynthetic derivative | antibacterial drug | 2004 | 2016 | 14.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| isosorbide-5-mononitrate | | glucitol derivative;
nitrate ester | nitric oxide donor;
vasodilator agent | 2004 | 2010 | 16.7 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| pentamethylmelamine | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ornidazole | | C-nitro compound;
imidazoles;
organochlorine compound;
secondary alcohol | antiamoebic agent;
antibacterial drug;
antiinfective agent;
antiprotozoal drug;
antitrichomonal drug;
epitope | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| calusterone | | 3-hydroxy steroid | androgen | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| danazol | | 17beta-hydroxy steroid;
terminal acetylenic compound | anti-estrogen;
estrogen antagonist;
geroprotector | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| fenclozic acid | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lisuride | | monocarboxylic acid amide | antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
serotonergic agonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| etoprine | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| laxagetten 4,4'-diacetoxydiphenylpyridylemethane | | | | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| daunorubicin | | aminoglycoside antibiotic;
anthracycline;
p-quinones;
tetracenequinones | antineoplastic agent;
bacterial metabolite | 2004 | 2016 | 14.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| razoxane | | N-alkylpiperazine | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cephapirin | | cephalosporin | antibacterial drug | 2004 | 2008 | 18.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| fludarabine phosphate | | nucleoside analogue;
organofluorine compound;
purine arabinonucleoside monophosphate | antimetabolite;
antineoplastic agent;
antiviral agent;
DNA synthesis inhibitor;
immunosuppressive agent;
prodrug | 2008 | 2016 | 11.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| alclofenac | | aromatic ether;
monocarboxylic acid;
monochlorobenzenes | drug allergen;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| carbimazole | | 1,3-dihydroimidazole-2-thiones;
carbamate ester | antithyroid drug;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bromocriptine | | indole alkaloid | antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
hormone antagonist | 2004 | 2016 | 14.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| triamcinolone | | 11beta-hydroxy steroid;
16alpha-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
fluorinated steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | anti-allergic agent;
anti-inflammatory drug | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| oxyphenisatin | | indoles | | 2010 | 2016 | 11.0 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| azetepa | | phosphoramide | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| tetrachloroethylene | | chlorocarbon;
chloroethenes | nephrotoxic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fludrocortisone | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
fluorinated steroid;
mineralocorticoid | adrenergic agent;
anti-inflammatory drug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ursodeoxycholic acid | | bile acid;
C24-steroid;
dihydroxy-5beta-cholanic acid | human metabolite;
mouse metabolite | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| metipranolol | | acetate ester;
aromatic ether;
propanolamine;
secondary amino compound | anti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| benzonidazole | | C-nitro compound;
imidazoles;
monocarboxylic acid amide | antiprotozoal drug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| halazepam | | organic molecular entity | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| butachlor | | aromatic amide;
organochlorine compound;
tertiary carboxamide | environmental contaminant;
herbicide;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| du-21220 | | benzyl alcohols;
polyphenol;
secondary alcohol;
secondary amino compound | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| rose bengal b disodium salt | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| glutamic acid | | glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid | Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dexchlorpheniramine | | chlorphenamine | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| clometacin | | N-acylindole | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cefazolin | | beta-lactam antibiotic allergen;
cephalosporin;
tetrazoles;
thiadiazoles | antibacterial drug | 2004 | 2016 | 14.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| ripazepam | | benzenes | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| amoxicillin | | penicillin allergen;
penicillin | antibacterial drug | 2004 | 2016 | 13.7 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| timolol | | timolol | anti-arrhythmia drug;
antiglaucoma drug;
antihypertensive agent;
beta-adrenergic antagonist | 2004 | 2016 | 13.7 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| indoramin | | tryptamines | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| almitrine | | piperazines;
triamino-1,3,5-triazine | central nervous system stimulant | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nicergoline | | organic heterotetracyclic compound;
organonitrogen heterocyclic compound | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxcarbazepine | | cyclic ketone;
dibenzoazepine | anticonvulsant;
drug allergen | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| carbidopa | | catechols;
hydrazines;
monocarboxylic acid | antiparkinson drug;
dopaminergic agent;
EC 4.1.1.28 (aromatic-L-amino-acid decarboxylase) inhibitor | 2013 | 2016 | 9.5 | medium | 0 | 0 | 0 | 0 | 2 | 0 |
| prednimustine | | corticosteroid hormone | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| moricizine | | carbamate ester;
morpholines;
phenothiazines | anti-arrhythmia drug | 2004 | 2016 | 13.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| amygdalin | | cyanogenic glycoside;
disaccharide derivative;
gentiobioside | plant metabolite | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| amineptin | | amino acid;
carbocyclic fatty acid;
carbotricyclic compound;
secondary amino compound | antidepressant;
dopamine uptake inhibitor | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| bitolterol | | carboxylic ester;
diester;
ethanolamines;
secondary alcohol;
secondary amino compound | anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
prodrug | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| zidovudine | | azide;
pyrimidine 2',3'-dideoxyribonucleoside | antimetabolite;
antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| feprazone | | organic molecular entity | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pirprofen | | pyrroline | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| tobramycin | | amino cyclitol glycoside | antibacterial agent;
antimicrobial agent;
toxin | 2004 | 2013 | 14.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| paclitaxel | | taxane diterpenoid;
tetracyclic diterpenoid | antineoplastic agent;
human metabolite;
metabolite;
microtubule-stabilising agent | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| etoposide | | beta-D-glucoside;
furonaphthodioxole;
organic heterotetracyclic compound | antineoplastic agent;
DNA synthesis inhibitor | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| dobutamine | | catecholamine;
secondary amine | beta-adrenergic agonist;
cardiotonic drug;
sympathomimetic agent | 2004 | 2016 | 14.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| ticarcillin | | penicillin allergen;
penicillin | antibacterial drug | 2008 | 2011 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| penbutolol | | ethanolamines | | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| etidocaine | | amino acid amide | local anaesthetic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ribavirin | | 1-ribosyltriazole;
aromatic amide;
monocarboxylic acid amide;
primary carboxamide | anticoronaviral agent;
antiinfective agent;
antimetabolite;
antiviral agent;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| amikacin | | alpha-D-glucoside;
amino cyclitol glycoside;
aminoglycoside;
carboxamide | antibacterial drug;
antimicrobial agent;
nephrotoxin | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| cephradine | | beta-lactam antibiotic allergen;
cephalosporin | antibacterial drug | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| ticrynafen | | aromatic ether;
aromatic ketone;
dichlorobenzene;
monocarboxylic acid;
thiophenes | antihypertensive agent;
hepatotoxic agent;
loop diuretic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| guanadrel | | guanidines;
spiroketal | adrenergic antagonist;
antihypertensive agent | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methyldopa | | L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid | alpha-adrenergic agonist;
antihypertensive agent;
hapten;
peripheral nervous system drug;
sympatholytic agent | 2004 | 2016 | 14.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| tocainide | | monocarboxylic acid amide | anti-arrhythmia drug;
local anaesthetic;
sodium channel blocker | 2004 | 2008 | 18.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| bezafibrate | | aromatic ether;
monocarboxylic acid amide;
monocarboxylic acid;
monochlorobenzenes | antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sq-11725 | | | | 2004 | 2011 | 15.8 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| diltiazem | | 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate | antihypertensive agent;
calcium channel blocker;
vasodilator agent | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| nimustine | | aminopyrimidine;
N-nitrosoureas;
organochlorine compound | alkylating agent;
antineoplastic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| levobunolol | | aromatic ether;
cyclic ketone;
propanolamine | antiglaucoma drug;
beta-adrenergic antagonist | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| vecuronium bromide | | organic bromide salt;
quaternary ammonium salt | muscle relaxant;
neuromuscular agent;
nicotinic antagonist | 2004 | 2013 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| vecuronium | | acetate ester;
androstane;
quaternary ammonium ion | drug allergen;
muscle relaxant;
neuromuscular agent;
nicotinic antagonist | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| benoxaprofen | | 1,3-benzoxazoles;
monocarboxylic acid;
monochlorobenzenes | antipsoriatic;
antipyretic;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
hepatotoxic agent;
nephrotoxin;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
protein kinase C agonist | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| permethrin | | cyclopropanecarboxylate ester;
cyclopropanes | agrochemical;
ectoparasiticide;
pyrethroid ester acaricide;
pyrethroid ester insecticide;
scabicide | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| exifone | | benzophenones | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pirfenidone | | pyridone | antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mefloquine | | [2,8-bis(trifluoromethyl)quinolin-4-yl]-(2-piperidyl)methanol | antimalarial | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| desogestrel | | 17beta-hydroxy steroid;
terminal acetylenic compound | contraceptive drug;
progestin;
synthetic oral contraceptive | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| muzolimine | | dichlorobenzene | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| butibufen | | monoterpenoid | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nitazoxanide | | benzamides;
carboxylic ester | | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| sufentanil | | anilide;
ether;
piperidines;
thiophenes | anaesthesia adjuvant;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| acarbose | | tetrasaccharide derivative | EC 3.2.1.1 (alpha-amylase) inhibitor;
EC 3.2.1.20 (alpha-glucosidase) inhibitor;
geroprotector;
hypoglycemic agent | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| torsemide | | aminopyridine;
N-sulfonylurea;
secondary amino compound | antihypertensive agent;
loop diuretic | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| epirubicin | | aminoglycoside;
anthracycline antibiotic;
anthracycline;
deoxy hexoside;
monosaccharide derivative;
p-quinones;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | antimicrobial agent;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| spiromustine | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cefmetazole | | cephalosporin | antibacterial drug | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| desflurane | | organofluorine compound | inhalation anaesthetic | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| diaziquone | | 1,4-benzoquinones;
aziridines;
carbamate ester;
enamine | alkylating agent;
antineoplastic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lorcainide | | acetamides | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| idarubicin | | anthracycline antibiotic;
deoxy hexoside;
monosaccharide derivative | | 2004 | 2016 | 14.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| cefonicid | | cephalosporin | antibacterial drug | 2004 | 2008 | 18.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| piperacillin | | penicillin allergen;
penicillin | antibacterial drug | 2004 | 2016 | 14.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| paroxetine | | aromatic ether;
benzodioxoles;
organofluorine compound;
piperidines | antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| triciribine phosphate | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| captopril | | alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2000 | 2016 | 15.1 | low | 0 | 0 | 1 | 3 | 3 | 0 |
| cefoperazone | | cephalosporin | antibacterial drug | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| staurosporine | | indolocarbazole alkaloid;
organic heterooctacyclic compound | apoptosis inducer;
bacterial metabolite;
EC 2.7.11.13 (protein kinase C) inhibitor;
geroprotector | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| foscarnet sodium | | one-carbon compound;
organic sodium salt | antiviral drug | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| lodoxamide | | organonitrogen compound;
organooxygen compound | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| atracurium | | diester;
quaternary ammonium ion | muscle relaxant;
nicotinic antagonist | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| atracurium besylate | | organosulfonate salt;
quaternary ammonium salt | muscle relaxant;
nicotinic antagonist | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| butoconazole | | aryl sulfide;
conazole antifungal drug;
dichlorobenzene;
imidazole antifungal drug;
imidazoles;
monochlorobenzenes | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| moxalactam | | cephalosporin;
oxacephem | antibacterial drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nicorandil | | nitrate ester;
pyridinecarboxamide | potassium channel opener;
vasodilator agent | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| naftifine | | allylamine antifungal drug;
naphthalenes;
tertiary amine | EC 1.14.13.132 (squalene monooxygenase) inhibitor;
sterol biosynthesis inhibitor | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bw-755c | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pergolide | | diamine;
methyl sulfide;
organic heterotetracyclic compound | antiparkinson drug;
dopamine agonist | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| pergolide mesylate | | methanesulfonate salt | antiparkinson drug;
dopamine agonist;
geroprotector | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cefadroxil anhydrous | | cephalosporin | antibacterial drug | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| encainide | | benzamides;
piperidines | anti-arrhythmia drug;
sodium channel blocker | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| talniflumate | | benzofurans | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fenoldopam mesylate | | benzazepine | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| nedocromil | | dicarboxylic acid;
organic heterotricyclic compound | anti-allergic agent;
anti-asthmatic drug;
non-steroidal anti-inflammatory drug | 2004 | 2011 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| fialuridine | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cefaclor anhydrous | | cephalosporin | antibacterial drug;
drug allergen | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| pefloxacin | | fluoroquinolone antibiotic;
monocarboxylic acid;
N-alkylpiperazine;
N-arylpiperazine;
quinolone antibiotic;
quinolone | antibacterial drug;
antiinfective agent;
DNA synthesis inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| alfentanil | | monocarboxylic acid amide;
piperidines | central nervous system depressant;
intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
peripheral nervous system drug | 2004 | 2016 | 14.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| miglustat | | piperidines;
tertiary amino compound | anti-HIV agent;
EC 2.4.1.80 (ceramide glucosyltransferase) inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| haloperidol decanoate | | organic molecular entity | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cefotetan | | | | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| recainam | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lovastatin | | delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring) | anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| flupirtine | | aminopyridine | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tolrestat | | naphthalenes | EC 1.1.1.21 (aldehyde reductase) inhibitor | 2011 | 2016 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| enoximone | | aromatic ketone | | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| stepronin | | N-acyl-amino acid | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| piritrexim | | | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| levocabastine | | piperidines | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| simvastatin | | delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic) | EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| idazoxan | | benzodioxine;
imidazolines | alpha-adrenergic antagonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| remoxipride | | dimethoxybenzene | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| balsalazide | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pravastatin | | 3-hydroxy carboxylic acid;
carbobicyclic compound;
carboxylic ester;
hydroxy monocarboxylic acid;
secondary alcohol;
statin (semi-synthetic) | anticholesteremic drug;
environmental contaminant;
metabolite;
xenobiotic | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| cabergoline | | N-acylurea | antineoplastic agent;
antiparkinson drug;
dopamine agonist | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| caracemide | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bambuterol | | carbamate ester;
phenylethanolamines | anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
prodrug;
sympathomimetic agent;
tocolytic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| atomoxetine hydrochloride | | hydrochloride | adrenergic uptake inhibitor;
antidepressant | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| atomoxetine | | aromatic ether;
secondary amino compound;
toluenes | adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
xenobiotic | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| quinapril | | dicarboxylic acid monoester;
ethyl ester;
isoquinolines;
tertiary carboxamide | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 2000 | 2016 | 14.2 | low | 0 | 0 | 1 | 3 | 4 | 0 |
| alpidem | | imidazoles | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| gepirone | | N-arylpiperazine | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mifepristone | | 3-oxo-Delta(4) steroid;
acetylenic compound;
tertiary amino compound | abortifacient;
contraceptive drug;
hormone antagonist;
synthetic oral contraceptive | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| cilazapril, anhydrous | | dicarboxylic acid monoester;
ethyl ester;
pyridazinodiazepine | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fosphenytoin | | imidazolidine-2,4-dione | | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| salmeterol xinafoate | | naphthoic acid | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ranolazine | | aromatic amide;
monocarboxylic acid amide;
monomethoxybenzene;
N-alkylpiperazine;
secondary alcohol | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| finasteride | | 3-oxo steroid;
aza-steroid;
delta-lactam | androgen antagonist;
antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| imiquimod | | imidazoquinoline | antineoplastic agent;
interferon inducer | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| esmolol | | aromatic ether;
ethanolamines;
methyl ester;
secondary alcohol;
secondary amino compound | | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| sertindole | | heteroarylpiperidine;
imidazolidinone;
organochlorine compound;
organofluorine compound;
phenylindole | alpha-adrenergic antagonist;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic antagonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| adapalene | | adamantanes;
monocarboxylic acid;
naphthoic acid | dermatologic drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor;
non-steroidal anti-inflammatory drug | 2004 | 2013 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| adefovir | | 6-aminopurines;
ether;
phosphonic acids | antiviral drug;
DNA synthesis inhibitor;
drug metabolite;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent | 2011 | 2016 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| aromasil | | 17-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid | antineoplastic agent;
EC 1.14.14.14 (aromatase) inhibitor;
environmental contaminant;
xenobiotic | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| sparfloxacin | | fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone | | 2004 | 2013 | 15.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| zileuton | | 1-benzothiophenes;
ureas | anti-asthmatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
ferroptosis inhibitor;
leukotriene antagonist;
non-steroidal anti-inflammatory drug | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| clopidogrel | | methyl ester;
monochlorobenzenes;
thienopyridine | anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor | 2010 | 2016 | 11.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| cidofovir anhydrous | | phosphonic acids;
pyrimidone | anti-HIV agent;
antineoplastic agent;
antiviral drug;
photosensitizing agent | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| tiagabine | | beta-amino acid;
piperidinemonocarboxylic acid;
tertiary amino compound;
thiophenes | anticonvulsant;
GABA reuptake inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mibefradil | | tetralins | T-type calcium channel blocker | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| topotecan | | pyranoindolizinoquinoline | antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| tenidap | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bromfenac | | aromatic amino acid;
benzophenones;
organobromine compound;
substituted aniline | non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| gemcitabine hydrochloride | | hydrochloride;
organofluorine compound | anticoronaviral agent;
antimetabolite;
antineoplastic agent;
antiviral drug;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
immunosuppressive agent;
radiosensitizing agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| gemcitabine | | organofluorine compound;
pyrimidine 2'-deoxyribonucleoside | antimetabolite;
antineoplastic agent;
antiviral drug;
DNA synthesis inhibitor;
EC 1.17.4.1 (ribonucleoside-diphosphate reductase) inhibitor;
environmental contaminant;
immunosuppressive agent;
photosensitizing agent;
prodrug;
radiosensitizing agent;
xenobiotic | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| ibutilide | | benzenes;
organic amino compound | | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| aripiprazole | | aromatic ether;
delta-lactam;
dichlorobenzene;
N-alkylpiperazine;
N-arylpiperazine;
quinolone | drug metabolite;
H1-receptor antagonist;
second generation antipsychotic;
serotonergic agonist | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| remifentanil | | alpha-amino acid ester;
anilide;
monocarboxylic acid amide;
piperidinecarboxylate ester | intravenous anaesthetic;
mu-opioid receptor agonist;
opioid analgesic;
sedative | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| atorvastatin calcium anhydrous | | organic calcium salt | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| atorvastatin | | aromatic amide;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrroles;
statin (synthetic) | environmental contaminant;
xenobiotic | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| lamivudine | | monothioacetal;
nucleoside analogue;
oxacycle;
primary alcohol | allergen;
anti-HBV agent;
antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor;
HIV-1 reverse transcriptase inhibitor;
prodrug | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| duloxetine hydrochloride | | duloxetine hydrochloride | antidepressant | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| duloxetine | | duloxetine | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| irinotecan | | carbamate ester;
delta-lactone;
N-acylpiperidine;
pyranoindolizinoquinoline;
ring assembly;
tertiary alcohol;
tertiary amino compound | antineoplastic agent;
apoptosis inducer;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| valsartan | | biphenylyltetrazole;
monocarboxylic acid amide;
monocarboxylic acid | angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| ibandronic acid | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ziprasidone | | 1,2-benzisothiazole;
indolones;
organochlorine compound;
piperazines | antipsychotic agent;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
psychotropic drug;
serotonergic antagonist | 2011 | 2016 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| zolmitriptan | | oxazolidinone;
tryptamines | anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| adefovir dipivoxil | | 6-aminopurines;
carbonate ester;
ether;
organic phosphonate | antiviral drug;
DNA synthesis inhibitor;
HIV-1 reverse transcriptase inhibitor;
nephrotoxic agent;
prodrug | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| emtricitabine | | monothioacetal;
nucleoside analogue;
organofluorine compound;
pyrimidone | antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| tasosartan | | biphenyls | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tiludronic acid | | organochlorine compound | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tirofiban | | L-tyrosine derivative;
piperidines;
sulfonamide | anticoagulant;
fibrin modulating drug;
platelet glycoprotein-IIb/IIIa receptor antagonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| capecitabine | | carbamate ester;
cytidines;
organofluorine compound | antimetabolite;
antineoplastic agent;
prodrug | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| xemilofiban | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| adenosine | | adenosines;
purines D-ribonucleoside | analgesic;
anti-arrhythmia drug;
fundamental metabolite;
human metabolite;
vasodilator agent | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| 2,5-bis(1-aziridinyl)-3,6-bis(2-methoxyethoxy)-4-benzoquinone | | 1,4-benzoquinones | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| morzid | | morpholines | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| paroxetine hydrochloride | | hydrochloride | antidepressant;
anxiolytic drug;
hepatotoxic agent;
P450 inhibitor;
serotonin uptake inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bupropion hydrochloride | | aromatic ketone | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| halofuginone | | quinazolines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trazodone hydrochloride | | hydrochloride | adrenergic antagonist;
antidepressant;
H1-receptor antagonist;
sedative;
serotonin uptake inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ortho-cept | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trovafloxacin | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cefprozil | | cephalosporin;
semisynthetic derivative | antibacterial drug | 2004 | 2016 | 14.0 | high | 0 | 0 | 0 | 2 | 1 | 0 |
| doxazosin mesylate | | methanesulfonate salt | geroprotector | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methylprednisolone aceponate | | corticosteroid hormone | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dexamethasone 17-valerate | | 21-hydroxy steroid | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dexamethasone dipropionate | | corticosteroid hormone | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 4-[1-[4-[2-(dimethylamino)ethoxy]phenyl]-2-phenylbut-1-enyl]phenol | | stilbenoid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| febrifugine | | quinazolines | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| efavirenz | | acetylenic compound;
benzoxazine;
cyclopropanes;
organochlorine compound;
organofluorine compound | antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| nelfinavir | | aryl sulfide;
benzamides;
organic heterobicyclic compound;
phenols;
secondary alcohol;
tertiary amino compound | antineoplastic agent;
HIV protease inhibitor | 2000 | 2016 | 14.2 | low | 0 | 0 | 1 | 1 | 2 | 0 |
| doxapram hydrochloride | | hydrochloride | central nervous system stimulant | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| mevastatin | | 2-pyranones;
carboxylic ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring) | antifungal agent;
apoptosis inducer;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
fungal metabolite;
Penicillium metabolite | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bupivacaine hydrochloride | | hydrochloride;
racemate | adrenergic antagonist;
amphiphile;
EC 3.1.1.8 (cholinesterase) inhibitor;
EC 3.6.3.8 (Ca(2+)-transporting ATPase) inhibitor;
local anaesthetic | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fenofibric acid | | aromatic ketone;
chlorobenzophenone;
monocarboxylic acid | drug metabolite;
marine xenobiotic metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 1,5-anhydroglucitol | | anhydro sugar | human metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| betulinic acid | | hydroxy monocarboxylic acid;
pentacyclic triterpenoid | anti-HIV agent;
anti-inflammatory agent;
antimalarial;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| plerixafor | | azacycloalkane;
azamacrocycle;
benzenes;
crown amine;
secondary amino compound;
tertiary amino compound | anti-HIV agent;
antineoplastic agent;
C-X-C chemokine receptor type 4 antagonist;
immunological adjuvant | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| amprenavir | | carbamate ester;
sulfonamide;
tetrahydrofuryl ester | antiviral drug;
HIV protease inhibitor | 2000 | 2016 | 14.2 | low | 0 | 0 | 1 | 1 | 2 | 0 |
| oseltamivir | | acetamides;
amino acid ester;
cyclohexenecarboxylate ester;
primary amino compound | antiviral drug;
EC 3.2.1.18 (exo-alpha-sialidase) inhibitor;
environmental contaminant;
prodrug;
xenobiotic | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thymine arabinoside | | N-glycosyl compound | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| psicofuranine | | psicose derivative;
purine nucleoside | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ticlopidine hydrochloride | | hydrochloride | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| epirubicin hydrochloride | | | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| glutathione disulfide | | glutathione derivative;
organic disulfide | Escherichia coli metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| triciribine | | nucleoside analogue | EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| iopamidol | | benzenedicarboxamide;
organoiodine compound;
pentol | environmental contaminant;
radioopaque medium;
xenobiotic | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 5-chloro-2'-deoxyuridine | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| histamine phosphate | | phosphate salt | histamine agonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tilbroquinol | | organohalogen compound;
quinolines | | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| bendamustine | | benzimidazoles | | 2008 | 2016 | 12.7 | medium | 0 | 0 | 0 | 2 | 1 | 0 |
| erdosteine | | N-acyl-amino acid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| droxicam | | organic heterotricyclic compound;
pyridines | cyclooxygenase 1 inhibitor;
hepatotoxic agent;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
platelet aggregation inhibitor;
prodrug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| trofosfamide | | ifosfamides | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 4-aminobenzoic acid-n-xyloside | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fotrin | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sufosfamide | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| lercanidipine | | diarylmethane | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ebrotidine | | sulfonamide | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mizolastine | | benzimidazoles | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| azelnidipine | | isopropyl ester | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| intoplicine | | pyridoindole | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pazufloxacin | | quinolines | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| repaglinide | | piperidines | | 2011 | 2016 | 10.7 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| telmisartan | | benzimidazoles;
biphenyls;
carboxybiphenyl | angiotensin receptor antagonist;
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
environmental contaminant;
xenobiotic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| inogatran | | | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| propatyl nitrate | | nitrate ester | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| dexfenfluramine | | fenfluramine | appetite depressant;
serotonergic agonist;
serotonin uptake inhibitor | 2004 | 2010 | 16.7 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| 2-methoxyestradiol | | 17beta-hydroxy steroid;
3-hydroxy steroid | angiogenesis modulating agent;
antimitotic;
antineoplastic agent;
human metabolite;
metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulfamidochrysoidine | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| miconazole nitrate | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ibopamine | | benzoate ester;
phenols | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| medetomidine | | imidazoles | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sertraline | | dichlorobenzene;
secondary amino compound;
tetralins | antidepressant;
serotonin uptake inhibitor | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| picosulfate sodium | | aryl sulfate;
pyridines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pumitepa | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| arbekacin | | aminoglycoside;
kanamycins | antibacterial agent;
antibacterial drug;
antimicrobial agent;
protein synthesis inhibitor | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| zoledronic acid | | 1,1-bis(phosphonic acid);
imidazoles | bone density conservation agent | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| elmustine | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| artemisinin | | organic peroxide;
sesquiterpene lactone | antimalarial;
plant metabolite | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| brinzolamide | | sulfonamide;
thienothiazine | antiglaucoma drug;
EC 4.2.1.1 (carbonic anhydrase) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dienogest | | 17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
aliphatic nitrile;
steroid hormone | progesterone receptor agonist;
progestin;
synthetic oral contraceptive | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| drospirenone | | 3-oxo-Delta(4) steroid;
steroid lactone | aldosterone antagonist;
contraceptive drug;
progestin | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| forphenicinol | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| artemether | | artemisinin derivative;
cyclic acetal;
organic peroxide;
semisynthetic derivative;
sesquiterpenoid | antimalarial | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| morphazinamide | | morpholines;
pyrazines;
secondary carboxamide | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dipropylacetamide | | fatty amide | geroprotector;
metabolite;
teratogenic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pafenolol | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| acamprosate | | acetamides;
organosulfonic acid | environmental contaminant;
neurotransmitter agent;
xenobiotic | 2011 | 2016 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| isaxonine | | aminopyrimidine | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| erythromycin propionate | | erythromycin derivative | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nebivolol | | chromanes;
diol;
organofluorine compound;
secondary alcohol;
secondary amino compound | | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| uk 68798 | | aromatic ether;
sulfonamide;
tertiary amino compound | anti-arrhythmia drug;
potassium channel blocker | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| hp 873 | | 1,2-benzoxazoles;
aromatic ether;
aromatic ketone;
methyl ketone;
monoamine;
organofluorine compound;
piperidines;
tertiary amino compound | dopaminergic antagonist;
second generation antipsychotic;
serotonergic antagonist | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| dexrazoxane | | razoxane | antineoplastic agent;
cardiovascular drug;
chelator;
immunosuppressive agent | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| loxapine succinate | | succinate salt | geroprotector | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fenoxypropazine | | aromatic ether | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| antebate | | corticosteroid hormone | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| voriconazole | | conazole antifungal drug;
difluorobenzene;
pyrimidines;
tertiary alcohol;
triazole antifungal drug | P450 inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| inproquone | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| betamipron | | organonitrogen compound;
organooxygen compound | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| uroxatral | | hydrochloride | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| aceclofenac | | amino acid;
carboxylic ester;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound | EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| nitrefazole | | imidazoles | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cyclobutyrol | | hydroxy monocarboxylic acid | bile therapy drug | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| thiocolchicoside | | glycoside | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| terlipressin | | polypeptide | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| isoflavone | | isoflavones | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| clevudine | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| neplanocin a | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| palinavir | | N-acyl-amino acid | | 2000 | 2000 | 24.0 | medium | 0 | 0 | 1 | 0 | 0 | 0 |
| tetrandrine | | bisbenzylisoquinoline alkaloid;
isoquinolines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| doripenem | | carbapenems | | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| calpeptin | | amino acid amide | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| atovaquone | | hydroxy-1,2-naphthoquinone | | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| 1-ethoxysilatrane | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| rivastigmine | | carbamate ester;
tertiary amino compound | cholinergic drug;
EC 3.1.1.8 (cholinesterase) inhibitor;
neuroprotective agent | 2011 | 2016 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| frovatriptan | | carbazoles | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| eletriptan | | indoles;
N-alkylpyrrolidine;
sulfone | non-steroidal anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| rosiglitazone | | aminopyridine;
thiazolidinediones | EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| tamiflu | | phosphate salt | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bexarotene | | benzoic acids;
naphthalenes;
retinoid | antineoplastic agent | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| s20098 | | acetamides | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| flunisolide | | 11beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic ketal;
fluorinated steroid;
primary alpha-hydroxy ketone | anti-asthmatic drug;
anti-inflammatory drug;
immunosuppressive agent | 2004 | 2013 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| ketorolac tromethamine | | organoammonium salt | analgesic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| clarithromycin | | macrolide antibiotic | antibacterial drug;
environmental contaminant;
protein synthesis inhibitor;
xenobiotic | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| tretazicar | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nicotine | | 3-(1-methylpyrrolidin-2-yl)pyridine | anxiolytic drug;
biomarker;
immunomodulator;
mitogen;
neurotoxin;
nicotinic acetylcholine receptor agonist;
peripheral nervous system drug;
phytogenic insecticide;
plant metabolite;
psychotropic drug;
teratogenic agent;
xenobiotic | 2004 | 2013 | 15.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| nsc-172755 | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| moexipril | | peptide | | 2000 | 2016 | 15.4 | low | 0 | 0 | 1 | 1 | 3 | 0 |
| streptovitacin a | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| gliquidone | | isoquinolines | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cb 10375 | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| zofenopril | | aryl sulfide;
L-proline derivative;
N-acyl-L-amino acid;
thioester | anticonvulsant;
apoptosis inhibitor;
cardioprotective agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug;
vasodilator agent | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| mci 9038 | | peptide | | 2000 | 2016 | 16.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| lopinavir | | amphetamines;
dicarboxylic acid diamide | anticoronaviral agent;
antiviral drug;
HIV protease inhibitor | 2000 | 2013 | 16.3 | low | 0 | 0 | 1 | 1 | 1 | 0 |
| carbenicillin indanyl | | penicillin | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cb 1837 | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| hexaphosphamide | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dipin | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| phosphazine | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diiodobenzotepa | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| icig 1163 | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| bimolane | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| thiodipin | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| fluoxydine | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| moxifloxacin hydrochloride | | hydrochloride | antibacterial drug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| imiphos | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| fulvestrant | | 17beta-hydroxy steroid;
3-hydroxy steroid;
organofluorine compound;
sulfoxide | antineoplastic agent;
estrogen antagonist;
estrogen receptor antagonist | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| mizoribine | | imidazoles | anticoronaviral agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| imipenem, anhydrous | | beta-lactam antibiotic allergen;
carbapenems;
zwitterion | antibacterial drug | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sr141716 | | amidopiperidine;
carbohydrazide;
dichlorobenzene;
monochlorobenzenes;
pyrazoles | anti-obesity agent;
appetite depressant;
CB1 receptor antagonist | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| bosentan anhydrous | | primary alcohol;
pyrimidines;
sulfonamide | antihypertensive agent;
endothelin receptor antagonist | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| selenomethionine | | amino acid zwitterion;
selenomethionine | plant metabolite | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| sivelestat | | N-acylglycine;
pivalate ester | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| aldophosphamide | | nitrogen mustard | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| racecadotril | | N-acyl-amino acid | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| perindopril | | alpha-amino acid ester;
dicarboxylic acid monoester;
ethyl ester;
organic heterobicyclic compound | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2008 | 2016 | 12.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| fingolimod | | aminodiol;
primary amino compound | antineoplastic agent;
CB1 receptor antagonist;
immunosuppressive agent;
prodrug;
sphingosine-1-phosphate receptor agonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sepimostate mesilate | | | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| ecteinascidin 743 | | acetate ester;
azaspiro compound;
bridged compound;
hemiaminal;
isoquinoline alkaloid;
lactone;
organic heteropolycyclic compound;
organic sulfide;
oxaspiro compound;
polyphenol;
tertiary amino compound | alkylating agent;
angiogenesis modulating agent;
anti-inflammatory agent;
antineoplastic agent;
marine metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tadalafil | | benzodioxoles;
pyrazinopyridoindole | EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| 3,6-bis(5-chloro-2-piperidyl)-2,5-piperazinedione | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oxymatrine | | alkaloid;
tertiary amine oxide | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| paliperidone | | 1,2-benzoxazoles;
heteroarylpiperidine;
organofluorine compound;
pyridopyrimidine;
secondary alcohol | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nitisinone | | (trifluoromethyl)benzenes;
C-nitro compound;
cyclohexanones;
mesotrione | EC 1.13.11.27 (4-hydroxyphenylpyruvate dioxygenase) inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| plavix | | azaheterocycle sulfate salt;
organoammonium sulfate salt | anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| marimastat | | hydroxamic acid;
secondary carboxamide | antineoplastic agent;
matrix metalloproteinase inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clofarabine | | adenosines;
organofluorine compound | antimetabolite;
antineoplastic agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| 1,1,2-trichloroethanol | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pramipexole | | benzothiazoles;
diamine | antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
radical scavenger | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| valdecoxib | | isoxazoles;
sulfonamide | antipyretic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| mitiglinide | | benzenes;
monocarboxylic acid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| l 658758 | | | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| dx 9065 | | | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| acetylphenylalanyl-prolyl-boroarginine | | acetamides;
C-terminal boronic acid peptide;
guanidines | anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| imatinib mesylate | | methanesulfonate salt | anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
tyrosine kinase inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| almotriptan | | indoles;
sulfonamide;
tertiary amine | non-steroidal anti-inflammatory drug;
serotonergic agonist;
vasoconstrictor agent | 2011 | 2016 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| mk 0663 | | bipyridines;
organochlorine compound;
sulfone | cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| gefitinib | | aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound | antineoplastic agent;
epidermal growth factor receptor antagonist | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| n(6)-(3-iodobenzyl)-5'-n-methylcarboxamidoadenosine | | adenosines;
monocarboxylic acid amide;
organoiodine compound | adenosine A3 receptor agonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ramatroban | | organic molecular entity | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| e 64 | | dicarboxylic acid monoamide;
epoxy monocarboxylic acid;
guanidines;
L-leucine derivative;
zwitterion | antimalarial;
antiparasitic agent;
protease inhibitor | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| desloratadine | | benzocycloheptapyridine | anti-allergic agent;
cholinergic antagonist;
drug metabolite;
H1-receptor antagonist | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| desvenlafaxine | | cyclohexanols;
phenols;
tertiary amino compound | antidepressant;
drug metabolite;
marine xenobiotic metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| benzyloxycarbonylphenylalanylphenylalanine diazomethyl ketone | | carboxylic ester;
diazo compound;
L-phenylalanine derivative;
secondary carboxamide | cathepsin L (EC 3.4.22.15) inhibitor | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| iremycin | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| methotrexate | | dicarboxylic acid;
monocarboxylic acid amide;
pteridines | abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| n,n'-bis((2-chloroethyl)nitrosocarbamoyl)cystamine | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hainanensine | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| tamsulosin | | 5-(2-{[2-(2-ethoxyphenoxy)ethyl]amino}propyl)-2-methoxybenzenesulfonamide | alpha-adrenergic antagonist;
antineoplastic agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| rufinamide | | aromatic amide;
heteroarene | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| antiprimod | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulbactam | | penicillanic acids | | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| olmesartan medoxomil | | biphenyls | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| dexpanthenol | | amino alcohol;
monocarboxylic acid amide | cholinergic drug;
provitamin | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fosamprenavir | | sulfonamide | prodrug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ilomastat | | hydroxamic acid;
L-tryptophan derivative;
N-acyl-amino acid | anti-inflammatory agent;
antibacterial agent;
antineoplastic agent;
EC 3.4.24.24 (gelatinase A) inhibitor;
neuroprotective agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| abiraterone | | 3beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
pyridines | antineoplastic agent;
EC 1.14.99.9 (steroid 17alpha-monooxygenase) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| febuxostat | | 1,3-thiazolemonocarboxylic acid;
aromatic ether;
nitrile | EC 1.17.3.2 (xanthine oxidase) inhibitor | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| ritrosulfan | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| escitalopram | | 1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile | antidepressant;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lexapro | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 10-propargyl-10-deazaaminopterin | | N-acyl-L-glutamic acid;
pteridines;
terminal acetylenic compound | antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| docetaxel | | hydrate;
secondary alpha-hydroxy ketone | antineoplastic agent | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| docetaxel anhydrous | | secondary alpha-hydroxy ketone;
tetracyclic diterpenoid | antimalarial;
antineoplastic agent;
photosensitizing agent | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| atazanavir | | carbohydrazide | antiviral drug;
HIV protease inhibitor | 2000 | 2016 | 15.3 | low | 0 | 0 | 1 | 1 | 1 | 0 |
| levofloxacin | | 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid;
fluoroquinolone antibiotic;
quinolone antibiotic | antibacterial drug;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
topoisomerase IV inhibitor | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| ezetimibe | | azetidines;
beta-lactam;
organofluorine compound | anticholesteremic drug;
antilipemic drug;
antimetabolite | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| ertapenem | | carbapenemcarboxylic acid;
pyrrolidinecarboxamide | antibacterial drug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cox 189 | | amino acid;
monocarboxylic acid;
organochlorine compound;
organofluorine compound;
secondary amino compound | cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| conivaptan | | benzazepine | aquaretic;
vasopressin receptor antagonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cariporide | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tezosentan | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| damvar | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| moxifloxacin | | aromatic ether;
cyclopropanes;
fluoroquinolone antibiotic;
pyrrolidinopiperidine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone | antibacterial drug | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| pralnacasan | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| clevidipine | | dihydropyridine | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| jtt 501 | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| solifenacin | | isoquinolines | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dexmethylphenidate | | methyl phenyl(piperidin-2-yl)acetate | adrenergic agent | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| xamoterol | | morpholines | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| naproxen | | methoxynaphthalene;
monocarboxylic acid | antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| cinacalcet | | (trifluoromethyl)benzenes;
naphthalenes;
secondary amino compound | calcimimetic;
P450 inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bila 2157 bs | | | | 2000 | 2000 | 24.0 | medium | 0 | 0 | 1 | 0 | 0 | 0 |
| lubiprostone | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| telbivudine | | pyrimidine 2'-deoxyribonucleoside | antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| cyc 202 | | 2,6-diaminopurines | antiviral drug;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| benzo-tepa | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| tevenel | | sulfonamide | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| tac 278 | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| paromomycin | | amino cyclitol glycoside;
aminoglycoside antibiotic | anthelminthic drug;
antibacterial drug;
antiparasitic agent;
antiprotozoal drug | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| anidulafungin | | antibiotic antifungal drug;
azamacrocycle;
echinocandin;
heterodetic cyclic peptide;
semisynthetic derivative | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| avasimibe | | monoterpenoid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| aminopterin | | dicarboxylic acid | EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
mutagen | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 17 alpha-hydroxyprogesterone caproate | | corticosteroid hormone | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| varenicline | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| biotin | | biotins;
vitamin B7 | coenzyme;
cofactor;
Escherichia coli metabolite;
fundamental metabolite;
human metabolite;
mouse metabolite;
nutraceutical;
prosthetic group;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| (4r)-3-((2s)-3-mercapto-2-methylpropanoyl)-4- thiazolidinecarboxylic acid | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fiduxosin | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| atropine | | | | 2008 | 2016 | 12.4 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| ropivacaine | | piperidinecarboxamide;
ropivacaine | local anaesthetic | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| erlotinib | | aromatic ether;
quinazolines;
secondary amino compound;
terminal acetylenic compound | antineoplastic agent;
epidermal growth factor receptor antagonist;
protein kinase inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| melagatran | | azetidines;
carboxamidine;
dicarboxylic acid monoamide;
non-proteinogenic alpha-amino acid;
secondary amino compound | anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor;
serine protease inhibitor | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| deflazacort | | corticosteroid hormone | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hexestrol diphosphate | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| carbocysteine | | L-cysteine thioether;
non-proteinogenic L-alpha-amino acid | mucolytic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| etravirine | | aminopyrimidine;
aromatic ether;
dinitrile;
organobromine compound | antiviral agent;
HIV-1 reverse transcriptase inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| troleandomycin | | acetate ester;
epoxide;
macrolide antibiotic;
monosaccharide derivative;
polyketide;
semisynthetic derivative | EC 1.14.13.97 (taurochenodeoxycholate 6alpha-hydroxylase) inhibitor;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dronedarone | | 1-benzofurans;
aromatic ether;
aromatic ketone;
sulfonamide;
tertiary amino compound | anti-arrhythmia drug;
environmental contaminant;
xenobiotic | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ramelteon | | indanes | | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| lapatinib | | furans;
organochlorine compound;
organofluorine compound;
quinazolines | antineoplastic agent;
tyrosine kinase inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| darunavir | | carbamate ester;
furofuran;
sulfonamide | antiviral drug;
HIV protease inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| deferasirox | | benzoic acids;
monocarboxylic acid;
phenols;
triazoles | iron chelator | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| bms204352 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tbc-11251 | | benzodioxoles | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| tolvaptan | | benzazepine;
benzenedicarboxamide | aquaretic;
vasopressin receptor antagonist | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| sorafenib | | (trifluoromethyl)benzenes;
aromatic ether;
monochlorobenzenes;
phenylureas;
pyridinecarboxamide | angiogenesis inhibitor;
anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
ferroptosis inducer;
tyrosine kinase inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lenalidomide | | aromatic amine;
dicarboximide;
isoindoles;
piperidones | angiogenesis inhibitor;
antineoplastic agent;
immunomodulator | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| regadenoson | | purine nucleoside | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lacosamide | | N-acyl-amino acid | | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| demecolcine | | alkaloid;
secondary amino compound | antineoplastic agent;
microtubule-destabilising agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sitosterol, (3beta)-isomer | | 3beta-hydroxy-Delta(5)-steroid;
3beta-sterol;
C29-steroid;
phytosterols;
stigmastane sterol | anticholesteremic drug;
antioxidant;
mouse metabolite;
plant metabolite;
sterol methyltransferase inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| estradiol 3-benzoate | | 17beta-hydroxy steroid;
benzoate ester | estrogen receptor agonist;
xenoestrogen | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| vincaleukoblastine | | acetate ester;
indole alkaloid fundamental parent;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
tertiary alcohol;
tertiary amino compound;
vinca alkaloid | antineoplastic agent;
immunosuppressive agent;
microtubule-destabilising agent;
plant metabolite | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| vincristine sulfate | | organic sulfate salt | antineoplastic agent;
geroprotector | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| benzarone | | 1-benzofurans | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| nsc-89199 | | carbamate ester;
organochlorine compound;
steroid phosphate | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| estramustine | | 17beta-hydroxy steroid;
carbamate ester;
organochlorine compound | alkylating agent;
antineoplastic agent;
radiation protective agent | 2004 | 2016 | 14.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| phenethicillin | | penicillin allergen;
penicillin | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| noscapine | | aromatic ether;
benzylisoquinoline alkaloid;
cyclic acetal;
isobenzofuranone;
organic heterobicyclic compound;
organic heterotricyclic compound;
tertiary amino compound | antineoplastic agent;
antitussive;
apoptosis inducer;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| indicine-n-oxide | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| homoharringtonine | | alkaloid ester;
enol ether;
organic heteropentacyclic compound;
tertiary alcohol | anticoronaviral agent;
antineoplastic agent;
apoptosis inducer;
protein synthesis inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| wortmannin | | acetate ester;
cyclic ketone;
delta-lactone;
organic heteropentacyclic compound | anticoronaviral agent;
antineoplastic agent;
autophagy inhibitor;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
geroprotector;
Penicillium metabolite;
radiosensitizing agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| trimethoprim, sulfamethoxazole drug combination | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| o-(chloroacetylcarbamoyl)fumagillol | | carbamate ester;
organochlorine compound;
semisynthetic derivative;
sesquiterpenoid;
spiro-epoxide | angiogenesis inhibitor;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
methionine aminopeptidase 2 inhibitor;
retinoic acid receptor alpha antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bortezomib | | amino acid amide;
L-phenylalanine derivative;
pyrazines | antineoplastic agent;
antiprotozoal drug;
protease inhibitor;
proteasome inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| ritonavir | | 1,3-thiazoles;
carbamate ester;
carboxamide;
L-valine derivative;
ureas | antiviral drug;
environmental contaminant;
HIV protease inhibitor;
xenobiotic | 2000 | 2016 | 15.4 | low | 0 | 0 | 1 | 2 | 2 | 0 |
| nexavar | | organosulfonate salt | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| rimiterol | | catechols | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| glucosamine | | D-glucosamine | Escherichia coli metabolite;
geroprotector;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| raffinose | | raffinose family oligosaccharide;
trisaccharide | mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| oxytocin | | heterodetic cyclic peptide;
peptide hormone | oxytocic;
vasodilator agent | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| ouabain | | 11alpha-hydroxy steroid;
14beta-hydroxy steroid;
5beta-hydroxy steroid;
alpha-L-rhamnoside;
cardenolide glycoside;
steroid hormone | anti-arrhythmia drug;
cardiotonic drug;
EC 2.3.3.1 [citrate (Si)-synthase] inhibitor;
EC 3.1.3.41 (4-nitrophenylphosphatase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
ion transport inhibitor;
plant metabolite | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pentostatin | | coformycins | antimetabolite;
antineoplastic agent;
Aspergillus metabolite;
bacterial metabolite;
EC 3.5.4.4 (adenosine deaminase) inhibitor | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| quinidine | | cinchona alkaloid | alpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| meropenem | | alpha,beta-unsaturated monocarboxylic acid;
carbapenemcarboxylic acid;
organic sulfide;
pyrrolidinecarboxamide | antibacterial agent;
antibacterial drug;
drug allergen | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| griseofulvin | | 1-benzofurans;
antibiotic antifungal drug;
benzofuran antifungal drug;
organochlorine compound;
oxaspiro compound | antibacterial agent;
Penicillium metabolite | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| cefoxitin | | beta-lactam antibiotic allergen;
cephalosporin;
cephamycin;
semisynthetic derivative | antibacterial drug | 2004 | 2016 | 14.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| digitoxin | | cardenolide glycoside | EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor | 2008 | 2013 | 13.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| saquinavir | | L-asparagine derivative;
quinolines | antiviral drug;
HIV protease inhibitor | 2000 | 2016 | 15.4 | low | 0 | 0 | 1 | 2 | 2 | 0 |
| pancuronium | | acetate ester;
steroid ester | cholinergic antagonist;
muscle relaxant;
nicotinic antagonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| abacavir | | 2,6-diaminopurines | antiviral drug;
drug allergen;
HIV-1 reverse transcriptase inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| netilmicin | | | | 2004 | 2011 | 15.8 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| trimethaphan camsylate | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| perindopril erbumine | | addition compound | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| miglitol | | piperidines | | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| metyrosine | | L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid | antihypertensive agent;
EC 1.14.16.2 (tyrosine 3-monooxygenase) inhibitor | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| rocuronium bromide | | organic bromide salt;
quaternary ammonium salt | muscle relaxant;
neuromuscular agent | 2004 | 2013 | 15.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| erythromycin estolate | | aminoglycoside sulfate salt;
erythromycin derivative | enzyme inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| terconazole | | 1-(4-{[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)-4-isopropylpiperazine | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bacampicillin | | penicillanic acid ester | prodrug | 2004 | 2008 | 18.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| linezolid | | acetamides;
morpholines;
organofluorine compound;
oxazolidinone | antibacterial drug;
protein synthesis inhibitor | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| angustibalin | | sesquiterpene lactone | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| cyclopamine | | piperidines | glioma-associated oncogene inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| devazepide | | 1,4-benzodiazepinone;
indolecarboxamide | antineoplastic agent;
apoptosis inducer;
cholecystokinin antagonist;
gastrointestinal drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| candoxatrilat | | | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| clindamycin phosphate | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pemirolast potassium salt | | | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| eplerenone | | 3-oxo-Delta(4) steroid;
epoxy steroid;
gamma-lactone;
methyl ester;
organic heteropentacyclic compound;
oxaspiro compound;
steroid acid ester | aldosterone antagonist;
antihypertensive agent | 2012 | 2016 | 10.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| temocapril | | dipeptide | | 2012 | 2012 | 12.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| tolterodine | | tertiary amine | antispasmodic drug;
muscarinic antagonist;
muscle relaxant | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| doxorubicin hydrochloride | | anthracycline | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| metrizamide | | amino sugar | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| erythromycin ethylsuccinate | | cyclic ketone;
erythromycin derivative;
ethyl ester;
succinate ester | | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| amcinonide | | 11beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
acetate ester;
corticosteroid;
fluorinated steroid;
spiroketal | anti-inflammatory drug | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| betamethasone acetate | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
acetate ester;
fluorinated steroid;
steroid ester;
tertiary alpha-hydroxy ketone | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ao 128 | | organic molecular entity | | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| loteprednol etabonate | | 11beta-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
etabonate ester;
organochlorine compound;
steroid acid ester;
steroid ester | anti-inflammatory drug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| darifenacin | | 1-benzofurans;
monocarboxylic acid amide;
pyrrolidines | antispasmodic drug;
muscarinic antagonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fluticasone propionate | | 11beta-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
corticosteroid;
fluorinated steroid;
propanoate ester;
steroid ester;
thioester | adrenergic agent;
anti-allergic agent;
anti-asthmatic drug;
anti-inflammatory drug;
bronchodilator agent;
dermatologic drug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| acarbose | | amino cyclitol;
glycoside | | 2004 | 2011 | 15.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| tretinoin | | retinoic acid;
vitamin A | anti-inflammatory agent;
antineoplastic agent;
antioxidant;
AP-1 antagonist;
human metabolite;
keratolytic drug;
retinoic acid receptor agonist;
retinoid X receptor agonist;
signalling molecule | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| retinol | | retinol;
vitamin A | human metabolite;
mouse metabolite;
plant metabolite | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| alpha-D-fructofuranose 1,6-bisphosphate | | D-fructofuranose 1,6-bisphosphate | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| docosahexaenoate | | docosahexaenoic acid;
omega-3 fatty acid | algal metabolite;
antineoplastic agent;
Daphnia tenebrosa metabolite;
human metabolite;
mouse metabolite;
nutraceutical | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| oleic acid | | octadec-9-enoic acid | antioxidant;
Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
Escherichia coli metabolite;
mouse metabolite;
plant metabolite;
solvent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tacrolimus | | macrolide lactam | bacterial metabolite;
immunosuppressive agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| cerivastatin | | dihydroxy monocarboxylic acid;
pyridines;
statin (synthetic) | | 2010 | 2011 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| rosuvastatin | | dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrimidines;
statin (synthetic);
sulfonamide | anti-inflammatory agent;
antilipemic drug;
cardioprotective agent;
CETP inhibitor;
environmental contaminant;
xenobiotic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cocaine | | benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid | adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| eicosapentaenoic acid | | icosapentaenoic acid;
omega-3 fatty acid | anticholesteremic drug;
antidepressant;
antineoplastic agent;
Daphnia galeata metabolite;
fungal metabolite;
micronutrient;
mouse metabolite;
nutraceutical | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mycophenolic acid | | 2-benzofurans;
gamma-lactone;
monocarboxylic acid;
phenols | anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
environmental contaminant;
immunosuppressive agent;
mycotoxin;
Penicillium metabolite;
xenobiotic | 2004 | 2016 | 14.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| mupirocin | | alpha,beta-unsaturated carboxylic ester;
epoxide;
monocarboxylic acid;
oxanes;
secondary alcohol;
triol | antibacterial drug;
bacterial metabolite;
protein synthesis inhibitor | 2004 | 2013 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| clindamycin | | | | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| brivudine | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fosfomycin | | epoxide;
phosphonic acids | antimicrobial agent;
EC 2.5.1.7 (UDP-N-acetylglucosamine 1-carboxyvinyltransferase) inhibitor | 2004 | 2016 | 14.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| zithromax | | macrolide antibiotic | antibacterial drug;
environmental contaminant;
xenobiotic | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| formycin | | formycin | antineoplastic agent | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| drf 2725 | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cgp 38560a | | | | 2000 | 2000 | 24.0 | medium | 0 | 0 | 1 | 0 | 0 | 0 |
| diethylstilbestrol | | olefinic compound;
polyphenol | antifungal agent;
antineoplastic agent;
autophagy inducer;
calcium channel blocker;
carcinogenic agent;
EC 1.1.1.146 (11beta-hydroxysteroid dehydrogenase) inhibitor;
EC 3.6.3.10 (H(+)/K(+)-exchanging ATPase) inhibitor;
endocrine disruptor;
xenoestrogen | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| octreotide | | | | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| eptifibatide | | homodetic cyclic peptide;
macrocycle;
organic disulfide | anticoagulant;
platelet aggregation inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| alitretinoin | | retinoic acid | antineoplastic agent;
keratolytic drug;
metabolite;
retinoid X receptor agonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| decitabine | | 2'-deoxyribonucleoside | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| teniposide | | aromatic ether;
beta-D-glucoside;
cyclic acetal;
furonaphthodioxole;
gamma-lactone;
monosaccharide derivative;
phenols;
thiophenes | antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 2004 | 2016 | 13.8 | medium | 0 | 0 | 0 | 3 | 2 | 0 |
| valrubicin | | anthracycline;
trifluoroacetamide | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cefamandole | | cephalosporin;
semisynthetic derivative | antibacterial drug | 2004 | 2008 | 18.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| dactinomycin | | actinomycin | mutagen | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| tiazofurin | | 1,3-thiazoles;
C-glycosyl compound;
monocarboxylic acid amide | antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
prodrug | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| azaserine | | carboxylic ester;
diazo compound;
L-serine derivative;
non-proteinogenic L-alpha-amino acid | antifungal agent;
antimetabolite;
antimicrobial agent;
antineoplastic agent;
glutamine antagonist;
immunosuppressive agent;
metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| melphalan | | L-phenylalanine derivative;
nitrogen mustard;
non-proteinogenic L-alpha-amino acid;
organochlorine compound | alkylating agent;
antineoplastic agent;
carcinogenic agent;
drug allergen;
immunosuppressive agent | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| benzyloxycarbonylleucyl-leucyl-leucine aldehyde | | amino aldehyde;
carbamate ester;
tripeptide | proteasome inhibitor | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| tenofovir | | nucleoside analogue;
phosphonic acids | antiviral drug;
drug metabolite;
HIV-1 reverse transcriptase inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| prinomastat | | aromatic ether;
hydroxamic acid;
pyridines;
sulfonamide;
thiomorpholines | antineoplastic agent;
EC 3.4.24.35 (gelatinase B) inhibitor;
matrix metalloproteinase inhibitor | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| posaconazole | | aromatic ether;
conazole antifungal drug;
N-arylpiperazine;
organofluorine compound;
oxolanes;
triazole antifungal drug;
triazoles | trypanocidal drug | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| rubitecan | | C-nitro compound;
delta-lactone;
pyranoindolizinoquinoline;
semisynthetic derivative;
tertiary alcohol | antineoplastic agent;
EC 5.99.1.2 (DNA topoisomerase) inhibitor;
prodrug | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| micafungin | | antibiotic antifungal drug;
echinocandin | antiinfective agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| riboflavin | | flavin;
vitamin B2 | anti-inflammatory agent;
antioxidant;
cofactor;
Escherichia coli metabolite;
food colouring;
fundamental metabolite;
human urinary metabolite;
mouse metabolite;
photosensitizing agent;
plant metabolite | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| sodium bicarbonate | | one-carbon compound;
organic sodium salt | antacid;
food anticaking agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| sodium acetate, anhydrous | | organic sodium salt | NMR chemical shift reference compound | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sodium benzoate | | organic sodium salt | algal metabolite;
antimicrobial food preservative;
drug allergen;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor;
human xenobiotic metabolite;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| arsenic trioxide | | arsenic oxide | antineoplastic agent;
insecticide | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| dipyrone | | organic sodium salt | anti-inflammatory agent;
antipyretic;
antirheumatic drug;
cyclooxygenase 3 inhibitor;
non-narcotic analgesic;
peripheral nervous system drug;
prodrug | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| ditiocarb sodium | | organic molecular entity | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 4-[[bis(2-hydroxyethyl)amino]methyl]-2,6-ditert-butylphenol | | alkylbenzene | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| aceglatone | | organic molecular entity | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| sch 22219 | | 11beta-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
glucocorticoid;
propanoate ester;
steroid ester | anti-inflammatory drug | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sr 90107 | | | | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| carbenoxolone | | | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| meglumine iodipamide | | organoammonium salt | radioopaque medium | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thyrotropin-releasing hormone | | peptide hormone;
tripeptide | human metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| discodermolide | | diterpenoid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cannabidiol | | olefinic compound;
phytocannabinoid;
resorcinols | antimicrobial agent;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| arginine vasopressin | | vasopressin | cardiovascular drug;
hematologic agent;
mitogen | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| s 1033 | | (trifluoromethyl)benzenes;
imidazoles;
pyridines;
pyrimidines;
secondary amino compound;
secondary carboxamide | anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mezlocillin | | penicillin allergen;
penicillin | antibacterial drug | 2004 | 2011 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| amygdalin | | amygdalin | antineoplastic agent;
apoptosis inducer;
plant metabolite | 2008 | 2011 | 14.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| trilostane | | 17beta-hydroxy steroid;
3-hydroxy steroid;
androstanoid;
epoxy steroid;
nitrile | abortifacient;
antineoplastic agent;
EC 1.1.1.210 [3beta(or 20alpha)-hydroxysteroid dehydrogenase] inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cholinophyllin | | | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mitobronitol | | alcohol;
organobromine compound | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| leuprolide acetate | | acetate salt | antineoplastic agent;
gonadotropin releasing hormone agonist | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| leuprolide | | oligopeptide | anti-estrogen;
antineoplastic agent;
gonadotropin releasing hormone agonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| octotropine methylbromide | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fludarabine | | purine nucleoside | | 2004 | 2008 | 18.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| propylthiouracil | | pyrimidinethione | antidote to paracetamol poisoning;
antimetabolite;
antioxidant;
antithyroid drug;
carcinogenic agent;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
hormone antagonist | 2004 | 2016 | 13.7 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| ipratropium bromide anhydrous | | | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methylatropine nitrate | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| prothionamide | | pyridines | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| etomidate | | ethyl ester;
imidazoles | intravenous anaesthetic;
sedative | 2004 | 2016 | 13.5 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| mercaptopurine | | aryl thiol;
purines;
thiocarbonyl compound | anticoronaviral agent;
antimetabolite;
antineoplastic agent | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| thioinosine | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| levosulpiride | | sulpiride | antidepressant;
antiemetic;
antipsychotic agent;
dopaminergic antagonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pyrantel | | 1,4,5,6-tetrahydropyrimidines;
carboxamidine;
thiophenes | antinematodal drug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thiothixene | | N-methylpiperazine | anticoronaviral agent | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| eszopiclone | | zopiclone | central nervous system depressant;
sedative | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| benztropine | | diarylmethane | | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| thiouracil | | nucleobase analogue;
thiocarbonyl compound | antithyroid drug;
metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methimazole | | 1,3-dihydroimidazole-2-thiones | antithyroid drug | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| cinnarizine | | diarylmethane;
N-alkylpiperazine;
olefinic compound | anti-allergic agent;
antiemetic;
calcium channel blocker;
geroprotector;
H1-receptor antagonist;
histamine antagonist;
muscarinic antagonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sulindac | | monocarboxylic acid;
organofluorine compound;
sulfoxide | analgesic;
antineoplastic agent;
antipyretic;
apoptosis inducer;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
prodrug;
tocolytic agent | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| capsaicin | | capsaicinoid | non-narcotic analgesic;
TRPV1 agonist;
voltage-gated sodium channel blocker | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| enclomiphene | | | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| terbinafine | | acetylenic compound;
allylamine antifungal drug;
enyne;
naphthalenes;
tertiary amine | EC 1.14.13.132 (squalene monooxygenase) inhibitor;
P450 inhibitor;
sterol biosynthesis inhibitor | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| epalrestat | | monocarboxylic acid;
thiazolidines | EC 1.1.1.21 (aldehyde reductase) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| drotaverin | | isoquinolines | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thioguanine anhydrous | | 2-aminopurines | anticoronaviral agent;
antimetabolite;
antineoplastic agent | 2004 | 2016 | 14.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| tacrine hydrochloride | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sodium propionate | | organic sodium salt | antifungal drug;
food preservative | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| succimer | | dicarboxylic acid;
dithiol;
sulfur-containing carboxylic acid | chelator | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| digoxin | | cardenolide glycoside;
steroid saponin | anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| 6-thioguanosine | | purine nucleoside | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| streptozocin | | | | 2004 | 2016 | 14.2 | high | 0 | 0 | 0 | 3 | 2 | 0 |
| tamoxifen | | stilbenoid;
tertiary amino compound | angiogenesis inhibitor;
antineoplastic agent;
bone density conservation agent;
EC 1.2.3.1 (aldehyde oxidase) inhibitor;
EC 2.7.11.13 (protein kinase C) inhibitor;
estrogen antagonist;
estrogen receptor antagonist;
estrogen receptor modulator | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| ethionamide | | pyridines;
thiocarboxamide | antilipemic drug;
antitubercular agent;
fatty acid synthesis inhibitor;
leprostatic drug;
prodrug | 2004 | 2016 | 14.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| cancidas | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fusidic acid | | 11alpha-hydroxy steroid;
3alpha-hydroxy steroid;
alpha,beta-unsaturated monocarboxylic acid;
steroid acid;
steroid antibiotic;
sterol ester | EC 2.7.1.33 (pantothenate kinase) inhibitor;
Escherichia coli metabolite;
protein synthesis inhibitor | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| lincomycin | | carbohydrate-containing antibiotic;
L-proline derivative;
monocarboxylic acid amide;
pyrrolidinecarboxamide;
S-glycosyl compound | antimicrobial agent;
bacterial metabolite | 2008 | 2016 | 12.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| valinomycin | | cyclodepsipeptide;
macrocycle | antimicrobial agent;
antiviral agent;
bacterial metabolite;
potassium ionophore | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| estrone sulfate | | 17-oxo steroid;
steroid sulfate | human metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ranitidine | | C-nitro compound;
furans;
organic sulfide;
tertiary amino compound | anti-ulcer drug;
drug allergen;
environmental contaminant;
H2-receptor antagonist;
xenobiotic | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| aplaviroc | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thiocarlide | | thioureas | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hmr 3647 | | | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| latoconazole | | conazole antifungal drug;
imidazole antifungal drug | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| maraviroc | | tropane alkaloid | | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| toremifene citrate | | stilbenoid | anticoronaviral agent | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| toremifene | | aromatic ether;
organochlorine compound;
tertiary amine | antineoplastic agent;
bone density conservation agent;
estrogen antagonist;
estrogen receptor modulator | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| telaprevir | | cyclopentapyrrole;
cyclopropanes;
oligopeptide;
pyrazines | antiviral drug;
hepatitis C protease inhibitor;
peptidomimetic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nelarabine | | beta-D-arabinoside;
monosaccharide derivative;
purine nucleoside | antineoplastic agent;
DNA synthesis inhibitor;
prodrug | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| dermatan sulfate | | amino disaccharide;
glycosylgalactose derivative;
iduronic acids;
oligosaccharide sulfate | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dezocine | | phenols;
primary amino compound | opioid analgesic | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dapiprazole | | N-alkylpiperazine;
N-arylpiperazine;
pyridines | alpha-adrenergic antagonist;
antipsychotic agent;
miotic;
ophthalmology drug | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| droloxifene | | stilbenoid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dolasetron | | indolyl carboxylic acid | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| or 1259 | | hydrazone;
nitrile;
pyridazinone | anti-arrhythmia drug;
cardiotonic drug;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mannomustine | | amino alcohol | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| gestodene | | steroid | estrogen | 2008 | 2013 | 13.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| glucametacin | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| orlistat | | beta-lactone;
carboxylic ester;
formamides;
L-leucine derivative | anti-obesity agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| idoxifene | | stilbenoid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| quinine | | cinchona alkaloid | antimalarial;
muscle relaxant;
non-narcotic analgesic | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| 1-(2-(2-(4-pyridyl)-2-imidazoline-1-yl)ethyl)-3-(4-carboxyphenyl)urea | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| fospropofol | | alkylbenzene | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| azilect | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| rasagiline | | indanes;
secondary amine;
terminal acetylenic compound | EC 1.4.3.4 (monoamine oxidase) inhibitor;
neuroprotective agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dasatinib | | 1,3-thiazoles;
aminopyrimidine;
monocarboxylic acid amide;
N-(2-hydroxyethyl)piperazine;
N-arylpiperazine;
organochlorine compound;
secondary amino compound;
tertiary amino compound | anticoronaviral agent;
antineoplastic agent;
tyrosine kinase inhibitor | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| zd 6474 | | aromatic ether;
organobromine compound;
organofluorine compound;
piperidines;
quinazolines;
secondary amine | antineoplastic agent;
tyrosine kinase inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| silybin | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| rs-130830 | | | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| chloramine-t | | organic sodium salt | allergen;
antifouling biocide;
disinfectant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sitagliptin | | triazolopyrazine;
trifluorobenzene | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
environmental contaminant;
hypoglycemic agent;
serine proteinase inhibitor;
xenobiotic | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| thiorphan | | | | 2000 | 2000 | 24.0 | medium | 0 | 0 | 1 | 0 | 0 | 0 |
| flosequinan | | quinolines | | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| tolcapone | | 2-nitrophenols;
benzophenones;
catechols | antiparkinson drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| quercetin | | 7-hydroxyflavonol;
pentahydroxyflavone | antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dinoprostone | | prostaglandins E | human metabolite;
mouse metabolite;
oxytocic | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dinoprost | | monocarboxylic acid;
prostaglandins Falpha | human metabolite;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| calcitriol | | D3 vitamins;
hydroxycalciol;
triol | antineoplastic agent;
antipsoriatic;
bone density conservation agent;
calcium channel agonist;
calcium channel modulator;
hormone;
human metabolite;
immunomodulator;
metabolite;
mouse metabolite;
nutraceutical | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| beta carotene | | carotenoid beta-end derivative;
cyclic carotene | antioxidant;
biological pigment;
cofactor;
ferroptosis inhibitor;
human metabolite;
mouse metabolite;
plant metabolite;
provitamin A | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hymecromone | | hydroxycoumarin | antineoplastic agent;
hyaluronic acid synthesis inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| alprostadil | | prostaglandins E | anticoagulant;
human metabolite;
platelet aggregation inhibitor;
vasodilator agent | 2004 | 2013 | 15.2 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| vitamin d 2 | | hydroxy seco-steroid;
seco-ergostane;
vitamin D | bone density conservation agent;
nutraceutical;
plant metabolite;
rodenticide | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| cholecalciferol | | D3 vitamins;
hydroxy seco-steroid;
seco-cholestane;
secondary alcohol;
steroid hormone | geroprotector;
human metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| amphotericin b | | antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic | antiamoebic agent;
antiprotozoal drug;
bacterial metabolite | 2004 | 2016 | 14.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| clavulanic acid | | oxapenam | antibacterial drug;
anxiolytic drug;
bacterial metabolite;
EC 3.5.2.6 (beta-lactamase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pulmicort | | 11beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
cyclic acetal;
glucocorticoid;
primary alpha-hydroxy ketone | anti-inflammatory drug;
bronchodilator agent;
drug allergen | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| oxymetholone | | | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| eprosartan | | dicarboxylic acid;
imidazoles;
thiophenes | angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| montelukast | | aliphatic sulfide;
monocarboxylic acid;
quinolines | anti-arrhythmia drug;
anti-asthmatic drug;
leukotriene antagonist | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| mivacurium | | isoquinolines | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| brompheniramine maleate | | maleate salt | anti-allergic agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dexchlorpheniramine maleate | | organic molecular entity | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| olopatadine | | | | 2004 | 2004 | 20.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| hemabate | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mycophenolate mofetil | | carboxylic ester;
ether;
gamma-lactone;
phenols;
tertiary amino compound | anticoronaviral agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
immunosuppressive agent;
prodrug | 2010 | 2016 | 11.0 | medium | 0 | 0 | 0 | 1 | 2 | 0 |
| bw b1090u | | isoquinolines | | 2004 | 2004 | 20.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| entacapone | | 2-nitrophenols;
catechols;
monocarboxylic acid amide;
nitrile | antidyskinesia agent;
antiparkinson drug;
central nervous system drug;
EC 2.1.1.6 (catechol O-methyltransferase) inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| paricalcitol | | hydroxy seco-steroid;
seco-cholestane | antiparathyroid drug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| astaxanthine | | carotenol;
carotenone | animal metabolite;
anticoagulant;
antioxidant;
food colouring;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diosmin | | dihydroxyflavanone;
disaccharide derivative;
glycosyloxyflavone;
monomethoxyflavone;
rutinoside | anti-inflammatory agent;
antioxidant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cynarine | | alkyl caffeate ester;
quinic acid | plant metabolite | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| sdz psc 833 | | homodetic cyclic peptide | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| l 660,711 | | quinolines | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| coenzyme q10 | | ubiquinones | antioxidant;
ferroptosis inhibitor;
human metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| travoprost | | (trifluoromethyl)benzenes;
isopropyl ester;
prostaglandins Falpha | antiglaucoma drug;
antihypertensive agent;
ophthalmology drug;
prodrug;
prostaglandin receptor agonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tranilast | | amidobenzoic acid;
cinnamamides;
dimethoxybenzene;
secondary carboxamide | anti-allergic agent;
anti-asthmatic drug;
antineoplastic agent;
aryl hydrocarbon receptor agonist;
calcium channel blocker;
hepatoprotective agent;
nephroprotective agent | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| 7432 s | | cephalosporin;
dicarboxylic acid | antibacterial drug | 2004 | 2016 | 14.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| imipenem | | carbapenems | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| etretinate | | enoate ester;
ethyl ester;
retinoid | keratolytic drug | 2004 | 2013 | 15.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| isotretinoin | | retinoic acid | antineoplastic agent;
keratolytic drug;
teratogenic agent | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| misoprostol | | | | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| ketotifen fumarate | | organoammonium salt | anti-asthmatic drug;
H1-receptor antagonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| epoprostenol | | prostaglandins I | mouse metabolite | 2004 | 2016 | 14.0 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| indocyanine green | | 1,1-diunsubstituted alkanesulfonate;
benzoindole;
cyanine dye | | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| dinoprost tromethamine | | organic molecular entity | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ozagrel | | cinnamic acids | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| triprolidine | | N-alkylpyrrolidine;
olefinic compound;
pyridines | H1-receptor antagonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pitavastatin | | cyclopropanes;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
quinolines;
statin (synthetic) | antioxidant | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| rosuvastatin calcium | | N-acyl-15-methylhexadecasphinganine-1-phosphoethanolamine;
organic calcium salt | anti-inflammatory agent;
cardioprotective agent;
CETP inhibitor | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| terbinafine hydrochloride | | allylamine antifungal drug;
hydrochloride | EC 1.14.13.132 (squalene monooxygenase) inhibitor;
P450 inhibitor | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| ethamolin | | long-chain fatty acid | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| betamethasone benzoate | | 21-hydroxy steroid | | 2004 | 2004 | 20.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| alatrofloxacin mesylate | | | | 2010 | 2016 | 11.0 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| codeine | | morphinane alkaloid;
organic heteropentacyclic compound | antitussive;
drug allergen;
environmental contaminant;
opioid analgesic;
opioid receptor agonist;
prodrug;
xenobiotic | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| cyclosporine | | homodetic cyclic peptide | anti-asthmatic drug;
anticoronaviral agent;
antifungal agent;
antirheumatic drug;
carcinogenic agent;
dermatologic drug;
EC 3.1.3.16 (phosphoprotein phosphatase) inhibitor;
geroprotector;
immunosuppressive agent;
metabolite | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| natamycin | | antibiotic antifungal drug;
dicarboxylic acid monoester;
epoxide;
macrolide antibiotic;
monosaccharide derivative;
polyene antibiotic | antifungal agrochemical;
antimicrobial food preservative;
apoptosis inducer;
bacterial metabolite;
ophthalmology drug | 2010 | 2013 | 12.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| acitretin | | acitretin;
alpha,beta-unsaturated monocarboxylic acid;
retinoid | keratolytic drug | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| dihydrocodeine | | morphinane alkaloid | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dorzolamide | | sulfonamide;
thiophenes | antiglaucoma drug;
antihypertensive agent;
EC 4.2.1.1 (carbonic anhydrase) inhibitor | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dothiepin | | dothiepin | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| estropipate | | piperazinium salt;
steroid sulfate | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| hydromorphone | | morphinane alkaloid;
organic heteropentacyclic compound | mu-opioid receptor agonist;
opioid analgesic | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| levetiracetam | | pyrrolidin-2-ones | anticonvulsant;
environmental contaminant;
xenobiotic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| ly 163892 | | carbacephem;
zwitterion | antibacterial drug;
antimicrobial agent | 2004 | 2016 | 14.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| nabilone | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nalmefene | | morphinane alkaloid | | 2004 | 2013 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| nalorphine | | morphinane alkaloid | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| naloxone | | morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol | antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| oxycodone | | organic heteropentacyclic compound;
semisynthetic derivative | antitussive;
mu-opioid receptor agonist;
opioid analgesic | 2011 | 2016 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| oxymorphone | | morphinane alkaloid | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| vitamin k 1 | | phylloquinones;
vitamin K | cofactor;
human metabolite;
plant metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| sirolimus | | antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol | antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| topiramate | | cyclic ketal;
ketohexose derivative;
sulfamate ester | anticonvulsant;
sodium channel blocker | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| trospium chloride | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| alvocidib | | dihydroxyflavone;
hydroxypiperidine;
monochlorobenzenes;
tertiary amino compound | antineoplastic agent;
antirheumatic drug;
apoptosis inducer;
EC 2.7.11.22 (cyclin-dependent kinase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| seocalcitol | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fenretinide | | monocarboxylic acid amide;
retinoid | antineoplastic agent;
antioxidant | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| geldanamycin | | 1,4-benzoquinones;
ansamycin;
carbamate ester;
organic heterobicyclic compound | antimicrobial agent;
antineoplastic agent;
antiviral agent;
cysteine protease inhibitor;
Hsp90 inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| calcipotriene | | cyclopropanes;
hydroxy seco-steroid;
seco-cholestane;
secondary alcohol;
triol | antipsoriatic;
drug allergen | 2004 | 2004 | 20.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| morphine | | morphinane alkaloid;
organic heteropentacyclic compound;
tertiary amino compound | anaesthetic;
drug allergen;
environmental contaminant;
geroprotector;
mu-opioid receptor agonist;
opioid analgesic;
plant metabolite;
vasodilator agent;
xenobiotic | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| pactamycin | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| demycarosylturimycin h | | | | 2010 | 2013 | 12.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| acipimox | | pyrazinecarboxylic acid | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| anthramycin | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| atosiban | | oligopeptide | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| benzphetamine | | amphetamines;
tertiary amine | adrenergic uptake inhibitor;
appetite depressant;
dopamine uptake inhibitor;
sympathomimetic agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bimatoprost | | monocarboxylic acid amide | antiglaucoma drug;
antihypertensive agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| clobetasol | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
3-oxo-Delta(1),Delta(4)-steroid;
chlorinated steroid;
fluorinated steroid;
glucocorticoid;
tertiary alpha-hydroxy ketone | anti-inflammatory drug;
SMO receptor agonist | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| deamino arginine vasopressin | | heterodetic cyclic peptide | diagnostic agent;
renal agent;
vasopressin receptor agonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dexmedetomidine | | medetomidine | alpha-adrenergic agonist;
analgesic;
non-narcotic analgesic;
sedative | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fluticasone | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
3-oxo-Delta(4) steroid;
corticosteroid;
fluorinated steroid;
thioester | anti-allergic agent;
anti-asthmatic drug | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| goserelin | | organic molecular entity | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| halobetasol | | corticosteroid hormone | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| iloprost | | carbobicyclic compound;
monocarboxylic acid;
secondary alcohol | platelet aggregation inhibitor;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lacidipine | | cinnamate ester;
tert-butyl ester | | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| latanoprost | | isopropyl ester;
prostaglandins Falpha;
triol | antiglaucoma drug;
antihypertensive agent;
EC 4.2.1.1 (carbonic anhydrase) inhibitor;
prodrug | 2004 | 2013 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cytochalasin b | | cytochalasin;
lactam;
lactone;
organic heterotricyclic compound | actin polymerisation inhibitor;
metabolite;
mycotoxin;
platelet aggregation inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nalbuphine | | organic heteropentacyclic compound | mu-opioid receptor antagonist;
opioid analgesic | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| nateglinide | | phenylalanine derivative | | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| alatriopril | | | | 2000 | 2000 | 24.0 | medium | 0 | 0 | 1 | 0 | 0 | 0 |
| rimexolone | | 20-oxo steroid | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| spirapril | | azaspiro compound;
dicarboxylic acid monoester;
dipeptide;
dithioketal;
ethyl ester;
pyrrolidinecarboxylic acid;
secondary amino compound;
tertiary carboxamide | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| vinorelbine | | acetate ester;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
ring assembly;
vinca alkaloid | antineoplastic agent;
photosensitizing agent | 2004 | 2016 | 14.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| silodosin | | indolecarboxamide | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| irisquinone | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| furazolidone | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| fluvoxamine | | (trifluoromethyl)benzenes;
5-methoxyvalerophenone O-(2-aminoethyl)oxime | antidepressant;
anxiolytic drug;
serotonin uptake inhibitor | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| semaxinib | | olefinic compound;
oxindoles;
pyrroles | angiogenesis modulating agent;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
vascular endothelial growth factor receptor antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| orantinib | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| su 11248 | | monocarboxylic acid amide;
pyrroles | angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor;
immunomodulator;
neuroprotective agent;
vascular endothelial growth factor receptor antagonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mitoguazone | | guanidines;
hydrazone | antineoplastic agent;
apoptosis inducer;
EC 4.1.1.50 (adenosylmethionine decarboxylase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| (6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid | | dihydroxy monocarboxylic acid;
indoles;
organofluorine compound | | 2004 | 2016 | 13.2 | medium | 0 | 0 | 0 | 2 | 2 | 0 |
| molsidomine | | ethyl ester;
morpholines;
oxadiazole;
zwitterion | antioxidant;
apoptosis inhibitor;
cardioprotective agent;
nitric oxide donor;
vasodilator agent | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| oxiconazole | | conazole antifungal drug;
dichlorobenzene;
imidazole antifungal drug;
imidazoles;
oxime O-ether | antiinfective agent | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| levorphanol | | morphinane alkaloid | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| naltrexone | | cyclopropanes;
morphinane-like compound;
organic heteropentacyclic compound | antidote to opioid poisoning;
central nervous system depressant;
environmental contaminant;
mu-opioid receptor antagonist;
xenobiotic | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| dextromethorphan | | 6-methoxy-11-methyl-1,3,4,9,10,10a-hexahydro-2H-10,4a-(epiminoethano)phenanthrene | antitussive;
environmental contaminant;
neurotoxin;
NMDA receptor antagonist;
oneirogen;
prodrug;
xenobiotic | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| butorphanol | | morphinane alkaloid | antitussive;
kappa-opioid receptor agonist;
mu-opioid receptor agonist;
opioid analgesic | 2004 | 2016 | 13.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| cefodizime | | 1,3-thiazoles;
cephalosporin;
oxime O-ether | antibacterial drug;
EC 1.14.18.1 (tyrosinase) inhibitor | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cefixime | | cephalosporin | antibacterial drug;
drug allergen | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| lisinopril | | dipeptide | EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2000 | 2016 | 13.8 | low | 0 | 0 | 1 | 2 | 5 | 0 |
| benazepril | | benzazepine;
dicarboxylic acid monoester;
ethyl ester;
lactam | EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 2000 | 2016 | 13.8 | low | 0 | 0 | 1 | 1 | 6 | 0 |
| verteporfin | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| indinavir sulfate | | dicarboxylic acid diamide;
N-(2-hydroxyethyl)piperazine;
piperazinecarboxamide | HIV protease inhibitor | 2000 | 2016 | 15.4 | low | 0 | 0 | 1 | 2 | 2 | 0 |
| zimeldine | | styrenes | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| enalapril maleate | | maleate salt | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 2011 | 2013 | 12.0 | medium | 0 | 0 | 0 | 0 | 2 | 0 |
| enalapril | | dicarboxylic acid monoester;
dipeptide | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
geroprotector;
prodrug | 2000 | 2016 | 14.9 | low | 0 | 0 | 1 | 3 | 3 | 0 |
| nitrofurazone | | | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| trientine hydrochloride | | | | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| n-methylscopolamine bromide | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bleomycin | | bleomycin | antineoplastic agent;
metabolite | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| enalaprilat anhydrous | | dicarboxylic acid;
dipeptide | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| ramiprilat | | azabicycloalkane;
cyclopentapyrrole;
dicarboxylic acid;
dipeptide | bradykinin receptor B2 agonist;
cardioprotective agent;
drug metabolite;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
matrix metalloproteinase inhibitor | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| imidapril | | dicarboxylic acid monoester;
dipeptide;
ethyl ester;
imidazolidines;
N-acylurea;
secondary amino compound | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sulindac sulfone | | monocarboxylic acid;
organofluorine compound;
sulfone | apoptosis inducer;
cyclooxygenase 2 inhibitor;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pepstatin | | pentapeptide;
secondary carboxamide | bacterial metabolite;
EC 3.4.23.* (aspartic endopeptidase) inhibitor | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| ximelagatran | | amidoxime;
azetidines;
carboxamide;
ethyl ester;
hydroxylamines;
secondary amino compound;
secondary carboxamide;
tertiary carboxamide | anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor;
prodrug;
serine protease inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cefuroxime | | 3-(carbamoyloxymethyl)cephalosporin;
furans;
oxime O-ether | drug allergen | 2004 | 2016 | 14.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| ceftriaxone | | 1,2,4-triazines;
1,3-thiazoles;
cephalosporin;
oxime O-ether | antibacterial drug;
drug allergen;
EC 3.5.2.6 (beta-lactamase) inhibitor | 2004 | 2016 | 14.2 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| cefepime | | cephalosporin;
oxime O-ether | antibacterial drug | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| pafuramidine | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ceftazidime | | cephalosporin;
oxime O-ether | antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor | 2004 | 2016 | 14.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| trandolapril | | dicarboxylic acid monoester;
dipeptide;
ethyl ester;
organic heterobicyclic compound;
secondary amino compound;
tertiary carboxamide | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 2000 | 2016 | 15.0 | low | 0 | 0 | 1 | 2 | 3 | 0 |
| pregabalin | | gamma-amino acid | anticonvulsant;
calcium channel blocker | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| tiotropium | | | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| alvimopan anhydrous | | peptide | | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| oxyfedrine | | aromatic ketone | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| aliskiren | | monocarboxylic acid amide;
monomethoxybenzene | antihypertensive agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| guanabenz acetate | | dichlorobenzene | geroprotector | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| guanabenz | | dichlorobenzene | | 2004 | 2011 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| famotidine | | 1,3-thiazoles;
guanidines;
sulfonamide | anti-ulcer drug;
H2-receptor antagonist;
P450 inhibitor | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| cefotaxime | | 1,3-thiazoles;
cephalosporin;
oxime O-ether | antibacterial drug;
drug allergen | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| aztreonam | | beta-lactam antibiotic allergen;
monobactam | antibacterial drug;
drug allergen;
EC 2.4.1.129 (peptidoglycan glycosyltransferase) inhibitor | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| proguanil | | biguanides;
monochlorobenzenes | antimalarial;
antiprotozoal drug;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cci 15641 | | cephalosporin | | 2004 | 2013 | 15.5 | high | 0 | 0 | 0 | 1 | 1 | 0 |
| rifamycin sv | | acetate ester;
cyclic ketal;
lactam;
macrocycle;
organic heterotetracyclic compound;
polyphenol;
rifamycins | antimicrobial agent;
antitubercular agent;
bacterial metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ro 42-5892 | | cyclopropanes;
diol;
L-histidine derivative;
secondary carboxamide;
sulfone | antihypertensive agent;
EC 3.4.23.15 (renin) inhibitor;
peptidomimetic;
vasodilator agent | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| ceftiofur | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| cefpodoxime | | carboxylic acid;
cephalosporin | antibacterial drug | 2004 | 2016 | 14.0 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| palonosetron | | azabicycloalkane;
delta-lactam;
organic heterotricyclic compound | antiemetic;
serotonergic antagonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| epoprostenol sodium | | prostanoid | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| tenofovir disoproxil fumarate | | fumarate salt | antiviral drug;
HIV-1 reverse transcriptase inhibitor;
prodrug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cefatrizine | | amino acid amide;
carboxylic acid;
cephalosporin;
phenols;
semisynthetic derivative;
triazoles | antibacterial drug;
EC 2.7.11.20 (elongation factor 2 kinase) inhibitor | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dexbrompheniramine maleate | | brompheniramine maleate | anti-allergic agent;
H1-receptor antagonist | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cilastatin | | carboxamide;
L-cysteine derivative;
non-proteinogenic L-alpha-amino acid;
organic sulfide | EC 3.4.13.19 (membrane dipeptidase) inhibitor;
environmental contaminant;
protease inhibitor;
xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| rifaximin | | acetate ester;
cyclic ketal;
lactam;
macrocycle;
organic heterohexacyclic compound;
rifamycins;
semisynthetic derivative | antimicrobial agent;
gastrointestinal drug;
orphan drug | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| sibiromycin | | aminoglycoside antibiotic;
hemiaminal;
phenols;
pyrrolobenzodiazepine | antineoplastic agent;
bacterial metabolite | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| rupintrivir | | | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| everolimus | | cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
primary alcohol;
secondary alcohol | anticoronaviral agent;
antineoplastic agent;
geroprotector;
immunosuppressive agent;
mTOR inhibitor | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| ixabepilone | | 1,3-thiazoles;
beta-hydroxy ketone;
epoxide;
lactam;
macrocycle | antineoplastic agent;
microtubule-destabilising agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| dirithromycin | | macrolide antibiotic | prodrug | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| azlocillin | | penicillin allergen;
penicillin;
semisynthetic derivative | antibacterial drug | 2010 | 2011 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cefpodoxime proxetil | | carboxylic acid;
carboxylic ester;
cephalosporin | antibacterial drug;
prodrug | 2004 | 2013 | 14.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| ceftizoxime | | cephalosporin | antibacterial drug | 2004 | 2016 | 14.7 | medium | 0 | 0 | 0 | 2 | 1 | 0 |
| 1-methyl-d-lysergic acid butanolamide | | ergot alkaloid;
monocarboxylic acid amide | serotonergic antagonist;
sympatholytic agent;
vasoconstrictor agent | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| fluphenazine | | | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| dantrolene sodium | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nitrofurantoin | | imidazolidine-2,4-dione;
nitrofuran antibiotic;
organonitrogen heterocyclic antibiotic;
organooxygen heterocyclic antibiotic | antibacterial drug;
antiinfective agent;
hepatotoxic agent | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| nifurtimox | | nitrofuran antibiotic | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| butylscopolammonium bromide | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dantrolene | | | | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| roxithromycin | | roxithromycin | environmental contaminant;
xenobiotic | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cefdinir | | cephalosporin;
ketoxime | antibacterial drug | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| fumagillin | | antibiotic antifungal drug;
carboxylic ester;
dicarboxylic acid monoester;
meroterpenoid;
organooxygen heterocyclic antibiotic;
spiro-epoxide | angiogenesis inhibitor;
antibacterial drug;
antimicrobial agent;
antiprotozoal drug;
fungal metabolite;
methionine aminopeptidase 2 inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| etonogestrel | | 17beta-hydroxy steroid;
3-oxo-Delta(4) steroid;
terminal acetylenic compound | contraceptive drug;
female contraceptive drug;
progestin | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bisoprolol, fumarate (1:1) salt | | | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| artesunate | | artemisinin derivative;
cyclic acetal;
dicarboxylic acid monoester;
hemisuccinate;
semisynthetic derivative;
sesquiterpenoid | antimalarial;
antineoplastic agent;
ferroptosis inducer | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| beraprost | | enyne;
monocarboxylic acid;
organic heterotricyclic compound;
secondary alcohol;
secondary allylic alcohol | anti-inflammatory agent;
antihypertensive agent;
platelet aggregation inhibitor;
prostaglandin receptor agonist;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lanreotide | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| etoposide phosphate | | furonaphthodioxole | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ciclesonide | | organic molecular entity | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| napsagatran | | | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| temsirolimus | | macrolide lactam | | 2013 | 2016 | 9.5 | medium | 0 | 0 | 0 | 0 | 2 | 0 |
| dutasteride | | (trifluoromethyl)benzenes;
aza-steroid;
delta-lactam | antihyperplasia drug;
EC 1.3.1.22 [3-oxo-5alpha-steroid 4-dehydrogenase (NADP(+))] inhibitor | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| bay 12-9566 | | biphenyls;
organochlorine compound | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| tekturna | | fumarate salt | antihypertensive agent | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| lu 208075 | | diarylmethane | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| bibx 1382bs | | substituted aniline | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| vildagliptin | | amino acid amide | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fesoterodine | | diarylmethane | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| acetylcarnitine | | O-acetylcarnitine;
saturated fatty acyl-L-carnitine | human metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| sgd 301-76 | | conazole antifungal drug;
imidazole antifungal drug;
organic nitrate salt | antiinfective agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fluvoxamine maleate | | (trifluoromethyl)benzenes | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thioacetazone | | | | 2008 | 2013 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| nifurtoinol | | hydrazone;
imidazolidine-2,4-dione;
nitrofuran antibiotic;
organonitrogen heterocyclic antibiotic | antibacterial drug;
antiinfective agent;
hepatotoxic agent | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| gemifloxacin | | 1,8-naphthyridine derivative;
fluoroquinolone antibiotic;
monocarboxylic acid;
quinolone antibiotic | antibacterial drug;
antimicrobial agent;
topoisomerase IV inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dexlansoprazole | | benzimidazoles;
sulfoxide | | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| gemifloxacin mesylate | | methanesulfonate salt | antimicrobial agent;
topoisomerase IV inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fosinopril | | | | 2000 | 2016 | 16.5 | high | 0 | 0 | 1 | 2 | 1 | 0 |
| armodafinil | | 2-[(diphenylmethyl)sulfinyl]acetamide | central nervous system stimulant;
eugeroic | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| gw 501516 | | 1,3-thiazoles;
aromatic ether;
aryl sulfide;
monocarboxylic acid;
organofluorine compound | carcinogenic agent;
PPARbeta/delta agonist | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| eflucimibe | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ym 60828 | | | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| ro 32-3555 | | | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| sincalide | | oligopeptide | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tapentadol | | alkylbenzene | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| etomoxir | | aromatic ether | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pentagastrin | | organic molecular entity | | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| cefditoren | | carboxylic acid;
cephalosporin | antibacterial drug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| rivaroxaban | | aromatic amide;
lactam;
monocarboxylic acid amide;
morpholines;
organochlorine compound;
oxazolidinone;
thiophenes | anticoagulant;
EC 3.4.21.6 (coagulation factor Xa) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| treosulfan | | methanesulfonate ester | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| gentamicin sulfate | | | | 2008 | 2011 | 14.3 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| zd 8321 | | | | 2000 | 2000 | 24.0 | medium | 0 | 0 | 1 | 0 | 0 | 0 |
| hki 272 | | nitrile;
quinolines | antineoplastic agent;
tyrosine kinase inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nkp 608 | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| tofacitinib | | N-acylpiperidine;
nitrile;
pyrrolopyrimidine;
tertiary amino compound | antirheumatic drug;
EC 2.7.10.2 (non-specific protein-tyrosine kinase) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ganu | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pazopanib | | aminopyrimidine;
indazoles;
sulfonamide | angiogenesis modulating agent;
antineoplastic agent;
tyrosine kinase inhibitor;
vascular endothelial growth factor receptor antagonist | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| azd 6244 | | benzimidazoles;
bromobenzenes;
hydroxamic acid ester;
monochlorobenzenes;
organofluorine compound;
secondary amino compound | anticoronaviral agent;
antineoplastic agent;
EC 2.7.11.24 (mitogen-activated protein kinase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| prasugrel hydrochloride | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| amg 009 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| vinflunine | | acetate ester;
methyl ester;
organic heteropentacyclic compound;
organic heterotetracyclic compound;
semisynthetic derivative;
vinca alkaloid | antineoplastic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cefotaxime sodium | | organic sodium salt | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| baci-im | | homodetic cyclic peptide;
polypeptide;
zwitterion | antibacterial agent;
antimicrobial agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| metamelfalan | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| bms 477118 | | adamantanes;
azabicycloalkane;
monocarboxylic acid amide;
nitrile;
tertiary alcohol | EC 3.4.14.5 (dipeptidyl-peptidase IV) inhibitor;
hypoglycemic agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nystatin a1 | | nystatins | | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| milnacipran | | acetamides | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| vindesine | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| losartan potassium | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| diflucortolone | | 21-hydroxy steroid | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| scopolamine hydrobromide | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dactolisib | | imidazoquinoline;
nitrile;
quinolines;
ring assembly;
ureas | antineoplastic agent;
EC 2.7.1.137 (phosphatidylinositol 3-kinase) inhibitor;
mTOR inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pf 03491390 | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 2-((3-chloroethyl)-3-nitrosoureido)glucopyranose | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| ro 6-4563 | | monoterpenoid | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| rabeprazole sodium | | organic sodium salt | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| amodiaquine hydrochloride | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bivalirudin | | polypeptide | anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| somatostatin | | heterodetic cyclic peptide;
peptide hormone | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tannins | | tannin | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| enfuvirtide | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ganirelix | | polypeptide | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| teriparatide | | polypeptide | | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| salmon calcitonin | | heterodetic cyclic peptide;
peptide hormone;
polypeptide | bone density conservation agent;
metabolite | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| ly-146032 | | heterodetic cyclic peptide;
lipopeptide antibiotic;
lipopeptide;
macrocycle;
macrolide | antibacterial drug;
bacterial metabolite;
calcium-dependent antibiotics | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ilys-prolyl-alaninamide | | polypeptide | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| exenatide | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| warfarin sodium | | | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| pravastatin sodium | | organic sodium salt;
statin (semi-synthetic) | anticholesteremic drug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| alendronate sodium | | | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| sl 80.0750 | | | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| flucloronide | | 21-hydroxy steroid | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| lucifer yellow | | organic lithium salt | fluorochrome | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| mesna | | organosulfonic acid | | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| cerivastatin sodium | | organic sodium salt;
statin (synthetic) | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| clavulanate potassium | | potassium salt | antibacterial drug;
antimicrobial agent;
EC 3.5.2.6 (beta-lactamase) inhibitor | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| cefamandole nafate | | organic sodium salt | antibacterial drug;
prodrug | 2004 | 2004 | 20.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| sodium lactate | | lactate salt;
organic sodium salt | food acidity regulator;
food preservative | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| piperacillin sodium | | organic sodium salt | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| monensin | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| sodium iothalamate | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| oxacillin sodium | | organic sodium salt | | 2010 | 2013 | 12.5 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| sodium diatrizoate | | organic sodium salt;
organoiodine compound | radioopaque medium | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cefazolin sodium | | organic sodium salt | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| azlocillin sodium | | organic sodium salt | | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| cetrorelix | | oligopeptide | antineoplastic agent;
GnRH antagonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| hainanolide | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| gliocladic acid | | p-menthane monoterpenoid | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| cleistanthin | | cleistanthins;
xylose derivative | alpha-adrenergic antagonist;
antihypertensive agent;
diuretic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nimorazole | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ascorbic acid | | ascorbic acid;
vitamin C | coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| raltegravir | | 1,2,4-oxadiazole;
dicarboxylic acid amide;
hydroxypyrimidine;
monofluorobenzenes;
pyrimidone;
secondary carboxamide | antiviral drug;
HIV-1 integrase inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| novobiocin | | carbamate ester;
ether;
hexoside;
hydroxycoumarin;
monocarboxylic acid amide;
monosaccharide derivative;
phenols | antibacterial agent;
antimicrobial agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
Escherichia coli metabolite;
hepatoprotective agent | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| tetracycline | | | | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| chlortetracycline | | | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| oxytetracycline, anhydrous | | | | 2008 | 2016 | 12.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| minocycline | | | | 2004 | 2016 | 14.5 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| dicumarol | | hydroxycoumarin | anticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor;
Hsp90 inhibitor;
vitamin K antagonist | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| piroxicam | | benzothiazine;
monocarboxylic acid amide;
pyridines | analgesic;
antirheumatic drug;
cyclooxygenase 1 inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| roquinimex | | aromatic amide | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| acenocoumarol | | C-nitro compound;
hydroxycoumarin;
methyl ketone | anticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| meclocycline | | | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bactobolin | | amino acid amide | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mobic | | 1,3-thiazoles;
benzothiazine;
monocarboxylic acid amide | analgesic;
antirheumatic drug;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| mobiflex | | heteroaryl hydroxy compound;
monocarboxylic acid amide;
pyridines;
thienothiazine | antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2008 | 2013 | 13.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| isoxicam | | benzothiazine;
isoxazoles;
monocarboxylic acid amide | antirheumatic drug;
non-steroidal anti-inflammatory drug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| warfarin | | benzenes;
hydroxycoumarin;
methyl ketone | | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| demeclocycline | | | | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| phenprocoumon | | hydroxycoumarin | anticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tipranavir | | sulfonamide | antiviral drug;
HIV protease inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| rolitetracycline | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| minocycline hydrochloride | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tigecycline | | | | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| lornoxicam | | heteroaryl hydroxy compound;
monocarboxylic acid amide;
organochlorine compound;
pyridines;
thienothiazine | antipyretic;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| ajmaline | | | | 2010 | 2010 | 14.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| fertinex | | | | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| entecavir | | 2-aminopurines;
oxopurine;
primary alcohol;
secondary alcohol | antiviral drug;
EC 2.7.7.49 (RNA-directed DNA polymerase) inhibitor | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| acyclovir | | 2-aminopurines;
oxopurine | antimetabolite;
antiviral drug | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| inosine | | inosines;
purines D-ribonucleoside | Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| folic acid | | folic acids;
N-acyl-amino acid | human metabolite;
mouse metabolite;
nutrient | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| rifampin | | cyclic ketal;
hydrazone;
N-iminopiperazine;
N-methylpiperazine;
rifamycins;
semisynthetic derivative;
zwitterion | angiogenesis inhibitor;
antiamoebic agent;
antineoplastic agent;
antitubercular agent;
DNA synthesis inhibitor;
EC 2.7.7.6 (RNA polymerase) inhibitor;
Escherichia coli metabolite;
geroprotector;
leprostatic drug;
neuroprotective agent;
pregnane X receptor agonist;
protein synthesis inhibitor | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| clozapine | | benzodiazepine;
N-arylpiperazine;
N-methylpiperazine;
organochlorine compound | adrenergic antagonist;
dopaminergic antagonist;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
environmental contaminant;
GABA antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
xenobiotic | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| dacarbazine | | dacarbazine | | 2008 | 2016 | 12.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| didanosine | | purine 2',3'-dideoxyribonucleoside | antimetabolite;
antiviral drug;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor;
geroprotector;
HIV-1 reverse transcriptase inhibitor | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| ganciclovir | | 2-aminopurines;
oxopurine | antiinfective agent;
antiviral drug | 2004 | 2016 | 13.7 | low | 0 | 0 | 0 | 3 | 3 | 0 |
| valtrex | | organic molecular entity | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| valacyclovir | | L-valyl ester | antiviral drug | 2004 | 2016 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| sildenafil | | piperazines;
pyrazolopyrimidine;
sulfonamide | EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent | 2010 | 2016 | 11.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| olanzapine | | benzodiazepine;
N-arylpiperazine;
N-methylpiperazine | antiemetic;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
serotonin uptake inhibitor | 2004 | 2016 | 13.2 | low | 0 | 0 | 0 | 2 | 2 | 0 |
| penciclovir | | 2-aminopurines;
propane-1,3-diols | antiviral drug | 2004 | 2010 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| oxypurinol | | pyrazolopyrimidine | drug metabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| raltitrexed | | N-acyl-amino acid | | 2010 | 2013 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| vardenafil | | imidazotriazine;
N-alkylpiperazine;
N-sulfonylpiperazine | EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| allopurinol | | nucleobase analogue;
organic heterobicyclic compound | antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger | 2004 | 2016 | 13.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| azaguanine | | nucleobase analogue;
triazolopyrimidines | antimetabolite;
antineoplastic agent;
EC 2.4.2.1 (purine-nucleoside phosphorylase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| citrovorum factor | | tetrahydrofolic acid | | 2013 | 2016 | 9.5 | high | 0 | 0 | 0 | 0 | 2 | 0 |
| leucovorin | | formyltetrahydrofolic acid | Escherichia coli metabolite;
mouse metabolite | 2010 | 2016 | 11.0 | medium | 0 | 0 | 0 | 1 | 1 | 0 |
| rifapentine | | N-alkylpiperazine;
N-iminopiperazine;
rifamycins | antitubercular agent;
leprostatic drug | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| alanosine | | | | 2008 | 2010 | 15.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| bl 4162a | | imidazoquinazoline | anticoagulant;
antifibrinolytic drug;
cardiovascular drug;
platelet aggregation inhibitor | 2011 | 2016 | 10.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| tegaserod | | carboxamidine;
guanidines;
hydrazines;
indoles | gastrointestinal drug;
serotonergic agonist | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pemetrexed | | N-acyl-L-glutamic acid;
pyrrolopyrimidine | antimetabolite;
antineoplastic agent;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
EC 2.1.1.45 (thymidylate synthase) inhibitor;
EC 2.1.2.2 (phosphoribosylglycinamide formyltransferase) inhibitor | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 7-deazaguanosine | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tirapazamine | | aromatic amine;
benzotriazines;
N-oxide | antibacterial agent;
antineoplastic agent;
apoptosis inducer | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sildenafil citrate | | citrate salt | EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| valganciclovir | | L-valyl ester;
purines | antiviral drug;
prodrug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| aprepitant | | (trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
triazoles | antidepressant;
antiemetic;
neurokinin-1 receptor antagonist;
peripheral nervous system drug;
substance P receptor antagonist | 2013 | 2016 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| fosaprepitant | | (trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
phosphoramide;
triazoles | antiemetic;
neurokinin-1 receptor antagonist;
prodrug | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tegaserod maleate | | maleate salt | serotonergic agonist | 2013 | 2013 | 11.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
| pyrazofurin | | C-glycosyl compound;
pyrazoles | antimetabolite;
antimicrobial agent;
antineoplastic agent;
EC 4.1.1.23 (orotidine-5'-phosphate decarboxylase) inhibitor | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| rifabutin | | | | 2004 | 2016 | 13.2 | medium | 0 | 0 | 0 | 2 | 2 | 0 |
| n(10)-methylfolate | | folic acids | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 5-methyltetrahydrohomofolic acid | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ninopterin | | | | 2008 | 2008 | 16.0 | medium | 0 | 0 | 0 | 1 | 0 | 0 |
| levomefolate calcium | | organic calcium salt | antidepressant | 2016 | 2016 | 8.0 | medium | 0 | 0 | 0 | 0 | 1 | 0 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 21, Issue:12, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 22, Issue:2, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 21, Issue:12, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 21, Issue:12, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 21, Issue:12, 2011
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 22, Issue:2, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 22, Issue:2, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 21, Issue:12, 2011
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 21, Issue:12, 2011
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 21, Issue:12, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 21, Issue:12, 2011
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 21, Issue:12, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 22, Issue:2, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 21, Issue:12, 2011
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 21, Issue:12, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 22, Issue:2, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 22, Issue:2, 2012
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 22, Issue:2, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 22, Issue:2, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 22, Issue:2, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 22, Issue:2, 2012
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 21, Issue:12, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 21, Issue:12, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 21, Issue:12, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 22, Issue:2, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Design, synthesis and evaluation of novel 2-butyl-4-chloroimidazole derived peptidomimetics as Angiotensin Converting Enzyme (ACE) inhibitors.Bioorganic & medicinal chemistry, , Jul-01, Volume: 23, Issue:13, 2015
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 22, Issue:2, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 22, Issue:2, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 21, Issue:12, 2011
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 22, Issue:2, 2012
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 22, Issue:2, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 22, Issue:2, 2012
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 22, Issue:2, 2012
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 22, Issue:2, 2012
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Design, synthesis and evaluation of novel 2-butyl-4-chloroimidazole derived peptidomimetics as Angiotensin Converting Enzyme (ACE) inhibitors.Bioorganic & medicinal chemistry, , Jul-01, Volume: 23, Issue:13, 2015
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Design, synthesis and evaluation of novel 2-hydroxypyrrolobenzodiazepine-5,11-dione analogues as potent angiotensin converting enzyme (ACE) inhibitors.Bioorganic & medicinal chemistry, , Aug-01, Volume: 21, Issue:15, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Design, synthesis and evaluation of novel 2-butyl-4-chloroimidazole derived peptidomimetics as Angiotensin Converting Enzyme (ACE) inhibitors.Bioorganic & medicinal chemistry, , Jul-01, Volume: 23, Issue:13, 2015
Design, synthesis and evaluation of novel 2-hydroxypyrrolobenzodiazepine-5,11-dione analogues as potent angiotensin converting enzyme (ACE) inhibitors.Bioorganic & medicinal chemistry, , Aug-01, Volume: 21, Issue:15, 2013
Capture hydrolysis signals in the microsomal stability assay: molecular mechanisms of the alkyl ester drug and prodrug metabolism.Bioorganic & medicinal chemistry letters, , Jan-15, Volume: 22, Issue:2, 2012
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 21, Issue:12, 2011
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Design, synthesis and evaluation of novel 2-butyl-4-chloroimidazole derived peptidomimetics as Angiotensin Converting Enzyme (ACE) inhibitors.Bioorganic & medicinal chemistry, , Jul-01, Volume: 23, Issue:13, 2015
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 21, Issue:12, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
Protease inhibitors: current status and future prospects.Journal of medicinal chemistry, , Feb-10, Volume: 43, Issue:3, 2000
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Lipophilicity of acidic compounds: impact of ion pair partitioning on drug design.Bioorganic & medicinal chemistry letters, , Jun-15, Volume: 21, Issue:12, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Prediction of drug intestinal absorption by new linear and non-linear QSPR.European journal of medicinal chemistry, , Volume: 46, Issue:1, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.Journal of medicinal chemistry, , Nov-13, Volume: 51, Issue:21, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
| Substance | Studies | Classes | Roles | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| acetic acid | | monocarboxylic acid | antimicrobial food preservative;
Daphnia magna metabolite;
food acidity regulator;
protic solvent | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| quinacrine | | acridines;
aromatic ether;
organochlorine compound;
tertiary amino compound | antimalarial;
EC 1.8.1.12 (trypanothione-disulfide reductase) inhibitor | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| formic acid | | monocarboxylic acid | antibacterial agent;
astringent;
metabolite;
protic solvent;
solvent | 2006 | 2006 | 18.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| citric acid, anhydrous | | tricarboxylic acid | antimicrobial agent;
chelator;
food acidity regulator;
fundamental metabolite | 1992 | 2010 | 20.0 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| chlorine | | halide anion;
monoatomic chlorine | cofactor;
Escherichia coli metabolite;
human metabolite | 1990 | 1993 | 32.7 | low | 1 | 0 | 3 | 0 | 0 | 0 |
| salicylic acid | | monohydroxybenzoic acid | algal metabolite;
antifungal agent;
antiinfective agent;
EC 1.11.1.11 (L-ascorbate peroxidase) inhibitor;
keratolytic drug;
plant hormone;
plant metabolite | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| gallic acid | | trihydroxybenzoic acid | antineoplastic agent;
antioxidant;
apoptosis inducer;
astringent;
cyclooxygenase 2 inhibitor;
EC 1.13.11.33 (arachidonate 15-lipoxygenase) inhibitor;
geroprotector;
human xenobiotic metabolite;
plant metabolite | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| hydrogen sulfide | | gas molecular entity;
hydracid;
mononuclear parent hydride;
sulfur hydride | Escherichia coli metabolite;
genotoxin;
metabolite;
signalling molecule;
toxin;
vasodilator agent | 2008 | 2016 | 12.7 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| n(g),n(g')-dimethyl-l-arginine | | alpha-amino acid | | 2007 | 2015 | 13.0 | low | 3 | 0 | 0 | 2 | 3 | 0 |
| creatine | | glycine derivative;
guanidines;
zwitterion | geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent;
nutraceutical | 2005 | 2014 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| lactic acid | | 2-hydroxy monocarboxylic acid | algal metabolite;
Daphnia magna metabolite | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| dimethyl sulfoxide | | sulfoxide;
volatile organic compound | alkylating agent;
antidote;
Escherichia coli metabolite;
geroprotector;
MRI contrast agent;
non-narcotic analgesic;
polar aprotic solvent;
radical scavenger | 1989 | 1990 | 34.5 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| formaldehyde | | aldehyde;
one-carbon compound | allergen;
carcinogenic agent;
disinfectant;
EC 3.5.1.4 (amidase) inhibitor;
environmental contaminant;
Escherichia coli metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| glycerol | | alditol;
triol | algal metabolite;
detergent;
Escherichia coli metabolite;
geroprotector;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
solvent | 2008 | 2020 | 10.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| glyoxylic acid | | 2-oxo monocarboxylic acid;
aldehydic acid | Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| dalteparin | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| histamine | | aralkylamino compound;
imidazoles | human metabolite;
mouse metabolite;
neurotransmitter | 1987 | 1987 | 37.0 | low | 1 | 1 | 0 | 0 | 0 | 0 |
| methanol | | alkyl alcohol;
one-carbon compound;
primary alcohol;
volatile organic compound | amphiprotic solvent;
Escherichia coli metabolite;
fuel;
human metabolite;
mouse metabolite;
Mycoplasma genitalium metabolite | 2006 | 2006 | 18.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| niacinamide | | pyridine alkaloid;
pyridinecarboxamide;
vitamin B3 | anti-inflammatory agent;
antioxidant;
cofactor;
EC 2.4.2.30 (NAD(+) ADP-ribosyltransferase) inhibitor;
EC 3.5.1.98 (histone deacetylase) inhibitor;
Escherichia coli metabolite;
geroprotector;
human urinary metabolite;
metabolite;
mouse metabolite;
neuroprotective agent;
Saccharomyces cerevisiae metabolite;
Sir2 inhibitor | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| niacin | | pyridine alkaloid;
pyridinemonocarboxylic acid;
vitamin B3 | antidote;
antilipemic drug;
EC 3.5.1.19 (nicotinamidase) inhibitor;
Escherichia coli metabolite;
human urinary metabolite;
metabolite;
mouse metabolite;
plant metabolite;
vasodilator agent | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| nitrates | | monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species | | 1998 | 2007 | 22.7 | low | 0 | 0 | 2 | 1 | 0 | 0 |
| nitric acid | | nitrogen oxoacid | protic solvent;
reagent | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| nitrites | | monovalent inorganic anion;
nitrogen oxoanion;
reactive nitrogen species | human metabolite | 1997 | 2010 | 21.4 | low | 0 | 0 | 3 | 2 | 0 | 0 |
| 4-aminobenzoic acid | | aminobenzoic acid;
aromatic amino-acid zwitterion | allergen;
Escherichia coli metabolite;
plant metabolite | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pyrogallol | | benzenetriol;
phenolic donor | plant metabolite | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| uric acid | | uric acid | Escherichia coli metabolite;
human metabolite;
mouse metabolite | 1987 | 1996 | 32.8 | low | 2 | 1 | 3 | 0 | 0 | 0 |
| urea | | isourea;
monocarboxylic acid amide;
one-carbon compound | Daphnia magna metabolite;
Escherichia coli metabolite;
fertilizer;
flour treatment agent;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 1991 | 1991 | 33.0 | low | 1 | 0 | 1 | 0 | 0 | 0 |
| 1-anilino-8-naphthalenesulfonate | | aminonaphthalene;
naphthalenesulfonic acid | fluorescent probe | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mercaptoethanol | | alkanethiol;
primary alcohol | geroprotector | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| 3,4-dichloroisocoumarin | | isocoumarins;
organochlorine compound | geroprotector;
serine protease inhibitor | 1998 | 1999 | 25.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| phenytoin | | imidazolidine-2,4-dione | anticonvulsant;
drug allergen;
sodium channel blocker;
teratogenic agent | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| acetaminophen | | acetamides;
phenols | antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
cyclooxygenase 3 inhibitor;
environmental contaminant;
ferroptosis inducer;
geroprotector;
hepatotoxic agent;
human blood serum metabolite;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| albuterol | | phenols;
phenylethanolamines;
secondary amino compound | beta-adrenergic agonist;
bronchodilator agent;
environmental contaminant;
xenobiotic | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pimagedine | | guanidines;
one-carbon compound | EC 1.14.13.39 (nitric oxide synthase) inhibitor;
EC 1.4.3.4 (monoamine oxidase) inhibitor | 2000 | 2003 | 22.6 | low | 0 | 0 | 1 | 4 | 0 | 0 |
| p-aminohippuric acid | | N-acylglycine | Daphnia magna metabolite | 1989 | 2009 | 25.2 | low | 3 | 1 | 2 | 2 | 0 | 0 |
| amiodarone | | 1-benzofurans;
aromatic ketone;
organoiodine compound;
tertiary amino compound | cardiovascular drug | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| amitriptyline | | carbotricyclic compound;
tertiary amine | adrenergic uptake inhibitor;
antidepressant;
environmental contaminant;
tropomyosin-related kinase B receptor agonist;
xenobiotic | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| amlodipine | | dihydropyridine;
ethyl ester;
methyl ester;
monochlorobenzenes;
primary amino compound | antihypertensive agent;
calcium channel blocker;
vasodilator agent | 1994 | 2022 | 15.8 | low | 31 | 0 | 13 | 41 | 31 | 4 |
| acetovanillone | | acetophenones;
aromatic ketone;
methyl ketone | antirheumatic drug;
EC 1.6.3.1. [NAD(P)H oxidase (H2O2-forming)] inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
peripheral nervous system drug;
plant metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| aspirin | | benzoic acids;
phenyl acetates;
salicylates | anticoagulant;
antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
EC 1.1.1.188 (prostaglandin-F synthase) inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
plant activator;
platelet aggregation inhibitor;
prostaglandin antagonist;
teratogenic agent | 1996 | 2023 | 11.7 | low | 10 | 0 | 4 | 10 | 24 | 4 |
| atenolol | | ethanolamines;
monocarboxylic acid amide;
propanolamine | anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
sympatholytic agent;
xenobiotic | 1991 | 2020 | 17.4 | low | 19 | 0 | 9 | 13 | 12 | 0 |
| azathioprine | | aryl sulfide;
C-nitro compound;
imidazoles;
thiopurine | antimetabolite;
antineoplastic agent;
carcinogenic agent;
DNA synthesis inhibitor;
hepatotoxic agent;
immunosuppressive agent;
prodrug | 2010 | 2014 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| bay-k-8644 | | (trifluoromethyl)benzenes;
C-nitro compound;
dihydropyridine;
methyl ester | | 1993 | 2002 | 27.7 | low | 0 | 0 | 2 | 1 | 0 | 0 |
| bendroflumethiazide | | benzothiadiazine;
sulfonamide | antihypertensive agent;
diuretic | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| bepridil | | pyrrolidines;
tertiary amine | anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| bisoprolol | | secondary alcohol;
secondary amine | anti-arrhythmia drug;
antihypertensive agent;
beta-adrenergic antagonist;
sympatholytic agent | 1995 | 2021 | 11.2 | low | 4 | 0 | 1 | 3 | 14 | 2 |
| bumetanide | | amino acid;
benzoic acids;
sulfonamide | diuretic;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor | 2001 | 2003 | 22.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| caffeine | | purine alkaloid;
trimethylxanthine | adenosine A2A receptor antagonist;
adenosine receptor antagonist;
adjuvant;
central nervous system stimulant;
diuretic;
EC 2.7.11.1 (non-specific serine/threonine protein kinase) inhibitor;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
environmental contaminant;
food additive;
fungal metabolite;
geroprotector;
human blood serum metabolite;
mouse metabolite;
mutagen;
plant metabolite;
psychotropic drug;
ryanodine receptor agonist;
xenobiotic | 1993 | 2001 | 27.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| verapamil | | aromatic ether;
nitrile;
polyether;
tertiary amino compound | | 1991 | 2014 | 18.5 | low | 3 | 0 | 1 | 3 | 2 | 0 |
| candesartan cilexetil | | biphenyls | | 1999 | 2007 | 20.2 | low | 0 | 0 | 1 | 3 | 0 | 0 |
| candesartan | | benzimidazolecarboxylic acid;
biphenylyltetrazole | angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic | 1999 | 2022 | 14.7 | low | 10 | 0 | 2 | 18 | 10 | 1 |
| carvedilol | | carbazoles;
secondary alcohol;
secondary amino compound | alpha-adrenergic antagonist;
antihypertensive agent;
beta-adrenergic antagonist;
cardiovascular drug;
vasodilator agent | 2002 | 2019 | 13.3 | low | 3 | 0 | 0 | 6 | 5 | 0 |
| celecoxib | | organofluorine compound;
pyrazoles;
sulfonamide;
toluenes | cyclooxygenase 2 inhibitor;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2005 | 2021 | 11.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| celiprolol | | aromatic ketone | | 1996 | 1997 | 27.5 | low | 2 | 0 | 2 | 0 | 0 | 0 |
| chlorpheniramine | | monochlorobenzenes;
pyridines;
tertiary amino compound | anti-allergic agent;
antidepressant;
antipruritic drug;
H1-receptor antagonist;
histamine antagonist;
serotonin uptake inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| chlorthalidone | | isoindoles;
monochlorobenzenes;
sulfonamide | | 1995 | 2018 | 18.7 | low | 1 | 0 | 1 | 1 | 1 | 0 |
| cilostazol | | lactam;
tetrazoles | anticoagulant;
bronchodilator agent;
EC 3.1.4.17 (3',5'-cyclic-nucleotide phosphodiesterase) inhibitor;
fibrin modulating drug;
neuroprotective agent;
platelet aggregation inhibitor;
vasodilator agent | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ciprofloxacin | | aminoquinoline;
cyclopropanes;
fluoroquinolone antibiotic;
N-arylpiperazine;
quinolinemonocarboxylic acid;
quinolone antibiotic;
quinolone;
zwitterion | antibacterial drug;
antiinfective agent;
antimicrobial agent;
DNA synthesis inhibitor;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor;
environmental contaminant;
topoisomerase IV inhibitor;
xenobiotic | 2008 | 2022 | 9.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| clonidine | | clonidine;
imidazoline | | 1984 | 2011 | 26.5 | low | 0 | 1 | 0 | 0 | 1 | 0 |
| desipramine | | dibenzoazepine;
secondary amino compound | adrenergic uptake inhibitor;
alpha-adrenergic antagonist;
antidepressant;
cholinergic antagonist;
drug allergen;
EC 3.1.4.12 (sphingomyelin phosphodiesterase) inhibitor;
EC 3.4.21.26 (prolyl oligopeptidase) inhibitor;
H1-receptor antagonist;
serotonin uptake inhibitor | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| diclofenac | | amino acid;
aromatic amine;
dichlorobenzene;
monocarboxylic acid;
secondary amino compound | antipyretic;
drug allergen;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic | 1994 | 2022 | 16.8 | low | 0 | 0 | 2 | 0 | 1 | 1 |
| diphenhydramine | | ether;
tertiary amino compound | anti-allergic agent;
antidyskinesia agent;
antiemetic;
antiparkinson drug;
antipruritic drug;
antitussive;
H1-receptor antagonist;
local anaesthetic;
muscarinic antagonist;
oneirogen;
sedative | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| valproic acid | | branched-chain fatty acid;
branched-chain saturated fatty acid | anticonvulsant;
antimanic drug;
EC 3.5.1.98 (histone deacetylase) inhibitor;
GABA agent;
neuroprotective agent;
psychotropic drug;
teratogenic agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| thiorphan | | N-acyl-amino acid | | 1998 | 1999 | 25.2 | low | 0 | 0 | 4 | 0 | 0 | 0 |
| doxazosin | | aromatic amine;
benzodioxine;
monocarboxylic acid amide;
N-acylpiperazine;
N-arylpiperazine;
quinazolines | alpha-adrenergic antagonist;
antihyperplasia drug;
antihypertensive agent;
antineoplastic agent;
vasodilator agent | 2007 | 2020 | 7.5 | low | 3 | 0 | 0 | 1 | 5 | 0 |
| felodipine | | dichlorobenzene;
dihydropyridine;
ethyl ester;
methyl ester | anti-arrhythmia drug;
antihypertensive agent;
calcium channel blocker;
vasodilator agent | 1991 | 2016 | 25.3 | low | 18 | 0 | 20 | 6 | 1 | 0 |
| fenofibrate | | aromatic ether;
chlorobenzophenone;
isopropyl ester;
monochlorobenzenes | antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| fluoxetine | | (trifluoromethyl)benzenes;
aromatic ether;
secondary amino compound | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| flurbiprofen | | fluorobiphenyl;
monocarboxylic acid | antipyretic;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| furosemide | | chlorobenzoic acid;
furans;
sulfonamide | environmental contaminant;
loop diuretic;
xenobiotic | 1989 | 2022 | 17.5 | low | 10 | 2 | 7 | 5 | 7 | 5 |
| gliclazide | | N-sulfonylurea | hypoglycemic agent;
insulin secretagogue;
radical scavenger | 2009 | 2021 | 9.0 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| glimepiride | | sulfonamide | | 2005 | 2018 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| glyburide | | monochlorobenzenes;
N-sulfonylurea | anti-arrhythmia drug;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 3.6.3.49 (channel-conductance-controlling ATPase) inhibitor;
hypoglycemic agent | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| haloperidol | | aromatic ketone;
hydroxypiperidine;
monochlorobenzenes;
organofluorine compound;
tertiary alcohol | antidyskinesia agent;
antiemetic;
dopaminergic antagonist;
first generation antipsychotic;
serotonergic antagonist | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| hydralazine | | azaarene;
hydrazines;
ortho-fused heteroarene;
phthalazines | antihypertensive agent;
vasodilator agent | 1993 | 2017 | 20.8 | low | 1 | 0 | 5 | 1 | 3 | 0 |
| hydrochlorothiazide | | benzothiadiazine;
organochlorine compound;
sulfonamide | antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic | 1987 | 2020 | 17.7 | low | 26 | 3 | 12 | 19 | 25 | 0 |
| ibuprofen | | monocarboxylic acid | antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
geroprotector;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
radical scavenger;
xenobiotic | 2003 | 2022 | 12.3 | low | 0 | 0 | 0 | 2 | 0 | 1 |
| lidocaine | | benzenes;
monocarboxylic acid amide;
tertiary amino compound | anti-arrhythmia drug;
drug allergen;
environmental contaminant;
local anaesthetic;
xenobiotic | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| indapamide | | indoles;
organochlorine compound;
sulfonamide | antihypertensive agent;
diuretic | 2003 | 2016 | 17.2 | low | 0 | 0 | 0 | 4 | 1 | 0 |
| indomethacin | | aromatic ether;
indole-3-acetic acids;
monochlorobenzenes;
N-acylindole | analgesic;
drug metabolite;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
environmental contaminant;
gout suppressant;
non-steroidal anti-inflammatory drug;
xenobiotic metabolite;
xenobiotic | 1987 | 2002 | 30.0 | low | 1 | 5 | 8 | 1 | 0 | 0 |
| avapro | | azaspiro compound;
biphenylyltetrazole | angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic | 2001 | 2020 | 15.0 | low | 12 | 0 | 0 | 16 | 7 | 0 |
| 1-methyl-3-isobutylxanthine | | 3-isobutyl-1-methylxanthine | | 1992 | 1994 | 31.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| 2-propanol | | secondary alcohol;
secondary fatty alcohol | protic solvent | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| isoproterenol | | catechols;
secondary alcohol;
secondary amino compound | beta-adrenergic agonist;
bronchodilator agent;
cardiotonic drug;
sympathomimetic agent | 1993 | 2023 | 17.9 | low | 0 | 0 | 4 | 2 | 2 | 1 |
| isradipine | | benzoxadiazole;
dihydropyridine;
isopropyl ester;
methyl ester | | 1994 | 2000 | 27.5 | low | 0 | 0 | 4 | 0 | 0 | 0 |
| kynurenic acid | | monohydroxyquinoline;
quinolinemonocarboxylic acid | G-protein-coupled receptor agonist;
human metabolite;
neuroprotective agent;
nicotinic antagonist;
NMDA receptor antagonist;
Saccharomyces cerevisiae metabolite | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| labetalol | | benzamides;
benzenes;
phenols;
primary carboxamide;
salicylamides;
secondary alcohol;
secondary amino compound | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| loratadine | | benzocycloheptapyridine;
ethyl ester;
N-acylpiperidine;
organochlorine compound;
tertiary carboxamide | anti-allergic agent;
cholinergic antagonist;
geroprotector;
H1-receptor antagonist | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| losartan | | biphenylyltetrazole;
imidazoles | angiotensin receptor antagonist;
anti-arrhythmia drug;
antihypertensive agent;
endothelin receptor antagonist | 1991 | 2022 | 19.8 | low | 21 | 0 | 30 | 49 | 20 | 1 |
| manidipine | | diarylmethane | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| meclofenamic acid | | aminobenzoic acid;
organochlorine compound;
secondary amino compound | analgesic;
anticonvulsant;
antineoplastic agent;
antipyretic;
antirheumatic drug;
EC 1.13.11.34 (arachidonate 5-lipoxygenase) inhibitor;
EC 1.14.99.1 (prostaglandin-endoperoxide synthase) inhibitor;
non-steroidal anti-inflammatory drug | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| mesalamine | | amino acid;
aromatic amine;
monocarboxylic acid;
monohydroxybenzoic acid;
phenols | non-steroidal anti-inflammatory drug | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| metformin | | guanidines | environmental contaminant;
geroprotector;
hypoglycemic agent;
xenobiotic | 2002 | 2022 | 10.7 | low | 0 | 0 | 0 | 3 | 1 | 2 |
| metolazone | | organochlorine compound;
quinazolines;
sulfonamide | antihypertensive agent;
diuretic;
ion transport inhibitor | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| metoprolol | | aromatic ether;
propanolamine;
secondary alcohol;
secondary amino compound | antihypertensive agent;
beta-adrenergic antagonist;
environmental contaminant;
geroprotector;
xenobiotic | 1994 | 2023 | 16.9 | low | 18 | 0 | 7 | 18 | 10 | 1 |
| midazolam | | imidazobenzodiazepine;
monofluorobenzenes;
organochlorine compound | anticonvulsant;
antineoplastic agent;
anxiolytic drug;
apoptosis inducer;
central nervous system depressant;
GABAA receptor agonist;
general anaesthetic;
muscle relaxant;
sedative | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| activins | | | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nevirapine | | cyclopropanes;
dipyridodiazepine | antiviral drug;
HIV-1 reverse transcriptase inhibitor | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nicardipine | | benzenes;
C-nitro compound;
diester;
dihydropyridine;
methyl ester;
tertiary amino compound | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| nifedipine | | C-nitro compound;
dihydropyridine;
methyl ester | calcium channel blocker;
human metabolite;
tocolytic agent;
vasodilator agent | 1989 | 2020 | 21.0 | low | 1 | 1 | 3 | 2 | 2 | 0 |
| nisoldipine | | C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
methyl ester | | 1999 | 1999 | 25.0 | low | 1 | 0 | 1 | 0 | 0 | 0 |
| nitrendipine | | C-nitro compound;
dicarboxylic acids and O-substituted derivatives;
diester;
dihydropyridine;
ethyl ester;
methyl ester | antihypertensive agent;
calcium channel blocker;
geroprotector;
vasodilator agent | 1992 | 1999 | 28.2 | low | 4 | 0 | 5 | 0 | 0 | 0 |
| nitroglycerin | | nitroglycerol | explosive;
muscle relaxant;
nitric oxide donor;
prodrug;
tocolytic agent;
vasodilator agent;
xenobiotic | 1993 | 2006 | 25.8 | low | 0 | 0 | 4 | 1 | 0 | 0 |
| n-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide | | aromatic ether;
C-nitro compound;
sulfonamide | antineoplastic agent;
cyclooxygenase 2 inhibitor | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ofloxacin | | 3-oxo monocarboxylic acid;
N-arylpiperazine;
N-methylpiperazine;
organofluorine compound;
oxazinoquinoline | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| omeprazole | | aromatic ether;
benzimidazoles;
pyridines;
sulfoxide | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| oxidopamine | | benzenetriol;
catecholamine;
primary amino compound | drug metabolite;
human metabolite;
neurotoxin | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| aminosalicylic acid | | aminobenzoic acid;
phenols | antitubercular agent | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| moxonidine | | organohalogen compound;
pyrimidines | | 1996 | 2004 | 25.3 | low | 0 | 0 | 2 | 1 | 0 | 0 |
| pimobendan | | benzimidazoles;
pyridazinone | cardiotonic drug;
EC 3.1.4.* (phosphoric diester hydrolase) inhibitor;
vasodilator agent | 2002 | 2021 | 8.1 | low | 2 | 0 | 0 | 2 | 1 | 4 |
| pioglitazone | | aromatic ether;
pyridines;
thiazolidinediones | antidepressant;
cardioprotective agent;
EC 2.7.1.33 (pantothenate kinase) inhibitor;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
geroprotector;
hypoglycemic agent;
insulin-sensitizing drug;
PPARgamma agonist;
xenobiotic | 2008 | 2014 | 13.8 | low | 2 | 0 | 0 | 2 | 2 | 0 |
| piretanide | | aromatic ether | | 1987 | 1995 | 33.0 | low | 4 | 4 | 5 | 0 | 0 | 0 |
| potassium chloride | | inorganic chloride;
inorganic potassium salt;
potassium salt | fertilizer | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| 4-aminobenzoic acid | | aminobenzoate;
aromatic amino-acid anion | Escherichia coli metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| propidium | | phenanthridines;
quaternary ammonium ion | fluorochrome;
intercalator | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| propranolol | | naphthalenes;
propanolamine;
secondary amine | anti-arrhythmia drug;
antihypertensive agent;
anxiolytic drug;
beta-adrenergic antagonist;
environmental contaminant;
human blood serum metabolite;
vasodilator agent;
xenobiotic | 1993 | 2014 | 18.2 | low | 2 | 0 | 1 | 3 | 1 | 0 |
| rofecoxib | | butenolide;
sulfone | analgesic;
cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug | 2000 | 2001 | 23.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| sibutramine | | organochlorine compound;
tertiary amino compound | anti-obesity agent;
serotonin uptake inhibitor | 2007 | 2007 | 17.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| sulfamethoxazole | | isoxazoles;
substituted aniline;
sulfonamide antibiotic;
sulfonamide | antibacterial agent;
antiinfective agent;
antimicrobial agent;
drug allergen;
EC 1.1.1.153 [sepiapterin reductase (L-erythro-7,8-dihydrobiopterin forming)] inhibitor;
EC 2.5.1.15 (dihydropteroate synthase) inhibitor;
environmental contaminant;
epitope;
P450 inhibitor;
xenobiotic | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| sulfasalazine | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| terbutaline | | phenylethanolamines;
resorcinols | anti-asthmatic drug;
beta-adrenergic agonist;
bronchodilator agent;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
hypoglycemic agent;
sympathomimetic agent;
tocolytic agent | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tetraethylammonium | | quaternary ammonium ion | | 1994 | 2002 | 26.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| 2,4-thiazolidinedione | | thiazolidenedione | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ticlopidine | | monochlorobenzenes;
thienopyridine | anticoagulant;
fibrin modulating drug;
hematologic agent;
P2Y12 receptor antagonist;
platelet aggregation inhibitor | 1993 | 2016 | 15.2 | low | 1 | 0 | 1 | 2 | 3 | 0 |
| 8-(n,n-diethylamino)octyl-3,4,5-trimethoxybenzoate | | trihydroxybenzoic acid | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| trimethoprim | | aminopyrimidine;
methoxybenzenes | antibacterial drug;
diuretic;
drug allergen;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
environmental contaminant;
xenobiotic | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| troglitazone | | chromanes;
thiazolidinone | anticoagulant;
anticonvulsant;
antineoplastic agent;
antioxidant;
EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
hypoglycemic agent;
platelet aggregation inhibitor;
vasodilator agent | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tyramine | | monoamine molecular messenger;
primary amino compound;
tyramines | EC 3.1.1.8 (cholinesterase) inhibitor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
neurotransmitter | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| urapidil | | piperazines | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| corticosterone | | 11beta-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone | human metabolite;
mouse metabolite | 1991 | 2012 | 23.2 | low | 0 | 0 | 2 | 1 | 1 | 0 |
| prednisolone | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
drug metabolite;
environmental contaminant;
immunosuppressive agent;
xenobiotic | 2003 | 2018 | 14.8 | low | 1 | 0 | 0 | 2 | 2 | 0 |
| alloxan | | pyrimidone | hyperglycemic agent;
metabolite | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| thymidine | | pyrimidine 2'-deoxyribonucleoside | Escherichia coli metabolite;
human metabolite;
metabolite;
mouse metabolite | 1993 | 1995 | 30.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| hydroxyproline | | 4-hydroxyproline;
L-alpha-amino acid zwitterion | human metabolite;
mouse metabolite;
plant metabolite | 2000 | 2008 | 20.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| thyroxine | | 2-halophenol;
iodophenol;
L-phenylalanine derivative;
non-proteinogenic L-alpha-amino acid;
thyroxine zwitterion;
thyroxine | antithyroid drug;
human metabolite;
mouse metabolite;
thyroid hormone | 1997 | 2017 | 17.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| carbachol | | ammonium salt;
carbamate ester | cardiotonic drug;
miotic;
muscarinic agonist;
nicotinic acetylcholine receptor agonist;
non-narcotic analgesic | 1997 | 2001 | 25.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| spironolactone | | 3-oxo-Delta(4) steroid;
oxaspiro compound;
steroid lactone;
thioester | aldosterone antagonist;
antihypertensive agent;
diuretic;
environmental contaminant;
xenobiotic | 1997 | 2023 | 13.2 | low | 5 | 0 | 3 | 7 | 13 | 2 |
| aldosterone | | 11beta-hydroxy steroid;
18-oxo steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid hormone;
mineralocorticoid;
primary alpha-hydroxy ketone;
steroid aldehyde | human metabolite;
mouse metabolite | 1984 | 2020 | 24.1 | low | 16 | 5 | 9 | 13 | 3 | 0 |
| penicillamine | | non-proteinogenic alpha-amino acid;
penicillamine | antirheumatic drug;
chelator;
copper chelator;
drug allergen | 1999 | 2001 | 24.0 | low | 0 | 0 | 4 | 2 | 0 | 0 |
| prednisone | | 11-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(1),Delta(4)-steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | adrenergic agent;
anti-inflammatory drug;
antineoplastic agent;
immunosuppressive agent;
prodrug | 1993 | 2019 | 16.3 | low | 2 | 0 | 1 | 4 | 1 | 0 |
| desoxycorticosterone acetate | | corticosteroid hormone | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lysine | | aspartate family amino acid;
L-alpha-amino acid zwitterion;
L-alpha-amino acid;
lysine;
organic molecular entity;
proteinogenic amino acid | algal metabolite;
anticonvulsant;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite | 1998 | 2021 | 17.5 | low | 0 | 0 | 1 | 4 | 0 | 1 |
| sucrose | | glycosyl glycoside | algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
osmolyte;
Saccharomyces cerevisiae metabolite;
sweetening agent | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tubocurarine | | bisbenzylisoquinoline alkaloid | drug allergen;
muscle relaxant;
nicotinic antagonist | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| adenosine diphosphate | | adenosine 5'-phosphate;
purine ribonucleoside 5'-diphosphate | fundamental metabolite;
human metabolite | 1994 | 2012 | 20.0 | low | 1 | 0 | 1 | 1 | 1 | 0 |
| carbostyril | | monohydroxyquinoline;
quinolone | bacterial xenobiotic metabolite | 1995 | 1997 | 28.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| phenylephrine | | phenols;
phenylethanolamines;
secondary amino compound | alpha-adrenergic agonist;
cardiotonic drug;
mydriatic agent;
nasal decongestant;
protective agent;
sympathomimetic agent;
vasoconstrictor agent | 1993 | 2023 | 23.7 | low | 0 | 0 | 4 | 1 | 0 | 1 |
| leucine | | amino acid zwitterion;
L-alpha-amino acid;
leucine;
proteinogenic amino acid;
pyruvate family amino acid | algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| phenylalanine | | amino acid zwitterion;
erythrose 4-phosphate/phosphoenolpyruvate family amino acid;
L-alpha-amino acid;
phenylalanine;
proteinogenic amino acid | algal metabolite;
EC 3.1.3.1 (alkaline phosphatase) inhibitor;
Escherichia coli metabolite;
human xenobiotic metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
Saccharomyces cerevisiae metabolite | 2001 | 2002 | 22.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| desoxycorticosterone | | 20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
mineralocorticoid;
primary alpha-hydroxy ketone | human metabolite;
mouse metabolite | 1994 | 2001 | 26.0 | low | 0 | 0 | 2 | 1 | 0 | 0 |
| egtazic acid | | diether;
tertiary amino compound;
tetracarboxylic acid | chelator | 1988 | 1993 | 33.3 | low | 0 | 1 | 2 | 0 | 0 | 0 |
| mannitol | | mannitol | allergen;
antiglaucoma drug;
compatible osmolytes;
Escherichia coli metabolite;
food anticaking agent;
food bulking agent;
food humectant;
food stabiliser;
food thickening agent;
hapten;
metabolite;
osmotic diuretic;
sweetening agent | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cytarabine | | beta-D-arabinoside;
monosaccharide derivative;
pyrimidine nucleoside | antimetabolite;
antineoplastic agent;
antiviral agent;
immunosuppressive agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ornithine | | non-proteinogenic L-alpha-amino acid;
ornithine | algal metabolite;
hepatoprotective agent;
mouse metabolite | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| valine | | L-alpha-amino acid zwitterion;
L-alpha-amino acid;
proteinogenic amino acid;
pyruvate family amino acid;
valine | algal metabolite;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite | 1995 | 2013 | 17.7 | low | 13 | 0 | 6 | 21 | 8 | 0 |
| arginine | | arginine;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid | biomarker;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical | 1992 | 2015 | 25.1 | low | 6 | 0 | 18 | 7 | 3 | 0 |
| tromethamine | | primary amino compound;
triol | buffer | 1993 | 2012 | 21.5 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| ethyl citrate | | carbonyl compound | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methylprednisolone | | 6-methylprednisolone;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | adrenergic agent;
anti-inflammatory drug;
antiemetic;
environmental contaminant;
neuroprotective agent;
xenobiotic | 1993 | 2008 | 23.5 | low | 1 | 0 | 1 | 1 | 0 | 0 |
| dichlorodicyanobenzoquinone | | | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| isosorbide dinitrate | | glucitol derivative;
nitrate ester | nitric oxide donor;
vasodilator agent | 2003 | 2006 | 19.5 | low | 2 | 0 | 0 | 2 | 0 | 0 |
| n-vinyl-2-pyrrolidinone | | pyrrolidin-2-ones | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pyrroles | | pyrrole;
secondary amine | | 1986 | 2011 | 31.2 | low | 2 | 15 | 19 | 4 | 3 | 0 |
| thiophenes | | mancude organic heteromonocyclic parent;
monocyclic heteroarene;
thiophenes;
volatile organic compound | non-polar solvent | 2009 | 2013 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| carbitol | | diether;
glycol ether;
hydroxypolyether;
primary alcohol | protic solvent | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| pyrazolanthrone | | anthrapyrazole;
aromatic ketone;
cyclic ketone | antineoplastic agent;
c-Jun N-terminal kinase inhibitor;
geroprotector | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| quinazolines | | azaarene;
mancude organic heterobicyclic parent;
ortho-fused heteroarene;
quinazolines | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| indazoles | | indazole | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| adamantane | | adamantanes;
polycyclic alkane | | 2008 | 2017 | 11.5 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| cyclopentane | | cycloalkane;
cyclopentanes;
volatile organic compound | non-polar solvent | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| oxazoles | | 1,3-oxazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene | | 2004 | 2011 | 16.0 | low | 0 | 0 | 0 | 2 | 1 | 0 |
| thiazoles | | 1,3-thiazoles;
mancude organic heteromonocyclic parent;
monocyclic heteroarene | | 2002 | 2007 | 20.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| calcium gluconate | | calcium salt | nutraceutical | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| evans blue | | organic sodium salt | fluorochrome;
histological dye;
sodium channel blocker;
teratogenic agent | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| citrulline | | amino acid zwitterion;
citrulline | Daphnia magna metabolite;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
Escherichia coli metabolite;
human metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
plant metabolite;
protective agent;
Saccharomyces cerevisiae metabolite | 2002 | 2004 | 21.0 | low | 1 | 0 | 0 | 2 | 0 | 0 |
| fluorobenzenes | | monofluorobenzenes | NMR chemical shift reference compound | 2012 | 2012 | 12.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| dihydralazine | | phthalazines | | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| oleanolic acid | | hydroxy monocarboxylic acid;
pentacyclic triterpenoid | plant metabolite | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| malondialdehyde | | dialdehyde | biomarker | 2003 | 2016 | 16.4 | low | 5 | 0 | 0 | 11 | 2 | 0 |
| eosine yellowish-(ys) | | organic sodium salt;
organobromine compound | fluorochrome;
histological dye | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| acetylcysteine | | acetylcysteine;
L-cysteine derivative;
N-acetyl-L-amino acid | antidote to paracetamol poisoning;
antiinfective agent;
antioxidant;
antiviral drug;
ferroptosis inhibitor;
geroprotector;
human metabolite;
mucolytic;
radical scavenger;
vulnerary | 2008 | 2020 | 8.0 | low | 1 | 0 | 0 | 1 | 2 | 0 |
| 4-nitrophenyl acetate | | C-nitro compound;
phenyl acetates | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| canrenone | | steroid lactone | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| d-alpha tocopherol | | alpha-tocopherol | algal metabolite;
antiatherogenic agent;
anticoagulant;
antioxidant;
antiviral agent;
EC 2.7.11.13 (protein kinase C) inhibitor;
immunomodulator;
micronutrient;
nutraceutical;
plant metabolite | 1996 | 2023 | 21.8 | low | 14 | 0 | 9 | 14 | 0 | 1 |
| tocopherols | | | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| amiloride | | aromatic amine;
guanidines;
organochlorine compound;
pyrazines | diuretic;
sodium channel blocker | 2012 | 2014 | 11.0 | low | 2 | 0 | 0 | 0 | 2 | 0 |
| fructosamine | | | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| trimetazidine | | aromatic amine | | 2010 | 2010 | 14.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| molybdenum | | chromium group element atom | micronutrient | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| samarium | | f-block element atom;
lanthanoid atom | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cadmium | | cadmium molecular entity;
zinc group element atom | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| acetylglucosamine | | N-acetyl-D-glucosamine | epitope | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| phosphoric acid, trisodium salt | | sodium phosphate | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| hypochlorous acid | | chlorine oxoacid;
reactive oxygen species | EC 2.5.1.18 (glutathione transferase) inhibitor;
EC 3.1.1.7 (acetylcholinesterase) inhibitor;
human metabolite | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| chlorine | | diatomic chlorine;
gas molecular entity | bleaching agent | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| 4-chloro-7-nitrobenzofurazan | | benzoxadiazole;
C-nitro compound;
organochlorine compound | EC 1.4.3.4 (monoamine oxidase) inhibitor;
EC 3.6.1.3 (adenosinetriphosphatase) inhibitor;
fluorescent probe;
fluorochrome | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| trolamine salicylate | | | | 1986 | 1986 | 38.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| isosorbide-5-mononitrate | | glucitol derivative;
nitrate ester | nitric oxide donor;
vasodilator agent | 2003 | 2006 | 19.5 | low | 2 | 0 | 0 | 2 | 0 | 0 |
| tetradecanoylphorbol acetate | | acetate ester;
diester;
phorbol ester;
tertiary alpha-hydroxy ketone;
tetradecanoate ester | antineoplastic agent;
apoptosis inducer;
carcinogenic agent;
mitogen;
plant metabolite;
protein kinase C agonist;
reactive oxygen species generator | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bromocriptine | | indole alkaloid | antidyskinesia agent;
antiparkinson drug;
dopamine agonist;
hormone antagonist | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cetylpyridinium chloride anhydrous | | chloride salt;
organic chloride salt | antiseptic drug;
surfactant | 2007 | 2007 | 17.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| fludrocortisone | | 11beta-hydroxy steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
fluorinated steroid;
mineralocorticoid | adrenergic agent;
anti-inflammatory drug | 2002 | 2016 | 15.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| 4-methoxyamphetamine | | | | 2001 | 2001 | 23.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| transferrin | | | | 1998 | 2000 | 25.0 | low | 1 | 0 | 2 | 0 | 0 | 0 |
| glutamic acid | | glutamic acid;
glutamine family amino acid;
L-alpha-amino acid;
proteinogenic amino acid | Escherichia coli metabolite;
ferroptosis inducer;
micronutrient;
mouse metabolite;
neurotransmitter;
nutraceutical | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| substance p | | peptide | neurokinin-1 receptor agonist;
neurotransmitter;
vasodilator agent | 1995 | 2017 | 21.0 | low | 0 | 0 | 2 | 1 | 1 | 0 |
| dobutamine | | catecholamine;
secondary amine | beta-adrenergic agonist;
cardiotonic drug;
sympathomimetic agent | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| methyldopa | | L-tyrosine derivative;
non-proteinogenic L-alpha-amino acid | alpha-adrenergic agonist;
antihypertensive agent;
hapten;
peripheral nervous system drug;
sympatholytic agent | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bezafibrate | | aromatic ether;
monocarboxylic acid amide;
monocarboxylic acid;
monochlorobenzenes | antilipemic drug;
environmental contaminant;
geroprotector;
xenobiotic | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| sq-11725 | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| diltiazem | | 5-[2-(dimethylamino)ethyl]-2-(4-methoxyphenyl)-4-oxo-2,3,4,5-tetrahydro-1,5-benzothiazepin-3-yl acetate | antihypertensive agent;
calcium channel blocker;
vasodilator agent | 1998 | 2014 | 19.9 | low | 4 | 0 | 3 | 2 | 2 | 0 |
| ng-nitroarginine methyl ester | | alpha-amino acid ester;
L-arginine derivative;
methyl ester;
N-nitro compound | EC 1.14.13.39 (nitric oxide synthase) inhibitor | 1994 | 2022 | 24.5 | low | 2 | 0 | 24 | 4 | 1 | 1 |
| torsemide | | aminopyridine;
N-sulfonylurea;
secondary amino compound | antihypertensive agent;
loop diuretic | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| epirubicin | | aminoglycoside;
anthracycline antibiotic;
anthracycline;
deoxy hexoside;
monosaccharide derivative;
p-quinones;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | antimicrobial agent;
antineoplastic agent;
EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor | 1996 | 1996 | 28.0 | low | 1 | 0 | 1 | 0 | 0 | 0 |
| enkephalin, methionine | | | | 1986 | 1987 | 37.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| captopril | | alkanethiol;
L-proline derivative;
N-acylpyrrolidine;
pyrrolidinemonocarboxylic acid | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 1984 | 2021 | 25.9 | low | 18 | 26 | 38 | 25 | 14 | 1 |
| nicorandil | | nitrate ester;
pyridinecarboxamide | potassium channel opener;
vasodilator agent | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| colforsin | | acetate ester;
cyclic ketone;
labdane diterpenoid;
organic heterotricyclic compound;
tertiary alpha-hydroxy ketone;
triol | adenylate cyclase agonist;
anti-HIV agent;
antihypertensive agent;
plant metabolite;
platelet aggregation inhibitor;
protein kinase A agonist | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| fomesafen | | aromatic ether;
C-nitro compound;
monochlorobenzenes;
N-sulfonylcarboxamide;
organofluorine compound;
phenols | agrochemical;
EC 1.3.3.4 (protoporphyrinogen oxidase) inhibitor;
herbicide | 1989 | 2010 | 29.8 | low | 2 | 3 | 0 | 1 | 0 | 0 |
| lovastatin | | delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
polyketide;
statin (naturally occurring) | anticholesteremic drug;
antineoplastic agent;
Aspergillus metabolite;
prodrug | 1994 | 1994 | 30.0 | low | 1 | 0 | 1 | 0 | 0 | 0 |
| simvastatin | | delta-lactone;
fatty acid ester;
hexahydronaphthalenes;
statin (semi-synthetic) | EC 1.1.1.34/EC 1.1.1.88 (hydroxymethylglutaryl-CoA reductase) inhibitor;
EC 3.4.24.83 (anthrax lethal factor endopeptidase) inhibitor;
ferroptosis inducer;
geroprotector;
prodrug | 1994 | 2022 | 14.1 | low | 13 | 0 | 3 | 12 | 15 | 1 |
| pravastatin | | 3-hydroxy carboxylic acid;
carbobicyclic compound;
carboxylic ester;
hydroxy monocarboxylic acid;
secondary alcohol;
statin (semi-synthetic) | anticholesteremic drug;
environmental contaminant;
metabolite;
xenobiotic | 2002 | 2015 | 18.0 | low | 1 | 0 | 0 | 3 | 1 | 0 |
| quinapril | | dicarboxylic acid monoester;
ethyl ester;
isoquinolines;
tertiary carboxamide | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 1991 | 2015 | 20.5 | low | 0 | 0 | 3 | 5 | 3 | 0 |
| moexiprilat | | | | 1992 | 1996 | 30.4 | medium | 0 | 0 | 5 | 0 | 0 | 0 |
| cilazapril, anhydrous | | dicarboxylic acid monoester;
ethyl ester;
pyridazinodiazepine | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 1985 | 2011 | 28.1 | low | 1 | 1 | 4 | 1 | 1 | 0 |
| fura-2 | | | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| clopidogrel | | methyl ester;
monochlorobenzenes;
thienopyridine | anticoagulant;
P2Y12 receptor antagonist;
platelet aggregation inhibitor | 2006 | 2016 | 12.0 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| mibefradil | | tetralins | T-type calcium channel blocker | 1998 | 2006 | 21.3 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| technetium tc 99m mertiatide | | | | 1990 | 1990 | 34.0 | low | 1 | 0 | 1 | 0 | 0 | 0 |
| atorvastatin | | aromatic amide;
dihydroxy monocarboxylic acid;
monofluorobenzenes;
pyrroles;
statin (synthetic) | environmental contaminant;
xenobiotic | 2004 | 2023 | 9.0 | low | 4 | 0 | 0 | 4 | 15 | 4 |
| valsartan | | biphenylyltetrazole;
monocarboxylic acid amide;
monocarboxylic acid | angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic | 1995 | 2023 | 13.6 | low | 21 | 0 | 6 | 21 | 12 | 10 |
| simendan | | | | 2016 | 2023 | 4.5 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| venlafaxine hydrochloride | | hydrochloride | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fosinoprilat | | L-proline derivative;
phosphinic acids | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 1991 | 1992 | 32.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| glucose, (beta-d)-isomer | | D-glucopyranose | epitope;
mouse metabolite | 1994 | 2013 | 20.5 | low | 1 | 0 | 1 | 0 | 1 | 0 |
| cilazaprilat | | non-proteinogenic alpha-amino acid | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| n-methylnicotinamide | | pyridinecarboxamide | metabolite | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| glutathione disulfide | | glutathione derivative;
organic disulfide | Escherichia coli metabolite;
mouse metabolite | 2000 | 2008 | 20.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| lercanidipine | | diarylmethane | | 2004 | 2015 | 14.5 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| goralatide | | oligopeptide;
tetrapeptide | anti-inflammatory agent;
pro-angiogenic agent | 2006 | 2013 | 14.7 | low | 1 | 0 | 0 | 2 | 1 | 0 |
| telmisartan | | benzimidazoles;
biphenyls;
carboxybiphenyl | angiotensin receptor antagonist;
antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
environmental contaminant;
xenobiotic | 2001 | 2022 | 14.2 | low | 57 | 0 | 0 | 101 | 54 | 4 |
| naphthalimides | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| triazoles | | 1,2,3-triazole | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| isocoumarins | | isocoumarins | | 1998 | 1999 | 25.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| rilmenidine | | isourea | | 2004 | 2011 | 16.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| zoledronic acid | | 1,1-bis(phosphonic acid);
imidazoles | bone density conservation agent | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| zabicipril | | | | 1993 | 1998 | 28.5 | medium | 0 | 0 | 2 | 0 | 0 | 0 |
| uk 68798 | | aromatic ether;
sulfonamide;
tertiary amino compound | anti-arrhythmia drug;
potassium channel blocker | 2000 | 2002 | 23.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| danofloxacin | | quinolines | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| masoprocol | | nordihydroguaiaretic acid | antineoplastic agent;
hypoglycemic agent;
lipoxygenase inhibitor;
metabolite | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| alacepril | | dipeptide;
thioacetate ester | EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| ubenimex | | | | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| rosiglitazone | | aminopyridine;
thiazolidinediones | EC 6.2.1.3 (long-chain-fatty-acid--CoA ligase) inhibitor;
ferroptosis inhibitor;
insulin-sensitizing drug | 2004 | 2019 | 15.8 | low | 12 | 0 | 0 | 22 | 3 | 0 |
| fibrinogen | | iditol | fungal metabolite | 1989 | 2010 | 22.8 | low | 4 | 1 | 1 | 4 | 0 | 0 |
| moexipril | | peptide | | 1992 | 2002 | 27.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| homocysteine | | amino acid zwitterion;
homocysteine;
serine family amino acid | fundamental metabolite;
mouse metabolite | 2003 | 2016 | 14.5 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| zofenopril | | aryl sulfide;
L-proline derivative;
N-acyl-L-amino acid;
thioester | anticonvulsant;
apoptosis inhibitor;
cardioprotective agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug;
vasodilator agent | 1989 | 2018 | 14.3 | low | 5 | 1 | 2 | 3 | 9 | 0 |
| glycylsarcosine | | dipeptide zwitterion;
dipeptide | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| hippuryl-histidyl-leucine | | | | 1994 | 1996 | 29.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| pyrogallol sulfonphthalein | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| p-methoxy-n-methylphenethylamine | | aromatic ether;
secondary amino compound | metabolite | 1989 | 1990 | 34.5 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| 1,4-dihydropyridine | | | | 2005 | 2005 | 19.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| cremophor el | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| sr141716 | | amidopiperidine;
carbohydrazide;
dichlorobenzene;
monochlorobenzenes;
pyrazoles | anti-obesity agent;
appetite depressant;
CB1 receptor antagonist | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bosentan anhydrous | | primary alcohol;
pyrimidines;
sulfonamide | antihypertensive agent;
endothelin receptor antagonist | 1997 | 2013 | 18.0 | low | 0 | 0 | 1 | 2 | 1 | 0 |
| cp 96345 | | | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| sr 48968 | | | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| fpl 55712 | | aromatic ketone | | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| bradykinin, des-arg(9)- | | oligopeptide | bradykinin receptor B2 agonist | 1992 | 2005 | 26.2 | low | 0 | 0 | 2 | 2 | 0 | 0 |
| eudragit-e | | | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| perindopril | | alpha-amino acid ester;
dicarboxylic acid monoester;
ethyl ester;
organic heterobicyclic compound | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 1985 | 2022 | 20.7 | low | 0 | 5 | 7 | 21 | 9 | 1 |
| quinaprilat | | dicarboxylic acid;
isoquinolines;
tertiary carboxamide | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
vasodilator agent | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| 1-hexadecyl-2-acetyl-glycero-3-phosphocholine | | 2-acetyl-1-alkyl-sn-glycero-3-phosphocholine | antihypertensive agent;
beta-adrenergic antagonist;
bronchoconstrictor agent;
hematologic agent;
vasodilator agent | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| exp3174 | | biphenylyltetrazole;
imidazoles;
organochlorine compound | metabolite | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| deoxyglucose | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| tadalafil | | benzodioxoles;
pyrazinopyridoindole | EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent | 2009 | 2015 | 12.0 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| 3-deoxyglucosone | | deoxyglucose;
deoxyketohexose | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| opc 21268 | | | | 1995 | 1997 | 28.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| glyceraldehyde 3-phosphate dehydrogenase (304-313) | | | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mozavaptan | | benzamides | aquaretic | 1997 | 1998 | 26.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| pentosidine | | imidazopyridine;
non-proteinogenic L-alpha-amino acid | biomarker;
cross-linking reagent | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 7-fluoro-4-nitrobenzo-2-oxa-1,3-diazole | | | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| peroxynitrous acid | | nitrogen oxoacid | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| mk 0663 | | bipyridines;
organochlorine compound;
sulfone | cyclooxygenase 2 inhibitor;
non-steroidal anti-inflammatory drug | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| gefitinib | | aromatic ether;
monochlorobenzenes;
monofluorobenzenes;
morpholines;
quinazolines;
secondary amino compound;
tertiary amino compound | antineoplastic agent;
epidermal growth factor receptor antagonist | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| enkephalin-met, arg(6)-phe(7)- | | organic molecular entity | | 1986 | 1987 | 37.5 | low | 0 | 2 | 0 | 0 | 0 | 0 |
| enkephalin-met, arg(6)-gly(7)-leu(8)- | | | | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| n(6)-carboxymethyllysine | | L-lysine derivative;
non-proteinogenic L-alpha-amino acid | antigen | 2003 | 2007 | 19.0 | low | 0 | 0 | 0 | 4 | 0 | 0 |
| angiotensin ii, des-phe(8)- | | amino acid zwitterion;
angiotensin | vasodilator agent | 1996 | 2017 | 16.0 | low | 0 | 0 | 1 | 0 | 2 | 0 |
| n,n-dimethylarginine | | dimethylarginine;
guanidines;
L-arginine derivative;
non-proteinogenic L-alpha-amino acid | EC 1.14.13.39 (nitric oxide synthase) inhibitor | 2007 | 2015 | 13.0 | low | 3 | 0 | 0 | 2 | 3 | 0 |
| bradykinin, leu(8)-des-arg(9)- | | | | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| b 4162 | | | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| methotrexate | | dicarboxylic acid;
monocarboxylic acid amide;
pteridines | abortifacient;
antimetabolite;
antineoplastic agent;
antirheumatic drug;
dermatologic drug;
DNA synthesis inhibitor;
EC 1.5.1.3 (dihydrofolate reductase) inhibitor;
immunosuppressive agent | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| olmesartan medoxomil | | biphenyls | | 2003 | 2012 | 13.9 | low | 3 | 0 | 0 | 2 | 5 | 0 |
| omega-n-methylarginine | | amino acid zwitterion;
arginine derivative;
guanidines;
L-arginine derivative;
non-proteinogenic L-alpha-amino acid | | 1992 | 2012 | 24.2 | low | 2 | 0 | 3 | 1 | 1 | 0 |
| mdl 100240 | | | | 2002 | 2006 | 20.5 | medium | 0 | 0 | 0 | 4 | 0 | 0 |
| proline | | amino acid zwitterion;
glutamine family amino acid;
L-alpha-amino acid;
proline;
proteinogenic amino acid | algal metabolite;
compatible osmolytes;
Escherichia coli metabolite;
micronutrient;
mouse metabolite;
nutraceutical;
Saccharomyces cerevisiae metabolite | 1984 | 1998 | 35.1 | low | 0 | 5 | 3 | 0 | 0 | 0 |
| cariporide | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| naproxen | | methoxynaphthalene;
monocarboxylic acid | antipyretic;
cyclooxygenase 1 inhibitor;
cyclooxygenase 2 inhibitor;
drug allergen;
environmental contaminant;
gout suppressant;
non-narcotic analgesic;
non-steroidal anti-inflammatory drug;
xenobiotic | 2006 | 2022 | 10.3 | low | 1 | 0 | 0 | 1 | 1 | 1 |
| hydroxyl radical | | oxygen hydride;
oxygen radical;
reactive oxygen species | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| olmesartan | | biphenylyltetrazole | angiotensin receptor antagonist;
antihypertensive agent | 2005 | 2018 | 12.6 | low | 2 | 0 | 0 | 3 | 5 | 0 |
| atrasentan | | pyrrolidines | | 2007 | 2022 | 9.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| symmetric dimethylarginine | | amino acid zwitterion;
dimethylarginine;
guanidines;
L-arginine derivative;
non-proteinogenic L-alpha-amino acid | EC 1.14.13.39 (nitric oxide synthase) inhibitor | 2007 | 2007 | 17.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| bradykinin, hydroxy-pro(3)- | | oligopeptide;
peptide hormone | bradykinin receptor agonist;
human urinary metabolite | 1994 | 1994 | 30.0 | medium | 0 | 0 | 1 | 0 | 0 | 0 |
| biotin | | biotins;
vitamin B7 | coenzyme;
cofactor;
Escherichia coli metabolite;
fundamental metabolite;
human metabolite;
mouse metabolite;
nutraceutical;
prosthetic group;
Saccharomyces cerevisiae metabolite | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| angiotensin ii | | amino acid zwitterion;
angiotensin II | human metabolite | 1984 | 2023 | 26.0 | low | 20 | 26 | 50 | 39 | 8 | 3 |
| lignin | | | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| organophosphonates | | divalent inorganic anion;
phosphite ion | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| l 158809 | | | | 1997 | 2014 | 21.4 | low | 0 | 0 | 2 | 2 | 1 | 0 |
| ceronapril | | N-acyl-amino acid | | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| hmr 1766 | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| alagebrium | | | | 2003 | 2007 | 19.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| cortisone | | 11-oxo steroid;
17alpha-hydroxy steroid;
20-oxo steroid;
21-hydroxy steroid;
3-oxo-Delta(4) steroid;
C21-steroid;
glucocorticoid;
primary alpha-hydroxy ketone;
tertiary alpha-hydroxy ketone | human metabolite;
mouse metabolite | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bardoxolone methyl | | cyclohexenones | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| dihydropyridines | | | | 1996 | 2015 | 17.8 | low | 2 | 0 | 2 | 3 | 3 | 0 |
| lithium chloride | | inorganic chloride;
lithium salt | antimanic drug;
geroprotector | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| glycogen | | | | 1992 | 1994 | 31.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| fibrin | | peptide | | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| bradykinin | | oligopeptide | human blood serum metabolite;
vasodilator agent | 1984 | 2016 | 27.1 | low | 5 | 11 | 100 | 25 | 6 | 0 |
| elastin | | oligopeptide | | 2005 | 2005 | 19.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| amastatin | | tetrapeptide | EC 3.4.11.* (aminopeptidase) inhibitor;
protease inhibitor | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| puromycin | | puromycins | antiinfective agent;
antimicrobial agent;
antineoplastic agent;
EC 3.4.11.14 (cytosol alanyl aminopeptidase) inhibitor;
EC 3.4.14.2 (dipeptidyl-peptidase II) inhibitor;
nucleoside antibiotic;
protein synthesis inhibitor | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| nitroarginine | | guanidines;
L-arginine derivative;
N-nitro compound;
non-proteinogenic L-alpha-amino acid | | 1992 | 1996 | 30.6 | low | 0 | 0 | 7 | 0 | 0 | 0 |
| quinidine | | cinchona alkaloid | alpha-adrenergic antagonist;
anti-arrhythmia drug;
antimalarial;
drug allergen;
EC 1.14.13.181 (13-deoxydaunorubicin hydroxylase) inhibitor;
EC 3.6.3.44 (xenobiotic-transporting ATPase) inhibitor;
muscarinic antagonist;
P450 inhibitor;
potassium channel blocker;
sodium channel blocker | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| naringin | | (2S)-flavan-4-one;
4'-hydroxyflavanones;
dihydroxyflavanone;
disaccharide derivative;
neohesperidoside | anti-inflammatory agent;
antineoplastic agent;
metabolite | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bq 123 | | cyclic peptide | | 2005 | 2009 | 17.0 | low | 1 | 0 | 0 | 2 | 0 | 0 |
| n-formylmethionine leucyl-phenylalanine | | tripeptide | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| teprotide | | peptide | | 1984 | 1984 | 40.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| eplerenone | | 3-oxo-Delta(4) steroid;
epoxy steroid;
gamma-lactone;
methyl ester;
organic heteropentacyclic compound;
oxaspiro compound;
steroid acid ester | aldosterone antagonist;
antihypertensive agent | 2004 | 2020 | 9.7 | low | 1 | 0 | 0 | 2 | 4 | 0 |
| temocapril hydrochloride | | dipeptide | | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| betadex | | cyclodextrin | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| arachidonic acid | | icosa-5,8,11,14-tetraenoic acid;
long-chain fatty acid;
omega-6 fatty acid | Daphnia galeata metabolite;
EC 3.1.1.1 (carboxylesterase) inhibitor;
human metabolite;
mouse metabolite | 1987 | 1997 | 32.0 | low | 0 | 1 | 1 | 0 | 0 | 0 |
| phosphoramidon | | deoxyaldohexose phosphate;
dipeptide | bacterial metabolite;
EC 3.4.24.11 (neprilysin) inhibitor;
EC 3.4.24.71 (endothelin-converting enzyme 1) inhibitor | 1998 | 1999 | 25.2 | low | 0 | 0 | 4 | 0 | 0 | 0 |
| resveratrol | | resveratrol | antioxidant;
phytoalexin;
plant metabolite;
quorum sensing inhibitor;
radical scavenger | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| tacrolimus | | macrolide lactam | bacterial metabolite;
immunosuppressive agent | 2002 | 2015 | 15.5 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| cocaine | | benzoate ester;
methyl ester;
tertiary amino compound;
tropane alkaloid | adrenergic uptake inhibitor;
central nervous system stimulant;
dopamine uptake inhibitor;
environmental contaminant;
local anaesthetic;
mouse metabolite;
plant metabolite;
serotonin uptake inhibitor;
sodium channel blocker;
sympathomimetic agent;
vasoconstrictor agent;
xenobiotic | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| eicosapentaenoic acid | | icosapentaenoic acid;
omega-3 fatty acid | anticholesteremic drug;
antidepressant;
antineoplastic agent;
Daphnia galeata metabolite;
fungal metabolite;
micronutrient;
mouse metabolite;
nutraceutical | 2009 | 2009 | 15.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| mycophenolic acid | | 2-benzofurans;
gamma-lactone;
monocarboxylic acid;
phenols | anticoronaviral agent;
antimicrobial agent;
antineoplastic agent;
EC 1.1.1.205 (IMP dehydrogenase) inhibitor;
environmental contaminant;
immunosuppressive agent;
mycotoxin;
Penicillium metabolite;
xenobiotic | 2010 | 2012 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| apstatin | | | | 1997 | 2003 | 24.6 | high | 0 | 0 | 3 | 2 | 0 | 0 |
| imidazolidines | | azacycloalkane;
imidazolidines;
saturated organic heteromonocyclic parent | | 1998 | 2013 | 18.2 | low | 1 | 0 | 2 | 0 | 2 | 0 |
| sodium bicarbonate | | one-carbon compound;
organic sodium salt | antacid;
food anticaking agent | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| isomethyleugenol | | isomethyleugenol | | 2006 | 2011 | 15.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| arginine vasopressin | | vasopressin | cardiovascular drug;
hematologic agent;
mitogen | 1994 | 1997 | 28.5 | low | 1 | 0 | 2 | 0 | 0 | 0 |
| omapatrilat | | dipeptide | | 2000 | 2005 | 20.6 | low | 0 | 0 | 1 | 4 | 0 | 0 |
| propylthiouracil | | pyrimidinethione | antidote to paracetamol poisoning;
antimetabolite;
antioxidant;
antithyroid drug;
carcinogenic agent;
EC 1.14.13.39 (nitric oxide synthase) inhibitor;
hormone antagonist | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| methimazole | | 1,3-dihydroimidazole-2-thiones | antithyroid drug | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| D-fructopyranose | | cyclic hemiketal;
D-fructose;
fructopyranose | sweetening agent | 1998 | 1998 | 26.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| digoxin | | cardenolide glycoside;
steroid saponin | anti-arrhythmia drug;
cardiotonic drug;
EC 3.6.3.9 (Na(+)/K(+)-transporting ATPase) inhibitor;
epitope | 1987 | 2022 | 21.0 | low | 2 | 2 | 2 | 0 | 3 | 1 |
| 1,1-diphenyl-2-picrylhydrazyl | | | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| rwj 67657 | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| lithium | | alkali metal atom | | 1995 | 2001 | 26.5 | low | 0 | 0 | 3 | 1 | 0 | 0 |
| orlistat | | beta-lactone;
carboxylic ester;
formamides;
L-leucine derivative | anti-obesity agent;
bacterial metabolite;
EC 2.3.1.85 (fatty acid synthase) inhibitor;
EC 3.1.1.3 (triacylglycerol lipase) inhibitor | 2002 | 2005 | 20.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| quinine | | cinchona alkaloid | antimalarial;
muscle relaxant;
non-narcotic analgesic | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| zofenoprilate | | aryl sulfide;
L-proline derivative;
N-acyl-L-amino acid;
thiol | anticonvulsant;
apoptosis inhibitor;
cardioprotective agent;
drug metabolite;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
vasodilator agent | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| cystine | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| angiotensin i, ile(5)- | | angiotensin;
peptide zwitterion | human metabolite;
neurotransmitter agent | 1988 | 1988 | 36.0 | medium | 0 | 1 | 0 | 0 | 0 | 0 |
| sto 609 | | naphthoic acid | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| zinc protoporphyrin ix | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| quercetin | | 7-hydroxyflavonol;
pentahydroxyflavone | antibacterial agent;
antineoplastic agent;
antioxidant;
Aurora kinase inhibitor;
chelator;
EC 1.10.99.2 [ribosyldihydronicotinamide dehydrogenase (quinone)] inhibitor;
geroprotector;
phytoestrogen;
plant metabolite;
protein kinase inhibitor;
radical scavenger | 2020 | 2022 | 3.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| dinoprostone | | prostaglandins E | human metabolite;
mouse metabolite;
oxytocic | 1989 | 2012 | 20.8 | low | 0 | 1 | 0 | 4 | 1 | 0 |
| dinoprost | | monocarboxylic acid;
prostaglandins Falpha | human metabolite;
mouse metabolite | 2006 | 2008 | 17.0 | low | 1 | 0 | 0 | 2 | 0 | 0 |
| apigenin | | trihydroxyflavone | antineoplastic agent;
metabolite | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| calcitriol | | D3 vitamins;
hydroxycalciol;
triol | antineoplastic agent;
antipsoriatic;
bone density conservation agent;
calcium channel agonist;
calcium channel modulator;
hormone;
human metabolite;
immunomodulator;
metabolite;
mouse metabolite;
nutraceutical | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| vitamin k semiquinone radical | | | | 2012 | 2012 | 12.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| beta carotene | | carotenoid beta-end derivative;
cyclic carotene | antioxidant;
biological pigment;
cofactor;
ferroptosis inhibitor;
human metabolite;
mouse metabolite;
plant metabolite;
provitamin A | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| thromboxane a2 | | epoxy monocarboxylic acid;
thromboxanes A | mouse metabolite | 1994 | 2005 | 24.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| vitamin d 2 | | hydroxy seco-steroid;
seco-ergostane;
vitamin D | bone density conservation agent;
nutraceutical;
plant metabolite;
rodenticide | 2011 | 2014 | 11.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| rutin | | disaccharide derivative;
quercetin O-glucoside;
rutinoside;
tetrahydroxyflavone | antioxidant;
metabolite | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 6-ketoprostaglandin f1 alpha | | prostaglandins Falpha | human metabolite;
mouse metabolite | 1986 | 2017 | 26.0 | low | 1 | 2 | 3 | 2 | 1 | 0 |
| amphotericin b | | antibiotic antifungal drug;
macrolide antibiotic;
polyene antibiotic | antiamoebic agent;
antiprotozoal drug;
bacterial metabolite | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| eprosartan | | dicarboxylic acid;
imidazoles;
thiophenes | angiotensin receptor antagonist;
antihypertensive agent;
environmental contaminant;
xenobiotic | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| paricalcitol | | hydroxy seco-steroid;
seco-cholestane | antiparathyroid drug | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| coenzyme q10 | | ubiquinones | antioxidant;
ferroptosis inhibitor;
human metabolite | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 8-epi-prostaglandin f2alpha | | F2-isoprostane | biomarker;
bronchoconstrictor agent;
vasoconstrictor agent | 2006 | 2008 | 17.0 | low | 1 | 0 | 0 | 2 | 0 | 0 |
| thromboxane b2 | | thromboxanes B | human metabolite;
mouse metabolite | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 4-hydroxy-2-nonenal | | 4-hydroxynon-2-enal;
4-hydroxynonenal | | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| naloxone | | morphinane alkaloid;
organic heteropentacyclic compound;
tertiary alcohol | antidote to opioid poisoning;
central nervous system depressant;
mu-opioid receptor antagonist | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| sirolimus | | antibiotic antifungal drug;
cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
organic heterotricyclic compound;
secondary alcohol | antibacterial drug;
anticoronaviral agent;
antineoplastic agent;
bacterial metabolite;
geroprotector;
immunosuppressive agent;
mTOR inhibitor | 2005 | 2020 | 11.6 | low | 2 | 0 | 0 | 2 | 3 | 0 |
| kallidin | | peptide | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| fr 190997 | | | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| lacidipine | | cinnamate ester;
tert-butyl ester | | 1996 | 2012 | 20.2 | low | 0 | 0 | 2 | 1 | 1 | 0 |
| pd 123319 | | imidazopyridine | angiotensin receptor antagonist;
endothelin receptor antagonist;
vasoconstrictor agent | 1997 | 2017 | 19.2 | low | 0 | 0 | 1 | 3 | 1 | 0 |
| r 715 | | | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| casein kinase ii | | | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| 15-hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic acid | | | | 1992 | 1994 | 31.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| delapril | | peptide | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| lisinopril | | dipeptide | EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 1985 | 2022 | 18.9 | low | 0 | 2 | 15 | 16 | 14 | 2 |
| benazepril | | benzazepine;
dicarboxylic acid monoester;
ethyl ester;
lactam | EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 1985 | 2015 | 22.4 | low | 0 | 1 | 3 | 2 | 3 | 0 |
| candoxatril | | | | 2004 | 2005 | 19.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| enalapril | | dicarboxylic acid monoester;
dipeptide | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
geroprotector;
prodrug | 1984 | 2021 | 24.8 | low | 15 | 20 | 27 | 33 | 11 | 1 |
| fumarates | | butenedioate;
C4-dicarboxylate | human metabolite;
metabolite;
Saccharomyces cerevisiae metabolite | 2006 | 2021 | 11.9 | low | 20 | 0 | 0 | 14 | 20 | 1 |
| cysteine | | cysteinium | fundamental metabolite | 2016 | 2016 | 8.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| enalaprilat anhydrous | | dicarboxylic acid;
dipeptide | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 1984 | 1999 | 31.1 | low | 1 | 3 | 14 | 0 | 0 | 0 |
| 2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid | | | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| ramiprilat | | azabicycloalkane;
cyclopentapyrrole;
dicarboxylic acid;
dipeptide | bradykinin receptor B2 agonist;
cardioprotective agent;
drug metabolite;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
matrix metalloproteinase inhibitor | 1986 | 2016 | 26.8 | high | 8 | 15 | 108 | 33 | 10 | 0 |
| imidapril | | dicarboxylic acid monoester;
dipeptide;
ethyl ester;
imidazolidines;
N-acylurea;
secondary amino compound | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 1998 | 2013 | 16.3 | low | 1 | 0 | 1 | 0 | 2 | 0 |
| imidaprilat | | dicarboxylic acid;
dipeptide;
imidazolidines;
N-acylurea;
secondary amino compound | antihypertensive agent;
drug metabolite;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| trandolapril | | dicarboxylic acid monoester;
dipeptide;
ethyl ester;
organic heterobicyclic compound;
secondary amino compound;
tertiary carboxamide | antihypertensive agent;
EC 3.4.15.1 (peptidyl-dipeptidase A) inhibitor;
prodrug | 1987 | 2014 | 21.1 | low | 1 | 1 | 1 | 10 | 1 | 0 |
| ro 48-3657 | | N-acylglycine | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| aliskiren | | monocarboxylic acid amide;
monomethoxybenzene | antihypertensive agent | 2006 | 2021 | 11.9 | low | 20 | 0 | 0 | 14 | 19 | 1 |
| resiniferatoxin | | carboxylic ester;
diterpenoid;
enone;
monomethoxybenzene;
organic heteropentacyclic compound;
ortho ester;
phenols;
tertiary alpha-hydroxy ketone | analgesic;
neurotoxin;
plant metabolite;
TRPV1 agonist | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| n-(1-carboxy-3-phenylpropyl)-alanyl-alanyl-phenylalanine-4-aminobenzoate | | | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| saralasin | | oligopeptide | | 1989 | 2003 | 30.0 | low | 0 | 1 | 1 | 1 | 0 | 0 |
| oxalates | | | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| everolimus | | cyclic acetal;
cyclic ketone;
ether;
macrolide lactam;
primary alcohol;
secondary alcohol | anticoronaviral agent;
antineoplastic agent;
geroprotector;
immunosuppressive agent;
mTOR inhibitor | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| s-nitroso-n-acetylpenicillamine | | nitroso compound;
nitrosothio compound | nitric oxide donor;
vasodilator agent | 1999 | 2001 | 23.8 | low | 0 | 0 | 2 | 2 | 0 | 0 |
| pentopril | | | | 1985 | 2004 | 29.5 | low | 0 | 1 | 0 | 1 | 0 | 0 |
| mc 838 | | | | 1989 | 1989 | 35.0 | medium | 0 | 1 | 0 | 0 | 0 | 0 |
| rhc 3659 | | N-acyl-amino acid | | 1985 | 1985 | 39.0 | medium | 0 | 1 | 0 | 0 | 0 | 0 |
| vildagliptin | | amino acid amide | | 2008 | 2008 | 16.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| phosphocreatine | | phosphagen;
phosphoamino acid | human metabolite;
mouse metabolite | 1992 | 1994 | 31.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| sacubitril | | biphenyls | | 2022 | 2023 | 1.8 | low | 3 | 0 | 0 | 0 | 0 | 4 |
| mocetinostat | | aminopyrimidine;
benzamides;
pyridines;
secondary amino compound;
secondary carboxamide;
substituted aniline | antineoplastic agent;
apoptosis inducer;
autophagy inducer;
cardioprotective agent;
EC 3.5.1.98 (histone deacetylase) inhibitor;
hepatotoxic agent | 1992 | 2006 | 26.7 | low | 0 | 0 | 2 | 1 | 0 | 0 |
| eht 1864 | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| prasugrel hydrochloride | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| bibw 2992 | | aromatic ether;
enamide;
furans;
monochlorobenzenes;
organofluorine compound;
quinazolines;
secondary carboxamide;
tertiary amino compound | antineoplastic agent;
tyrosine kinase inhibitor | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| indolapril hydrochloride | | | | 1985 | 1985 | 39.0 | medium | 0 | 1 | 0 | 0 | 0 | 0 |
| oxadiazoles | | | | 2013 | 2015 | 9.7 | low | 1 | 0 | 0 | 0 | 3 | 0 |
| ucn 1028 c | | | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| mitoquinone | | | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| abt 869 | | aromatic amine;
indazoles;
phenylureas | angiogenesis inhibitor;
antineoplastic agent;
EC 2.7.10.1 (receptor protein-tyrosine kinase) inhibitor | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| dorsomorphin | | aromatic ether;
piperidines;
pyrazolopyrimidine;
pyridines | bone morphogenetic protein receptor antagonist;
EC 2.7.11.31 {[hydroxymethylglutaryl-CoA reductase (NADPH)] kinase} inhibitor | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| fonsartan | | | | 1997 | 2002 | 24.5 | medium | 0 | 0 | 1 | 1 | 0 | 0 |
| sitagliptin phosphate | | | | 2022 | 2022 | 2.0 | low | 1 | 0 | 0 | 0 | 0 | 1 |
| losartan potassium | | | | 1990 | 2014 | 22.0 | low | 1 | 0 | 2 | 1 | 1 | 0 |
| glycyl-prolyl-hydroxyproline | | oligopeptide | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| empagliflozin | | aromatic ether;
C-glycosyl compound;
monochlorobenzenes;
tetrahydrofuryl ether | hypoglycemic agent;
sodium-glucose transport protein subtype 2 inhibitor | 2013 | 2023 | 3.8 | low | 1 | 0 | 0 | 0 | 1 | 3 |
| calcimycin | | benzoxazole | | 1997 | 1997 | 27.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| scopolamine hydrobromide | | | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| pituitrin | | | | 1987 | 2010 | 28.8 | low | 4 | 2 | 3 | 1 | 0 | 0 |
| n-monoacetylcystine | | | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| icatibant | | | | 1990 | 2016 | 26.6 | low | 1 | 0 | 57 | 12 | 2 | 0 |
| nad | | organophosphate oxoanion | cofactor;
human metabolite;
hydrogen acceptor;
Saccharomyces cerevisiae metabolite | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| ceruletide | | oligopeptide | diagnostic agent;
gastrointestinal drug | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| bivalirudin | | polypeptide | anticoagulant;
EC 3.4.21.5 (thrombin) inhibitor | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| atrial natriuretic factor | | polypeptide | | 1989 | 2011 | 24.4 | low | 9 | 1 | 10 | 8 | 1 | 0 |
| omega-conotoxin (conus magus) | | | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| glucagon | | peptide hormone | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| beta-endorphin | | | | 1989 | 1989 | 35.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| neuropeptide y | | | | 1994 | 1998 | 28.0 | low | 1 | 0 | 2 | 0 | 0 | 0 |
| angiotensinogen | | | | 1986 | 2014 | 21.0 | low | 1 | 1 | 1 | 2 | 2 | 0 |
| liraglutide | | lipopeptide;
polypeptide | glucagon-like peptide-1 receptor agonist;
neuroprotective agent | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| glucagon-like peptide 1 | | | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 2 |
| c-peptide | | | | 1991 | 1991 | 33.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| natriuretic peptide, c-type | | | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| endothelin-1 | | | | 1996 | 2022 | 19.6 | low | 1 | 0 | 2 | 4 | 0 | 1 |
| ubiquinone | | | | 2012 | 2017 | 9.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| hoe k86-4321 | | | | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| s-nitro-n-acetylpenicillamine | | | | 1999 | 2001 | 24.0 | low | 0 | 0 | 2 | 1 | 0 | 0 |
| cardiovascular agents | | | | 1996 | 2023 | 12.1 | low | 3 | 0 | 4 | 3 | 8 | 3 |
| 2-cyano-3,12-dioxooleana-1,9(11)-dien-28-oic acid ethyl amide | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| piperidines | | | | 1995 | 2013 | 21.4 | low | 1 | 0 | 4 | 2 | 1 | 0 |
| interleukin-8 | | | | 2003 | 2014 | 15.2 | low | 1 | 0 | 0 | 2 | 2 | 0 |
| anagliptin | | amino acid amide | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| fosinopril | | | | 1989 | 2015 | 22.5 | low | 1 | 1 | 6 | 7 | 3 | 0 |
| natriuretic peptide, brain | | polypeptide | | 1996 | 2019 | 17.0 | low | 10 | 0 | 1 | 11 | 3 | 0 |
| heparitin sulfate | | | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ascorbic acid | | ascorbic acid;
vitamin C | coenzyme;
cofactor;
flour treatment agent;
food antioxidant;
food colour retention agent;
geroprotector;
plant metabolite;
skin lightening agent | 2001 | 2005 | 21.0 | low | 1 | 0 | 0 | 4 | 0 | 0 |
| warfarin | | benzenes;
hydroxycoumarin;
methyl ketone | | 1998 | 2011 | 21.1 | low | 0 | 0 | 4 | 3 | 1 | 0 |
| phenprocoumon | | hydroxycoumarin | anticoagulant;
EC 1.6.5.2 [NAD(P)H dehydrogenase (quinone)] inhibitor | 1989 | 1989 | 35.0 | low | 1 | 1 | 0 | 0 | 0 | 0 |
| transforming growth factor beta | | | | 1996 | 2009 | 21.1 | low | 3 | 0 | 4 | 13 | 0 | 0 |
| bay 94-8862 | | | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| osimertinib | | acrylamides;
aminopyrimidine;
biaryl;
indoles;
monomethoxybenzene;
secondary amino compound;
secondary carboxamide;
substituted aniline;
tertiary amino compound | antineoplastic agent;
epidermal growth factor receptor antagonist | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| hirudin | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| nov 002 | | | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| nitrophenols | | | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| angiotensin i | | angiotensin;
peptide zwitterion | human metabolite;
neurotransmitter agent | 1984 | 2017 | 29.8 | low | 1 | 15 | 19 | 2 | 4 | 0 |
| adrenomedullin | | | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| angiotensin iii | | | | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| nephrin | | | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| cyclosporine | | | | 1994 | 2002 | 26.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| thromboplastin | | | | 2007 | 2007 | 17.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| muramidase | | | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| cyclic gmp | | 3',5'-cyclic purine nucleotide;
guanyl ribonucleotide | Escherichia coli metabolite;
human metabolite;
mouse metabolite;
plant metabolite;
Saccharomyces cerevisiae metabolite | 1991 | 2012 | 28.4 | low | 2 | 0 | 18 | 3 | 1 | 0 |
| guanosine monophosphate | | guanosine 5'-phosphate;
purine ribonucleoside 5'-monophosphate | biomarker;
Escherichia coli metabolite;
metabolite;
mouse metabolite | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| guanine | | 2-aminopurines;
oxopurine;
purine nucleobase | algal metabolite;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| folic acid | | folic acids;
N-acyl-amino acid | human metabolite;
mouse metabolite;
nutrient | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| valacyclovir | | L-valyl ester | antiviral drug | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| olanzapine | | benzodiazepine;
N-arylpiperazine;
N-methylpiperazine | antiemetic;
dopaminergic antagonist;
histamine antagonist;
muscarinic antagonist;
second generation antipsychotic;
serotonergic antagonist;
serotonin uptake inhibitor | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| allopurinol | | nucleobase analogue;
organic heterobicyclic compound | antimetabolite;
EC 1.17.3.2 (xanthine oxidase) inhibitor;
gout suppressant;
radical scavenger | 2006 | 2018 | 12.0 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| tak 491 | | 1,2,4-oxadiazole;
aromatic ether;
benzimidazoles;
carboxylic ester;
cyclic carbonate ester;
dioxolane | angiotensin receptor antagonist;
antihypertensive agent;
prodrug | 2013 | 2015 | 9.7 | low | 1 | 0 | 0 | 0 | 3 | 0 |
| sildenafil citrate | | citrate salt | EC 3.1.4.35 (3',5'-cyclic-GMP phosphodiesterase) inhibitor;
vasodilator agent | 2005 | 2005 | 19.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| aprepitant | | (trifluoromethyl)benzenes;
cyclic acetal;
morpholines;
triazoles | antidepressant;
antiemetic;
neurokinin-1 receptor antagonist;
peripheral nervous system drug;
substance P receptor antagonist | 2022 | 2022 | 2.0 | low | 1 | 0 | 0 | 0 | 0 | 1 |
| azilsartan | | 1,2,4-oxadiazole;
aromatic ether;
benzimidazolecarboxylic acid | angiotensin receptor antagonist;
antihypertensive agent | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| 8-hydroxyguanine | | oxopurine | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| concanavalin a | | | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| leptin | | | | 2006 | 2012 | 15.0 | low | 2 | 0 | 0 | 2 | 1 | 0 |
| Condition | Indicated | Studies | First Year | Last Year | Average Age | Relationship Strength | Trials | pre-1990 | 1990's | 2000's | 2010's | post-2020 |
|---|
| 2019 Novel Coronavirus Disease | 0 | | 2020 | 2023 | 3.1 | low | 2 | 0 | 0 | 0 | 3 | 6 |
| 48,XXYY Syndrome | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Abdominal Aortic Aneurysm | 0 | | 2014 | 2019 | 7.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Abdominal Obesity | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Abdominal Pain | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Abnormalities, Multiple | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Abnormality, Heart | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Abortion, Spontaneous | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Abortion, Tubal | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Ache | 0 | | 2000 | 2019 | 13.4 | low | 1 | 0 | 1 | 1 | 3 | 0 |
| Acidosis, Lactic | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Acidosis, Renal Tubular Type IV | 0 | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Acne Inversa | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Actinic Reticuloid Syndrome | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Active Hyperemia | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Acute Autoimmune Neuropathy | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Acute Brain Injuries | 0 | | 2008 | 2014 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Acute Confusional Senile Dementia | 0 | | 2012 | 2014 | 11.0 | low | 1 | 0 | 0 | 0 | 2 | 0 |
| Acute Coronary Syndrome | 0 | | 2009 | 2011 | 14.0 | low | 3 | 0 | 0 | 2 | 1 | 0 |
| Acute Disease | 0 | | 1986 | 2013 | 20.8 | low | 1 | 1 | 1 | 9 | 1 | 0 |
| Acute Edematous Pancreatitis | 0 | | 2003 | 2012 | 17.7 | low | 0 | 0 | 0 | 5 | 1 | 0 |
| Acute Hypercapnic Respiratory Failure | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Acute Ischemic Stroke | 0 | | 2022 | 2022 | 2.0 | low | 1 | 0 | 0 | 0 | 0 | 1 |
| Acute Kidney Failure | 0 | | 2005 | 2022 | 11.9 | low | 0 | 0 | 0 | 4 | 5 | 1 |
| Acute Kidney Injury | 0 | | 2005 | 2022 | 11.9 | low | 0 | 0 | 0 | 4 | 5 | 1 |
| Acute Liver Injury, Drug-Induced | 0 | | 2010 | 2022 | 9.6 | low | 0 | 0 | 0 | 1 | 5 | 1 |
| Addison Disease | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Addison's Disease | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Adenoma, Prostatic | 0 | | 2000 | 2005 | 21.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Adipocere | 0 | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Adjuvant Arthritis | 0 | | 1986 | 2023 | 13.7 | low | 0 | 1 | 0 | 0 | 4 | 1 |
| ADPKD | 0 | | 2002 | 2012 | 16.0 | low | 3 | 0 | 0 | 4 | 1 | 0 |
| Adrenal Gland Hypofunction | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Adrenal Insufficiency | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Adverse Drug Event | 0 | | 2004 | 2016 | 13.6 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| Afferent Pupillary Defect | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Age-Related Memory Disorders | 0 | | 2006 | 2019 | 11.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Aging | 0 | | 1990 | 2015 | 24.8 | low | 3 | 0 | 12 | 2 | 2 | 0 |
| Agranulocytosis | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Airflow Obstruction, Chronic | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Airway Obstruction | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Albuminuria | 1 | | 1989 | 2020 | 20.7 | low | 40 | 1 | 28 | 30 | 13 | 0 |
| Alcohol Drinking | 0 | | 2000 | 2000 | 24.0 | low | 1 | 0 | 1 | 0 | 0 | 0 |
| Aldosteronism | 0 | | 2005 | 2020 | 11.5 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| Allergic Angiitis | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Allergy, Drug | 0 | | 2006 | 2016 | 12.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| Allergy, Latex | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Allodynia | 0 | | 2008 | 2015 | 12.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Alloxan Diabetes | 0 | | 1989 | 2023 | 18.0 | low | 0 | 1 | 17 | 22 | 9 | 6 |
| Alport Syndrome | 0 | | 2003 | 2023 | 10.2 | low | 2 | 0 | 0 | 2 | 3 | 1 |
| Alveolitis, Fibrosing | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Alzheimer Disease | 0 | | 2012 | 2014 | 11.0 | low | 1 | 0 | 0 | 0 | 2 | 0 |
| Amentia | 0 | | 2004 | 2015 | 13.0 | low | 2 | 0 | 0 | 1 | 2 | 0 |
| Amyloid Deposits | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Amyloidosis | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Anaphylactic Reaction | 0 | | 2007 | 2019 | 9.8 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| Anaphylaxis | 0 | | 2007 | 2019 | 9.8 | low | 0 | 0 | 0 | 1 | 3 | 0 |
| Anasarca | 0 | | 2003 | 2010 | 17.2 | low | 1 | 0 | 0 | 4 | 0 | 0 |
| Anemia, Fanconi | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Anemia, Hemolytic | 0 | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Anemia, Hemolytic, Acquired | 0 | | 1998 | 1998 | 26.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Anemia, Hypochromic | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Anemia, Sickle Cell | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Anesthesia | 0 | | 1984 | 2012 | 28.5 | low | 0 | 1 | 2 | 0 | 1 | 0 |
| Aneurysm, Aortic | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Aneurysm, Arteriovenous | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Angiitis | 0 | | 2004 | 2008 | 17.2 | low | 2 | 0 | 0 | 4 | 0 | 0 |
| Angina at Rest | 0 | | 2000 | 2004 | 21.8 | low | 2 | 0 | 1 | 3 | 0 | 0 |
| Angina Pectoris | 0 | | 1998 | 2010 | 20.7 | low | 9 | 0 | 2 | 10 | 0 | 0 |
| Angina Pectoris with Normal Coronary Arteriogram | 0 | | 1999 | 2018 | 17.0 | low | 3 | 0 | 1 | 1 | 1 | 0 |
| Angina, Unstable | 0 | | 2000 | 2004 | 21.8 | low | 2 | 0 | 1 | 3 | 0 | 0 |
| Angioedema | 0 | | 1995 | 2021 | 13.2 | low | 2 | 0 | 1 | 10 | 14 | 1 |
| Angiogenesis, Pathologic | 0 | | 1997 | 2005 | 24.0 | low | 0 | 0 | 2 | 1 | 0 | 0 |
| Angioneurotic Edema | 0 | | 1995 | 2021 | 13.2 | low | 2 | 0 | 1 | 10 | 14 | 1 |
| Angor Pectoris | 0 | | 1998 | 2010 | 20.7 | low | 9 | 0 | 2 | 10 | 0 | 0 |
| Anoxemia | 0 | | 1996 | 2008 | 22.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Anterior Choroidal Artery Infarction | 0 | | 2002 | 2004 | 21.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Anterior Circulation Transient Ischemic Attack | 0 | | 2002 | 2017 | 14.5 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| Anterior Fascicular Block | 0 | | 2009 | 2009 | 15.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Anti-Phospholipid Antibody Syndrome | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Antiphospholipid Syndrome | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Antopol Disease | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Anuria | 0 | | 2003 | 2003 | 21.0 | low | 1 | 0 | 0 | 2 | 0 | 0 |
| Aortic Aneurysm | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Aortic Aneurysm, Abdominal | 0 | | 2014 | 2019 | 7.5 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Aortic Coarctation | 0 | | 1994 | 2008 | 24.8 | low | 1 | 0 | 3 | 1 | 0 | 0 |
| Aortic Diseases | 0 | | 1999 | 2004 | 22.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Aortic Stenosis | 0 | | 1991 | 2018 | 14.9 | low | 4 | 0 | 1 | 2 | 4 | 0 |
| Aortic Valve Stenosis | 0 | | 1991 | 2018 | 14.9 | low | 4 | 0 | 1 | 2 | 4 | 0 |
| Apical Ballooning Syndrome | 0 | | 2009 | 2020 | 7.7 | low | 1 | 0 | 0 | 1 | 6 | 0 |
| Apoplexy | 0 | | 1999 | 2019 | 17.8 | low | 20 | 0 | 7 | 40 | 17 | 0 |
| Arrhythmia | 0 | | 1990 | 2012 | 24.8 | low | 1 | 0 | 7 | 2 | 1 | 0 |
| Arrhythmias, Cardiac | 0 | | 1990 | 2012 | 24.8 | low | 1 | 0 | 7 | 2 | 1 | 0 |
| Arrhythmogenic Right Ventricular Cardiomyopathy | 0 | | 2018 | 2018 | 6.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Arrhythmogenic Right Ventricular Dysplasia | 0 | | 2018 | 2018 | 6.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Arterial Diseases, Carotid | 0 | | 1996 | 2017 | 20.5 | low | 4 | 0 | 2 | 5 | 1 | 0 |
| Arterial Obstructive Diseases | 0 | | 1997 | 2000 | 25.5 | low | 1 | 0 | 2 | 0 | 0 | 0 |
| Arterial Occlusive Diseases | 0 | | 1997 | 2000 | 25.5 | low | 1 | 0 | 2 | 0 | 0 | 0 |
| Arteriosclerosis | 0 | | 1991 | 2008 | 23.1 | low | 6 | 0 | 11 | 21 | 0 | 0 |
| Arteriosclerosis, Coronary | 0 | | 1994 | 2016 | 18.5 | low | 10 | 0 | 3 | 12 | 4 | 0 |
| Arthralgia | 0 | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Arthritis | 0 | | 1986 | 1986 | 38.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Arthritis, Rheumatoid | 1 | | 2008 | 2015 | 12.5 | low | 1 | 0 | 0 | 2 | 4 | 0 |
| Asthma | 0 | | 1987 | 2012 | 26.3 | low | 1 | 1 | 1 | 0 | 1 | 0 |
| Asthma, Bronchial | 0 | | 1987 | 2012 | 26.3 | low | 1 | 1 | 1 | 0 | 1 | 0 |
| Asymmetric Diabetic Proximal Motor Neuropathy | 0 | | 2008 | 2021 | 9.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| Asystole | 0 | | 2004 | 2004 | 20.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Atherogenesis | 0 | | 2005 | 2019 | 15.3 | low | 4 | 0 | 0 | 10 | 2 | 0 |
| Atheroma | 0 | | 2012 | 2012 | 12.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Atherosclerosis | 1 | | 2005 | 2019 | 15.3 | low | 4 | 0 | 0 | 10 | 2 | 0 |
| Atrial Fibrillation | 1 | | 2000 | 2022 | 14.4 | low | 8 | 0 | 1 | 7 | 6 | 1 |
| Atrial Flutter | 1 | | 2022 | 2022 | 2.0 | low | 1 | 0 | 0 | 0 | 0 | 1 |
| Atrioventricular Nodal Re-Entrant Tachycardia | 0 | | 2003 | 2018 | 13.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| Atrophy | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Auricular Fibrillation | 0 | | 2000 | 2022 | 14.4 | low | 8 | 0 | 1 | 7 | 6 | 1 |
| Auricular Flutter | 0 | | 2022 | 2022 | 2.0 | low | 1 | 0 | 0 | 0 | 0 | 1 |
| Autoimmune Diabetes | 0 | | 1991 | 2017 | 23.0 | low | 9 | 0 | 13 | 8 | 2 | 0 |
| Autoimmune Disease | 0 | | 1998 | 2012 | 19.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| Autoimmune Diseases | 0 | | 1998 | 2012 | 19.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| Autoimmune Thyroiditis | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| B-Cell Chronic Lymphocytic Leukemia | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Basal Ganglia Cerebrovascular Disease | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Behavior Disorders | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Benign Neoplasms | 0 | | 2009 | 2012 | 13.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| Berger Disease | 0 | | 2003 | 2019 | 14.4 | low | 4 | 0 | 0 | 5 | 2 | 0 |
| Besnier-Boeck Disease | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Bilateral Headache | 0 | | 2008 | 2013 | 13.5 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| Bile Duct Obstruction, Intrahepatic | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Biliary Cirrhosis | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Bites | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Blood Clot | 0 | | 1997 | 2016 | 17.5 | low | 1 | 0 | 1 | 0 | 1 | 0 |
| Blood Poisoning | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Blood Pressure, High | 0 | | 1984 | 2022 | 21.0 | low | 219 | 43 | 184 | 207 | 125 | 5 |
| Blood Pressure, Low | 0 | | 2002 | 2021 | 12.6 | low | 4 | 0 | 0 | 5 | 5 | 1 |
| Blunt Injuries | 0 | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Body Weight | 0 | | 1989 | 2020 | 22.1 | low | 3 | 3 | 13 | 16 | 6 | 0 |
| Bone Fractures | 0 | | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Bouillaud Disease | 0 | | 1995 | 2021 | 20.0 | low | 1 | 0 | 2 | 0 | 0 | 1 |
| Brachial Paresis | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Bradyarrhythmia | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Bradycardia | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Brain Injuries | 0 | | 2008 | 2014 | 13.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Brain Ischemia | 0 | | 2008 | 2019 | 11.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| Brain Vascular Disorders | 0 | | 1993 | 2020 | 24.2 | low | 0 | 0 | 4 | 0 | 1 | 0 |
| Branch Vein Occlusion | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Breast Cancer | 0 | | 1996 | 2021 | 10.5 | low | 2 | 0 | 1 | 0 | 2 | 1 |
| Breast Neoplasms | 0 | | 1996 | 2021 | 10.5 | low | 2 | 0 | 1 | 0 | 2 | 1 |
| Breathlessness | 0 | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Bright Disease | 0 | | 1988 | 2007 | 25.8 | low | 7 | 1 | 5 | 4 | 0 | 0 |
| Bronchial Spasm | 0 | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Bronchiolitis Obliterans | 0 | | 2006 | 2008 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Bronchiolitis, Exudative | 0 | | 2006 | 2008 | 17.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Bronchitis | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Bronchospasm | 0 | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Bullous Dermatoses | 0 | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Burning Mouth Syndrome | 0 | | 1999 | 1999 | 25.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Cancer of Lung | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cancer of Skin | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Canine Diseases | 0 | | 1996 | 2020 | 17.2 | low | 4 | 0 | 1 | 2 | 1 | 0 |
| Capillary Leak Syndrome | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Carbon Tetrachloride Poisoning | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Carcinoma, Non-Small Cell Lung | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Carcinoma, Non-Small-Cell Lung | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cardiac Arrest, Sudden | 0 | | 1994 | 2006 | 23.2 | low | 5 | 0 | 5 | 4 | 0 | 0 |
| Cardiac Complex, Premature | 0 | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Cardiac Death | 0 | | 2001 | 2001 | 23.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Cardiac Diseases | 0 | | 1997 | 2021 | 19.7 | low | 6 | 0 | 2 | 6 | 0 | 1 |
| Cardiac Failure | 0 | | 1987 | 2023 | 20.7 | low | 57 | 11 | 59 | 53 | 26 | 13 |
| Cardiac Hypertrophy | 0 | | 1987 | 2023 | 24.3 | low | 1 | 5 | 17 | 7 | 6 | 1 |
| Cardiac Output, Low | 0 | | 1994 | 1999 | 26.6 | low | 4 | 0 | 5 | 0 | 0 | 0 |
| Cardiac Remodeling, Ventricular | 0 | | 1998 | 2022 | 18.1 | low | 8 | 0 | 4 | 23 | 7 | 1 |
| Cardiac Rupture, Traumatic | 0 | | 1995 | 2014 | 21.7 | low | 1 | 0 | 2 | 0 | 1 | 0 |
| Cardiac Tamponade | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cardiac Toxicity | 0 | | 2014 | 2020 | 7.2 | low | 1 | 0 | 0 | 0 | 4 | 0 |
| Cardiomegaly | 0 | | 1987 | 2023 | 24.3 | low | 1 | 5 | 17 | 7 | 6 | 1 |
| Cardiometabolic Syndrome | 0 | | 2004 | 2012 | 16.2 | low | 5 | 0 | 0 | 8 | 2 | 0 |
| Cardiomyopathies | 0 | | 1988 | 2016 | 18.3 | low | 1 | 1 | 1 | 3 | 2 | 0 |
| Cardiomyopathies, Primary | 0 | | 1988 | 2016 | 18.3 | low | 1 | 1 | 1 | 3 | 2 | 0 |
| Cardiomyopathy, Congestive | 0 | | 1995 | 2013 | 22.8 | low | 2 | 0 | 4 | 3 | 1 | 0 |
| Cardiomyopathy, Dilated | 0 | | 1995 | 2013 | 22.8 | low | 2 | 0 | 4 | 3 | 1 | 0 |
| Cardiomyopathy, Hypertrophic | 0 | | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Cardiomyopathy, Hypertrophic Obstructive | 0 | | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Cardiotoxicity | 0 | | 2014 | 2020 | 7.2 | low | 1 | 0 | 0 | 0 | 4 | 0 |
| Cardiovascular Diseases | 1 | | 1990 | 2022 | 17.3 | low | 76 | 0 | 41 | 146 | 55 | 5 |
| Cardiovascular Pregnancy Complications | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cardiovascular Stroke | 0 | | 1990 | 2023 | 19.4 | low | 61 | 0 | 63 | 80 | 33 | 12 |
| Carditis | 0 | | 2010 | 2019 | 11.0 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| Carotid Arteriopathies, Traumatic | 0 | | 1992 | 2001 | 27.3 | low | 0 | 0 | 2 | 1 | 0 | 0 |
| Carotid Artery Diseases | 0 | | 1996 | 2017 | 20.5 | low | 4 | 0 | 2 | 5 | 1 | 0 |
| Carotid Artery Narrowing | 0 | | 1996 | 2001 | 25.5 | low | 1 | 0 | 1 | 1 | 0 | 0 |
| Carotid Stenosis | 0 | | 1996 | 2001 | 25.5 | low | 1 | 0 | 1 | 1 | 0 | 0 |
| Cataract | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cataract, Membranous | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cerebral Arteriosclerosis | 0 | | 1996 | 1996 | 28.0 | low | 1 | 0 | 1 | 0 | 0 | 0 |
| Cerebral Hemorrhage, Hypertensive | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cerebral Infarction | 0 | | 2002 | 2004 | 21.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Cerebral Infarction, Middle Cerebral Artery | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cerebral Ischemia | 0 | | 2008 | 2019 | 11.8 | low | 0 | 0 | 0 | 3 | 2 | 0 |
| Cerebrovascular Disorders | 0 | | 1993 | 2020 | 24.2 | low | 0 | 0 | 4 | 0 | 1 | 0 |
| Chemical and Drug Induced Liver Injury | 0 | | 2010 | 2022 | 9.6 | low | 0 | 0 | 0 | 1 | 5 | 1 |
| Chemical and Drug Induced Liver Injury, Chronic | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cholecystoduodenal Fistula | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cholestasis, Intrahepatic | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Choroid Diseases | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Chronic Disease | 0 | | 1987 | 2021 | 21.7 | low | 14 | 3 | 13 | 13 | 4 | 1 |
| Chronic Illness | 0 | | 1987 | 2021 | 21.7 | low | 14 | 3 | 13 | 13 | 4 | 1 |
| Chronic Kidney Diseases | 0 | | 2009 | 2023 | 9.7 | low | 5 | 0 | 0 | 2 | 12 | 1 |
| Chronic Kidney Failure | 0 | | 1987 | 2022 | 19.3 | low | 40 | 3 | 19 | 33 | 16 | 1 |
| Chronic Lymphocytic Thyroiditis | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Chronic Pancreatitis | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Churg-Strauss Syndrome | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cicatrix | 0 | | 2015 | 2019 | 7.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Cicatrization | 0 | | 2015 | 2019 | 7.0 | low | 0 | 0 | 0 | 0 | 2 | 0 |
| Circulatory Collapse | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cirrhosis | 0 | | 1988 | 2023 | 13.4 | low | 1 | 1 | 4 | 11 | 12 | 6 |
| Cirrhosis, Liver | 0 | | 1997 | 2016 | 14.3 | low | 0 | 0 | 1 | 0 | 2 | 0 |
| Click-Murmur Syndrome | 0 | | 1997 | 2010 | 20.5 | low | 1 | 0 | 1 | 1 | 0 | 0 |
| Coagulation, Disseminated Intravascular | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Coarctation of Aorta | 0 | | 1994 | 2008 | 24.8 | low | 1 | 0 | 3 | 1 | 0 | 0 |
| Cochlear Hearing Loss | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Cognition Disorders | 0 | | 2009 | 2015 | 11.6 | low | 2 | 0 | 0 | 1 | 4 | 0 |
| Cognitive Decline | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Cognitive Dysfunction | 0 | | 2023 | 2023 | 1.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Colicky Pain | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Colitis | 0 | | 2005 | 2014 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Colitis, Granulomatous | 0 | | 2010 | 2011 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Compartment Syndromes | 0 | | 2007 | 2017 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Compensatory Hyperinsulinemia | 0 | | 1998 | 2006 | 22.0 | low | 1 | 0 | 1 | 1 | 0 | 0 |
| Complication, Intraoperative | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Complication, Postoperative | 0 | | 1998 | 2018 | 14.5 | low | 9 | 0 | 2 | 5 | 8 | 0 |
| Complications of Diabetes Mellitus | 0 | | 1991 | 2019 | 19.8 | low | 19 | 0 | 14 | 20 | 7 | 0 |
| Complications, Pregnancy | 0 | | 2005 | 2008 | 17.5 | low | 1 | 0 | 0 | 2 | 0 | 0 |
| Congenital Myasthenia | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Congenital Zika Syndrome | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Constriction, Pathologic | 0 | | 1990 | 2015 | 20.2 | low | 0 | 0 | 2 | 1 | 2 | 0 |
| Constriction, Pathological | 0 | | 1990 | 2015 | 20.2 | low | 0 | 0 | 2 | 1 | 2 | 0 |
| Cor Pulmonale | 0 | | 1999 | 2008 | 22.2 | low | 1 | 0 | 2 | 2 | 0 | 0 |
| Coronary Artery Disease | 1 | | 1994 | 2016 | 18.5 | low | 10 | 0 | 3 | 12 | 4 | 0 |
| Coronary Artery Vasospasm | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Coronary Disease | 0 | | 1986 | 2016 | 24.5 | low | 6 | 4 | 13 | 15 | 3 | 0 |
| Coronary Heart Disease | 0 | | 1986 | 2016 | 24.5 | low | 6 | 4 | 13 | 15 | 3 | 0 |
| Coronary Restenosis | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Coronary Thrombosis | 0 | | 2008 | 2016 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Coronary Vasospasm | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Coronavirus Infections | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Cough | 0 | | 1989 | 2013 | 20.5 | low | 3 | 1 | 4 | 8 | 2 | 0 |
| Cranial Nerve Diseases | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Cranial Nerve II Diseases | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Critical Illness | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Crohn Disease | 0 | | 2010 | 2011 | 13.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Cystic Kidney Diseases | 0 | | 2012 | 2012 | 12.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Day Blindness | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| DDD MPGNII | 0 | | 1993 | 2011 | 22.0 | low | 2 | 0 | 1 | 0 | 1 | 0 |
| Death, Sudden | 0 | | 2009 | 2009 | 15.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Death, Sudden, Cardiac | 0 | | 1994 | 2006 | 23.2 | low | 5 | 0 | 5 | 4 | 0 | 0 |
| Decerebrate Posturing | 0 | | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Deficiency, Glucosephosphatase | 0 | | 2001 | 2002 | 22.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Deficiency, IgA | 0 | | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Deficiency, IgG | 0 | | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Deficiency, Muscle Phosphorylase | 0 | | 2008 | 2014 | 13.0 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| Deficiency, Yin | 0 | | 2008 | 2008 | 16.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Dehydration | 0 | | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Delayed Effects, Prenatal Exposure | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Dementia | 0 | | 2004 | 2015 | 13.0 | low | 2 | 0 | 0 | 1 | 2 | 0 |
| Depression | 0 | | 2009 | 2020 | 9.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Dermatitis Medicamentosa | 0 | | 1996 | 2013 | 20.0 | low | 0 | 0 | 2 | 4 | 1 | 0 |
| Dermatitis, Occupational | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Diabetes Mellitus | 1 | | 1996 | 2022 | 18.2 | low | 14 | 0 | 6 | 33 | 3 | 1 |
| Diabetes Mellitus, Adult-Onset | 0 | | 1990 | 2023 | 18.0 | low | 48 | 0 | 23 | 69 | 20 | 3 |
| Diabetes Mellitus, Gestational | 0 | | 2004 | 2008 | 18.0 | low | 2 | 0 | 0 | 2 | 0 | 0 |
| Diabetes Mellitus, Type 1 | 1 | | 1991 | 2017 | 23.0 | low | 9 | 0 | 13 | 8 | 2 | 0 |
| Diabetes Mellitus, Type 2 | 1 | | 1990 | 2023 | 18.0 | low | 48 | 0 | 23 | 69 | 20 | 3 |
| Diabetes, Gestational | 0 | | 2004 | 2008 | 18.0 | low | 2 | 0 | 0 | 2 | 0 | 0 |
| Diabetic Angiopathies | 0 | | 1996 | 2010 | 20.3 | low | 12 | 0 | 8 | 24 | 0 | 0 |
| Diabetic Cardiomyopathies | 0 | | 2012 | 2016 | 9.3 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Diabetic Glomerulosclerosis | 0 | | 1991 | 2023 | 18.8 | low | 23 | 0 | 23 | 41 | 14 | 3 |
| Diabetic Nephropathies | 1 | | 1991 | 2023 | 18.8 | low | 23 | 0 | 23 | 41 | 14 | 3 |
| Diabetic Neuropathies | 0 | | 2008 | 2021 | 9.5 | low | 0 | 0 | 0 | 1 | 0 | 1 |
| Diabetic Retinopathy | 0 | | 2000 | 2008 | 19.0 | low | 0 | 0 | 1 | 4 | 0 | 0 |
| Diarrhea | 0 | | 2002 | 2003 | 21.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Diastolic Heart Failure | 0 | | 2008 | 2008 | 16.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Diathesis | 0 | | 1993 | 1993 | 31.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Diffuse Cutaneous Systemic Sclerosis | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Disease Exacerbation | 0 | | 1996 | 2021 | 17.9 | low | 23 | 0 | 12 | 32 | 15 | 1 |
| Disease Models, Animal | 0 | | 1986 | 2020 | 17.9 | low | 3 | 1 | 16 | 38 | 27 | 0 |
| Diseases, Peripheral Vascular | 0 | | 2001 | 2008 | 18.5 | low | 7 | 0 | 0 | 10 | 0 | 0 |
| Disseminated Intravascular Coagulation | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Dizziness | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Dizzyness | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Drop Attack | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Drug Hypersensitivity | 0 | | 2006 | 2016 | 12.7 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| Drug Overdose | 0 | | 2000 | 2020 | 14.2 | low | 0 | 0 | 1 | 2 | 2 | 0 |
| Drug Withdrawal Symptoms | 0 | | 2011 | 2011 | 13.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Drug-Induced Stevens Johnson Syndrome | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Drug-Related Side Effects and Adverse Reactions | 0 | | 2004 | 2016 | 13.6 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| Dysesthesia | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Dysgammaglobulinemia | 0 | | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Dyspnea | 0 | | 1994 | 1994 | 30.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Edema | 0 | | 2003 | 2010 | 17.2 | low | 1 | 0 | 0 | 4 | 0 | 0 |
| Edema-Proteinuria-Hypertension Gestosis | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Edema, Pulmonary | 0 | | 2006 | 2013 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Electric Injuries | 0 | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Electrolytes | 0 | | 1985 | 1996 | 33.7 | low | 3 | 5 | 4 | 0 | 0 | 0 |
| Elevated Cholesterol | 0 | | 1997 | 2015 | 17.9 | low | 5 | 0 | 1 | 5 | 3 | 0 |
| Emergencies | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Encephalopathy, Toxic | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Endomyocardial Fibrosis | 0 | | 1992 | 2012 | 24.0 | low | 0 | 0 | 2 | 0 | 1 | 0 |
| Eosinophilia | 0 | | 2002 | 2007 | 19.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Eosinophilia, Tropical | 0 | | 2002 | 2007 | 19.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Erectile Dysfunction | 0 | | 2007 | 2011 | 14.7 | low | 2 | 0 | 0 | 2 | 1 | 0 |
| Erythema | 0 | | 1993 | 2016 | 19.5 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| Erythrocytosis | 0 | | 1995 | 1998 | 27.5 | low | 2 | 0 | 2 | 0 | 0 | 0 |
| Essential Polyarteritis | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Experimental Lung Inflammation | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Experimental Neoplasms | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Experimental Radiation Injuries | 0 | | 2004 | 2021 | 11.1 | low | 0 | 0 | 0 | 3 | 4 | 1 |
| Extramembranous Glomerulopathy | 0 | | 2000 | 2003 | 22.5 | low | 1 | 0 | 1 | 1 | 0 | 0 |
| Eye Abnormalities | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Fallot's Tetralogy | 0 | | 2012 | 2019 | 6.8 | low | 2 | 0 | 0 | 0 | 5 | 0 |
| Fanconi Anemia | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Fasciitis | 0 | | 2000 | 2007 | 20.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Fever | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Fibrosis | 0 | | 1988 | 2023 | 13.4 | low | 1 | 1 | 4 | 11 | 12 | 6 |
| Focal Segmental Glomerulosclerosis | 0 | | 2003 | 2019 | 13.8 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| Foot Dermatoses | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Foot Diseases | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Forearm Injuries | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Fractures, Bone | 0 | | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Gastroenteritis | 0 | | 2002 | 2002 | 22.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Gastrointestinal Hemorrhage | 0 | | 1998 | 2015 | 17.5 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| Genetic Predisposition | 0 | | 1998 | 2015 | 17.5 | low | 1 | 0 | 2 | 0 | 2 | 0 |
| Gingival Hyperplasia | 0 | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Glaucoma | 0 | | 2002 | 2002 | 22.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Glaucoma, Suspect | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Glomerulonephritis | 1 | | 1988 | 2007 | 25.8 | low | 7 | 1 | 5 | 4 | 0 | 0 |
| Glomerulonephritis, IGA | 0 | | 2003 | 2019 | 14.4 | low | 4 | 0 | 0 | 5 | 2 | 0 |
| Glomerulonephritis, Lupus | 0 | | 1998 | 2005 | 22.5 | low | 1 | 0 | 1 | 1 | 0 | 0 |
| Glomerulonephritis, Membranoproliferative | 0 | | 1993 | 2011 | 22.0 | low | 2 | 0 | 1 | 0 | 1 | 0 |
| Glomerulonephritis, Membranous | 0 | | 2000 | 2003 | 22.5 | low | 1 | 0 | 1 | 1 | 0 | 0 |
| Glomerulonephritis, Minimal Change | 0 | | 2001 | 2008 | 19.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| Glomerulosclerosis, Focal Segmental | 0 | | 2003 | 2019 | 13.8 | low | 0 | 0 | 0 | 3 | 1 | 0 |
| Glossitis | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Glucose Intolerance | 1 | | 2006 | 2019 | 14.8 | low | 6 | 0 | 0 | 8 | 1 | 0 |
| Glucose Metabolic Disorder | 0 | | 2015 | 2015 | 9.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Glycogen Storage Disease Type I | 0 | | 2001 | 2002 | 22.5 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Glycogen Storage Disease Type V | 0 | | 2008 | 2014 | 13.0 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| Glycosuria | 0 | | 2000 | 2000 | 24.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Goldblatt Syndrome | 0 | | 1984 | 2015 | 29.4 | low | 1 | 3 | 10 | 0 | 1 | 0 |
| Graft Occlusion, Vascular | 0 | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Granuloma | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Granuloma, Hodgkin | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Granulomas | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Grippe | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Guillain-Barre Syndrome | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hand Dermatoses | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hand Dermatosis | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hashimoto Disease | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| HbS Disease | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Headache | 0 | | 2008 | 2013 | 13.5 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| Hearing Loss, Sensorineural | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Heart Arrest | 0 | | 2004 | 2004 | 20.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Heart Defects, Congenital | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Heart Disease, Ischemic | 0 | | 1992 | 2013 | 24.2 | low | 2 | 0 | 19 | 10 | 2 | 0 |
| Heart Diseases | 1 | | 1997 | 2021 | 19.7 | low | 6 | 0 | 2 | 6 | 0 | 1 |
| Heart Failure | 1 | | 1987 | 2023 | 20.7 | low | 57 | 11 | 59 | 53 | 26 | 13 |
| Heart Failure, Diastolic | 0 | | 2008 | 2008 | 16.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Heart Failure, Systolic | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hematochezia | 0 | | 1998 | 2015 | 17.5 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| Hematuria | 0 | | 2004 | 2015 | 14.7 | low | 1 | 0 | 0 | 2 | 1 | 0 |
| Hemorrhagic Shock | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hibernation, Myocardial | 0 | | 1994 | 1996 | 29.0 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| Hidradenitis Suppurativa | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hip Fractures | 0 | | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Hodgkin Disease | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Hydronephrosis | 0 | | 1987 | 1987 | 37.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Hyperaldosteronism | 0 | | 2005 | 2020 | 11.5 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| Hypercholesterolemia | 1 | | 1997 | 2015 | 17.9 | low | 5 | 0 | 1 | 5 | 3 | 0 |
| Hyperemia | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Hypergammaglobulinemia | 0 | | 1990 | 1990 | 34.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Hyperglycemia | 0 | | 1997 | 2012 | 18.5 | low | 6 | 0 | 3 | 8 | 1 | 0 |
| Hyperglycemia, Postprandial | 0 | | 1997 | 2012 | 18.5 | low | 6 | 0 | 3 | 8 | 1 | 0 |
| Hyperinsulinism | 0 | | 1998 | 2006 | 22.0 | low | 1 | 0 | 1 | 1 | 0 | 0 |
| Hyperkalemia | 0 | | 1987 | 2022 | 16.9 | low | 4 | 1 | 1 | 3 | 3 | 1 |
| Hyperlipemia | 0 | | 1993 | 2010 | 24.2 | low | 1 | 0 | 3 | 1 | 0 | 0 |
| Hyperlipidemias | 0 | | 1993 | 2010 | 24.2 | low | 1 | 0 | 3 | 1 | 0 | 0 |
| Hyperphosphatemia | 0 | | 2019 | 2019 | 5.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Hyperplasia | 0 | | 1995 | 1996 | 28.5 | low | 0 | 0 | 2 | 0 | 0 | 0 |
| Hyperpotassemia | 0 | | 1987 | 2022 | 16.9 | low | 4 | 1 | 1 | 3 | 3 | 1 |
| Hypertension | 1 | | 1984 | 2022 | 21.0 | low | 219 | 43 | 184 | 207 | 125 | 5 |
| Hypertension, Malignant | 0 | | 1998 | 2014 | 18.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| Hypertension, Renal | 0 | | 1988 | 2010 | 23.4 | low | 12 | 4 | 11 | 20 | 0 | 0 |
| Hypertension, Renovascular | 0 | | 1984 | 2015 | 29.4 | low | 1 | 3 | 10 | 0 | 1 | 0 |
| Hyperthyroid | 0 | | 2007 | 2009 | 16.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Hyperthyroidism | 0 | | 2007 | 2009 | 16.0 | low | 0 | 0 | 0 | 2 | 0 | 0 |
| Hypertrophy | 0 | | 1992 | 2013 | 22.7 | low | 0 | 0 | 6 | 2 | 1 | 0 |
| Hypertrophy, Left Ventricular | 0 | | 1993 | 2014 | 23.1 | low | 27 | 0 | 42 | 26 | 5 | 0 |
| Hypertrophy, Right Ventricular | 0 | | 1997 | 2003 | 24.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Hypokalemia | 0 | | 2005 | 2014 | 14.5 | low | 2 | 0 | 0 | 1 | 1 | 0 |
| Hyponatremia | 0 | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Hypotension | 0 | | 2002 | 2021 | 12.6 | low | 4 | 0 | 0 | 5 | 5 | 1 |
| Hypotension, Orthostatic | 0 | | 2018 | 2018 | 6.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Hypotension, Postural | 0 | | 2018 | 2018 | 6.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Hypoxia | 0 | | 1996 | 2008 | 22.0 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Icterus | 0 | | 2003 | 2013 | 16.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| IgA Vasculitis | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Ileal Diseases | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Impaired Glucose Tolerance | 0 | | 2006 | 2019 | 14.8 | low | 6 | 0 | 0 | 8 | 1 | 0 |
| Implant Capsular Contracture | 0 | | 2021 | 2021 | 3.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Impotence | 0 | | 2007 | 2011 | 14.7 | low | 2 | 0 | 0 | 2 | 1 | 0 |
| Incompetence, Pulmonary Valve | 0 | | 2012 | 2019 | 6.8 | low | 2 | 0 | 0 | 0 | 5 | 0 |
| Infarction, Middle Cerebral Artery | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Infections, Coronavirus | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Infections, Parvoviridae | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Inflammation | 0 | | 1986 | 2022 | 14.6 | low | 12 | 1 | 1 | 10 | 8 | 2 |
| Influenza, Human | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Injuries, Radiation | 0 | | 2014 | 2019 | 7.8 | low | 1 | 0 | 0 | 0 | 4 | 0 |
| Injuries, Spinal Cord | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Injury, Ischemia-Reperfusion | 0 | | 1994 | 2017 | 22.3 | low | 0 | 0 | 4 | 1 | 1 | 0 |
| Injury, Myocardial Reperfusion | 0 | | 1988 | 2016 | 24.3 | low | 0 | 3 | 9 | 8 | 3 | 0 |
| Innate Inflammatory Response | 0 | | 1986 | 2022 | 14.6 | low | 12 | 1 | 1 | 10 | 8 | 2 |
| Insulin Resistance | 0 | | 1996 | 2017 | 18.6 | low | 9 | 0 | 4 | 19 | 2 | 0 |
| Insulin Sensitivity | 0 | | 1996 | 2017 | 18.6 | low | 9 | 0 | 4 | 19 | 2 | 0 |
| Intermittent Claudication | 0 | | 2004 | 2015 | 12.5 | low | 5 | 0 | 0 | 4 | 12 | 0 |
| Interstitial Nephritis | 0 | | 2000 | 2012 | 20.0 | low | 1 | 0 | 1 | 3 | 1 | 0 |
| Intertrochanteric Fractures | 0 | | 2013 | 2013 | 11.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Intracranial Arteriosclerosis | 0 | | 1996 | 1996 | 28.0 | low | 1 | 0 | 1 | 0 | 0 | 0 |
| Intraocular Pressure | 0 | | 2002 | 2002 | 22.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Ischemia | 0 | | 2000 | 2014 | 19.7 | low | 2 | 0 | 1 | 4 | 1 | 0 |
| Ischemic Attack, Transient | 0 | | 2002 | 2017 | 14.5 | low | 1 | 0 | 0 | 1 | 1 | 0 |
| Ischemic Stroke | 0 | | 2022 | 2022 | 2.0 | low | 1 | 0 | 0 | 0 | 0 | 1 |
| Jaundice | 0 | | 2003 | 2013 | 16.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Jejunal Diseases | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Joint Pain | 0 | | 1995 | 1995 | 29.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Kidney Diseases | 1 | | 1987 | 2017 | 19.6 | low | 17 | 5 | 10 | 26 | 14 | 0 |
| Kidney Diseases, Cystic | 0 | | 2012 | 2012 | 12.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Kidney Failure | 0 | | 1994 | 2017 | 20.3 | low | 8 | 0 | 3 | 19 | 3 | 0 |
| Kidney Failure, Chronic | 0 | | 1987 | 2022 | 19.3 | low | 40 | 3 | 19 | 33 | 16 | 1 |
| Kidney, Polycystic | 0 | | 1997 | 2003 | 23.3 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| Klinefelter Syndrome | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Koch's Disease | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Lactic Acidosis | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Left Sided Breast Cancer | 0 | | 2019 | 2019 | 5.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Left Ventricular Dysfunction | 0 | | 1995 | 2022 | 17.8 | low | 25 | 0 | 12 | 25 | 11 | 3 |
| Left Ventricular Hypertrophy | 0 | | 1993 | 2014 | 23.1 | low | 27 | 0 | 42 | 26 | 5 | 0 |
| Lesion of Sciatic Nerve | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Leukoencephalopathy Syndrome, Posterior | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Leukostasis | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Libman-Sacks Disease | 0 | | 2005 | 2023 | 7.8 | low | 2 | 0 | 0 | 1 | 1 | 2 |
| Lichen Planus | 0 | | 1997 | 2006 | 22.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Lichen Planus, Oral | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Lichen Ruber Planus | 0 | | 1997 | 2006 | 22.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Liver Cirrhosis | 0 | | 1997 | 2016 | 14.3 | low | 0 | 0 | 1 | 0 | 2 | 0 |
| Liver Cirrhosis, Biliary | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Liver Diseases | 0 | | 1994 | 2003 | 25.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Liver Dysfunction | 0 | | 1994 | 2003 | 25.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Lung Neoplasms | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Lupus Erythematosus, Systemic | 1 | | 2005 | 2023 | 7.8 | low | 2 | 0 | 0 | 1 | 1 | 2 |
| Lupus Nephritis | 0 | | 1998 | 2005 | 22.5 | low | 1 | 0 | 1 | 1 | 0 | 0 |
| Malignant Hypertension | 0 | | 1998 | 2014 | 18.0 | low | 0 | 0 | 1 | 0 | 1 | 0 |
| Malignant Melanoma | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Marfan Syndrome | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Marfan Syndrome, Type I | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Melanoma | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Memory Disorders | 0 | | 2006 | 2019 | 11.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Mental Disorders | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Metabolic Syndrome | 1 | | 2004 | 2012 | 16.2 | low | 5 | 0 | 0 | 8 | 2 | 0 |
| Microglossia | 0 | | 2007 | 2017 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Mitral Incompetence | 0 | | 1997 | 2010 | 19.3 | low | 2 | 0 | 1 | 5 | 0 | 0 |
| Mitral Stenosis | 0 | | 2004 | 2021 | 11.5 | low | 2 | 0 | 0 | 1 | 0 | 1 |
| Mitral Valve Insufficiency | 0 | | 1997 | 2010 | 19.3 | low | 2 | 0 | 1 | 5 | 0 | 0 |
| Mitral Valve Stenosis | 0 | | 2004 | 2021 | 11.5 | low | 2 | 0 | 0 | 1 | 0 | 1 |
| MODS | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| MS (Multiple Sclerosis) | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Mucositis, Oral | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Multiple Organ Failure | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Multiple Sclerosis | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Muscle Contraction | 0 | | 1993 | 2016 | 23.6 | low | 0 | 0 | 7 | 2 | 2 | 0 |
| Muscle Relaxation | 0 | | 1991 | 2013 | 26.5 | low | 0 | 0 | 10 | 2 | 1 | 0 |
| Muscle Weakness | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Muscular Weakness | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Myasthenic Syndromes, Congenital | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Myelopathy | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Myocardial Infarction | 1 | | 1990 | 2023 | 19.4 | low | 61 | 0 | 63 | 80 | 33 | 12 |
| Myocardial Ischemia | 1 | | 1992 | 2013 | 24.2 | low | 2 | 0 | 19 | 10 | 2 | 0 |
| Myocarditis | 0 | | 2010 | 2019 | 11.0 | low | 0 | 0 | 0 | 2 | 3 | 0 |
| Myopia | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Nausea | 0 | | 2008 | 2008 | 16.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Nearsightedness | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Necrosis | 0 | | 1995 | 2020 | 18.7 | low | 0 | 0 | 3 | 2 | 2 | 0 |
| Neointima | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Neoplasms | 0 | | 2009 | 2012 | 13.3 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| Nephritis, Hereditary | 0 | | 2003 | 2023 | 10.2 | low | 2 | 0 | 0 | 2 | 3 | 1 |
| Nephritis, Interstitial | 0 | | 2000 | 2012 | 20.0 | low | 1 | 0 | 1 | 3 | 1 | 0 |
| Nephrocalcinosis | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Nephrosclerosis | 0 | | 2001 | 2013 | 19.4 | low | 5 | 0 | 0 | 8 | 1 | 0 |
| Nephrosis | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Nephrosis, Lipoid | 0 | | 2001 | 2008 | 19.0 | low | 0 | 0 | 0 | 3 | 0 | 0 |
| Nephrotic Syndrome | 0 | | 1988 | 2018 | 17.2 | low | 1 | 1 | 0 | 6 | 3 | 0 |
| Nerve Pain | 0 | | 2015 | 2021 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Neuralgia | 0 | | 2015 | 2021 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 1 |
| Neuroleptic Malignant Syndrome | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| No-Reflow Phenomenon | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Obesity | 0 | | 1996 | 2022 | 16.8 | low | 6 | 0 | 4 | 9 | 6 | 1 |
| Ocular Hypertension | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Oligohydramnios | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Optic Nerve Diseases | 0 | | 2007 | 2007 | 17.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Orphan Diseases | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Overweight | 0 | | 2011 | 2017 | 10.0 | low | 2 | 0 | 0 | 0 | 3 | 0 |
| Pain | 0 | | 2000 | 2019 | 13.4 | low | 1 | 0 | 1 | 1 | 3 | 0 |
| Pain, Intractable | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Palsy | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Pancreatitis | 0 | | 2003 | 2012 | 17.7 | low | 0 | 0 | 0 | 5 | 1 | 0 |
| Pancreatitis, Chronic | 0 | | 2016 | 2016 | 8.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Paralysis | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Parodontosis | 0 | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Pelvic Pain | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Pemphigoid | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Pemphigoid, Bullous | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Pemphigus | 0 | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Pemphigus Foliaceus | 0 | | 1996 | 1996 | 28.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Pericarditis | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Periodontal Diseases | 0 | | 1997 | 1997 | 27.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Peripheral Arterial Disease | 0 | | 2013 | 2019 | 10.0 | low | 2 | 0 | 0 | 0 | 10 | 0 |
| Peripheral Arterial Diseases | 0 | | 2013 | 2019 | 10.0 | low | 2 | 0 | 0 | 0 | 10 | 0 |
| Peripheral Vascular Diseases | 0 | | 2001 | 2008 | 18.5 | low | 7 | 0 | 0 | 10 | 0 | 0 |
| Pityriasis Rubra Pilaris | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Pleural Effusion | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Pleuropericarditis | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Pneumonia | 0 | | 2015 | 2015 | 9.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Pneumonia, Viral | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 3 | 0 |
| Polyarthritis | 0 | | 1986 | 1986 | 38.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Polycystic Kidney Diseases | 0 | | 1997 | 2003 | 23.3 | low | 0 | 0 | 1 | 2 | 0 | 0 |
| Polycystic Kidney, Autosomal Dominant | 0 | | 2002 | 2012 | 16.0 | low | 3 | 0 | 0 | 4 | 1 | 0 |
| Polyuria | 0 | | 1997 | 2010 | 20.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Postoperative Complications | 0 | | 1998 | 2018 | 14.5 | low | 9 | 0 | 2 | 5 | 8 | 0 |
| Pre-Eclampsia | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Prediabetes | 0 | | 2003 | 2012 | 17.8 | low | 2 | 0 | 0 | 7 | 1 | 0 |
| Prediabetic State | 0 | | 2003 | 2012 | 17.8 | low | 2 | 0 | 0 | 7 | 1 | 0 |
| Pregnancy | 0 | | 1984 | 2018 | 22.8 | low | 2 | 1 | 3 | 5 | 1 | 0 |
| Pregnancy in Diabetes | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Prostatic Hyperplasia | 0 | | 2000 | 2005 | 21.5 | low | 0 | 0 | 1 | 1 | 0 | 0 |
| Prosthesis Durability | 0 | | 2010 | 2010 | 14.0 | low | 1 | 0 | 0 | 1 | 0 | 0 |
| Proteinuria | 0 | | 1988 | 2019 | 19.0 | low | 45 | 1 | 20 | 49 | 17 | 0 |
| Pulmonary Arterial Remodeling | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Pulmonary Consumption | 0 | | 1999 | 2001 | 23.7 | low | 1 | 0 | 1 | 2 | 0 | 0 |
| Pulmonary Disease, Chronic Obstructive | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Pulmonary Edema | 0 | | 2006 | 2013 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Pulmonary Fibrosis | 0 | | 2004 | 2004 | 20.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Pulmonary Stenoses | 0 | | 1992 | 1992 | 32.0 | low | 0 | 0 | 1 | 0 | 0 | 0 |
| Pyrexia | 0 | | 2011 | 2011 | 13.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Recrudescence | 0 | | 1994 | 2022 | 16.2 | low | 6 | 0 | 3 | 4 | 4 | 1 |
| Remission, Spontaneous | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Renal Artery Obstruction | 0 | | 1987 | 2015 | 20.2 | low | 0 | 1 | 0 | 2 | 1 | 0 |
| Renal Artery Stenosis | 0 | | 1987 | 2015 | 20.2 | low | 0 | 1 | 0 | 2 | 1 | 0 |
| Renal Insufficiency | 0 | | 1994 | 2017 | 20.3 | low | 8 | 0 | 3 | 19 | 3 | 0 |
| Renal Insufficiency, Chronic | 1 | | 2009 | 2023 | 9.7 | low | 5 | 0 | 0 | 2 | 12 | 1 |
| Reperfusion Injury | 0 | | 1994 | 2017 | 22.3 | low | 0 | 0 | 4 | 1 | 1 | 0 |
| Respiratory Insufficiency | 0 | | 2019 | 2019 | 5.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Retinal Detachment | 0 | | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Retinal Diseases | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Retinal Pigment Epithelial Detachment | 0 | | 2008 | 2012 | 14.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Retinal Vein Occlusion | 0 | | 2010 | 2010 | 14.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Rhabdomyolysis | 0 | | 2007 | 2017 | 12.0 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Rheumatic Heart Disease | 0 | | 1995 | 2021 | 20.0 | low | 1 | 0 | 2 | 0 | 0 | 1 |
| Rheumatoid Arthritis | 0 | | 2008 | 2015 | 12.5 | low | 1 | 0 | 0 | 2 | 4 | 0 |
| Right Ventricular Dysfunction | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Rupture | 0 | | 1997 | 1997 | 27.0 | low | 1 | 0 | 1 | 0 | 0 | 0 |
| Rupture, Spontaneous | 0 | | 2001 | 2001 | 23.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Sarcoidosis | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Scleroderma, Diffuse | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Sensitivity and Specificity | 0 | | 1997 | 2014 | 18.6 | low | 2 | 0 | 2 | 11 | 5 | 0 |
| Sepsis | 0 | | 2009 | 2009 | 15.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Serositis | 0 | | 2005 | 2005 | 19.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Shock | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Shock, Cardiogenic | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Skin Neoplasms | 0 | | 2014 | 2014 | 10.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Small Fiber Neuropathy | 0 | | 2017 | 2017 | 7.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Spider Veins | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Spinal Cord Diseases | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Spinal Cord Injuries | 0 | | 2018 | 2018 | 6.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| ST Elevated Myocardial Infarction | 0 | | 2021 | 2021 | 3.0 | low | 1 | 0 | 0 | 0 | 0 | 1 |
| ST Elevation Myocardial Infarction | 0 | | 2021 | 2021 | 3.0 | low | 1 | 0 | 0 | 0 | 0 | 1 |
| Stevens-Johnson Syndrome | 0 | | 2003 | 2003 | 21.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Stomatitis | 0 | | 2006 | 2006 | 18.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Stroke | 1 | | 1999 | 2019 | 17.8 | low | 20 | 0 | 7 | 40 | 17 | 0 |
| Substance Withdrawal Syndrome | 0 | | 2011 | 2011 | 13.0 | low | 1 | 0 | 0 | 0 | 1 | 0 |
| Symptom Cluster | 0 | | 1998 | 2019 | 14.0 | low | 0 | 0 | 1 | 1 | 2 | 0 |
| Syncope | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Syndrome | 0 | | 1998 | 2019 | 14.0 | low | 0 | 0 | 1 | 1 | 2 | 0 |
| Systolic Heart Failure | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Tachycardia, Ventricular | 0 | | 2003 | 2018 | 13.0 | low | 0 | 0 | 0 | 1 | 2 | 0 |
| Takotsubo Cardiomyopathy | 0 | | 2009 | 2020 | 7.7 | low | 1 | 0 | 0 | 1 | 6 | 0 |
| Taste Disorder, Anterior Tongue | 0 | | 1985 | 1985 | 39.0 | low | 0 | 1 | 0 | 0 | 0 | 0 |
| Telangiectasis | 0 | | 2013 | 2013 | 11.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Tetralogy of Fallot | 0 | | 2012 | 2019 | 6.8 | low | 2 | 0 | 0 | 0 | 5 | 0 |
| Thrombocytopenia | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Thrombopenia | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Thrombosis | 0 | | 1997 | 2016 | 17.5 | low | 1 | 0 | 1 | 0 | 1 | 0 |
| Thrombotic Microangiopathies | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Tuberculosis | 0 | | 2012 | 2012 | 12.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
| Tuberculosis, Pulmonary | 0 | | 1999 | 2001 | 23.7 | low | 1 | 0 | 1 | 2 | 0 | 0 |
| Uremia | 0 | | 1988 | 2009 | 25.0 | low | 1 | 2 | 2 | 3 | 0 | 0 |
| Vascular Diseases | 0 | | 1998 | 2009 | 20.9 | low | 5 | 0 | 2 | 6 | 0 | 0 |
| Vasculitis | 0 | | 2004 | 2008 | 17.2 | low | 2 | 0 | 0 | 4 | 0 | 0 |
| Ventricular Dysfunction | 0 | | 2008 | 2008 | 16.0 | low | 0 | 0 | 0 | 1 | 0 | 0 |
| Ventricular Dysfunction, Left | 0 | | 1995 | 2022 | 17.8 | low | 25 | 0 | 12 | 25 | 11 | 3 |
| Ventricular Fibrillation | 0 | | 1991 | 2012 | 24.4 | low | 0 | 0 | 3 | 1 | 1 | 0 |
| Weight Gain | 0 | | 2007 | 2012 | 14.5 | low | 0 | 0 | 0 | 1 | 1 | 0 |
| Weight Loss | 0 | | 2000 | 2015 | 17.5 | low | 0 | 0 | 1 | 2 | 1 | 0 |
| Weight Reduction | 0 | | 2000 | 2015 | 17.5 | low | 0 | 0 | 1 | 2 | 1 | 0 |
| Wet Macular Degeneration | 0 | | 2022 | 2022 | 2.0 | low | 0 | 0 | 0 | 0 | 0 | 1 |
| Zika Virus Infection | 0 | | 2020 | 2020 | 4.0 | low | 0 | 0 | 0 | 0 | 1 | 0 |
Ramipril and hydrochlorothiazide treatment of hypertensive urgency in the ED.The American journal of emergency medicine, , Volume: 31, Issue:10, 2013
Incidence, severity, and etiology of drug-induced acute pancreatitis.Digestive diseases and sciences, , Volume: 55, Issue:10, 2010
A case of acute myocarditis caused by pandemic (H1N1) 2009 influenza virus.Journal of the Formosan Medical Association = Taiwan yi zhi, , Volume: 109, Issue:11, 2010
Differential effects of olmesartan and ramipril on inflammatory response after myocardial infarction in rats.Blood pressure, , Volume: 15, Issue:2, 2006
Cardiac angiotensin is upregulated in the hearts of unstable angina patients.Circulation research, , Jun-25, Volume: 94, Issue:12, 2004
The problem of underdosing of angiotensin-converting enzyme inhibitors is markedly overrated: results from a study of patients discharged from hospital after an acute myocardial infarction.European journal of clinical pharmacology, , Volume: 60, Issue:3, 2004
Angiotensin II and the fibroproliferative response to acute lung injury.American journal of physiology. Lung cellular and molecular physiology, , Volume: 286, Issue:1, 2004
Acute pancreatitis due to ramipril therapy.Postgraduate medical journal, , Volume: 80, Issue:948, 2004
Differential effects of saralasin and ramiprilat, the inhibitors of renin-angiotensin system, on cerulein-induced acute pancreatitis.Regulatory peptides, , Mar-28, Volume: 111, Issue:1-3, 2003
Fulminant pancreatitis associated with ramipril therapy.Pancreas, , Volume: 27, Issue:3, 2003
The Acute Infarction Ramipril Efficacy (AIRE) Study: rationale, design, organization, and outcome definitions.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Influence of the new angiotensin converting enzyme inhibitor ramipril on several models of acute inflammation and the adjuvant arthritis in the rat.Arzneimittel-Forschung, , Volume: 36, Issue:11, 1986
Dysglycemia and Cognitive Dysfunction and Ill Health in People With High CV Risk: Results From the ONTARGET/TRANSCEND Studies.The Journal of clinical endocrinology and metabolism, , Volume: 100, Issue:7, 2015
Reciprocal regulation of NO signaling and TXNIP expression in humans: impact of aging and ramipril therapy.International journal of cardiology, , Oct-12, Volume: 168, Issue:5, 2013
Aliskiren versus ramipril in hypertension.Therapeutic advances in cardiovascular disease, , Volume: 4, Issue:3, 2010
Atrial natriuretic peptide prevents diabetes-induced endothelial dysfunction.Life sciences, , Apr-09, Volume: 82, Issue:15-16, 2008
The HOPE Study (Heart Outcomes Prevention Evaluation).Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 1, Issue:1, 2000
Influence of age on cardiovascular effects of increased dietary sodium and angiotensin-converting enzyme inhibition in normotensive Wistar rats.The Journal of pharmacy and pharmacology, , Volume: 49, Issue:9, 1997
Aging and fluid homeostasis in rats.The American journal of physiology, , Volume: 273, Issue:4, 1997
Influence of age and dietary sodium on the cardiovascular and renal effects of ramipril in spontaneously hypertensive rats.Methods and findings in experimental and clinical pharmacology, , Volume: 19, Issue:5, 1997
Effects on the pharmacokinetics and pharmacodynamics in the elderly of coadministering ramipril with water, apple juice, and applesauce.Pharmaceutical research, , Volume: 13, Issue:4, 1996
Ramipril. An updated review of its therapeutic use in essential hypertension and heart failure.Drugs, , Volume: 49, Issue:3, 1995
Resetting blood pressure in spontaneously hypertensive rats. The role of bradykinin.Hypertension (Dallas, Tex. : 1979), , Volume: 25, Issue:2, 1995
Attenuation of genetic hypertension after short-term vasopressin V1A receptor antagonism.Hypertension (Dallas, Tex. : 1979), , Volume: 26, Issue:5, 1995
Long-term effects of brief antihypertensive treatment on systolic blood pressure and vascular reactivity in young genetically hypertensive rats.Cardiovascular drugs and therapy, , Volume: 9, Issue:3, 1995
Long-term low-dose angiotensin converting enzyme inhibitor treatment increases vascular cyclic guanosine 3',5'-monophosphate.Hypertension (Dallas, Tex. : 1979), , Volume: 22, Issue:5, 1993
Antihypertensive efficacy, tolerance, and safety of ramipril in young vs. old patients: a retrospective study.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Age-related variations in tissue angiotensin converting enzyme activities: comparison between spontaneously hypertensive and Wistar-Kyoto rats.Journal of hypertension, , Volume: 8, Issue:8, 1990
Long-term ACE inhibition in Alport syndrome: are the benefits worth the risks?Kidney international, , Volume: 97, Issue:6, 2020
The effects of single and combined application of ramipril and losartan on renal structure and function in hypertensive rats.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 40, Issue:7, 2018
Effects of Direct Renin Blockade on Renal & Systemic Hemodynamics and on RAAS Activity, in Weight Excess and Hypertension: A Randomized Clinical Trial.PloS one, , Volume: 12, Issue:1, 2017
Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 16, Issue:4, 2015
Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading.Clinical and experimental nephrology, , Volume: 18, Issue:4, 2014
Renal antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.American journal of nephrology, , Volume: 37, Issue:1, 2013
Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria.Expert opinion on pharmacotherapy, , Volume: 14, Issue:4, 2013
Effect of imidapril versus ramipril on urinary albumin excretion in hypertensive patients with type 2 diabetes and microalbuminuria.Expert opinion on pharmacotherapy, , Volume: 14, Issue:18, 2013
Albuminuria and rapid loss of GFR and risk of new hip and pelvic fractures.Clinical journal of the American Society of Nephrology : CJASN, , Volume: 8, Issue:2, 2013
Activation of Rac-1 and RhoA contributes to podocyte injury in chronic kidney disease.PloS one, , Volume: 8, Issue:11, 2013
A pilot study on the effect of telmisartan & ramipril on 24 h blood pressure profile & dipping pattern in type 1 diabetes patients with nephropathy.The Indian journal of medical research, , Volume: 134, Issue:5, 2011
Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET).Circulation, , Oct-18, Volume: 124, Issue:16, 2011
Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.Circulation, , Mar-15, Volume: 123, Issue:10, 2011
Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease.Current diabetes reports, , Volume: 10, Issue:4, 2010
Preservation of kidney function with combined inhibition of NADPH oxidase and angiotensin-converting enzyme in diabetic nephropathy.American journal of nephrology, , Volume: 32, Issue:1, 2010
Anti-albuminuric efficacy of a combination of angiotensin converting enzyme inhibitor & angiotensin receptor blocker in type 1 DM with nephropathy.The Indian journal of medical research, , Volume: 132, 2010
Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 10, Issue:3, 2009
Hypertension-mediated albuminuria is associated with reduced lysosomal activity in the kidney and the heart.American journal of nephrology, , Volume: 29, Issue:5, 2009
Reduced cortical renal GLUT1 expression induced by angiotensin-converting enzyme inhibition in diabetic spontaneously hypertensive rats.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, , Volume: 41, Issue:11, 2008
Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular events, and Ramipril (DIABHYCAR), Diabete dDiabetes care, , Volume: 31, Issue:10, 2008
Evaluation of fixed dose combination (FDC) of telmisartan+ramipril usage in patients with micro-albuminuria and persistent hypertension: A TRIUMPH study.Journal of the Indian Medical Association, , Volume: 106, Issue:3, 2008
Pharmacological blockade of B2-kinin receptor reduces renal protective effect of angiotensin-converting enzyme inhibition in db/db mice model.American journal of physiology. Renal physiology, , Volume: 294, Issue:5, 2008
Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial.Kidney international, , Volume: 72, Issue:7, 2007
Albuminuria reduction: the holy grail for kidney protection.Kidney international, , Volume: 72, Issue:7, 2007
Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study)*.Journal of hypertension, , Volume: 24, Issue:3, 2006
Vasopeptidase inhibition prevents target organ damage and improves survival in spontaneously hypertensive rats.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 7, Issue:3, 2006
Modulation of the renal response to ACE inhibition by ACE insertion/deletion polymorphism during hyperglycemia in normotensive, normoalbuminuric type 1 diabetic patients.Diabetes, , Volume: 54, Issue:10, 2005
Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina).Diabetes, nutrition & metabolism, , Volume: 17, Issue:5, 2004
Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).BMJ (Clinical research ed.), , Feb-28, Volume: 328, Issue:7438, 2004
Evaluation of efficacy and tolerability of Losartan and Ramipril combination in the management of hypertensive patients with associated diabetes mellitus in India (LORD Trial).The Journal of the Association of Physicians of India, , Volume: 52, 2004
Parallel renal and extremity blood supply abnormalities in nonmodulation: responses to ACE inhibition.Hypertension (Dallas, Tex. : 1979), , Volume: 41, Issue:4, 2003
Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease.Archives of biochemistry and biophysics, , Nov-01, Volume: 419, Issue:1, 2003
Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 42, Issue:5, 2003
Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study.Diabetes care, , Volume: 26, Issue:3, 2003
The effect of ramipril on albumin excretion in diabetes and hypertension: the role of increased lysosomal activity and decreased transforming growth factor-beta expression.Journal of hypertension, , Volume: 21, Issue:2, 2003
Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty rats.Cardiovascular research, , Nov-01, Volume: 60, Issue:2, 2003
Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study.Journal of the American Society of Nephrology : JASN, , Volume: 14, Issue:3, 2003
Diarrhea, nephrotic syndrome and hidradenitis suppurativa: an unusual case.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 18, Issue:1, 2003
Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.The Canadian journal of cardiology, , Volume: 18 Suppl A, 2002
Results from the TIP (Tritace in Proteinuria) intensified monitoring project.Kidney & blood pressure research, , Volume: 25, Issue:2, 2002
[Prediction, screening and treatment of renal complications of diabetes].La Revue du praticien, , Oct-15, Volume: 51, Issue:16, 2001
Reduction of ACE activity is insufficient to decrease microalbuminuria in normotensive patients with type 1 diabetes.Diabetes care, , Volume: 24, Issue:5, 2001
The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 16, Issue:11, 2001
Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial.Diabetes care, , Volume: 23, Issue:12, 2000
The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: design, organization, and patient recruitment. DIABHYCAR Study Group.Controlled clinical trials, , Volume: 21, Issue:4, 2000
Determinants of elevated urinary albumin in the 4,937 type 2 diabetic subjects recruited for the DIABHYCAR Study in Western Europe and North Africa.Diabetes care, , Volume: 23 Suppl 2, 2000
The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not.Cleveland Clinic journal of medicine, , Volume: 67, Issue:4, 2000
[Protein markers in evaluation of nephroprotective effects of antihypertensive drugs in patients with arterial hypertension].Klinicheskaia laboratornaia diagnostika, , Issue:7, 2000
Effect of ramipril on ambulatory blood pressure and albuminuria in renal hypertension.Pediatric nephrology (Berlin, Germany), , Volume: 15, Issue:1-2, 2000
Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C.Diabetes, , Volume: 49, Issue:1, 2000
Influence of ramipril on the course of plasma thrombomodulin in patients with diabetes mellitus.VASA. Zeitschrift fur Gefasskrankheiten, , Volume: 28, Issue:3, 1999
Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function.Journal of human hypertension, , Volume: 13, Issue:1, 1999
[The effect of ramipril on metabolic, renal and cardiac function in hypertension and type II diabetes mellitus].Vnitrni lekarstvi, , Volume: 44, Issue:6, 1998
Beneficial impact of ramipril on left ventricular hypertrophy in normotensive nonalbuminuric NIDDM patients.Diabetes care, , Volume: 21, Issue:5, 1998
Impediment of the progressions of microalbuminuria and hyperlipidemia in normotensive type 2 diabetes by low-dose ramipril.Journal of the Medical Association of Thailand = Chotmaihet thangphaet, , Volume: 81, Issue:9, 1998
EUCLID study.Lancet (London, England), , Oct-11, Volume: 350, Issue:9084, 1997
A comparison of the effect of ramipril, felodipine and placebo on glomerular filtration rate, albuminuria, blood pressure and vasoactive hormones in chronic glomerulonephritis. A randomized, prospective, double-blind, placebo-controlled study over two yeaScandinavian journal of clinical and laboratory investigation, , Volume: 57, Issue:8, 1997
Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies.Diabetes, , Volume: 46, Issue:10, 1997
Short-term treatment with ramipril normalizes renal haemodynamics and the natriuretic response to a sodium load in type 1 diabetic patients with early nephropathy.Acta diabetologica, , Volume: 34, Issue:1, 1997
The DIAB-HYCAR Study.Diabetologia, , Volume: 39, Issue:12, 1996
Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria.Diabetologia, , Volume: 39, Issue:12, 1996
Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes PrevenDiabetes care, , Volume: 19, Issue:11, 1996
Angiotensin-converting enzyme inhibition in experimental in-situ immune complex glomerulonephritis: influence on renal function, proteinuria, and morphology.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 11, Issue:1, 1996
Effect of ramipril on blood pressure and protein excretion rate in normotensive nondiabetic patients with proteinuria.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 28, Issue:6, 1996
Effects of intensified blood-pressure reduction on renal function and albumin excretion in primary hypertension. Addition of felodipine or ramipril to long-term treatment with beta-blockade.American journal of hypertension, , Volume: 8, Issue:2, 1995
Comparative effects of ramipril and nitrendipine on albuminuria in hypertensive patients with non-insulin-dependent diabetes mellitus and impaired renal function.Journal of human hypertension, , Volume: 9, Issue:2, 1995
Comparison of ramipril and nitrendipine.Journal of human hypertension, , Volume: 9, Issue:11, 1995
Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group.American journal of hypertension, , Volume: 8, Issue:9, 1995
Small doses of ramipril to reduce microalbuminuria in diabetic patients with incipient nephropathy independently of blood pressure changes.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Influence of ramipril on renal function in patients with chronic congestive heart failure.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
[Dissociation of hypotensive and renal hemodynamic effects of an angiotensin converting enzyme inhibitor in insulin-dependent diabetic patients with incipient nephropathy].Archives des maladies du coeur et des vaisseaux, , Volume: 84, Issue:3, 1991
Ramipril reduces albuminuria in diabetic rats fed a high protein diet.Clinical and experimental pharmacology & physiology, , Volume: 16, Issue:8, 1989
Diabetic vascular hypertrophy and albuminuria: effect of angiotensin converting enzyme inhibition.Journal of diabetes and its complications, , Volume: 9, Issue:4
Glomerular mRNA expression of angiotensinase A after renal ablation.Experimental nephrology, , Volume: 3, Issue:4
Renoprotective therapy: is it blood pressure or albuminuria that matters?Lancet (London, England), , Volume: 365, Issue:9463
Caution in diagnosing angioedema as anaphylaxis.BMJ case reports, , Sep-04, Volume: 12, Issue:9, 2019
Basophil activation test, skin prick test, and anaphylaxis after drug hypersensitivity.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, , Volume: 116, Issue:5, 2016
Ramipril and metoprolol intake aggravate human and murine anaphylaxis: evidence for direct mast cell priming.The Journal of allergy and clinical immunology, , Volume: 135, Issue:2, 2015
[Anaphylactoid reaction in hemodyalisis: converting enzyme inhibitors interaction with no PAN 69 membrane].Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, , Volume: 27, Issue:3, 2007
[Successful use of C1 esterase inhibitor in capillary leak syndrome].Der Anaesthesist, , Volume: 61, Issue:11, 2012
The urinary bladder angiotensin system: response to infusions of angiotensin I and angiotensin-converting enzyme inhibitors.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 28, Issue:4, 1996
Local inhibition of bradykinin degradation in ischemic hearts.Journal of cardiovascular pharmacology, , Volume: 15 Suppl 6, 1990
Cardiovascular and antihypertensive activities of the novel non-sulfhydryl converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).Arzneimittel-Forschung, , Volume: 34, Issue:10B, 1984
Effects of ramipril on serum monocyte chemoattractant protein 1, interleukin-18, and interleukin-10 in elderly patients with acute coronary syndrome.Heart and vessels, , Volume: 25, Issue:2, 2010
Cardiac angiotensin II participates in coronary microvessel inflammation of unstable angina and strengthens the immunomediated component.Circulation research, , Jun-25, Volume: 94, Issue:12, 2004
Ischemic preconditioning in coronary heart disease: a therapeutic golden fleece?Journal of the American College of Cardiology, , May-05, Volume: 43, Issue:9, 2004
Simvastatin combined with ramipril treatment in hypercholesterolemic patients.Hypertension (Dallas, Tex. : 1979), , Volume: 44, Issue:2, 2004
Extended follow-up of patients randomly assigned in the Angiotensin-converting enzyme inhibition Post-Revascularization Study (APRES).American heart journal, , Volume: 148, Issue:3, 2004
Cardiac angiotensin is upregulated in the hearts of unstable angina patients.Circulation research, , Jun-25, Volume: 94, Issue:12, 2004
Angina pectoris prior to myocardial infarction protects against subsequent left ventricular remodeling.Journal of the American College of Cardiology, , May-05, Volume: 43, Issue:9, 2004
Effect of ramipril on postrevascularization prevalence of angina and quality of life.International journal of cardiology, , Volume: 95, Issue:2-3, 2004
["Using chance, despite high NNT"].MMW Fortschritte der Medizin, , Sep-18, Volume: 145, Issue:38, 2003
Beneficial effects of ramipril on left ventricular end-diastolic and end-systolic volume indexes after uncomplicated invasive revascularization are associated with a reduction in cardiac events in patients with moderately impaired left ventricular functioJournal of the American College of Cardiology, , Volume: 37, Issue:5, 2001
The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES).Journal of the American College of Cardiology, , Mar-15, Volume: 35, Issue:4, 2000
The Angiotensin Converting Enzyme Inhibition Post Revascularization Study (APRES). Effects of ramipril in patients with reduced left ventricular function. Rationale, design, methods, baseline characteristics and first-year experience.Scandinavian cardiovascular journal : SCJ, , Volume: 32, Issue:4, 1998
Cardiac angiotensin II participates in coronary microvessel inflammation of unstable angina and strengthens the immunomediated component.Circulation research, , Jun-25, Volume: 94, Issue:12, 2004
Cardiac angiotensin is upregulated in the hearts of unstable angina patients.Circulation research, , Jun-25, Volume: 94, Issue:12, 2004
Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study.Circulation, , Jul-31, Volume: 104, Issue:5, 2001
ACE inhibitors: new hope for old drugs?South Dakota journal of medicine, , Volume: 53, Issue:8, 2000
ACE inhibitor-related angioedema in a COVID-19 patient-a plausible contribution of the viral infection?European journal of clinical pharmacology, , Volume: 77, Issue:6, 2021
Caution in diagnosing angioedema as anaphylaxis.BMJ case reports, , Sep-04, Volume: 12, Issue:9, 2019
Angioedema Two Weeks After the Initial Administration of an ACE Inhibitor.Deutsches Arzteblatt international, , 03-02, Volume: 115, Issue:9, 2018
Fatal outcome of late-onset angiotensin-converting enzyme inhibitor induced angioedema: A case report.Medicine, , Volume: 97, Issue:31, 2018
Potential Biomarkers for the Diagnosis of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema.ORL; journal for oto-rhino-laryngology and its related specialties, , Volume: 79, Issue:1-2, 2017
A transient ischemic attack mimic.Acta neurologica Belgica, , Volume: 117, Issue:4, 2017
Drug-Induced Inhibition of Angiotensin Converting Enzyme and Dipeptidyl Peptidase 4 Results in Nearly Therapy Resistant Bradykinin Induced Angioedema: A Case Report.The American journal of case reports, , May-25, Volume: 18, 2017
Intestinal Angioedema in a Palliative Care Setting.The American journal of medicine, , Volume: 129, Issue:11, 2016
Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema.Pharmacogenetics and genomics, , Volume: 23, Issue:9, 2013
Using a bradykinin blocker in ACE inhibitor-associated angioedema in the emergency department.BMJ case reports, , Jan-31, Volume: 2013, 2013
Pharmacogenetic markers for antihypertensive drug-related adverse reactions.Pharmacogenomics, , Volume: 14, Issue:15, 2013
Icatibant and ACE inhibitor angioedema.BMJ case reports, , Aug-30, Volume: 2012, 2012
Fresh frozen plasma in the treatment of ACE inhibitor-induced angioedema.BMJ case reports, , Aug-24, Volume: 2012, 2012
Imaging findings in angiotensin-converting enzyme inhibitor induced angioedema.Emergency medicine journal : EMJ, , Volume: 28, Issue:7, 2011
[Dental care with local anesthesia: should the patient first discontinue ACE inhibitors?].MMW Fortschritte der Medizin, , Mar-03, Volume: 153, Issue:9, 2011
[ Therapy of patients at high risk for vascular events: telmisartan, ramipril or a combination? ].Der Internist, , Volume: 49, Issue:9, 2008
Telmisartan, ramipril, or both in patients at high risk of vascular events.The New England journal of medicine, , Jul-24, Volume: 359, Issue:4, 2008
Telmisartan, ramipril, or both in patients at high risk for vascular events.The New England journal of medicine, , Apr-10, Volume: 358, Issue:15, 2008
[Choroidal effusion after uncomplicated cataract surgery].Klinische Monatsblatter fur Augenheilkunde, , Volume: 225, Issue:6, 2008
[Fasciitis with eosinophilia: a possible causal role of angiotensin converting enzyme inhibitor].Revue neurologique, , Volume: 163, Issue:2, 2007
Acute upper airway obstruction from acquired angioedema.Emergency medicine Australasia : EMA, , Volume: 19, Issue:1, 2007
Fresh frozen plasma in the treatment of resistant angiotensin-converting enzyme inhibitor angioedema.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, , Volume: 92, Issue:5, 2004
Delayed diagnosis of angiotensin-converting enzyme (ACE) inhibitor induced angioedema and urticaria.Clinical and experimental dermatology, , Volume: 28, Issue:3, 2003
[Tongue angioedema associated with angiotensin-converting enzyme inhibitor (diagnosis, differential diagnosis, treatment)].Medicina (Kaunas, Lithuania), , Volume: 39, Issue:6, 2003
Severe angioedema induced by angiotensin converting enzyme inhibitors: role of precipitating factors.The Journal of dermatology, , Volume: 29, Issue:6, 2002
Angioedema caused by ramipril.The Annals of pharmacotherapy, , Volume: 29, Issue:4, 1995
[Bradykinin mediated angioedema with ACE inhibitor in combination with immunosupressive agents].Therapie, , Volume: 69, Issue:2
The African American Study of Kidney Disease and Hypertension (AASK) trial: what more have we learned?Journal of clinical hypertension (Greenwich, Conn.), , Volume: 5, Issue:2
Effects of ramipril on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young normotensive subjects with successfully repaired coarctation of aorta: a randomized cross-over study.Journal of the American College of Cardiology, , Feb-19, Volume: 51, Issue:7, 2008
Effect of ACE inhibitor on DOCA-salt- and aortic coarctation-induced hypertension in mice: do kinin B2 receptors play a role?Hypertension (Dallas, Tex. : 1979), , Volume: 33, Issue:1 Pt 2, 1999
Nitric oxide and the depressor response to angiotensin blockade in hypertension.Hypertension (Dallas, Tex. : 1979), , Volume: 27, Issue:1, 1996
Role of kinins and nitric oxide in the antihypertrophic effect of ramipril.Hypertension (Dallas, Tex. : 1979), , Volume: 23, Issue:6 Pt 2, 1994
Impact of renin-angiotensin system inhibitors on clinical outcomes and ventricular remodelling after transcatheter aortic valve implantation: rationale and design of the RASTAVI randomised multicentre study.BMJ open, , 02-13, Volume: 8, Issue:2, 2018
A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial).European heart journal. Cardiovascular Imaging, , Volume: 16, Issue:8, 2015
ACE inhibitors in aortic stenosis: no fear just hope.European heart journal. Cardiovascular Imaging, , Volume: 16, Issue:8, 2015
Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations.British journal of pharmacology, , Volume: 162, Issue:3, 2011
Dual renin-angiotensin system blockade for patients with prosthesis-patient mismatch.The Annals of thoracic surgery, , Volume: 90, Issue:6, 2010
Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function.Journal of investigative medicine : the official publication of the American Federation for Clinical Research, , Volume: 52, Issue:3, 2004
Effect of angiotensin converting enzyme inhibition on pressure-induced left ventricular hypertrophy in rats.Circulation research, , Volume: 69, Issue:3, 1991
Influence of ramiprilat and losartan on ischemia reperfusion injury in rat hearts.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 13, Issue:1, 2012
[Cardioprotection of ramipril and BQ-123 against myocardial ischemia/reperfusion injury in vivo in rats].Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology, , Volume: 25, Issue:4, 2009
Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction.Circulation, , Sep-14, Volume: 110, Issue:11, 2004
Cardioprotective effects of the aminopeptidase P inhibitor apstatin: studies on ischemia/reperfusion injury in the isolated rat heart.Journal of cardiovascular pharmacology, , Volume: 34, Issue:4, 1999
Postinfarction survival and inducibility of ventricular arrhythmias in the spontaneously hypertensive rat : effects of ramipril and hydralazine.Circulation, , Nov-10, Volume: 98, Issue:19, 1998
Attenuation of reperfusion arrhythmias by selective inhibition of angiotensin-converting enzyme/kininase II in the ischemic zone: mediated by endogenous bradykinin?Journal of cardiovascular pharmacology, , Volume: 27, Issue:3, 1996
[The efficacy of treatment with the angiotensin-converting enzyme inhibitor ramipril in patients with congestive heart failure of rheumatic etiology].Terapevticheskii arkhiv, , Volume: 68, Issue:2, 1996
Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats.Hypertension (Dallas, Tex. : 1979), , Volume: 27, Issue:1, 1996
ACE-inhibition induces NO-formation in cultured bovine endothelial cells and protects isolated ischemic rat hearts.Journal of molecular and cellular cardiology, , Volume: 24, Issue:8, 1992
Local inhibition of bradykinin degradation in ischemic hearts.Journal of cardiovascular pharmacology, , Volume: 15 Suppl 6, 1990
Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril.Journal of the American College of Cardiology, , Volume: 36, Issue:2, 2000
Early induction of angiotensin I-converting enzyme in rat carotid artery after balloon injury.Hypertension (Dallas, Tex. : 1979), , Volume: 30, Issue:2 Pt 1, 1997
ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.Therapeutic advances in cardiovascular disease, , Volume: 2, Issue:4, 2008
Effects of angiotensin II on connexin 43 of VSMCs in arteriosclerosis.Journal of Zhejiang University. Science. B, , Volume: 7, Issue:8, 2006
[Association between angiotensin converting enzyme I/D polymorphism and high-sensitivity C-reactive protein in type 2 diabetic patients with atherosclerosis treated with ramipril].Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA, , Volume: 25, Issue:6, 2005
Endothelin receptor blockade improves endothelial function in atherosclerotic patients on angiotensin converting enzyme inhibition.Journal of internal medicine, , Volume: 257, Issue:3, 2005
Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis.Zeitschrift fur Kardiologie, , Volume: 94, Issue:5, 2005
Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus.Arthritis and rheumatism, , Oct-15, Volume: 53, Issue:5, 2005
[Can coronary risks be further reduced?].Presse medicale (Paris, France : 1983), , Sep-25, Volume: 33, Issue:16, 2004
[Is the supplementation with antioxidants effective in the treatment of atherosclerosis?].Deutsche medizinische Wochenschrift (1946), , Feb-13, Volume: 129, Issue:7, 2004
Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone.Circulation, , May-11, Volume: 109, Issue:18, 2004
[Involvement of angiotensin II in pathogenesis of hypertension and target organ damage].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 62 Suppl 3, 2004
[The status of atherosclerosis prevention in Austria].Wiener medizinische Wochenschrift (1946), , Volume: 153, Issue:15-16, 2003
[Fast and strong lowering of pressure. The newest sartan has passed the practice test].MMW Fortschritte der Medizin, , Oct-30, Volume: 145, Issue:44, 2003
Effect of chronic treatment with the vasopeptidase inhibitor AVE 7688 and ramipril on endothelial function in atherogenic diet rabbits.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 4, Issue:3, 2003
Ramipril administration to atherosclerotic mice reduces oxidized low-density lipoprotein uptake by their macrophages and blocks the progression of atherosclerosis.Atherosclerosis, , Volume: 161, Issue:1, 2002
[Dangerous plaque often symptom-free. ACE inhibitors prevent rupture].MMW Fortschritte der Medizin, , Aug-22, Volume: 144, Issue:33-34, 2002
[Atherosclerosis. High dosage ACE inhibitor keeps event rate under control].MMW Fortschritte der Medizin, , Mar-29, Volume: 143, Issue:13, 2001
ACE inhibitor inhibits atherosclerosis.Harvard heart letter : from Harvard Medical School, , Volume: 11, Issue:9, 2001
Modifying the natural history of atherosclerosis: the SECURE trial.International journal of clinical practice. Supplement, , Issue:117, 2001
[Atherosclerosis. High ACE activity in plaque: risk of rupture!].MMW Fortschritte der Medizin, , Oct-25, Volume: 143, Issue:43, 2001
[Ramipril can do more. Halting progression of atherosclerosis].MMW Fortschritte der Medizin, , Sep-06, Volume: 143, Issue:35-36, 2001
Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE).Circulation, , Feb-20, Volume: 103, Issue:7, 2001
Attenuation of atherosclerosis in apolipoprotein E-deficient mice by ramipril is dissociated from its antihypertensive effect and from potentiation of bradykinin.Journal of cardiovascular pharmacology, , Volume: 35, Issue:1, 2000
[New hope concerning the prognosis of atherosclerosis].Duodecim; laaketieteellinen aikakauskirja, , Volume: 116, Issue:21, 2000
The HOPE study.Cleveland Clinic journal of medicine, , Volume: 67, Issue:6, 2000
[Endothelium and endogenous fibrinolysis].Zeitschrift fur Kardiologie, , Volume: 89, Issue:3, 2000
Improved endothelial function with angiotensin-converting enzyme inhibitors.The American journal of cardiology, , Mar-06, Volume: 79, Issue:5A, 1997
Study design and baseline characteristics of the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E: SECURE.The American journal of cardiology, , Oct-15, Volume: 78, Issue:8, 1996
Angiotensin-converting enzyme inhibitors reduce neointimal thickening and maintain endothelial nitric oxide function in rabbit carotid arteries.The American journal of cardiology, , Nov-24, Volume: 76, Issue:15, 1995
Comparison of the antiatherogenic effects of isradipine and ramipril in cholesterol-fed rabbits: II. Effect on regression of atherosclerosis and restoration of endothelial function.Journal of cardiovascular pharmacology, , Volume: 23, Issue:3, 1994
Comparison of the antiatherogenic effects of isradipine and ramipril in cholesterol-fed rabbits: I. Effect on progression of atherosclerosis and endothelial dysfunction.Journal of cardiovascular pharmacology, , Volume: 23, Issue:3, 1994
Contribution of bradykinin to the cardiovascular effects of ramipril.Journal of cardiovascular pharmacology, , Volume: 22 Suppl 9, 1993
Effect of angiotensin-converting enzyme inhibition on human tissue renin.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Ramipril and haloperidol as promising approaches in managing rheumatoid arthritis in rats.European journal of pharmacology, , Oct-15, Volume: 765, 2015
Response to 'Ramipril attenuates lipid peroxidation and cardiac fibrosis in an experimental model of rheumatoid arthritis' - authors' reply.Arthritis research & therapy, , Apr-03, Volume: 15, Issue:2, 2013
Response to 'Ramipril attenuates lipid peroxidation and cardiac fibrosis in an experimental model of rheumatoid arthritis'.Arthritis research & therapy, , Apr-03, Volume: 15, Issue:2, 2013
Ramipril attenuates lipid peroxidation and cardiac fibrosis in an experimental model of rheumatoid arthritis.Arthritis research & therapy, , Oct-18, Volume: 14, Issue:5, 2012
Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis.Circulation, , Apr-29, Volume: 117, Issue:17, 2008
Letter by Popa and Netea regarding article, "Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis".Circulation, , Nov-04, Volume: 118, Issue:19, 2008
Ramipril-induced generalized pustular psoriasis: case report and literature review.American journal of therapeutics, , Volume: 17, Issue:1
Factors that favor the occurrence of cough in patients treated with ramipril--a pharmacoepidemiological study.Medical science monitor : international medical journal of experimental and clinical research, , Volume: 18, Issue:9, 2012
Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors.BMJ (Clinical research ed.), , Jan-01, Volume: 308, Issue:6920, 1994
The effect of an angiotensin converting enzyme inhibitor, ramipril, on bronchial responses to inhaled histamine and bradykinin in asthmatic subjects.British journal of clinical pharmacology, , Volume: 23, Issue:1, 1987
Prevention of Atrial Fibrillation After Atrial Flutter Ablation With Ramipril (from the PREFACE Study).The American journal of cardiology, , 01-01, Volume: 162, 2022
Risk of renal dysfunction in an elderly patient with chronic heart failure.Medizinische Monatsschrift fur Pharmazeuten, , Volume: 39, Issue:10, 2016
Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtoleranJournal of hypertension, , Volume: 30, Issue:5, 2012
Precardiac surgery angiotensin-converting enzymes and mineralocorticoid blockers do not trump atrial fibrillation but possibly acute kidney injury: the value of a negative randomized study.Critical care medicine, , Volume: 40, Issue:10, 2012
Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation.Journal of cardiovascular pharmacology and therapeutics, , Volume: 17, Issue:1, 2012
Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery.Critical care medicine, , Volume: 40, Issue:10, 2012
Prediction and prevention of atrial fibrillation in patients with high blood pressure or history of hypertension.Journal of hypertension, , Volume: 30, Issue:5, 2012
[Role of ACE-inhibitors in preventing atrial fibrillation relapses in normotensive patients].Recenti progressi in medicina, , Volume: 100, Issue:11, 2009
Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients.Journal of the American College of Cardiology, , Jan-06, Volume: 53, Issue:1, 2009
Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation.American journal of hypertension, , Volume: 21, Issue:9, 2008
Effect of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on the frequency of post-cardiothoracic surgery atrial fibrillation.The Annals of pharmacotherapy, , Volume: 41, Issue:3, 2007
Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study.American heart journal, , Volume: 154, Issue:3, 2007
Angiotensin-converting enzyme inhibitors and stroke prevention: what about the influence of atrial fibrillation and antithrombotic therapy?Stroke, , Volume: 34, Issue:11, 2003
[Arrhythmogenic dilated cardiomyopathy].Medicina (Kaunas, Lithuania), , Volume: 39, Issue:7, 2003
Management of heart failure.Current cardiology reports, , Volume: 2, Issue:3, 2000
[Inappropriate antidiuretic hormone secretion syndrome associated with ramipril treatment].Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, , Volume: 34, Issue:3
Angiotensin-Converting Enzyme Inhibitor Reduces Radiation-Induced Periprosthetic Capsular Fibrosis.The Journal of surgical research, , Volume: 263, 2021
Anthracycline-induced cardiotoxicity prevention with angiotensin-converting enzyme inhibitor ramipril in women with low-risk breast cancer: results of a prospective randomized study.Kardiologia polska, , 02-25, Volume: 78, Issue:2, 2020
SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab.Medical oncology (Northwood, London, England), , Volume: 34, Issue:5, 2017
Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy.Lancet (London, England), , Feb-03, Volume: 347, Issue:8997, 1996
Tenascin-C as predictor of left ventricular remodeling and mortality in patients with dilated cardiomyopathy.Journal of investigative medicine : the official publication of the American Federation for Clinical Research, , Volume: 61, Issue:4, 2013
Role of echocardiography in assessing the mechanism and effect of ramipril on functional mitral regurgitation in dilated cardiomyopathy.Echocardiography (Mount Kisco, N.Y.), , Volume: 22, Issue:4, 2005
[Arrhythmogenic dilated cardiomyopathy].Medicina (Kaunas, Lithuania), , Volume: 39, Issue:7, 2003
[Competitive sports and dilated cardiomyopathy: the case of a 32-year-old soccer player with ventricular tachycardia].Deutsche medizinische Wochenschrift (1946), , Jan-24, Volume: 128, Issue:4, 2003
Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.The Journal of pharmacology and experimental therapeutics, , Volume: 295, Issue:2, 2000
Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy.Lancet (London, England), , Feb-03, Volume: 347, Issue:8997, 1996
Quantitative assessment of daily physical activity levels in patients with chronic heart failure by measuring energy expenditure--effects of converting enzyme inhibitor therapy.Japanese circulation journal, , Volume: 59, Issue:10, 1995
[The use of ramipril in treating patients with chronic heart failure].Terapevticheskii arkhiv, , Volume: 67, Issue:5, 1995
Reversible dilated cardiomyopathy in a patient with Cushing's syndrome.Congestive heart failure (Greenwich, Conn.), , Volume: 16, Issue:2
Polypill Strategy in Secondary Cardiovascular Prevention.The New England journal of medicine, , 09-15, Volume: 387, Issue:11, 2022
Effects of ACE inhibitors and angiotensin receptor blockers: protocol for a UK cohort study using routinely collected electronic health records with validation against the ONTARGET trial.BMJ open, , 03-08, Volume: 12, Issue:3, 2022
Efficacy of Sacubitril-Valsartan in Patients With Reduced Left Ventricular Ejection Fraction.The American journal of cardiology, , 08-15, Volume: 153, 2021
Pharmacodynamic study of the cardiovascular polypill. Is there any interaction among the monocomponents?Revista espanola de cardiologia (English ed.), , Volume: 74, Issue:1, 2021
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.The New England journal of medicine, , 11-11, Volume: 385, Issue:20, 2021
Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension.The Cochrane database of systematic reviews, , 10-22, Volume: 10, 2020
Analysis of quinary therapy targeting multiple cardiovascular diseases using UV spectrophotometry and chemometric tools.Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, , Sep-05, Volume: 238, 2020
Association of egg intake with blood lipids, cardiovascular disease, and mortality in 177,000 people in 50 countries.The American journal of clinical nutrition, , 04-01, Volume: 111, Issue:4, 2020
Does diabetes prevention translate into reduced long-term vascular complications of diabetes?Diabetologia, , Volume: 62, Issue:8, 2019
Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.American heart journal, , Volume: 214, 2019
Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk.European heart journal, , 07-01, Volume: 40, Issue:25, 2019
Update to the Consensus Document on Clinical Use of the Polypill: New Dose Containing Atorvastatin 40 mg.Revista espanola de cardiologia (English ed.), , Volume: 71, Issue:7, 2018
Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.European heart journal, , 09-01, Volume: 39, Issue:33, 2018
Use of Health Care Databases to Support Supplemental Indications of Approved Medications.JAMA internal medicine, , 01-01, Volume: 178, Issue:1, 2018
Cardiovascular safety of novel non-small cell lung cancer oncotherapy in a patient treated with novel generations of tyrosine kinase inhibitors.Kardiologia polska, , Volume: 76, Issue:3, 2018
Hypertension Treatment Effects on Orthostatic Hypotension and Its Relationship With Cardiovascular Disease.Hypertension (Dallas, Tex. : 1979), , Volume: 72, Issue:4, 2018
The International Polycap Study-3 (TIPS-3): Design, baseline characteristics and challenges in conduct.American heart journal, , Volume: 206, 2018
Usefulness of a Cardiovascular Polypill in the Treatment of Secondary Prevention Patients in Spain: A Cost-effectiveness Study.Revista espanola de cardiologia (English ed.), , Volume: 70, Issue:1, 2017
Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.Kidney international, , Volume: 91, Issue:3, 2017
Consensus document for the use of the Polypill in the secondary prevention of cardiovascular disease.Medicina clinica, , Feb-09, Volume: 148, Issue:3, 2017
Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.Lancet (London, England), , Jun-03, Volume: 389, Issue:10085, 2017
Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients.Hypertension (Dallas, Tex. : 1979), , Volume: 70, Issue:5, 2017
Improving cardiovascular protection: focus on a cardiovascular polypill.Future cardiology, , Volume: 12, Issue:2, 2016
Target Blood Pressure in Patients with Diabetes: Asian Perspective.Yonsei medical journal, , Volume: 57, Issue:6, 2016
Therapy discontinuation or substitution in patients with cardiovascular disease, switching among different products of the same off-patent active substance: a 'real-world' retrospective cohort study.BMJ open, , 11-02, Volume: 6, Issue:11, 2016
A Step Ahead in Secondary Prevention of Cardiovascular Risk. Consensus Document on Clinical Use of the Polypill.Revista espanola de cardiologia (English ed.), , Volume: 69, Issue:6, 2016
Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SMILE-4 Randomized, Double-Blind Study in Diabetic Patients.Cardiovascular therapeutics, , Volume: 34, Issue:2, 2016
The Association of Losartan and Ramipril Therapy With Kidney and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: A Chinese Nation-Wide Cohort Study in Taiwan.Medicine, , Volume: 94, Issue:48, 2015
Angiotensin Converting Enzyme Inhibitor Dialyzability and Outcomes in Older Patients Receiving Hemodialysis.Blood purification, , Volume: 40, Issue:3, 2015
Dysglycemia and Cognitive Dysfunction and Ill Health in People With High CV Risk: Results From the ONTARGET/TRANSCEND Studies.The Journal of clinical endocrinology and metabolism, , Volume: 100, Issue:7, 2015
The Fuster-CNIC-Ferrer Cardiovascular Polypill: a polypill for secondary cardiovascular prevention.International journal of cardiology, , Volume: 201 Suppl 1, 2015
Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk.Hypertension (Dallas, Tex. : 1979), , Volume: 65, Issue:3, 2015
Type 2 diabetes-induced cardiovascular complications: comparative evaluation of spironolactone, atenolol, metoprolol, ramipril and perindopril.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 36, Issue:5, 2014
The mini-mental state examination, clinical factors, and motor vehicle crash risk.Journal of the American Geriatrics Society, , Volume: 62, Issue:8, 2014
Recent clinical trials.Journal of the American Society of Hypertension : JASH, , Volume: 8, Issue:10, 2014
[Comprehensive organoprotection in patients with high cardiovascular risk: the possibility of ramipril from positions of evidence-based medicine].Kardiologiia, , Volume: 53, Issue:9, 2013
Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril.Postgraduate medicine, , Volume: 125, Issue:4, 2013
Effect of contrasted sodium diets on the pharmacokinetics and pharmacodynamic effects of renin-angiotensin system blockers.Hypertension (Dallas, Tex. : 1979), , Volume: 61, Issue:6, 2013
Albuminuria and rapid loss of GFR and risk of new hip and pelvic fractures.Clinical journal of the American Society of Nephrology : CJASN, , Volume: 8, Issue:2, 2013
A 'polypill' aimed at preventing cardiovascular disease could prove highly cost-effective for use in Latin America.Health affairs (Project Hope), , Volume: 32, Issue:1, 2013
Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease.American heart journal, , Volume: 166, Issue:2, 2013
Medication adherence in hypertensive patients of different cardiovascular risk treated in primary health care.Przeglad lekarski, , Volume: 70, Issue:6, 2013
Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study.Cardiovascular diabetology, , Jan-09, Volume: 11, 2012
Prediction and prevention of atrial fibrillation in patients with high blood pressure or history of hypertension.Journal of hypertension, , Volume: 30, Issue:5, 2012
Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtoleranJournal of hypertension, , Volume: 30, Issue:5, 2012
[Critically appraised article].Revista medica de Chile, , Volume: 140, Issue:1, 2012
A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.The Annals of pharmacotherapy, , Volume: 46, Issue:5, 2012
Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.Circulation. Cardiovascular quality and outcomes, , Jul-01, Volume: 5, Issue:4, 2012
[Training for LCA (Hope study)].La Revue du praticien, , Volume: 62, Issue:5, 2012
Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).Journal of the American College of Cardiology, , Jan-03, Volume: 59, Issue:1, 2012
Is a blood pressure target of <130/80 mm Hg still appropriate for high-risk patients?Circulation, , Oct-18, Volume: 124, Issue:16, 2011
The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study.Journal of medical economics, , Volume: 14, Issue:6, 2011
Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET).Circulation, , Oct-18, Volume: 124, Issue:16, 2011
Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study.Journal of diabetes science and technology, , Jul-01, Volume: 5, Issue:4, 2011
Impact of methylation of acyl glucuronide metabolites on incurred sample reanalysis evaluation: ramiprilat case study.Bioanalysis, , Volume: 3, Issue:9, 2011
Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesartan and ramipril.International journal of clinical practice, , Volume: 65, Issue:2, 2011
Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies.The Lancet. Neurology, , Volume: 10, Issue:1, 2011
Impact of ACE inhibitors on mortality and morbidity in patients with AMI: Does tissue selectivity matter?Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 14, Issue:1, 2011
Telmisartan in high-risk cardiovascular patients. No need to change standard practice.Prescrire international, , Volume: 20, Issue:117, 2011
New clinical concepts after the ONTARGET trial.Expert review of cardiovascular therapy, , Volume: 9, Issue:6, 2011
Telmisartan in high-risk cardiovascular patients.The American journal of cardiology, , Jan-04, Volume: 105, Issue:1 Suppl, 2010
Renin-angiotensin system blockade and cardiovascular and renal protection.The American journal of cardiology, , Jan-04, Volume: 105, Issue:1 Suppl, 2010
Choosing an angiotensin-receptor blocker: blood pressure lowering, cardiovascular protection or both?Future cardiology, , Volume: 6, Issue:1, 2010
Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerCirculation, , Mar-30, Volume: 121, Issue:12, 2010
New standards in hypertension and cardiovascular risk management: focus on telmisartan.Vascular health and risk management, , Mar-24, Volume: 6, 2010
Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers.American journal of cardiovascular drugs : drugs, devices, and other interventions, , Volume: 10, Issue:2, 2010
From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors.Cardiology, , Volume: 117, Issue:3, 2010
In a subgroup of high-risk Asians, telmisartan was non-inferior to ramipril and better tolerated in the prevention of cardiovascular events.PloS one, , Dec-21, Volume: 5, Issue:12, 2010
Where does the evidence lead us for the proper use of angiotensin II inhibitors in the management of cardiovascular disease?Cardiology, , Volume: 117, Issue:3, 2010
[Possibilities of ramipril in primary and secondary prevention of cardiovascular diseases].Kardiologiia, , Volume: 50, Issue:8, 2010
Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized AssessmentCirculation, , Oct-06, Volume: 120, Issue:14, 2009
Lessons learned from the ONTARGET and TRANSCEND trials.Current atherosclerosis reports, , Volume: 11, Issue:5, 2009
Proteinuria: Is the ONTARGET renal substudy actually off target?Nature reviews. Nephrology, , Volume: 5, Issue:8, 2009
Cardiovascular protection: a breakthrough for high-risk patients?Journal of hypertension. Supplement : official journal of the International Society of Hypertension, , Volume: 27, Issue:5, 2009
[Renin-angiotensin-aldosterone system inhibition and cardiovascular protection].Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir, , Volume: 37 Suppl 6, 2009
The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial.Journal of cardiovascular electrophysiology, , Volume: 20, Issue:7, 2009
Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET): implications for reduced cardiovascular risk.Preventive cardiology, ,Winter, Volume: 12, Issue:1, 2009
Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS): a phase II, double-blind, randomised trial.Lancet (London, England), , Apr-18, Volume: 373, Issue:9672, 2009
The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics.Clinical research in cardiology : official journal of the German Cardiac Society, , Volume: 98, Issue:7, 2009
Telmisartan prevents cardiovascular events in a broad group of at-risk patients.Expert opinion on pharmacotherapy, , Volume: 10, Issue:18, 2009
Recent advances in cardiovascular risk reduction: implications of ONTARGET.Clinical cornerstone, , Volume: 9 Suppl 3, 2009
ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?Blood pressure, , Volume: 18, Issue:1-2, 2009
Focus on the ONTARGET results.Journal of hypertension. Supplement : official journal of the International Society of Hypertension, , Volume: 27, Issue:2, 2009
Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET/TRANSCEND research programme.Diabetes research and clinical practice, , Volume: 83, Issue:3, 2009
The need to test the theories behind the Polypill: rationale behind the Indian Polycap Study.Nature clinical practice. Cardiovascular medicine, , Volume: 6, Issue:2, 2009
Introduction: Reducing cardiovascular risk: ONTARGET--a new standard in cardiovascular protection.Journal of hypertension. Supplement : official journal of the International Society of Hypertension, , Volume: 27, Issue:5, 2009
Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor.Journal of hypertension. Supplement : official journal of the International Society of Hypertension, , Volume: 27, Issue:5, 2009
[The ONTARGET trial].Giornale italiano di cardiologia (2006), , Volume: 10, Issue:2, 2009
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.Lancet (London, England), , Aug-16, Volume: 372, Issue:9638, 2008
[ Therapy of patients at high risk for vascular events: telmisartan, ramipril or a combination? ].Der Internist, , Volume: 49, Issue:9, 2008
Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?Nature clinical practice. Cardiovascular medicine, , Volume: 5, Issue:9, 2008
[No advantage of the combination of ACE-inhibition and angiotensin receptor blockade in patients with high cardiovascular risk].Nederlands tijdschrift voor geneeskunde, , Jun-14, Volume: 152, Issue:24, 2008
[ONTARGET, PROFESS, TRANSCEND large scale studies. AT1 blockers: evidence based advantage, but less than expected].MMW Fortschritte der Medizin, , Sep-18, Volume: 150, Issue:38, 2008
Telmisartan, ramipril, or both in patients at high risk of vascular events.The New England journal of medicine, , Jul-24, Volume: 359, Issue:4, 2008
Telmisartan, ramipril, or both in patients at high risk of vascular events.The New England journal of medicine, , Jul-24, Volume: 359, Issue:4, 2008
Safety and tolerability of ramipril 10 mg in patients at high risk of cardiovascular events: an observational study.Journal of the Indian Medical Association, , Volume: 106, Issue:7, 2008
[Treatment of patients at high cardiovascular risk: confirmation and surprising results of the ONTARGET-Study].Praxis, , May-14, Volume: 97, Issue:10, 2008
A new dawn in cardiovascular protection: total cardiovascular risk: rigorous treatment of risk factors. Introduction.Nature clinical practice. Cardiovascular medicine, , Volume: 5 Suppl 1, 2008
Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular events, and Ramipril (DIABHYCAR), Diabete dDiabetes care, , Volume: 31, Issue:10, 2008
[ONTARGET: similar protection of telmisartan and ramipril and lack of benefit of combined therapy in patients at high risk for vascular events].Revue medicale de Liege, , Volume: 63, Issue:4, 2008
ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.Therapeutic advances in cardiovascular disease, , Volume: 2, Issue:4, 2008
The ADVANCE trial.Lancet (London, England), , Jan-05, Volume: 371, Issue:9606, 2008
[What is better here: ACE inhibitor or AT1 blocker?].MMW Fortschritte der Medizin, , Apr-17, Volume: 150, Issue:16, 2008
ONTARGET: questions asked, questions answered.Journal of clinical hypertension (Greenwich, Conn.), , Volume: 10, Issue:6, 2008
Telmisartan, ramipril, or both in patients at high risk for vascular events.The New England journal of medicine, , Apr-10, Volume: 358, Issue:15, 2008
Determining the cost-effectiveness of preventing cardiovascular disease: are estimates calculated over the duration of a clinical trial adequate?The Canadian journal of cardiology, , Volume: 24, Issue:4, 2008
The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League.Journal of hypertension, , Volume: 26, Issue:7, 2008
Cardiac and vascular protection: the potential of ONTARGET.Medscape journal of medicine, , Mar-26, Volume: 10 Suppl, 2008
ACE inhibitors in cardiovascular disease--unbeatable?The New England journal of medicine, , Apr-10, Volume: 358, Issue:15, 2008
Effect of long-term ACE-inhibitor therapy in elderly vascular disease patients.European heart journal, , Volume: 28, Issue:11, 2007
Diabetes prevention: still no effective drugs.Prescrire international, , Volume: 16, Issue:92, 2007
Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/TelmAmerican heart journal, , Volume: 154, Issue:1, 2007
[Therapy of hypertension with expanded outlook. Constant pressure decline and organ protection].MMW Fortschritte der Medizin, , Dec-06, Volume: 149, Issue:49-50, 2007
Investigation of the effect of a countywide protected learning time scheme on prescribing rates of ramipril: interrupted time series study.Family practice, , Volume: 24, Issue:1, 2007
Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial.Kidney international, , Volume: 72, Issue:7, 2007
Clinical decision making and the expected value of information.Clinical trials (London, England), , Volume: 4, Issue:3, 2007
Estimating the cost effectiveness of ramipril used for specific clinical indications: comparing the outcomes in four clinical trials with a common economic model.American journal of cardiovascular drugs : drugs, devices, and other interventions, , Volume: 7, Issue:6, 2007
Clinical trial update: focus on the ONTARGET study.Vascular health and risk management, , Volume: 3, Issue:6, 2007
Chronic endothelin-A receptor antagonism is as protective as angiotensin converting enzyme inhibition against cardiac dysfunction in diabetic rats.British journal of pharmacology, , Volume: 151, Issue:8, 2007
Assessment of single versus twice daily dosing of ramipril by ambulatory blood pressure monitoring in patients similar to those included in the HOPE study.Journal of human hypertension, , Volume: 21, Issue:7, 2007
The question of whether diabetes and its cardiovascular risks can be prevented: a realistic DREAM?Blood pressure, , Volume: 15, Issue:5, 2006
Ramipril: a review of its use in preventing cardiovascular outcomes in high-risk patients.American journal of cardiovascular drugs : drugs, devices, and other interventions, , Volume: 6, Issue:6, 2006
[HOPE study].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 64 Suppl 6, 2006
[In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension].MMW Fortschritte der Medizin, , Jun-29, Volume: 148, Issue:26, 2006
Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study)*.Journal of hypertension, , Volume: 24, Issue:3, 2006
Differential effects of olmesartan and ramipril on inflammatory response after myocardial infarction in rats.Blood pressure, , Volume: 15, Issue:2, 2006
Differential antiplatelet effects of angiotensin converting enzyme inhibitors: comparison of ex vivo platelet aggregation in cardiovascular patients with ramipril, captopril and enalapril.Clinical research in cardiology : official journal of the German Cardiac Society, , Volume: 95, Issue:4, 2006
[Experiences with the realisation of innovative study designs using the example of the HOPE-study].Deutsche medizinische Wochenschrift (1946), , Jul-08, Volume: 130 Suppl 2, 2005
Cost-effectiveness in Italy of preventive treatment with ramipril in patients at high risk of cardiovascular events.Current medical research and opinion, , Volume: 21, Issue:6, 2005
The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis.Diabetologia, , Volume: 48, Issue:9, 2005
Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension.Circulation, , Aug-30, Volume: 112, Issue:9, 2005
The HOPE TIPS: the HOPE study translated into practices.Cardiovascular drugs and therapy, , Volume: 19, Issue:3, 2005
Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE study.Clinical nephrology, , Volume: 63, Issue:3, 2005
[Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].Italian heart journal : official journal of the Italian Federation of Cardiology, , Volume: 6 Suppl 7, 2005
Impact of cigarette smoking in high-risk patients participating in a clinical trial. A substudy from the Heart Outcomes Prevention Evaluation (HOPE) trial.European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology, , Volume: 12, Issue:1, 2005
The ONTARGET/TRANSCEND Trial Programme: baseline data.Acta diabetologica, , Volume: 42 Suppl 1, 2005
Tolerability of ramipril 10 mg daily in high-risk cardiovascular patients in Taiwan: experience from Kaohsiung Medical University Chung-Ho Memorial Hospital.The Kaohsiung journal of medical sciences, , Volume: 21, Issue:11, 2005
[Experiences with the realisation of the innovative study designs using the example of the HOPE study -- concerning the contribution in DMW Supplement 2/2005].Deutsche medizinische Wochenschrift (1946), , Nov-25, Volume: 130, Issue:47, 2005
Cardiovascular risk in patients with mild renal insufficiency: implications for the use of ACE inhibitors.Presse medicale (Paris, France : 1983), , Oct-22, Volume: 34, Issue:18, 2005
Rationale and design of the cardiac magnetic resonance imaging substudy of The ONTARGET Trial Programme.The Journal of international medical research, , Volume: 33 Suppl 1, 2005
Effects of an angiotensin-converting enzyme inhibitor (ramipril) on inflammatory markers in secondary prevention patients: RAICES Study.Coronary artery disease, , Volume: 16, Issue:7, 2005
Ramipril in the treatment of vascular diseases.Expert opinion on pharmacotherapy, , Volume: 6, Issue:11, 2005
Cost effectiveness of ramipril in patients at high risk for cardiovascular events : economic evaluation of the HOPE (Heart Outcomes Prevention Evaluation) study for Germany from the Statutory Health Insurance perspective.PharmacoEconomics, , Volume: 22, Issue:15, 2004
Cost-effectiveness of ramipril in patients at high risk for cardiovascular events: a Swiss perspective.Swiss medical weekly, , Jul-10, Volume: 134, Issue:27-28, 2004
[Is the supplementation with antioxidants effective in the treatment of atherosclerosis?].Deutsche medizinische Wochenschrift (1946), , Feb-13, Volume: 129, Issue:7, 2004
Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/TelmiAmerican heart journal, , Volume: 148, Issue:1, 2004
Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE?Current medical research and opinion, , Volume: 20, Issue:3, 2004
Cardiovascular protection with ace inhibitors--more HOPE for EUROPA?Medical science monitor : international medical journal of experimental and clinical research, , Volume: 10, Issue:12, 2004
[Can coronary risks be further reduced?].Presse medicale (Paris, France : 1983), , Sep-25, Volume: 33, Issue:16, 2004
Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial.Journal of the American College of Cardiology, , Jun-16, Volume: 43, Issue:12, 2004
Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study.Circulation, , Mar-11, Volume: 107, Issue:9, 2003
More hype than HOPE.Hypertension (Dallas, Tex. : 1979), , Volume: 41, Issue:4, 2003
[Dangerous duo: hypertension and pre-diabetes--the underestimated risk].MMW Fortschritte der Medizin, , Jan-23, Volume: 145, Issue:3-4, 2003
Ramipril use in Canada: HOPE or HYPE?CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , Mar-04, Volume: 168, Issue:5, 2003
The striking effect of the Heart Outcomes Prevention Evaluation (HOPE) on ramipril prescribing in Ontario.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , Mar-04, Volume: 168, Issue:5, 2003
Ramipril for the prevention and treatment of cardiovascular disease.The Annals of pharmacotherapy, , Volume: 37, Issue:3, 2003
Economic impact of ramipril on hospitalization of high-risk cardiovascular patients.The Annals of pharmacotherapy, , Volume: 37, Issue:3, 2003
HOPE study impact on ACE inhibitors use.The Annals of pharmacotherapy, , Volume: 37, Issue:5, 2003
Best bang for the buck?Current hypertension reports, , Volume: 5, Issue:1, 2003
How cost-effective are new preventive strategies for cardiovascular disease?The American journal of cardiology, , May-22, Volume: 91, Issue:10A, 2003
The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.The American journal of cardiology, , May-22, Volume: 91, Issue:10A, 2003
Assessment of the effect of ramipril therapy on direct health care costs for first and recurrent strokes in high-risk cardiovascular patients using data from the Heart Outcomes Prevention Evaluation (HOPE) study.Clinical therapeutics, , Volume: 25, Issue:4, 2003
More than just hype.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , Jun-24, Volume: 168, Issue:13, 2003
More than just hype.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , Jun-24, Volume: 168, Issue:13, 2003
More than just hype.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , Jun-24, Volume: 168, Issue:13, 2003
[Further options with ramipril. Besides cardio- and nephro-protection diabetes prevention, too?].MMW Fortschritte der Medizin, , Sep-25, Volume: 145, Issue:39, 2003
[Added organ protection at little cost. Double savings with ACE inhibitors].MMW Fortschritte der Medizin, , Nov-27, Volume: 145, Issue:48, 2003
Spotlight on ramipril in the prevention of cardiovascular outcomes.American journal of cardiovascular drugs : drugs, devices, and other interventions, , Volume: 3, Issue:2, 2003
[Vascular patient with high infarction risk. Does the AT-1 blocker protect as well as an ACE inhibitor?].MMW Fortschritte der Medizin, , Dec-18, Volume: 145, Issue:51-52, 2003
Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study.Journal of the American Society of Nephrology : JASN, , Volume: 14, Issue:3, 2003
[Cost-effectiveness analysis of Ramipril treatment of patients at high-risk of cardiovascular events in Spain].Anales de medicina interna (Madrid, Spain : 1984), , Volume: 19, Issue:10, 2002
Ramipril and risk of diabetes.JAMA, , Jan-09, Volume: 287, Issue:2, 2002
Ramipril and risk of diabetes.JAMA, , Jan-09, Volume: 287, Issue:2, 2002
Combined endpoints: can we use them?Statistics in medicine, , Oct-15, Volume: 21, Issue:19, 2002
Comparative effects of estrogen and angiotensin-converting enzyme inhibition on plasminogen activator inhibitor-1 in healthy postmenopausal women.Circulation, , Jan-22, Volume: 105, Issue:3, 2002
Angiotensin II and trials of cardiovascular outcomes.The American journal of cardiology, , Jan-24, Volume: 89, Issue:2A, 2002
From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.The American journal of cardiology, , Jan-24, Volume: 89, Issue:2A, 2002
Cardiovascular risk in patients with early renal insufficiency: implications for the use of ACE inhibitors.American journal of cardiovascular drugs : drugs, devices, and other interventions, , Volume: 2, Issue:3, 2002
Comparative effects of the dual ACE-NEP inhibitor MDL-100,240 and ramipril on hypertension and cardiovascular disease in endogenous angiotensin II-dependent hypertension.American journal of hypertension, , Volume: 15, Issue:2 Pt 1, 2002
Risk reduction for stroke and coronary events.Lancet (London, England), , Apr-06, Volume: 359, Issue:9313, 2002
Effect of long-term therapy with ramipril in high-risk women.Journal of the American College of Cardiology, , Aug-21, Volume: 40, Issue:4, 2002
The cost-effectiveness of ramipril in the treatment of patients at high risk of cardiovascular events: a Swedish sub-study to the HOPE study.Journal of internal medicine, , Volume: 251, Issue:6, 2002
Using ACE inhibitors appropriately.American family physician, , Aug-01, Volume: 66, Issue:3, 2002
Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.The Canadian journal of cardiology, , Volume: 18 Suppl A, 2002
Ramipril: a review of its use in the prevention of cardiovascular outcomes.Drugs, , Volume: 62, Issue:9, 2002
Results from the TIP (Tritace in Proteinuria) intensified monitoring project.Kidney & blood pressure research, , Volume: 25, Issue:2, 2002
Ramipril and cardiovascular risk reduction.Circulation, , Jun-25, Volume: 105, Issue:25, 2002
Blood pressure and cardiovascular risk in the HOPE study.Lancet (London, England), , Jun-15, Volume: 359, Issue:9323, 2002
Who is fooling us?Lancet (London, England), , Jul-06, Volume: 360, Issue:9326, 2002
Ask the doctor. Recently, I read that the ACE inhibitor ramipril is very good at preventing heart problems, particularly in people with diabetes. I'm diabetic, and for years I have been on a different ACE inhibitor (lisinopril). Should I be taking ramipriHarvard heart letter : from Harvard Medical School, , Volume: 11, Issue:8, 2001
Summaries for patients. Trial of a drug to decrease the risk for heart disease in patients with mild kidney failure.Annals of internal medicine, , Apr-17, Volume: 134, Issue:8, 2001
The kidney in cardiovascular disease.Annals of internal medicine, , Apr-17, Volume: 134, Issue:8, 2001
Cost effectiveness of ramipril treatment for cardiovascular risk reduction.Heart (British Cardiac Society), , Volume: 85, Issue:5, 2001
The HOPE study: comparison with other trials of secondary prevention.European heart journal, , Volume: 22, Issue:15, 2001
The Heart Outcomes Prevention Evaluation study: angiotensin-converting enzyme inhibitors: are their benefits a class effect or do individual agents differ?Current opinion in nephrology and hypertension, , Volume: 10, Issue:5, 2001
What is the relevance of the HOPE study in general practice?International journal of clinical practice, , Volume: 55, Issue:7, 2001
Ramipril and the development of diabetes.JAMA, , Oct-17, Volume: 286, Issue:15, 2001
Pharmacoeconomic impact of HOPE.International journal of clinical practice. Supplement, , Issue:117, 2001
Future perspectives and implications.International journal of clinical practice. Supplement, , Issue:117, 2001
Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy.Hypertension (Dallas, Tex. : 1979), , Dec-01, Volume: 38, Issue:6, 2001
[Prediction, screening and treatment of renal complications of diabetes].La Revue du praticien, , Oct-15, Volume: 51, Issue:16, 2001
[Type 2 diabetes and cardiovascular risk: lessons from therapeutic trials].La Revue du praticien, , Oct-15, Volume: 51, Issue:16, 2001
Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.Annals of internal medicine, , Apr-17, Volume: 134, Issue:8, 2001
Clinical, public health, and research implications of the Heart Outcomes Prevention Evaluation (HOPE) Study.European heart journal, , Volume: 22, Issue:2, 2001
What are 'tissue ACE inhibitors,' and should they be used instead of other ACE inhibitors?Cleveland Clinic journal of medicine, , Volume: 68, Issue:3, 2001
HOPE for patients with Type 2 diabetes: an application of the findings of the MICRO-HOPE substudy in a British hospital diabetes clinic.Diabetic medicine : a journal of the British Diabetic Association, , Volume: 18, Issue:8, 2001
Effect of ramipril on cardiovascular events in high-risk patients.The New England journal of medicine, , Jul-06, Volume: 343, Issue:1, 2000
The HOPE study and diabetes. Heart Outcomes Prevention Evaluation.Lancet (London, England), , Apr-01, Volume: 355, Issue:9210, 2000
The HOPE study and diabetes. Heart Outcomes Prevention Evaluation.Lancet (London, England), , Apr-01, Volume: 355, Issue:9210, 2000
[How should ACE inhibitors be used in myocardial infarction?].Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, , Nov-20, Volume: 120, Issue:28, 2000
The HOPE study.Cleveland Clinic journal of medicine, , Volume: 67, Issue:6, 2000
HOPE for diabetes in the new millennium. Heart Outcomes Prevention Evaluation.Diabetes, obesity & metabolism, , Volume: 2, Issue:1, 2000
Don't keep that ACE (inhibitor) up your sleeve! Is ramipril effective for secondary prevention of cardiovascular disease and stroke?Canadian family physician Medecin de famille canadien, , Volume: 46, 2000
HOPE for all people with diabetes? Heart Outcomes Prevention Evaluation.Diabetic medicine : a journal of the British Diabetic Association, , Volume: 17 Suppl 2, 2000
The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not.Cleveland Clinic journal of medicine, , Volume: 67, Issue:4, 2000
ACE inhibitors to prevent cardiovascular events in high-risk patients.The Journal of family practice, , Volume: 49, Issue:4, 2000
Vitamin E does not prevent cardiovascular events in high-risk patients.The Journal of family practice, , Volume: 49, Issue:4, 2000
[Effect of a converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients].Presse medicale (Paris, France : 1983), , Apr-15, Volume: 29, Issue:14, 2000
ACE inhibitor reduces cardiovascular events by 22%.Indian journal of medical sciences, , Volume: 54, Issue:3, 2000
[Clinical study of the month. The HOPE study, a two-by-two factorial clinical trial with contrasted results].Revue medicale de Liege, , Volume: 55, Issue:2, 2000
Should you take an ACE inhibitor?The Johns Hopkins medical letter health after 50, , Volume: 12, Issue:1, 2000
Ramipril.International journal of clinical practice, , Volume: 54, Issue:4, 2000
[The reduction of cardiovascular risk with ramipril].Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology, , Volume: 1, Issue:5, 2000
The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: design, organization, and patient recruitment. DIABHYCAR Study Group.Controlled clinical trials, , Volume: 21, Issue:4, 2000
Effect of ramipril on cardiovascular events in high-risk patients.The New England journal of medicine, , Jul-06, Volume: 343, Issue:1, 2000
The HOPE Study (Heart Outcomes Prevention Evaluation).Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 1, Issue:1, 2000
From the Food and Drug Administration.JAMA, , Dec-06, Volume: 284, Issue:21, 2000
The renin angiotensin system and cardiovascular disease: hope or hype?Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 1, Issue:2, 2000
Should the results of the HOPE study affect nephrological practice? For the HOPE investigators.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 15, Issue:4, 2000
The HOPE study and diabetes. Heart Outcomes Prevention Evaluation.Lancet (London, England), , Apr-01, Volume: 355, Issue:9210, 2000
[The HOPE Study. What does it contribute to general practice?].MMW Fortschritte der Medizin, , Nov-23, Volume: 142, Issue:47, 2000
ACE inhibition in cardiovascular disease.The New England journal of medicine, , Jan-20, Volume: 342, Issue:3, 2000
ACE inhibitors and high-risk patients.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , Aug-08, Volume: 163, Issue:3, 2000
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.The New England journal of medicine, , 01-20, Volume: 342, Issue:3, 2000
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.Lancet (London, England), , Jan-22, Volume: 355, Issue:9200, 2000
HOPE and extension of the indications for ACE inhibitors? Heart Outcomes Prevention Evaluation.Lancet (London, England), , Jan-22, Volume: 355, Issue:9200, 2000
Determinants of elevated urinary albumin in the 4,937 type 2 diabetic subjects recruited for the DIABHYCAR Study in Western Europe and North Africa.Diabetes care, , Volume: 23 Suppl 2, 2000
HOPE for cardiovascular disease prevention with ACE-inhibitor ramipril. Heart Outcomes Prevention Evaluation.Lancet (London, England), , Sep-04, Volume: 354, Issue:9181, 1999
[Info-Congress. The HOPE Study: Demonstration of the cardiovascular protection of ramipril, an ACE-inhibitor].Revue medicale de Liege, , Volume: 54, Issue:10, 1999
[New breakthrough for ACE inhibitors. HOPE Study: hope for all vascular patients?].MMW Fortschritte der Medizin, , Oct-21, Volume: 141, Issue:42, 1999
ACE in the hole for heart patients....Health news (Waltham, Mass.), , Dec-15, Volume: 5, Issue:15, 1999
A safe new dose of heart protection. Study shows drug can prevent attacks, strokes.U.S. news & world report, , Nov-22, Volume: 127, Issue:20, 1999
[Cardiology on its way into the next millenium].Der Internist, , Volume: 40, Issue:12, 1999
Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes PrevenDiabetes care, , Volume: 19, Issue:11, 1996
The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. The HOPE study investigators.The Canadian journal of cardiology, , Volume: 12, Issue:2, 1996
The DIAB-HYCAR Study.Diabetologia, , Volume: 39, Issue:12, 1996
Ramipril. A review of its pharmacological properties and therapeutic efficacy in cardiovascular disorders.Drugs, , Volume: 39, Issue:1, 1990
Use of the cardiovascular polypill 40mg in secondary cardiovascular prevention.Clinica e investigacion en arteriosclerosis : publicacion oficial de la Sociedad Espanola de Arteriosclerosis, , Volume: 30, Issue:5
ARBs for cardiovascular and renal protection in high-risk patients.Cardiovascular journal of Africa, , Volume: 22, Issue:4
Study at up to 700 sites will build on landmark HOPE trial.Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners, , Volume: 12, Issue:2
Lessons from ONTARGET.Acta clinica Belgica, , Volume: 63, Issue:3
Renal insufficiency predicts cardiovascular disease in high-risk individuals: the benefit of ramipril in the HOPE study. Heart Outcomes and Prevention Evaluation.Journal of clinical hypertension (Greenwich, Conn.), , Volume: 3, Issue:4
Are ACE-inhibitors or ARB's still needed for cardiovascular prevention in high risk patients? Insights from profess and transcend.Acta clinica Belgica, , Volume: 65, Issue:2
From Tritace to Tri-Plen - the South African journey.Cardiovascular journal of Africa, , Volume: 20, Issue:1
Blood-pressure reduction and cardiovascular risk in HOPE study.Lancet (London, England), , Volume: 358, Issue:9299
Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE.Diabetes/metabolism research and reviews, , Volume: 18 Suppl 3
Tolerability of 10 mg of ramipril in normotensive Indian patients.The National medical journal of India, , Volume: 15, Issue:4
HOPE in PROGRESS--a tale of two trials: blood pressure reduction or drug mechanism?The American journal of geriatric cardiology, , Volume: 11, Issue:5
ONTARGET programme of cardio- and vascular protection - first results are imminent.Cardiovascular journal of Africa, , Volume: 19, Issue:1
Cost-effectiveness of the CNIC-Polypill versus separate monocomponents in cardiovascular secondary prevention in Spain.Revista clinica espanola, , Volume: 223, Issue:7
[Clinical effectiveness of metformin and ramipril combination in complex therapy of patients with metabolic syndrome].Likars'ka sprava, , Issue:1
Clinical and economic benefits of ramipril: an Australian analysis of the HOPE study.Internal medicine journal, , Volume: 33, Issue:9-10
Published pharmacoeconomic analyses: science or marketing?Internal medicine journal, , Volume: 33, Issue:9-10
[Ten years after publishing results from The Heart Outcomes Prevention Evaluation Study--HOPE: implications on treatment with angiotensin converting enzyme inhibitors in clinical practice].Lijecnicki vjesnik, , Volume: 133, Issue:1-2
ONTARGET proves telmisartan efficacy compared to ramipril in cardiovascular protection of patients at high risk and without heart failure.Cardiovascular journal of Africa, , Volume: 19, Issue:2
Need for new hypertension guidelines for high-risk patients.Cardiovascular journal of Africa, , Volume: 20, Issue:4
A transient ischemic attack mimic.Acta neurologica Belgica, , Volume: 117, Issue:4, 2017
Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone).Journal of the American College of Cardiology, , Jun-02, Volume: 53, Issue:22, 2009
Effect of ramipril and vitamin E on atherosclerosis.Circulation, , Jan-15, Volume: 105, Issue:2, 2002
From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.The American journal of cardiology, , Jan-24, Volume: 89, Issue:2A, 2002
ACE inhibitor inhibits atherosclerosis.Harvard heart letter : from Harvard Medical School, , Volume: 11, Issue:9, 2001
Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE).Circulation, , Feb-20, Volume: 103, Issue:7, 2001
Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril.Journal of the American College of Cardiology, , Volume: 36, Issue:2, 2000
Study design and baseline characteristics of the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E: SECURE.The American journal of cardiology, , Oct-15, Volume: 78, Issue:8, 1996
Twenty-and-a-half syndrome: a case report.Journal of medical case reports, , Feb-15, Volume: 13, Issue:1, 2019
Churg-Strauss syndrome with endocardial injury, clot formation in heart's chambers, and neurological complications.Kardiologia polska, , Volume: 74, Issue:11, 2016
Reduced cerebrovascular remodeling and functional impairment in spontaneously hypertensive rats following combined treatment with suboptimal doses of telmisartan and ramipril: is less really more?Journal of hypertension, , Volume: 28, Issue:7, 2010
Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats.Journal of hypertension, , Volume: 26, Issue:3, 2008
Ramipril protects from free radical induced white matter damage in chronic hypoperfusion in the rat.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, , Volume: 15, Issue:2, 2008
Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients.Cerebrovascular diseases extra, , Volume: 10, Issue:3, 2020
Nephroprotection by long-term ACE inhibition with ramipril in spontaneously hypertensive stroke prone rats.Kidney international, , Volume: 54, Issue:6, 1998
Replacement of salt by a novel potassium- and magnesium-enriched salt alternative improves the cardiovascular effects of ramipril.British journal of pharmacology, , Volume: 111, Issue:4, 1994
Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin.Hypertension (Dallas, Tex. : 1979), , Volume: 23, Issue:4, 1994
Effect of ramipril on alpha-adrenoceptor-mediated oscillatory contractions in tail artery of hypertensive rats.European journal of pharmacology, , Oct-05, Volume: 242, Issue:3, 1993
Impact of the COVID-19 pandemic on the management of chronic heart failure.Reviews in cardiovascular medicine, , 06-30, Volume: 22, Issue:2, 2021
Dysglycemia and Cognitive Dysfunction and Ill Health in People With High CV Risk: Results From the ONTARGET/TRANSCEND Studies.The Journal of clinical endocrinology and metabolism, , Volume: 100, Issue:7, 2015
Effect of zofenopril and ramipril on cardiovascular mortality in patients with chronic heart failure.The American journal of cardiology, , Jul-01, Volume: 112, Issue:1, 2013
REIN on obesity, proteinuria and CKD.Journal of the American Society of Nephrology : JASN, , Volume: 22, Issue:6, 2011
ACE inhibition is renoprotective among obese patients with proteinuria.Journal of the American Society of Nephrology : JASN, , Volume: 22, Issue:6, 2011
Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 25, Issue:7, 2010
Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway?Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 25, Issue:10, 2010
Is therapy of people with chronic kidney disease ONTARGET?Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 25, Issue:1, 2010
ONTARGET should not be over interpreted.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 25, Issue:1, 2010
The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial.Journal of cardiovascular electrophysiology, , Volume: 20, Issue:7, 2009
Ramipril protects from free radical induced white matter damage in chronic hypoperfusion in the rat.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, , Volume: 15, Issue:2, 2008
Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure.European journal of heart failure, , Volume: 9, Issue:11, 2007
Ramipril in the treatment of hypertension and proteinuria in children with chronic kidney diseases.American journal of hypertension, , Volume: 17, Issue:5 Pt 1, 2004
[ACE inhibitor therapy until end of life?].Deutsche medizinische Wochenschrift (1946), , Oct-29, Volume: 129, Issue:44, 2004
Improvement in endothelial progenitor cells from peripheral blood by ramipril therapy in patients with stable coronary artery disease.Cardiovascular drugs and therapy, , Volume: 18, Issue:3, 2004
Effects of diuretic treatment on cardiac and circulating RAS in chronic heart failure post-myocardial infarction in rats.European journal of heart failure, , Volume: 5, Issue:3, 2003
Aspirin alters arterial function in patients with chronic heart failure treated with ACE inhibitors: a dose-mediated deleterious effect.European journal of heart failure, , Volume: 5, Issue:3, 2003
Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies.Kidney international, , Volume: 59, Issue:1, 2001
Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen)Journal of the American Society of Nephrology : JASN, , Volume: 11, Issue:1, 2000
Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 35, Issue:6, 2000
Effects of ACE inhibitor, AT1 antagonist, and combined treatment in mice with heart failure.Journal of cardiovascular pharmacology, , Volume: 36, Issue:4, 2000
Pretreatment blood pressure reliably predicts progression of chronic nephropathies. GISEN Group.Kidney international, , Volume: 58, Issue:5, 2000
[Ramipril treatment of heart failure in disseminated forms of pulmonary tuberculosis].Problemy tuberkuleza, , Issue:2, 1999
[Efficiency of ramipril treatment in patients with chronic obstructive bronchitis complicated by chronic cor pulmonale].Problemy tuberkuleza, , Issue:6, 1999
In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia.Journal of the American Society of Nephrology : JASN, , Volume: 10, Issue:5, 1999
[Renal hemodynamics and proteinuria in chronic glomerulonephritis treated with beta-receptor blockers or ace inhibitors].Deutsche medizinische Wochenschrift (1946), , Aug-01, Volume: 122, Issue:31-32, 1997
Randomized controlled trial of ACE-inhibitors and beta-blockers with and without vasodilating activity in chronic glomerulonephritis.International journal of clinical pharmacology and therapeutics, , Volume: 34, Issue:11, 1996
Meta-analysis of morbidity and mortality in five exercise capacity trials evaluating ramipril in chronic congestive cardiac failure.The American journal of cardiology, , Jun-01, Volume: 77, Issue:14, 1996
[The use of ramipril in treating patients with chronic heart failure].Terapevticheskii arkhiv, , Volume: 67, Issue:5, 1995
A comparison of the efficacy and safety of ramipril and digoxin added to maintenance diuretic treatment in patients with chronic heart failure.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Influence of ramipril on renal function in patients with chronic congestive heart failure.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Acute effects of the new angiotensin converting enzyme inhibitor ramipril on hemodynamics and carotid sinus baroreflex activity in congestive heart failure.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Acute hemodynamic and hormonal effects of ramipril in chronic congestive heart failure and comparison with captopril.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Acute hemodynamic, hormonal and electrolyte effects of ramipril in severe congestive heart failure.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Myocarditis and pericarditis in the course of colitis ulcerosa.Kardiologia polska, , Volume: 72, Issue:4, 2014
Renal failure following bowel cleansing with a sodium phosphate purgative.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 20, Issue:7, 2005
[Usefulness of capsule endoscopy in obscure gastrointestinal bleeding].Gastroenterologia y hepatologia, , Volume: 38, Issue:10, 2015
Ameliorative potential of angiotensin-converting enzyme inhibitor (ramipril) on chronic constriction injury of sciatic nerve induced neuropathic pain in mice.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 16, Issue:1, 2015
Right ventricular hypertrophy and apoptosis after pulmonary artery banding: regulation of PKC isozymes.Cardiovascular research, , Sep-01, Volume: 59, Issue:3, 2003
ACE inhibition decreases postoperative mortality in rats with left ventricular hypertrophy and myocardial infarction.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 18, Issue:5, 1996
Influence of ramipril on right ventricular hypertrophy induced by pulmonary artery stenosis in rats.Journal of cardiovascular pharmacology, , Volume: 16, Issue:3, 1990
Target Blood Pressure in Patients with Diabetes: Asian Perspective.Yonsei medical journal, , Volume: 57, Issue:6, 2016
Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease.Hypertension (Dallas, Tex. : 1979), , Volume: 65, Issue:1, 2015
Systolic blood pressure target levels: evidence for benefits in stroke.Hypertension (Dallas, Tex. : 1979), , Volume: 65, Issue:1, 2015
Angiotensin II impairs endothelial progenitor cell number and function in vitro and in vivo: implications for vascular regeneration.Hypertension (Dallas, Tex. : 1979), , Volume: 58, Issue:3, 2011
Effect of angiotensin-converting enzyme inhibition on C-reactive protein levels: the ramipril C-reactive pRotein randomized evaluation (4R) trial results.The Canadian journal of cardiology, , Volume: 25, Issue:7, 2009
Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes.Current atherosclerosis reports, , Volume: 10, Issue:2, 2008
Inflammatory activation during coronary artery surgery and its dose-dependent modulation by statin/ACE-inhibitor combination.Arteriosclerosis, thrombosis, and vascular biology, , Volume: 27, Issue:12, 2007
Differential antiplatelet effects of angiotensin converting enzyme inhibitors: comparison of ex vivo platelet aggregation in cardiovascular patients with ramipril, captopril and enalapril.Clinical research in cardiology : official journal of the German Cardiac Society, , Volume: 95, Issue:4, 2006
Lack of effect on coronary atherosclerotic disease biomarkers with modest dosing of an angiotensin-converting enzyme inhibitor, angiotensin II type-1 receptor blocker, and the combination.Coronary artery disease, , Volume: 17, Issue:5, 2006
Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study.Circulation, , Jul-18, Volume: 114, Issue:3, 2006
Do all patients with coronary artery disease benefit from angiotensin converting enzyme inhibitors?Journal of cardiovascular pharmacology and therapeutics, , Volume: 10, Issue:4, 2005
Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis.Zeitschrift fur Kardiologie, , Volume: 94, Issue:5, 2005
Vascular effects of simvastatin combined with ramipril in hypercholesterolemic patients with coronary artery disease, compared with simvastatin alone: a randomized, double-blind, placebo-controlled, crossover study.Atherosclerosis, , Volume: 177, Issue:1, 2004
Modulating atherosclerosis through inhibition or blockade of angiotensin.Clinical cardiology, , Volume: 26, Issue:7, 2003
[The status of atherosclerosis prevention in Austria].Wiener medizinische Wochenschrift (1946), , Volume: 153, Issue:15-16, 2003
[Preventing cardiovascular diseases. Discovering the optimal approach].MMW Fortschritte der Medizin, , Oct-11, Volume: 143, Issue:41, 2001
Study design and baseline characteristics of the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E: SECURE.The American journal of cardiology, , Oct-15, Volume: 78, Issue:8, 1996
ACE inhibition, atherosclerosis and myocardial infarction--the AIRE Study in practice. Acute Infarction Ramipril Efficacy Study.European heart journal, , Volume: 15 Suppl B, 1994
[ACE inhibition and atherosclerosis in the animal model].Zeitschrift fur Kardiologie, , Volume: 83 Suppl 4, 1994
Do ACE inhibitors have a real role in coronary artery disease?Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners, , Volume: 14, Issue:3
[Combination drug improves adherence].MMW Fortschritte der Medizin, , Apr-28, Volume: 158, Issue:8, 2016
[Polypill for secondary coronary heart disease prevention].MMW Fortschritte der Medizin, , Dec-14, Volume: 157, Issue:21-22, 2015
Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril.Postgraduate medicine, , Volume: 125, Issue:4, 2013
The common -866G>A variant in the promoter of UCP2 is associated with decreased risk of coronary artery disease in type 2 diabetic men.Diabetes, , Volume: 57, Issue:4, 2008
Noninvasive pulse waveform analysis in clinical trials: similarity of two methods for calculating aortic systolic pressure.American journal of hypertension, , Volume: 20, Issue:8, 2007
Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis.Zeitschrift fur Kardiologie, , Volume: 94, Issue:5, 2005
Improvement in endothelial progenitor cells from peripheral blood by ramipril therapy in patients with stable coronary artery disease.Cardiovascular drugs and therapy, , Volume: 18, Issue:3, 2004
Ischemic preconditioning in coronary heart disease: a therapeutic golden fleece?Journal of the American College of Cardiology, , May-05, Volume: 43, Issue:9, 2004
[Preventive therapy with ACE inhibitors for coronary patients].Orvosi hetilap, , Feb-29, Volume: 145, Issue:9, 2004
Combine EUROPA and HOPE.Lancet (London, England), , Dec-06, Volume: 362, Issue:9399, 2003
["Using chance, despite high NNT"].MMW Fortschritte der Medizin, , Sep-18, Volume: 145, Issue:38, 2003
The EUROPA trial.Lancet (London, England), , Dec-06, Volume: 362, Issue:9399, 2003
Should all patients with coronary disease receive angiotensin-converting-enzyme inhibitors?Lancet (London, England), , Sep-06, Volume: 362, Issue:9386, 2003
Vitamins, antioxidants and endothelial function in coronary artery disease.Cardiovascular drugs and therapy, , Volume: 16, Issue:5, 2002
[New indications. ACE inhibitor is now included in coronary heart disease therapy].MMW Fortschritte der Medizin, , May-02, Volume: 144, Issue:18, 2002
Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase.Circulation, , Feb-13, Volume: 103, Issue:6, 2001
Management of asymptomatic left ventricular dysfunction.Cleveland Clinic journal of medicine, , Volume: 68, Issue:3, 2001
An ACE inhibitor to coronary patients: ramipril reduces mortality according to HOPE trial.Prescrire international, , Volume: 10, Issue:52, 2001
Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.QJM : monthly journal of the Association of Physicians, , Volume: 93, Issue:9, 2000
[Endothelium and endogenous fibrinolysis].Zeitschrift fur Kardiologie, , Volume: 89, Issue:3, 2000
Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril.Journal of the American College of Cardiology, , Volume: 36, Issue:2, 2000
Management of heart failure.Current cardiology reports, , Volume: 2, Issue:3, 2000
Hidden benefits of ACE inhibitors.Harvard heart letter : from Harvard Medical School, , Volume: 10, Issue:6, 2000
ACE inhibition with ramipril improves left ventricular function at rest and post exercise in patients with stable ischaemic heart disease and preserved left ventricular systolic function.European heart journal, , Volume: 20, Issue:22, 1999
Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure:the effects of ramipril, nifedipine and moxonidine.Journal of the American Society of Nephrology : JASN, , Volume: 7, Issue:5, 1996
[ACE inhibition: mechanisms of "cardioprotection" in acute myocardial ischemia].Klinische Wochenschrift, , Volume: 69 Suppl 24, 1991
[Are the radical scavenging properties of ACE inhibitors with sulfhydryl groups in therapeutically effective concentrations of quantitative significance?].Klinische Wochenschrift, , Volume: 69 Suppl 24, 1991
Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardioprotection.The Journal of pharmacology and experimental therapeutics, , Volume: 257, Issue:3, 1991
Effect of angiotensin converting enzyme inhibitors on cardiac noradrenaline release.European heart journal, , Volume: 12 Suppl F, 1991
[Acute effects of the angiotensin converting enzyme inhibitor ramipril in patients with coronary heart disease].Medizinische Klinik (Munich, Germany : 1983), , Feb-15, Volume: 85, Issue:2, 1990
Local inhibition of bradykinin degradation in ischemic hearts.Journal of cardiovascular pharmacology, , Volume: 15 Suppl 6, 1990
Ramiprilat attenuates the local release of noradrenaline in the ischemic myocardium.European journal of pharmacology, , Jul-18, Volume: 166, Issue:2, 1989
[Pharmacologic modification of the converting enzyme--local and systemic effects on the heart and blood vessels].Zeitschrift fur Kardiologie, , Volume: 77 Suppl 3, 1988
Cardiovascular effects of the converting enzyme inhibitor ramipril (HOE 498) in anesthetized dogs with acute ischemic left ventricular failure.Clinical and experimental hypertension. Part A, Theory and practice, , Volume: 8, Issue:6, 1986
Beneficial effects of the converting enzyme inhibitor, ramipril, in ischemic rat hearts.Journal of cardiovascular pharmacology, , Volume: 8 Suppl 10, 1986
Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: a comparison of captopril, enalapril, and HOE 498.Journal of cardiovascular pharmacology, , Volume: 8, Issue:4
Ileostomy and ramipril-induced acute renal failure and shock.Heart & lung : the journal of critical care, , Volume: 36, Issue:4
Urticarial vasculitis from simvastatin: what is the alternative drug?Dermatitis : contact, atopic, occupational, drug, , Volume: 21, Issue:4
[Evaluation of efficacy and safety of hypertension treatment with original angiotensin-converting enzyme inhibitors: the comparison of original and generic formulations].Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, , Volume: 34, Issue:201, 2013
Factors that favor the occurrence of cough in patients treated with ramipril--a pharmacoepidemiological study.Medical science monitor : international medical journal of experimental and clinical research, , Volume: 18, Issue:9, 2012
Effects of zofenopril and ramipril on cough reflex responses in anesthetized and awake rabbits.Journal of cardiovascular pharmacology and therapeutics, , Volume: 15, Issue:4, 2010
Differences between zofenopril and ramipril, two ACE inhibitors, on cough induced by citric acid in guinea pigs: role of bradykinin and PGE2.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 382, Issue:5-6, 2010
Can aliskiren reduce the incidence of cough caused by ramipril?Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 9, Issue:3, 2008
[A 60-year-old man with heart failure, dry cough and elevated INR values].Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, , Aug-14, Volume: 128, Issue:15, 2008
Safety and tolerability of ramipril 10 mg in patients at high risk of cardiovascular events: an observational study.Journal of the Indian Medical Association, , Volume: 106, Issue:7, 2008
The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I).Journal of hypertension, , Volume: 24, Issue:1, 2006
Tolerability of ramipril 10 mg daily in high-risk cardiovascular patients in Taiwan: experience from Kaohsiung Medical University Chung-Ho Memorial Hospital.The Kaohsiung journal of medical sciences, , Volume: 21, Issue:11, 2005
The HOPE TIPS: the HOPE study translated into practices.Cardiovascular drugs and therapy, , Volume: 19, Issue:3, 2005
Angiotensin converting enzyme inhibitors and cough--a north Indian study.The Journal of the Association of Physicians of India, , Volume: 46, Issue:5, 1998
ACE-inhibitor-induced cough, an adverse drug reaction unrecognised for several years: studies in prescription-event monitoring.European journal of clinical pharmacology, , Volume: 49, Issue:6, 1996
Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors.BMJ (Clinical research ed.), , Jan-01, Volume: 308, Issue:6920, 1994
Tolerability of ramipril in a multicenter study of mild-to-moderate hypertension in general practice.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Change in cough reflex after treatment with enalapril and ramipril.BMJ (Clinical research ed.), , Jul-01, Volume: 299, Issue:6690, 1989
Safety and tolerability of ramipril 10 mg in patients at high risk of cardiovascular events: an observational study.Indian heart journal, , Volume: 60, Issue:3
The African American Study of Kidney Disease and Hypertension (AASK) trial: what more have we learned?Journal of clinical hypertension (Greenwich, Conn.), , Volume: 5, Issue:2
Ramiprilate inhibits functional matrix metalloproteinase activity in Crohn's disease fistulas.Basic & clinical pharmacology & toxicology, , Volume: 109, Issue:3, 2011
Incidence, severity, and etiology of drug-induced acute pancreatitis.Digestive diseases and sciences, , Volume: 55, Issue:10, 2010
Dysglycemia and Cognitive Dysfunction and Ill Health in People With High CV Risk: Results From the ONTARGET/TRANSCEND Studies.The Journal of clinical endocrinology and metabolism, , Volume: 100, Issue:7, 2015
The mini-mental state examination, clinical factors, and motor vehicle crash risk.Journal of the American Geriatrics Society, , Volume: 62, Issue:8, 2014
Protection against stroke and dementia: an update on the latest clinical trial evidence.Current hypertension reports, , Volume: 6, Issue:4, 2004
Differential effects of RYGB surgery and best medical treatment for obesity-diabetes on intestinal and islet adaptations in obese-diabetic ZDSD rats.PloS one, , Volume: 17, Issue:9, 2022
Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk.European heart journal, , 07-01, Volume: 40, Issue:25, 2019
Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?Journal of hypertension, , Volume: 30, Issue:4, 2012
Long-term effect of rosiglitazone and/or ramipril on the incidence of diabetes.Diabetologia, , Volume: 54, Issue:3, 2011
Renin-angiotensin system blockade and cardiovascular and renal protection.The American journal of cardiology, , Jan-04, Volume: 105, Issue:1 Suppl, 2010
Telmisartan in high-risk cardiovascular patients.The American journal of cardiology, , Jan-04, Volume: 105, Issue:1 Suppl, 2010
Role of renin-angiotensin system blockade in patients with diabetes mellitus.The American journal of cardiology, , Sep-15, Volume: 104, Issue:6, 2009
Proteinuria: Is the ONTARGET renal substudy actually off target?Nature reviews. Nephrology, , Volume: 5, Issue:8, 2009
Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET/TRANSCEND research programme.Diabetes research and clinical practice, , Volume: 83, Issue:3, 2009
Telmisartan, ramipril, or both in patients at high risk of vascular events.The New England journal of medicine, , Jul-24, Volume: 359, Issue:4, 2008
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.Lancet (London, England), , Aug-16, Volume: 372, Issue:9638, 2008
Telmisartan, ramipril, or both in patients at high risk for vascular events.The New England journal of medicine, , Apr-10, Volume: 358, Issue:15, 2008
Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes.Current atherosclerosis reports, , Volume: 10, Issue:2, 2008
Drivers for change in primary care of diabetes following a protected learning time educational event: interview study of practitioners.BMC medical education, , Jan-19, Volume: 8, 2008
Effect of ramipril on the incidence of diabetes.The New England journal of medicine, , Feb-01, Volume: 356, Issue:5, 2007
[The DREAM of diabetes prevention].Revue medicale suisse, , Jan-17, Volume: 3, Issue:94, 2007
The new clinical trials with thiazolidinediones--DREAM, ADOPT, and CHICAGO: promises fulfilled?Current opinion in lipidology, , Volume: 18, Issue:4, 2007
Effect of ramipril on the incidence of diabetes.The New England journal of medicine, , Feb-01, Volume: 356, Issue:5, 2007
Assessment of single versus twice daily dosing of ramipril by ambulatory blood pressure monitoring in patients similar to those included in the HOPE study.Journal of human hypertension, , Volume: 21, Issue:7, 2007
Effect of ramipril on the incidence of diabetes.The New England journal of medicine, , Feb-01, Volume: 356, Issue:5, 2007
Angiotensin-converting-enzyme inhibitors for impaired glucose tolerance--is there still hope?The New England journal of medicine, , Oct-12, Volume: 355, Issue:15, 2006
Effect of ramipril on the incidence of diabetes.The New England journal of medicine, , Oct-12, Volume: 355, Issue:15, 2006
The question of whether diabetes and its cardiovascular risks can be prevented: a realistic DREAM?Blood pressure, , Volume: 15, Issue:5, 2006
DREAM study and its impact on India.The Journal of the Association of Physicians of India, , Volume: 54, 2006
Long-term effects of ramipril on cardiovascular events and on diabetes: results of the HOPE study extension.Circulation, , Aug-30, Volume: 112, Issue:9, 2005
The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis.Diabetologia, , Volume: 48, Issue:9, 2005
Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/TelmiAmerican heart journal, , Volume: 148, Issue:1, 2004
Angina pectoris prior to myocardial infarction protects against subsequent left ventricular remodeling.Journal of the American College of Cardiology, , May-05, Volume: 43, Issue:9, 2004
Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.Diabetologia, , Volume: 47, Issue:9, 2004
[Fast and strong lowering of pressure. The newest sartan has passed the practice test].MMW Fortschritte der Medizin, , Oct-30, Volume: 145, Issue:44, 2003
[Further options with ramipril. Besides cardio- and nephro-protection diabetes prevention, too?].MMW Fortschritte der Medizin, , Sep-25, Volume: 145, Issue:39, 2003
The effect of ramipril on albumin excretion in diabetes and hypertension: the role of increased lysosomal activity and decreased transforming growth factor-beta expression.Journal of hypertension, , Volume: 21, Issue:2, 2003
Blood pressure drug may prevent diabetes in some people.Mayo Clinic health letter (English ed.), , Volume: 20, Issue:2, 2002
Ramipril and risk of diabetes.JAMA, , Jan-09, Volume: 287, Issue:2, 2002
Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.The Canadian journal of cardiology, , Volume: 18 Suppl A, 2002
Ramipril and risk of diabetes.JAMA, , Jan-09, Volume: 287, Issue:2, 2002
Ramipril and the development of diabetes.JAMA, , Oct-17, Volume: 286, Issue:15, 2001
Ramipril.International journal of clinical practice, , Volume: 54, Issue:4, 2000
ACE inhibition in cardiovascular disease.The New England journal of medicine, , Jan-20, Volume: 342, Issue:3, 2000
ACE inhibitors and high-risk patients.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , Aug-08, Volume: 163, Issue:3, 2000
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.The New England journal of medicine, , 01-20, Volume: 342, Issue:3, 2000
[A comparison of the effect of Capoten (captopril) and ramipril on the circadian profile of the arterial pressure and peripheral hemodynamics in patients with hypertension combined with diabetes mellitus].Terapevticheskii arkhiv, , Volume: 68, Issue:5, 1996
Effect of ramipril on blood pressure and protein excretion rate in normotensive nondiabetic patients with proteinuria.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 28, Issue:6, 1996
Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE.Diabetes/metabolism research and reviews, , Volume: 18 Suppl 3
Apigenin ameliorates streptozotocin-induced diabetic nephropathy in rats via MAPK-NF-κB-TNF-α and TGF-β1-MAPK-fibronectin pathways.American journal of physiology. Renal physiology, , Aug-01, Volume: 313, Issue:2, 2017
A pilot study on the effect of telmisartan & ramipril on 24 h blood pressure profile & dipping pattern in type 1 diabetes patients with nephropathy.The Indian journal of medical research, , Volume: 134, Issue:5, 2011
Anti-albuminuric efficacy of a combination of angiotensin converting enzyme inhibitor & angiotensin receptor blocker in type 1 DM with nephropathy.The Indian journal of medical research, , Volume: 132, 2010
Atrial natriuretic peptide prevents diabetes-induced endothelial dysfunction.Life sciences, , Apr-09, Volume: 82, Issue:15-16, 2008
[Hypertension and diabetic nephropathy, a dangerous duo].Medizinische Klinik (Munich, Germany : 1983), , Nov-15, Volume: 100, Issue:11, 2005
Modulation of the renal response to ACE inhibition by ACE insertion/deletion polymorphism during hyperglycemia in normotensive, normoalbuminuric type 1 diabetic patients.Diabetes, , Volume: 54, Issue:10, 2005
Effects of ACE inhibition and AT1-receptor blockade on haemodynamic responses to L-arginine in Type 1 diabetes.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 5, Issue:1, 2004
[Chronopharmacological approaches to the therapeutic prophylaxis of chronic cardiac insufficiency in type I diabetes mellitus].Vestnik Rossiiskoi akademii meditsinskikh nauk, , Issue:4, 2003
[Prediction, screening and treatment of renal complications of diabetes].La Revue du praticien, , Oct-15, Volume: 51, Issue:16, 2001
Reduction of ACE activity is insufficient to decrease microalbuminuria in normotensive patients with type 1 diabetes.Diabetes care, , Volume: 24, Issue:5, 2001
Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial.Diabetes care, , Volume: 23, Issue:12, 2000
Studies examining risk reduction in subjects with multiple metabolic and cardiovascular risk factors.Current hypertension reports, , Volume: 2, Issue:2, 2000
Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 34, Issue:5, 1999
Influence of ramipril on the course of plasma thrombomodulin in patients with diabetes mellitus.VASA. Zeitschrift fur Gefasskrankheiten, , Volume: 28, Issue:3, 1999
[Best antihypotensive agents for the treatment of type 2 diabetes. Ramipril, the first choice, in combination with felodipin is a sensible treatment plan].Der Internist, , Volume: 40, Issue:7, 1999
Microcirculation in hyperglycemic patients with IDDM without diabetic complications--effect of low-dose angiotensin-converting enzyme inhibition.Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, , Volume: 106, Issue:1, 1998
EUCLID study.Lancet (London, England), , Oct-11, Volume: 350, Issue:9084, 1997
Short-term treatment with ramipril normalizes renal haemodynamics and the natriuretic response to a sodium load in type 1 diabetic patients with early nephropathy.Acta diabetologica, , Volume: 34, Issue:1, 1997
Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes PrevenDiabetes care, , Volume: 19, Issue:11, 1996
Reversible hyperkalemia at the initiation of ACE inhibitors in a young diabetic patient with latent hyporeninemic hypoaldosteronism.Diabetes care, , Volume: 19, Issue:7, 1996
The study of the effect of intensity of blood pressure management on the progression of type 1 diabetic nephropathy: study design and baseline patient characteristics. Collaborative Study Group.Journal of the American Society of Nephrology : JASN, , Volume: 5, Issue:10, 1995
[Dissociation of hypotensive and renal hemodynamic effects of an angiotensin converting enzyme inhibitor in insulin-dependent diabetic patients with incipient nephropathy].Archives des maladies du coeur et des vaisseaux, , Volume: 84, Issue:3, 1991
Small doses of ramipril to reduce microalbuminuria in diabetic patients with incipient nephropathy independently of blood pressure changes.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Double-blind, placebo-controlled study of ramipril in diabetics with mild to moderate hypertension.Clinical therapeutics, , Volume: 15, Issue:1
The effect of ramipril therapy on cytokines and parameters of incipient diabetic nephropathy in patients with type 1 diabetes mellitus.The Journal of international medical research, , Volume: 35, Issue:3
Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3-/- Mice.Journal of the American Society of Nephrology : JASN, , 09-01, Volume: 34, Issue:9, 2023
Enhanced Cardiorenal Protective Effects of Combining SGLT2 Inhibition, Endothelin Receptor Antagonism and RAS Blockade in Type 2 Diabetic Mice.International journal of molecular sciences, , Oct-24, Volume: 23, Issue:21, 2022
DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment.Hypertension (Dallas, Tex. : 1979), , Volume: 79, Issue:4, 2022
A Prospective Single-Blind Randomized Trial of Ramipril, Eplerenone and Their Combination in Type 2 Diabetic Nephropathy.Cardiorenal medicine, , Volume: 10, Issue:6, 2020
Does diabetes prevention translate into reduced long-term vascular complications of diabetes?Diabetologia, , Volume: 62, Issue:8, 2019
Benefits of Fixed Dose Combination of Ramipril/Amlodipine in Hypertensive Diabetic Patients: A Subgroup Analysis of RAMONA Trial.Chinese medical journal, , May-20, Volume: 129, Issue:10, 2016
Target Blood Pressure in Patients with Diabetes: Asian Perspective.Yonsei medical journal, , Volume: 57, Issue:6, 2016
Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 16, Issue:4, 2015
Recent clinical trials.Journal of the American Society of Hypertension : JASH, , Volume: 8, Issue:10, 2014
Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy.American journal of nephrology, , Volume: 40, Issue:3, 2014
Effects of a long-term treatment with aliskiren or ramipril on structural alterations of subcutaneous small-resistance arteries of diabetic hypertensive patients.Hypertension (Dallas, Tex. : 1979), , Volume: 64, Issue:4, 2014
[The role of ramipril in the therapy of diabetic nephropathy].Orvosi hetilap, , Feb-16, Volume: 155, Issue:7, 2014
Type 2 diabetes-induced cardiovascular complications: comparative evaluation of spironolactone, atenolol, metoprolol, ramipril and perindopril.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 36, Issue:5, 2014
Acute regulation of pancreatic islet microcirculation and glycaemia by telmisartan and ramipril: discordant effects between normal and type 2 diabetic rats.Clinical science (London, England : 1979), , Volume: 125, Issue:9, 2013
Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria.Expert opinion on pharmacotherapy, , Volume: 14, Issue:4, 2013
Effect of imidapril versus ramipril on urinary albumin excretion in hypertensive patients with type 2 diabetes and microalbuminuria.Expert opinion on pharmacotherapy, , Volume: 14, Issue:18, 2013
Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus.JAMA internal medicine, , Oct-14, Volume: 173, Issue:18, 2013
Moving dietary management of diabetes forward.JAMA internal medicine, , Oct-14, Volume: 173, Issue:18, 2013
Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).Journal of the American College of Cardiology, , Jan-03, Volume: 59, Issue:1, 2012
Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes.Diabetologia, , Volume: 55, Issue:5, 2012
Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study.Cardiovascular diabetology, , Jan-09, Volume: 11, 2012
Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy.Expert opinion on pharmacotherapy, , Volume: 13, Issue:8, 2012
Incidence of diabetes following ramipril or rosiglitazone withdrawal.Diabetes care, , Volume: 34, Issue:6, 2011
Angiotensin converting enzyme inhibitor or angiotensin II receptor blocker for the prevention of type 2 diabetes mellitus?Diabetes research and clinical practice, , Volume: 90, Issue:2, 2010
Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.Diabetic medicine : a journal of the British Diabetic Association, , Volume: 27, Issue:11, 2010
Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial.Diabetes care, , Volume: 33, Issue:3, 2010
Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.Diabetes care, , Volume: 33, Issue:10, 2010
Renal vascular endothelial function in hypertensive patients with type 2 diabetes mellitus.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 53, Issue:2, 2009
Normal pregnancy and healthy child after continued exposure to gliclazide and ramipril during pregnancy.The Annals of pharmacotherapy, , Volume: 43, Issue:1, 2009
Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria.Clinical journal of the American Society of Nephrology : CJASN, , Volume: 4, Issue:3, 2009
Role of renin-angiotensin system blockade in patients with diabetes mellitus.The American journal of cardiology, , Sep-15, Volume: 104, Issue:6, 2009
[The study of effects of ramipril and amlodipine combination in patients with arterial hypertension and type 2 diabetes mellitus].Kardiologiia, , Volume: 49, Issue:5, 2009
[Parameters of vasomotor function of endothelium and elasticity of arterial wall during therapy with angiotensin converting enzyme inhibitor ramiprilin patients with type 2 diabetes mellitus].Kardiologiia, , Volume: 48, Issue:11, 2008
Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms.Diabetes care, , Volume: 31, Issue:1, 2008
Dysglycemia and a history of reproductive risk factors.Diabetes care, , Volume: 31, Issue:8, 2008
[The effectiveness in type 2 diabetes prevention: a forced landing to reality].Medicina clinica, , Mar-08, Volume: 130, Issue:8, 2008
First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation.Cardiovascular diabetology, , Jul-24, Volume: 7, 2008
[Acute renal insufficiency after flurbiprofen treatment in a patient treated with angiotensin converting enzyme inhibitor].La Revue de medecine interne, , Volume: 29, Issue:7, 2008
Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular events, and Ramipril (DIABHYCAR), Diabete dDiabetes care, , Volume: 31, Issue:10, 2008
Ramipril improves oxidative stress-related vascular endothelial dysfunction in db/db mice.The journal of physiological sciences : JPS, , Volume: 58, Issue:6, 2008
The common -866G>A variant in the promoter of UCP2 is associated with decreased risk of coronary artery disease in type 2 diabetic men.Diabetes, , Volume: 57, Issue:4, 2008
The ADVANCE trial.Lancet (London, England), , Jan-05, Volume: 371, Issue:9606, 2008
Effects of telmisartan and ramipril on adiponectin and blood pressure in patients with type 2 diabetes.American journal of hypertension, , Volume: 21, Issue:12, 2008
Diabetes prevention between RAAS inhibition and PPAR-gamma stimulation: the diabetes reduction assessment with ramipril and rosiglitazone medication (DREAM) trial.Journal of the cardiometabolic syndrome, ,Spring, Volume: 2, Issue:2, 2007
[Three studies in type 2 diabetes: DREAM the wash-out results].Annales d'endocrinologie, , Volume: 68 Suppl 1, 2007
[Influence of diabetes incidence by ramipril and rosiglitazone: DREAM study (diabetes reduction assessment with ramipril and rosiglitazone medication)].Der Internist, , Volume: 48, Issue:10, 2007
Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes.Diabetes care, , Volume: 30, Issue:6, 2007
DREAM and ADOPT: rosiglitazone does what it says on the packet.Diabetic medicine : a journal of the British Diabetic Association, , Volume: 24, Issue:2, 2007
The therapeutic effects of angiotensin-converting enzyme inhibitors in severe non-proliferative diabetic retinopathy.Korean journal of ophthalmology : KJO, , Volume: 21, Issue:1, 2007
Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1+2 in patients with type 2 diabetes.Atherosclerosis, , Volume: 194, Issue:1, 2007
Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled study.European journal of clinical pharmacology, , Volume: 63, Issue:8, 2007
Trials that matter: rosiglitazone, ramipril, and the prevention of type 2 diabetes.Annals of internal medicine, , Mar-20, Volume: 146, Issue:6, 2007
Beneficial effects of ramipril on myocardial diastolic function in patients with type 2 diabetes mellitus, normal LV systolic function and without coronary artery disease: a prospective study using tissue Doppler.Diabetes & vascular disease research, , Volume: 4, Issue:4, 2007
Diabetes prevention: still no effective drugs.Prescrire international, , Volume: 16, Issue:92, 2007
Estimating the cost effectiveness of ramipril used for specific clinical indications: comparing the outcomes in four clinical trials with a common economic model.American journal of cardiovascular drugs : drugs, devices, and other interventions, , Volume: 7, Issue:6, 2007
[Experiences of the DREAM trial].Orvosi hetilap, , Dec-31, Volume: 147, Issue:52, 2006
[DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease].Revue medicale de Liege, , Volume: 61, Issue:10, 2006
Urinary TGF-beta1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy.Diabetes research and clinical practice, , Volume: 72, Issue:3, 2006
[In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension].MMW Fortschritte der Medizin, , Jun-29, Volume: 148, Issue:26, 2006
[Effects and mechanism of ShenQi compound recipe on inflammation maker in GK rats].Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials, , Volume: 29, Issue:3, 2006
Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 21, Issue:3, 2006
Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease.Archives of internal medicine, , Apr-10, Volume: 166, Issue:7, 2006
Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes.Hypertension (Dallas, Tex. : 1979), , Volume: 45, Issue:6, 2005
[Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].Italian heart journal : official journal of the Italian Federation of Cardiology, , Volume: 6 Suppl 7, 2005
Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus.The American journal of cardiology, , Jun-01, Volume: 95, Issue:11, 2005
[Association between angiotensin converting enzyme I/D polymorphism and high-sensitivity C-reactive protein in type 2 diabetic patients with atherosclerosis treated with ramipril].Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA, , Volume: 25, Issue:6, 2005
Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition.Diabetologia, , Volume: 48, Issue:8, 2005
[Hypertension and diabetic nephropathy, a dangerous duo].Medizinische Klinik (Munich, Germany : 1983), , Nov-15, Volume: 100, Issue:11, 2005
[Effects of angiotensin receptor blocker and angiotensin-coverting enzyme inhibitor on vascular endothelial function in type 2 diabetic patients with atherosclerosis: a comparative study].Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA, , Volume: 25, Issue:8, 2005
Ramipril in the treatment of vascular diseases.Expert opinion on pharmacotherapy, , Volume: 6, Issue:11, 2005
Losartan-ramipril combination treatment.The Journal of the Association of Physicians of India, , Volume: 52, 2004
Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats.Biochemical and biophysical research communications, , Mar-26, Volume: 316, Issue:1, 2004
The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy.Journal of clinical hypertension (Greenwich, Conn.), , Volume: 6, Issue:8, 2004
Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina).Diabetes, nutrition & metabolism, , Volume: 17, Issue:5, 2004
Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme.Expert opinion on pharmacotherapy, , Volume: 5, Issue:5, 2004
Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).BMJ (Clinical research ed.), , Feb-28, Volume: 328, Issue:7438, 2004
Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study.Diabetes care, , Volume: 26, Issue:3, 2003
Long-term treatment with ramipril attenuates renal osteopontin expression in diabetic rats.Kidney international, , Volume: 63, Issue:2, 2003
More than just hype.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , Jun-24, Volume: 168, Issue:13, 2003
Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease.Archives of biochemistry and biophysics, , Nov-01, Volume: 419, Issue:1, 2003
Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 42, Issue:5, 2003
[Corner points of antihypertensive therapy in prediabetic state. Success with a combination].MMW Fortschritte der Medizin, , Jul-10, Volume: 145, Issue:27-28, 2003
Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty rats.Cardiovascular research, , Nov-01, Volume: 60, Issue:2, 2003
[Dangerous duo: hypertension and pre-diabetes--the underestimated risk].MMW Fortschritte der Medizin, , Jan-23, Volume: 145, Issue:3-4, 2003
[Primary prevention of diabetes mellitus by pharmacological intervention].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 60 Suppl 9, 2002
[Therapy of hypertension with ACE inhibitors. One third fewer cases of diabetes].MMW Fortschritte der Medizin, , Mar-07, Volume: 144, Issue:10, 2002
Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes.The Medical journal of Australia, , Mar-18, Volume: 176, Issue:6, 2002
[ACE inhibitors for diabetic patients. passed the test on the heart and kidneys].MMW Fortschritte der Medizin, , Oct-31, Volume: 144, Issue:44, 2002
HOPE for patients with Type 2 diabetes: an application of the findings of the MICRO-HOPE substudy in a British hospital diabetes clinic.Diabetic medicine : a journal of the British Diabetic Association, , Volume: 18, Issue:8, 2001
[Diabetic nephropathy. Smoking also damages the kidney].MMW Fortschritte der Medizin, , Aug-23, Volume: 143, Issue:33-34, 2001
[Prediction, screening and treatment of renal complications of diabetes].La Revue du praticien, , Oct-15, Volume: 51, Issue:16, 2001
[Type 2 diabetes and cardiovascular risk: lessons from therapeutic trials].La Revue du praticien, , Oct-15, Volume: 51, Issue:16, 2001
ACE inhibitors: new hope for old drugs?South Dakota journal of medicine, , Volume: 53, Issue:8, 2000
HOPE for all people with diabetes? Heart Outcomes Prevention Evaluation.Diabetic medicine : a journal of the British Diabetic Association, , Volume: 17 Suppl 2, 2000
The HOPE study and diabetes. Heart Outcomes Prevention Evaluation.Lancet (London, England), , Apr-01, Volume: 355, Issue:9210, 2000
[Endothelium and endogenous fibrinolysis].Zeitschrift fur Kardiologie, , Volume: 89, Issue:3, 2000
Determinants of elevated urinary albumin in the 4,937 type 2 diabetic subjects recruited for the DIABHYCAR Study in Western Europe and North Africa.Diabetes care, , Volume: 23 Suppl 2, 2000
Effect of ramipril on cardiovascular events in high-risk patients.The New England journal of medicine, , Jul-06, Volume: 343, Issue:1, 2000
The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: design, organization, and patient recruitment. DIABHYCAR Study Group.Controlled clinical trials, , Volume: 21, Issue:4, 2000
Influence of ramipril on the course of plasma thrombomodulin in patients with diabetes mellitus.VASA. Zeitschrift fur Gefasskrankheiten, , Volume: 28, Issue:3, 1999
Beneficial impact of ramipril on left ventricular hypertrophy in normotensive nonalbuminuric NIDDM patients.Diabetes care, , Volume: 22, Issue:1, 1999
Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function.Journal of human hypertension, , Volume: 13, Issue:1, 1999
[Best antihypotensive agents for the treatment of type 2 diabetes. Ramipril, the first choice, in combination with felodipin is a sensible treatment plan].Der Internist, , Volume: 40, Issue:7, 1999
[ACE inhibitor even prevents diabetes. Sensational HOPE Study].MMW Fortschritte der Medizin, , Sep-30, Volume: 141, Issue:39, 1999
[The effect of ramipril on metabolic, renal and cardiac function in hypertension and type II diabetes mellitus].Vnitrni lekarstvi, , Volume: 44, Issue:6, 1998
Impediment of the progressions of microalbuminuria and hyperlipidemia in normotensive type 2 diabetes by low-dose ramipril.Journal of the Medical Association of Thailand = Chotmaihet thangphaet, , Volume: 81, Issue:9, 1998
Beneficial impact of ramipril on left ventricular hypertrophy in normotensive nonalbuminuric NIDDM patients.Diabetes care, , Volume: 21, Issue:5, 1998
Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria.Diabetologia, , Volume: 39, Issue:12, 1996
Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes PrevenDiabetes care, , Volume: 19, Issue:11, 1996
The DIAB-HYCAR Study.Diabetologia, , Volume: 39, Issue:12, 1996
Comparative effects of ramipril and nitrendipine on albuminuria in hypertensive patients with non-insulin-dependent diabetes mellitus and impaired renal function.Journal of human hypertension, , Volume: 9, Issue:2, 1995
Comparison of ramipril and nitrendipine.Journal of human hypertension, , Volume: 9, Issue:11, 1995
Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group.American journal of hypertension, , Volume: 8, Issue:9, 1995
[The nephroprotective effect of ramipril. Effect on blood pressure and metabolic control in insulin-treated patients with type-2 diabetes mellitus].Fortschritte der Medizin, , Jan-30, Volume: 112, Issue:3, 1994
Metabolic effects of ramipril treatment in hypertensive subjects with non-insulin-dependent diabetes mellitus.Arzneimittel-Forschung, , Volume: 40, Issue:4, 1990
[Inappropriate antidiuretic hormone secretion syndrome associated with ramipril treatment].Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, , Volume: 34, Issue:3
Projecting the potential cost-effectiveness of dapagliflozin for chronic kidney disease in Kuwait.Journal of medical economics, , Volume: 26, Issue:1
[Efficacy of complex therapy with metformin and ramipril combination for patients with metabolic syndrome].Likars'ka sprava, , Issue:7-8
[The metabolic effects of isradipine, ramipril, Ednit and beta-adrenoblockers in patients with non-insulin-dependent diabetes mellitus and arterial hypertension].Eksperimental'naia i klinicheskaia farmakologiia, , Volume: 62, Issue:2
Double-blind, placebo-controlled study of ramipril in diabetics with mild to moderate hypertension.Clinical therapeutics, , Volume: 15, Issue:1
[Clinical effectiveness of metformin and ramipril combination in complex therapy of patients with metabolic syndrome].Likars'ka sprava, , Issue:1
The membrane-associated protein 17 (MAP17) is up-regulated in response to empagliflozin on top of RAS blockade in experimental diabetic nephropathy.Clinical science (London, England : 1979), , 01-13, Volume: 137, Issue:1, 2023
Inhibition of Lysine 63 Ubiquitination Prevents the Progression of Renal Fibrosis in Diabetic DBA/2J Mice.International journal of molecular sciences, , May-14, Volume: 22, Issue:10, 2021
A Prospective Single-Blind Randomized Trial of Ramipril, Eplerenone and Their Combination in Type 2 Diabetic Nephropathy.Cardiorenal medicine, , Volume: 10, Issue:6, 2020
RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.The Journal of physiology, , Volume: 597, Issue:1, 2019
Ramipril and resveratrol co-treatment attenuates RhoA/ROCK pathway-regulated early-stage diabetic nephropathy-associated glomerulosclerosis in streptozotocin-induced diabetic rats.Environmental toxicology, , Volume: 34, Issue:7, 2019
Ramipril can alleviate the accumulation of renal mesangial matrix in rats with diabetic nephropathy by inhibiting insulin-like growth factor-1.Acta cirurgica brasileira, , 02-14, Volume: 34, Issue:1, 2019
Combination of ramipril and rutin alleviate alloxan induced diabetic nephropathy targeting multiple stress pathways in vivo.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 108, 2018
The superoxide dismutase mimetic tempol blunts diabetes-induced upregulation of NADPH oxidase and endoplasmic reticulum stress in a rat model of diabetic nephropathy.European journal of pharmacology, , Jul-15, Volume: 807, 2017
Apigenin ameliorates streptozotocin-induced diabetic nephropathy in rats via MAPK-NF-κB-TNF-α and TGF-β1-MAPK-fibronectin pathways.American journal of physiology. Renal physiology, , Aug-01, Volume: 313, Issue:2, 2017
Targeted mitochondrial therapy using MitoQ shows equivalent renoprotection to angiotensin converting enzyme inhibition but no combined synergy in diabetes.Scientific reports, , 11-09, Volume: 7, Issue:1, 2017
Discovery and Preclinical Characterization of 6-Chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1H-indole-3-carboxylic Acid (PF-06409577), a Direct Activator of Adenosine Monophosphate-activated Protein Kinase (AMPK), for the Potential Treatment of Diabetic NephJournal of medicinal chemistry, , 09-08, Volume: 59, Issue:17, 2016
Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy.American journal of nephrology, , Volume: 40, Issue:3, 2014
[The role of ramipril in the therapy of diabetic nephropathy].Orvosi hetilap, , Feb-16, Volume: 155, Issue:7, 2014
Renal antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.American journal of nephrology, , Volume: 37, Issue:1, 2013
Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects.American journal of physiology. Renal physiology, , Mar-15, Volume: 304, Issue:6, 2013
A pilot study on the effect of telmisartan & ramipril on 24 h blood pressure profile & dipping pattern in type 1 diabetes patients with nephropathy.The Indian journal of medical research, , Volume: 134, Issue:5, 2011
Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway?Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 25, Issue:10, 2010
Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters.American journal of physiology. Renal physiology, , Volume: 299, Issue:6, 2010
Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease.Current diabetes reports, , Volume: 10, Issue:4, 2010
Effect of ramipril alone compared to ramipril with eplerenone on diabetic nephropathy in streptozocin-induced diabetic rats.Pharmacology, , Volume: 86, Issue:2, 2010
Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy.Nephrology (Carlton, Vic.), , Volume: 15, Issue:2, 2010
Anti-albuminuric efficacy of a combination of angiotensin converting enzyme inhibitor & angiotensin receptor blocker in type 1 DM with nephropathy.The Indian journal of medical research, , Volume: 132, 2010
Preservation of kidney function with combined inhibition of NADPH oxidase and angiotensin-converting enzyme in diabetic nephropathy.American journal of nephrology, , Volume: 32, Issue:1, 2010
Renal protection in diabetes: lessons from ONTARGET.Cardiovascular diabetology, , Oct-01, Volume: 9, 2010
Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria.Clinical journal of the American Society of Nephrology : CJASN, , Volume: 4, Issue:3, 2009
Inhibition of renin angiotensin system decreases renal protein oxidative damage in diabetic rats.Biochemical and biophysical research communications, , Apr-11, Volume: 368, Issue:3, 2008
Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular events, and Ramipril (DIABHYCAR), Diabete dDiabetes care, , Volume: 31, Issue:10, 2008
Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease.Archives of internal medicine, , Apr-10, Volume: 166, Issue:7, 2006
Urinary TGF-beta1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy.Diabetes research and clinical practice, , Volume: 72, Issue:3, 2006
Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 21, Issue:3, 2006
[Hypertension and diabetic nephropathy, a dangerous duo].Medizinische Klinik (Munich, Germany : 1983), , Nov-15, Volume: 100, Issue:11, 2005
An update of irbesartan and renin-angiotensin system blockade in diabetic nephropathy.Expert opinion on pharmacotherapy, , Volume: 6, Issue:9, 2005
Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition.Diabetologia, , Volume: 48, Issue:8, 2005
Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy.Journal of the American Society of Nephrology : JASN, , Volume: 16, Issue:8, 2005
Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).BMJ (Clinical research ed.), , Feb-28, Volume: 328, Issue:7438, 2004
Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina).Diabetes, nutrition & metabolism, , Volume: 17, Issue:5, 2004
Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study.Journal of the American Society of Nephrology : JASN, , Volume: 14, Issue:3, 2003
Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty rats.Cardiovascular research, , Nov-01, Volume: 60, Issue:2, 2003
Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy.Hypertension (Dallas, Tex. : 1979), , Volume: 41, Issue:3, 2003
Ramipril prevents microtubular changes in proximal tubules from streptozotocin diabetic rats.Nephrology (Carlton, Vic.), , Volume: 8, Issue:4, 2003
Reduced tubular cation transport in diabetes: prevented by ACE inhibition.Kidney international, , Volume: 63, Issue:6, 2003
The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.Clinical nephrology, , Volume: 60, Issue:5, 2003
[Hypertension and prediabetes. "Don't trust anybody over 130/80"].MMW Fortschritte der Medizin, , Mar-27, Volume: 145, Issue:13, 2003
Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products.Journal of human hypertension, , Volume: 17, Issue:4, 2003
Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease.Archives of biochemistry and biophysics, , Nov-01, Volume: 419, Issue:1, 2003
Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.International immunopharmacology, , Volume: 3, Issue:3, 2003
Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 42, Issue:5, 2003
Long-term treatment with ramipril attenuates renal osteopontin expression in diabetic rats.Kidney international, , Volume: 63, Issue:2, 2003
Using ACE inhibitors appropriately.American family physician, , Aug-01, Volume: 66, Issue:3, 2002
Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes.The Medical journal of Australia, , Mar-18, Volume: 176, Issue:6, 2002
Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.The Canadian journal of cardiology, , Volume: 18 Suppl A, 2002
Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy.Diabetes, , Volume: 51, Issue:11, 2002
Diabetes and the HOPE study: implications for macrovascular and microvascular disease.International journal of clinical practice. Supplement, , Issue:117, 2001
Prevention, protection, and the intrarenal renin-angiotensin systems.Seminars in nephrology, , Volume: 21, Issue:6, 2001
[Diabetic nephropathy. Smoking also damages the kidney].MMW Fortschritte der Medizin, , Aug-23, Volume: 143, Issue:33-34, 2001
[Prediction, screening and treatment of renal complications of diabetes].La Revue du praticien, , Oct-15, Volume: 51, Issue:16, 2001
Ramipril and aminoguanidine restore renal lysosomal processing in streptozotocin diabetic rats.Diabetologia, , Volume: 44, Issue:2, 2001
The HOPE study and diabetes. Heart Outcomes Prevention Evaluation.Lancet (London, England), , Apr-01, Volume: 355, Issue:9210, 2000
Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 35, Issue:6, 2000
The HOPE study and diabetes. Heart Outcomes Prevention Evaluation.Lancet (London, England), , Apr-01, Volume: 355, Issue:9210, 2000
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.Lancet (London, England), , Jan-22, Volume: 355, Issue:9200, 2000
HOPE and extension of the indications for ACE inhibitors? Heart Outcomes Prevention Evaluation.Lancet (London, England), , Jan-22, Volume: 355, Issue:9200, 2000
HOPE for all people with diabetes? Heart Outcomes Prevention Evaluation.Diabetic medicine : a journal of the British Diabetic Association, , Volume: 17 Suppl 2, 2000
Influence of ramipril on the course of plasma thrombomodulin in patients with diabetes mellitus.VASA. Zeitschrift fur Gefasskrankheiten, , Volume: 28, Issue:3, 1999
Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 34, Issue:5, 1999
Upregulation of osteopontin expression in renal cortex of streptozotocin-induced diabetic rats is mediated by bradykinin.Diabetes, , Volume: 47, Issue:9, 1998
Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition.Diabetes, , Volume: 47, Issue:3, 1998
[The effectiveness of ramipril in the treatment of diabetic nephropathy in normotensive children and adolescents].Klinicheskaia meditsina, , Volume: 75, Issue:12, 1997
Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies.Diabetes, , Volume: 46, Issue:10, 1997
Stabilization of glomerular filtration rate over 2 years in patients with diabetic nephropathy under intensified therapy regimens. Diabetes Treatment and Teaching Programmes Working Group.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 12, Issue:9, 1997
Short-term treatment with ramipril normalizes renal haemodynamics and the natriuretic response to a sodium load in type 1 diabetic patients with early nephropathy.Acta diabetologica, , Volume: 34, Issue:1, 1997
EUCLID study.Lancet (London, England), , Oct-11, Volume: 350, Issue:9084, 1997
The DIAB-HYCAR Study.Diabetologia, , Volume: 39, Issue:12, 1996
Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria.Diabetologia, , Volume: 39, Issue:12, 1996
Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes PrevenDiabetes care, , Volume: 19, Issue:11, 1996
The study of the effect of intensity of blood pressure management on the progression of type 1 diabetic nephropathy: study design and baseline patient characteristics. Collaborative Study Group.Journal of the American Society of Nephrology : JASN, , Volume: 5, Issue:10, 1995
[The nephroprotective effect of ramipril. Effect on blood pressure and metabolic control in insulin-treated patients with type-2 diabetes mellitus].Fortschritte der Medizin, , Jan-30, Volume: 112, Issue:3, 1994
[Dissociation of hypotensive and renal hemodynamic effects of an angiotensin converting enzyme inhibitor in insulin-dependent diabetic patients with incipient nephropathy].Archives des maladies du coeur et des vaisseaux, , Volume: 84, Issue:3, 1991
Salt blocks the renal benefits of ramipril in diabetic hypertensive rats.Hypertension (Dallas, Tex. : 1979), , Volume: 17, Issue:4, 1991
Small doses of ramipril to reduce microalbuminuria in diabetic patients with incipient nephropathy independently of blood pressure changes.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
ACE-inhibitors and progression of chronic renal insufficiency: a contribution of Italian clinical research.Journal of nephrology, , Volume: 11, Issue:3
Diabetic vascular hypertrophy and albuminuria: effect of angiotensin converting enzyme inhibition.Journal of diabetes and its complications, , Volume: 9, Issue:4
Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency.Journal of nephrology, , Volume: 15, Issue:4
The effect of ramipril therapy on cytokines and parameters of incipient diabetic nephropathy in patients with type 1 diabetes mellitus.The Journal of international medical research, , Volume: 35, Issue:3
A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.Indian journal of pharmacology, , Volume: 47, Issue:2
[Ramipril and new therapeutic possibilities for ACE-inhibitors].La Clinica terapeutica, , Volume: 151, Issue:4
Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE.Diabetes/metabolism research and reviews, , Volume: 18 Suppl 3
[Acute renal insufficiency after flurbiprofen treatment in a patient treated with angiotensin converting enzyme inhibitor].La Revue de medecine interne, , Volume: 29, Issue:7, 2008
The therapeutic effects of angiotensin-converting enzyme inhibitors in severe non-proliferative diabetic retinopathy.Korean journal of ophthalmology : KJO, , Volume: 21, Issue:1, 2007
Role of angiotensin II in retinal leukostasis in the diabetic rat.Experimental eye research, , Volume: 83, Issue:5, 2006
Identification of angiotensin converting enzyme 2 in the rodent retina.Current eye research, , Volume: 29, Issue:6, 2004
Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes.Diabetologia, , Volume: 43, Issue:11, 2000
[Ramipril and new therapeutic possibilities for ACE-inhibitors].La Clinica terapeutica, , Volume: 151, Issue:4
Diarrhea, nephrotic syndrome and hidradenitis suppurativa: an unusual case.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 18, Issue:1, 2003
Angiotensin-converting enzyme inhibitors and diarrhea.Journal of clinical gastroenterology, , Volume: 35, Issue:1, 2002
Basophil activation test, skin prick test, and anaphylaxis after drug hypersensitivity.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, , Volume: 116, Issue:5, 2016
[Successful use of C1 esterase inhibitor in capillary leak syndrome].Der Anaesthesist, , Volume: 61, Issue:11, 2012
Lichenoid and granulomatous stomatitis: an entity or a non-specific inflammatory process?Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, , Volume: 35, Issue:5, 2006
Ramipril-induced drug reaction with eosinophilia and systemic symptoms (DRESS).European journal of dermatology : EJD, , Volume: 21, Issue:4
Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.Diabetes care, , Volume: 33, Issue:10, 2010
An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.Clinical therapeutics, , Volume: 30, Issue:9, 2008
Minimal change disease in association with fire coral (Millepora species) exposure.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 47, Issue:1, 2006
Differential effects of saralasin and ramiprilat, the inhibitors of renin-angiotensin system, on cerulein-induced acute pancreatitis.Regulatory peptides, , Mar-28, Volume: 111, Issue:1-3, 2003
Chronic kinin blockade and effect of ramipril in renal adaptation to sodium restriction.Hypertension (Dallas, Tex. : 1979), , Volume: 27, Issue:1, 1996
Replacement of salt by a novel potassium- and magnesium-enriched salt alternative improves the cardiovascular effects of ramipril.British journal of pharmacology, , Volume: 111, Issue:4, 1994
Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
A study of the acute pharmacodynamic interaction of ramipril and felodipine in normotensive subjects.British journal of clinical pharmacology, , Volume: 31, Issue:2, 1991
Frusemide, ACE inhibition, renal dopamine and prostaglandins: acute interactions in normal man.British journal of clinical pharmacology, , Volume: 28, Issue:6, 1989
Acute and chronic effects of ramipril and captopril in congestive heart failure.International journal of cardiology, , Volume: 23, Issue:1, 1989
Global and regional hemodynamic effects of ramipril in congestive heart failure.Journal of cardiovascular pharmacology, , Volume: 14, Issue:5, 1989
Loop diuretics combined with an ACE inhibitor for treatment of hypertension: a study with furosemide, piretanide, and ramipril in spontaneously hypertensive rats.Journal of cardiovascular pharmacology, , Volume: 13 Suppl 3, 1989
Physical performance during sustained converting enzyme inhibition with Hoe 498 in conscious dogs.Archives internationales de pharmacodynamie et de therapie, , Volume: 278, Issue:2, 1985
Effects of ramipril therapy on some components of insulin resistance syndrome in patients with essential hypertension.Medicinski pregled, , Volume: 55, Issue:7-8
[Fasciitis with eosinophilia: a possible causal role of angiotensin converting enzyme inhibitor].Revue neurologique, , Volume: 163, Issue:2, 2007
Angiotensin-converting enzyme inhibitors and diarrhea.Journal of clinical gastroenterology, , Volume: 35, Issue:1, 2002
Ramipril-induced drug reaction with eosinophilia and systemic symptoms (DRESS).European journal of dermatology : EJD, , Volume: 21, Issue:4
Basophil activation test, skin prick test, and anaphylaxis after drug hypersensitivity.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, , Volume: 116, Issue:5, 2016
Different proinflammatory profile of three ACE inhibitors: cilazapril, enalaprilat, and ramiprilat.The American journal of medicine, , Apr-23, Volume: 94, Issue:4A, 1993
Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3-/- Mice.Journal of the American Society of Nephrology : JASN, , 09-01, Volume: 34, Issue:9, 2023
Effect of pharmacological heart failure drugs and gene therapy on Danon's cardiomyopathy.Biochemical pharmacology, , Volume: 215, 2023
QGC606: A Best-in-Class Orally Active Centrally Acting Aminopeptidase A Inhibitor Prodrug for Treating Heart Failure Following Myocardial Infarction.The Canadian journal of cardiology, , Volume: 38, Issue:6, 2022
Angiotensin-Converting Enzyme Inhibitor Reduces Radiation-Induced Periprosthetic Capsular Fibrosis.The Journal of surgical research, , Volume: 263, 2021
Inhibition of Lysine 63 Ubiquitination Prevents the Progression of Renal Fibrosis in Diabetic DBA/2J Mice.International journal of molecular sciences, , May-14, Volume: 22, Issue:10, 2021
Randomised controlled trial into the role of ramipril in fibrosis reduction in rheumatic heart disease: the RamiRHeD trial protocol.BMJ open, , 09-13, Volume: 11, Issue:9, 2021
RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.The Journal of physiology, , Volume: 597, Issue:1, 2019
Low-dose hydralazine prevents fibrosis in a murine model of acute kidney injury-to-chronic kidney disease progression.Kidney international, , Volume: 91, Issue:1, 2017
The superoxide dismutase mimetic tempol blunts diabetes-induced upregulation of NADPH oxidase and endoplasmic reticulum stress in a rat model of diabetic nephropathy.European journal of pharmacology, , Jul-15, Volume: 807, 2017
Apigenin ameliorates streptozotocin-induced diabetic nephropathy in rats via MAPK-NF-κB-TNF-α and TGF-β1-MAPK-fibronectin pathways.American journal of physiology. Renal physiology, , Aug-01, Volume: 313, Issue:2, 2017
Ramipril attenuates left ventricular remodeling by regulating the expression of activin A-follistatin in a rat model of heart failure.Scientific reports, , 09-19, Volume: 6, 2016
MicroRNAs mediate the cardioprotective effect of angiotensin-converting enzyme inhibition in acute kidney injury.American journal of physiology. Renal physiology, , Dec-01, Volume: 309, Issue:11, 2015
Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.Basic research in cardiology, , Volume: 109, Issue:4, 2014
Antifibrotic, nephroprotective effects of paricalcitol versus calcitriol on top of ACE-inhibitor therapy in the COL4A3 knockout mouse model for progressive renal fibrosis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 29, Issue:5, 2014
Ramipril and telmisartan exhibit differential effects in cardiac pressure overload-induced hypertrophy without an additional benefit of the combination of both drugs.Journal of cardiovascular pharmacology and therapeutics, , Volume: 18, Issue:1, 2013
A comparison between imidapril and ramipril on attenuation of ventricular remodeling after myocardial infarction.Journal of cardiovascular pharmacology, , Volume: 59, Issue:4, 2012
Ramipril attenuates lipid peroxidation and cardiac fibrosis in an experimental model of rheumatoid arthritis.Arthritis research & therapy, , Oct-18, Volume: 14, Issue:5, 2012
Impact of nephron number dosing on cardiorenal damage and effects of ACE inhibition.American journal of hypertension, , Volume: 24, Issue:4, 2011
The cardiac renin-angiotensin system is responsible for high-salt diet-induced left ventricular hypertrophy in mice.European journal of heart failure, , Volume: 12, Issue:11, 2010
Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.Clinical science (London, England : 1979), , Oct-26, Volume: 118, Issue:3, 2009
Hypertension-mediated albuminuria is associated with reduced lysosomal activity in the kidney and the heart.American journal of nephrology, , Volume: 29, Issue:5, 2009
Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction.American journal of physiology. Heart and circulatory physiology, , Volume: 294, Issue:4, 2008
Chronic endothelin-A receptor antagonism is as protective as angiotensin converting enzyme inhibition against cardiac dysfunction in diabetic rats.British journal of pharmacology, , Volume: 151, Issue:8, 2007
Vasopeptidase inhibition prevents target organ damage and improves survival in spontaneously hypertensive rats.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 7, Issue:3, 2006
The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension.Journal of hypertension, , Volume: 24, Issue:7, 2006
High glucose increases extracellular matrix production in pancreatic stellate cells by activating the renin-angiotensin system.Journal of cellular biochemistry, , May-15, Volume: 98, Issue:2, 2006
Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 19, Issue:7, 2004
Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats.Biochemical and biophysical research communications, , Mar-26, Volume: 316, Issue:1, 2004
Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome.Kidney international, , Volume: 63, Issue:2, 2003
Raised blood pressure, not renin-angiotensin systems, causes cardiac fibrosis in TGR m(Ren2)27 rats.Cardiovascular research, , Volume: 47, Issue:1, 2000
Effect of long-term ACE inhibition on myocardial tissue in hypertensive stroke-prone rats.Journal of molecular and cellular cardiology, , Volume: 31, Issue:8, 1999
Postinfarction survival and inducibility of ventricular arrhythmias in the spontaneously hypertensive rat : effects of ramipril and hydralazine.Circulation, , Nov-10, Volume: 98, Issue:19, 1998
Extracellular matrix deposition in hypertensive hearts antifibrotic effects of ramipril.European heart journal, , Volume: 16 Suppl C, 1995
Myocardial interstitial fibrosis in experimental uremia--implications for cardiac compliance.Kidney international, , Volume: 33, Issue:4, 1988
The effect of ramipril on left ventricular mass, myocardial fibrosis, diastolic function, and plasma neurohormones in Maine Coon cats with familial hypertrophic cardiomyopathy without heart failure.Journal of veterinary internal medicine, , Volume: 20, Issue:5
Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis.Molecular and cellular biochemistry, , Volume: 147, Issue:1-2
Comparison of higher dose of losartan treatment with losartan plus carvedilol and losartan plus ramipril in patients with glomerulonephritis and proteinuria.Renal failure, , Volume: 29, Issue:2, 2007
Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products.Journal of human hypertension, , Volume: 17, Issue:4, 2003
Maximal suppression of renin-angiotensin system in nonproliferative glomerulonephritis.Kidney international, , Volume: 63, Issue:6, 2003
Acute and long-term effects of ACE inhibition on renal haemodynamics in glomerular and interstitial nephropathies.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 3, Issue:1, 2002
[Renal hemodynamics and proteinuria in chronic glomerulonephritis treated with beta-receptor blockers or ace inhibitors].Deutsche medizinische Wochenschrift (1946), , Aug-01, Volume: 122, Issue:31-32, 1997
A comparison of the effect of ramipril, felodipine and placebo on glomerular filtration rate, albuminuria, blood pressure and vasoactive hormones in chronic glomerulonephritis. A randomized, prospective, double-blind, placebo-controlled study over two yeaScandinavian journal of clinical and laboratory investigation, , Volume: 57, Issue:8, 1997
Angiotensin-converting enzyme inhibition in experimental in-situ immune complex glomerulonephritis: influence on renal function, proteinuria, and morphology.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 11, Issue:1, 1996
Randomized controlled trial of ACE-inhibitors and beta-blockers with and without vasodilating activity in chronic glomerulonephritis.International journal of clinical pharmacology and therapeutics, , Volume: 34, Issue:11, 1996
Treatment of idiopathic glomerulonephritis in the elderly. Personal data.Contributions to nephrology, , Volume: 105, 1993
[Effect of the angiotensin-converting enzyme inhibitor ramipril on proteinuria, blood pressure and kidney function in histologically confirmed glomerulonephritis with nephrotic syndrome].Zeitschrift fur Kardiologie, , Volume: 77 Suppl 3, 1988
Successful Use of Aliskiren in a Case of IgA- Mesangial Glomerulonephritis Unresponsive to Conventional Therapies.Reviews on recent clinical trials, , Volume: 14, Issue:1, 2019
Treatment of early immunoglobulin A nephropathy by angiotensin-converting enzyme inhibitor.The American journal of medicine, , Volume: 126, Issue:2, 2013
Glomerular disease: ACEIs with or without corticosteroids in IgA nephropathy?Nature reviews. Nephrology, , Volume: 6, Issue:5, 2010
Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 24, Issue:12, 2009
Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 24, Issue:1, 2009
Can young adult patients with proteinuric IgA nephropathy perform physical exercise?American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 44, Issue:2, 2004
The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.Clinical nephrology, , Volume: 60, Issue:5, 2003
ACE inhibitors and angiotensin II receptor blockers in IgA nephropathy with mild proteinuria: the ACEARB study.Journal of nephrology, , Volume: 19, Issue:4
Prospective randomized controlled multicenter trial on steroids plus ramipril in proteinuric IgA nephropathy.Journal of nephrology, , Volume: 14, Issue:4
Ramipril and resveratrol co-treatment attenuates RhoA/ROCK pathway-regulated early-stage diabetic nephropathy-associated glomerulosclerosis in streptozotocin-induced diabetic rats.Environmental toxicology, , Volume: 34, Issue:7, 2019
Marfan syndrome and focal segmental glomerulosclerosis: a novel association.Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, , Volume: 21, Issue:4, 2010
Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation.Transplant international : official journal of the European Society for Organ Transplantation, , Volume: 22, Issue:11, 2009
Collapsing glomerulopathy coexisting with membranous glomerulonephritis in native kidney biopsies: a report of 3 HIV-negative patients.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 42, Issue:3, 2003
Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V).The Cochrane database of systematic reviews, , Nov-12, Issue:11, 2014
Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle's disease.Muscle & nerve, , Volume: 37, Issue:3, 2008
[Evaluation of efficacy and safety of hypertension treatment with original angiotensin-converting enzyme inhibitors: the comparison of original and generic formulations].Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, , Volume: 34, Issue:201, 2013
Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.Journal of clinical pharmacology, , Volume: 48, Issue:1, 2008
Comparison of the Efficacy and Safety of Sacubitril/Valsartan versus Ramipril in Patients With ST-Segment Elevation Myocardial Infarction.The American journal of cardiology, , 03-15, Volume: 143, 2021
Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study.Circulation, , Jul-18, Volume: 114, Issue:3, 2006
Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme.Expert opinion on pharmacotherapy, , Volume: 5, Issue:5, 2004
Extended follow-up of patients randomly assigned in the Angiotensin-converting enzyme inhibition Post-Revascularization Study (APRES).American heart journal, , Volume: 148, Issue:3, 2004
Combine EUROPA and HOPE.Lancet (London, England), , Dec-06, Volume: 362, Issue:9399, 2003
Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study.Circulation, , Feb-25, Volume: 107, Issue:7, 2003
Why were the results of the Heart Outcomes Prevention Evaluation (HOPE) trial so astounding?The Canadian journal of cardiology, , Volume: 17 Suppl A, 2001
Should you take an ACE inhibitor?The Johns Hopkins medical letter health after 50, , Volume: 12, Issue:1, 2000
Incidence and natural history of left ventricular thrombus following anterior wall acute myocardial infarction.The American journal of cardiology, , Aug-15, Volume: 80, Issue:4, 1997
Effects of ACE inhibitor therapy on quality of life in patients with heart failure.Pharmacotherapy, , Volume: 18, Issue:6
Effect of pharmacological heart failure drugs and gene therapy on Danon's cardiomyopathy.Biochemical pharmacology, , Volume: 215, 2023
Adverse cardiac effects of exogenous angiotensin 1-7 in rats with subtotal nephrectomy are prevented by ACE inhibition.PloS one, , Volume: 12, Issue:2, 2017
MicroRNAs mediate the cardioprotective effect of angiotensin-converting enzyme inhibition in acute kidney injury.American journal of physiology. Renal physiology, , Dec-01, Volume: 309, Issue:11, 2015
Ramipril and telmisartan exhibit differential effects in cardiac pressure overload-induced hypertrophy without an additional benefit of the combination of both drugs.Journal of cardiovascular pharmacology and therapeutics, , Volume: 18, Issue:1, 2013
Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes.Diabetologia, , Volume: 55, Issue:5, 2012
Angiotensin-(1-7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy.Clinical science (London, England : 1979), , Volume: 120, Issue:8, 2011
Hypertension augments cardiac Toll-like receptor 4 expression and activity.Hypertension research : official journal of the Japanese Society of Hypertension, , Volume: 34, Issue:5, 2011
Hypertension-mediated albuminuria is associated with reduced lysosomal activity in the kidney and the heart.American journal of nephrology, , Volume: 29, Issue:5, 2009
Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction.American journal of physiology. Heart and circulatory physiology, , Volume: 294, Issue:4, 2008
[Involvement of angiotensin II in pathogenesis of hypertension and target organ damage].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 62 Suppl 3, 2004
Acute antihypertrophic actions of bradykinin in the rat heart: importance of cyclic GMP.Hypertension (Dallas, Tex. : 1979), , Volume: 40, Issue:4, 2002
Inhibition of angiotensin-converting enzyme reduces susceptibility of hypertrophied rat myocardium to ventricular fibrillation.Circulation journal : official journal of the Japanese Circulation Society, , Volume: 66, Issue:11, 2002
Low-dose ramipril treatment improves relaxation and calcium cycling after established cardiac hypertrophy.American journal of physiology. Heart and circulatory physiology, , Volume: 280, Issue:3, 2001
Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study.Annals of internal medicine, , Mar-20, Volume: 134, Issue:6, 2001
Effects of ACE inhibition and bradykinin antagonism on cardiovascular changes in uremic rats.Kidney international, , Volume: 58, Issue:1, 2000
Combined treatment with ramipril and metoprolol prevents changes in the creatine kinase isoenzyme system and improves hemodynamic function in rat hearts after myocardial infarction.Cardiovascular drugs and therapy, , Volume: 14, Issue:6, 2000
Interaction between the renin-angiotensin system and insulin-like growth factor I in aorto-caval fistula-induced cardiac hypertrophy in rats.Acta physiologica Scandinavica, , Volume: 165, Issue:2, 1999
Late treatment with ramipril increases survival in old spontaneously hypertensive rats.Hypertension (Dallas, Tex. : 1979), , Volume: 34, Issue:2, 1999
The effect of non-antihypertensive doses of angiotensin converting enzyme inhibitor on myocardial necrosis and hypertrophy in young rats with renovascular hypertension.International journal of experimental pathology, , Volume: 80, Issue:2, 1999
Effects of endothelin receptor antagonism and angiotensin-converting enzyme inhibition on cardiac and renal remodeling in the rat.Journal of cardiovascular pharmacology, , Volume: 31 Suppl 1, 1998
Sub-antihypertensive doses of ramipril normalize sarcoplasmic reticulum calcium ATPase expression and function following cardiac hypertrophy in rats.Journal of molecular and cellular cardiology, , Volume: 30, Issue:12, 1998
Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade.American journal of hypertension, , Volume: 9, Issue:9, 1996
Ramipril prevents the detrimental sequels of chronic NO synthase inhibition in rats: hypertension, cardiac hypertrophy and renal insufficiency.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 350, Issue:6, 1994
Role of kinins and nitric oxide in the antihypertrophic effect of ramipril.Hypertension (Dallas, Tex. : 1979), , Volume: 23, Issue:6 Pt 2, 1994
Role of angiotensin in pressure overload-induced hypertrophy in rats: effects of angiotensin-converting enzyme inhibitors, an AT1 receptor antagonist, and surgical reversal.Journal of cardiovascular pharmacology, , Volume: 23, Issue:2, 1994
A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril.British journal of pharmacology, , Volume: 105, Issue:4, 1992
Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats.British journal of pharmacology, , Volume: 107, Issue:4, 1992
Development and modulation of experimental right ventricular hypertrophy in rats.Journal of cardiovascular pharmacology, , Volume: 20 Suppl 1, 1992
Effect of angiotensin converting enzyme inhibition on pressure-induced left ventricular hypertrophy in rats.Circulation research, , Volume: 69, Issue:3, 1991
Role of angiotensin II receptor antagonism and converting enzyme inhibition in the progression and regression of cardiac hypertrophy in rats.Journal of hypertension. Supplement : official journal of the International Society of Hypertension, , Volume: 9, Issue:6, 1991
Influence of ramipril on right ventricular hypertrophy induced by pulmonary artery stenosis in rats.Journal of cardiovascular pharmacology, , Volume: 16, Issue:3, 1990
Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats.Clinical and experimental hypertension. Part A, Theory and practice, , Volume: 11, Issue:7, 1989
The renin-angiotensin system and ramipril, a new converting enzyme inhibitor.Journal of cardiovascular pharmacology, , Volume: 14 Suppl 4, 1989
Regression of left ventricular hypertrophy under ramipril treatment investigated by nuclear magnetic resonance imaging.Journal of cardiovascular pharmacology, , Volume: 13 Suppl 3, 1989
[Pharmacologic modification of the converting enzyme--local and systemic effects on the heart and blood vessels].Zeitschrift fur Kardiologie, , Volume: 77 Suppl 3, 1988
Use of nuclear magnetic resonance imaging to show regression of hypertrophy with ramipril treatment.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Effect of chronic high- and low-dose ACE inhibitor treatment on cardiac and vascular hypertrophy and vascular function in spontaneously hypertensive rats.Experimental nephrology, , Volume: 2, Issue:2
Modulation of hemodynamics, endogenous antioxidant enzymes, and pathophysiological changes by Angiotensin-converting enzyme inhibitors in pressure-overload rats.Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese, , Volume: 52, Issue:3
Effect of pharmacological heart failure drugs and gene therapy on Danon's cardiomyopathy.Biochemical pharmacology, , Volume: 215, 2023
Comparative Efficacy of Levosimendan, Ramipril, and Sacubitril/ Valsartan in Isoproterenol-induced Experimental Heart Failure: A Hemodynamic and Molecular Approach.Current molecular pharmacology, , Volume: 16, Issue:6, 2023
Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial.Circulation, , 01-04, Volume: 145, Issue:1, 2022
QGC606: A Best-in-Class Orally Active Centrally Acting Aminopeptidase A Inhibitor Prodrug for Treating Heart Failure Following Myocardial Infarction.The Canadian journal of cardiology, , Volume: 38, Issue:6, 2022
Angiotensin Receptor-Neprilysin Inhibitor in Acute Myocardial Infarction.The Journal of the Association of Physicians of India, , Volume: 70, Issue:4, 2022
Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial.European journal of heart failure, , Volume: 24, Issue:10, 2022
The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial.Circulation, , 12-06, Volume: 146, Issue:23, 2022
Angiotensin-converting enzyme inhibitors, angiotensin-II-receptor antagonists and angiotensin-receptor blocker/neprilysin inhibitor utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic.Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, , Volume: 166, Issue:3, 2022
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.The New England journal of medicine, , 11-11, Volume: 385, Issue:20, 2021
Comparison of the Efficacy and Safety of Sacubitril/Valsartan versus Ramipril in Patients With ST-Segment Elevation Myocardial Infarction.The American journal of cardiology, , 03-15, Volume: 143, 2021
Long-term survival benefit of ramipril in patients with acute myocardial infarction complicated by heart failure.Heart (British Cardiac Society), , Volume: 107, Issue:5, 2021
Efficacy of Sacubitril-Valsartan in Patients With Reduced Left Ventricular Ejection Fraction.The American journal of cardiology, , 08-15, Volume: 153, 2021
Impact of the COVID-19 pandemic on the management of chronic heart failure.Reviews in cardiovascular medicine, , 06-30, Volume: 22, Issue:2, 2021
Long-term clinical outcomes with use of an angiotensin-converting enzyme inhibitor early after heart transplantation.American heart journal, , Volume: 222, 2020
Impact of different angiotensin-converting inhibitors on outcomes of post-myocardial infarction patients.Wiadomosci lekarskie (Warsaw, Poland : 1960), , Volume: 73, Issue:3, 2020
Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial.Journal of veterinary internal medicine, , Volume: 34, Issue:6, 2020
Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure.BMC pharmacology & toxicology, , 05-03, Volume: 20, Issue:1, 2019
Expectoration of bronchial casts in association with Ramipril treatment.Cardiology in the young, , Volume: 29, Issue:12, 2019
Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk.European heart journal, , 07-01, Volume: 40, Issue:25, 2019
Angioedema Two Weeks After the Initial Administration of an ACE Inhibitor.Deutsches Arzteblatt international, , 03-02, Volume: 115, Issue:9, 2018
Efficacy and Safety of Zofenopril Versus Ramipril in the Treatment of Myocardial Infarction and Heart Failure: A Review of the Published and Unpublished Data of the Randomized Double-Blind SMILE-4 Study.Advances in therapy, , Volume: 35, Issue:5, 2018
Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.European heart journal, , 09-01, Volume: 39, Issue:33, 2018
Comparative effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: a propensity score-matched cohort study.European heart journal. Cardiovascular pharmacotherapy, , 04-01, Volume: 4, Issue:2, 2018
Ramipril attenuates left ventricular remodeling by regulating the expression of activin A-follistatin in a rat model of heart failure.Scientific reports, , 09-19, Volume: 6, 2016
Ramipril and Losartan Exert a Similar Long-Term Effect upon Markers of Heart Failure, Endogenous Fibrinolysis, and Platelet Aggregation in Survivors of ST-Elevation Myocardial Infarction: A Single Centre Randomized Trial.BioMed research international, , Volume: 2016, 2016
Angiotensin converting enzyme inhibitors for heart failure with reduced ejection fraction or left ventricular dysfunction: A complementary network meta-analyses.International journal of cardiology, , Jul-01, Volume: 214, 2016
Risk of renal dysfunction in an elderly patient with chronic heart failure.Medizinische Monatsschrift fur Pharmazeuten, , Volume: 39, Issue:10, 2016
Takotsubo-like syndrome triggered by fludrocortisone overdose for Addison's disease: a case report.Journal of medical case reports, , Oct-12, Volume: 10, Issue:1, 2016
A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors.British journal of clinical pharmacology, , Volume: 80, Issue:4, 2015
The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.European journal of preventive cardiology, , Volume: 21, Issue:3, 2014
Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.Basic research in cardiology, , Volume: 109, Issue:4, 2014
Effect of zofenopril and ramipril on cardiovascular mortality in patients with chronic heart failure.The American journal of cardiology, , Jul-01, Volume: 112, Issue:1, 2013
Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril.Postgraduate medicine, , Volume: 125, Issue:4, 2013
Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European studClinical cardiology, , Volume: 35, Issue:7, 2012
The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study.Journal of medical economics, , Volume: 14, Issue:6, 2011
Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.Circulation, , Mar-15, Volume: 123, Issue:10, 2011
Telmisartan for the management of patients at high cardiovascular risk.Current medical research and opinion, , Volume: 27, Issue:8, 2011
Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.Chinese medical journal, , Volume: 124, Issue:12, 2011
Impact of ACE inhibitors on mortality and morbidity in patients with AMI: Does tissue selectivity matter?Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 14, Issue:1, 2011
New data on ONTARGET: more confusion?Journal of clinical hypertension (Greenwich, Conn.), , Volume: 12, Issue:3, 2010
The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial.Journal of cardiovascular electrophysiology, , Volume: 20, Issue:7, 2009
[Renal effect of treatment for heart failure].Ugeskrift for laeger, , Feb-23, Volume: 171, Issue:9, 2009
The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats.Acta pharmacologica Sinica, , Volume: 30, Issue:7, 2009
[A 60-year-old man with heart failure, dry cough and elevated INR values].Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, , Aug-14, Volume: 128, Issue:15, 2008
[The use of angiotensin converting enzyme inhibitors in patients after myocardial infarction].Kardiologiia, , Volume: 48, Issue:11, 2008
Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , May-06, Volume: 178, Issue:10, 2008
Comparative effectiveness of angiotensin-converting-enzyme inhibitors: is an ACE always an ace?CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , May-06, Volume: 178, Issue:10, 2008
Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk.Circulation, , Mar-20, Volume: 115, Issue:11, 2007
Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure.European journal of heart failure, , Volume: 9, Issue:11, 2007
Left ventricular eccentric remodeling and matrix loss are mediated by bradykinin and precede cardiomyocyte elongation in rats with volume overload.Journal of the American College of Cardiology, , Feb-20, Volume: 49, Issue:7, 2007
Estimating the cost effectiveness of ramipril used for specific clinical indications: comparing the outcomes in four clinical trials with a common economic model.American journal of cardiovascular drugs : drugs, devices, and other interventions, , Volume: 7, Issue:6, 2007
Lipid peroxidation is not increased in heart failure patients on modern pharmacological therapy.International journal of cardiology, , Oct-10, Volume: 112, Issue:3, 2006
Effects of ramipril on renal function during progressive overpacing-induced heart failure in dogs.American journal of veterinary research, , Volume: 67, Issue:7, 2006
Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease.The Journal of small animal practice, , Volume: 46, Issue:3, 2005
Combined effects of ramipril and angiotensin II receptor blocker TCV116 on rat congestive heart failure after myocardial infarction.Chinese medical journal, , Jan-20, Volume: 118, Issue:2, 2005
Comparison of angiotensin-converting enzyme inhibitors in the treatment of congestive heart failure.The American journal of cardiology, , Jan-15, Volume: 95, Issue:2, 2005
Inhibition of angiotensin-converting enzyme and phosphodiesterase type 5 improves endothelial function in heart failure.Clinical science (London, England : 1979), , Volume: 108, Issue:4, 2005
Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.European journal of heart failure, , Volume: 7, Issue:5, 2005
The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences.Scandinavian journal of clinical and laboratory investigation. Supplementum, , Volume: 240, 2005
[A patient with severe hyperkalaemia -- an emergency after RALES].Deutsche medizinische Wochenschrift (1946), , Sep-09, Volume: 130, Issue:36, 2005
Ramipril in the treatment of vascular diseases.Expert opinion on pharmacotherapy, , Volume: 6, Issue:11, 2005
Effects of combined inhibition of the Na+-H+ exchanger and angiotensin-converting enzyme in rats with congestive heart failure after myocardial infarction.British journal of pharmacology, , Volume: 146, Issue:5, 2005
[Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].Italian heart journal : official journal of the Italian Federation of Cardiology, , Volume: 6 Suppl 7, 2005
[ACE inhibitor therapy until end of life?].Deutsche medizinische Wochenschrift (1946), , Oct-29, Volume: 129, Issue:44, 2004
Extended follow-up of patients randomly assigned in the Angiotensin-converting enzyme inhibition Post-Revascularization Study (APRES).American heart journal, , Volume: 148, Issue:3, 2004
Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure.Journal of cardiac failure, , Volume: 10, Issue:1, 2004
Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study.Circulation, , Mar-11, Volume: 107, Issue:9, 2003
Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study.Diabetes care, , Volume: 26, Issue:3, 2003
Ramipril improves nitric oxide availability in hypertensive rats with failing hearts after myocardial infarction.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 4, Issue:3, 2003
[Therapy of hypertension. Lasting organ protection moves into the foreground].MMW Fortschritte der Medizin, , Nov-20, Volume: 145, Issue:47, 2003
[New possibilities in clinical use of angiotensin II receptor inhibitors].Orvosi hetilap, , Dec-07, Volume: 144, Issue:49, 2003
[Added organ protection at little cost. Double savings with ACE inhibitors].MMW Fortschritte der Medizin, , Nov-27, Volume: 145, Issue:48, 2003
Aspirin alters arterial function in patients with chronic heart failure treated with ACE inhibitors: a dose-mediated deleterious effect.European journal of heart failure, , Volume: 5, Issue:3, 2003
Effects of diuretic treatment on cardiac and circulating RAS in chronic heart failure post-myocardial infarction in rats.European journal of heart failure, , Volume: 5, Issue:3, 2003
Aldosterone receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure.Cardiovascular research, , Jun-01, Volume: 58, Issue:3, 2003
[Chronopharmacological approaches to the therapeutic prophylaxis of chronic cardiac insufficiency in type I diabetes mellitus].Vestnik Rossiiskoi akademii meditsinskikh nauk, , Issue:4, 2003
Economic impact of ramipril on hospitalization of high-risk cardiovascular patients.The Annals of pharmacotherapy, , Volume: 37, Issue:3, 2003
"Preemptive strike" heart medications. A.C.E. inhibitors gain new ground as multi-purpose cardiac drugs.Heart advisor, , Volume: 5, Issue:2, 2002
Effect of ramipril and furosemide treatment on interstitial remodeling in post-infarction heart failure rat hearts.Journal of molecular and cellular cardiology, , Volume: 34, Issue:2, 2002
Using ACE inhibitors appropriately.American family physician, , Aug-01, Volume: 66, Issue:3, 2002
Cost-effectiveness of the treatment of heart failure with ramipril: a Spanish analysis of the AIRE study.European journal of heart failure, , Volume: 4, Issue:4, 2002
Haemorheological and endothelial-dependent alterations in heart failure after ACE inhibitor, calcium antagonist and beta blocker.Clinical hemorheology and microcirculation, , Volume: 27, Issue:3-4, 2002
Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B(2) kinin receptor gene knockout mice.Circulation research, , May-25, Volume: 88, Issue:10, 2001
Management of asymptomatic left ventricular dysfunction.Cleveland Clinic journal of medicine, , Volume: 68, Issue:3, 2001
What are 'tissue ACE inhibitors,' and should they be used instead of other ACE inhibitors?Cleveland Clinic journal of medicine, , Volume: 68, Issue:3, 2001
[Effects of angiotensin-converting enzyme inhibitors and cosaar on quality of life of patients with pulmonary tuberculosis and chronic heart failure].Problemy tuberkuleza, , Issue:8, 2001
Simvastatin reverses impaired regulation of renal oxygen consumption in congestive heart failure.American journal of physiology. Renal physiology, , Volume: 281, Issue:5, 2001
[Activity of the renin-angiotensin-aldosterone system and its impact on the effectiveness of treatment of chronic heart failure in patients with pulmonary tuberculosis].Problemy tuberkuleza, , Issue:5, 2001
Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril.Circulation, , Oct-02, Volume: 104, Issue:14, 2001
Modulation of renal oxygen consumption by nitric oxide is impaired after development of congestive heart failure in dogs.Journal of cardiovascular pharmacology, , Volume: 37, Issue:3, 2001
The HOPE study: comparison with other trials of secondary prevention.European heart journal, , Volume: 22, Issue:15, 2001
Beneficial effects of ramipril on left ventricular end-diastolic and end-systolic volume indexes after uncomplicated invasive revascularization are associated with a reduction in cardiac events in patients with moderately impaired left ventricular functioJournal of the American College of Cardiology, , Volume: 37, Issue:5, 2001
[Results of the RALES trial: good news for patients with heart failure and ... for health administrations].Medicina clinica, , Apr-15, Volume: 114, Issue:14, 2000
Effects of ACE inhibitor, AT1 antagonist, and combined treatment in mice with heart failure.Journal of cardiovascular pharmacology, , Volume: 36, Issue:4, 2000
Management of heart failure.Current cardiology reports, , Volume: 2, Issue:3, 2000
The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES).Journal of the American College of Cardiology, , Mar-15, Volume: 35, Issue:4, 2000
Epidemiology and pathophysiology of heart failure.Current cardiology reports, , Volume: 2, Issue:3, 2000
ACE inhibitor dosage at the time of listing predicts survival.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, , Volume: 19, Issue:2, 2000
Ramipril.International journal of clinical practice, , Volume: 54, Issue:4, 2000
Effect of angiotensin-converting enzyme inhibition on protein kinase C and SR proteins in heart failure.The American journal of physiology, , Volume: 276, Issue:1, 1999
[Ramipril treatment of heart failure in disseminated forms of pulmonary tuberculosis].Problemy tuberkuleza, , Issue:2, 1999
Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure.The Journal of pharmacology and experimental therapeutics, , Volume: 288, Issue:2, 1999
Ramipril reduces QT dispersion in patients with acute myocardial infarction and heart failure.The American journal of cardiology, , Mar-15, Volume: 83, Issue:6, 1999
Synergy of amlodipine and angiotensin-converting enzyme inhibitors in regulating myocardial oxygen consumption in normal canine and failing human hearts.The American journal of cardiology, , Jun-17, Volume: 83, Issue:12A, 1999
beta blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: evidence from the AIRE study.Heart (British Cardiac Society), , Volume: 81, Issue:1, 1999
Angiotensin inhibition and atrial natriuretic peptide release after acute volume expansion in rats with aortocaval shunt.Cardiovascular research, , Volume: 42, Issue:3, 1999
ACE inhibition improves cardiac NE uptake and attenuates sympathetic nerve terminal abnormalities in heart failure.The American journal of physiology, , Volume: 277, Issue:4, 1999
Treatment with ramipril improves systolic function even in patients with mild systolic dysfunction and symptoms of heart failure after acute myocardial infarction.Clinical cardiology, , Volume: 21, Issue:11, 1998
Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance.PharmacoEconomics, , Volume: 14, Issue:6, 1998
Effects of chronic AVP V2R blockade in congestive heart failure in sheep. Comparison with chronic ACE inhibition.Advances in experimental medicine and biology, , Volume: 449, 1998
Development of heart failure following isoproterenol administration in the rat: role of the renin-angiotensin system.Cardiovascular research, , Volume: 37, Issue:1, 1998
Possible protective effects of kinins and converting enzyme inhibitors in cardiovascular tissues.Immunopharmacology, , Volume: 36, Issue:2-3, 1997
Cost effectiveness in the treatment of heart failure with ramipril. A Swedish substudy of the AIRE study. Acute Infarction Ramipril Efficacy.PharmacoEconomics, , Volume: 12, Issue:2 Pt 2, 1997
ACE inhibitors in heart failure: effect on mode of death.European heart journal, , Volume: 18, Issue:1, 1997
AIRE Extension (AIREX) Study.Lancet (London, England), , Aug-02, Volume: 350, Issue:9074, 1997
Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators.European heart journal, , Volume: 18, Issue:1, 1997
Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.The Journal of clinical investigation, , Apr-15, Volume: 99, Issue:8, 1997
Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy.Lancet (London, England), , May-24, Volume: 349, Issue:9064, 1997
Effect of ramipril on heart rate variability in digitalis-treated patients with chronic heart failure.Cardiovascular drugs and therapy, , Volume: 11, Issue:4, 1997
[The efficacy of treatment with the angiotensin-converting enzyme inhibitor ramipril in patients with congestive heart failure of rheumatic etiology].Terapevticheskii arkhiv, , Volume: 68, Issue:2, 1996
Mega-trials: is meta-analysis an alternative?European journal of clinical pharmacology, , Volume: 49 Suppl 1, 1996
Meta-analysis of morbidity and mortality in five exercise capacity trials evaluating ramipril in chronic congestive cardiac failure.The American journal of cardiology, , Jun-01, Volume: 77, Issue:14, 1996
[The effectiveness and tolerance of ramipril in comparison to captopril for heart failure in dogs].DTW. Deutsche tierarztliche Wochenschrift, , Volume: 103, Issue:5, 1996
Angiotensin-converting enzyme inhibition, autonomic activity, and hemodynamics in patients with heart failure who perform isometric exercise.American heart journal, , Volume: 131, Issue:5, 1996
[The use of ramipril in treating patients with chronic heart failure].Terapevticheskii arkhiv, , Volume: 67, Issue:5, 1995
Neurohormonal activation in patients with acute myocardial infarction or chronic congestive heart failure. With special reference to treatment with angiotensin converting enzyme inhibitors.Blood pressure. Supplement, , Volume: 1, 1995
Quantitative assessment of daily physical activity levels in patients with chronic heart failure by measuring energy expenditure--effects of converting enzyme inhibitor therapy.Japanese circulation journal, , Volume: 59, Issue:10, 1995
Effects of 12 weeks of ramipril treatment on the quality of life in patients with moderate congestive heart failure: results of a placebo-controlled trial. Ramipril Study Group.Cardiovascular drugs and therapy, , Volume: 9, Issue:4, 1995
Ramipril. An updated review of its therapeutic use in essential hypertension and heart failure.Drugs, , Volume: 49, Issue:3, 1995
Inhibition of ACE/Kininase-II after myocardial infarction--addendum.Cardiovascular research, , Volume: 28, Issue:2, 1994
Absence of effect on exercise capacity of 12-weeks treatment with ramipril in patients with moderate congestive heart failure. Ramipril Study Group.European heart journal, , Volume: 15, Issue:12, 1994
Clinical pharmacokinetics of ramipril.Clinical pharmacokinetics, , Volume: 26, Issue:1, 1994
ACE inhibition, atherosclerosis and myocardial infarction--the AIRE Study in practice. Acute Infarction Ramipril Efficacy Study.European heart journal, , Volume: 15 Suppl B, 1994
Exercise testing in heart failure. A critical review.Drugs, , Volume: 47 Suppl 4, 1994
Effects of ramipril on the neurohormonal response to exercise in patients with mild or moderate congestive heart failure.European heart journal, , Volume: 15, Issue:2, 1994
Influence of angiotensin converting enzyme inhibition on relation of atrial natriuretic peptide concentration to atrial pressure in heart failure.British heart journal, , Volume: 72, Issue:6, 1994
ACE-inhibitor therapy after myocardial infarction--a new treatment strategy.Zeitschrift fur Kardiologie, , Volume: 83 Suppl 4, 1994
[Reduction of infarct size and remodeling after ramipril].Zeitschrift fur Kardiologie, , Volume: 83 Suppl 4, 1994
Response of plasma neuropeptide Y and noradrenaline to dynamic exercise and ramipril treatment in patients with congestive heart failure.Clinical physiology (Oxford, England), , Volume: 14, Issue:2, 1994
Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. The Ramipril Trial Study Group.British heart journal, , Volume: 72, Issue:5, 1994
Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.Lancet (London, England), , Oct-02, Volume: 342, Issue:8875, 1993
Validation of primary and secondary outcomes and classification of mode of death among patients with clinical evidence of heart failure after a myocardial infarction: a report from the Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.Journal of cardiovascular pharmacology, , Volume: 22 Suppl 9, 1993
Multiple-dose pharmacokinetics of ramipril in patients with chronic congestive heart failure.Journal of cardiovascular pharmacology, , Volume: 22 Suppl 9, 1993
Acute haemodynamic effects and pharmacokinetics of ramipril in patients with heart failure. A placebo controlled three-dose study.European journal of clinical pharmacology, , Volume: 45, Issue:3, 1993
ACE inhibitors: review of four new agents.American family physician, , Volume: 48, Issue:5, 1993
Ramipril: a review of the new ACE inhibitor.The Journal of the Arkansas Medical Society, , Volume: 88, Issue:9, 1992
Influence of ramipril on plasma atrial natriuretic peptide, antidiuretic hormone, angiotensin II and aldosterone in patients with chronic congestive heart failure.Clinical physiology and biochemistry, , Volume: 9, Issue:3, 1992
Three new ACE inhibitors for hypertension.The Medical letter on drugs and therapeutics, , Sep-06, Volume: 33, Issue:852, 1991
A comparison of the efficacy and safety of ramipril and digoxin added to maintenance diuretic treatment in patients with chronic heart failure.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Influence of ramipril on renal function in patients with chronic congestive heart failure.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
[Acute effects of the angiotensin converting enzyme inhibitor ramipril in patients with coronary heart disease].Medizinische Klinik (Munich, Germany : 1983), , Feb-15, Volume: 85, Issue:2, 1990
Global and regional hemodynamic effects of ramipril in congestive heart failure.Journal of cardiovascular pharmacology, , Volume: 14, Issue:5, 1989
Pharmacokinetic and pharmacodynamic properties of ramipril in patients with congestive heart failure (NYHA III-IV).Journal of cardiovascular pharmacology, , Volume: 13 Suppl 3, 1989
Atrial natriuretic peptide levels in congestive heart failure in man before and during converting enzyme inhibition.Clinical and experimental pharmacology & physiology, , Volume: 16, Issue:5, 1989
Acute and chronic effects of ramipril and captopril in congestive heart failure.International journal of cardiology, , Volume: 23, Issue:1, 1989
[Pharmacologic modification of the converting enzyme--local and systemic effects on the heart and blood vessels].Zeitschrift fur Kardiologie, , Volume: 77 Suppl 3, 1988
Ramipril: review of pharmacology.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Clinical pharmacology of ramipril.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Acute hemodynamic and hormonal effects of ramipril in chronic congestive heart failure and comparison with captopril.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Acute hemodynamic, hormonal and electrolyte effects of ramipril in severe congestive heart failure.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Acute effects of the new angiotensin converting enzyme inhibitor ramipril on hemodynamics and carotid sinus baroreflex activity in congestive heart failure.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Ramipril and captopril in patients with heart failure: effects on hemodynamics and vasoconstrictor systems.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
ACE inhibitors after myocardial infarction.The British journal of clinical practice, , Volume: 49, Issue:4
Achieving blood preSsure goals sTudy in uncontrolled hypeRtensive pAtients treated with a fixed-dose combination of ramipriL/hydrochlorothiazide: the ASTRAL study.Cardiovascular journal of Africa, , Volume: 22, Issue:2
[Therapeutic perspectives: association of ACE inhibitors and angiotensin receptor blockers].La Clinica terapeutica, , Volume: 152, Issue:2
Primary Aldosteronism: The Next Decade.Hypertension (Dallas, Tex. : 1979), , Volume: 76, Issue:2, 2020
Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives.American journal of hypertension, , Volume: 18, Issue:1, 2005
High Incidence of ACE/PAI-1 in Association to a Spectrum of Other Polymorphic Cardiovascular Genes Involving PBMCs Proinflammatory Cytokines in Hypertensive Hypercholesterolemic Patients: Reversibility with a Combination of ACE Inhibitor and Statin.PloS one, , Volume: 10, Issue:5, 2015
Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.Circulation. Cardiovascular quality and outcomes, , Jul-01, Volume: 5, Issue:4, 2012
Simvastatin enhances the antihypertensive effect of ramipril in hypertensive hypercholesterolemic animals and patients. Possible role of nitric oxide, oxidative stress, and high sensitivity C-reactive protein.Fundamental & clinical pharmacology, , Volume: 26, Issue:6, 2012
Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1+2 in patients with type 2 diabetes.Atherosclerosis, , Volume: 194, Issue:1, 2007
Simvastatin combined with ramipril treatment in hypercholesterolemic patients.Hypertension (Dallas, Tex. : 1979), , Volume: 44, Issue:2, 2004
Vascular effects of simvastatin combined with ramipril in hypercholesterolemic patients with coronary artery disease, compared with simvastatin alone: a randomized, double-blind, placebo-controlled, crossover study.Atherosclerosis, , Volume: 177, Issue:1, 2004
Effect of chronic treatment with the vasopeptidase inhibitor AVE 7688 and ramipril on endothelial function in atherogenic diet rabbits.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 4, Issue:3, 2003
[Type 2 diabetes and cardiovascular risk: lessons from therapeutic trials].La Revue du praticien, , Oct-15, Volume: 51, Issue:16, 2001
Effects of hypercholesterolemia on the contractions to angiotensin II in the isolated aorta and iliac artery of the rabbit: role of arachidonic acid metabolites.Journal of cardiovascular pharmacology, , Volume: 30, Issue:1, 1997
Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes.Diabetologia, , Volume: 55, Issue:5, 2012
Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.Diabetic medicine : a journal of the British Diabetic Association, , Volume: 27, Issue:11, 2010
Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone).Journal of the American College of Cardiology, , Jun-02, Volume: 53, Issue:22, 2009
Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes.Current atherosclerosis reports, , Volume: 10, Issue:2, 2008
The new clinical trials with thiazolidinediones--DREAM, ADOPT, and CHICAGO: promises fulfilled?Current opinion in lipidology, , Volume: 18, Issue:4, 2007
Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk.Circulation, , Mar-20, Volume: 115, Issue:11, 2007
[Three studies in type 2 diabetes: DREAM the wash-out results].Annales d'endocrinologie, , Volume: 68 Suppl 1, 2007
[DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease].Revue medicale de Liege, , Volume: 61, Issue:10, 2006
Modulation of the renal response to ACE inhibition by ACE insertion/deletion polymorphism during hyperglycemia in normotensive, normoalbuminuric type 1 diabetic patients.Diabetes, , Volume: 54, Issue:10, 2005
The effect of urapidil and ramipril on hyperglycemia in streptozotocin diabetic rats.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 361, Issue:1, 2000
Microcirculation in hyperglycemic patients with IDDM without diabetic complications--effect of low-dose angiotensin-converting enzyme inhibition.Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, , Volume: 106, Issue:1, 1998
Interactions of the kallikrein-kinin and renin-angiotensin systems in experimental diabetes.Diabetes, , Volume: 46, Issue:1, 1997
Effect of short-term ACE inhibitor treatment on peripheral insulin sensitivity in obese insulin-resistant subjects.Diabetologia, , Volume: 49, Issue:12, 2006
Contribution of bradykinin to the beneficial effects of ramipril in the fructose-fed rat.Journal of cardiovascular pharmacology, , Volume: 31, Issue:4, 1998
Significance of exaggerated natriuresis after angiotensin AT1 receptor blockade or angiotensin- converting enzyme inhibition in obese Zucker rats.Clinical and experimental pharmacology & physiology, , Volume: 28, Issue:5-6
Effects of Ramipril on Biomarkers of Endothelial Dysfunction and Inflammation in Hypertensive Children on Maintenance Hemodialysis: the SEARCH Randomized Placebo-Controlled Trial.Hypertension (Dallas, Tex. : 1979), , Volume: 79, Issue:8, 2022
Runner's new diet, his collapse, and his ECG: when a rapid ECG diagnosis can save the day.Canadian family physician Medecin de famille canadien, , Volume: 60, Issue:4, 2014
The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.European journal of preventive cardiology, , Volume: 21, Issue:3, 2014
Ramipril and risk of hyperkalemia in chronic hemodialysis patients.Collegium antropologicum, , Volume: 35, Issue:2, 2011
Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease.Current diabetes reports, , Volume: 10, Issue:4, 2010
[A patient with severe hyperkalaemia -- an emergency after RALES].Deutsche medizinische Wochenschrift (1946), , Sep-09, Volume: 130, Issue:36, 2005
Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE study.Clinical nephrology, , Volume: 63, Issue:3, 2005
Reversible hyperkalemia at the initiation of ACE inhibitors in a young diabetic patient with latent hyporeninemic hypoaldosteronism.Diabetes care, , Volume: 19, Issue:7, 1996
Pharmacokinetic interaction study with ramipril and digoxin in healthy volunteers.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Comparative effect of Ocimum sanctum, Commiphora mukul, folic acid and ramipril on lipid peroxidation in experimentally-induced hyperlipidemia.Indian journal of experimental biology, , Volume: 48, Issue:3, 2010
Impediment of the progressions of microalbuminuria and hyperlipidemia in normotensive type 2 diabetes by low-dose ramipril.Journal of the Medical Association of Thailand = Chotmaihet thangphaet, , Volume: 81, Issue:9, 1998
Contribution of bradykinin to the beneficial effects of ramipril in the fructose-fed rat.Journal of cardiovascular pharmacology, , Volume: 31, Issue:4, 1998
Ramipril prevents impaired endothelium-dependent relaxation in arteries from rabbits fed an atherogenic diet.Atherosclerosis, , Volume: 100, Issue:2, 1993
Angiotensin converting enzyme inhibitor potentiates the hypoglycaemic effect of NG-nitro-L-arginine methyl ester (L-NAME) in rats.Archives of physiology and biochemistry, , Volume: 128, Issue:6, 2022
Effects of Ramipril on Biomarkers of Endothelial Dysfunction and Inflammation in Hypertensive Children on Maintenance Hemodialysis: the SEARCH Randomized Placebo-Controlled Trial.Hypertension (Dallas, Tex. : 1979), , Volume: 79, Issue:8, 2022
INDICATORS OF ENDOTHELIAL DYSFUNCTION, MARKERS OF INFLAMMATION AND LIPID METABOLISM IN PATIENTS WITH HYPERTENSION WITH THE ADMINISTRATION OF QUERCETIN.Wiadomosci lekarskie (Warsaw, Poland : 1960), , Volume: 75, Issue:7, 2022
Heat-based transdermal delivery of a ramipril loaded cream for treating hypertension.Nanoscale, , Sep-02, Volume: 14, Issue:34, 2022
Study of possible sex features of ramipril and candesartan treatment under experimental arterial hypertension in rats.Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti, ,Summer, Volume: 71, Issue:3, 2022
Primary Aldosteronism: The Next Decade.Hypertension (Dallas, Tex. : 1979), , Volume: 76, Issue:2, 2020
ACE-inhibitor/calcium antagonist combination: is this the first-choice therapy in arterial hypertension?Minerva medica, , Volume: 110, Issue:6, 2019
The interrelation of endothelial function and microvascular reactivity in different vascular beds, and risk assessment in hypertension: results from the Doxazosin-ramipril study.Heart and vessels, , Volume: 34, Issue:3, 2019
Angiotensin converting enzyme and neprilysin inhibition alter pain response in dexhamethasone-induced hypertensive rats.Pharmacological reports : PR, , Volume: 71, Issue:2, 2019
Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk.European heart journal, , 07-01, Volume: 40, Issue:25, 2019
[Effects of Ramipril on the expression of connexin 43 in cerebral arteries of spontaneously hypertensive rats].Sheng li xue bao : [Acta physiologica Sinica], , Jun-25, Volume: 71, Issue:3, 2019
The effects of single and combined application of ramipril and losartan on renal structure and function in hypertensive rats.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 40, Issue:7, 2018
Effects of Angiotensin-Converting Enzyme Inhibition and Alpha 1-Adrenergic Receptor Blockade on Inflammation and Hemostasis in Human Hypertension.Journal of cardiovascular pharmacology, , Volume: 71, Issue:4, 2018
Fixed-dose vs free-dose combinations for the management of hypertension-An analysis of 81Â 958 patients.Journal of clinical hypertension (Greenwich, Conn.), , Volume: 20, Issue:4, 2018
Antihypertensive drug use in resistant and nonresistant hypertension and in controlled and uncontrolled resistant hypertension.Journal of hypertension, , Volume: 36, Issue:7, 2018
PATHOMORPHOLOGY OF THE MYOCARDIUM, KIDNEY AND LIVER IN SPONTANEOUSLY HYPERTENSIVE RATS TREATED WITH SHORT AND LONG-TERM USE RAMIPRIL AND CANDESARTAN.Georgian medical news, , Issue:276, 2018
Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.European heart journal, , 09-01, Volume: 39, Issue:33, 2018
The effect of nebivolol and ramipril on selected biochemical parameters, arterial stiffness, and circadian profile of blood pressure in young men with primary hypertension: A 12-week prospective randomized, open-label study trial.Medicine, , Volume: 97, Issue:30, 2018
Fatal outcome of late-onset angiotensin-converting enzyme inhibitor induced angioedema: A case report.Medicine, , Volume: 97, Issue:31, 2018
How to Treat Hypertension in Venlafaxine-Medicated Patients-Pharmacokinetic Considerations in Prescribing Amlodipine and Ramipril.Journal of clinical psychopharmacology, , Volume: 38, Issue:5, 2018
Hypertension Treatment Effects on Orthostatic Hypotension and Its Relationship With Cardiovascular Disease.Hypertension (Dallas, Tex. : 1979), , Volume: 72, Issue:4, 2018
Adverse cardiac effects of exogenous angiotensin 1-7 in rats with subtotal nephrectomy are prevented by ACE inhibition.PloS one, , Volume: 12, Issue:2, 2017
Effects of Direct Renin Blockade on Renal & Systemic Hemodynamics and on RAAS Activity, in Weight Excess and Hypertension: A Randomized Clinical Trial.PloS one, , Volume: 12, Issue:1, 2017
The effects of alpha 1-adrenoceptor blockade and angiotensin converting enzyme inhibition on central and brachial blood pressure and vascular reactivity: the doxazosin-ramipril study.Heart and vessels, , Volume: 32, Issue:6, 2017
Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.Lancet (London, England), , Jun-03, Volume: 389, Issue:10085, 2017
Short-term changes of serum potassium concentration induced by physical exercise in patient with arterial hypertension treated with angiotensin-converting enzyme inhibitor alone or in combination with statin.Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, , Volume: 68, Issue:1, 2017
Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients.Hypertension (Dallas, Tex. : 1979), , Volume: 70, Issue:5, 2017
[One year adherence of ramipril versus ramipril/amlodipine fixed dose combination therapy in hypertension].Orvosi hetilap, , Volume: 158, Issue:42, 2017
Clinical efficacy of African traditional medicines in hypertension: A randomized controlled trial with Combretum micranthum and Hibiscus sabdariffa.Journal of human hypertension, , Volume: 32, Issue:1, 2017
Potential Biomarkers for the Diagnosis of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema.ORL; journal for oto-rhino-laryngology and its related specialties, , Volume: 79, Issue:1-2, 2017
Target Blood Pressure in Patients with Diabetes: Asian Perspective.Yonsei medical journal, , Volume: 57, Issue:6, 2016
Ramipril + amlodipine and ramipril + hydrochlorothiazide fixed-dose combinations in relation to patient adherence.The Journal of international medical research, , Volume: 44, Issue:5, 2016
Benefits of Fixed Dose Combination of Ramipril/Amlodipine in Hypertensive Diabetic Patients: A Subgroup Analysis of RAMONA Trial.Chinese medical journal, , May-20, Volume: 129, Issue:10, 2016
[Ramipril plus amlodipine and lisinopril plus amlodipine fixed dose combinations and patient's adherence].Orvosi hetilap, , Jan-03, Volume: 157, Issue:1, 2016
Risk of renal dysfunction in an elderly patient with chronic heart failure.Medizinische Monatsschrift fur Pharmazeuten, , Volume: 39, Issue:10, 2016
[Comparative Assessment of Effects of Free and Fixed Combinations of Hypotensive Drugs on Quality of Life of Patients With Arterial Hypertension of High and Very High Risk].Kardiologiia, , Volume: 56, Issue:3, 2016
High Incidence of ACE/PAI-1 in Association to a Spectrum of Other Polymorphic Cardiovascular Genes Involving PBMCs Proinflammatory Cytokines in Hypertensive Hypercholesterolemic Patients: Reversibility with a Combination of ACE Inhibitor and Statin.PloS one, , Volume: 10, Issue:5, 2015
[Usefulness of capsule endoscopy in obscure gastrointestinal bleeding].Gastroenterologia y hepatologia, , Volume: 38, Issue:10, 2015
Patients With Newly Diagnosed Hypertension Treated With the Renin Angiotensin Receptor Blocker Azilsartan Medoxomil vs Angiotensin-Converting Enzyme Inhibitors: The Prospective EARLY Registry.Journal of clinical hypertension (Greenwich, Conn.), , Volume: 17, Issue:12, 2015
Association of the ADRB2 (rs2053044) polymorphism and angiotensin-converting enzyme-inhibitor blood pressure response in the African American Study of Kidney Disease and Hypertension.Pharmacogenetics and genomics, , Volume: 25, Issue:9, 2015
Olmesartan vs ramipril in the treatment of hypertension and associated clinical conditions in the elderly: a reanalysis of two large double-blind, randomized studies at the light of the most recent blood pressure targets recommended by guidelines.Clinical interventions in aging, , Volume: 10, 2015
The Association of Losartan and Ramipril Therapy With Kidney and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: A Chinese Nation-Wide Cohort Study in Taiwan.Medicine, , Volume: 94, Issue:48, 2015
The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry.Trials, , Dec-19, Volume: 16, 2015
[A 93-year-old patient with hypertensive crises and renal failure due to bilateral renal artery stenosis].MMW Fortschritte der Medizin, , Nov-05, Volume: 157, Issue:19, 2015
Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 16, Issue:4, 2015
Single-pill combination therapy in the initial treatment of marked hypertension: a propensity-matched analysis.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 37, Issue:5, 2015
Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk.Hypertension (Dallas, Tex. : 1979), , Volume: 65, Issue:3, 2015
[The influence of combined therapy with calcium antagonist and angiotensin-converting enzyme inhibitor on the circadian profile of arterial pressure in patients with arterial hypertension in the Far North].Klinicheskaia meditsina, , Volume: 92, Issue:10, 2014
Effect of telmisartan vs. ramipril on 'dipping' status and blood pressure variability: pooled analysis of the PRISMA studies.Hypertension research : official journal of the Japanese Society of Hypertension, , Volume: 37, Issue:2, 2014
Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading.Clinical and experimental nephrology, , Volume: 18, Issue:4, 2014
The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.European journal of preventive cardiology, , Volume: 21, Issue:3, 2014
Olmesartan vs. ramipril in elderly hypertensive patients: review of data from two published randomized, double-blind studies.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, , Volume: 21, Issue:1, 2014
The effect of aliskiren versus ramipril-based treatment on the Ambulatory Arterial Stiffness Index in hypertensive patients.International angiology : a journal of the International Union of Angiology, , Volume: 33, Issue:1, 2014
[The role of ramipril in the therapy of diabetic nephropathy].Orvosi hetilap, , Feb-16, Volume: 155, Issue:7, 2014
Effects of a long-term treatment with aliskiren or ramipril on structural alterations of subcutaneous small-resistance arteries of diabetic hypertensive patients.Hypertension (Dallas, Tex. : 1979), , Volume: 64, Issue:4, 2014
Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension.Journal of hypertension, , Volume: 32, Issue:10, 2014
Effects of aliskiren- and ramipril-based treatment on central aortic blood pressure in elderly with systolic hypertension: a substudy of AGELESS.Vascular health and risk management, , Volume: 10, 2014
Childhood polyarteritis nodosa presenting as stroke and arterial hypertension.BMJ case reports, , Oct-29, Volume: 2014, 2014
Constitutive activation of the renin-angiotensin system reduces visceral fat and improves glucose tolerance in mice.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 15, Issue:4, 2014
[Medication adherence with the fixed combination of ramipril and amlodipine].Orvosi hetilap, , Nov-23, Volume: 155, Issue:47, 2014
Recent clinical trials.Journal of the American Society of Hypertension : JASH, , Volume: 8, Issue:10, 2014
Ramipril/amlodipine single pill - effectiveness, tolerance and patient satisfaction with antihypertensive therapy in relation to nutritional status.Pharmacological reports : PR, , Volume: 66, Issue:6, 2014
Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria.Expert opinion on pharmacotherapy, , Volume: 14, Issue:4, 2013
Suits you? A qualitative study exploring preferences regarding the tailoring of consumer medicines information.The International journal of pharmacy practice, , Volume: 21, Issue:4, 2013
Response to nondipping and cardiovascular risk after morning renin–angiotensin blockade.Hypertension (Dallas, Tex. : 1979), , Volume: 61, Issue:2, 2013
[Telangiectasia during amlodipine therapy].Annales de dermatologie et de venereologie, , Volume: 140, Issue:3, 2013
Etoricoxib attenuates effect of antihypertensives in a rodent model of DOCA-salt induced hypertension.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 35, Issue:8, 2013
Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril.Journal of human hypertension, , Volume: 27, Issue:8, 2013
Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a retrospective analysis in hypertensive patients of the SMILE-4 study.Journal of hypertension, , Volume: 31, Issue:6, 2013
Effect of aliskiren on arterial stiffness, compared with ramipril in patients with mild to moderate essential hypertension.Chinese medical journal, , Volume: 126, Issue:7, 2013
Efficacy and safety of two ramipril and hydrochlorothiazide fixed-dose combination formulations in adults with stage 1 or stage 2 arterial hypertension evaluated by using ABPM.Clinical therapeutics, , Volume: 35, Issue:5, 2013
Long-term control of ambulatory hypertension in children: improving with time but still not achieving new blood pressure goals.American journal of hypertension, , Volume: 26, Issue:7, 2013
Hypertension is difficult to control in children, too.American journal of hypertension, , Volume: 26, Issue:7, 2013
[Evaluation of efficacy and safety of hypertension treatment with original angiotensin-converting enzyme inhibitors: the comparison of original and generic formulations].Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, , Volume: 34, Issue:201, 2013
Ramipril-induced liver injury: case report and review of the literature.American journal of hypertension, , Volume: 26, Issue:9, 2013
Drugs for treating hypertension.Nursing, , Volume: 43, Issue:8, 2013
Effect of naproxen and acetaminophen on blood pressure lowering by ramipril, valsartan and aliskiren in hypertensive patients.Expert opinion on pharmacotherapy, , Volume: 14, Issue:14, 2013
Assessment of arterial stiffness: combine the pieces of the puzzle.Chinese medical journal, , Volume: 126, Issue:15, 2013
Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril.Postgraduate medicine, , Volume: 125, Issue:4, 2013
Ramipril and hydrochlorothiazide treatment of hypertensive urgency in the ED.The American journal of emergency medicine, , Volume: 31, Issue:10, 2013
Medication adherence in hypertensive patients of different cardiovascular risk treated in primary health care.Przeglad lekarski, , Volume: 70, Issue:6, 2013
[Effect of RAAS antagonist on the expression of gap junction cx43 in myocardium of spontaneously hypertensive rat].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, , Volume: 44, Issue:4, 2013
Treatment of early immunoglobulin A nephropathy by angiotensin-converting enzyme inhibitor.The American journal of medicine, , Volume: 126, Issue:2, 2013
[Advantages of ramipril/amlodipin fixed combination therapy. When should we use it?].Orvosi hetilap, , Oct-20, Volume: 154, Issue:42, 2013
Nonpharmacologic treatment is an indispensable part of antihypertensive therapy in all hypertensive children.American journal of hypertension, , Volume: 26, Issue:12, 2013
Nondipping and cardiovascular risk after morning renin-angiotensin blockade.Hypertension (Dallas, Tex. : 1979), , Volume: 61, Issue:2, 2013
Effect of imidapril versus ramipril on urinary albumin excretion in hypertensive patients with type 2 diabetes and microalbuminuria.Expert opinion on pharmacotherapy, , Volume: 14, Issue:18, 2013
Impact of angiotensin-converting enzyme gene polymorphism on proteinuria and arterial hypertension.Collegium antropologicum, , Volume: 37, Issue:3, 2013
Long-term treatment with ramipril favourably modifies the haemostatic response to acute submaximal exercise in hypertensives.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 14, Issue:4, 2013
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.Hypertension (Dallas, Tex. : 1979), , Volume: 61, Issue:1, 2013
[Possibilities of rational combination antihypertensive therapy: results of HEMERA international clinical trial].Terapevticheskii arkhiv, , Volume: 85, Issue:10, 2013
Thrombin activatable fibrinolysis inhibitor (TAFI) levels in hypertensive patients and a comparison of the effects of amlodipine and ramipril on TAFI levels.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 35, Issue:2, 2013
Cardiovascular and systemic microvascular effects of anti-vascular endothelial growth factor therapy for cancer.Journal of the American College of Cardiology, , Aug-14, Volume: 60, Issue:7, 2012
Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension.Hypertension research : official journal of the Japanese Society of Hypertension, , Volume: 35, Issue:1, 2012
Simvastatin enhances the antihypertensive effect of ramipril in hypertensive hypercholesterolemic animals and patients. Possible role of nitric oxide, oxidative stress, and high sensitivity C-reactive protein.Fundamental & clinical pharmacology, , Volume: 26, Issue:6, 2012
Finding a place for aliskiren in the wide spectrum of blood pressure lowering agents.Hypertension research : official journal of the Japanese Society of Hypertension, , Volume: 35, Issue:1, 2012
Twenty-four hour and early morning blood pressure control of olmesartan vs. ramipril in elderly hypertensive patients: pooled individual data analysis of two randomized, double-blind, parallel-group studies.Journal of hypertension, , Volume: 30, Issue:7, 2012
Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy.Expert opinion on pharmacotherapy, , Volume: 13, Issue:8, 2012
Effect of aliskiren treatment on endothelium-dependent vasodilation and aortic stiffness in essential hypertensive patients.European heart journal, , Volume: 33, Issue:12, 2012
Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).Journal of the American College of Cardiology, , Jan-03, Volume: 59, Issue:1, 2012
Chronic kidney disease: cardiac and renal angiotensin-converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition.Experimental physiology, , Volume: 97, Issue:4, 2012
Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?Journal of hypertension, , Volume: 30, Issue:4, 2012
Renin-angiotensin-aldosterone system blockade is safe and effective in elderly hypertensive patients with and without impaired renal function.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, , Volume: 19, Issue:4, 2012
Antihypertensive efficacy of olmesartan medoxomil and ramipril in elderly patients with mild to moderate hypertension grouped according to renal function status : a retrospective analysis.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, , Volume: 19, Issue:4, 2012
Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation.Journal of cardiovascular pharmacology and therapeutics, , Volume: 17, Issue:1, 2012
[Dual blockade of the renin-angiotensin system in hypertensive treatment: yes].Deutsche medizinische Wochenschrift (1946), , Volume: 137, Issue:48, 2012
Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly mild to moderate essential hypertensive patients with or without metabolic syndrome: a pooled post hoc analysis of two comparative trials.Drugs & aging, , Volume: 29, Issue:12, 2012
Antihypertensive and laxative effects by pharmacological inhibition of sodium-proton-exchanger subtype 3-mediated sodium absorption in the gut.Hypertension (Dallas, Tex. : 1979), , Volume: 60, Issue:6, 2012
Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study.Cardiovascular diabetology, , Jan-09, Volume: 11, 2012
Ambulatory blood pressure values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET).Hypertension (Dallas, Tex. : 1979), , Volume: 60, Issue:6, 2012
Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.Circulation. Cardiovascular quality and outcomes, , Jul-01, Volume: 5, Issue:4, 2012
Additional drug treatment in resistant hypertension: need for randomized studies.Journal of hypertension, , Volume: 30, Issue:8, 2012
A comparison of the antihypertensive and anti-inflammatory effects of aliskiren and ramipril add-on therapy in peritoneal dialysis patients--a pilot open label study.Kidney & blood pressure research, , Volume: 36, Issue:1, 2012
Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study.Journal of hypertension, , Volume: 30, Issue:8, 2012
[High blood pressure in the morning].MMW Fortschritte der Medizin, , Dec-08, Volume: 153, Issue:49-50, 2011
Effect of ramipril therapy on abnormal left atrial appendage function.The Journal of international medical research, , Volume: 39, Issue:6, 2011
Comparison between nebivolol and ramipril in patients with hypertension and left ventricular hypertrophy: a randomized open blinded end-point (PROBE) trial.European review for medical and pharmacological sciences, , Volume: 15, Issue:12, 2011
Impact of nephron number dosing on cardiorenal damage and effects of ACE inhibition.American journal of hypertension, , Volume: 24, Issue:4, 2011
Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension.Blood pressure. Supplement, , Volume: 1, 2011
Angiotensin-(1-7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy.Clinical science (London, England : 1979), , Volume: 120, Issue:8, 2011
Stimulation of cardiac apoptosis in ovariectomized hypertensive rats: potential role of the renin-angiotensin system.Journal of hypertension, , Volume: 29, Issue:2, 2011
Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients.Hypertension research : official journal of the Japanese Society of Hypertension, , Volume: 34, Issue:1, 2011
Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesartan and ramipril.International journal of clinical practice, , Volume: 65, Issue:2, 2011
Hypertension augments cardiac Toll-like receptor 4 expression and activity.Hypertension research : official journal of the Japanese Society of Hypertension, , Volume: 34, Issue:5, 2011
[Prevention of hypertension by drugs and immunization against angiotensin II].Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, , Feb-10, Volume: 100, Issue:2, 2011
Limitations of analyses based on achieved blood pressure: lessons from the African American study of kidney disease and hypertension trial.Hypertension (Dallas, Tex. : 1979), , Volume: 57, Issue:6, 2011
Mixed messages on blood pressure goals.Hypertension (Dallas, Tex. : 1979), , Volume: 57, Issue:6, 2011
Combination delapril/manidipine as antihypertensive therapy in high-risk patients.Clinical drug investigation, , Volume: 31, Issue:7, 2011
[Dental care with local anesthesia: should the patient first discontinue ACE inhibitors?].MMW Fortschritte der Medizin, , Mar-03, Volume: 153, Issue:9, 2011
New clinical concepts after the ONTARGET trial.Expert review of cardiovascular therapy, , Volume: 9, Issue:6, 2011
New data on ONTARGET: more confusion?Journal of clinical hypertension (Greenwich, Conn.), , Volume: 12, Issue:3, 2010
Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial.Journal of human hypertension, , Volume: 24, Issue:9, 2010
Aliskiren versus ramipril in hypertension.Therapeutic advances in cardiovascular disease, , Volume: 4, Issue:3, 2010
ACE inhibition reduces infarction in normotensive but not hypertensive rats: correlation with cortical ACE activity.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, , Volume: 30, Issue:8, 2010
Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial.Cardiovascular therapeutics, , Volume: 28, Issue:6, 2010
Images in cardiovascular medicine. Wide-field scanning laser ophthalmoscope imaging and angiography of central retinal vein occlusion.Circulation, , Mar-30, Volume: 121, Issue:12, 2010
Kidney flow and function in hypertension: protective effects of pycnogenol in hypertensive participants--a controlled study.Journal of cardiovascular pharmacology and therapeutics, , Volume: 15, Issue:1, 2010
[An experience with the use of direct renin inhibitor aliskiren in a patient with obesity and arterial hypertension].Kardiologiia, , Volume: 50, Issue:2, 2010
Choosing an angiotensin-receptor blocker: blood pressure lowering, cardiovascular protection or both?Future cardiology, , Volume: 6, Issue:1, 2010
Reduced cerebrovascular remodeling and functional impairment in spontaneously hypertensive rats following combined treatment with suboptimal doses of telmisartan and ramipril: is less really more?Journal of hypertension, , Volume: 28, Issue:7, 2010
Effects of suboptimal doses of the AT1 receptor blocker, telmisartan, with the angiotensin-converting enzyme inhibitor, ramipril, on cerebral arterioles in spontaneously hypertensive rat.Journal of hypertension, , Volume: 28, Issue:7, 2010
Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibition.Clinical science (London, England : 1979), , Volume: 118, Issue:4, 2010
Ramipril in the treatment of proteinuria in children after renal transplantation.Pediatric transplantation, , Volume: 14, Issue:2, 2010
Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients.Renal failure, , Volume: 32, Issue:8, 2010
A comparison of the effects of ramipril and losartan on blood pressure control and left ventricle hypertrophy in patients with autosomal dominant polycystic kidney disease.Renal failure, , Volume: 32, Issue:8, 2010
Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study.Journal of hypertension, , Volume: 28, Issue:11, 2010
Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.Journal of human hypertension, , Volume: 24, Issue:2, 2010
New standards in hypertension and cardiovascular risk management: focus on telmisartan.Vascular health and risk management, , Mar-24, Volume: 6, 2010
Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs.International journal of cardiology, , Apr-01, Volume: 140, Issue:1, 2010
[Role of ACE-inhibitors in preventing atrial fibrillation relapses in normotensive patients].Recenti progressi in medicina, , Volume: 100, Issue:11, 2009
Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).The American journal of cardiology, , Dec-01, Volume: 104, Issue:11, 2009
Blood-pressure control and delay in progression of kidney disease in children.The New England journal of medicine, , Oct-22, Volume: 361, Issue:17, 2009
Strict blood-pressure control and progression of renal failure in children.The New England journal of medicine, , Oct-22, Volume: 361, Issue:17, 2009
Severe paradoxical hypertension with angiotensin-converting enzyme inhibitors: an unusual feature of renal artery stenosis.Hypertension (Dallas, Tex. : 1979), , Volume: 54, Issue:3, 2009
Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 10, Issue:3, 2009
Achieving blood pressure goals: should angiotensin II receptor blockers become first-line treatment in hypertension?Journal of hypertension. Supplement : official journal of the International Society of Hypertension, , Volume: 27, Issue:5, 2009
Cardiovascular protection: a breakthrough for high-risk patients?Journal of hypertension. Supplement : official journal of the International Society of Hypertension, , Volume: 27, Issue:5, 2009
Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor.Journal of hypertension. Supplement : official journal of the International Society of Hypertension, , Volume: 27, Issue:5, 2009
Introduction: Reducing cardiovascular risk: ONTARGET--a new standard in cardiovascular protection.Journal of hypertension. Supplement : official journal of the International Society of Hypertension, , Volume: 27, Issue:5, 2009
Effect of angiotensin-converting enzyme inhibition on C-reactive protein levels: the ramipril C-reactive pRotein randomized evaluation (4R) trial results.The Canadian journal of cardiology, , Volume: 25, Issue:7, 2009
Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high- and low-baseline PRA levels, respectively.American journal of hypertension, , Volume: 22, Issue:9, 2009
Efficacy and tolerability of two formulations of ramipril in Korean adults with mild to moderate essential hypertension: an 8-week, multicenter, prospective, randomized, open-label, parallel-group noninferiority trial.Clinical therapeutics, , Volume: 31, Issue:5, 2009
CORD: COmparsion of Recommended Doses of ACE inhibitors and angiotensin II receptor blockers.Vnitrni lekarstvi, , Volume: 55, Issue:5, 2009
Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study.Journal of hypertension, , Volume: 27, Issue:7, 2009
[The study of effects of ramipril and amlodipine combination in patients with arterial hypertension and type 2 diabetes mellitus].Kardiologiia, , Volume: 49, Issue:5, 2009
Chronotherapy with the angiotensin-converting enzyme inhibitor ramipril in essential hypertension: improved blood pressure control with bedtime dosing.Hypertension (Dallas, Tex. : 1979), , Volume: 54, Issue:1, 2009
Does it matter when drugs are taken?Hypertension (Dallas, Tex. : 1979), , Volume: 54, Issue:1, 2009
Recent advances in cardiovascular risk reduction: implications of ONTARGET.Clinical cornerstone, , Volume: 9 Suppl 3, 2009
ACE inhibition promotes upregulation of endothelial progenitor cells and neoangiogenesis in cardiac pressure overload.Cardiovascular research, , Jul-01, Volume: 83, Issue:1, 2009
[The ONTARGET trial].Giornale italiano di cardiologia (2006), , Volume: 10, Issue:2, 2009
Conjugated linoleic acid supplementation enhances antihypertensive effect of ramipril in Chinese patients with obesity-related hypertension.American journal of hypertension, , Volume: 22, Issue:6, 2009
Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials.Journal of human hypertension, , Volume: 23, Issue:9, 2009
ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?Blood pressure, , Volume: 18, Issue:1-2, 2009
Normal pregnancy and healthy child after continued exposure to gliclazide and ramipril during pregnancy.The Annals of pharmacotherapy, , Volume: 43, Issue:1, 2009
Renal vascular endothelial function in hypertensive patients with type 2 diabetes mellitus.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 53, Issue:2, 2009
Hypertension-mediated albuminuria is associated with reduced lysosomal activity in the kidney and the heart.American journal of nephrology, , Volume: 29, Issue:5, 2009
Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials.Journal of human hypertension, , Volume: 23, Issue:5, 2009
Utility of semiautomatic clinic and 24-h ambulatory blood pressure measurements to evaluate combination therapy: the Ramipril-Hydrochlorothiazide Hypertension trial.Journal of human hypertension, , Volume: 22, Issue:8, 2008
Evaluation of fixed dose combination (FDC) of telmisartan+ramipril usage in patients with micro-albuminuria and persistent hypertension: A TRIUMPH study.Journal of the Indian Medical Association, , Volume: 106, Issue:3, 2008
Combination of amlodipine 10 mg and valsartan 160 mg lowers blood pressure in patients with hypertension not controlled by an ACE inhibitor/CCB combination.Blood pressure. Supplement, , Volume: 2, 2008
Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 23, Issue:2, 2008
Renal and cardiac effects of antihypertensive treatment with ramipril versus metoprolol in autosomal dominant polycystic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 23, Issue:2, 2008
[Parameters of vasomotor function of endothelium and elasticity of arterial wall during therapy with angiotensin converting enzyme inhibitor ramiprilin patients with type 2 diabetes mellitus].Kardiologiia, , Volume: 48, Issue:11, 2008
Comparative effects of N-acetyl-L-cysteine and ramipril on arterial hypertension, insulin resistance, and oxidative stress in chronically glucose-fed rats.Canadian journal of physiology and pharmacology, , Volume: 86, Issue:11, 2008
Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives.Journal of hypertension, , Volume: 26, Issue:12, 2008
Effects of dual blockade of Renin-Angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study.American journal of hypertension, , Volume: 21, Issue:2, 2008
Safety and tolerability of ramipril 10 mg in patients at high risk of cardiovascular events: an observational study.Journal of the Indian Medical Association, , Volume: 106, Issue:7, 2008
Can aliskiren reduce the incidence of cough caused by ramipril?Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 9, Issue:3, 2008
Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?Cerebrovascular diseases (Basel, Switzerland), , Volume: 26, Issue:5, 2008
The smoothness of blood pressure control of ramipril in essential hypertensive Thai patients evaluation by 24-hour ambulatory blood pressure monitoring.Journal of the Medical Association of Thailand = Chotmaihet thangphaet, , Volume: 91, Issue:9, 2008
An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.Clinical therapeutics, , Volume: 30, Issue:9, 2008
Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular events, and Ramipril (DIABHYCAR), Diabete dDiabetes care, , Volume: 31, Issue:10, 2008
Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction.American journal of physiology. Heart and circulatory physiology, , Volume: 294, Issue:4, 2008
Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial.Journal of hypertension, , Volume: 26, Issue:3, 2008
[Treatment of patients at high cardiovascular risk: confirmation and surprising results of the ONTARGET-Study].Praxis, , May-14, Volume: 97, Issue:10, 2008
A stunning day in hypertension research - Results of ONTARGET, ACCOMPLISH and HYVET.Blood pressure, , Volume: 17, Issue:2, 2008
[Beneficial effects of Hartil on cardiovascular remodeling process in elderly and old patients with isolated systolic arterial hypertension].Georgian medical news, , Issue:154, 2008
Blockade of sensory abnormalities and kinin B(1) receptor expression by N-acetyl-L-cysteine and ramipril in a rat model of insulin resistance.European journal of pharmacology, , Jul-28, Volume: 589, Issue:1-3, 2008
The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League.Journal of hypertension, , Volume: 26, Issue:7, 2008
ONTARGET: questions asked, questions answered.Journal of clinical hypertension (Greenwich, Conn.), , Volume: 10, Issue:6, 2008
[Choroidal effusion after uncomplicated cataract surgery].Klinische Monatsblatter fur Augenheilkunde, , Volume: 225, Issue:6, 2008
Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans.Archives of internal medicine, , Apr-28, Volume: 168, Issue:8, 2008
Effect of dual blockade of renin-angiotensin system on TGFbeta1 and left ventricular structure and function in hypertensive patients.Journal of human hypertension, , Volume: 21, Issue:4, 2007
Effect of ramipril on the incidence of diabetes.The New England journal of medicine, , Feb-01, Volume: 356, Issue:5, 2007
Effect of ramipril on the incidence of diabetes.The New England journal of medicine, , Feb-01, Volume: 356, Issue:5, 2007
A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity.Journal of hypertension, , Volume: 25, Issue:1, 2007
Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.Hypertension (Dallas, Tex. : 1979), , Volume: 49, Issue:2, 2007
Ramipril dose-dependently increases nitric oxide availability in the radial artery of essential hypertension patients.Journal of hypertension, , Volume: 25, Issue:2, 2007
Effects of ACE inhibition and beta-blockade on plasminogen activator inhibitor-1 and transforming growth factor-beta1 in carotid glomus and autonomic ganglia in hypertensive rats.American journal of hypertension, , Volume: 20, Issue:3, 2007
Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes.Diabetes care, , Volume: 30, Issue:6, 2007
[Fasciitis with eosinophilia: a possible causal role of angiotensin converting enzyme inhibitor].Revue neurologique, , Volume: 163, Issue:2, 2007
Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome.Nephrology (Carlton, Vic.), , Volume: 12, Issue:2, 2007
Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients.American journal of hypertension, , Volume: 20, Issue:4, 2007
Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.Circulation, , Apr-17, Volume: 115, Issue:15, 2007
Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients.European heart journal, , Volume: 28, Issue:12, 2007
The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials.Blood pressure monitoring, , Volume: 12, Issue:3, 2007
Rationale for double renin-angiotensin-aldosterone system blockade.The American journal of cardiology, , Aug-06, Volume: 100, Issue:3A, 2007
Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial.Kidney international, , Volume: 72, Issue:7, 2007
Differential effects of ramipril on ambulatory blood pressure in African Americans and Caucasians.American journal of hypertension, , Volume: 20, Issue:8, 2007
Regression of left-ventricular hypertrophy in children and adolescents with hypertension during ramipril monotherapy.American journal of hypertension, , Volume: 20, Issue:9, 2007
Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial.Journal of hypertension, , Volume: 25, Issue:10, 2007
Clinical trial update: focus on the ONTARGET study.Vascular health and risk management, , Volume: 3, Issue:6, 2007
Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 8, Issue:4, 2007
[Therapy of hypertension with expanded outlook. Constant pressure decline and organ protection].MMW Fortschritte der Medizin, , Dec-06, Volume: 149, Issue:49-50, 2007
Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study)*.Journal of hypertension, , Volume: 24, Issue:3, 2006
Lessons from the African-American Study of Kidney Disease and Hypertension: an update.Current hypertension reports, , Volume: 8, Issue:5, 2006
Antihypertensive agents have different ability to modulate arterial pressure and heart rate variability in 2K1C rats.American journal of hypertension, , Volume: 19, Issue:10, 2006
Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.International journal of clinical practice, , Volume: 60, Issue:11, 2006
Redefining the ACE-inhibitor dose-response relationship: substantial blood pressure lowering after massive doses.European journal of clinical pharmacology, , Volume: 62, Issue:12, 2006
Vasopeptidase inhibition prevents target organ damage and improves survival in spontaneously hypertensive rats.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 7, Issue:3, 2006
Initiation of hypertension treatment with a fixed-dose combination or its monocomponents -- does it really matter?International journal of clinical practice, , Volume: 60, Issue:3, 2006
Lichen planus pemphigoides associated with ramipril.International journal of dermatology, , Volume: 45, Issue:12, 2006
Differential antiplatelet effects of angiotensin converting enzyme inhibitors: comparison of ex vivo platelet aggregation in cardiovascular patients with ramipril, captopril and enalapril.Clinical research in cardiology : official journal of the German Cardiac Society, , Volume: 95, Issue:4, 2006
Quality of life in the African American Study of Kidney Disease and Hypertension: effects of blood pressure management.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 47, Issue:6, 2006
The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension.Journal of hypertension, , Volume: 24, Issue:7, 2006
The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I).Journal of hypertension, , Volume: 24, Issue:1, 2006
Oxidative stress: a potentially important new marker in renal transplantation.The Journal of pediatrics, , Volume: 149, Issue:1, 2006
[In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension].MMW Fortschritte der Medizin, , Jun-29, Volume: 148, Issue:26, 2006
Urinary TGF-beta1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy.Diabetes research and clinical practice, , Volume: 72, Issue:3, 2006
A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring.American journal of hypertension, , Volume: 19, Issue:1, 2006
Smart damping modulation of carotid wall energetics in human hypertension: effects of angiotensin-converting enzyme inhibition.Hypertension (Dallas, Tex. : 1979), , Volume: 47, Issue:3, 2006
Different pathomechanisms of essential and obesity-associated hypertension in adolescents.Pediatric nephrology (Berlin, Germany), , Volume: 21, Issue:10, 2006
[Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].Italian heart journal : official journal of the Italian Federation of Cardiology, , Volume: 6 Suppl 7, 2005
ACE inhibition reduces activity of the plasminogen/plasmin and MMP systems in the brain of spontaneous hypertensive stroke-prone rats.Neuroscience letters, , Mar-16, Volume: 376, Issue:3, 2005
Comparative effects of the angiotensin II receptor blocker, telmisartan, and the angiotensin-converting enzyme inhibitor, ramipril, on cerebrovascular structure in spontaneously hypertensive rats.Journal of hypertension, , Volume: 23, Issue:5, 2005
Benefits from angiotensin-converting enzyme inhibitor 'beyond blood pressure lowering': beyond blood pressure or beyond the brachial artery?Journal of hypertension, , Volume: 23, Issue:3, 2005
Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients.Transplantation proceedings, , Volume: 37, Issue:2, 2005
Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives.American journal of hypertension, , Volume: 18, Issue:1, 2005
The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.Archives of internal medicine, , Apr-25, Volume: 165, Issue:8, 2005
The ONTARGET/TRANSCEND Trial Programme: baseline data.Acta diabetologica, , Volume: 42 Suppl 1, 2005
Effect of the renin-angiotensin system or calcium channel blockade on the circadian variation of heart rate variability, blood pressure and circulating catecholamines in hypertensive patients.Journal of hypertension, , Volume: 23, Issue:6, 2005
Blood pressure control, drug therapy, and kidney disease.Hypertension (Dallas, Tex. : 1979), , Volume: 46, Issue:1, 2005
Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses.Journal of the American Society of Nephrology : JASN, , Volume: 16 Suppl 1, 2005
Ramipril induced polyserositis with pericardial tamponade and pleural effusion.International journal of cardiology, , Jul-10, Volume: 102, Issue:2, 2005
[Experiences with the realisation of innovative study designs using the example of the HOPE-study].Deutsche medizinische Wochenschrift (1946), , Jul-08, Volume: 130 Suppl 2, 2005
Ramipril prevents extracellular matrix accumulation in cerebral microvessels.Neurological research, , Volume: 27, Issue:5, 2005
The comparative effects of telmisartan and ramipril on P-wave dispersion in hypertensive patients: a randomized clinical study.Clinical cardiology, , Volume: 28, Issue:6, 2005
An update of irbesartan and renin-angiotensin system blockade in diabetic nephropathy.Expert opinion on pharmacotherapy, , Volume: 6, Issue:9, 2005
Ramipril/felodipine extended-release fixed-dose combination: a review of its use in the management of essential hypertension.Drugs, , Volume: 65, Issue:13, 2005
[A patient with severe hyperkalaemia -- an emergency after RALES].Deutsche medizinische Wochenschrift (1946), , Sep-09, Volume: 130, Issue:36, 2005
Ramipril in the treatment of vascular diseases.Expert opinion on pharmacotherapy, , Volume: 6, Issue:11, 2005
Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients.The Journal of international medical research, , Volume: 33 Suppl 1, 2005
Cardiovascular risk in patients with mild renal insufficiency: implications for the use of ACE inhibitors.Presse medicale (Paris, France : 1983), , Oct-22, Volume: 34, Issue:18, 2005
[Experiences with the realisation of the innovative study designs using the example of the HOPE study -- concerning the contribution in DMW Supplement 2/2005].Deutsche medizinische Wochenschrift (1946), , Nov-25, Volume: 130, Issue:47, 2005
[Hypertension and diabetic nephropathy, a dangerous duo].Medizinische Klinik (Munich, Germany : 1983), , Nov-15, Volume: 100, Issue:11, 2005
[Effects of losartan, ramipril and their combination on left ventricular remodeling and function in spontaneous hypertensive rats].Zhonghua yi xue za zhi, , Nov-30, Volume: 85, Issue:45, 2005
Losartan-ramipril combination treatment.The Journal of the Association of Physicians of India, , Volume: 52, 2004
Evaluation of efficacy and tolerability of Losartan and Ramipril combination in the management of hypertensive patients with associated diabetes mellitus in India (LORD Trial).The Journal of the Association of Physicians of India, , Volume: 52, 2004
The PROGRESS trial three years later: HOPE trial may shed some light.BMJ (Clinical research ed.), , Dec-11, Volume: 329, Issue:7479, 2004
[ACE inhibitor therapy until end of life?].Deutsche medizinische Wochenschrift (1946), , Oct-29, Volume: 129, Issue:44, 2004
A comparison of the efficacy and duration of action of telmisartan, amlodipine and ramipril in patients with confirmed ambulatory hypertension.Blood pressure monitoring, , Volume: 9, Issue:5, 2004
Acute pancreatitis due to ramipril therapy.Postgraduate medical journal, , Volume: 80, Issue:948, 2004
Effects of graded-release diltiazem versus ramipril, dosed at bedtime, on early morning blood pressure, heart rate, and the rate-pressure product.American heart journal, , Volume: 148, Issue:4, 2004
[Case report: hypertension after stroke].Wiener medizinische Wochenschrift (1946), , Volume: 154 Spec No 1, Issue:1, 2004
The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy.Journal of clinical hypertension (Greenwich, Conn.), , Volume: 6, Issue:8, 2004
Ramipril: clinical and economic benefits.Internal medicine journal, , Volume: 34, Issue:7, 2004
Fresh frozen plasma in the treatment of resistant angiotensin-converting enzyme inhibitor angioedema.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, , Volume: 92, Issue:5, 2004
Simvastatin combined with ramipril treatment in hypercholesterolemic patients.Hypertension (Dallas, Tex. : 1979), , Volume: 44, Issue:2, 2004
[Hypertensive nephrosclerosis].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 62 Suppl 3, 2004
[Involvement of angiotensin II in pathogenesis of hypertension and target organ damage].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 62 Suppl 3, 2004
Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme.Expert opinion on pharmacotherapy, , Volume: 5, Issue:5, 2004
Bradykinin and matrix metalloproteinases are involved the structural alterations of rat small resistance arteries with inhibition of ACE and NEP.Journal of hypertension, , Volume: 22, Issue:4, 2004
Ramipril in the treatment of hypertension and proteinuria in children with chronic kidney diseases.American journal of hypertension, , Volume: 17, Issue:5 Pt 1, 2004
Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina).Diabetes, nutrition & metabolism, , Volume: 17, Issue:5, 2004
Combined blockade of AT1-receptors and ACE synergistically potentiates antihypertensive effects in SHR.Journal of hypertension, , Volume: 22, Issue:3, 2004
Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE?Current medical research and opinion, , Volume: 20, Issue:3, 2004
An unusual cause of exertional leg pain.Current sports medicine reports, , Volume: 3, Issue:2, 2004
Timing of drug treatment is crucial.BMJ (Clinical research ed.), , Jan-17, Volume: 328, Issue:7432, 2004
[Fast and strong lowering of pressure. The newest sartan has passed the practice test].MMW Fortschritte der Medizin, , Oct-30, Volume: 145, Issue:44, 2003
[Improved protection of heart and kidneys in the hypertensive patient. ACE inhibitor and AT1 blocker combined?].MMW Fortschritte der Medizin, , Jun-05, Volume: 145, Issue:23, 2003
Parallel renal and extremity blood supply abnormalities in nonmodulation: responses to ACE inhibition.Hypertension (Dallas, Tex. : 1979), , Volume: 41, Issue:4, 2003
Recommendations for the management of special populations: racial and ethnic populations.American journal of hypertension, , Volume: 16, Issue:11 Pt 2, 2003
Ramipril improves nitric oxide availability in hypertensive rats with failing hearts after myocardial infarction.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 4, Issue:3, 2003
[Standpoint on the use of angiotensin receptor blockers in the treatment of hypertension].Harefuah, , Volume: 142, Issue:4, 2003
[Corner points of antihypertensive therapy in prediabetic state. Success with a combination].MMW Fortschritte der Medizin, , Jul-10, Volume: 145, Issue:27-28, 2003
[Hypertension and prediabetes. "Don't trust anybody over 130/80"].MMW Fortschritte der Medizin, , Mar-27, Volume: 145, Issue:13, 2003
Conundrum of the HOPE study: time of taking ramipril may account for lack of relation between blood pressure and outcome.BMJ (Clinical research ed.), , Sep-20, Volume: 327, Issue:7416, 2003
[Comparative assessment of antihypertensive effects of angiotensin-converting enzyme inhibitors ramipril and captopril in patients with hypertension in ambulatory settings].Kardiologiia, , Volume: 43, Issue:3, 2003
[Therapy of hypertension. Lasting organ protection moves into the foreground].MMW Fortschritte der Medizin, , Nov-20, Volume: 145, Issue:47, 2003
[Ramipril in elderly patients with mild and moderate hypertension. Clinical efficacy, effect on cerebral blood flow and intellectual functioning].Kardiologiia, , Volume: 43, Issue:6, 2003
[Health care too costly? Saving more than 10 million euros in 2 months!].MMW Fortschritte der Medizin, , Nov-20, Volume: 145, Issue:47, 2003
[Therapy of hypertension. Cost conscious prevention of complications].MMW Fortschritte der Medizin, , Nov-20, Volume: 145, Issue:47, 2003
[Added organ protection at little cost. Double savings with ACE inhibitors].MMW Fortschritte der Medizin, , Nov-27, Volume: 145, Issue:48, 2003
More hype than HOPE.Hypertension (Dallas, Tex. : 1979), , Volume: 41, Issue:4, 2003
Antihypertensive drugs and renal protection.JAMA, , Mar-05, Volume: 289, Issue:9, 2003
[Dangerous duo: hypertension and pre-diabetes--the underestimated risk].MMW Fortschritte der Medizin, , Jan-23, Volume: 145, Issue:3-4, 2003
Angiotensin-converting enzyme inhibitors for stroke prevention: is there HOPE for PROGRESS After LIFE?Stroke, , Volume: 34, Issue:2, 2003
The effect of ramipril on albumin excretion in diabetes and hypertension: the role of increased lysosomal activity and decreased transforming growth factor-beta expression.Journal of hypertension, , Volume: 21, Issue:2, 2003
Best bang for the buck?Current hypertension reports, , Volume: 5, Issue:1, 2003
[Relationship between regression of hypertensive left ventricular hypertrophy and improvement of coronary flow reserve].Zhonghua yi xue za zhi, , Apr-25, Volume: 83, Issue:8, 2003
Ramipril improves hemodynamic recovery but not microvascular response to ischemia in spontaneously hypertensive rats.American journal of hypertension, , Volume: 15, Issue:5, 2002
Effect of ramipril versus amlodipine on renal outcomes in hypertensive nephrosclerosis.Current hypertension reports, , Volume: 4, Issue:3, 2002
Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes.The Medical journal of Australia, , Mar-18, Volume: 176, Issue:6, 2002
[The plasma levels of proinsulin and true insulin and the effects of ramipril in hypertension].Zhonghua nei ke za zhi, , Volume: 41, Issue:2, 2002
[Therapy of hypertension with ACE inhibitors. One third fewer cases of diabetes].MMW Fortschritte der Medizin, , Mar-07, Volume: 144, Issue:10, 2002
Comparative effects of the dual ACE-NEP inhibitor MDL-100,240 and ramipril on hypertension and cardiovascular disease in endogenous angiotensin II-dependent hypertension.American journal of hypertension, , Volume: 15, Issue:2 Pt 1, 2002
The 24-hour blood pressure pattern: does it have implications for morbidity and mortality?The American journal of cardiology, , Jan-24, Volume: 89, Issue:2A, 2002
[Assessment of acute blood pressure variability during a stress test].Annales de cardiologie et d'angeiologie, , Volume: 51, Issue:2, 2002
ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time.Hypertension (Dallas, Tex. : 1979), , Volume: 40, Issue:6, 2002
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.JAMA, , Nov-20, Volume: 288, Issue:19, 2002
Oxidative stress in kidney transplant patients with calcineurin inhibitor-induced hypertension: effect of ramipril.Journal of cardiovascular pharmacology, , Volume: 40, Issue:4, 2002
Using ACE inhibitors appropriately.American family physician, , Aug-01, Volume: 66, Issue:3, 2002
Long-term angiotensin-converting enzyme inhibition with ramipril reduces thrombin generation in human hypertension.Clinical science (London, England : 1979), , Volume: 103, Issue:2, 2002
Dual ACE and NEP inhibitor MDL-100,240 prevents and regresses severe angiotensin II-dependent hypertension partially through bradykinin type 2 receptor.Journal of hypertension, , Volume: 20, Issue:7, 2002
Severe angioedema induced by angiotensin converting enzyme inhibitors: role of precipitating factors.The Journal of dermatology, , Volume: 29, Issue:6, 2002
[Type 2 diabetes and cardiovascular risk: lessons from therapeutic trials].La Revue du praticien, , Oct-15, Volume: 51, Issue:16, 2001
[Prediction, screening and treatment of renal complications of diabetes].La Revue du praticien, , Oct-15, Volume: 51, Issue:16, 2001
Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy.Hypertension (Dallas, Tex. : 1979), , Dec-01, Volume: 38, Issue:6, 2001
Mechanical vs intrinsic components in the improvement of brachial arterial compliance. Comparison of the effects of atenolol versus ramipril in hypertensive patients.Medicina, , Volume: 61, Issue:5 Pt 1, 2001
Clinical trials report. The effect of Ramipril versus Amlodipine on renal outcomes in hypertension nephrosclerosis.Current hypertension reports, , Volume: 3, Issue:5, 2001
Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance.PharmacoEconomics, , Volume: 19, Issue:5 Pt 1, 2001
Right atrial function in hypertensive patients: effects of antihypertensive therapy.Journal of human hypertension, , Volume: 15, Issue:7, 2001
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.JAMA, , Jun-06, Volume: 285, Issue:21, 2001
Hypertensive African Americans with kidney disease should seek advice from doctor about blood pressure medication.Ethnicity & disease, ,Winter, Volume: 11, Issue:1, 2001
Management of asymptomatic left ventricular dysfunction.Cleveland Clinic journal of medicine, , Volume: 68, Issue:3, 2001
Effects of angiotensin-converting enzyme inhibitor and angiotensin type 1 receptor antagonist in deoxycorticosterone acetate-salt hypertensive mice lacking Ren-2 gene.Hypertension (Dallas, Tex. : 1979), , Volume: 37, Issue:3, 2001
[Achieving vascular protection. ACE inhibitor lowers not only blood pressure].MMW Fortschritte der Medizin, , Sep-06, Volume: 143, Issue:35-36, 2001
The renin angiotensin system and cardiovascular disease: hope or hype?Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 1, Issue:2, 2000
Improvement in midwall myocardial shortening with regression of left ventricular hypertrophy.Hypertension (Dallas, Tex. : 1979), , Volume: 36, Issue:5, 2000
Circulating amylin in human essential hypertension: heritability and early increase in individuals at genetic risk.Journal of hypertension, , Volume: 18, Issue:11, 2000
Treatment of arterial hypertension in the elderly with diltiazem vs ramipril.Minerva cardioangiologica, , Volume: 48, Issue:6, 2000
Rationale for angiotensin II receptor blockers in patients with low-renin hypertension.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 36, Issue:3 Suppl 1, 2000
[Protein markers in evaluation of nephroprotective effects of antihypertensive drugs in patients with arterial hypertension].Klinicheskaia laboratornaia diagnostika, , Issue:7, 2000
Angiotensin-converting enzyme inhibitors in antihypertensive therapy.Current hypertension reports, , Volume: 2, Issue:2, 2000
Studies examining risk reduction in subjects with multiple metabolic and cardiovascular risk factors.Current hypertension reports, , Volume: 2, Issue:2, 2000
HOPE gives reason for hope. Heart Outcomes Prevention Evaluation.Current hypertension reports, , Volume: 2, Issue:1, 2000
[PHARAO Study of the Hypertension League. Can development of hypertension be prevented with drugs?].MMW Fortschritte der Medizin, , Jul-20, Volume: 142, Issue:28-29, 2000
Practice vs ambulatory blood pressure measurement under treatment with ramipril (PLUR Study): a randomised, prospective long-term study to evaluate the benefits of ABPM in patients on antihypertensive treatment.Journal of human hypertension, , Volume: 14, Issue:7, 2000
Ramipril.International journal of clinical practice, , Volume: 54, Issue:4, 2000
Renal protection: progression, regression, remission from nephropathy beyond blood pressure control.International journal of clinical practice. Supplement, , Issue:110, 2000
Raised blood pressure, not renin-angiotensin systems, causes cardiac fibrosis in TGR m(Ren2)27 rats.Cardiovascular research, , Volume: 47, Issue:1, 2000
Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 35, Issue:6, 2000
The HOPE study and diabetes. Heart Outcomes Prevention Evaluation.Lancet (London, England), , Apr-01, Volume: 355, Issue:9210, 2000
The HOPE study and diabetes. Heart Outcomes Prevention Evaluation.Lancet (London, England), , Apr-01, Volume: 355, Issue:9210, 2000
The HOPE study and diabetes. Heart Outcomes Prevention Evaluation.Lancet (London, England), , Apr-01, Volume: 355, Issue:9210, 2000
The HOPE study and diabetes. Heart Outcomes Prevention Evaluation.Lancet (London, England), , Apr-01, Volume: 355, Issue:9210, 2000
The HOPE study and diabetes. Heart Outcomes Prevention Evaluation.Lancet (London, England), , Apr-01, Volume: 355, Issue:9210, 2000
[Effects of angiotensin-converting enzyme (ACE) inhibitors on water-salt homeostasis in hypertensive patients living in Far North].Klinicheskaia meditsina, , Volume: 78, Issue:3, 2000
The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not.Cleveland Clinic journal of medicine, , Volume: 67, Issue:4, 2000
Increased apoptosis in the heart of genetic hypertension, associated with increased fibroblasts.Cardiovascular research, , Volume: 45, Issue:3, 2000
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.Lancet (London, England), , Jan-22, Volume: 355, Issue:9200, 2000
Antihypertensive profiles with ascending dose combinations of ramipril and felodipine ER.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 21, Issue:8, 1999
The prognostic significance of a history of systemic hypertension in patients randomised to either placebo or ramipril following acute myocardial infarction: evidence from the AIRE study. Acute Infarction Ramipril Efficacy.Journal of human hypertension, , Volume: 13, Issue:8, 1999
Late treatment with ramipril increases survival in old spontaneously hypertensive rats.Hypertension (Dallas, Tex. : 1979), , Volume: 34, Issue:2, 1999
Effect of long-term ACE inhibition on myocardial tissue in hypertensive stroke-prone rats.Journal of molecular and cellular cardiology, , Volume: 31, Issue:8, 1999
Reciprocal role of the AT1 receptor in modulating renal and neuronal AT1 mRNA expression.Journal of the American Society of Nephrology : JASN, , Volume: 10 Suppl 11, 1999
Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function.Journal of human hypertension, , Volume: 13, Issue:1, 1999
Long-term effects of angiotensin-converting enzyme inhibition on renal medullary neutral lipid in spontaneously hypertensive rats.Hypertension (Dallas, Tex. : 1979), , Volume: 33, Issue:5, 1999
Effect of ACE inhibitor on DOCA-salt- and aortic coarctation-induced hypertension in mice: do kinin B2 receptors play a role?Hypertension (Dallas, Tex. : 1979), , Volume: 33, Issue:1 Pt 2, 1999
The effects of ramipril on sympathetic nervous system function in older patients with hypertension.Clinical pharmacology and therapeutics, , Volume: 65, Issue:4, 1999
The relationship between apoptosis and spontaneous hypertension.Chinese medical journal, , Volume: 112, Issue:6, 1999
[Investigation of inhibitory effect of ramipril on apoptosis in spontaneously hypertensive rats].Hua xi yi ke da xue xue bao = Journal of West China University of Medical Sciences = Huaxi yike daxue xuebao, , Volume: 30, Issue:1, 1999
[Ambulatory long-term blood pressure determination improves therapy of hypertension].MMW Fortschritte der Medizin, , Jul-22, Volume: 141, Issue:28-29, 1999
Prostacyclin: its pathogenic role in essential hypertension and the class effect of ACE inhibitors on prostaglandin metabolism.Blood pressure, , Volume: 8, Issue:5-6, 1999
Antihypertensive efficacy and tolerability of once-daily sustained-release diltiazem alone and in combination with ramipril in hypertension.The Journal of the Association of Physicians of India, , Volume: 47, Issue:10, 1999
[Time-dependent effects of ramipril in patients with hypertension of 2 stage].Klinicheskaia meditsina, , Volume: 77, Issue:10, 1999
The influence of long-term ACE inhibitor treatment on circulatory responses to stress in human hypertension.American journal of hypertension, , Volume: 12, Issue:12 Pt 1-2, 1999
Inhibition of tissue angiotensin converting enzyme activity prevents malignant hypertension in TGR(mREN2)27.Journal of hypertension, , Volume: 16, Issue:5, 1998
[Ramipril in the treatment of moderate to moderately severe hypertension. A multicenter open study].Vnitrni lekarstvi, , Volume: 44, Issue:6, 1998
[The effect of ramipril on metabolic, renal and cardiac function in hypertension and type II diabetes mellitus].Vnitrni lekarstvi, , Volume: 44, Issue:6, 1998
[Ramipril effects on 24 hour profile of blood pressure in patients with mild and moderate hypertension].Terapevticheskii arkhiv, , Volume: 70, Issue:9, 1998
Response of serum total renin to ramipril and metoprolol in hypertensive patients.Scandinavian journal of clinical and laboratory investigation, , Volume: 58, Issue:8, 1998
Angiotensin converting enzyme inhibitors and cough--a north Indian study.The Journal of the Association of Physicians of India, , Volume: 46, Issue:5, 1998
Influence of dietary salts on the cardiovascular effects of low-dose combination of ramipril and felodipine in spontaneously hypertensive rats.British journal of pharmacology, , Volume: 123, Issue:2, 1998
The arterial length-densities under preventive angiotensin-converting-enzyme inhibiting treatment in the myocardium of spontaneously hypertensive rats.Basic research in cardiology, , Volume: 93, Issue:1, 1998
Contribution of bradykinin to the beneficial effects of ramipril in the fructose-fed rat.Journal of cardiovascular pharmacology, , Volume: 31, Issue:4, 1998
[Improvement in diastolic function in hypertensive patients with left ventricular hypertrophy with inhibitors of the angiotensin converting enzyme].Revista clinica espanola, , Volume: 198, Issue:1, 1998
Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy.American journal of hypertension, , Volume: 11, Issue:4 Pt 1, 1998
Vagal cardiac activity in essential hypertension: the effects of metoprolol and ramipril.American journal of hypertension, , Volume: 11, Issue:6 Pt 1, 1998
Differential responses of the heart and vasculature to chronic blood pressure reduction in essential hypertension.Clinical pharmacology and therapeutics, , Volume: 64, Issue:1, 1998
Effects of Ramipril and Isradipin on hemorheological profiles in patients with arterial hypertension.Clinical hemorheology and microcirculation, , Volume: 18, Issue:2-3, 1998
Efficacy of ramipril in therapy-resistant hypertension.Current medical research and opinion, , Volume: 14, Issue:2, 1998
Accelerated cholesteryl ester transfer in patients with essential hypertension and the effect of ramipril treatment.Atherosclerosis, , Volume: 140, Issue:1, 1998
Cardiovascular kinin-generating capability in hypertensive fructose-fed rats.Journal of hypertension, , Volume: 16, Issue:9, 1998
Regulation of extracellular matrix proteins in pressure-overload cardiac hypertrophy: effects of angiotensin converting enzyme inhibition.Journal of hypertension, , Volume: 16, Issue:9, 1998
L-type calcium channels modulate the regression of left ventricular hypertrophy after ace-inhibition in genetic hypertension.Pharmacological research, , Volume: 38, Issue:4, 1998
Effects of chronic ramipril treatment in streptozotocin-induced diabetic rats.Indian journal of physiology and pharmacology, , Volume: 41, Issue:4, 1997
EUCLID study.Lancet (London, England), , Oct-11, Volume: 350, Issue:9084, 1997
Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke-prone spontaneously hypertensive rats.Hypertension (Dallas, Tex. : 1979), , Volume: 29, Issue:1 Pt 2, 1997
Ramipril therapy improves arterial dilation in experimental hypertension.Cardiovascular research, , Volume: 33, Issue:1, 1997
Modulation of genetic hypertension by short-term AVP V1A or V2 receptor antagonism in young SHR.The American journal of physiology, , Volume: 272, Issue:2 Pt 2, 1997
Impaired renal haemodynamic response to amino acid infusion in essential hypertension during angiotensin converting enzyme inhibitor treatment.Journal of hypertension, , Volume: 15, Issue:5, 1997
Cardiovascular effects of a low-dose combination of ramipril and felodipine in spontaneously hypertensive rats.British journal of pharmacology, , Volume: 121, Issue:3, 1997
[A decrease in left ventricular hypertrophy and the dynamics of the parameters of circadian BP monitoring under the influence of ramipril in patients with essential arterial hypertension].Terapevticheskii arkhiv, , Volume: 69, Issue:4, 1997
ACE inhibition reduces left ventricular mass independent of pressure without affecting coronary flow and flow reserve in spontaneously hypertensive rats.The American journal of the medical sciences, , Volume: 314, Issue:1, 1997
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)Lancet (London, England), , Jun-28, Volume: 349, Issue:9069, 1997
Effects of ramipril on the hormone concentrations in serum of hypertensive patients.European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies, , Volume: 35, Issue:6, 1997
Possible protective effects of kinins and converting enzyme inhibitors in cardiovascular tissues.Immunopharmacology, , Volume: 36, Issue:2-3, 1997
Is ramipril anti-arrhythmic?Australian family physician, , Volume: 26, Issue:8, 1997
Secreted protein acidic and rich in cysteine expression after subtotal nephrectomy and blockade of the renin-angiotensin system.Journal of the American Society of Nephrology : JASN, , Volume: 8, Issue:9, 1997
[Clinical effectiveness of and tolerance to ramipril in the treatment of essential arterial hypertension phase 1 and 2. Results of a multicenter study].Revista medica de Chile, , Volume: 125, Issue:1, 1997
Arterial responses to bradykinin after ramipril therapy in experimental hypertension.Pharmacology & toxicology, , Volume: 81, Issue:4, 1997
Angiotensin-converting enzyme inhibition alters nitric oxide and superoxide release in normotensive and hypertensive rats.Hypertension (Dallas, Tex. : 1979), , Volume: 30, Issue:5, 1997
Influence of age and dietary sodium on the cardiovascular and renal effects of ramipril in spontaneously hypertensive rats.Methods and findings in experimental and clinical pharmacology, , Volume: 19, Issue:5, 1997
Sustained diurnal blood pressure reduction in SHR with ramipril assessed by telemetric monitoring.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 19, Issue:8, 1997
ACE inhibition decreases postoperative mortality in rats with left ventricular hypertrophy and myocardial infarction.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 18, Issue:5, 1996
Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade.American journal of hypertension, , Volume: 9, Issue:9, 1996
Monitoring antihypertensive therapy through blood pressure measurements taken casually, at rest, during exercise, and under outpatient conditions.Zeitschrift fur Kardiologie, , Volume: 85 Suppl 3, 1996
Kinetics, safety, and efficacy of ramipril after long-term administration in hemodialyzed patients.Journal of cardiovascular pharmacology, , Volume: 27, Issue:2, 1996
Left ventricular hypertrophy and QT dispersion in hypertension.Hypertension (Dallas, Tex. : 1979), , Volume: 28, Issue:5, 1996
Interruption of prolonged ramipril treatment in hypertensive patients: effects on the renin-angiotensin system.Fundamental & clinical pharmacology, , Volume: 10, Issue:5, 1996
Therapeutic, but not low-dose, angiotensin-converting enzyme inhibition causes regression of cardiovascular changes in spontaneously hypertensive rats.Journal of cardiovascular pharmacology, , Volume: 27, Issue:3, 1996
Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production.Circulation, , Jun-01, Volume: 93, Issue:11, 1996
Nitric oxide and the depressor response to angiotensin blockade in hypertension.Hypertension (Dallas, Tex. : 1979), , Volume: 27, Issue:1, 1996
Vascular and cardiac protection by ramipril in spontaneously hypertensive rats: prevention versus regression study.British journal of clinical practice. Supplement, , Volume: 84, 1996
Ramipril and felodipine: a comparison of the efficacy and safety of monotherapy versus combination therapy.Current medical research and opinion, , Volume: 13, Issue:8, 1996
[Antihypertensive effect of ramipril. Ambultory monitoring of arterial blood pressure in mild to moderate hypertension].Recenti progressi in medicina, , Volume: 87, Issue:9, 1996
The DIAB-HYCAR Study.Diabetologia, , Volume: 39, Issue:12, 1996
[A comparison of the effect of Capoten (captopril) and ramipril on the circadian profile of the arterial pressure and peripheral hemodynamics in patients with hypertension combined with diabetes mellitus].Terapevticheskii arkhiv, , Volume: 68, Issue:5, 1996
Regulation of ANG II receptor in hypertension: role of ANG II.The American journal of physiology, , Volume: 271, Issue:1 Pt 2, 1996
[New therapeutic principle in the management of hypertension].Der Internist, , Volume: 37, Issue:4 Suppl Ne, 1996
Comparative effects of ramipril and nitrendipine on albuminuria in hypertensive patients with non-insulin-dependent diabetes mellitus and impaired renal function.Journal of human hypertension, , Volume: 9, Issue:2, 1995
European postmarketing surveillance of ramipril in hypertension. 1. Feasibility and study cohort.European journal of clinical pharmacology, , Volume: 49, Issue:1-2, 1995
Ramipril decreases chlorthalidone-induced loss of magnesium and potassium in hypertensive patients.Journal of clinical pharmacology, , Volume: 35, Issue:12, 1995
Nitric oxide and prostaglandins in the prolonged effects of losartan and ramipril in hypertension.Hypertension (Dallas, Tex. : 1979), , Volume: 26, Issue:2, 1995
Angioedema caused by ramipril.The Annals of pharmacotherapy, , Volume: 29, Issue:4, 1995
Attenuation of genetic hypertension after short-term vasopressin V1A receptor antagonism.Hypertension (Dallas, Tex. : 1979), , Volume: 26, Issue:5, 1995
Double-blind comparison of antihypertensive treatment with ramipril and piretanide, given alone or in combination.Journal of cardiovascular pharmacology, , Volume: 26, Issue:1, 1995
Extracellular matrix deposition in hypertensive hearts antifibrotic effects of ramipril.European heart journal, , Volume: 16 Suppl C, 1995
The effects of antihypertensive therapy on carotid vascular structure in man.Cardiovascular research, , Volume: 30, Issue:1, 1995
ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group.Journal of hypertension, , Volume: 13, Issue:11, 1995
Comparison of ramipril and nitrendipine.Journal of human hypertension, , Volume: 9, Issue:11, 1995
[Effects of bisoprolol and ramipril on short-term variability of systolic blood pressure during mental stress test: spectrum analysis].Archives des maladies du coeur et des vaisseaux, , Volume: 88, Issue:8, 1995
Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group.American journal of hypertension, , Volume: 8, Issue:9, 1995
Long-term effects of brief antihypertensive treatment on systolic blood pressure and vascular reactivity in young genetically hypertensive rats.Cardiovascular drugs and therapy, , Volume: 9, Issue:3, 1995
Myalgia and arthralgia associated with enalapril and ramipril.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Jan-15, Volume: 52, Issue:2, 1995
Differential effects of chronic oral antihypertensive therapies on systemic arterial circulation and ventricular energetics in African-American patients.Circulation, , Feb-15, Volume: 91, Issue:4, 1995
Resetting blood pressure in spontaneously hypertensive rats. The role of bradykinin.Hypertension (Dallas, Tex. : 1979), , Volume: 25, Issue:2, 1995
Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. HYCAR Study Group.Hypertension (Dallas, Tex. : 1979), , Volume: 25, Issue:1, 1995
Effects of intensified blood-pressure reduction on renal function and albumin excretion in primary hypertension. Addition of felodipine or ramipril to long-term treatment with beta-blockade.American journal of hypertension, , Volume: 8, Issue:2, 1995
Ramipril. An updated review of its therapeutic use in essential hypertension and heart failure.Drugs, , Volume: 49, Issue:3, 1995
Role of kinins and nitric oxide in the antihypertrophic effect of ramipril.Hypertension (Dallas, Tex. : 1979), , Volume: 23, Issue:6 Pt 2, 1994
[Study report: Hypertension therapy with organ protection. Piretanid and Ramipril: advantages with fixed combination].Fortschritte der Medizin. Supplement : die Kongressinformation fur die Praxis, , Volume: 164, 1994
Ramipril prevents the detrimental sequels of chronic NO synthase inhibition in rats: hypertension, cardiac hypertrophy and renal insufficiency.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 350, Issue:6, 1994
Remission of high blood pressure reverses arterial potassium channel alterations.Hypertension (Dallas, Tex. : 1979), , Volume: 23, Issue:6 Pt 2, 1994
Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin.Hypertension (Dallas, Tex. : 1979), , Volume: 23, Issue:4, 1994
[The nephroprotective effect of ramipril. Effect on blood pressure and metabolic control in insulin-treated patients with type-2 diabetes mellitus].Fortschritte der Medizin, , Jan-30, Volume: 112, Issue:3, 1994
Clinical pharmacokinetics of ramipril.Clinical pharmacokinetics, , Volume: 26, Issue:1, 1994
Amlodipine versus ramipril in the treatment of mild to moderate hypertension: evaluation by 24-hour ambulatory blood pressure monitoring.Cardiology, , Volume: 85, Issue:1, 1994
Heterogeneity of the arterial tree in essential hypertension: a noninvasive study of the terminal aorta and the common carotid artery.Journal of human hypertension, , Volume: 8, Issue:7, 1994
Study of the efficacy and safety of the combination ramipril 2.5 mg plus hydrochlorothiazide 12.5 mg in patients with mild-to-moderate hypertension. ATHES Study Group.International journal of clinical pharmacology research, , Volume: 14, Issue:1, 1994
Effects of ramipril on contractile oscillations in arteries from genetically hypertensive rats.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 16, Issue:6, 1994
[A comparison of the efficacy of cilazapril and ramipril in treating arterial hypertension patients (a randomized study)].Terapevticheskii arkhiv, , Volume: 66, Issue:12, 1994
Does lipophilicity of angiotensin converting enzyme inhibitors selectively influence autonomic neural function in human hypertension?Journal of hypertension, , Volume: 12, Issue:11, 1994
Ramipril vs captopril in mild to moderate hypertension.The Journal of the Association of Physicians of India, , Volume: 42, Issue:2, 1994
Angiotensin-converting enzyme inhibition during development alters calcium regulation in adult hypertensive rats.The Journal of pharmacology and experimental therapeutics, , Volume: 267, Issue:3, 1993
Combination of ramipril and hydrochlorothiazide in the treatment of mild to moderate hypertension--Part 2: An open long-term study of efficacy and safety.Clinical cardiology, , Volume: 16, Issue:1, 1993
Vascular remodeling in systemic hypertension.The American journal of cardiology, , Jun-24, Volume: 71, Issue:17, 1993
Short report: ramipril and hydrochlorothiazide combination therapy in hypertension: a clinical trial of factorial design. The East Germany Collaborative Trial Group.Journal of hypertension, , Volume: 11, Issue:2, 1993
Effect of ramipril on alpha-adrenoceptor-mediated oscillatory contractions in tail artery of hypertensive rats.European journal of pharmacology, , Oct-05, Volume: 242, Issue:3, 1993
Usefulness of piretanide plus ramipril for systemic hypertension: a multicenter trial.The American journal of cardiology, , Sep-15, Volume: 72, Issue:9, 1993
[Ramipril, a new antagonist of angiotensin converting enzyme].Arquivos brasileiros de cardiologia, , Volume: 60, Issue:2, 1993
Long-term low-dose angiotensin converting enzyme inhibitor treatment increases vascular cyclic guanosine 3',5'-monophosphate.Hypertension (Dallas, Tex. : 1979), , Volume: 22, Issue:5, 1993
ACE inhibitors: review of four new agents.American family physician, , Volume: 48, Issue:5, 1993
[Ramipril in the treatment of hypertension. The pharmacodynamic validation of its efficacy in the therapy of initial cardiac and renal involvement].Terapevticheskii arkhiv, , Volume: 65, Issue:4, 1993
Kinins, nitric oxide, and the hypotensive effect of captopril and ramiprilat in hypertension.Hypertension (Dallas, Tex. : 1979), , Volume: 19, Issue:2, 1992
Ramipril: a review of the new ACE inhibitor.The Journal of the Arkansas Medical Society, , Volume: 88, Issue:9, 1992
[New possibilities for preparations suppressing the activity of the angiotensin-converting enzyme].Terapevticheskii arkhiv, , Volume: 64, Issue:9, 1992
Combination of ramipril and hydrochlorothiazide in the treatment of mild to moderate hypertension: Part 1--A double-blind, comparative, multicenter study in nonresponders to ramipril monotherapy.Clinical cardiology, , Volume: 15, Issue:12, 1992
[Monotherapy with the ACE-inhibitor ramipril or the calcium antagonist nitrendipine in essential hypertension].Schweizerische medizinische Wochenschrift, , Oct-03, Volume: 122, Issue:40, 1992
[Long-term blood pressure measurement for evaluating the first dose response of captopril and ramipril in patients with a stimulated renin system].Zeitschrift fur Kardiologie, , Volume: 81 Suppl 2, 1992
Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats.British journal of pharmacology, , Volume: 107, Issue:4, 1992
Effect of early onset angiotensin converting enzyme inhibition on myocardial capillaries.Hypertension (Dallas, Tex. : 1979), , Volume: 20, Issue:4, 1992
A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril.British journal of pharmacology, , Volume: 105, Issue:4, 1992
The French multicentre study of ramipril in ambulatory patients with mild-to-moderate hypertension.Clinical physiology and biochemistry, , Volume: 9, Issue:3, 1992
The analysis of a multiple-dose, combination-drug clinical trial using response surface methodology.Journal of biopharmaceutical statistics, , Volume: 2, Issue:1, 1992
Role of bradykinin in chronic antihypertensive actions of ramipril in different hypertension models.Journal of cardiovascular pharmacology, , Volume: 20 Suppl 9, 1992
Changes in peripheral sympathetic outflow of pithed spontaneously hypertensive rats after bradykinin and DesArg-bradykinin infusions: influence of converting-enzyme inhibition.Journal of cardiovascular pharmacology, , Volume: 20 Suppl 9, 1992
Role of angiotensin II receptor antagonism and converting enzyme inhibition in the progression and regression of cardiac hypertrophy in rats.Journal of hypertension. Supplement : official journal of the International Society of Hypertension, , Volume: 9, Issue:6, 1991
Long lasting arterial effects of the ACE inhibitor ramipril.Journal of human hypertension, , Volume: 5, Issue:5, 1991
24-hour blood pressure profiles in hypertensive patients administered ramipril or placebo once daily: magnitude and duration of antihypertensive effects. Ramipril Multicenter Study Group.Clinical cardiology, , Volume: 14, Issue:9, 1991
More ACE inhibitors--quinapril, perindopril & ramipril.Drug and therapeutics bulletin, , Apr-15, Volume: 29, Issue:8, 1991
The influence of ramipril on blood pressure, ACE-activity, sperm density and motility of spontaneously hypertensive rats during puberty.Die Pharmazie, , Volume: 46, Issue:5, 1991
Three new ACE inhibitors for hypertension.The Medical letter on drugs and therapeutics, , Sep-06, Volume: 33, Issue:852, 1991
Salt blocks the renal benefits of ramipril in diabetic hypertensive rats.Hypertension (Dallas, Tex. : 1979), , Volume: 17, Issue:4, 1991
Efficacy and safety of ramipril in combination with hydrochlorothiazide: results of a long-term study.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Assessment of the efficacy, tolerance, and safety of ramipril in diabetic patients with mild-to-moderate hypertension: a retrospective analysis.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
The effects of ramipril on glucose tolerance, insulin secretion, and insulin sensitivity in patients with hypertension.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Comparison of ramipril against atenolol in controlling mild-to-moderate hypertension.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Effects of ramipril on arterial hemodynamics.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Efficacy and safety of a new angiotensin-converting enzyme inhibitor, ramipril, vs. enalapril in essential hypertension: a multicenter trial.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Comparison of response rates to the angiotensin-converting enzyme inhibitor ramipril in mild-to-moderate hypertension in a double-blind, parallel-group study and an open single-blind study.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Tolerability of ramipril in a multicenter study of mild-to-moderate hypertension in general practice.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Antihypertensive efficacy, tolerance, and safety of long-term treatment with ramipril in patients with mild-to-moderate essential hypertension.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Antihypertensive efficacy, tolerance, and safety of ramipril in young vs. old patients: a retrospective study.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
The effect of ramipril on ambulatory blood pressure: a multicenter trial.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Dose-response relationship of ramipril in patients with mild-to-moderate hypertension.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
The pharmacokinetics of ramipril in a group of ten elderly patients with essential hypertension.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Effect of angiotensin-converting enzyme inhibition on human tissue renin.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Age-related variations in tissue angiotensin converting enzyme activities: comparison between spontaneously hypertensive and Wistar-Kyoto rats.Journal of hypertension, , Volume: 8, Issue:8, 1990
The measurement of intrarenal plasma flow distribution in essential hypertension. The effect of angiotensin-converting enzyme inhibition.Contributions to nephrology, , Volume: 79, 1990
In vivo concentrations of kinins and angiotensins.Hormone and metabolic research. Supplement series, , Volume: 22, 1990
[The French ambulatory multicenter trial of Triatec: conclusions of the trial].La Revue du praticien, , Jun-21, Volume: 40, Issue:18 Suppl, 1990
[Ambulatory multicenter study of Triatec (ramipril). Observations concerning the lessons of the trial for the realization of future trials and for the management of hypertensive patients].La Revue du praticien, , Jun-21, Volume: 40, Issue:18 Suppl, 1990
[Tolerance to Triatec in monotherapy and in combination with Lasilix in a French multicenter study].La Revue du praticien, , Jun-21, Volume: 40, Issue:18 Suppl, 1990
[French multicenter study of Triatec (ramipril) in ambulatory patients: methodology and trial structure].La Revue du praticien, , Jun-21, Volume: 40, Issue:18 Suppl, 1990
[Efficacy of Triatec in monotherapy and in combination with Lasilix in a French multicenter study].La Revue du praticien, , Jun-21, Volume: 40, Issue:18 Suppl, 1990
Metabolic effects of ramipril treatment in hypertensive subjects with non-insulin-dependent diabetes mellitus.Arzneimittel-Forschung, , Volume: 40, Issue:4, 1990
[Immunological effects of captopril and ramipril in patients with hypertension].Klinicheskaia meditsina, , Volume: 68, Issue:2, 1990
Role of the kidney in primary hypertension: a renal transplantation study in rats.The American journal of physiology, , Volume: 258, Issue:3 Pt 2, 1990
The effect of ramipril, a new angiotensin-converting enzyme inhibitor on cortical nephron flow and effective renal plasma flow in patients with essential hypertension.Nephron, , Volume: 54, Issue:1, 1990
Cardiovascular and renal effects of ramipril.Lancet (London, England), , Apr-15, Volume: 1, Issue:8642, 1989
Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE).British journal of clinical pharmacology, , Volume: 28 Suppl 2, 1989
Change in cough reflex after treatment with enalapril and ramipril.BMJ (Clinical research ed.), , Jul-01, Volume: 299, Issue:6690, 1989
Significance of kallikrein-kinin and renin-angiotensin systems in the hypotensive mechanism of angiotensin-I converting enzyme inhibitors in essential hypertensives.Advances in experimental medicine and biology, , Volume: 247A, 1989
Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats.Clinical and experimental hypertension. Part A, Theory and practice, , Volume: 11, Issue:7, 1989
The renin-angiotensin system and ramipril, a new converting enzyme inhibitor.Journal of cardiovascular pharmacology, , Volume: 14 Suppl 4, 1989
An open multicenter study to assess the long-term efficacy, tolerance, and safety of the oral angiotensin converting enzyme inhibitor ramipril in patients with mild to moderate essential hypertension.Journal of cardiovascular pharmacology, , Volume: 13 Suppl 3, 1989
Role of kallikrein-kinin system in the hypotensive mechanisms of converting enzyme inhibitors in essential hypertension.Journal of cardiovascular pharmacology, , Volume: 13 Suppl 3, 1989
Loop diuretics combined with an ACE inhibitor for treatment of hypertension: a study with furosemide, piretanide, and ramipril in spontaneously hypertensive rats.Journal of cardiovascular pharmacology, , Volume: 13 Suppl 3, 1989
Renin-angiotensin and vasopressin in the development of salt-induced hypertension.Journal of hypertension, , Volume: 6, Issue:12, 1988
Amelioration of systemic hypertension by converting enzyme inhibition in the renal ablation model.American journal of hypertension, , Volume: 1, Issue:2, 1988
First dose response and 24-hour antihypertensive efficacy of the new once-daily angiotensin converting enzyme inhibitor, ramipril.The American journal of cardiology, , Aug-01, Volume: 62, Issue:4, 1988
Myocardial interstitial fibrosis in experimental uremia--implications for cardiac compliance.Kidney international, , Volume: 33, Issue:4, 1988
[Interaction of chronic inhibition of the angiotensin-converting enzyme and the sympathetic system: effect of added sodium chloride load].Zeitschrift fur Kardiologie, , Volume: 77 Suppl 3, 1988
A multi-centre comparative study between ramipril and enalapril in patients with mild to moderate essential hypertension.Current medical research and opinion, , Volume: 11, Issue:2, 1988
[Pharmacologic modification of the converting enzyme--local and systemic effects on the heart and blood vessels].Zeitschrift fur Kardiologie, , Volume: 77 Suppl 3, 1988
Combined treatment of severe essential hypertension with the new angiotensin converting enzyme inhibitor ramipril.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Efficacy and safety of ramipril (HOE 498) in the treatment of hypertension: dose finding study.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Dose-response relation of the angiotensin converting enzyme inhibitor ramipril in mild to moderate essential hypertension.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
A double-blind study to compare the efficacy, tolerance and safety of two doses of the angiotensin converting enzyme inhibitor ramipril with placebo.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Comparative double-blind study of ramipril and captopril in mild to moderate essential hypertension.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Efficacy, tolerance and hormonal effects of a new oral angiotensin converting enzyme inhibitor, ramipril (HOE 498), in mild to moderate primary hypertension.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
[Influence of acute administration of ramipril on the excretion of uric acid].Archives des maladies du coeur et des vaisseaux, , Volume: 80, Issue:6, 1987
Pharmacokinetics of a single dose of ramipril in patients with renal dysfunction: comparison with essential hypertension.Journal of cardiovascular pharmacology, , Volume: 10 Suppl 7, 1987
Interference with the autonomic nervous system by the converting enzyme inhibitor ramipril in conscious spontaneously hypertensive rats.Journal of cardiovascular pharmacology, , Volume: 10 Suppl 7, 1987
Use of nuclear magnetic resonance imaging to show regression of hypertrophy with ramipril treatment.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Blood pressure response of nephrectomized subjects and patients with essential hypertension to ramipril: indirect evidence that inhibition of tissue angiotensin converting enzyme is important.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Effect of ramipril, a new angiotensin converting enzyme inhibitor, on diurnal variations of blood pressure in essential hypertension.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Short- and long-term effects of ramipril in hypertension.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Effect of ramipril on 24-hour variability of blood pressure and heart rate in essential hypertension.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Ramipril: review of pharmacology.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Clinical pharmacology of ramipril.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Effect of converting enzyme inhibitors on hypertensive large arteries in humans.Journal of hypertension. Supplement : official journal of the International Society of Hypertension, , Volume: 4, Issue:5, 1986
Humoral and blood pressure effects of the angiotensin converting enzyme inhibitor ramipril in essential hypertension.Arzneimittel-Forschung, , Volume: 36, Issue:11, 1986
[Antihypertensive action and inhibition of tissue conversion enzyme by ramipril, perindopril and enalapril in the spontaneously hypertensive rat (SHRSP)].Archives des maladies du coeur et des vaisseaux, , Volume: 79, Issue:6, 1986
Antihypertensive action and inhibition of tissue converting enzyme (CE) by three prodrug CE inhibitors, enalapril, ramipril and perindopril in stroke-prone spontaneously hypertensive rats.Journal of hypertension. Supplement : official journal of the International Society of Hypertension, , Volume: 4, Issue:3, 1986
Studies on the antihypertensive effect of single doses of the angiotensin converting enzyme inhibitor ramipril (HOE 498) in man.European journal of clinical pharmacology, , Volume: 30, Issue:5, 1986
Effects of the new angiotensin-converting enzyme inhibitor, ramipril, in patients with essential hypertension.Klinische Wochenschrift, , Jun-16, Volume: 64, Issue:12, 1986
Vascular angiotensin conversion in humans.Journal of cardiovascular pharmacology, , Volume: 8 Suppl 10, 1986
Levels of brain angiotensin in the spontaneously hypertensive rat and treatment with ramiprilat.Journal of hypertension. Supplement : official journal of the International Society of Hypertension, , Volume: 4, Issue:6, 1986
Disappearance of captopril-induced taste disturbance after substitution with angiotensin-converting-enzyme inhibitor HOE 498.Lancet (London, England), , Mar-02, Volume: 1, Issue:8427, 1985
2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498): antihypertensive action and persistent inhibition of tissue converting enzyme activity in spontaneously hypertensive rats.Arzneimittel-Forschung, , Volume: 34, Issue:10B, 1984
Effects of the new oral angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) in essential hypertension.Arzneimittel-Forschung, , Volume: 34, Issue:10B, 1984
True versus immunoreactive angiotensin II in human plasma.Hypertension (Dallas, Tex. : 1979), , Volume: 7, Issue:3 Pt 2
Persistent tissue converting enzyme inhibition following chronic treatment with Hoe498 and MK421 in spontaneously hypertensive rats.Journal of cardiovascular pharmacology, , Volume: 7, Issue:1
ARBs for cardiovascular and renal protection in high-risk patients.Cardiovascular journal of Africa, , Volume: 22, Issue:4
[spACE, the last frontier? Renin inhibition in hypertension].Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, , Volume: 25, Issue:3
The African American Study of Kidney Disease and Hypertension (AASK): new findings.Journal of clinical hypertension (Greenwich, Conn.), , Volume: 3, Issue:4
Authors' reply.Journal of postgraduate medicine, , Volume: 61, Issue:2
Antihypertensive action of the converting enzyme inhibitor perindopril (S9490-3) in spontaneously hypertensive rats: comparison with enalapril (MK421) and ramipril (Hoe498).Journal of cardiovascular pharmacology, , Volume: 8, Issue:2
Preliminary experiences with HOE 498, a novel long-acting converting enzyme inhibitor, in hypertensive patients.Journal of cardiovascular pharmacology, , Volume: 7, Issue:6
Ramipril and methyldopa compared in patients with mild to moderate hypertension.Clinical therapeutics, , Volume: 12, Issue:5
Ambulatory 24-h blood pressure monitoring in essential hypertensives treated with the angiotensin-converting enzyme inhibitor ramipril.The Journal of international medical research, , Volume: 19, Issue:1
FIXED DOSE COMBINATIONS WITH SELECTIVE BETA-BLOCKERS: QUANTITATIVE DETERMINATION IN BIOLOGICAL FLUIDS.Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi, , Volume: 119, Issue:2
Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with the two different compounds, Hoe498 and MK421, in spontaneously hypertensive rats.Journal of cardiovascular pharmacology, , Volume: 6, Issue:5
[Effect of ramipril on the glucose/insulin coefficient and the ventricular mass index in patients with light to moderate arterial hypertension].Archivos de cardiologia de Mexico, , Volume: 73, Issue:1
[Fixed combinations of antihypertensive medications--new opportunity in treatment of hypertension].Lijecnicki vjesnik, , Volume: 132, Issue:3-4
The African American Study of Kidney Disease and Hypertension (AASK) trial: what more have we learned?Journal of clinical hypertension (Greenwich, Conn.), , Volume: 5, Issue:2
[The metabolic effects of isradipine, ramipril, Ednit and beta-adrenoblockers in patients with non-insulin-dependent diabetes mellitus and arterial hypertension].Eksperimental'naia i klinicheskaia farmakologiia, , Volume: 62, Issue:2
[Inappropriate antidiuretic hormone secretion syndrome associated with ramipril treatment].Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, , Volume: 34, Issue:3
Effect of acute and long-term administration of ramipril on circadian rhythm of blood pressure in essential hypertension.Advances in therapy, , Volume: 12, Issue:1
Effect of atenolol and ramipril on regression of left ventricular hypertrophy: comparative echocardiographic assessment.Advances in therapy, , Volume: 12, Issue:2
Loss of captopril-bound Fe by end-stage renal failure patients during hemodialysis.Journal of nephrology, , Volume: 17, Issue:1
Blacks with hypertension, renal insufficiency, and baseline proteinuria benefit more from ACE inhibition than from calcium channel blockade.Journal of clinical hypertension (Greenwich, Conn.), , Volume: 3, Issue:5
Comparative Efficacy of Antihypertensive Drugs in Dogs: A Systematic Review.Topics in companion animal medicine, , Volume: 50
[Therapeutic perspectives: association of ACE inhibitors and angiotensin receptor blockers].La Clinica terapeutica, , Volume: 152, Issue:2
[Severe hypoglycemia secondary to angiotensin-converting-enzyme inhibitors in the absence of diabetes mellitus. Report of a case].Gaceta medica de Mexico, , Volume: 137, Issue:3
Urticarial vasculitis from simvastatin: what is the alternative drug?Dermatitis : contact, atopic, occupational, drug, , Volume: 21, Issue:4
An open-label, noncomparative, multicenter study of ramipril in the treatment of patients with mild-to-moderate hypertension.Clinical therapeutics, , Volume: 18, Issue:6
The role of angiotensin converting enzyme and nitric oxide in the enhanced systemic depressor responses to bradykinin in pregnant rats.Clinical and experimental pharmacology & physiology, , Volume: 22, Issue:6-7
Renal medulla and bradykinin during the development of hypertension in SHR.Clinical and experimental pharmacology & physiology, , Volume: 22, Issue:6-7
Need for new hypertension guidelines for high-risk patients.Cardiovascular journal of Africa, , Volume: 20, Issue:4
Ramipril-induced generalized pustular psoriasis: case report and literature review.American journal of therapeutics, , Volume: 17, Issue:1
Ileostomy and ramipril-induced acute renal failure and shock.Heart & lung : the journal of critical care, , Volume: 36, Issue:4
Double-blind, placebo-controlled study of ramipril in diabetics with mild to moderate hypertension.Clinical therapeutics, , Volume: 15, Issue:1
Rheological changes in hypertensive patients treated with ramipril.Clinical hemorheology and microcirculation, , Volume: 17, Issue:1
Effects of ramipril therapy on some components of insulin resistance syndrome in patients with essential hypertension.Medicinski pregled, , Volume: 55, Issue:7-8
Lessons learned with ambulatory blood pressure monitoring: a focus on ramipril.Clinical therapeutics, , Volume: 15, Issue:3
Comparison of ramipril and enalapril in patients with essential hypertension.Pharmacotherapy, , Volume: 13, Issue:3
From Tritace to Tri-Plen - the South African journey.Cardiovascular journal of Africa, , Volume: 20, Issue:1
Renin-angiotensin-aldosterone system (RAAS) block revisited.The National medical journal of India, , Volume: 21, Issue:4
Effect of ramipril therapy on cognitive functions in cases of mild to moderate essential hypertension.Indian journal of physiology and pharmacology, , Volume: 51, Issue:1
Renal tissue angiotensins during converting enzyme inhibition in the spontaneously hypertensive rat.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 19, Issue:5-6
Safety and tolerability of ramipril 10 mg in patients at high risk of cardiovascular events: an observational study.Indian heart journal, , Volume: 60, Issue:3
Tolerability of 10 mg of ramipril in normotensive Indian patients.The National medical journal of India, , Volume: 15, Issue:4
Ramipril: the better angiotensin-converting enzyme inhibitor?Indian heart journal, , Volume: 60, Issue:3
Large prospective study of ramipril in patients with hypertension. CARE Investigators.Clinical therapeutics, , Volume: 15, Issue:5
Beta blockers & left ventricular hypertrophy regression.Indian heart journal, , Volume: 62, Issue:2
[Bradykinin mediated angioedema with ACE inhibitor in combination with immunosupressive agents].Therapie, , Volume: 69, Issue:2
Achieving blood preSsure goals sTudy in uncontrolled hypeRtensive pAtients treated with a fixed-dose combination of ramipriL/hydrochlorothiazide: the ASTRAL study.Cardiovascular journal of Africa, , Volume: 22, Issue:2
[New studies on hypertension of great significance to clinical practice. Also very old persons benefit from blood pressure reduction].Lakartidningen, , Volume: 105, Issue:19
Modulation of hemodynamics, endogenous antioxidant enzymes, and pathophysiological changes by Angiotensin-converting enzyme inhibitors in pressure-overload rats.Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese, , Volume: 52, Issue:3
Correlation of renin angiotensin system (RAS) candidate gene polymorphisms with response to Ramipril in patients with essential hypertension.Journal of postgraduate medicine, , Volume: 61, Issue:1
Establishing correlation between genetics and nonresponse.Journal of postgraduate medicine, , Volume: 61, Issue:2
[Is it feasible to improve the duration and the efficiency of Ramipril anti-proteinuric response?].Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, , Volume: 32, Issue:1
[A 93-year-old patient with hypertensive crises and renal failure due to bilateral renal artery stenosis].MMW Fortschritte der Medizin, , Nov-05, Volume: 157, Issue:19, 2015
Alterations in myocardial collagen content affect rat papillary muscle function.American journal of physiology. Heart and circulatory physiology, , Volume: 279, Issue:4, 2000
The effect of non-antihypertensive doses of angiotensin converting enzyme inhibitor on myocardial necrosis and hypertrophy in young rats with renovascular hypertension.International journal of experimental pathology, , Volume: 80, Issue:2, 1999
Effect of ACE inhibitor on DOCA-salt- and aortic coarctation-induced hypertension in mice: do kinin B2 receptors play a role?Hypertension (Dallas, Tex. : 1979), , Volume: 33, Issue:1 Pt 2, 1999
Experimental evidence for effects of ramipril on cardiac and vascular hypertrophy beyond blood pressure reduction.Archives des maladies du coeur et des vaisseaux, , Volume: 88 Spec No 2, 1995
Interrelation between renin mRNA levels, renin secretion, and blood pressure in two-kidney, one clip rats.Hypertension (Dallas, Tex. : 1979), , Volume: 24, Issue:2, 1994
Control of renin gene expression in 2 kidney-1 clip rats.Kidney international, , Volume: 46, Issue:6, 1994
Plasma renin activity and changes in tissue angiotensin converting enzyme.Journal of hypertension, , Volume: 12, Issue:5, 1994
Kinin contribution to chronic antihypertensive actions of ACE-inhibitors in hypertensive rats.Agents and actions. Supplements, , Volume: 38 ( Pt 2), 1992
[Inhibition of the enzyme of conversion and cardioprotection: role of bradykinins].Diabete & metabolisme, , Volume: 18, Issue:2 Pt 2, 1992
Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril.Hypertension (Dallas, Tex. : 1979), , Volume: 20, Issue:1, 1992
Role of vascular angiotensin converting enzyme in hypertension.Journal of hypertension. Supplement : official journal of the International Society of Hypertension, , Volume: 6, Issue:3, 1988
Ramipril for hypertension secondary to renal artery stenosis. Changes in blood pressure, the renin-angiotensin system and total and divided renal function.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Cardiovascular and antihypertensive activities of the novel non-sulfhydryl converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).Arzneimittel-Forschung, , Volume: 34, Issue:10B, 1984
[Takayasu arteritis with aortic coarctation and multiple stenosis of aortic branches].Recenti progressi in medicina, , Volume: 101, Issue:7-8
High pulsatility flow stimulates smooth muscle cell hypertrophy and contractile protein expression.American journal of physiology. Lung cellular and molecular physiology, , Jan-01, Volume: 304, Issue:1, 2013
Effect of ramipril alone compared to ramipril with eplerenone on diabetic nephropathy in streptozocin-induced diabetic rats.Pharmacology, , Volume: 86, Issue:2, 2010
ACE inhibition promotes upregulation of endothelial progenitor cells and neoangiogenesis in cardiac pressure overload.Cardiovascular research, , Jul-01, Volume: 83, Issue:1, 2009
Effects of endothelin receptor antagonism and angiotensin-converting enzyme inhibition on cardiac and renal remodeling in the rat.Journal of cardiovascular pharmacology, , Volume: 31 Suppl 1, 1998
Angiotensin converting enzyme inhibition and calcium antagonism attenuate streptozotocin-diabetes-associated mesenteric vascular hypertrophy independently of their hypotensive action.Journal of hypertension, , Volume: 16, Issue:6, 1998
Influence of dietary salts on the cardiovascular effects of low-dose combination of ramipril and felodipine in spontaneously hypertensive rats.British journal of pharmacology, , Volume: 123, Issue:2, 1998
Nephroprotection by long-term ACE inhibition with ramipril in spontaneously hypertensive stroke prone rats.Kidney international, , Volume: 54, Issue:6, 1998
Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade.American journal of hypertension, , Volume: 9, Issue:9, 1996
Effect of early onset angiotensin converting enzyme inhibition on myocardial capillaries.Hypertension (Dallas, Tex. : 1979), , Volume: 20, Issue:4, 1992
Effect of chronic high- and low-dose ACE inhibitor treatment on cardiac and vascular hypertrophy and vascular function in spontaneously hypertensive rats.Experimental nephrology, , Volume: 2, Issue:2
Diabetic vascular hypertrophy and albuminuria: effect of angiotensin converting enzyme inhibition.Journal of diabetes and its complications, , Volume: 9, Issue:4
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.The New England journal of medicine, , 11-11, Volume: 385, Issue:20, 2021
Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.Lancet (London, England), , Jun-03, Volume: 389, Issue:10085, 2017
Acute Bradykinin Receptor Blockade During Hemorrhagic Shock in Mice Prevents the Worsening Hypotensive Effect of Angiotensin-Converting Enzyme Inhibitor.Critical care medicine, , Volume: 44, Issue:9, 2016
Target Blood Pressure in Patients with Diabetes: Asian Perspective.Yonsei medical journal, , Volume: 57, Issue:6, 2016
[Evaluation of efficacy and safety of hypertension treatment with original angiotensin-converting enzyme inhibitors: the comparison of original and generic formulations].Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, , Volume: 34, Issue:201, 2013
Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).Journal of the American College of Cardiology, , Jan-03, Volume: 59, Issue:1, 2012
Prophylactic vasopressin in patients receiving the angiotensin-converting enzyme inhibitor ramipril undergoing coronary artery bypass graft surgery.Journal of cardiothoracic and vascular anesthesia, , Volume: 24, Issue:2, 2010
Telmisartan, ramipril, or both in patients at high risk of vascular events.The New England journal of medicine, , Jul-24, Volume: 359, Issue:4, 2008
[ Therapy of patients at high risk for vascular events: telmisartan, ramipril or a combination? ].Der Internist, , Volume: 49, Issue:9, 2008
Ramipril prior to thrombolysis attenuates the early increase of PAI-1 in patients with acute myocardial infarction.Thrombosis and haemostasis, , Volume: 88, Issue:2, 2002
Induction of functional bradykinin b(1)-receptors in normotensive rats and mice under chronic Angiotensin-converting enzyme inhibitor treatment.Circulation, , Feb-05, Volume: 105, Issue:5, 2002
Telmisartan, ramipril and their combination improve endothelial function in different tissues in a murine model of cholesterol-induced atherosclerosis.British journal of pharmacology, , Volume: 163, Issue:4, 2011
Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerCirculation, , Mar-30, Volume: 121, Issue:12, 2010
Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/TelmAmerican heart journal, , Volume: 154, Issue:1, 2007
Effects of Ramipril on Biomarkers of Endothelial Dysfunction and Inflammation in Hypertensive Children on Maintenance Hemodialysis: the SEARCH Randomized Placebo-Controlled Trial.Hypertension (Dallas, Tex. : 1979), , Volume: 79, Issue:8, 2022
INDICATORS OF ENDOTHELIAL DYSFUNCTION, MARKERS OF INFLAMMATION AND LIPID METABOLISM IN PATIENTS WITH HYPERTENSION WITH THE ADMINISTRATION OF QUERCETIN.Wiadomosci lekarskie (Warsaw, Poland : 1960), , Volume: 75, Issue:7, 2022
Mitigation of radiation myelopathy and reduction of microglial infiltration by Ramipril, ACE inhibitor.Spinal cord, , Volume: 56, Issue:8, 2018
Effects of Angiotensin-Converting Enzyme Inhibition and Alpha 1-Adrenergic Receptor Blockade on Inflammation and Hemostasis in Human Hypertension.Journal of cardiovascular pharmacology, , Volume: 71, Issue:4, 2018
Angiotensin-converting enzyme inhibitor prevents oxidative stress, inflammation, and fibrosis in carbon tetrachloride-treated rat liver.Toxicology mechanisms and methods, , Volume: 26, Issue:1, 2016
ACE inhibitors potently reduce vascular inflammation, results of an open proof-of-concept study in the abdominal aortic aneurysm.PloS one, , Volume: 9, Issue:12, 2014
Comparative effects of angiotensin receptor blockade and ACE inhibition on the fibrinolytic and inflammatory responses to cardiopulmonary bypass.Clinical pharmacology and therapeutics, , Volume: 91, Issue:6, 2012
Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis.Journal of the American Society of Nephrology : JASN, , Volume: 23, Issue:2, 2012
The crossroad of RAAS modulation, inflammation, and oxidative stress in dialysis patients: light at the end of the tunnel?Journal of the American Society of Nephrology : JASN, , Volume: 23, Issue:2, 2012
Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study.Journal of diabetes science and technology, , Jul-01, Volume: 5, Issue:4, 2011
Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy.Nephrology (Carlton, Vic.), , Volume: 15, Issue:2, 2010
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.Current protocols in cytometry, , Volume: Chapter 13, 2010
Effect of angiotensin-converting enzyme inhibition on C-reactive protein levels: the ramipril C-reactive pRotein randomized evaluation (4R) trial results.The Canadian journal of cardiology, , Volume: 25, Issue:7, 2009
Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms.Diabetes care, , Volume: 31, Issue:1, 2008
Inflammatory activation during coronary artery surgery and its dose-dependent modulation by statin/ACE-inhibitor combination.Arteriosclerosis, thrombosis, and vascular biology, , Volume: 27, Issue:12, 2007
Differential effects of olmesartan and ramipril on inflammatory response after myocardial infarction in rats.Blood pressure, , Volume: 15, Issue:2, 2006
Lack of effect on coronary atherosclerotic disease biomarkers with modest dosing of an angiotensin-converting enzyme inhibitor, angiotensin II type-1 receptor blocker, and the combination.Coronary artery disease, , Volume: 17, Issue:5, 2006
The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences.Scandinavian journal of clinical and laboratory investigation. Supplementum, , Volume: 240, 2005
Effects of an angiotensin-converting enzyme inhibitor (ramipril) on inflammatory markers in secondary prevention patients: RAICES Study.Coronary artery disease, , Volume: 16, Issue:7, 2005
[Can coronary risks be further reduced?].Presse medicale (Paris, France : 1983), , Sep-25, Volume: 33, Issue:16, 2004
Different proinflammatory profile of three ACE inhibitors: cilazapril, enalaprilat, and ramiprilat.The American journal of medicine, , Apr-23, Volume: 94, Issue:4A, 1993
Influence of the new angiotensin converting enzyme inhibitor ramipril on several models of acute inflammation and the adjuvant arthritis in the rat.Arzneimittel-Forschung, , Volume: 36, Issue:11, 1986
The effect of ramipril therapy on cytokines and parameters of incipient diabetic nephropathy in patients with type 1 diabetes mellitus.The Journal of international medical research, , Volume: 35, Issue:3
Ramipril pretreatment worsened renal injury and survival despite a reduction in renal inflammation in experimentally induced sepsis in mice.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 21, Issue:2
Protective effect of losartan and ramipril against stress induced insulin resistance and related complications: Anti-inflammatory mechanisms.European journal of pharmacology, , Apr-15, Volume: 801, 2017
Ramipril protects the endothelium from high glucose-induced dysfunction through CaMKKβ/AMPK and heme oxygenase-1 activation.The Journal of pharmacology and experimental therapeutics, , Volume: 350, Issue:1, 2014
Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy.Nephrology (Carlton, Vic.), , Volume: 15, Issue:2, 2010
Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes.Current atherosclerosis reports, , Volume: 10, Issue:2, 2008
Comparative effects of N-acetyl-L-cysteine and ramipril on arterial hypertension, insulin resistance, and oxidative stress in chronically glucose-fed rats.Canadian journal of physiology and pharmacology, , Volume: 86, Issue:11, 2008
Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives.Journal of hypertension, , Volume: 26, Issue:12, 2008
Blockade of sensory abnormalities and kinin B(1) receptor expression by N-acetyl-L-cysteine and ramipril in a rat model of insulin resistance.European journal of pharmacology, , Jul-28, Volume: 589, Issue:1-3, 2008
Effect of ramipril on the incidence of diabetes.The New England journal of medicine, , Feb-01, Volume: 356, Issue:5, 2007
Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome.Nephrology (Carlton, Vic.), , Volume: 12, Issue:2, 2007
Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan.Blood purification, , Volume: 25, Issue:4, 2007
Effect of short-term ACE inhibitor treatment on peripheral insulin sensitivity in obese insulin-resistant subjects.Diabetologia, , Volume: 49, Issue:12, 2006
[Experiences of the DREAM trial].Orvosi hetilap, , Dec-31, Volume: 147, Issue:52, 2006
Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes.Hypertension (Dallas, Tex. : 1979), , Volume: 45, Issue:6, 2005
Insulin-sensitizing and cardiovascular effects of the sodium-hydrogen exchange inhibitor, cariporide, in the JCR: LA-cp rat and db/db mouse.Journal of cardiovascular pharmacology, , Volume: 46, Issue:6, 2005
Vasopeptidase inhibition improves insulin sensitivity and endothelial function in the JCR:LA-cp rat.Journal of cardiovascular pharmacology, , Volume: 44, Issue:2, 2004
Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE?Current medical research and opinion, , Volume: 20, Issue:3, 2004
[Involvement of angiotensin II in pathogenesis of hypertension and target organ damage].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 62 Suppl 3, 2004
Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats.Biochemical and biophysical research communications, , Mar-26, Volume: 316, Issue:1, 2004
Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: Studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptCirculation, , Apr-15, Volume: 107, Issue:14, 2003
[Hypertension and prediabetes. "Don't trust anybody over 130/80"].MMW Fortschritte der Medizin, , Mar-27, Volume: 145, Issue:13, 2003
ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time.Hypertension (Dallas, Tex. : 1979), , Volume: 40, Issue:6, 2002
Circulating amylin in human essential hypertension: heritability and early increase in individuals at genetic risk.Journal of hypertension, , Volume: 18, Issue:11, 2000
Ramipril increases the protein level of skeletal muscle IRS-1 and alters protein tyrosine phosphatase activity in spontaneously hypertensive rats.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 362, Issue:1, 2000
[The effect of ramipril on metabolic, renal and cardiac function in hypertension and type II diabetes mellitus].Vnitrni lekarstvi, , Volume: 44, Issue:6, 1998
Effect of ramipril on insulin sensitivity in obese patients. Time-course study of glucose infusion rate during euglycaemic hyperinsulinaemic clamp.Diabetes & metabolism, , Volume: 22, Issue:3, 1996
[Severe hypoglycemia secondary to angiotensin-converting-enzyme inhibitors in the absence of diabetes mellitus. Report of a case].Gaceta medica de Mexico, , Volume: 137, Issue:3
Effects of ramipril therapy on some components of insulin resistance syndrome in patients with essential hypertension.Medicinski pregled, , Volume: 55, Issue:7-8
Ramipril research papers are retracted over faked data.BMJ (Clinical research ed.), , Sep-21, Volume: 351, 2015
Ramipril improves walking times and quality of life in patients with stable intermittent claudication.Evidence-based medicine, , Volume: 19, Issue:1, 2014
Potential vascular mechanisms of ramipril induced increases in walking ability in patients with intermittent claudication.Circulation research, , Mar-28, Volume: 114, Issue:7, 2014
Ramipril helps reduce claudication.BMJ (Clinical research ed.), , Feb-06, Volume: 346, 2013
Randomized clinical trial of angiotensin-converting enzyme inhibitor, ramipril, in patients with intermittent claudication.The British journal of surgery, , Volume: 100, Issue:9, 2013
PURLs: ramipril for claudication?The Journal of family practice, , Volume: 62, Issue:10, 2013
Ramipril for treatment of intermittent claudication.VASA. Zeitschrift fur Gefasskrankheiten, , Volume: 42, Issue:4, 2013
Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. Journal of the American Medical Association 2013; 309: 453-460.Vascular medicine (London, England), , Volume: 18, Issue:4, 2013
Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial.JAMA, , Feb-06, Volume: 309, Issue:5, 2013
[Not Available].MMW Fortschritte der Medizin, , May-29, Volume: 155, Issue:10, 2013
ACP Journal Club. Ramipril improved walking times and QOL in peripheral artery disease and intermittent claudication.Annals of internal medicine, , Jun-18, Volume: 158, Issue:12, 2013
Medications for improving walking performance in peripheral artery disease: still miles to go.JAMA, , Feb-06, Volume: 309, Issue:5, 2013
Effect of ramipril on renal function in patients with intermittent claudication.Vascular health and risk management, , Volume: 4, Issue:2, 2008
Summaries for patients. Ramipril improves walking ability in patients with peripheral arterial disease.Annals of internal medicine, , May-02, Volume: 144, Issue:9, 2006
Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial.Annals of internal medicine, , May-02, Volume: 144, Issue:9, 2006
An unusual cause of exertional leg pain.Current sports medicine reports, , Volume: 3, Issue:2, 2004
Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy.American journal of nephrology, , Volume: 40, Issue:3, 2014
Inhibition of angiotensin-converting enzyme reduces rat liver reperfusion injury via bradykinin-2-receptor.The Journal of surgical research, , Volume: 134, Issue:2, 2006
Ramipril prior to thrombolysis attenuates the early increase of PAI-1 in patients with acute myocardial infarction.Thrombosis and haemostasis, , Volume: 88, Issue:2, 2002
Angiotensin AT(1) receptor signalling modulates reparative angiogenesis induced by limb ischaemia.British journal of pharmacology, , Volume: 135, Issue:1, 2002
Ramipril improves hemodynamic recovery but not microvascular response to ischemia in spontaneously hypertensive rats.American journal of hypertension, , Volume: 15, Issue:5, 2002
Alterations in myocardial collagen content affect rat papillary muscle function.American journal of physiology. Heart and circulatory physiology, , Volume: 279, Issue:4, 2000
Effects of Direct Renin Blockade on Renal & Systemic Hemodynamics and on RAAS Activity, in Weight Excess and Hypertension: A Randomized Clinical Trial.PloS one, , Volume: 12, Issue:1, 2017
Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.Kidney international, , Volume: 91, Issue:3, 2017
Pioglitazone, a PPARγ agonist, provides comparable protection to angiotensin converting enzyme inhibitor ramipril against adriamycin nephropathy in rat.European journal of pharmacology, , May-05, Volume: 730, 2014
Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading.Clinical and experimental nephrology, , Volume: 18, Issue:4, 2014
Mitigation of experimental radiation nephropathy by renin-equivalent doses of angiotensin converting enzyme inhibitors.International journal of radiation biology, , Volume: 90, Issue:9, 2014
The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.European journal of preventive cardiology, , Volume: 21, Issue:3, 2014
Antifibrotic, nephroprotective effects of paricalcitol versus calcitriol on top of ACE-inhibitor therapy in the COL4A3 knockout mouse model for progressive renal fibrosis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 29, Issue:5, 2014
[Renal amyloidosis: uncommon complication of sickle cell disease].Medecine tropicale : revue du Corps de sante colonial, , Volume: 71, Issue:2, 2011
ACE inhibition is renoprotective among obese patients with proteinuria.Journal of the American Society of Nephrology : JASN, , Volume: 22, Issue:6, 2011
Limitations of analyses based on achieved blood pressure: lessons from the African American study of kidney disease and hypertension trial.Hypertension (Dallas, Tex. : 1979), , Volume: 57, Issue:6, 2011
Mixed messages on blood pressure goals.Hypertension (Dallas, Tex. : 1979), , Volume: 57, Issue:6, 2011
REIN on obesity, proteinuria and CKD.Journal of the American Society of Nephrology : JASN, , Volume: 22, Issue:6, 2011
Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET).Circulation, , Oct-18, Volume: 124, Issue:16, 2011
Is a blood pressure target of <130/80 mm Hg still appropriate for high-risk patients?Circulation, , Oct-18, Volume: 124, Issue:16, 2011
Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway?Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 25, Issue:10, 2010
Is therapy of people with chronic kidney disease ONTARGET?Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 25, Issue:1, 2010
ONTARGET should not be over interpreted.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 25, Issue:1, 2010
Kidney flow and function in hypertension: protective effects of pycnogenol in hypertensive participants--a controlled study.Journal of cardiovascular pharmacology and therapeutics, , Volume: 15, Issue:1, 2010
Telmisartan in high-risk cardiovascular patients.The American journal of cardiology, , Jan-04, Volume: 105, Issue:1 Suppl, 2010
Renin-angiotensin system blockade and cardiovascular and renal protection.The American journal of cardiology, , Jan-04, Volume: 105, Issue:1 Suppl, 2010
Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 25, Issue:7, 2010
ONTARGET: How much RAS inhibition is enough?Current hypertension reports, , Volume: 11, Issue:1, 2009
ACE-inhibitor, AT1-receptor-antagonist, or both? A clinical pharmacologist's perspective after publication of the results of ONTARGET.Therapeutic advances in cardiovascular disease, , Volume: 2, Issue:4, 2008
Renin-angiotensin system blockade is effective in reducing proteinuria of patients with progressive nephropathy caused by MYH9 mutations (Fechtner-Epstein syndrome).Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 23, Issue:8, 2008
Quality of life in the African American Study of Kidney Disease and Hypertension: effects of blood pressure management.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 47, Issue:6, 2006
Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 45, Issue:5, 2005
The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis.Diabetologia, , Volume: 48, Issue:9, 2005
The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences.Scandinavian journal of clinical and laboratory investigation. Supplementum, , Volume: 240, 2005
Ramipril in the treatment of hypertension and proteinuria in children with chronic kidney diseases.American journal of hypertension, , Volume: 17, Issue:5 Pt 1, 2004
Mast cell infiltration and chemokine expression in progressive renal disease.Kidney international, , Volume: 64, Issue:3, 2003
Converting enzyme inhibitor or AT1-receptor blocker for decreasing long-term mortality in patients with stroke history and renal dysfunction?Stroke, , Volume: 34, Issue:1, 2003
[Further options with ramipril. Besides cardio- and nephro-protection diabetes prevention, too?].MMW Fortschritte der Medizin, , Sep-25, Volume: 145, Issue:39, 2003
Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.The Canadian journal of cardiology, , Volume: 18 Suppl A, 2002
Ramipril treatment in a patient with glycogen storage disease I non-A.Journal of inherited metabolic disease, , Volume: 25, Issue:6, 2002
The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 16, Issue:11, 2001
Prevention, protection, and the intrarenal renin-angiotensin systems.Seminars in nephrology, , Volume: 21, Issue:6, 2001
Hypertensive African Americans with kidney disease should seek advice from doctor about blood pressure medication.Ethnicity & disease, ,Winter, Volume: 11, Issue:1, 2001
Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies.Kidney international, , Volume: 59, Issue:1, 2001
Renal and vascular injury induced by exogenous angiotensin II is AT1 receptor-dependent.Nephron, , Volume: 87, Issue:1, 2001
ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy.Journal of the American Society of Nephrology : JASN, , Volume: 12, Issue:12, 2001
[Further evidence for the renoprotective effect of ACE inhibitors: ramipril protects against the progression of chronic renal insufficiency in non-diabetic nephropathy with nephrotic proteinuria].Schweizerische medizinische Wochenschrift, , Apr-01, Volume: 130, Issue:13, 2000
Should the results of the HOPE study affect nephrological practice? For the HOPE investigators.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 15, Issue:4, 2000
Renin-angiotensin system inhibitors as antihypertrophic agents.Die Pharmazie, , Volume: 55, Issue:8, 2000
Pretreatment blood pressure reliably predicts progression of chronic nephropathies. GISEN Group.Kidney international, , Volume: 58, Issue:5, 2000
Renoprotective therapy: how good can it get?Kidney international, , Volume: 57, Issue:1, 2000
Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 35, Issue:6, 2000
In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia.Journal of the American Society of Nephrology : JASN, , Volume: 10, Issue:5, 1999
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)Lancet (London, England), , Jun-28, Volume: 349, Issue:9069, 1997
Effect of ramipril on blood pressure and protein excretion rate in normotensive nondiabetic patients with proteinuria.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 28, Issue:6, 1996
[Borderline Kidney Function. Results with Piretanide and Ramipril. Symposium. Vienna, 14 December 1991].Der Internist, , Volume: 33 Suppl 1, 1992
Pharmacodynamic effects of a single 10-mg dose of the angiotensin converting enzyme inhibitor ramipril in patients with impaired renal function.Journal of cardiovascular pharmacology, , Volume: 13 Suppl 3, 1989
Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency.European journal of clinical pharmacology, , Volume: 37, Issue:3, 1989
Acute, subchronic and chronic toxicity of the new angiotensin converting enzyme inhibitor ramipril.Arzneimittel-Forschung, , Volume: 38, Issue:1, 1988
Influence of renal function on the pharmacokinetics of ramipril (HOE 498).The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Pharmacokinetics of a single dose of ramipril in patients with renal dysfunction: comparison with essential hypertension.Journal of cardiovascular pharmacology, , Volume: 10 Suppl 7, 1987
[Double blockade of the renin-angiotensin system (RAS): what has the ONTARGET study taught us?].Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, , Volume: 25, Issue:6
ARBs for cardiovascular and renal protection in high-risk patients.Cardiovascular journal of Africa, , Volume: 22, Issue:4
Renoprotective therapy: is it blood pressure or albuminuria that matters?Lancet (London, England), , Volume: 365, Issue:9463
[Is it feasible to improve the duration and the efficiency of Ramipril anti-proteinuric response?].Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, , Volume: 32, Issue:1
The African American Study of Kidney Disease and Hypertension (AASK): new findings.Journal of clinical hypertension (Greenwich, Conn.), , Volume: 3, Issue:4
Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial.Lancet (London, England), , Volume: 365, Issue:9463
Effects of Ramipril on Biomarkers of Endothelial Dysfunction and Inflammation in Hypertensive Children on Maintenance Hemodialysis: the SEARCH Randomized Placebo-Controlled Trial.Hypertension (Dallas, Tex. : 1979), , Volume: 79, Issue:8, 2022
Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension.The Cochrane database of systematic reviews, , 10-22, Volume: 10, 2020
The win ratio approach did not alter study conclusions and may mitigate concerns regarding unequal composite end points in kidney transplant trials.Journal of clinical epidemiology, , Volume: 98, 2018
Angiotensin receptor blocker vs ACE inhibitor effects on HDL functionality in patients on maintenance hemodialysis.Nutrition, metabolism, and cardiovascular diseases : NMCD, , Volume: 28, Issue:6, 2018
Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial.The lancet. Diabetes & endocrinology, , Volume: 4, Issue:4, 2016
Risk of renal dysfunction in an elderly patient with chronic heart failure.Medizinische Monatsschrift fur Pharmazeuten, , Volume: 39, Issue:10, 2016
Angiotensin Converting Enzyme Inhibitor Dialyzability and Outcomes in Older Patients Receiving Hemodialysis.Blood purification, , Volume: 40, Issue:3, 2015
Angiotensin converting enzyme inhibition increases ADMA concentration in patients on maintenance hemodialysis--a randomized cross-over study.BMC nephrology, , Oct-22, Volume: 16, 2015
Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, , Volume: 15, Issue:12, 2015
Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy.American journal of nephrology, , Volume: 40, Issue:3, 2014
Sodium intake, ACE inhibition, and progression to ESRD.Journal of the American Society of Nephrology : JASN, , Volume: 23, Issue:1, 2012
Chronic kidney disease: cardiac and renal angiotensin-converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition.Experimental physiology, , Volume: 97, Issue:4, 2012
Sodium intake, ACE inhibition, and progression to ESRD.Journal of the American Society of Nephrology : JASN, , Volume: 23, Issue:1, 2012
Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis.Journal of the American Society of Nephrology : JASN, , Volume: 23, Issue:2, 2012
Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.Circulation, , Mar-15, Volume: 123, Issue:10, 2011
ACE inhibition is renoprotective among obese patients with proteinuria.Journal of the American Society of Nephrology : JASN, , Volume: 22, Issue:6, 2011
REIN on obesity, proteinuria and CKD.Journal of the American Society of Nephrology : JASN, , Volume: 22, Issue:6, 2011
Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients.Renal failure, , Volume: 32, Issue:8, 2010
Strict blood-pressure control and progression of renal failure in children.The New England journal of medicine, , Oct-22, Volume: 361, Issue:17, 2009
Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 24, Issue:1, 2009
Severe paradoxical hypertension with angiotensin-converting enzyme inhibitors: an unusual feature of renal artery stenosis.Hypertension (Dallas, Tex. : 1979), , Volume: 54, Issue:3, 2009
[Clinical study on Shen Shuai Fang in treating chronic renal failure].Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials, , Volume: 31, Issue:5, 2008
Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans.Archives of internal medicine, , Apr-28, Volume: 168, Issue:8, 2008
Renin-angiotensin blockade and kidney disease.Lancet (London, England), , Aug-16, Volume: 372, Issue:9638, 2008
The Canadian ACE-inhibitor trial to improve renal outcomes and patient survival in kidney transplantation--study design.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 23, Issue:1, 2008
Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan.Blood purification, , Volume: 25, Issue:4, 2007
Influence of angiotensin converting enzyme inhibitor treatment on cardiac autonomic modulation in patients receiving haemodialysis.Nephrology (Carlton, Vic.), , Volume: 11, Issue:6, 2006
Lessons from the African-American Study of Kidney Disease and Hypertension: an update.Current hypertension reports, , Volume: 8, Issue:5, 2006
Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 45, Issue:5, 2005
The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.Archives of internal medicine, , Apr-25, Volume: 165, Issue:8, 2005
An update of irbesartan and renin-angiotensin system blockade in diabetic nephropathy.Expert opinion on pharmacotherapy, , Volume: 6, Issue:9, 2005
Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses.Journal of the American Society of Nephrology : JASN, , Volume: 16 Suppl 1, 2005
Blood pressure control, drug therapy, and kidney disease.Hypertension (Dallas, Tex. : 1979), , Volume: 46, Issue:1, 2005
Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents.Journal of the American Society of Nephrology : JASN, , Volume: 16, Issue:2, 2005
Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure.Kidney international, , Volume: 66, Issue:2, 2004
[Renoprotective effect of ramipril in children with chronic renal failure--the experience of one centre].Srpski arhiv za celokupno lekarstvo, , Volume: 132 Suppl 1, 2004
Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study.Annals of internal medicine, , Jul-15, Volume: 139, Issue:2, 2003
Retarding progression of chronic renal disease: the neglected issue of residual proteinuria.Kidney international, , Volume: 63, Issue:6, 2003
Antihypertensive drugs and renal protection.JAMA, , Mar-05, Volume: 289, Issue:9, 2003
Summaries for patients. Preventing worsening kidney function in patients receiving peritoneal dialysis.Annals of internal medicine, , Jul-15, Volume: 139, Issue:2, 2003
Effect of high dose ramipril with or without indomethacin on glomerular selectivity.Kidney international, , Volume: 62, Issue:3, 2002
Cardiovascular risk in patients with early renal insufficiency: implications for the use of ACE inhibitors.American journal of cardiovascular drugs : drugs, devices, and other interventions, , Volume: 2, Issue:3, 2002
Acute and long-term effects of ACE inhibition on renal haemodynamics in glomerular and interstitial nephropathies.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 3, Issue:1, 2002
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.JAMA, , Nov-20, Volume: 288, Issue:19, 2002
What is the best treatment for slowing the progression to end-stage renal disease (ESRD) in African Americans with hypertensive nephropathy?The Journal of family practice, , Volume: 50, Issue:9, 2001
Can ACE inhibitor therapy prevent end-stage renal failure?The Medical journal of Australia, , Sep-03, Volume: 175, Issue:5, 2001
Clinical trials report. The effect of Ramipril versus Amlodipine on renal outcomes in hypertension nephrosclerosis.Current hypertension reports, , Volume: 3, Issue:5, 2001
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.JAMA, , Jun-06, Volume: 285, Issue:21, 2001
ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy.Journal of the American Society of Nephrology : JASN, , Volume: 12, Issue:12, 2001
Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies.Kidney international, , Volume: 59, Issue:1, 2001
Renal protection: progression, regression, remission from nephropathy beyond blood pressure control.International journal of clinical practice. Supplement, , Issue:110, 2000
Effects of ACE inhibition and bradykinin antagonism on cardiovascular changes in uremic rats.Kidney international, , Volume: 58, Issue:1, 2000
Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 35, Issue:6, 2000
[Further evidence for the renoprotective effect of ACE inhibitors: ramipril protects against the progression of chronic renal insufficiency in non-diabetic nephropathy with nephrotic proteinuria].Schweizerische medizinische Wochenschrift, , Apr-01, Volume: 130, Issue:13, 2000
Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen)Journal of the American Society of Nephrology : JASN, , Volume: 11, Issue:1, 2000
Pretreatment blood pressure reliably predicts progression of chronic nephropathies. GISEN Group.Kidney international, , Volume: 58, Issue:5, 2000
Non-diabetic nephropathies and ACE inhibition.Lancet (London, England), , Nov-27, Volume: 354, Issue:9193, 1999
Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.Lancet (London, England), , Jul-31, Volume: 354, Issue:9176, 1999
A subdepressor low dose of ramipril lowers urinary protein excretion without increasing plasma potassium.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 33, Issue:3, 1999
Renoprotective therapy: titration against urinary protein excretion.Lancet (London, England), , Jul-31, Volume: 354, Issue:9176, 1999
Role of kinins in the renoprotective effect of angiotensin-converting enzyme inhibitors in experimental chronic renal failure.Kidney & blood pressure research, , Volume: 21, Issue:5, 1998
The renoprotective effect of angiotensin-converting enzyme inhibitors in experimental chronic renal failure is not dependent on enhanced kinin activity.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 13, Issue:1, 1998
Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).Kidney international, , Volume: 53, Issue:5, 1998
Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy.Lancet (London, England), , Oct-17, Volume: 352, Issue:9136, 1998
ACE-inhibitors: panacea for progressive renal disease.Lancet (London, England), , Jun-28, Volume: 349, Issue:9069, 1997
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)Lancet (London, England), , Jun-28, Volume: 349, Issue:9069, 1997
Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 11, Issue:6, 1996
Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure:the effects of ramipril, nifedipine and moxonidine.Journal of the American Society of Nephrology : JASN, , Volume: 7, Issue:5, 1996
Long- versus short-term effects of two different ACE inhibitors on renal haemodynamics: preliminary results from an ongoing trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 10 Suppl 6, 1995
Steady-state kinetics of ramipril in renal failure.Journal of cardiovascular pharmacology, , Volume: 13 Suppl 3, 1989
Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure.Journal of cardiovascular pharmacology, , Volume: 13 Suppl 3, 1989
Pharmacokinetics and pharmacodynamics of ramipril in renal failure.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Renoprotective therapy: is it blood pressure or albuminuria that matters?Lancet (London, England), , Volume: 365, Issue:9463
Loss of captopril-bound Fe by end-stage renal failure patients during hemodialysis.Journal of nephrology, , Volume: 17, Issue:1
Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial.Lancet (London, England), , Volume: 365, Issue:9463
Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency.Journal of nephrology, , Volume: 15, Issue:4
ACE-inhibitors and progression of chronic renal insufficiency: a contribution of Italian clinical research.Journal of nephrology, , Volume: 11, Issue:3
REIN follow-up trial. Ramipril Efficacy in Nephropathy.Lancet (London, England), , Volume: 352, Issue:9145
REIN follow-up trial. Ramipril Efficacy in Nephropathy.Lancet (London, England), , Volume: 352, Issue:9145
Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products.Journal of human hypertension, , Volume: 17, Issue:4, 2003
Activity and functional significance of the renal kallikrein-kinin-system in polycystic kidney disease of the rat.Kidney international, , Volume: 61, Issue:6, 2002
Ramipril in non-diabetic renal failure (REIN study). Ramipril Efficiency in Nephropathy study.Lancet (London, England), , Sep-06, Volume: 350, Issue:9079, 1997
Angiotensin-converting enzyme inhibitor prevents oxidative stress, inflammation, and fibrosis in carbon tetrachloride-treated rat liver.Toxicology mechanisms and methods, , Volume: 26, Issue:1, 2016
Effects of renin-angiotensin system inhibitors on fibrosis in patients with alcoholic chronic pancreatitis.Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, , Volume: 67, Issue:1, 2016
Angiotensin-converting enzyme inhibition in cirrhotic patients--pharmacokinetics of ramipril.Acta medica Austriaca, , Volume: 24, Issue:1, 1997
Centrally acting ACE inhibitor (cACEi) and angiotensin receptor blocker (cARB) use and cognitive dysfunction in patients with SLE.Lupus science & medicine, , Volume: 10, Issue:2, 2023
Ramipril Improves Endothelial Function and Increases the Number of Endothelial Progenitor Cells in Patients With Systemic Lupus Erythematosus.Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, , Oct-01, Volume: 28, Issue:7, 2022
IgA vasculitis (formerly Henoch-Schönlein purpura) in an adult with systemic lupus erythematosus.BMJ case reports, , Sep-09, Volume: 2015, 2015
Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus.Arthritis and rheumatism, , Oct-15, Volume: 53, Issue:5, 2005
Spontaneous resolution of severe mitral regurgitation in a patient with a flail mitral valve.Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography, , Volume: 23, Issue:12, 2010
Minimal change disease in association with fire coral (Millepora species) exposure.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 47, Issue:1, 2006
Effects of angiotensin-converting enzyme inhibition on mitral regurgitation severity, left ventricular size, and functional capacity.American heart journal, , Volume: 150, Issue:5, 2005
Role of echocardiography in assessing the mechanism and effect of ramipril on functional mitral regurgitation in dilated cardiomyopathy.Echocardiography (Mount Kisco, N.Y.), , Volume: 22, Issue:4, 2005
Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease.The Journal of small animal practice, , Volume: 46, Issue:3, 2005
Effect of ramipril on mitral regurgitation secondary to mitral valve prolapse.The American journal of cardiology, , Sep-01, Volume: 80, Issue:5, 1997
Randomised controlled trial into the role of ramipril in fibrosis reduction in rheumatic heart disease: the RamiRHeD trial protocol.BMJ open, , 09-13, Volume: 11, Issue:9, 2021
Cardiac angiotensin II participates in coronary microvessel inflammation of unstable angina and strengthens the immunomediated component.Circulation research, , Jun-25, Volume: 94, Issue:12, 2004
Novel method to assess arterial insufficiency in rodent hind limb.The Journal of surgical research, , Volume: 201, Issue:1, 2016
The direct renin inhibitor aliskiren improves vascular remodelling in transgenic rats harbouring human renin and angiotensinogen genes.Clinical science (London, England : 1979), , Volume: 125, Issue:4, 2013
Differential radiation effect in tumor and normal tissue after treatment with ramipril, an angiotensin-converting enzyme inhibitor.Radiation research, , Volume: 168, Issue:4, 2007
Ramipril treatment alters Ca(2+) and K(+) channels in small mesenteric arteries from Wistar-Kyoto and spontaneously hypertensive rats.American journal of hypertension, , Volume: 15, Issue:10 Pt 1, 2002
Influence of age and dietary sodium on the cardiovascular and renal effects of ramipril in spontaneously hypertensive rats.Methods and findings in experimental and clinical pharmacology, , Volume: 19, Issue:5, 1997
Influence of age on cardiovascular effects of increased dietary sodium and angiotensin-converting enzyme inhibition in normotensive Wistar rats.The Journal of pharmacy and pharmacology, , Volume: 49, Issue:9, 1997
Effects of hypercholesterolemia on the contractions to angiotensin II in the isolated aorta and iliac artery of the rabbit: role of arachidonic acid metabolites.Journal of cardiovascular pharmacology, , Volume: 30, Issue:1, 1997
Long-term effects of brief antihypertensive treatment on systolic blood pressure and vascular reactivity in young genetically hypertensive rats.Cardiovascular drugs and therapy, , Volume: 9, Issue:3, 1995
Effects of ramipril on contractile oscillations in arteries from genetically hypertensive rats.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 16, Issue:6, 1994
Angiotensin-converting enzyme inhibition during development alters calcium regulation in adult hypertensive rats.The Journal of pharmacology and experimental therapeutics, , Volume: 267, Issue:3, 1993
Long-term low-dose angiotensin converting enzyme inhibitor treatment increases vascular cyclic guanosine 3',5'-monophosphate.Hypertension (Dallas, Tex. : 1979), , Volume: 22, Issue:5, 1993
The direct renin inhibitor aliskiren improves vascular remodelling in transgenic rats harbouring human renin and angiotensinogen genes.Clinical science (London, England : 1979), , Volume: 125, Issue:4, 2013
Atrial natriuretic peptide prevents diabetes-induced endothelial dysfunction.Life sciences, , Apr-09, Volume: 82, Issue:15-16, 2008
Low-dose ramipril treatment improves relaxation and calcium cycling after established cardiac hypertrophy.American journal of physiology. Heart and circulatory physiology, , Volume: 280, Issue:3, 2001
Influence of dietary salts on the cardiovascular effects of low-dose combination of ramipril and felodipine in spontaneously hypertensive rats.British journal of pharmacology, , Volume: 123, Issue:2, 1998
Effects of hypercholesterolemia on the contractions to angiotensin II in the isolated aorta and iliac artery of the rabbit: role of arachidonic acid metabolites.Journal of cardiovascular pharmacology, , Volume: 30, Issue:1, 1997
Arterial responses to bradykinin after ramipril therapy in experimental hypertension.Pharmacology & toxicology, , Volume: 81, Issue:4, 1997
Influence of age on cardiovascular effects of increased dietary sodium and angiotensin-converting enzyme inhibition in normotensive Wistar rats.The Journal of pharmacy and pharmacology, , Volume: 49, Issue:9, 1997
Comparison of the antiatherogenic effects of isradipine and ramipril in cholesterol-fed rabbits: I. Effect on progression of atherosclerosis and endothelial dysfunction.Journal of cardiovascular pharmacology, , Volume: 23, Issue:3, 1994
Attenuation of cyclosporine A-induced vascular toxicity by ramipril.Journal of cardiovascular pharmacology, , Volume: 24, Issue:1, 1994
Comparison of the antiatherogenic effects of isradipine and ramipril in cholesterol-fed rabbits: II. Effect on regression of atherosclerosis and restoration of endothelial function.Journal of cardiovascular pharmacology, , Volume: 23, Issue:3, 1994
Role of endothelium-derived bradykinin in the control of vascular tone.Journal of cardiovascular pharmacology, , Volume: 20 Suppl 9, 1992
Local potentiation of bradykinin-induced vasodilation by converting-enzyme inhibition in isolated coronary arteries.Journal of cardiovascular pharmacology, , Volume: 20 Suppl 9, 1992
Preservation of endothelial function by ramipril in rabbits on a long-term atherogenic diet.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Ramipril restores PPARβ/δ and PPARγ expressions and reduces cardiac NADPH oxidase but fails to restore cardiac function and accompanied myosin heavy chain ratio shift in severe anthracycline-induced cardiomyopathy in rat.European journal of pharmacology, , Nov-15, Volume: 791, 2016
[Postpartum cardiomyopathy].Deutsche medizinische Wochenschrift (1946), , Volume: 136, Issue:22, 2011
Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.Clinical science (London, England : 1979), , Oct-26, Volume: 118, Issue:3, 2009
[Renal effect of treatment for heart failure].Ugeskrift for laeger, , Feb-23, Volume: 171, Issue:9, 2009
Both ramipril and telmisartan reverse indices of early diabetic cardiomyopathy: a comparative study.European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology, , Volume: 8, Issue:6, 2007
Impaired nitric oxide modulation of myocardial oxygen consumption in genetically cardiomyopathic hamsters.Journal of molecular and cellular cardiology, , Volume: 32, Issue:12, 2000
Myocardial interstitial fibrosis in experimental uremia--implications for cardiac compliance.Kidney international, , Volume: 33, Issue:4, 1988
Comparative Efficacy of Levosimendan, Ramipril, and Sacubitril/ Valsartan in Isoproterenol-induced Experimental Heart Failure: A Hemodynamic and Molecular Approach.Current molecular pharmacology, , Volume: 16, Issue:6, 2023
Firibastat Versus Ramipril After Acute Mechanical Reperfusion of Anterior Myocardial Infarction: A Phase 2 Study.American journal of cardiovascular drugs : drugs, devices, and other interventions, , Volume: 23, Issue:2, 2023
Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial.European journal of heart failure, , Volume: 24, Issue:10, 2022
The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial.Circulation, , 12-06, Volume: 146, Issue:23, 2022
Polypill Strategy in Secondary Cardiovascular Prevention.The New England journal of medicine, , 09-15, Volume: 387, Issue:11, 2022
Angiotensin Receptor-Neprilysin Inhibitor in Acute Myocardial Infarction.The Journal of the Association of Physicians of India, , Volume: 70, Issue:4, 2022
QGC606: A Best-in-Class Orally Active Centrally Acting Aminopeptidase A Inhibitor Prodrug for Treating Heart Failure Following Myocardial Infarction.The Canadian journal of cardiology, , Volume: 38, Issue:6, 2022
ACE inhibitor-related angioedema in a COVID-19 patient-a plausible contribution of the viral infection?European journal of clinical pharmacology, , Volume: 77, Issue:6, 2021
Comparison of the Efficacy and Safety of Sacubitril/Valsartan versus Ramipril in Patients With ST-Segment Elevation Myocardial Infarction.The American journal of cardiology, , 03-15, Volume: 143, 2021
Long-term survival benefit of ramipril in patients with acute myocardial infarction complicated by heart failure.Heart (British Cardiac Society), , Volume: 107, Issue:5, 2021
Efficacy of Sacubitril-Valsartan in Patients With Reduced Left Ventricular Ejection Fraction.The American journal of cardiology, , 08-15, Volume: 153, 2021
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.The New England journal of medicine, , 11-11, Volume: 385, Issue:20, 2021
Impact of different angiotensin-converting inhibitors on outcomes of post-myocardial infarction patients.Wiadomosci lekarskie (Warsaw, Poland : 1960), , Volume: 73, Issue:3, 2020
Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension.The Cochrane database of systematic reviews, , 10-22, Volume: 10, 2020
Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk.European heart journal, , 07-01, Volume: 40, Issue:25, 2019
Efficacy and Safety of Zofenopril Versus Ramipril in the Treatment of Myocardial Infarction and Heart Failure: A Review of the Published and Unpublished Data of the Randomized Double-Blind SMILE-4 Study.Advances in therapy, , Volume: 35, Issue:5, 2018
Effects of the concomitant administration of xanthine oxidase inhibitors with zofenopril or other ACE-inhibitors in post-myocardial infarction patients: a meta-analysis of individual data of four randomized, double-blind, prospective studies.BMC cardiovascular disorders, , 06-05, Volume: 18, Issue:1, 2018
Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.European heart journal, , 09-01, Volume: 39, Issue:33, 2018
Early Treatment With Zofenopril and Ramipril in Combination With Acetyl Salicylic Acid in Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction: Results of a 5-Year Follow-up of Patients of the SMILE-4 Study.Journal of cardiovascular pharmacology, , Volume: 69, Issue:5, 2017
Risk of renal dysfunction in an elderly patient with chronic heart failure.Medizinische Monatsschrift fur Pharmazeuten, , Volume: 39, Issue:10, 2016
Effect of ethanolic extract of Cyperus rotundus L. against isoprenaline induced cardiotoxicity.Indian journal of experimental biology, , Volume: 54, Issue:10, 2016
Zofenopril and ramipril in patients with left ventricular systolic dysfunction after acute myocardial infarction: A propensity analysis of the Survival of Myocardial Infarction Long-term Evaluation (SMILE) 4 study.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 17, Issue:4, 2016
Ramipril attenuates left ventricular remodeling by regulating the expression of activin A-follistatin in a rat model of heart failure.Scientific reports, , 09-19, Volume: 6, 2016
Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SMILE-4 Randomized, Double-Blind Study in Diabetic Patients.Cardiovascular therapeutics, , Volume: 34, Issue:2, 2016
Ramipril and Losartan Exert a Similar Long-Term Effect upon Markers of Heart Failure, Endogenous Fibrinolysis, and Platelet Aggregation in Survivors of ST-Elevation Myocardial Infarction: A Single Centre Randomized Trial.BioMed research international, , Volume: 2016, 2016
Zofenopril Protects Against Myocardial Ischemia-Reperfusion Injury by Increasing Nitric Oxide and Hydrogen Sulfide Bioavailability.Journal of the American Heart Association, , 07-05, Volume: 5, Issue:7, 2016
Systolic blood pressure target levels: evidence for benefits in stroke.Hypertension (Dallas, Tex. : 1979), , Volume: 65, Issue:1, 2015
Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease.Hypertension (Dallas, Tex. : 1979), , Volume: 65, Issue:1, 2015
A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors.British journal of clinical pharmacology, , Volume: 80, Issue:4, 2015
Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.Basic research in cardiology, , Volume: 109, Issue:4, 2014
The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.European journal of preventive cardiology, , Volume: 21, Issue:3, 2014
Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril.Postgraduate medicine, , Volume: 125, Issue:4, 2013
Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease.American heart journal, , Volume: 166, Issue:2, 2013
Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a retrospective analysis in hypertensive patients of the SMILE-4 study.Journal of hypertension, , Volume: 31, Issue:6, 2013
Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in CombinatioCirculation, , Aug-21, Volume: 126, Issue:8, 2012
Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.Clinical science (London, England : 1979), , Volume: 123, Issue:11, 2012
Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European studClinical cardiology, , Volume: 35, Issue:7, 2012
Effect of ramipril on the electrophysiological characteristics of ventricular myocardium after myocardial infarction in rabbits.Journal of cardiovascular medicine (Hagerstown, Md.), , Volume: 13, Issue:5, 2012
Influence of ramiprilat and losartan on ischemia reperfusion injury in rat hearts.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 13, Issue:1, 2012
A comparison between imidapril and ramipril on attenuation of ventricular remodeling after myocardial infarction.Journal of cardiovascular pharmacology, , Volume: 59, Issue:4, 2012
Comparing effects of lacidipine, ramipril, and valsartan against experimentally induced myocardial infarcted rats.Cardiovascular toxicology, , Volume: 12, Issue:2, 2012
Impact of ACE inhibitors on mortality and morbidity in patients with AMI: Does tissue selectivity matter?Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 14, Issue:1, 2011
Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.Circulation, , Mar-15, Volume: 123, Issue:10, 2011
Telmisartan for the management of patients at high cardiovascular risk.Current medical research and opinion, , Volume: 27, Issue:8, 2011
The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study.Journal of medical economics, , Volume: 14, Issue:6, 2011
Ramipril-like activity of Spondias mombin linn against no-flow ischemia and isoproterenol-induced cardiotoxicity in rat heart.Cardiovascular toxicology, , Volume: 10, Issue:4, 2010
[Efficacy of ramipril, carvedilol, and trimetazidine MR in improvement of quality of life of patients after myocardial infarction].Kardiologiia, , Volume: 50, Issue:12, 2010
Age-related short-term effect of ramipril on N-terminal pro-brain natriuretic peptide and markers of hemostasis in patients after acute myocardial infarction.Wiener klinische Wochenschrift, , Volume: 122 Suppl 2, 2010
The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial.Journal of cardiovascular electrophysiology, , Volume: 20, Issue:7, 2009
Investigation of effects of Lacidipine, Ramipril and Valsartan on DNA damage and oxidative stress occurred in acute and chronic periods following isoproterenol-induced myocardial infarct in rats.Molecular and cellular biochemistry, , Volume: 328, Issue:1-2, 2009
The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice.Experimental physiology, , Volume: 94, Issue:3, 2009
[The use of angiotensin converting enzyme inhibitors in patients after myocardial infarction].Kardiologiia, , Volume: 48, Issue:11, 2008
Attenuation of left ventricular dysfunction by an ACE inhibitor after myocardial infarction in a kininogen-deficient rat model.Biological chemistry, , Volume: 389, Issue:6, 2008
Long-term but not short-term p38 mitogen-activated protein kinase inhibition improves cardiac function and reduces cardiac remodeling post-myocardial infarction.The Journal of pharmacology and experimental therapeutics, , Volume: 325, Issue:3, 2008
A proteomic study of the effects of ramipril on post-infarction left ventricular remodelling in the rabbit.European journal of heart failure, , Volume: 10, Issue:8, 2008
Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes.Current atherosclerosis reports, , Volume: 10, Issue:2, 2008
[Investigation of converting enzyme inhibitors in patients, survivors of myocardial infarction].Kardiologiia, , Volume: 48, Issue:7, 2008
Chronic angiotensin II receptor blockade induces cardioprotection during ischemia by increased PKC-epsilon expression in the mouse heart.Journal of cardiovascular pharmacology, , Volume: 49, Issue:1, 2007
Impact of ramipril on the circadian periodicity of acute myocardial infarction.The American journal of cardiology, , Sep-15, Volume: 98, Issue:6, 2006
Lipid peroxidation is not increased in heart failure patients on modern pharmacological therapy.International journal of cardiology, , Oct-10, Volume: 112, Issue:3, 2006
Differential effects of olmesartan and ramipril on inflammatory response after myocardial infarction in rats.Blood pressure, , Volume: 15, Issue:2, 2006
Is ramipril really better than other angiotensin-converting enzyme inhibitors after acute myocardial infarction?The American journal of cardiology, , Jul-01, Volume: 98, Issue:1, 2006
Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study.Circulation, , Jul-18, Volume: 114, Issue:3, 2006
Redefining the ACE-inhibitor dose-response relationship: substantial blood pressure lowering after massive doses.European journal of clinical pharmacology, , Volume: 62, Issue:12, 2006
Cardioprotective activity of alcoholic extract of Tinospora cordifolia in ischemia-reperfusion induced myocardial infarction in rats.Biological & pharmaceutical bulletin, , Volume: 28, Issue:12, 2005
[Experiences with the realisation of the innovative study designs using the example of the HOPE study -- concerning the contribution in DMW Supplement 2/2005].Deutsche medizinische Wochenschrift (1946), , Nov-25, Volume: 130, Issue:47, 2005
[Olmesartan after experimental myocardial infarct compared with ramipril: organ protective effect].Krankenpflege Journal, , Volume: 43, Issue:4-6, 2005
Effects of combined inhibition of the Na+-H+ exchanger and angiotensin-converting enzyme in rats with congestive heart failure after myocardial infarction.British journal of pharmacology, , Volume: 146, Issue:5, 2005
Effects of purified herbal extract of Salvia miltiorrhiza on ischemic rat myocardium after acute myocardial infarction.Life sciences, , Apr-29, Volume: 76, Issue:24, 2005
Combined effects of ramipril and angiotensin II receptor blocker TCV116 on rat congestive heart failure after myocardial infarction.Chinese medical journal, , Jan-20, Volume: 118, Issue:2, 2005
The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences.Scandinavian journal of clinical and laboratory investigation. Supplementum, , Volume: 240, 2005
Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia.FASEB journal : official publication of the Federation of American Societies for Experimental Biology, , Volume: 19, Issue:9, 2005
Impact of cigarette smoking in high-risk patients participating in a clinical trial. A substudy from the Heart Outcomes Prevention Evaluation (HOPE) trial.European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology, , Volume: 12, Issue:1, 2005
[Experiences with the realisation of innovative study designs using the example of the HOPE-study].Deutsche medizinische Wochenschrift (1946), , Jul-08, Volume: 130 Suppl 2, 2005
Myocardial infarction increases ACE2 expression in rat and humans.European heart journal, , Volume: 26, Issue:4, 2005
[Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].Italian heart journal : official journal of the Italian Federation of Cardiology, , Volume: 6 Suppl 7, 2005
The problem of underdosing of angiotensin-converting enzyme inhibitors is markedly overrated: results from a study of patients discharged from hospital after an acute myocardial infarction.European journal of clinical pharmacology, , Volume: 60, Issue:3, 2004
[Preventive therapy with ACE inhibitors for coronary patients].Orvosi hetilap, , Feb-29, Volume: 145, Issue:9, 2004
Angina pectoris prior to myocardial infarction protects against subsequent left ventricular remodeling.Journal of the American College of Cardiology, , May-05, Volume: 43, Issue:9, 2004
Ischemic preconditioning in coronary heart disease: a therapeutic golden fleece?Journal of the American College of Cardiology, , May-05, Volume: 43, Issue:9, 2004
[Can coronary risks be further reduced?].Presse medicale (Paris, France : 1983), , Sep-25, Volume: 33, Issue:16, 2004
Comparison of cardioprotective effects of mibefradil and ramipril in stroke-prone spontaneously hypertensive rats.Acta pharmacologica Sinica, , Volume: 25, Issue:6, 2004
Extended follow-up of patients randomly assigned in the Angiotensin-converting enzyme inhibition Post-Revascularization Study (APRES).American heart journal, , Volume: 148, Issue:3, 2004
Should all patients with coronary disease receive angiotensin-converting-enzyme inhibitors?Lancet (London, England), , Sep-06, Volume: 362, Issue:9386, 2003
Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study.Circulation, , Mar-11, Volume: 107, Issue:9, 2003
Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study.Circulation, , Feb-25, Volume: 107, Issue:7, 2003
Randomized, double-blind, placebo-controlled long-term study of isosorbide-5-mononitrate therapy in patients with left ventricular dysfunction after acute myocardial infarction.American heart journal, , Volume: 145, Issue:1, 2003
[Ramipril after myocardial infarct. Long lasting cardiovascular protective action].MMW Fortschritte der Medizin, , Sep-25, Volume: 145, Issue:39, 2003
[Fast and strong lowering of pressure. The newest sartan has passed the practice test].MMW Fortschritte der Medizin, , Oct-30, Volume: 145, Issue:44, 2003
Comparison of cardioprotective effects using ramipril and DanShen for the treatment of acute myocardial infarction in rats.Life sciences, , Aug-01, Volume: 73, Issue:11, 2003
Mechanisms of myocardial remodeling: ramiprilat blocks the expressional upregulation of protein kinase C-epsilon in the surviving myocardium early after infarction.Journal of cardiovascular pharmacology, , Volume: 41, Issue:5, 2003
Infarct size limiting effect of apstatin alone and in combination with enalapril, lisinopril and ramipril in rats with experimental myocardial infarction.Pharmacological research, , Volume: 48, Issue:6, 2003
[Therapy of hypertension. Lasting organ protection moves into the foreground].MMW Fortschritte der Medizin, , Nov-20, Volume: 145, Issue:47, 2003
Adding angiotensin II type 1 receptor blockade to angiotensin-converting enzyme inhibition limits myocyte remodeling after myocardial infarction.Journal of cardiac failure, , Volume: 9, Issue:3, 2003
Economic impact of ramipril on hospitalization of high-risk cardiovascular patients.The Annals of pharmacotherapy, , Volume: 37, Issue:3, 2003
[Vascular patient with high infarction risk. Does the AT-1 blocker protect as well as an ACE inhibitor?].MMW Fortschritte der Medizin, , Dec-18, Volume: 145, Issue:51-52, 2003
Effects of diuretic treatment on cardiac and circulating RAS in chronic heart failure post-myocardial infarction in rats.European journal of heart failure, , Volume: 5, Issue:3, 2003
Aldosterone receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure.Cardiovascular research, , Jun-01, Volume: 58, Issue:3, 2003
Ramipril improves nitric oxide availability in hypertensive rats with failing hearts after myocardial infarction.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 4, Issue:3, 2003
Effect of ramipril and furosemide treatment on interstitial remodeling in post-infarction heart failure rat hearts.Journal of molecular and cellular cardiology, , Volume: 34, Issue:2, 2002
Effect of long-term therapy with ramipril in high-risk women.Journal of the American College of Cardiology, , Aug-21, Volume: 40, Issue:4, 2002
"Preemptive strike" heart medications. A.C.E. inhibitors gain new ground as multi-purpose cardiac drugs.Heart advisor, , Volume: 5, Issue:2, 2002
Ramipril prior to thrombolysis attenuates the early increase of PAI-1 in patients with acute myocardial infarction.Thrombosis and haemostasis, , Volume: 88, Issue:2, 2002
Impact of ramipril versus other angiotensin-converting enzyme inhibitors on outcome of unselected patients with ST-elevation acute myocardial infarction.The American journal of cardiology, , Nov-15, Volume: 90, Issue:10, 2002
[Dangerous plaque often symptom-free. ACE inhibitors prevent rupture].MMW Fortschritte der Medizin, , Aug-22, Volume: 144, Issue:33-34, 2002
Using ACE inhibitors appropriately.American family physician, , Aug-01, Volume: 66, Issue:3, 2002
A prospective evaluation of the angiotensin-converting enzyme D/I polymorphism and left ventricular remodeling in the 'Healing and Early Afterload Reducing Therapy' study.Clinical genetics, , Volume: 61, Issue:1, 2002
The angiotensin-converting enzyme gene I/D polymorphism and heart rate variability following acute myocardial infarction.Clinical autonomic research : official journal of the Clinical Autonomic Research Society, , Volume: 12, Issue:2, 2002
Cost-effectiveness of the treatment of heart failure with ramipril: a Spanish analysis of the AIRE study.European journal of heart failure, , Volume: 4, Issue:4, 2002
Combined angiotensin II receptor antagonism and angiotensin-converting enzyme inhibition further attenuates postinfarction left ventricular remodeling.Circulation, , Jun-12, Volume: 103, Issue:23, 2001
Combined angiotensin converting enzyme inhibition and angiotensin AT(1) receptor blockade up-regulates myocardial AT(2) receptors in remodeled myocardium post-infarction.Cardiovascular research, , Volume: 51, Issue:1, 2001
Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B(2) kinin receptor gene knockout mice.Circulation research, , May-25, Volume: 88, Issue:10, 2001
[Atherosclerosis. High dosage ACE inhibitor keeps event rate under control].MMW Fortschritte der Medizin, , Mar-29, Volume: 143, Issue:13, 2001
Management of asymptomatic left ventricular dysfunction.Cleveland Clinic journal of medicine, , Volume: 68, Issue:3, 2001
What are 'tissue ACE inhibitors,' and should they be used instead of other ACE inhibitors?Cleveland Clinic journal of medicine, , Volume: 68, Issue:3, 2001
[ACE inhibition in patients with myocardial infarct and ventricular dysfunction: inappropriate application of therapy standards in patient samples].Zeitschrift fur Kardiologie, , Volume: 90, Issue:2, 2001
Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study.Annals of internal medicine, , Mar-20, Volume: 134, Issue:6, 2001
Regional wall stress predicts ventricular remodeling after anteroseptal myocardial infarction in the Healing and Early Afterload Reducing Trial (HEART): an echocardiography-based structural analysis.American heart journal, , Volume: 141, Issue:2, 2001
[Achieving vascular protection. ACE inhibitor lowers not only blood pressure].MMW Fortschritte der Medizin, , Sep-06, Volume: 143, Issue:35-36, 2001
Apstatin, a selective inhibitor of aminopeptidase P, reduces myocardial infarct size by a kinin-dependent pathway.British journal of pharmacology, , Volume: 134, Issue:2, 2001
Diabetes and the HOPE study: implications for macrovascular and microvascular disease.International journal of clinical practice. Supplement, , Issue:117, 2001
Inhibitors of bradykinin-inactivating enzymes decrease myocardial ischemia/reperfusion injury following 3 and 7 days of reperfusion.The Journal of pharmacology and experimental therapeutics, , Volume: 298, Issue:3, 2001
The Heart Outcomes Prevention Evaluation study: angiotensin-converting enzyme inhibitors: are their benefits a class effect or do individual agents differ?Current opinion in nephrology and hypertension, , Volume: 10, Issue:5, 2001
Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study.Circulation, , Jul-31, Volume: 104, Issue:5, 2001
Changes in vasoconstrictive hormones, natriuretic peptides, and left ventricular remodeling soon after anterior myocardial infarction.American heart journal, , Volume: 142, Issue:6, 2001
Angiotensin-converting enzyme inhibitors in antihypertensive therapy.Current hypertension reports, , Volume: 2, Issue:2, 2000
Combined treatment with ramipril and metoprolol prevents changes in the creatine kinase isoenzyme system and improves hemodynamic function in rat hearts after myocardial infarction.Cardiovascular drugs and therapy, , Volume: 14, Issue:6, 2000
[How should ACE inhibitors be used in myocardial infarction?].Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, , Nov-20, Volume: 120, Issue:28, 2000
Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT(1)-receptor antagonism.British journal of pharmacology, , Volume: 131, Issue:1, 2000
HOPE for all people with diabetes? Heart Outcomes Prevention Evaluation.Diabetic medicine : a journal of the British Diabetic Association, , Volume: 17 Suppl 2, 2000
Effects of ACE inhibitor, AT1 antagonist, and combined treatment in mice with heart failure.Journal of cardiovascular pharmacology, , Volume: 36, Issue:4, 2000
The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES).Journal of the American College of Cardiology, , Mar-15, Volume: 35, Issue:4, 2000
[Symposium "Emerging Approaches to Cardiovascular Diseases: Detailed results and implications of the HOPE Study". Atlanta, 10. November 1999].Der Internist, , Volume: 41, Issue:1, 2000
Effects of metoprolol and ramipril on action potentials after myocardial infarction in rats.European journal of pharmacology, , Feb-04, Volume: 388, Issue:3, 2000
ACE inhibition in cardiovascular disease.The New England journal of medicine, , Jan-20, Volume: 342, Issue:3, 2000
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.The New England journal of medicine, , 01-20, Volume: 342, Issue:3, 2000
Hidden benefits of ACE inhibitors.Harvard heart letter : from Harvard Medical School, , Volume: 10, Issue:6, 2000
Ramipril.International journal of clinical practice, , Volume: 54, Issue:4, 2000
ACE inhibitors: new hope for old drugs?South Dakota journal of medicine, , Volume: 53, Issue:8, 2000
[ACE inhibitor even prevents diabetes. Sensational HOPE Study].MMW Fortschritte der Medizin, , Sep-30, Volume: 141, Issue:39, 1999
Effects of ramipril on cardiac gene transcription levels of angiotensin II receptors after myocardial infarction.Zhongguo yao li xue bao = Acta pharmacologica Sinica, , Volume: 20, Issue:6, 1999
A safe new dose of heart protection. Study shows drug can prevent attacks, strokes.U.S. news & world report, , Nov-22, Volume: 127, Issue:20, 1999
Ramipril study suggests drug may benefit broad group of patients.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Dec-15, Volume: 56, Issue:24, 1999
Beta-blockade improves adjacent regional sympathetic innervation during postinfarction remodeling.The American journal of physiology, , Volume: 277, Issue:4, 1999
The prognostic significance of a history of systemic hypertension in patients randomised to either placebo or ramipril following acute myocardial infarction: evidence from the AIRE study. Acute Infarction Ramipril Efficacy.Journal of human hypertension, , Volume: 13, Issue:8, 1999
beta blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: evidence from the AIRE study.Heart (British Cardiac Society), , Volume: 81, Issue:1, 1999
Ramipril reduces QT dispersion in patients with acute myocardial infarction and heart failure.The American journal of cardiology, , Mar-15, Volume: 83, Issue:6, 1999
Effect of ramiprilat or captopril on myocardial infarct size: assessment in canine models of ischemia alone and ischemia with reperfusion.Pharmacology, , Volume: 57, Issue:1, 1998
Changes in left ventricular mass and volumes in patients receiving angiotensin-converting enzyme inhibitor therapy for left ventricular dysfunction after Q-wave myocardial infarction.American heart journal, , Volume: 136, Issue:2, 1998
Postinfarction survival and inducibility of ventricular arrhythmias in the spontaneously hypertensive rat : effects of ramipril and hydralazine.Circulation, , Nov-10, Volume: 98, Issue:19, 1998
Treatment with ramipril improves systolic function even in patients with mild systolic dysfunction and symptoms of heart failure after acute myocardial infarction.Clinical cardiology, , Volume: 21, Issue:11, 1998
Bradykinin and the therapeutic actions of angiotensin-converting enzyme inhibitors.The American journal of cardiology, , Nov-19, Volume: 82, Issue:10A, 1998
Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance.PharmacoEconomics, , Volume: 14, Issue:6, 1998
Angiotensin-converting enzyme inhibitor therapy affects left ventricular mass in patients with ejection fraction > 40% after acute myocardial infarction.Journal of the American College of Cardiology, , Volume: 29, Issue:1, 1997
ACE inhibitors in heart failure: effect on mode of death.European heart journal, , Volume: 18, Issue:1, 1997
Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators.European heart journal, , Volume: 18, Issue:1, 1997
Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.The Journal of clinical investigation, , Apr-15, Volume: 99, Issue:8, 1997
Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy.Lancet (London, England), , May-24, Volume: 349, Issue:9064, 1997
Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial.Circulation, , Jun-17, Volume: 95, Issue:12, 1997
Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators.Circulation, , Jul-15, Volume: 96, Issue:2, 1997
AIRE Extension (AIREX) Study.Lancet (London, England), , Aug-02, Volume: 350, Issue:9074, 1997
Incidence and natural history of left ventricular thrombus following anterior wall acute myocardial infarction.The American journal of cardiology, , Aug-15, Volume: 80, Issue:4, 1997
[Effects of ramipril and spironolactone on ventricular remodeling after acute myocardial infarction: randomized and double-blind study].Revista medica de Chile, , Volume: 125, Issue:6, 1997
ACE inhibition decreases postoperative mortality in rats with left ventricular hypertrophy and myocardial infarction.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 18, Issue:5, 1996
Angiotensin-converting enzyme inhibition limits dysfunction in adjacent noninfarcted regions during left ventricular remodeling.Journal of the American College of Cardiology, , Volume: 27, Issue:1, 1996
Effect of ramipril and losartan on collagen expression in right and left heart after myocardial infarction.Molecular and cellular biochemistry, , Dec-06, Volume: 165, Issue:1, 1996
Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats.Hypertension (Dallas, Tex. : 1979), , Volume: 27, Issue:1, 1996
How ACE inhibitors reduce death from myocardial infarction: hypotheses from the AIRE study. Acute Infarction Ramipril Efficacy study.British journal of clinical practice. Supplement, , Volume: 84, 1996
Quantitative assessment of daily physical activity levels in patients with chronic heart failure by measuring energy expenditure--effects of converting enzyme inhibitor therapy.Japanese circulation journal, , Volume: 59, Issue:10, 1995
The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors.The Annals of thoracic surgery, , Volume: 60, Issue:3, 1995
Ramipril. An updated review of its therapeutic use in essential hypertension and heart failure.Drugs, , Volume: 49, Issue:3, 1995
When a question has an answer: rationale for our early termination of the HEART Trial.The American journal of cardiology, , Jun-01, Volume: 75, Issue:16, 1995
Neurohormonal activation in patients with acute myocardial infarction or chronic congestive heart failure. With special reference to treatment with angiotensin converting enzyme inhibitors.Blood pressure. Supplement, , Volume: 1, 1995
Inhibition of ACE/Kininase-II after myocardial infarction--addendum.Cardiovascular research, , Volume: 28, Issue:2, 1994
[Angiotensin converting enzyme inhibitors during acute phase of myocardial infarct].Giornale italiano di cardiologia, , Volume: 24, Issue:1, 1994
ACE-inhibitor therapy after myocardial infarction--a new treatment strategy.Zeitschrift fur Kardiologie, , Volume: 83 Suppl 4, 1994
[Reduction of infarct size and remodeling after ramipril].Zeitschrift fur Kardiologie, , Volume: 83 Suppl 4, 1994
ACE inhibition, atherosclerosis and myocardial infarction--the AIRE Study in practice. Acute Infarction Ramipril Efficacy Study.European heart journal, , Volume: 15 Suppl B, 1994
Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition.European journal of pharmacology, , Apr-06, Volume: 234, Issue:2-3, 1993
Do angiotensin converting enzyme inhibitors limit myocardial infarct size?Clinical and experimental pharmacology & physiology, , Volume: 20, Issue:6, 1993
Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.Lancet (London, England), , Oct-02, Volume: 342, Issue:8875, 1993
Validation of primary and secondary outcomes and classification of mode of death among patients with clinical evidence of heart failure after a myocardial infarction: a report from the Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.Journal of cardiovascular pharmacology, , Volume: 22 Suppl 9, 1993
Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140.Journal of cardiovascular pharmacology, , Volume: 21, Issue:6, 1993
Acronyms and myocardial infarction studies.Clinical cardiology, , Volume: 15, Issue:4, 1992
The possible role of bradykinin in the antiischemic activity of ACE-inhibitors.Agents and actions. Supplements, , Volume: 38 ( Pt 3), 1992
Development and modulation of experimental right ventricular hypertrophy in rats.Journal of cardiovascular pharmacology, , Volume: 20 Suppl 1, 1992
The Acute Infarction Ramipril Efficacy (AIRE) Study: rationale, design, organization, and outcome definitions.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist.European journal of pharmacology, , Jul-03, Volume: 182, Issue:2, 1990
Multicap to improve adherence after acute coronary syndromes: results of a randomized controlled clinical trial.Therapeutic advances in cardiovascular disease, , Volume: 14
[Ramipril and new therapeutic possibilities for ACE-inhibitors].La Clinica terapeutica, , Volume: 151, Issue:4
Early administration of ramipril in acute myocardial infarction: neurohormonal and hemodynamic effects and tolerability.Cardiology, , Volume: 88, Issue:6
[Effect of the angiotensin-converting enzyme inhibitor ramipril on the processes of lipid peroxidation on the status of the endogenous antioxidant system in patients with myocardial infarction].Patologicheskaia fiziologiia i eksperimental'naia terapiia, , Issue:4
Angiotensin converting enzyme inhibitors in acute myocardial infarction.Indian heart journal, , Volume: 46, Issue:4
New uses for old drug: reducing risk of heart attacks and strokes.FDA consumer, , Volume: 35, Issue:1
ACE inhibitors after myocardial infarction.Lancet (London, England), , Volume: 2, Issue:8678-8679
A randomized trial comparing the effect of ramipril and losartan in survivors of ST-elevation myocardial infarction.The Journal of international medical research, , Volume: 37, Issue:5
Zofenopril versus ramipril in the early phase of acute myocardial infarction with systolic dysfunction: A retrospective study.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 21, Issue:3
Do ACE inhibitors have a real role in coronary artery disease?Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners, , Volume: 14, Issue:3
Study at up to 700 sites will build on landmark HOPE trial.Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners, , Volume: 12, Issue:2
ACE inhibitors after myocardial infarction.The British journal of clinical practice, , Volume: 49, Issue:4
Expectoration of bronchial casts in association with Ramipril treatment.Cardiology in the young, , Volume: 29, Issue:12, 2019
Myocarditis and pericarditis in the course of colitis ulcerosa.Kardiologia polska, , Volume: 72, Issue:4, 2014
A young patient with heart failure: picture quiz question.Acute medicine, , Volume: 11, Issue:1, 2012
[Improvement of left ventricular function during combined carvedilol, ramipril and spironolactone therapy after myocarditis in patient treated earlier by chemotherapy due to Hodgkin's lymphoma - 3-years follow-up].Kardiologia polska, , Volume: 68, Issue:7, 2010
A case of acute myocarditis caused by pandemic (H1N1) 2009 influenza virus.Journal of the Formosan Medical Association = Taiwan yi zhi, , Volume: 109, Issue:11, 2010
A Comparison of Ramipril and Bevacizumab to Mitigate Radiation-Induced Brain Necrosis: An Experimental Study.World neurosurgery, , Volume: 144, 2020
Effect of ethanolic extract of Cyperus rotundus L. against isoprenaline induced cardiotoxicity.Indian journal of experimental biology, , Volume: 54, Issue:10, 2016
Effects of blockade of the renin-angiotensin and endothelin systems on experimental bronchiolitis obliterans.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, , Volume: 25, Issue:11, 2006
Differential effects of saralasin and ramiprilat, the inhibitors of renin-angiotensin system, on cerulein-induced acute pancreatitis.Regulatory peptides, , Mar-28, Volume: 111, Issue:1-3, 2003
The effect of non-antihypertensive doses of angiotensin converting enzyme inhibitor on myocardial necrosis and hypertrophy in young rats with renovascular hypertension.International journal of experimental pathology, , Volume: 80, Issue:2, 1999
Nephroprotection by long-term ACE inhibition with ramipril in spontaneously hypertensive stroke prone rats.Kidney international, , Volume: 54, Issue:6, 1998
Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis.Circulation, , Apr-01, Volume: 91, Issue:7, 1995
Cardiovascular and systemic microvascular effects of anti-vascular endothelial growth factor therapy for cancer.Journal of the American College of Cardiology, , Aug-14, Volume: 60, Issue:7, 2012
Meta-analysis of randomized controlled trials on effect of angiotensin-converting enzyme inhibitors on cancer risk.The American journal of cardiology, , Jul-15, Volume: 108, Issue:2, 2011
Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growtThe Journal of pharmacology and experimental therapeutics, , Volume: 329, Issue:3, 2009
Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3-/- Mice.Journal of the American Society of Nephrology : JASN, , 09-01, Volume: 34, Issue:9, 2023
Long-term ACE inhibition in Alport syndrome: are the benefits worth the risks?Kidney international, , Volume: 97, Issue:6, 2020
A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndrome.Kidney international, , Volume: 97, Issue:6, 2020
Challenges for academic investigator-initiated pediatric trials for rare diseases.Clinical therapeutics, , Feb-01, Volume: 36, Issue:2, 2014
Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome.Kidney international, , Volume: 63, Issue:2, 2003
Renoprotection: clues from knockout models of rare diseases.Kidney international, , Volume: 63, Issue:2, 2003
Interstitial nephritis and autoimmune pancreatitis: a case report.International urology and nephrology, , Volume: 44, Issue:1, 2012
Long-term treatment with ramipril attenuates renal osteopontin expression in diabetic rats.Kidney international, , Volume: 63, Issue:2, 2003
Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products.Journal of human hypertension, , Volume: 17, Issue:4, 2003
Acute and long-term effects of ACE inhibition on renal haemodynamics in glomerular and interstitial nephropathies.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 3, Issue:1, 2002
Osteopontin expression in progressive renal injury in remnant kidney: role of angiotensin II.Kidney international, , Volume: 58, Issue:4, 2000
[Choroidal effusion after uncomplicated cataract surgery].Klinische Monatsblatter fur Augenheilkunde, , Volume: 225, Issue:6, 2008
Minimal change disease in association with fire coral (Millepora species) exposure.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 47, Issue:1, 2006
Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance.PharmacoEconomics, , Volume: 19, Issue:5 Pt 1, 2001
Heart rate variability in nephrotic syndrome: Role of sympathetic and parasympathetic system.European journal of internal medicine, , Volume: 54, 2018
An enigmatic trio of Klinefelter's syndrome, autoimmune hypothyroidism and nephrotic syndrome.The journal of the Royal College of Physicians of Edinburgh, , Volume: 47, Issue:2, 2017
Pierson syndrome in an adolescent girl with nephrotic range proteinuria but a normal GFR.Pediatric nephrology (Berlin, Germany), , Volume: 27, Issue:5, 2012
Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation.Transplant international : official journal of the European Society for Organ Transplantation, , Volume: 22, Issue:11, 2009
[Choroidal effusion after uncomplicated cataract surgery].Klinische Monatsblatter fur Augenheilkunde, , Volume: 225, Issue:6, 2008
Minimal change disease in association with fire coral (Millepora species) exposure.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 47, Issue:1, 2006
Comparative study of angiotensin converting enzyme inhibitor and calcium channel blocker in the treatment of steroid-resistant idiopathic nephrotic syndrome.The Journal of the Association of Physicians of India, , Volume: 52, 2004
Collapsing glomerulopathy coexisting with membranous glomerulonephritis in native kidney biopsies: a report of 3 HIV-negative patients.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 42, Issue:3, 2003
Diarrhea, nephrotic syndrome and hidradenitis suppurativa: an unusual case.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 18, Issue:1, 2003
[Effect of the angiotensin-converting enzyme inhibitor ramipril on proteinuria, blood pressure and kidney function in histologically confirmed glomerulonephritis with nephrotic syndrome].Zeitschrift fur Kardiologie, , Volume: 77 Suppl 3, 1988
A hepatitis C-positive patient with new onset of nephrotic syndrome and systemic amyloidosis secondary to common variable immunodeficiency.Annals of Saudi medicine, , Volume: 30, Issue:5
Differential effects of RYGB surgery and best medical treatment for obesity-diabetes on intestinal and islet adaptations in obese-diabetic ZDSD rats.PloS one, , Volume: 17, Issue:9, 2022
Ramipril/amlodipine single pill - effectiveness, tolerance and patient satisfaction with antihypertensive therapy in relation to nutritional status.Pharmacological reports : PR, , Volume: 66, Issue:6, 2014
Obesity and oxidative stress predict AKI after cardiac surgery.Journal of the American Society of Nephrology : JASN, , Volume: 23, Issue:7, 2012
Double blockade of angiotensin II (AT(1) )-receptors and ACE does not improve weight gain and glucose homeostasis better than single-drug treatments in obese rats.British journal of pharmacology, , Volume: 165, Issue:8, 2012
Combination delapril/manidipine as antihypertensive therapy in high-risk patients.Clinical drug investigation, , Volume: 31, Issue:7, 2011
REIN on obesity, proteinuria and CKD.Journal of the American Society of Nephrology : JASN, , Volume: 22, Issue:6, 2011
ACE inhibition is renoprotective among obese patients with proteinuria.Journal of the American Society of Nephrology : JASN, , Volume: 22, Issue:6, 2011
Conjugated linoleic acid supplementation enhances antihypertensive effect of ramipril in Chinese patients with obesity-related hypertension.American journal of hypertension, , Volume: 22, Issue:6, 2009
A new dawn in cardiovascular protection: total cardiovascular risk: rigorous treatment of risk factors. Introduction.Nature clinical practice. Cardiovascular medicine, , Volume: 5 Suppl 1, 2008
Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes.Current atherosclerosis reports, , Volume: 10, Issue:2, 2008
[Fasciitis with eosinophilia: a possible causal role of angiotensin converting enzyme inhibitor].Revue neurologique, , Volume: 163, Issue:2, 2007
Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.Circulation, , Apr-17, Volume: 115, Issue:15, 2007
Different pathomechanisms of essential and obesity-associated hypertension in adolescents.Pediatric nephrology (Berlin, Germany), , Volume: 21, Issue:10, 2006
Insulin-sensitizing and cardiovascular effects of the sodium-hydrogen exchange inhibitor, cariporide, in the JCR: LA-cp rat and db/db mouse.Journal of cardiovascular pharmacology, , Volume: 46, Issue:6, 2005
Vasopeptidase inhibition improves insulin sensitivity and endothelial function in the JCR:LA-cp rat.Journal of cardiovascular pharmacology, , Volume: 44, Issue:2, 2004
[Type 2 diabetes and cardiovascular risk: lessons from therapeutic trials].La Revue du praticien, , Oct-15, Volume: 51, Issue:16, 2001
HOPE for diabetes in the new millennium. Heart Outcomes Prevention Evaluation.Diabetes, obesity & metabolism, , Volume: 2, Issue:1, 2000
Studies examining risk reduction in subjects with multiple metabolic and cardiovascular risk factors.Current hypertension reports, , Volume: 2, Issue:2, 2000
Determinants of elevated urinary albumin in the 4,937 type 2 diabetic subjects recruited for the DIABHYCAR Study in Western Europe and North Africa.Diabetes care, , Volume: 23 Suppl 2, 2000
Effect of ramipril on insulin sensitivity in obese patients. Time-course study of glucose infusion rate during euglycaemic hyperinsulinaemic clamp.Diabetes & metabolism, , Volume: 22, Issue:3, 1996
Significance of exaggerated natriuresis after angiotensin AT1 receptor blockade or angiotensin- converting enzyme inhibition in obese Zucker rats.Clinical and experimental pharmacology & physiology, , Volume: 28, Issue:5-6
Angiotensin converting enzyme and neprilysin inhibition alter pain response in dexhamethasone-induced hypertensive rats.Pharmacological reports : PR, , Volume: 71, Issue:2, 2019
Rhabdomyolysis-induced compartment syndrome secondary to atorvastatin and strenuous exercise.BMJ case reports, , Mar-16, Volume: 2017, 2017
Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial.JAMA, , Feb-06, Volume: 309, Issue:5, 2013
An unusual cause of exertional leg pain.Current sports medicine reports, , Volume: 3, Issue:2, 2004
From the Food and Drug Administration.JAMA, , Dec-06, Volume: 284, Issue:21, 2000
Modulation of pain perception by ramipril and losartan in human volunteers.Indian journal of physiology and pharmacology, , Volume: 52, Issue:1
Interstitial nephritis and autoimmune pancreatitis: a case report.International urology and nephrology, , Volume: 44, Issue:1, 2012
Incidence, severity, and etiology of drug-induced acute pancreatitis.Digestive diseases and sciences, , Volume: 55, Issue:10, 2010
High glucose increases extracellular matrix production in pancreatic stellate cells by activating the renin-angiotensin system.Journal of cellular biochemistry, , May-15, Volume: 98, Issue:2, 2006
Acute pancreatitis due to ramipril therapy.Postgraduate medical journal, , Volume: 80, Issue:948, 2004
Fulminant pancreatitis associated with ramipril therapy.Pancreas, , Volume: 27, Issue:3, 2003
Differential effects of saralasin and ramiprilat, the inhibitors of renin-angiotensin system, on cerulein-induced acute pancreatitis.Regulatory peptides, , Mar-28, Volume: 111, Issue:1-3, 2003
Ramipril in High-Risk Patients With COVID-19.Journal of the American College of Cardiology, , 07-21, Volume: 76, Issue:3, 2020
Renin-Angiotensin System Blockade in COVID-19: Good, Bad, or Indifferent?Journal of the American College of Cardiology, , 07-21, Volume: 76, Issue:3, 2020
ACE Inhibitors and Angiotensin II Receptor Blockers May Have Different Impact on Prognosis of COVID-19.Journal of the American College of Cardiology, , 10-27, Volume: 76, Issue:17, 2020
Ramipril and left ventricular diastolic function in stable patients with pulmonary regurgitation after repair of tetralogy of Fallot.International journal of cardiology, , Dec-01, Volume: 272, 2018
The win ratio approach did not alter study conclusions and may mitigate concerns regarding unequal composite end points in kidney transplant trials.Journal of clinical epidemiology, , Volume: 98, 2018
Rhabdomyolysis-induced compartment syndrome secondary to atorvastatin and strenuous exercise.BMJ case reports, , Mar-16, Volume: 2017, 2017
Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial.The lancet. Diabetes & endocrinology, , Volume: 4, Issue:4, 2016
Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, , Volume: 15, Issue:12, 2015
Is administration of preoperative angiotensin-converting enzyme inhibitors important for renal protection after cardiac surgery?Renal failure, , Volume: 35, Issue:5, 2013
Obesity and oxidative stress predict AKI after cardiac surgery.Journal of the American Society of Nephrology : JASN, , Volume: 23, Issue:7, 2012
Comparative effects of angiotensin receptor blockade and ACE inhibition on the fibrinolytic and inflammatory responses to cardiopulmonary bypass.Clinical pharmacology and therapeutics, , Volume: 91, Issue:6, 2012
[Choroidal effusion after uncomplicated cataract surgery].Klinische Monatsblatter fur Augenheilkunde, , Volume: 225, Issue:6, 2008
Effect of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on the frequency of post-cardiothoracic surgery atrial fibrillation.The Annals of pharmacotherapy, , Volume: 41, Issue:3, 2007
Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 45, Issue:5, 2005
Effect of ramipril on postrevascularization prevalence of angina and quality of life.International journal of cardiology, , Volume: 95, Issue:2-3, 2004
Beneficial effects of ramipril on left ventricular end-diastolic and end-systolic volume indexes after uncomplicated invasive revascularization are associated with a reduction in cardiac events in patients with moderately impaired left ventricular functioJournal of the American College of Cardiology, , Volume: 37, Issue:5, 2001
Losartan versus ramipril in the treatment of postrenal transplant erythrocytosis.Transplantation proceedings, , Volume: 30, Issue:5, 1998
The Angiotensin Converting Enzyme Inhibition Post Revascularization Study (APRES). Effects of ramipril in patients with reduced left ventricular function. Rationale, design, methods, baseline characteristics and first-year experience.Scandinavian cardiovascular journal : SCJ, , Volume: 32, Issue:4, 1998
Ileostomy and ramipril-induced acute renal failure and shock.Heart & lung : the journal of critical care, , Volume: 36, Issue:4
Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study.Cardiovascular diabetology, , Jan-09, Volume: 11, 2012
Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes.Current atherosclerosis reports, , Volume: 10, Issue:2, 2008
First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation.Cardiovascular diabetology, , Jul-24, Volume: 7, 2008
Diabetes prevention between RAAS inhibition and PPAR-gamma stimulation: the diabetes reduction assessment with ramipril and rosiglitazone medication (DREAM) trial.Journal of the cardiometabolic syndrome, ,Spring, Volume: 2, Issue:2, 2007
DREAM study and its impact on India.The Journal of the Association of Physicians of India, , Volume: 54, 2006
[Dangerous duo: hypertension and pre-diabetes--the underestimated risk].MMW Fortschritte der Medizin, , Jan-23, Volume: 145, Issue:3-4, 2003
[Corner points of antihypertensive therapy in prediabetic state. Success with a combination].MMW Fortschritte der Medizin, , Jul-10, Volume: 145, Issue:27-28, 2003
[Hypertension and prediabetes. "Don't trust anybody over 130/80"].MMW Fortschritte der Medizin, , Mar-27, Volume: 145, Issue:13, 2003
Increased rate of birth defects after first trimester use of angiotensin converting enzyme inhibitors - Treatment or hypertension related? An observational cohort study.Pregnancy hypertension, , Volume: 13, 2018
Normal pregnancy and healthy child after continued exposure to gliclazide and ramipril during pregnancy.The Annals of pharmacotherapy, , Volume: 43, Issue:1, 2009
Dysglycemia and a history of reproductive risk factors.Diabetes care, , Volume: 31, Issue:8, 2008
Pregnancy outcome following exposure to orlistat, ramipril, glimepiride in a woman with metabolic syndrome.Saudi medical journal, , Volume: 26, Issue:3, 2005
Prolonged exposure to angiotensin-converting enzyme inhibitors during pregnancy. Fetal toxicity could be reversible.Canadian family physician Medecin de famille canadien, , Volume: 51, 2005
Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.Diabetologia, , Volume: 47, Issue:9, 2004
Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin.Hypertension (Dallas, Tex. : 1979), , Volume: 23, Issue:4, 1994
Long-term low-dose angiotensin converting enzyme inhibitor treatment increases vascular cyclic guanosine 3',5'-monophosphate.Hypertension (Dallas, Tex. : 1979), , Volume: 22, Issue:5, 1993
Effect of early onset angiotensin converting enzyme inhibition on myocardial capillaries.Hypertension (Dallas, Tex. : 1979), , Volume: 20, Issue:4, 1992
Pharmacokinetics and biotransformation of 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S, 5S)-2-azabicyclo [3.3.0]octane-3-carboxylic acid (Hoe 498) in rat, dog and man.Arzneimittel-Forschung, , Volume: 34, Issue:10B, 1984
The role of angiotensin converting enzyme and nitric oxide in the enhanced systemic depressor responses to bradykinin in pregnant rats.Clinical and experimental pharmacology & physiology, , Volume: 22, Issue:6-7
[A patient with severe hyperkalaemia -- an emergency after RALES].Deutsche medizinische Wochenschrift (1946), , Sep-09, Volume: 130, Issue:36, 2005
From the Food and Drug Administration.JAMA, , Dec-06, Volume: 284, Issue:21, 2000
Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 74, Issue:3, 2019
The win ratio approach did not alter study conclusions and may mitigate concerns regarding unequal composite end points in kidney transplant trials.Journal of clinical epidemiology, , Volume: 98, 2018
How to improve duration and efficiency of the antiproteinuric response to Ramipril: RamiPROT-a prospective cohort study.Journal of nephrology, , Volume: 30, Issue:1, 2017
Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial.The lancet. Diabetes & endocrinology, , Volume: 4, Issue:4, 2016
Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, , Volume: 15, Issue:12, 2015
Pioglitazone, a PPARγ agonist, provides comparable protection to angiotensin converting enzyme inhibitor ramipril against adriamycin nephropathy in rat.European journal of pharmacology, , May-05, Volume: 730, 2014
Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy.American journal of nephrology, , Volume: 40, Issue:3, 2014
Treatment of early immunoglobulin A nephropathy by angiotensin-converting enzyme inhibitor.The American journal of medicine, , Volume: 126, Issue:2, 2013
Impact of angiotensin-converting enzyme gene polymorphism on proteinuria and arterial hypertension.Collegium antropologicum, , Volume: 37, Issue:3, 2013
Sodium intake, ACE inhibition, and progression to ESRD.Journal of the American Society of Nephrology : JASN, , Volume: 23, Issue:1, 2012
[Critically appraised article].Revista medica de Chile, , Volume: 140, Issue:1, 2012
Pierson syndrome in an adolescent girl with nephrotic range proteinuria but a normal GFR.Pediatric nephrology (Berlin, Germany), , Volume: 27, Issue:5, 2012
Sodium intake, ACE inhibition, and progression to ESRD.Journal of the American Society of Nephrology : JASN, , Volume: 23, Issue:1, 2012
Effects of ramipril and valsartan on proteinuria and renal function in patients with nondiabetic proteinuria.Collegium antropologicum, , Volume: 35, Issue:4, 2011
Renin-angiotensin system inhibitors reduce the progression of mesangioproliferative glomerulonephritis: 10 year follow-up.European journal of internal medicine, , Volume: 22, Issue:6, 2011
REIN on obesity, proteinuria and CKD.Journal of the American Society of Nephrology : JASN, , Volume: 22, Issue:6, 2011
ACE inhibition is renoprotective among obese patients with proteinuria.Journal of the American Society of Nephrology : JASN, , Volume: 22, Issue:6, 2011
Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 25, Issue:7, 2010
Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway?Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 25, Issue:10, 2010
Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy.Nephrology (Carlton, Vic.), , Volume: 15, Issue:2, 2010
Effect of ramipril alone compared to ramipril with eplerenone on diabetic nephropathy in streptozocin-induced diabetic rats.Pharmacology, , Volume: 86, Issue:2, 2010
Ramipril in the treatment of proteinuria in children after renal transplantation.Pediatric transplantation, , Volume: 14, Issue:2, 2010
Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibition.Clinical science (London, England : 1979), , Volume: 118, Issue:4, 2010
Blood-pressure control and delay in progression of kidney disease in children.The New England journal of medicine, , Oct-22, Volume: 361, Issue:17, 2009
Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 24, Issue:1, 2009
Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria.Clinical journal of the American Society of Nephrology : CJASN, , Volume: 4, Issue:3, 2009
Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation.Transplant international : official journal of the European Society for Organ Transplantation, , Volume: 22, Issue:11, 2009
Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 24, Issue:12, 2009
Proteinuria: Is the ONTARGET renal substudy actually off target?Nature reviews. Nephrology, , Volume: 5, Issue:8, 2009
Strict blood-pressure control and progression of renal failure in children.The New England journal of medicine, , Oct-22, Volume: 361, Issue:17, 2009
Renin-angiotensin system blockade is effective in reducing proteinuria of patients with progressive nephropathy caused by MYH9 mutations (Fechtner-Epstein syndrome).Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 23, Issue:8, 2008
Renal outcomes with telmisartan, ramipril, or both, in people at high vascular risk (the ONTARGET study): a multicentre, randomised, double-blind, controlled trial.Lancet (London, England), , Aug-16, Volume: 372, Issue:9638, 2008
Vasopeptidase inhibition attenuates proteinuria and podocyte injury in Zucker diabetic fatty rats.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 375, Issue:2, 2007
Comparison of higher dose of losartan treatment with losartan plus carvedilol and losartan plus ramipril in patients with glomerulonephritis and proteinuria.Renal failure, , Volume: 29, Issue:2, 2007
Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan.Blood purification, , Volume: 25, Issue:4, 2007
Estimating the cost effectiveness of ramipril used for specific clinical indications: comparing the outcomes in four clinical trials with a common economic model.American journal of cardiovascular drugs : drugs, devices, and other interventions, , Volume: 7, Issue:6, 2007
Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study)*.Journal of hypertension, , Volume: 24, Issue:3, 2006
Angiotensin inhibition or blockade for the treatment of patients with quiescent lupus nephritis and persistent proteinuria.Lupus, , Volume: 14, Issue:12, 2005
Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients.Transplantation proceedings, , Volume: 37, Issue:2, 2005
The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.Archives of internal medicine, , Apr-25, Volume: 165, Issue:8, 2005
Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents.Journal of the American Society of Nephrology : JASN, , Volume: 16, Issue:2, 2005
Blood pressure control, drug therapy, and kidney disease.Hypertension (Dallas, Tex. : 1979), , Volume: 46, Issue:1, 2005
Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses.Journal of the American Society of Nephrology : JASN, , Volume: 16 Suppl 1, 2005
Angiotensin II-dependent induction of AT(2) receptor expression after renal ablation.American journal of physiology. Renal physiology, , Volume: 288, Issue:1, 2005
Ramipril in the treatment of vascular diseases.Expert opinion on pharmacotherapy, , Volume: 6, Issue:11, 2005
[Renoprotective effect of ramipril in children with chronic renal failure--the experience of one centre].Srpski arhiv za celokupno lekarstvo, , Volume: 132 Suppl 1, 2004
Can young adult patients with proteinuric IgA nephropathy perform physical exercise?American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 44, Issue:2, 2004
Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure.Kidney international, , Volume: 66, Issue:2, 2004
Ramipril in the treatment of hypertension and proteinuria in children with chronic kidney diseases.American journal of hypertension, , Volume: 17, Issue:5 Pt 1, 2004
The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.Clinical nephrology, , Volume: 60, Issue:5, 2003
[Standpoint on the use of angiotensin receptor blockers in the treatment of hypertension].Harefuah, , Volume: 142, Issue:4, 2003
Retarding progression of chronic renal disease: the neglected issue of residual proteinuria.Kidney international, , Volume: 63, Issue:6, 2003
Maximal suppression of renin-angiotensin system in nonproliferative glomerulonephritis.Kidney international, , Volume: 63, Issue:6, 2003
Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.International immunopharmacology, , Volume: 3, Issue:3, 2003
The antiproteinuric effect of high-dose ramipril: still an open question.Kidney international, , Volume: 63, Issue:2, 2003
Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome.Kidney international, , Volume: 63, Issue:2, 2003
Results from the TIP (Tritace in Proteinuria) intensified monitoring project.Kidney & blood pressure research, , Volume: 25, Issue:2, 2002
Ramipril treatment in a patient with glycogen storage disease I non-A.Journal of inherited metabolic disease, , Volume: 25, Issue:6, 2002
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.JAMA, , Nov-20, Volume: 288, Issue:19, 2002
Effect of high dose ramipril with or without indomethacin on glomerular selectivity.Kidney international, , Volume: 62, Issue:3, 2002
[Prediction, screening and treatment of renal complications of diabetes].La Revue du praticien, , Oct-15, Volume: 51, Issue:16, 2001
Effect of ramipril in a patient with glycogen storage disease type I and nephrotic-range proteinuria.Journal of inherited metabolic disease, , Volume: 24, Issue:6, 2001
ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy.Journal of the American Society of Nephrology : JASN, , Volume: 12, Issue:12, 2001
HOPE for patients with Type 2 diabetes: an application of the findings of the MICRO-HOPE substudy in a British hospital diabetes clinic.Diabetic medicine : a journal of the British Diabetic Association, , Volume: 18, Issue:8, 2001
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.JAMA, , Jun-06, Volume: 285, Issue:21, 2001
Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies.Kidney international, , Volume: 59, Issue:1, 2001
Pretreatment blood pressure reliably predicts progression of chronic nephropathies. GISEN Group.Kidney international, , Volume: 58, Issue:5, 2000
[Protein markers in evaluation of nephroprotective effects of antihypertensive drugs in patients with arterial hypertension].Klinicheskaia laboratornaia diagnostika, , Issue:7, 2000
Ramipril.International journal of clinical practice, , Volume: 54, Issue:4, 2000
Renal protection: progression, regression, remission from nephropathy beyond blood pressure control.International journal of clinical practice. Supplement, , Issue:110, 2000
Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 35, Issue:6, 2000
[Further evidence for the renoprotective effect of ACE inhibitors: ramipril protects against the progression of chronic renal insufficiency in non-diabetic nephropathy with nephrotic proteinuria].Schweizerische medizinische Wochenschrift, , Apr-01, Volume: 130, Issue:13, 2000
Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen)Journal of the American Society of Nephrology : JASN, , Volume: 11, Issue:1, 2000
Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.Lancet (London, England), , Jul-31, Volume: 354, Issue:9176, 1999
Renoprotective therapy: titration against urinary protein excretion.Lancet (London, England), , Jul-31, Volume: 354, Issue:9176, 1999
A subdepressor low dose of ramipril lowers urinary protein excretion without increasing plasma potassium.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 33, Issue:3, 1999
Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).Kidney international, , Volume: 53, Issue:5, 1998
Ramipril in non-diabetic renal failure (REIN study) Ramipril Efficiency in Nephropathy Study.Lancet (London, England), , Sep-06, Volume: 350, Issue:9079, 1997
[Renal hemodynamics and proteinuria in chronic glomerulonephritis treated with beta-receptor blockers or ace inhibitors].Deutsche medizinische Wochenschrift (1946), , Aug-01, Volume: 122, Issue:31-32, 1997
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)Lancet (London, England), , Jun-28, Volume: 349, Issue:9069, 1997
ACE-inhibitors: panacea for progressive renal disease.Lancet (London, England), , Jun-28, Volume: 349, Issue:9069, 1997
Effect of ramipril on blood pressure and protein excretion rate in normotensive nondiabetic patients with proteinuria.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 28, Issue:6, 1996
Randomized controlled trial of ACE-inhibitors and beta-blockers with and without vasodilating activity in chronic glomerulonephritis.International journal of clinical pharmacology and therapeutics, , Volume: 34, Issue:11, 1996
The DIAB-HYCAR Study.Diabetologia, , Volume: 39, Issue:12, 1996
Salt blocks the renal benefits of ramipril in diabetic hypertensive rats.Hypertension (Dallas, Tex. : 1979), , Volume: 17, Issue:4, 1991
High salt diet ameliorates effects of angiotensin converting enzyme inhibition in spontaneously hypertensive streptozotocin diabetic rats.Clinical and experimental pharmacology & physiology, , Volume: 17, Issue:3, 1990
[Effect of the angiotensin-converting enzyme inhibitor ramipril on proteinuria, blood pressure and kidney function in histologically confirmed glomerulonephritis with nephrotic syndrome].Zeitschrift fur Kardiologie, , Volume: 77 Suppl 3, 1988
ACE inhibitors and angiotensin II receptor blockers in IgA nephropathy with mild proteinuria: the ACEARB study.Journal of nephrology, , Volume: 19, Issue:4
Prospective randomized controlled multicenter trial on steroids plus ramipril in proteinuric IgA nephropathy.Journal of nephrology, , Volume: 14, Issue:4
[Is it feasible to improve the duration and the efficiency of Ramipril anti-proteinuric response?].Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, , Volume: 32, Issue:1
Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial.Lancet (London, England), , Volume: 365, Issue:9463
A hepatitis C-positive patient with new onset of nephrotic syndrome and systemic amyloidosis secondary to common variable immunodeficiency.Annals of Saudi medicine, , Volume: 30, Issue:5
[A 93-year-old patient with hypertensive crises and renal failure due to bilateral renal artery stenosis].MMW Fortschritte der Medizin, , Nov-05, Volume: 157, Issue:19, 2015
Severe paradoxical hypertension with angiotensin-converting enzyme inhibitors: an unusual feature of renal artery stenosis.Hypertension (Dallas, Tex. : 1979), , Volume: 54, Issue:3, 2009
Manipulation of the renin angiotensin system in peripheral arterial disease.European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, , Volume: 28, Issue:6, 2004
Ramipril for hypertension secondary to renal artery stenosis. Changes in blood pressure, the renin-angiotensin system and total and divided renal function.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
[Takayasu arteritis with aortic coarctation and multiple stenosis of aortic branches].Recenti progressi in medicina, , Volume: 101, Issue:7-8
Randomised controlled trial into the role of ramipril in fibrosis reduction in rheumatic heart disease: the RamiRHeD trial protocol.BMJ open, , 09-13, Volume: 11, Issue:9, 2021
[The efficacy of treatment with the angiotensin-converting enzyme inhibitor ramipril in patients with congestive heart failure of rheumatic etiology].Terapevticheskii arkhiv, , Volume: 68, Issue:2, 1996
[The use of ramipril in treating patients with chronic heart failure].Terapevticheskii arkhiv, , Volume: 67, Issue:5, 1995
Development and validation of bioanalytical method for simultaneous estimation of ramipril and hydrochlorothiazide in human plasma using liquid chromatography-tandem mass spectrometry.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, , Nov-01, Volume: 970, 2014
Impact of methylation of acyl glucuronide metabolites on incurred sample reanalysis evaluation: ramiprilat case study.Bioanalysis, , Volume: 3, Issue:9, 2011
Development of a capillary electrophoresis method for the assay of ramipril and its impurities: an issue of cis-trans isomerization.Journal of chromatography. A, , May-06, Volume: 1218, Issue:18, 2011
Development and validation of UPLC tandem mass spectrometry assay for separation of a phase II metabolite of ramipril using actual study samples and its application to a bioequivalence study.Biomedical chromatography : BMC, , Volume: 25, Issue:6, 2011
Simultaneous determination of atorvastatin, amlodipine, ramipril and benazepril in human plasma by LC-MS/MS and its application to a human pharmacokinetic study.Biomedical chromatography : BMC, , Volume: 25, Issue:4, 2011
Sensitivity enhancement and matrix effect evaluation during summation of multiple transition pairs-case studies of clopidogrel and ramiprilat.Biomedical chromatography : BMC, , Volume: 24, Issue:5, 2010
A novel analytical approach for reducing the consumption of organic solvents in the charge transfer-based spectrophotometric analysis: application in the analysis of certain antihypertensive drugs.Acta pharmaceutica (Zagreb, Croatia), , Volume: 60, Issue:4, 2010
Role of echocardiography in assessing the mechanism and effect of ramipril on functional mitral regurgitation in dilated cardiomyopathy.Echocardiography (Mount Kisco, N.Y.), , Volume: 22, Issue:4, 2005
Ramipril: clinical and economic benefits.Internal medicine journal, , Volume: 34, Issue:7, 2004
Square wave voltammetric determination of the angiotensin-converting enzyme inhibitors cilazapril, quinapril and ramipril in pharmaceutical formulations.Farmaco (Societa chimica italiana : 1989), , Volume: 58, Issue:5, 2003
[Competitive sports and dilated cardiomyopathy: the case of a 32-year-old soccer player with ventricular tachycardia].Deutsche medizinische Wochenschrift (1946), , Jan-24, Volume: 128, Issue:4, 2003
Retarding progression of chronic renal disease: the neglected issue of residual proteinuria.Kidney international, , Volume: 63, Issue:6, 2003
Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study.Circulation, , Feb-25, Volume: 107, Issue:7, 2003
Liquid chromatography-mass spectrometry method for determination of ramipril and its active metabolite ramiprilat in human plasma.Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, , Nov-05, Volume: 779, Issue:2, 2002
Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies.Kidney international, , Volume: 59, Issue:1, 2001
A stability-indicating LC method for the simultaneous determination of ramipril and hydrochlorothiazide in dosage forms.Journal of pharmaceutical and biomedical analysis, , Volume: 24, Issue:3, 2001
Biosensors for the enantioselective analysis of S-enalapril and S-ramipril.Preparative biochemistry & biotechnology, , Volume: 28, Issue:4, 1998
Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy.Lancet (London, England), , May-24, Volume: 349, Issue:9064, 1997
Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency.Journal of nephrology, , Volume: 15, Issue:4
Do ACE inhibitors have a real role in coronary artery disease?Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners, , Volume: 14, Issue:3
Twenty-and-a-half syndrome: a case report.Journal of medical case reports, , Feb-15, Volume: 13, Issue:1, 2019
Does this case hold the answer to one of the worse types of pain in medicine--that of loin pain haematuria syndrome (LPHS).BMJ case reports, , Apr-26, Volume: 2015, 2015
Renin-angiotensin system blockade is effective in reducing proteinuria of patients with progressive nephropathy caused by MYH9 mutations (Fechtner-Epstein syndrome).Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 23, Issue:8, 2008
Drug-induced Evans syndrome.Annals of internal medicine, , Feb-15, Volume: 128, Issue:4, 1998
Ramipril-induced drug reaction with eosinophilia and systemic symptoms (DRESS).European journal of dermatology : EJD, , Volume: 21, Issue:4
Ramipril for left ventricular diastolic function in patients with pulmonary regurgitation after repair of tetralogy of Fallot.International journal of cardiology, , 03-01, Volume: 278, 2019
Ramipril for left ventricular diastolic function in patients with pulmonary regurgitation after repair of tetralogy of Fallot.International journal of cardiology, , 03-01, Volume: 278, 2019
Renin-angiotensin-aldosterone system blockade in patients with repaired tetralogy of Fallot: When and how.International journal of cardiology, , 12-01, Volume: 272, 2018
Ramipril and left ventricular diastolic function in stable patients with pulmonary regurgitation after repair of tetralogy of Fallot.International journal of cardiology, , Dec-01, Volume: 272, 2018
Randomised trial of ramipril in repaired tetralogy of Fallot and pulmonary regurgitation: the APPROPRIATE study (Ace inhibitors for Potential PRevention Of the deleterious effects of Pulmonary Regurgitation In Adults with repaired TEtralogy of Fallot).International journal of cardiology, , Feb-09, Volume: 154, Issue:3, 2012
Renin-angiotensin system blockade is effective in reducing proteinuria of patients with progressive nephropathy caused by MYH9 mutations (Fechtner-Epstein syndrome).Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 23, Issue:8, 2008
A Forgotten Cause of Thrombocytopenia in Post Renal Transplant Setting.Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, , Volume: 31, Issue:5
Churg-Strauss syndrome with endocardial injury, clot formation in heart's chambers, and neurological complications.Kardiologia polska, , Volume: 74, Issue:11, 2016
Incidence and natural history of left ventricular thrombus following anterior wall acute myocardial infarction.The American journal of cardiology, , Aug-15, Volume: 80, Issue:4, 1997
[Renal effect of treatment for heart failure].Ugeskrift for laeger, , Feb-23, Volume: 171, Issue:9, 2009
Influence of angiotensin converting enzyme inhibitor treatment on cardiac autonomic modulation in patients receiving haemodialysis.Nephrology (Carlton, Vic.), , Volume: 11, Issue:6, 2006
Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome.Kidney international, , Volume: 63, Issue:2, 2003
Effects of ACE inhibition and bradykinin antagonism on cardiovascular changes in uremic rats.Kidney international, , Volume: 58, Issue:1, 2000
Ramipril prevents basal arterial constriction and enhanced myogenic tone in the femoral artery in mildly uraemic normotensive rats.Clinical science (London, England : 1979), , Volume: 97, Issue:2, 1999
Effect of converting enzyme inhibitors on cardiac changes in experimental uremia.Kidney international. Supplement, , Volume: 25, 1988
Myocardial interstitial fibrosis in experimental uremia--implications for cardiac compliance.Kidney international, , Volume: 33, Issue:4, 1988
The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial.Journal of cardiovascular electrophysiology, , Volume: 20, Issue:7, 2009
[ONTARGET: similar protection of telmisartan and ramipril and lack of benefit of combined therapy in patients at high risk for vascular events].Revue medicale de Liege, , Volume: 63, Issue:4, 2008
Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled study.European journal of clinical pharmacology, , Volume: 63, Issue:8, 2007
Summaries for patients. Trial of a drug to decrease the risk for heart disease in patients with mild kidney failure.Annals of internal medicine, , Apr-17, Volume: 134, Issue:8, 2001
The kidney in cardiovascular disease.Annals of internal medicine, , Apr-17, Volume: 134, Issue:8, 2001
Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.Annals of internal medicine, , Apr-17, Volume: 134, Issue:8, 2001
The HOPE Study (Heart Outcomes Prevention Evaluation).Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 1, Issue:1, 2000
Angiotensin converting enzyme inhibition reduces the expression of transforming growth factor-beta1 and type IV collagen in diabetic vasculopathy.Journal of hypertension, , Volume: 16, Issue:11, 1998
Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis.Circulation, , Apr-29, Volume: 117, Issue:17, 2008
Letter by Popa and Netea regarding article, "Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis".Circulation, , Nov-04, Volume: 118, Issue:19, 2008
Propylthiouracil-induced vasculitis associated with ANCA: a case report.Renal failure, , Volume: 29, Issue:2, 2007
Cardiac angiotensin II participates in coronary microvessel inflammation of unstable angina and strengthens the immunomediated component.Circulation research, , Jun-25, Volume: 94, Issue:12, 2004
Effect of ramipril on the electrophysiological characteristics of ventricular myocardium after myocardial infarction in rabbits.Journal of cardiovascular medicine (Hagerstown, Md.), , Volume: 13, Issue:5, 2012
Inhibition of angiotensin-converting enzyme reduces susceptibility of hypertrophied rat myocardium to ventricular fibrillation.Circulation journal : official journal of the Japanese Circulation Society, , Volume: 66, Issue:11, 2002
Cardioprotective effects of the aminopeptidase P inhibitor apstatin: studies on ischemia/reperfusion injury in the isolated rat heart.Journal of cardiovascular pharmacology, , Volume: 34, Issue:4, 1999
Ramipril prevents the detrimental sequels of chronic NO synthase inhibition in rats: hypertension, cardiac hypertrophy and renal insufficiency.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 350, Issue:6, 1994
[ACE inhibition: mechanisms of "cardioprotection" in acute myocardial ischemia].Klinische Wochenschrift, , Volume: 69 Suppl 24, 1991
Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: a comparison of captopril, enalapril, and HOE 498.Journal of cardiovascular pharmacology, , Volume: 8, Issue:4
Low-dose hydralazine prevents fibrosis in a murine model of acute kidney injury-to-chronic kidney disease progression.Kidney international, , Volume: 91, Issue:1, 2017
Inhibition of angiotensin-converting enzyme reduces rat liver reperfusion injury via bradykinin-2-receptor.The Journal of surgical research, , Volume: 134, Issue:2, 2006
Cardioprotective effects of the aminopeptidase P inhibitor apstatin: studies on ischemia/reperfusion injury in the isolated rat heart.Journal of cardiovascular pharmacology, , Volume: 34, Issue:4, 1999
Ramipril-induced delayed myocardial protection against free radical injury involves bradykinin B2 receptor-NO pathway and protein synthesis.British journal of pharmacology, , Volume: 125, Issue:3, 1998
Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats.Hypertension (Dallas, Tex. : 1979), , Volume: 27, Issue:1, 1996
Bradykinin accounts for improved postischemic function and decreased glutathione release of guinea pig heart treated with the angiotensin-converting enzyme inhibitor ramiprilat.Journal of cardiovascular pharmacology, , Volume: 23, Issue:4, 1994
[A 93-year-old patient with hypertensive crises and renal failure due to bilateral renal artery stenosis].MMW Fortschritte der Medizin, , Nov-05, Volume: 157, Issue:19, 2015
Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes.Current atherosclerosis reports, , Volume: 10, Issue:2, 2008
[Corner points of antihypertensive therapy in prediabetic state. Success with a combination].MMW Fortschritte der Medizin, , Jul-10, Volume: 145, Issue:27-28, 2003
Studies examining risk reduction in subjects with multiple metabolic and cardiovascular risk factors.Current hypertension reports, , Volume: 2, Issue:2, 2000
Renin-angiotensin system inhibitors reduce the progression of mesangioproliferative glomerulonephritis: 10 year follow-up.European journal of internal medicine, , Volume: 22, Issue:6, 2011
Treatment of idiopathic glomerulonephritis in the elderly. Personal data.Contributions to nephrology, , Volume: 105, 1993
Essential mixed cryoglobulinemia type II.Clinical and experimental rheumatology, , Volume: 24, Issue:3
[Telmisartan, ramipril, or both in patients at high risk for vascular events. Results of the ONTARGET trial].Kardiologiia, , Volume: 48, Issue:5, 2008
Reduced arterial stiffness may contribute to angiotensin-converting enzyme inhibitor induced improvements in walking time in peripheral arterial disease patients.Journal of hypertension, , Volume: 26, Issue:5, 2008
Effect of ramipril on renal function in patients with intermittent claudication.Vascular health and risk management, , Volume: 4, Issue:2, 2008
Summaries for patients. Ramipril improves walking ability in patients with peripheral arterial disease.Annals of internal medicine, , May-02, Volume: 144, Issue:9, 2006
Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial.Annals of internal medicine, , May-02, Volume: 144, Issue:9, 2006
Effects of ramipril on arterial stiffness.Hypertension (Dallas, Tex. : 1979), , Volume: 46, Issue:4, 2005
Ramipril reduces large-artery stiffness in peripheral arterial disease and promotes elastogenic remodeling in cell culture.Hypertension (Dallas, Tex. : 1979), , Volume: 45, Issue:6, 2005
Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease.European heart journal, , Volume: 25, Issue:1, 2004
Manipulation of the renin angiotensin system in peripheral arterial disease.European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, , Volume: 28, Issue:6, 2004
Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy.Hypertension (Dallas, Tex. : 1979), , Dec-01, Volume: 38, Issue:6, 2001
Dysglycemia and a history of reproductive risk factors.Diabetes care, , Volume: 31, Issue:8, 2008
Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.Diabetologia, , Volume: 47, Issue:9, 2004
Influence of angiotensin converting enzyme inhibitor treatment on cardiac autonomic modulation in patients receiving haemodialysis.Nephrology (Carlton, Vic.), , Volume: 11, Issue:6, 2006
[HOPE study].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 64 Suppl 6, 2006
[Preventive therapy with ACE inhibitors for coronary patients].Orvosi hetilap, , Feb-29, Volume: 145, Issue:9, 2004
Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction.Circulation, , Sep-14, Volume: 110, Issue:11, 2004
[Symposium "Emerging Approaches to Cardiovascular Diseases: Detailed results and implications of the HOPE Study". Atlanta, 10. November 1999].Der Internist, , Volume: 41, Issue:1, 2000
The prognostic significance of a history of systemic hypertension in patients randomised to either placebo or ramipril following acute myocardial infarction: evidence from the AIRE study. Acute Infarction Ramipril Efficacy.Journal of human hypertension, , Volume: 13, Issue:8, 1999
Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators.European heart journal, , Volume: 18, Issue:1, 1997
ACE inhibitors in heart failure: effect on mode of death.European heart journal, , Volume: 18, Issue:1, 1997
Inhibition of ACE/Kininase-II after myocardial infarction--addendum.Cardiovascular research, , Volume: 28, Issue:2, 1994
Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 27, Issue:9, 2012
A comparison of the effects of ramipril and losartan on blood pressure control and left ventricle hypertrophy in patients with autosomal dominant polycystic kidney disease.Renal failure, , Volume: 32, Issue:8, 2010
Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 23, Issue:2, 2008
Renal and cardiac effects of antihypertensive treatment with ramipril versus metoprolol in autosomal dominant polycystic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 23, Issue:2, 2008
Activity and functional significance of the renal kallikrein-kinin-system in polycystic kidney disease of the rat.Kidney international, , Volume: 61, Issue:6, 2002
[Gallop in the Routineergometrie: Only Chore or Diagnostic Challenge?]Deutsche medizinische Wochenschrift (1946), , Volume: 143, Issue:3, 2018
Effect of ramipril on the electrophysiological characteristics of ventricular myocardium after myocardial infarction in rabbits.Journal of cardiovascular medicine (Hagerstown, Md.), , Volume: 13, Issue:5, 2012
[Competitive sports and dilated cardiomyopathy: the case of a 32-year-old soccer player with ventricular tachycardia].Deutsche medizinische Wochenschrift (1946), , Jan-24, Volume: 128, Issue:4, 2003
Reverse evidence based medicine.The Pan African medical journal, , Volume: 16, 2013
Reciprocal regulation of NO signaling and TXNIP expression in humans: impact of aging and ramipril therapy.International journal of cardiology, , Oct-12, Volume: 168, Issue:5, 2013
Ramipril-like activity of Spondias mombin linn against no-flow ischemia and isoproterenol-induced cardiotoxicity in rat heart.Cardiovascular toxicology, , Volume: 10, Issue:4, 2010
Clinical practice guides.Clinical cardiology, , Volume: 32, Issue:4, 2009
ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?Blood pressure, , Volume: 18, Issue:1-2, 2009
Chronic angiotensin II receptor blockade induces cardioprotection during ischemia by increased PKC-epsilon expression in the mouse heart.Journal of cardiovascular pharmacology, , Volume: 49, Issue:1, 2007
Effects of purified herbal extract of Salvia miltiorrhiza on ischemic rat myocardium after acute myocardial infarction.Life sciences, , Apr-29, Volume: 76, Issue:24, 2005
The cardioprotective effect of dual metallopeptidase inhibition: respective roles of endogenous kinins and natriuretic peptides.Canadian journal of physiology and pharmacology, , Volume: 83, Issue:2, 2005
[Angiotensin converting enzyme inhibitors in patients with ischemic heart disease: in all cases or in high risk of complications].Kardiologiia, , Volume: 45, Issue:9, 2005
[Ischemic heart disease with low risk of vascular complications -- a novel indication for angiotensin converting enzyme inhibitors (results of EUROPA trial)].Kardiologiia, , Volume: 44, Issue:3, 2004
Effect of ACE-inhibitor ramiprilat and AT1-receptor antagonist candesartan on cardiac norepinephrine release: comparison between ischemic and nonischemic conditions.Journal of cardiovascular pharmacology, , Volume: 40, Issue:4, 2002
Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study.Circulation, , Jul-31, Volume: 104, Issue:5, 2001
Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.The Journal of pharmacology and experimental therapeutics, , Volume: 295, Issue:2, 2000
ACE inhibitor reduces cardiovascular events by 22%.Indian journal of medical sciences, , Volume: 54, Issue:3, 2000
Ramiprilat prevents the development of acute coronary endothelial dysfunction in the dog.Basic research in cardiology, , Volume: 94, Issue:4, 1999
Functional impact of an increase in ventricular mass after myocardial damage and its attenuation by converting enzyme inhibition.Journal of cardiac failure, , Volume: 4, Issue:3, 1998
Effect of ramiprilat or captopril on myocardial infarct size: assessment in canine models of ischemia alone and ischemia with reperfusion.Pharmacology, , Volume: 57, Issue:1, 1998
Attenuation of reperfusion arrhythmias by selective inhibition of angiotensin-converting enzyme/kininase II in the ischemic zone: mediated by endogenous bradykinin?Journal of cardiovascular pharmacology, , Volume: 27, Issue:3, 1996
Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats.Hypertension (Dallas, Tex. : 1979), , Volume: 27, Issue:1, 1996
Nitric oxide mitigates leukocyte adhesion and vascular leak after myocardial ischemia.Journal of molecular and cellular cardiology, , Volume: 28, Issue:3, 1996
[A comparison of the effect of Capoten (captopril) and ramipril on the circadian profile of the arterial pressure and peripheral hemodynamics in patients with hypertension combined with diabetes mellitus].Terapevticheskii arkhiv, , Volume: 68, Issue:5, 1996
The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors.The Annals of thoracic surgery, , Volume: 60, Issue:3, 1995
Influence of angiotensin converting enzyme inhibition on relation of atrial natriuretic peptide concentration to atrial pressure in heart failure.British heart journal, , Volume: 72, Issue:6, 1994
Cardioprotective actions of bradykinin in myocardial ischemia and left ventricular hypertrophy.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, , Volume: 27, Issue:8, 1994
Inhibition of nitric oxide synthase prevents myocardial protection by ramiprilat.The Journal of pharmacology and experimental therapeutics, , Volume: 270, Issue:3, 1994
Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition.European journal of pharmacology, , Apr-06, Volume: 234, Issue:2-3, 1993
Contribution of bradykinin to the cardiovascular effects of ramipril.Journal of cardiovascular pharmacology, , Volume: 22 Suppl 9, 1993
Ramiprilat increases bradykinin outflow from isolated hearts of rat.British journal of pharmacology, , Volume: 108, Issue:2, 1993
Cardioprotection by ramiprilat in isolated rabbit hearts.European journal of pharmacology, , Sep-14, Volume: 241, Issue:2-3, 1993
ACE-inhibition induces NO-formation in cultured bovine endothelial cells and protects isolated ischemic rat hearts.Journal of molecular and cellular cardiology, , Volume: 24, Issue:8, 1992
The possible role of bradykinin in the antiischemic activity of ACE-inhibitors.Agents and actions. Supplements, , Volume: 38 ( Pt 3), 1992
Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension.Journal of hypertension, , Volume: 32, Issue:10, 2014
Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy.Expert opinion on pharmacotherapy, , Volume: 13, Issue:8, 2012
Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtoleranJournal of hypertension, , Volume: 30, Issue:5, 2012
Chronic kidney disease: cardiac and renal angiotensin-converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition.Experimental physiology, , Volume: 97, Issue:4, 2012
Comparison between nebivolol and ramipril in patients with hypertension and left ventricular hypertrophy: a randomized open blinded end-point (PROBE) trial.European review for medical and pharmacological sciences, , Volume: 15, Issue:12, 2011
The cardiac renin-angiotensin system is responsible for high-salt diet-induced left ventricular hypertrophy in mice.European journal of heart failure, , Volume: 12, Issue:11, 2010
A comparison of the effects of ramipril and losartan on blood pressure control and left ventricle hypertrophy in patients with autosomal dominant polycystic kidney disease.Renal failure, , Volume: 32, Issue:8, 2010
Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients.Renal failure, , Volume: 32, Issue:8, 2010
Dual renin-angiotensin system blockade for patients with prosthesis-patient mismatch.The Annals of thoracic surgery, , Volume: 90, Issue:6, 2010
The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice.Experimental physiology, , Volume: 94, Issue:3, 2009
Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized AssessmentCirculation, , Oct-06, Volume: 120, Issue:14, 2009
Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).The American journal of cardiology, , Dec-01, Volume: 104, Issue:11, 2009
Effects of dual blockade of Renin-Angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study.American journal of hypertension, , Volume: 21, Issue:2, 2008
Regression of left-ventricular hypertrophy in children and adolescents with hypertension during ramipril monotherapy.American journal of hypertension, , Volume: 20, Issue:9, 2007
Effect of dual blockade of renin-angiotensin system on TGFbeta1 and left ventricular structure and function in hypertensive patients.Journal of human hypertension, , Volume: 21, Issue:4, 2007
Effect of ramipril on left ventricular mass in normotensive hemodialysis patients.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 47, Issue:3, 2006
Rationale and design of the cardiac magnetic resonance imaging substudy of The ONTARGET Trial Programme.The Journal of international medical research, , Volume: 33 Suppl 1, 2005
Combined blockade of AT1-receptors and ACE synergistically potentiates antihypertensive effects in SHR.Journal of hypertension, , Volume: 22, Issue:3, 2004
Left ventricular hypertrophy: a "factor of risk": mass is reversible, but is the risk?Journal of the American College of Cardiology, , Jun-16, Volume: 43, Issue:12, 2004
Effects of diuretic treatment on cardiac and circulating RAS in chronic heart failure post-myocardial infarction in rats.European journal of heart failure, , Volume: 5, Issue:3, 2003
[Improved protection of heart and kidneys in the hypertensive patient. ACE inhibitor and AT1 blocker combined?].MMW Fortschritte der Medizin, , Jun-05, Volume: 145, Issue:23, 2003
Cardiomyocyte loss in experimental renal failure: prevention by ramipril.Kidney international, , Volume: 63, Issue:5, 2003
[Relationship between regression of hypertensive left ventricular hypertrophy and improvement of coronary flow reserve].Zhonghua yi xue za zhi, , Apr-25, Volume: 83, Issue:8, 2003
"Preemptive strike" heart medications. A.C.E. inhibitors gain new ground as multi-purpose cardiac drugs.Heart advisor, , Volume: 5, Issue:2, 2002
Regression of ventricular and vascular hypertrophy: are there differences between structurally different angiotensin-converting enzyme inhibitors?Journal of hypertension, , Volume: 20, Issue:12, 2002
Ramipril and cardiovascular risk reduction.Circulation, , Jun-25, Volume: 105, Issue:25, 2002
Systemic immunosuppression fails to suppress cardiac cytokine induction in pressure overload hypertrophy in rats.Immunobiology, , Volume: 205, Issue:1, 2002
Left and right coronary circulation in left ventricular hypertrophy: effects of angiotensin converting enzyme inhibition.Circulation journal : official journal of the Japanese Circulation Society, , Volume: 66, Issue:12, 2002
Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril.Circulation, , Oct-02, Volume: 104, Issue:14, 2001
Effects of angiotensin-converting enzyme inhibitor and angiotensin type 1 receptor antagonist in deoxycorticosterone acetate-salt hypertensive mice lacking Ren-2 gene.Hypertension (Dallas, Tex. : 1979), , Volume: 37, Issue:3, 2001
[Effect of a non-antihypertensive dose of ramipril on the plasma and tissue renin-angiotensin system in 27 TGR (mRen2) rats].Archives des maladies du coeur et des vaisseaux, , Volume: 94, Issue:8, 2001
Raised blood pressure, not renin-angiotensin systems, causes cardiac fibrosis in TGR m(Ren2)27 rats.Cardiovascular research, , Volume: 47, Issue:1, 2000
Improvement in midwall myocardial shortening with regression of left ventricular hypertrophy.Hypertension (Dallas, Tex. : 1979), , Volume: 36, Issue:5, 2000
The effect of non-antihypertensive doses of angiotensin converting enzyme inhibitor on myocardial necrosis and hypertrophy in young rats with renovascular hypertension.International journal of experimental pathology, , Volume: 80, Issue:2, 1999
Beneficial impact of ramipril on left ventricular hypertrophy in normotensive nonalbuminuric NIDDM patients.Diabetes care, , Volume: 22, Issue:1, 1999
Central vasopressin is modulated by chronic blockade of the renin-angiotensin system in experimental left ventricular hypertrophy.American journal of hypertension, , Volume: 12, Issue:3, 1999
Effect of angiotensin-converting enzyme inhibition on protein kinase C and SR proteins in heart failure.The American journal of physiology, , Volume: 276, Issue:1, 1999
Prevention of left ventricular hypertrophy by ACE-inhibitor, ramipril in comparison with calcium-channel antagonist, felodipine.International journal of cardiology, , Jan-31, Volume: 63, Issue:2, 1998
Functional impact of an increase in ventricular mass after myocardial damage and its attenuation by converting enzyme inhibition.Journal of cardiac failure, , Volume: 4, Issue:3, 1998
L-type calcium channels modulate the regression of left ventricular hypertrophy after ace-inhibition in genetic hypertension.Pharmacological research, , Volume: 38, Issue:4, 1998
Postinfarction survival and inducibility of ventricular arrhythmias in the spontaneously hypertensive rat : effects of ramipril and hydralazine.Circulation, , Nov-10, Volume: 98, Issue:19, 1998
[Improvement in diastolic function in hypertensive patients with left ventricular hypertrophy with inhibitors of the angiotensin converting enzyme].Revista clinica espanola, , Volume: 198, Issue:1, 1998
Beneficial impact of ramipril on left ventricular hypertrophy in normotensive nonalbuminuric NIDDM patients.Diabetes care, , Volume: 21, Issue:5, 1998
Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy.American journal of hypertension, , Volume: 11, Issue:4 Pt 1, 1998
Role of bradykinin in the reduction of left ventricular hypertrophy induced by angiotensin-converting enzyme inhibitors in spontaneously hypertensive rats.Japanese journal of pharmacology, , Volume: 76, Issue:4, 1998
Changes in left ventricular mass and volumes in patients receiving angiotensin-converting enzyme inhibitor therapy for left ventricular dysfunction after Q-wave myocardial infarction.American heart journal, , Volume: 136, Issue:2, 1998
Influence of dietary salts on the cardiovascular effects of low-dose combination of ramipril and felodipine in spontaneously hypertensive rats.British journal of pharmacology, , Volume: 123, Issue:2, 1998
Regulation of extracellular matrix proteins in pressure-overload cardiac hypertrophy: effects of angiotensin converting enzyme inhibition.Journal of hypertension, , Volume: 16, Issue:9, 1998
[Effects of ramipril and spironolactone on ventricular remodeling after acute myocardial infarction: randomized and double-blind study].Revista medica de Chile, , Volume: 125, Issue:6, 1997
Cardiovascular effects of a low-dose combination of ramipril and felodipine in spontaneously hypertensive rats.British journal of pharmacology, , Volume: 121, Issue:3, 1997
Selective induction of the creatine kinase-B gene in chronic volume overload hypertrophy is not affected by ACE-inhibitor therapy.Journal of molecular and cellular cardiology, , Volume: 29, Issue:10, 1997
Possible protective effects of kinins and converting enzyme inhibitors in cardiovascular tissues.Immunopharmacology, , Volume: 36, Issue:2-3, 1997
Influence of age and dietary sodium on the cardiovascular and renal effects of ramipril in spontaneously hypertensive rats.Methods and findings in experimental and clinical pharmacology, , Volume: 19, Issue:5, 1997
[A decrease in left ventricular hypertrophy and the dynamics of the parameters of circadian BP monitoring under the influence of ramipril in patients with essential arterial hypertension].Terapevticheskii arkhiv, , Volume: 69, Issue:4, 1997
Angiotensin-converting enzyme inhibitor therapy affects left ventricular mass in patients with ejection fraction > 40% after acute myocardial infarction.Journal of the American College of Cardiology, , Volume: 29, Issue:1, 1997
ACE inhibition reduces left ventricular mass independent of pressure without affecting coronary flow and flow reserve in spontaneously hypertensive rats.The American journal of the medical sciences, , Volume: 314, Issue:1, 1997
Influence of age on cardiovascular effects of increased dietary sodium and angiotensin-converting enzyme inhibition in normotensive Wistar rats.The Journal of pharmacy and pharmacology, , Volume: 49, Issue:9, 1997
Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke-prone spontaneously hypertensive rats.Hypertension (Dallas, Tex. : 1979), , Volume: 29, Issue:1 Pt 2, 1997
Left ventricular hypertrophy and QT dispersion in hypertension.Hypertension (Dallas, Tex. : 1979), , Volume: 28, Issue:5, 1996
Functional activity and expression of the myocardial postreceptor adenylyl cyclase system in pressure overload hypertrophy in rat.Cardiovascular research, , Volume: 31, Issue:5, 1996
Vascular and cardiac protection by ramipril in spontaneously hypertensive rats: prevention versus regression study.British journal of clinical practice. Supplement, , Volume: 84, 1996
ACE inhibition decreases postoperative mortality in rats with left ventricular hypertrophy and myocardial infarction.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 18, Issue:5, 1996
Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production.Circulation, , Jun-01, Volume: 93, Issue:11, 1996
When a question has an answer: rationale for our early termination of the HEART Trial.The American journal of cardiology, , Jun-01, Volume: 75, Issue:16, 1995
[Remission of left ventricular hypertrophy with ramipril independently of blood pressure changes: the HYCAR study (cardiac hypertrophy and ramipril)].Archives des maladies du coeur et des vaisseaux, , Volume: 88 Spec No 2, 1995
Experimental evidence for effects of ramipril on cardiac and vascular hypertrophy beyond blood pressure reduction.Archives des maladies du coeur et des vaisseaux, , Volume: 88 Spec No 2, 1995
Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis.Circulation, , Apr-01, Volume: 91, Issue:7, 1995
Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. HYCAR Study Group.Hypertension (Dallas, Tex. : 1979), , Volume: 25, Issue:1, 1995
Ramipril. An updated review of its therapeutic use in essential hypertension and heart failure.Drugs, , Volume: 49, Issue:3, 1995
Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin.Hypertension (Dallas, Tex. : 1979), , Volume: 23, Issue:4, 1994
Replacement of salt by a novel potassium- and magnesium-enriched salt alternative improves the cardiovascular effects of ramipril.British journal of pharmacology, , Volume: 111, Issue:4, 1994
Cardioprotective actions of bradykinin in myocardial ischemia and left ventricular hypertrophy.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, , Volume: 27, Issue:8, 1994
Contribution of bradykinin to the cardiovascular effects of ramipril.Journal of cardiovascular pharmacology, , Volume: 22 Suppl 9, 1993
Beta blockers & left ventricular hypertrophy regression.Indian heart journal, , Volume: 62, Issue:2
The effect of ramipril on left ventricular mass, myocardial fibrosis, diastolic function, and plasma neurohormones in Maine Coon cats with familial hypertrophic cardiomyopathy without heart failure.Journal of veterinary internal medicine, , Volume: 20, Issue:5
Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis.Molecular and cellular biochemistry, , Volume: 147, Issue:1-2
Effect of atenolol and ramipril on regression of left ventricular hypertrophy: comparative echocardiographic assessment.Advances in therapy, , Volume: 12, Issue:2
Does diabetes prevention translate into reduced long-term vascular complications of diabetes?Diabetologia, , Volume: 62, Issue:8, 2019
Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.Diabetic medicine : a journal of the British Diabetic Association, , Volume: 27, Issue:11, 2010
Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial.Diabetes care, , Volume: 33, Issue:3, 2010
Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET/TRANSCEND research programme.Diabetes research and clinical practice, , Volume: 83, Issue:3, 2009
Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.Diabetes care, , Volume: 31, Issue:5, 2008
Dysglycemia and a history of reproductive risk factors.Diabetes care, , Volume: 31, Issue:8, 2008
Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled study.European journal of clinical pharmacology, , Volume: 63, Issue:8, 2007
Angiotensin-converting-enzyme inhibitors for impaired glucose tolerance--is there still hope?The New England journal of medicine, , Oct-12, Volume: 355, Issue:15, 2006
Effect of ramipril on the incidence of diabetes.The New England journal of medicine, , Oct-12, Volume: 355, Issue:15, 2006
Renin-Angiotensin System Blockade in COVID-19: Good, Bad, or Indifferent?Journal of the American College of Cardiology, , 07-21, Volume: 76, Issue:3, 2020
ACE Inhibitors and Angiotensin II Receptor Blockers May Have Different Impact on Prognosis of COVID-19.Journal of the American College of Cardiology, , 10-27, Volume: 76, Issue:17, 2020
Ramipril in High-Risk Patients With COVID-19.Journal of the American College of Cardiology, , 07-21, Volume: 76, Issue:3, 2020
The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial.Circulation, , 12-06, Volume: 146, Issue:23, 2022
Efficacy of Sacubitril-Valsartan in Patients With Reduced Left Ventricular Ejection Fraction.The American journal of cardiology, , 08-15, Volume: 153, 2021
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.The New England journal of medicine, , 11-11, Volume: 385, Issue:20, 2021
Ramipril and left ventricular diastolic function in stable patients with pulmonary regurgitation after repair of tetralogy of Fallot.International journal of cardiology, , Dec-01, Volume: 272, 2018
Impact of renin-angiotensin system inhibitors on clinical outcomes and ventricular remodelling after transcatheter aortic valve implantation: rationale and design of the RASTAVI randomised multicentre study.BMJ open, , 02-13, Volume: 8, Issue:2, 2018
Early Treatment With Zofenopril and Ramipril in Combination With Acetyl Salicylic Acid in Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction: Results of a 5-Year Follow-up of Patients of the SMILE-4 Study.Journal of cardiovascular pharmacology, , Volume: 69, Issue:5, 2017
Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SMILE-4 Randomized, Double-Blind Study in Diabetic Patients.Cardiovascular therapeutics, , Volume: 34, Issue:2, 2016
Zofenopril and ramipril in patients with left ventricular systolic dysfunction after acute myocardial infarction: A propensity analysis of the Survival of Myocardial Infarction Long-term Evaluation (SMILE) 4 study.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 17, Issue:4, 2016
Angiotensin converting enzyme inhibitors for heart failure with reduced ejection fraction or left ventricular dysfunction: A complementary network meta-analyses.International journal of cardiology, , Jul-01, Volume: 214, 2016
Takotsubo cardiomyopathy after an emotional outburst.The Ceylon medical journal, , Volume: 60, Issue:3, 2015
Usefulness of combined bedside lung ultrasound and echocardiography to assess weaning failure from mechanical ventilation: a suggestive case*.Critical care medicine, , Volume: 41, Issue:8, 2013
Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a retrospective analysis in hypertensive patients of the SMILE-4 study.Journal of hypertension, , Volume: 31, Issue:6, 2013
A young patient with heart failure: picture quiz question.Acute medicine, , Volume: 11, Issue:1, 2012
Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European studClinical cardiology, , Volume: 35, Issue:7, 2012
[Improvement of left ventricular function during combined carvedilol, ramipril and spironolactone therapy after myocarditis in patient treated earlier by chemotherapy due to Hodgkin's lymphoma - 3-years follow-up].Kardiologia polska, , Volume: 68, Issue:7, 2010
The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice.Experimental physiology, , Volume: 94, Issue:3, 2009
The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics.Clinical research in cardiology : official journal of the German Cardiac Society, , Volume: 98, Issue:7, 2009
Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).The American journal of cardiology, , Dec-01, Volume: 104, Issue:11, 2009
The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction.Heart (British Cardiac Society), , Volume: 94, Issue:5, 2008
Long-term but not short-term p38 mitogen-activated protein kinase inhibition improves cardiac function and reduces cardiac remodeling post-myocardial infarction.The Journal of pharmacology and experimental therapeutics, , Volume: 325, Issue:3, 2008
Attenuation of left ventricular dysfunction by an ACE inhibitor after myocardial infarction in a kininogen-deficient rat model.Biological chemistry, , Volume: 389, Issue:6, 2008
Delayed recovery of left ventricular systolic dysfunction: ''give time to medical therapy''.Minerva cardioangiologica, , Volume: 55, Issue:3, 2007
Lipid peroxidation is not increased in heart failure patients on modern pharmacological therapy.International journal of cardiology, , Oct-10, Volume: 112, Issue:3, 2006
[Effects of losartan, ramipril and their combination on left ventricular remodeling and function in spontaneous hypertensive rats].Zhonghua yi xue za zhi, , Nov-30, Volume: 85, Issue:45, 2005
Extended follow-up of patients randomly assigned in the Angiotensin-converting enzyme inhibition Post-Revascularization Study (APRES).American heart journal, , Volume: 148, Issue:3, 2004
Left ventricular hypertrophy: a "factor of risk": mass is reversible, but is the risk?Journal of the American College of Cardiology, , Jun-16, Volume: 43, Issue:12, 2004
Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial.Journal of the American College of Cardiology, , Jun-16, Volume: 43, Issue:12, 2004
Randomized, double-blind, placebo-controlled long-term study of isosorbide-5-mononitrate therapy in patients with left ventricular dysfunction after acute myocardial infarction.American heart journal, , Volume: 145, Issue:1, 2003
The EUROPA trial.Lancet (London, England), , Dec-06, Volume: 362, Issue:9399, 2003
Aldosterone receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure.Cardiovascular research, , Jun-01, Volume: 58, Issue:3, 2003
[ACE inhibitors in high risk heart patients. Primary analysis of the HOPE study].Der Internist, , Volume: 43, Issue:3, 2002
From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.The American journal of cardiology, , Jan-24, Volume: 89, Issue:2A, 2002
Regional wall stress predicts ventricular remodeling after anteroseptal myocardial infarction in the Healing and Early Afterload Reducing Trial (HEART): an echocardiography-based structural analysis.American heart journal, , Volume: 141, Issue:2, 2001
The Heart Outcomes Prevention Evaluation Study.Current cardiology reports, , Volume: 3, Issue:2, 2001
Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study.Annals of internal medicine, , Mar-20, Volume: 134, Issue:6, 2001
[ACE inhibition in patients with myocardial infarct and ventricular dysfunction: inappropriate application of therapy standards in patient samples].Zeitschrift fur Kardiologie, , Volume: 90, Issue:2, 2001
What are 'tissue ACE inhibitors,' and should they be used instead of other ACE inhibitors?Cleveland Clinic journal of medicine, , Volume: 68, Issue:3, 2001
Management of asymptomatic left ventricular dysfunction.Cleveland Clinic journal of medicine, , Volume: 68, Issue:3, 2001
Beneficial effects of ramipril on left ventricular end-diastolic and end-systolic volume indexes after uncomplicated invasive revascularization are associated with a reduction in cardiac events in patients with moderately impaired left ventricular functioJournal of the American College of Cardiology, , Volume: 37, Issue:5, 2001
[Effect of a converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients].Presse medicale (Paris, France : 1983), , Apr-15, Volume: 29, Issue:14, 2000
Management of heart failure.Current cardiology reports, , Volume: 2, Issue:3, 2000
[Symposium "Emerging Approaches to Cardiovascular Diseases: Detailed results and implications of the HOPE Study". Atlanta, 10. November 1999].Der Internist, , Volume: 41, Issue:1, 2000
The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES).Journal of the American College of Cardiology, , Mar-15, Volume: 35, Issue:4, 2000
Functional impact of an increase in ventricular mass after myocardial damage and its attenuation by converting enzyme inhibition.Journal of cardiac failure, , Volume: 4, Issue:3, 1998
Treatment with ramipril improves systolic function even in patients with mild systolic dysfunction and symptoms of heart failure after acute myocardial infarction.Clinical cardiology, , Volume: 21, Issue:11, 1998
The Angiotensin Converting Enzyme Inhibition Post Revascularization Study (APRES). Effects of ramipril in patients with reduced left ventricular function. Rationale, design, methods, baseline characteristics and first-year experience.Scandinavian cardiovascular journal : SCJ, , Volume: 32, Issue:4, 1998
Changes in left ventricular mass and volumes in patients receiving angiotensin-converting enzyme inhibitor therapy for left ventricular dysfunction after Q-wave myocardial infarction.American heart journal, , Volume: 136, Issue:2, 1998
[Effects of ramipril and spironolactone on ventricular remodeling after acute myocardial infarction: randomized and double-blind study].Revista medica de Chile, , Volume: 125, Issue:6, 1997
Incidence and natural history of left ventricular thrombus following anterior wall acute myocardial infarction.The American journal of cardiology, , Aug-15, Volume: 80, Issue:4, 1997
Angiotensin-converting enzyme inhibition limits dysfunction in adjacent noninfarcted regions during left ventricular remodeling.Journal of the American College of Cardiology, , Volume: 27, Issue:1, 1996
When a question has an answer: rationale for our early termination of the HEART Trial.The American journal of cardiology, , Jun-01, Volume: 75, Issue:16, 1995
Cutaneous vasculitis secondary to ramipril.Journal of drugs in dermatology : JDD, , Volume: 3, Issue:1
ACE inhibitors after myocardial infarction.The British journal of clinical practice, , Volume: 49, Issue:4
Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk.European heart journal, , 07-01, Volume: 40, Issue:25, 2019
Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.American heart journal, , Volume: 214, 2019
Twenty-and-a-half syndrome: a case report.Journal of medical case reports, , Feb-15, Volume: 13, Issue:1, 2019
Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.European heart journal, , 09-01, Volume: 39, Issue:33, 2018
Target Blood Pressure in Patients with Diabetes: Asian Perspective.Yonsei medical journal, , Volume: 57, Issue:6, 2016
Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease.Hypertension (Dallas, Tex. : 1979), , Volume: 65, Issue:1, 2015
Systolic blood pressure target levels: evidence for benefits in stroke.Hypertension (Dallas, Tex. : 1979), , Volume: 65, Issue:1, 2015
Childhood polyarteritis nodosa presenting as stroke and arterial hypertension.BMJ case reports, , Oct-29, Volume: 2014, 2014
The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.European journal of preventive cardiology, , Volume: 21, Issue:3, 2014
Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtoleranJournal of hypertension, , Volume: 30, Issue:5, 2012
A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.The Annals of pharmacotherapy, , Volume: 46, Issue:5, 2012
Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in CombinatioCirculation, , Aug-21, Volume: 126, Issue:8, 2012
The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study.Journal of medical economics, , Volume: 14, Issue:6, 2011
Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET).Circulation, , Oct-18, Volume: 124, Issue:16, 2011
Prevention and intervention studies with telmisartan, ramipril and their combination in different rat stroke models.PloS one, , Volume: 6, Issue:8, 2011
Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.Circulation, , Mar-15, Volume: 123, Issue:10, 2011
Impact of ACE inhibitors on mortality and morbidity in patients with AMI: Does tissue selectivity matter?Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 14, Issue:1, 2011
Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET/TRANSCEND research programme.Diabetes research and clinical practice, , Volume: 83, Issue:3, 2009
Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programs.Journal of hypertension. Supplement : official journal of the International Society of Hypertension, , Volume: 27, Issue:5, 2009
ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?Blood pressure, , Volume: 18, Issue:1-2, 2009
The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial.Journal of cardiovascular electrophysiology, , Volume: 20, Issue:7, 2009
Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats.Journal of hypertension, , Volume: 26, Issue:3, 2008
Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?Cerebrovascular diseases (Basel, Switzerland), , Volume: 26, Issue:5, 2008
Synergistic protective effects of erythropoietin and olmesartan on ischemic stroke survival and post-stroke memory dysfunctions in the gerbil.Journal of hypertension, , Volume: 24, Issue:11, 2006
Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study)*.Journal of hypertension, , Volume: 24, Issue:3, 2006
[HOPE study].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 64 Suppl 6, 2006
The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences.Scandinavian journal of clinical and laboratory investigation. Supplementum, , Volume: 240, 2005
[Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].Italian heart journal : official journal of the Italian Federation of Cardiology, , Volume: 6 Suppl 7, 2005
Impact of cigarette smoking in high-risk patients participating in a clinical trial. A substudy from the Heart Outcomes Prevention Evaluation (HOPE) trial.European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology, , Volume: 12, Issue:1, 2005
[Experiences with the realisation of the innovative study designs using the example of the HOPE study -- concerning the contribution in DMW Supplement 2/2005].Deutsche medizinische Wochenschrift (1946), , Nov-25, Volume: 130, Issue:47, 2005
Protection against stroke and dementia: an update on the latest clinical trial evidence.Current hypertension reports, , Volume: 6, Issue:4, 2004
[Can coronary risks be further reduced?].Presse medicale (Paris, France : 1983), , Sep-25, Volume: 33, Issue:16, 2004
The PROGRESS trial three years later: HOPE trial may shed some light.BMJ (Clinical research ed.), , Dec-11, Volume: 329, Issue:7479, 2004
Should all patients with coronary disease receive angiotensin-converting-enzyme inhibitors?Lancet (London, England), , Sep-06, Volume: 362, Issue:9386, 2003
Stroke prevention: indapamide, a forgotten option?Stroke, , Volume: 34, Issue:9, 2003
Blood pressure drugs may help prevent stroke.Mayo Clinic health letter (English ed.), , Volume: 21, Issue:1, 2003
Economic impact of ramipril on hospitalization of high-risk cardiovascular patients.The Annals of pharmacotherapy, , Volume: 37, Issue:3, 2003
Best bang for the buck?Current hypertension reports, , Volume: 5, Issue:1, 2003
Angiotensin-converting enzyme inhibitors for stroke prevention: is there HOPE for PROGRESS After LIFE?Stroke, , Volume: 34, Issue:2, 2003
Converting enzyme inhibitor or AT1-receptor blocker for decreasing long-term mortality in patients with stroke history and renal dysfunction?Stroke, , Volume: 34, Issue:1, 2003
Preventing stroke with ramipril--authors' reply.BMJ (Clinical research ed.), , Jan-04, Volume: 326, Issue:7379, 2003
Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study.Circulation, , Feb-25, Volume: 107, Issue:7, 2003
Angiotensin-converting enzyme inhibitors and stroke prevention: what about the influence of atrial fibrillation and antithrombotic therapy?Stroke, , Volume: 34, Issue:11, 2003
[Therapy of hypertension. Lasting organ protection moves into the foreground].MMW Fortschritte der Medizin, , Nov-20, Volume: 145, Issue:47, 2003
Preventing stroke.BMJ (Clinical research ed.), , Mar-23, Volume: 324, Issue:7339, 2002
Preventing stroke with ramipril. Benefits were considerably overstated.BMJ (Clinical research ed.), , Aug-24, Volume: 325, Issue:7361, 2002
Use of ramipril in preventing stroke: double blind randomised trial.BMJ (Clinical research ed.), , Mar-23, Volume: 324, Issue:7339, 2002
Blood pressure drug helps prevent stroke.Health news (Waltham, Mass.), , Volume: 8, Issue:5, 2002
Preventing stroke with ramipril. Presentation of data is misleading.BMJ (Clinical research ed.), , Aug-24, Volume: 325, Issue:7361, 2002
Effect of long-term therapy with ramipril in high-risk women.Journal of the American College of Cardiology, , Aug-21, Volume: 40, Issue:4, 2002
"Preemptive strike" heart medications. A.C.E. inhibitors gain new ground as multi-purpose cardiac drugs.Heart advisor, , Volume: 5, Issue:2, 2002
Preventing stroke with ramipril. Superiority of particular class of antihypertensive agent remains to be shown.BMJ (Clinical research ed.), , Aug-24, Volume: 325, Issue:7361, 2002
Preventing stroke with ramipril. Results should have been presented in ways that help practising clinicians.BMJ (Clinical research ed.), , Aug-24, Volume: 325, Issue:7361, 2002
Diabetes and the HOPE study: implications for macrovascular and microvascular disease.International journal of clinical practice. Supplement, , Issue:117, 2001
[Achieving vascular protection. ACE inhibitor lowers not only blood pressure].MMW Fortschritte der Medizin, , Sep-06, Volume: 143, Issue:35-36, 2001
What are 'tissue ACE inhibitors,' and should they be used instead of other ACE inhibitors?Cleveland Clinic journal of medicine, , Volume: 68, Issue:3, 2001
The Heart Outcomes Prevention Evaluation study: angiotensin-converting enzyme inhibitors: are their benefits a class effect or do individual agents differ?Current opinion in nephrology and hypertension, , Volume: 10, Issue:5, 2001
[Symposium "Emerging Approaches to Cardiovascular Diseases: Detailed results and implications of the HOPE Study". Atlanta, 10. November 1999].Der Internist, , Volume: 41, Issue:1, 2000
Don't keep that ACE (inhibitor) up your sleeve! Is ramipril effective for secondary prevention of cardiovascular disease and stroke?Canadian family physician Medecin de famille canadien, , Volume: 46, 2000
ACE inhibition in cardiovascular disease.The New England journal of medicine, , Jan-20, Volume: 342, Issue:3, 2000
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.The New England journal of medicine, , 01-20, Volume: 342, Issue:3, 2000
Ramipril study suggests drug may benefit broad group of patients.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Dec-15, Volume: 56, Issue:24, 1999
A safe new dose of heart protection. Study shows drug can prevent attacks, strokes.U.S. news & world report, , Nov-22, Volume: 127, Issue:20, 1999
[ACE inhibitor even prevents diabetes. Sensational HOPE Study].MMW Fortschritte der Medizin, , Sep-30, Volume: 141, Issue:39, 1999
[Prevention of stroke: should high risk patients be treated with angiotensin II converting enzyme inhibitors without regard to their blood pressure levels? ].Lijecnicki vjesnik, , Volume: 125, Issue:1-2
New uses for old drug: reducing risk of heart attacks and strokes.FDA consumer, , Volume: 35, Issue:1
Study at up to 700 sites will build on landmark HOPE trial.Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners, , Volume: 12, Issue:2
ONTARGET programme of cardio- and vascular protection - first results are imminent.Cardiovascular journal of Africa, , Volume: 19, Issue:1
Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation.Journal of cardiovascular pharmacology and therapeutics, , Volume: 17, Issue:1, 2012
Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly mild to moderate essential hypertensive patients with or without metabolic syndrome: a pooled post hoc analysis of two comparative trials.Drugs & aging, , Volume: 29, Issue:12, 2012
Kidney function in metabolic syndrome may be improved with Pycnogenol®.Panminerva medica, , Volume: 52, Issue:2 Suppl 1, 2010
Phosphodiesterase 5 inhibition improves beta-cell function in metabolic syndrome.Diabetes care, , Volume: 32, Issue:5, 2009
A new dawn in cardiovascular protection: total cardiovascular risk: rigorous treatment of risk factors. Introduction.Nature clinical practice. Cardiovascular medicine, , Volume: 5 Suppl 1, 2008
Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome.Nephrology (Carlton, Vic.), , Volume: 12, Issue:2, 2007
[In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension].MMW Fortschritte der Medizin, , Jun-29, Volume: 148, Issue:26, 2006
[Hypertension and diabetic nephropathy, a dangerous duo].Medizinische Klinik (Munich, Germany : 1983), , Nov-15, Volume: 100, Issue:11, 2005
Pregnancy outcome following exposure to orlistat, ramipril, glimepiride in a woman with metabolic syndrome.Saudi medical journal, , Volume: 26, Issue:3, 2005
Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE?Current medical research and opinion, , Volume: 20, Issue:3, 2004
[Efficacy of complex therapy with metformin and ramipril combination for patients with metabolic syndrome].Likars'ka sprava, , Issue:7-8
Effects of ramipril therapy on some components of insulin resistance syndrome in patients with essential hypertension.Medicinski pregled, , Volume: 55, Issue:7-8
[Clinical effectiveness of metformin and ramipril combination in complex therapy of patients with metabolic syndrome].Likars'ka sprava, , Issue:1
Does diabetes prevention translate into reduced long-term vascular complications of diabetes?Diabetologia, , Volume: 62, Issue:8, 2019
Telmisartan, ramipril and their combination improve endothelial function in different tissues in a murine model of cholesterol-induced atherosclerosis.British journal of pharmacology, , Volume: 163, Issue:4, 2011
Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients.Renal failure, , Volume: 32, Issue:8, 2010
Immobilization stress induces endothelial dysfunction by oxidative stress via the activation of the angiotensin II/its type I receptor pathway.Atherosclerosis, , Volume: 213, Issue:1, 2010
Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).The American journal of cardiology, , Dec-01, Volume: 104, Issue:11, 2009
Letter by Popa and Netea regarding article, "Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis".Circulation, , Nov-04, Volume: 118, Issue:19, 2008
Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis.Circulation, , Apr-29, Volume: 117, Issue:17, 2008
Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?Nature clinical practice. Cardiovascular medicine, , Volume: 5, Issue:9, 2008
Captopril inhibits the oxidative modification of apolipoprotein B-100 caused by myeloperoxydase in a comparative in vitro assay of angiotensin converting enzyme inhibitors.European journal of pharmacology, , May-10, Volume: 537, Issue:1-3, 2006
Ramipril in the treatment of vascular diseases.Expert opinion on pharmacotherapy, , Volume: 6, Issue:11, 2005
[Effects of angiotensin receptor blocker and angiotensin-coverting enzyme inhibitor on vascular endothelial function in type 2 diabetic patients with atherosclerosis: a comparative study].Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA, , Volume: 25, Issue:8, 2005
Combined effects of HMG-CoA-reductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis.Atherosclerosis, , Volume: 182, Issue:1, 2005
[Direct antiatherosclerotic therapy: possible approaches, results of clinical trials].Patologicheskaia fiziologiia i eksperimental'naia terapiia, , Issue:4
Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3-/- Mice.Journal of the American Society of Nephrology : JASN, , 09-01, Volume: 34, Issue:9, 2023
mTORC Pathway Activation and Effect of Sirolimus on Native Kidney Antiphospholipid Syndrome Nephropathy: A Case Report.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 76, Issue:2, 2020
Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 74, Issue:3, 2019
Low-dose hydralazine prevents fibrosis in a murine model of acute kidney injury-to-chronic kidney disease progression.Kidney international, , Volume: 91, Issue:1, 2017
Effects of Ramipril and Telmisartan on Plasma Concentrations of Low Molecular Weight and Protein Thiols and Carotid Intima Media Thickness in Patients with Chronic Kidney Disease.Disease markers, , Volume: 2016, 2016
The Association of Losartan and Ramipril Therapy With Kidney and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: A Chinese Nation-Wide Cohort Study in Taiwan.Medicine, , Volume: 94, Issue:48, 2015
Moving dietary management of diabetes forward.JAMA internal medicine, , Oct-14, Volume: 173, Issue:18, 2013
Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus.JAMA internal medicine, , Oct-14, Volume: 173, Issue:18, 2013
Activation of Rac-1 and RhoA contributes to podocyte injury in chronic kidney disease.PloS one, , Volume: 8, Issue:11, 2013
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.Hypertension (Dallas, Tex. : 1979), , Volume: 61, Issue:1, 2013
A comparison of the antihypertensive and anti-inflammatory effects of aliskiren and ramipril add-on therapy in peritoneal dialysis patients--a pilot open label study.Kidney & blood pressure research, , Volume: 36, Issue:1, 2012
Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition.Journal of the American Society of Nephrology : JASN, , Volume: 22, Issue:10, 2011
Phosphate REINs in the renoprotective benefit of ACE inhibition.Journal of the American Society of Nephrology : JASN, , Volume: 22, Issue:10, 2011
Strict blood-pressure control and progression of renal failure in children.The New England journal of medicine, , Oct-22, Volume: 361, Issue:17, 2009
Blood-pressure control and delay in progression of kidney disease in children.The New England journal of medicine, , Oct-22, Volume: 361, Issue:17, 2009
Projecting the potential cost-effectiveness of dapagliflozin for chronic kidney disease in Kuwait.Journal of medical economics, , Volume: 26, Issue:1
Adverse cardiac effects of exogenous angiotensin 1-7 in rats with subtotal nephrectomy are prevented by ACE inhibition.PloS one, , Volume: 12, Issue:2, 2017
Is administration of preoperative angiotensin-converting enzyme inhibitors important for renal protection after cardiac surgery?Renal failure, , Volume: 35, Issue:5, 2013
Angiotensin-(1-7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy.Clinical science (London, England : 1979), , Volume: 120, Issue:8, 2011
ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?Blood pressure, , Volume: 18, Issue:1-2, 2009
Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial.Journal of hypertension, , Volume: 25, Issue:10, 2007
Renal failure following bowel cleansing with a sodium phosphate purgative.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 20, Issue:7, 2005
Ramipril/felodipine extended-release fixed-dose combination: a review of its use in the management of essential hypertension.Drugs, , Volume: 65, Issue:13, 2005
Cardiovascular risk in patients with mild renal insufficiency: implications for the use of ACE inhibitors.Presse medicale (Paris, France : 1983), , Oct-22, Volume: 34, Issue:18, 2005
Transforming growth factor beta1 and additional renoprotective effect of combination ACE inhibitor and angiotensin II receptor blocker in hypertensive subjects with minor renal abnormalities: a 24-week randomized controlled trial.Journal of hypertension, , Volume: 23, Issue:3, 2005
Ramipril in the treatment of vascular diseases.Expert opinion on pharmacotherapy, , Volume: 6, Issue:11, 2005
ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: the African American Study of Kidney Disease and Hypertension (AASK) trial.Kidney international. Supplement, , Issue:83, 2003
Cardiomyocyte loss in experimental renal failure: prevention by ramipril.Kidney international, , Volume: 63, Issue:5, 2003
Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 42, Issue:5, 2003
Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome.Kidney international, , Volume: 63, Issue:2, 2003
[Improved protection of heart and kidneys in the hypertensive patient. ACE inhibitor and AT1 blocker combined?].MMW Fortschritte der Medizin, , Jun-05, Volume: 145, Issue:23, 2003
Ramipril for the prevention and treatment of cardiovascular disease.The Annals of pharmacotherapy, , Volume: 37, Issue:3, 2003
Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study.Journal of the American Society of Nephrology : JASN, , Volume: 14, Issue:3, 2003
Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes.The Medical journal of Australia, , Mar-18, Volume: 176, Issue:6, 2002
The kidney in cardiovascular disease.Annals of internal medicine, , Apr-17, Volume: 134, Issue:8, 2001
ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy.Journal of the American Society of Nephrology : JASN, , Volume: 12, Issue:12, 2001
Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.Annals of internal medicine, , Apr-17, Volume: 134, Issue:8, 2001
Summaries for patients. Trial of a drug to decrease the risk for heart disease in patients with mild kidney failure.Annals of internal medicine, , Apr-17, Volume: 134, Issue:8, 2001
Comparative effects of ramipril and nitrendipine on albuminuria in hypertensive patients with non-insulin-dependent diabetes mellitus and impaired renal function.Journal of human hypertension, , Volume: 9, Issue:2, 1995
Ramipril prevents the detrimental sequels of chronic NO synthase inhibition in rats: hypertension, cardiac hypertrophy and renal insufficiency.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 350, Issue:6, 1994
Clinical pharmacokinetics of ramipril.Clinical pharmacokinetics, , Volume: 26, Issue:1, 1994
Pharmacokinetic and pharmacodynamic parameters of ramipril and ramiprilat in healthy dogs and dogs with reduced glomerular filtration rate.Journal of veterinary internal medicine, , Volume: 20, Issue:3
Renal insufficiency predicts cardiovascular disease in high-risk individuals: the benefit of ramipril in the HOPE study. Heart Outcomes and Prevention Evaluation.Journal of clinical hypertension (Greenwich, Conn.), , Volume: 3, Issue:4
Blacks with hypertension, renal insufficiency, and baseline proteinuria benefit more from ACE inhibition than from calcium channel blockade.Journal of clinical hypertension (Greenwich, Conn.), , Volume: 3, Issue:5
Differential levels of circulating progenitor cells in acute coronary syndrome patients with a first event versus patients with recurring events.International journal of cardiology, , May-19, Volume: 149, Issue:1, 2011
Effects of ramipril on serum monocyte chemoattractant protein 1, interleukin-18, and interleukin-10 in elderly patients with acute coronary syndrome.Heart and vessels, , Volume: 25, Issue:2, 2010
Comparison of the effects of ramipril versus telmisartan on high-sensitivity C-reactive protein and endothelial progenitor cells after acute coronary syndrome.The American journal of cardiology, , Jun-01, Volume: 103, Issue:11, 2009
Multicap to improve adherence after acute coronary syndromes: results of a randomized controlled clinical trial.Therapeutic advances in cardiovascular disease, , Volume: 14
The N-AcetylCysteine and RAMipril in Takotsubo Syndrome Trial (NACRAM): Rationale and design of a randomised controlled trial of sequential N-Acetylcysteine and ramipril for the management of Takotsubo Syndrome.Contemporary clinical trials, , Volume: 90, 2020
Conceivable utility of the electrocardiogram in the N-acetylcysteine and RAMipril in takotsubo syndrome trial (NACRAM).Contemporary clinical trials, , Volume: 88, 2020
Reversible stress cardiomyopathy in Guillain-Barré syndrome: a case report.Journal of medical case reports, , May-20, Volume: 13, Issue:1, 2019
Takotsubo-like syndrome triggered by fludrocortisone overdose for Addison's disease: a case report.Journal of medical case reports, , Oct-12, Volume: 10, Issue:1, 2016
Takotsubo cardiomyopathy after an emotional outburst.The Ceylon medical journal, , Volume: 60, Issue:3, 2015
Rituximab-induced Takotsubo syndrome: more cardiotoxic than it appears?BMJ case reports, , Mar-02, Volume: 2015, 2015
Tako-tsubo cardiomyopathy observed in a patient with sepsis and transient hyperthyroidism.Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, , Volume: 72, Issue:1, 2009
A logistic regression model based on inpatient health records to predict drug-induced liver injury caused by ramipril-An angiotensin-converting enzyme inhibitor.PloS one, , Volume: 17, Issue:8, 2022
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
Angiotensin-converting enzyme inhibitor prevents oxidative stress, inflammation, and fibrosis in carbon tetrachloride-treated rat liver.Toxicology mechanisms and methods, , Volume: 26, Issue:1, 2016
Ramipril-induced liver injury: case report and review of the literature.American journal of hypertension, , Volume: 26, Issue:9, 2013
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).PLoS computational biology, , Volume: 7, Issue:12, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
Levosimendan suppresses oxidative injury, apoptotic signaling and mitochondrial degeneration in streptozotocin-induced diabetic cardiomyopathy.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 38, Issue:1, 2016
Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SMILE-4 Randomized, Double-Blind Study in Diabetic Patients.Cardiovascular therapeutics, , Volume: 34, Issue:2, 2016
Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes.Diabetologia, , Volume: 55, Issue:5, 2012
Medicine-Induced Acute Kidney Injury Findings from Spontaneous Reporting Systems, Sequence Symmetry Analysis and a Case-Control Study with a Focus on Medicines Used in Primary Care.Drug safety, , Volume: 45, Issue:11, 2022
Ramipril blunts glycerol-induced acute renal failure in rats through its antiapoptosis, anti-inflammatory, antioxidant, and renin-inhibiting properties.Journal of basic and clinical physiology and pharmacology, , Nov-06, Volume: 32, Issue:3, 2020
Low-dose hydralazine prevents fibrosis in a murine model of acute kidney injury-to-chronic kidney disease progression.Kidney international, , Volume: 91, Issue:1, 2017
MicroRNAs mediate the cardioprotective effect of angiotensin-converting enzyme inhibition in acute kidney injury.American journal of physiology. Renal physiology, , Dec-01, Volume: 309, Issue:11, 2015
Obesity and oxidative stress predict AKI after cardiac surgery.Journal of the American Society of Nephrology : JASN, , Volume: 23, Issue:7, 2012
Unexpected hospitalisation side effects in an elderly man.Internal and emergency medicine, , Volume: 6, Issue:2, 2011
[Acute renal insufficiency after flurbiprofen treatment in a patient treated with angiotensin converting enzyme inhibitor].La Revue de medecine interne, , Volume: 29, Issue:7, 2008
Minimal change disease in association with fire coral (Millepora species) exposure.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 47, Issue:1, 2006
[A patient with severe hyperkalaemia -- an emergency after RALES].Deutsche medizinische Wochenschrift (1946), , Sep-09, Volume: 130, Issue:36, 2005
Renal failure following bowel cleansing with a sodium phosphate purgative.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 20, Issue:7, 2005
Ileostomy and ramipril-induced acute renal failure and shock.Heart & lung : the journal of critical care, , Volume: 36, Issue:4
Ramipril pretreatment worsened renal injury and survival despite a reduction in renal inflammation in experimentally induced sepsis in mice.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 21, Issue:2
Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk.European heart journal, , 07-01, Volume: 40, Issue:25, 2019
Novel method to assess arterial insufficiency in rodent hind limb.The Journal of surgical research, , Volume: 201, Issue:1, 2016
Ramipril improves walking times and quality of life in patients with stable intermittent claudication.Evidence-based medicine, , Volume: 19, Issue:1, 2014
[Not Available].MMW Fortschritte der Medizin, , May-29, Volume: 155, Issue:10, 2013
Medications for improving walking performance in peripheral artery disease: still miles to go.JAMA, , Feb-06, Volume: 309, Issue:5, 2013
Ramipril for treatment of intermittent claudication.VASA. Zeitschrift fur Gefasskrankheiten, , Volume: 42, Issue:4, 2013
Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial.JAMA, , Feb-06, Volume: 309, Issue:5, 2013
PURLs: ramipril for claudication?The Journal of family practice, , Volume: 62, Issue:10, 2013
Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. Journal of the American Medical Association 2013; 309: 453-460.Vascular medicine (London, England), , Volume: 18, Issue:4, 2013
ACP Journal Club. Ramipril improved walking times and QOL in peripheral artery disease and intermittent claudication.Annals of internal medicine, , Jun-18, Volume: 158, Issue:12, 2013
Large underestimation of arterial pressure after vasodilator medication overdose.British journal of anaesthesia, , Volume: 125, Issue:3, 2020
Takotsubo-like syndrome triggered by fludrocortisone overdose for Addison's disease: a case report.Journal of medical case reports, , Oct-12, Volume: 10, Issue:1, 2016
Severe lactic acidosis and rhabdomyolysis following metformin and ramipril overdose.British journal of anaesthesia, , Volume: 98, Issue:2, 2007
Redefining the ACE-inhibitor dose-response relationship: substantial blood pressure lowering after massive doses.European journal of clinical pharmacology, , Volume: 62, Issue:12, 2006
Accidental over-anticoagulation: substitution error by a foreign pharmacy.The Annals of pharmacotherapy, , Volume: 34, Issue:10, 2000
Exploring consumer opinions on the presentation of side-effects information in Australian Consumer Medicine Information leaflets.Health expectations : an international journal of public participation in health care and health policy, , Volume: 19, Issue:3, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).PLoS computational biology, , Volume: 7, Issue:12, 2011
Safety and tolerability of ramipril 10 mg in patients at high risk of cardiovascular events: an observational study.Journal of the Indian Medical Association, , Volume: 106, Issue:7, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
Anthracycline-induced cardiotoxicity prevention with angiotensin-converting enzyme inhibitor ramipril in women with low-risk breast cancer: results of a prospective randomized study.Kardiologia polska, , 02-25, Volume: 78, Issue:2, 2020
SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab.Medical oncology (Northwood, London, England), , Volume: 34, Issue:5, 2017
Effect of ethanolic extract of Cyperus rotundus L. against isoprenaline induced cardiotoxicity.Indian journal of experimental biology, , Volume: 54, Issue:10, 2016
Effects of ramipril and darbepoetin on electromechanical activity of the heart in doxorubicin-induced cardiotoxicity.International journal of cardiology, , May-15, Volume: 173, Issue:3, 2014
Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension.Journal of hypertension, , Volume: 32, Issue:10, 2014
Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtoleranJournal of hypertension, , Volume: 30, Issue:5, 2012
Chronic kidney disease: cardiac and renal angiotensin-converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition.Experimental physiology, , Volume: 97, Issue:4, 2012
Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy.Expert opinion on pharmacotherapy, , Volume: 13, Issue:8, 2012
Comparison between nebivolol and ramipril in patients with hypertension and left ventricular hypertrophy: a randomized open blinded end-point (PROBE) trial.European review for medical and pharmacological sciences, , Volume: 15, Issue:12, 2011
Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients.Renal failure, , Volume: 32, Issue:8, 2010
A comparison of the effects of ramipril and losartan on blood pressure control and left ventricle hypertrophy in patients with autosomal dominant polycystic kidney disease.Renal failure, , Volume: 32, Issue:8, 2010
The cardiac renin-angiotensin system is responsible for high-salt diet-induced left ventricular hypertrophy in mice.European journal of heart failure, , Volume: 12, Issue:11, 2010
Dual renin-angiotensin system blockade for patients with prosthesis-patient mismatch.The Annals of thoracic surgery, , Volume: 90, Issue:6, 2010
Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized AssessmentCirculation, , Oct-06, Volume: 120, Issue:14, 2009
Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).The American journal of cardiology, , Dec-01, Volume: 104, Issue:11, 2009
The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice.Experimental physiology, , Volume: 94, Issue:3, 2009
Effects of dual blockade of Renin-Angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study.American journal of hypertension, , Volume: 21, Issue:2, 2008
Effect of dual blockade of renin-angiotensin system on TGFbeta1 and left ventricular structure and function in hypertensive patients.Journal of human hypertension, , Volume: 21, Issue:4, 2007
Regression of left-ventricular hypertrophy in children and adolescents with hypertension during ramipril monotherapy.American journal of hypertension, , Volume: 20, Issue:9, 2007
Effect of ramipril on left ventricular mass in normotensive hemodialysis patients.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 47, Issue:3, 2006
Rationale and design of the cardiac magnetic resonance imaging substudy of The ONTARGET Trial Programme.The Journal of international medical research, , Volume: 33 Suppl 1, 2005
Combined blockade of AT1-receptors and ACE synergistically potentiates antihypertensive effects in SHR.Journal of hypertension, , Volume: 22, Issue:3, 2004
Left ventricular hypertrophy: a "factor of risk": mass is reversible, but is the risk?Journal of the American College of Cardiology, , Jun-16, Volume: 43, Issue:12, 2004
[Relationship between regression of hypertensive left ventricular hypertrophy and improvement of coronary flow reserve].Zhonghua yi xue za zhi, , Apr-25, Volume: 83, Issue:8, 2003
Cardiomyocyte loss in experimental renal failure: prevention by ramipril.Kidney international, , Volume: 63, Issue:5, 2003
Effects of diuretic treatment on cardiac and circulating RAS in chronic heart failure post-myocardial infarction in rats.European journal of heart failure, , Volume: 5, Issue:3, 2003
[Improved protection of heart and kidneys in the hypertensive patient. ACE inhibitor and AT1 blocker combined?].MMW Fortschritte der Medizin, , Jun-05, Volume: 145, Issue:23, 2003
Regression of ventricular and vascular hypertrophy: are there differences between structurally different angiotensin-converting enzyme inhibitors?Journal of hypertension, , Volume: 20, Issue:12, 2002
Ramipril and cardiovascular risk reduction.Circulation, , Jun-25, Volume: 105, Issue:25, 2002
"Preemptive strike" heart medications. A.C.E. inhibitors gain new ground as multi-purpose cardiac drugs.Heart advisor, , Volume: 5, Issue:2, 2002
Systemic immunosuppression fails to suppress cardiac cytokine induction in pressure overload hypertrophy in rats.Immunobiology, , Volume: 205, Issue:1, 2002
Left and right coronary circulation in left ventricular hypertrophy: effects of angiotensin converting enzyme inhibition.Circulation journal : official journal of the Japanese Circulation Society, , Volume: 66, Issue:12, 2002
Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril.Circulation, , Oct-02, Volume: 104, Issue:14, 2001
[Effect of a non-antihypertensive dose of ramipril on the plasma and tissue renin-angiotensin system in 27 TGR (mRen2) rats].Archives des maladies du coeur et des vaisseaux, , Volume: 94, Issue:8, 2001
Effects of angiotensin-converting enzyme inhibitor and angiotensin type 1 receptor antagonist in deoxycorticosterone acetate-salt hypertensive mice lacking Ren-2 gene.Hypertension (Dallas, Tex. : 1979), , Volume: 37, Issue:3, 2001
Raised blood pressure, not renin-angiotensin systems, causes cardiac fibrosis in TGR m(Ren2)27 rats.Cardiovascular research, , Volume: 47, Issue:1, 2000
Improvement in midwall myocardial shortening with regression of left ventricular hypertrophy.Hypertension (Dallas, Tex. : 1979), , Volume: 36, Issue:5, 2000
Effect of angiotensin-converting enzyme inhibition on protein kinase C and SR proteins in heart failure.The American journal of physiology, , Volume: 276, Issue:1, 1999
The effect of non-antihypertensive doses of angiotensin converting enzyme inhibitor on myocardial necrosis and hypertrophy in young rats with renovascular hypertension.International journal of experimental pathology, , Volume: 80, Issue:2, 1999
Beneficial impact of ramipril on left ventricular hypertrophy in normotensive nonalbuminuric NIDDM patients.Diabetes care, , Volume: 22, Issue:1, 1999
Central vasopressin is modulated by chronic blockade of the renin-angiotensin system in experimental left ventricular hypertrophy.American journal of hypertension, , Volume: 12, Issue:3, 1999
Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy.American journal of hypertension, , Volume: 11, Issue:4 Pt 1, 1998
Beneficial impact of ramipril on left ventricular hypertrophy in normotensive nonalbuminuric NIDDM patients.Diabetes care, , Volume: 21, Issue:5, 1998
Functional impact of an increase in ventricular mass after myocardial damage and its attenuation by converting enzyme inhibition.Journal of cardiac failure, , Volume: 4, Issue:3, 1998
[Improvement in diastolic function in hypertensive patients with left ventricular hypertrophy with inhibitors of the angiotensin converting enzyme].Revista clinica espanola, , Volume: 198, Issue:1, 1998
Regulation of extracellular matrix proteins in pressure-overload cardiac hypertrophy: effects of angiotensin converting enzyme inhibition.Journal of hypertension, , Volume: 16, Issue:9, 1998
Prevention of left ventricular hypertrophy by ACE-inhibitor, ramipril in comparison with calcium-channel antagonist, felodipine.International journal of cardiology, , Jan-31, Volume: 63, Issue:2, 1998
Influence of dietary salts on the cardiovascular effects of low-dose combination of ramipril and felodipine in spontaneously hypertensive rats.British journal of pharmacology, , Volume: 123, Issue:2, 1998
Changes in left ventricular mass and volumes in patients receiving angiotensin-converting enzyme inhibitor therapy for left ventricular dysfunction after Q-wave myocardial infarction.American heart journal, , Volume: 136, Issue:2, 1998
Postinfarction survival and inducibility of ventricular arrhythmias in the spontaneously hypertensive rat : effects of ramipril and hydralazine.Circulation, , Nov-10, Volume: 98, Issue:19, 1998
Role of bradykinin in the reduction of left ventricular hypertrophy induced by angiotensin-converting enzyme inhibitors in spontaneously hypertensive rats.Japanese journal of pharmacology, , Volume: 76, Issue:4, 1998
L-type calcium channels modulate the regression of left ventricular hypertrophy after ace-inhibition in genetic hypertension.Pharmacological research, , Volume: 38, Issue:4, 1998
Angiotensin-converting enzyme inhibitor therapy affects left ventricular mass in patients with ejection fraction > 40% after acute myocardial infarction.Journal of the American College of Cardiology, , Volume: 29, Issue:1, 1997
Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke-prone spontaneously hypertensive rats.Hypertension (Dallas, Tex. : 1979), , Volume: 29, Issue:1 Pt 2, 1997
[Effects of ramipril and spironolactone on ventricular remodeling after acute myocardial infarction: randomized and double-blind study].Revista medica de Chile, , Volume: 125, Issue:6, 1997
Influence of age and dietary sodium on the cardiovascular and renal effects of ramipril in spontaneously hypertensive rats.Methods and findings in experimental and clinical pharmacology, , Volume: 19, Issue:5, 1997
Cardiovascular effects of a low-dose combination of ramipril and felodipine in spontaneously hypertensive rats.British journal of pharmacology, , Volume: 121, Issue:3, 1997
Selective induction of the creatine kinase-B gene in chronic volume overload hypertrophy is not affected by ACE-inhibitor therapy.Journal of molecular and cellular cardiology, , Volume: 29, Issue:10, 1997
[A decrease in left ventricular hypertrophy and the dynamics of the parameters of circadian BP monitoring under the influence of ramipril in patients with essential arterial hypertension].Terapevticheskii arkhiv, , Volume: 69, Issue:4, 1997
ACE inhibition reduces left ventricular mass independent of pressure without affecting coronary flow and flow reserve in spontaneously hypertensive rats.The American journal of the medical sciences, , Volume: 314, Issue:1, 1997
Influence of age on cardiovascular effects of increased dietary sodium and angiotensin-converting enzyme inhibition in normotensive Wistar rats.The Journal of pharmacy and pharmacology, , Volume: 49, Issue:9, 1997
Possible protective effects of kinins and converting enzyme inhibitors in cardiovascular tissues.Immunopharmacology, , Volume: 36, Issue:2-3, 1997
Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production.Circulation, , Jun-01, Volume: 93, Issue:11, 1996
ACE inhibition decreases postoperative mortality in rats with left ventricular hypertrophy and myocardial infarction.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 18, Issue:5, 1996
Vascular and cardiac protection by ramipril in spontaneously hypertensive rats: prevention versus regression study.British journal of clinical practice. Supplement, , Volume: 84, 1996
Left ventricular hypertrophy and QT dispersion in hypertension.Hypertension (Dallas, Tex. : 1979), , Volume: 28, Issue:5, 1996
Functional activity and expression of the myocardial postreceptor adenylyl cyclase system in pressure overload hypertrophy in rat.Cardiovascular research, , Volume: 31, Issue:5, 1996
Experimental evidence for effects of ramipril on cardiac and vascular hypertrophy beyond blood pressure reduction.Archives des maladies du coeur et des vaisseaux, , Volume: 88 Spec No 2, 1995
Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. HYCAR Study Group.Hypertension (Dallas, Tex. : 1979), , Volume: 25, Issue:1, 1995
[Remission of left ventricular hypertrophy with ramipril independently of blood pressure changes: the HYCAR study (cardiac hypertrophy and ramipril)].Archives des maladies du coeur et des vaisseaux, , Volume: 88 Spec No 2, 1995
Ramipril. An updated review of its therapeutic use in essential hypertension and heart failure.Drugs, , Volume: 49, Issue:3, 1995
When a question has an answer: rationale for our early termination of the HEART Trial.The American journal of cardiology, , Jun-01, Volume: 75, Issue:16, 1995
Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis.Circulation, , Apr-01, Volume: 91, Issue:7, 1995
Replacement of salt by a novel potassium- and magnesium-enriched salt alternative improves the cardiovascular effects of ramipril.British journal of pharmacology, , Volume: 111, Issue:4, 1994
Cardioprotective actions of bradykinin in myocardial ischemia and left ventricular hypertrophy.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, , Volume: 27, Issue:8, 1994
Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin.Hypertension (Dallas, Tex. : 1979), , Volume: 23, Issue:4, 1994
Contribution of bradykinin to the cardiovascular effects of ramipril.Journal of cardiovascular pharmacology, , Volume: 22 Suppl 9, 1993
Effect of atenolol and ramipril on regression of left ventricular hypertrophy: comparative echocardiographic assessment.Advances in therapy, , Volume: 12, Issue:2
Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis.Molecular and cellular biochemistry, , Volume: 147, Issue:1-2
The effect of ramipril on left ventricular mass, myocardial fibrosis, diastolic function, and plasma neurohormones in Maine Coon cats with familial hypertrophic cardiomyopathy without heart failure.Journal of veterinary internal medicine, , Volume: 20, Issue:5
Beta blockers & left ventricular hypertrophy regression.Indian heart journal, , Volume: 62, Issue:2
Effect of ACE-inhibition on coronary microvascular function and symptoms in normotensive women with microvascular angina: A randomized placebo-controlled trial.PloS one, , Volume: 13, Issue:6, 2018
Angiotensin-converting enzyme inhibitors and 3-hydroxy-3-methylglutaryl coenzyme A reductase in cardiac Syndrome X: role of superoxide dismutase activity.Circulation, , Jan-06, Volume: 109, Issue:1, 2004
Antianginal and anti-ischemic effects of nisoldipine and ramipril in patients with syndrome X.Clinical cardiology, , Volume: 22, Issue:5, 1999
Does diabetes prevention translate into reduced long-term vascular complications of diabetes?Diabetologia, , Volume: 62, Issue:8, 2019
Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial.Diabetes care, , Volume: 33, Issue:3, 2010
Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.Diabetic medicine : a journal of the British Diabetic Association, , Volume: 27, Issue:11, 2010
Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET/TRANSCEND research programme.Diabetes research and clinical practice, , Volume: 83, Issue:3, 2009
Dysglycemia and a history of reproductive risk factors.Diabetes care, , Volume: 31, Issue:8, 2008
Effects of ramipril and rosiglitazone on cardiovascular and renal outcomes in people with impaired glucose tolerance or impaired fasting glucose: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.Diabetes care, , Volume: 31, Issue:5, 2008
Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled study.European journal of clinical pharmacology, , Volume: 63, Issue:8, 2007
Effect of ramipril on the incidence of diabetes.The New England journal of medicine, , Oct-12, Volume: 355, Issue:15, 2006
Angiotensin-converting-enzyme inhibitors for impaired glucose tolerance--is there still hope?The New England journal of medicine, , Oct-12, Volume: 355, Issue:15, 2006
ACE Inhibitors and Angiotensin II Receptor Blockers May Have Different Impact on Prognosis of COVID-19.Journal of the American College of Cardiology, , 10-27, Volume: 76, Issue:17, 2020
Renin-Angiotensin System Blockade in COVID-19: Good, Bad, or Indifferent?Journal of the American College of Cardiology, , 07-21, Volume: 76, Issue:3, 2020
Ramipril in High-Risk Patients With COVID-19.Journal of the American College of Cardiology, , 07-21, Volume: 76, Issue:3, 2020
Investigating the beneficial effect of aliskiren in attenuating neuropathic pain in diabetic Sprague-Dawley rats.Endocrinology, diabetes & metabolism, , Volume: 4, Issue:2, 2021
Ramipril and resveratrol co-treatment attenuates RhoA/ROCK pathway-regulated early-stage diabetic nephropathy-associated glomerulosclerosis in streptozotocin-induced diabetic rats.Environmental toxicology, , Volume: 34, Issue:7, 2019
Acute change in glomerular filtration rate with inhibition of the renin-angiotensin system does not predict subsequent renal and cardiovascular outcomes.Kidney international, , Volume: 91, Issue:3, 2017
Low-dose hydralazine prevents fibrosis in a murine model of acute kidney injury-to-chronic kidney disease progression.Kidney international, , Volume: 91, Issue:1, 2017
A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial).European heart journal. Cardiovascular Imaging, , Volume: 16, Issue:8, 2015
Pioglitazone, a PPARγ agonist, provides comparable protection to angiotensin converting enzyme inhibitor ramipril against adriamycin nephropathy in rat.European journal of pharmacology, , May-05, Volume: 730, 2014
Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy.American journal of nephrology, , Volume: 40, Issue:3, 2014
Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading.Clinical and experimental nephrology, , Volume: 18, Issue:4, 2014
Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus.JAMA internal medicine, , Oct-14, Volume: 173, Issue:18, 2013
Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study.Cardiovascular diabetology, , Jan-09, Volume: 11, 2012
Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 27, Issue:9, 2012
Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations.British journal of pharmacology, , Volume: 162, Issue:3, 2011
REIN on obesity, proteinuria and CKD.Journal of the American Society of Nephrology : JASN, , Volume: 22, Issue:6, 2011
Renin-angiotensin system inhibitors reduce the progression of mesangioproliferative glomerulonephritis: 10 year follow-up.European journal of internal medicine, , Volume: 22, Issue:6, 2011
ACE inhibition is renoprotective among obese patients with proteinuria.Journal of the American Society of Nephrology : JASN, , Volume: 22, Issue:6, 2011
Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition.Journal of the American Society of Nephrology : JASN, , Volume: 22, Issue:10, 2011
From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors.Cardiology, , Volume: 117, Issue:3, 2010
Glomerular disease: ACEIs with or without corticosteroids in IgA nephropathy?Nature reviews. Nephrology, , Volume: 6, Issue:5, 2010
Role of renin-angiotensin system blockade in patients with diabetes mellitus.The American journal of cardiology, , Sep-15, Volume: 104, Issue:6, 2009
The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats.Acta pharmacologica Sinica, , Volume: 30, Issue:7, 2009
Proteinuria: Is the ONTARGET renal substudy actually off target?Nature reviews. Nephrology, , Volume: 5, Issue:8, 2009
Blood-pressure control and delay in progression of kidney disease in children.The New England journal of medicine, , Oct-22, Volume: 361, Issue:17, 2009
Strict blood-pressure control and progression of renal failure in children.The New England journal of medicine, , Oct-22, Volume: 361, Issue:17, 2009
Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans.Archives of internal medicine, , Apr-28, Volume: 168, Issue:8, 2008
First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation.Cardiovascular diabetology, , Jul-24, Volume: 7, 2008
Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?Nature clinical practice. Cardiovascular medicine, , Volume: 5, Issue:9, 2008
The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League.Journal of hypertension, , Volume: 26, Issue:7, 2008
The new clinical trials with thiazolidinediones--DREAM, ADOPT, and CHICAGO: promises fulfilled?Current opinion in lipidology, , Volume: 18, Issue:4, 2007
The therapeutic effects of angiotensin-converting enzyme inhibitors in severe non-proliferative diabetic retinopathy.Korean journal of ophthalmology : KJO, , Volume: 21, Issue:1, 2007
Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses.Journal of the American Society of Nephrology : JASN, , Volume: 16 Suppl 1, 2005
The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.Archives of internal medicine, , Apr-25, Volume: 165, Issue:8, 2005
Can young adult patients with proteinuric IgA nephropathy perform physical exercise?American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 44, Issue:2, 2004
Antihypertensive drugs and renal protection.JAMA, , Mar-05, Volume: 289, Issue:9, 2003
Retarding progression of chronic renal disease: the neglected issue of residual proteinuria.Kidney international, , Volume: 63, Issue:6, 2003
Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study.Journal of the American Society of Nephrology : JASN, , Volume: 14, Issue:3, 2003
Collapsing glomerulopathy coexisting with membranous glomerulonephritis in native kidney biopsies: a report of 3 HIV-negative patients.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 42, Issue:3, 2003
Mast cell infiltration and chemokine expression in progressive renal disease.Kidney international, , Volume: 64, Issue:3, 2003
Modulating atherosclerosis through inhibition or blockade of angiotensin.Clinical cardiology, , Volume: 26, Issue:7, 2003
Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 42, Issue:5, 2003
Ramipril: a review of its use in the prevention of cardiovascular outcomes.Drugs, , Volume: 62, Issue:9, 2002
Effect of ramipril and vitamin E on atherosclerosis.Circulation, , Jan-15, Volume: 105, Issue:2, 2002
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.JAMA, , Nov-20, Volume: 288, Issue:19, 2002
Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade.Diabetologia, , Volume: 44, Issue:7, 2001
[Ramipril can do more. Halting progression of atherosclerosis].MMW Fortschritte der Medizin, , Sep-06, Volume: 143, Issue:35-36, 2001
The effects of an ACE inhibitor and a calcium antagonist on the progression of renal disease: the Nephros Study.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 16, Issue:11, 2001
Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B(2) kinin receptor gene knockout mice.Circulation research, , May-25, Volume: 88, Issue:10, 2001
Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE).Circulation, , Feb-20, Volume: 103, Issue:7, 2001
Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies.Kidney international, , Volume: 59, Issue:1, 2001
Renal protection: progression, regression, remission from nephropathy beyond blood pressure control.International journal of clinical practice. Supplement, , Issue:110, 2000
[Further evidence for the renoprotective effect of ACE inhibitors: ramipril protects against the progression of chronic renal insufficiency in non-diabetic nephropathy with nephrotic proteinuria].Schweizerische medizinische Wochenschrift, , Apr-01, Volume: 130, Issue:13, 2000
Attenuation of atherosclerosis in apolipoprotein E-deficient mice by ramipril is dissociated from its antihypertensive effect and from potentiation of bradykinin.Journal of cardiovascular pharmacology, , Volume: 35, Issue:1, 2000
Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 35, Issue:6, 2000
Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen)Journal of the American Society of Nephrology : JASN, , Volume: 11, Issue:1, 2000
Pretreatment blood pressure reliably predicts progression of chronic nephropathies. GISEN Group.Kidney international, , Volume: 58, Issue:5, 2000
Epidemiology and pathophysiology of heart failure.Current cardiology reports, , Volume: 2, Issue:3, 2000
[Hemodynamic mechanisms of lupus nephritis progression].Terapevticheskii arkhiv, , Volume: 70, Issue:6, 1998
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)Lancet (London, England), , Jun-28, Volume: 349, Issue:9069, 1997
Ramipril in non-diabetic renal failure (REIN study). Ramipril Efficiency in Nephropathy study.Lancet (London, England), , Sep-06, Volume: 350, Issue:9079, 1997
ACE-inhibitors: panacea for progressive renal disease.Lancet (London, England), , Jun-28, Volume: 349, Issue:9069, 1997
Study design and baseline characteristics of the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E: SECURE.The American journal of cardiology, , Oct-15, Volume: 78, Issue:8, 1996
Renoprotective therapy: is it blood pressure or albuminuria that matters?Lancet (London, England), , Volume: 365, Issue:9463
Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial.Lancet (London, England), , Volume: 365, Issue:9463
REIN follow-up trial. Ramipril Efficacy in Nephropathy.Lancet (London, England), , Volume: 352, Issue:9145
The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial.Circulation, , 12-06, Volume: 146, Issue:23, 2022
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.The New England journal of medicine, , 11-11, Volume: 385, Issue:20, 2021
Efficacy of Sacubitril-Valsartan in Patients With Reduced Left Ventricular Ejection Fraction.The American journal of cardiology, , 08-15, Volume: 153, 2021
Ramipril and left ventricular diastolic function in stable patients with pulmonary regurgitation after repair of tetralogy of Fallot.International journal of cardiology, , Dec-01, Volume: 272, 2018
Impact of renin-angiotensin system inhibitors on clinical outcomes and ventricular remodelling after transcatheter aortic valve implantation: rationale and design of the RASTAVI randomised multicentre study.BMJ open, , 02-13, Volume: 8, Issue:2, 2018
Early Treatment With Zofenopril and Ramipril in Combination With Acetyl Salicylic Acid in Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction: Results of a 5-Year Follow-up of Patients of the SMILE-4 Study.Journal of cardiovascular pharmacology, , Volume: 69, Issue:5, 2017
Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SMILE-4 Randomized, Double-Blind Study in Diabetic Patients.Cardiovascular therapeutics, , Volume: 34, Issue:2, 2016
Angiotensin converting enzyme inhibitors for heart failure with reduced ejection fraction or left ventricular dysfunction: A complementary network meta-analyses.International journal of cardiology, , Jul-01, Volume: 214, 2016
Zofenopril and ramipril in patients with left ventricular systolic dysfunction after acute myocardial infarction: A propensity analysis of the Survival of Myocardial Infarction Long-term Evaluation (SMILE) 4 study.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 17, Issue:4, 2016
Takotsubo cardiomyopathy after an emotional outburst.The Ceylon medical journal, , Volume: 60, Issue:3, 2015
Usefulness of combined bedside lung ultrasound and echocardiography to assess weaning failure from mechanical ventilation: a suggestive case*.Critical care medicine, , Volume: 41, Issue:8, 2013
Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a retrospective analysis in hypertensive patients of the SMILE-4 study.Journal of hypertension, , Volume: 31, Issue:6, 2013
A young patient with heart failure: picture quiz question.Acute medicine, , Volume: 11, Issue:1, 2012
Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European studClinical cardiology, , Volume: 35, Issue:7, 2012
[Improvement of left ventricular function during combined carvedilol, ramipril and spironolactone therapy after myocarditis in patient treated earlier by chemotherapy due to Hodgkin's lymphoma - 3-years follow-up].Kardiologia polska, , Volume: 68, Issue:7, 2010
Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).The American journal of cardiology, , Dec-01, Volume: 104, Issue:11, 2009
The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice.Experimental physiology, , Volume: 94, Issue:3, 2009
The cardiac MRI substudy to ongoing telmisartan alone and in combination with ramipril global endpoint trial/telmisartan randomized assessment study in ACE-intolerant subjects with cardiovascular disease: analysis protocol and baseline characteristics.Clinical research in cardiology : official journal of the German Cardiac Society, , Volume: 98, Issue:7, 2009
The Hong Kong diastolic heart failure study: a randomised controlled trial of diuretics, irbesartan and ramipril on quality of life, exercise capacity, left ventricular global and regional function in heart failure with a normal ejection fraction.Heart (British Cardiac Society), , Volume: 94, Issue:5, 2008
Long-term but not short-term p38 mitogen-activated protein kinase inhibition improves cardiac function and reduces cardiac remodeling post-myocardial infarction.The Journal of pharmacology and experimental therapeutics, , Volume: 325, Issue:3, 2008
Attenuation of left ventricular dysfunction by an ACE inhibitor after myocardial infarction in a kininogen-deficient rat model.Biological chemistry, , Volume: 389, Issue:6, 2008
Delayed recovery of left ventricular systolic dysfunction: ''give time to medical therapy''.Minerva cardioangiologica, , Volume: 55, Issue:3, 2007
Lipid peroxidation is not increased in heart failure patients on modern pharmacological therapy.International journal of cardiology, , Oct-10, Volume: 112, Issue:3, 2006
[Effects of losartan, ramipril and their combination on left ventricular remodeling and function in spontaneous hypertensive rats].Zhonghua yi xue za zhi, , Nov-30, Volume: 85, Issue:45, 2005
Effects of ramipril on left ventricular mass and function in cardiovascular patients with controlled blood pressure and with preserved left ventricular ejection fraction: a substudy of the Heart Outcomes Prevention Evaluation (HOPE) Trial.Journal of the American College of Cardiology, , Jun-16, Volume: 43, Issue:12, 2004
Left ventricular hypertrophy: a "factor of risk": mass is reversible, but is the risk?Journal of the American College of Cardiology, , Jun-16, Volume: 43, Issue:12, 2004
Extended follow-up of patients randomly assigned in the Angiotensin-converting enzyme inhibition Post-Revascularization Study (APRES).American heart journal, , Volume: 148, Issue:3, 2004
The EUROPA trial.Lancet (London, England), , Dec-06, Volume: 362, Issue:9399, 2003
Aldosterone receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure.Cardiovascular research, , Jun-01, Volume: 58, Issue:3, 2003
Randomized, double-blind, placebo-controlled long-term study of isosorbide-5-mononitrate therapy in patients with left ventricular dysfunction after acute myocardial infarction.American heart journal, , Volume: 145, Issue:1, 2003
[ACE inhibitors in high risk heart patients. Primary analysis of the HOPE study].Der Internist, , Volume: 43, Issue:3, 2002
From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.The American journal of cardiology, , Jan-24, Volume: 89, Issue:2A, 2002
What are 'tissue ACE inhibitors,' and should they be used instead of other ACE inhibitors?Cleveland Clinic journal of medicine, , Volume: 68, Issue:3, 2001
Management of asymptomatic left ventricular dysfunction.Cleveland Clinic journal of medicine, , Volume: 68, Issue:3, 2001
Regional wall stress predicts ventricular remodeling after anteroseptal myocardial infarction in the Healing and Early Afterload Reducing Trial (HEART): an echocardiography-based structural analysis.American heart journal, , Volume: 141, Issue:2, 2001
The Heart Outcomes Prevention Evaluation Study.Current cardiology reports, , Volume: 3, Issue:2, 2001
Beneficial effects of ramipril on left ventricular end-diastolic and end-systolic volume indexes after uncomplicated invasive revascularization are associated with a reduction in cardiac events in patients with moderately impaired left ventricular functioJournal of the American College of Cardiology, , Volume: 37, Issue:5, 2001
Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study.Annals of internal medicine, , Mar-20, Volume: 134, Issue:6, 2001
[ACE inhibition in patients with myocardial infarct and ventricular dysfunction: inappropriate application of therapy standards in patient samples].Zeitschrift fur Kardiologie, , Volume: 90, Issue:2, 2001
[Symposium "Emerging Approaches to Cardiovascular Diseases: Detailed results and implications of the HOPE Study". Atlanta, 10. November 1999].Der Internist, , Volume: 41, Issue:1, 2000
The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES).Journal of the American College of Cardiology, , Mar-15, Volume: 35, Issue:4, 2000
[Effect of a converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients].Presse medicale (Paris, France : 1983), , Apr-15, Volume: 29, Issue:14, 2000
Management of heart failure.Current cardiology reports, , Volume: 2, Issue:3, 2000
Changes in left ventricular mass and volumes in patients receiving angiotensin-converting enzyme inhibitor therapy for left ventricular dysfunction after Q-wave myocardial infarction.American heart journal, , Volume: 136, Issue:2, 1998
The Angiotensin Converting Enzyme Inhibition Post Revascularization Study (APRES). Effects of ramipril in patients with reduced left ventricular function. Rationale, design, methods, baseline characteristics and first-year experience.Scandinavian cardiovascular journal : SCJ, , Volume: 32, Issue:4, 1998
Functional impact of an increase in ventricular mass after myocardial damage and its attenuation by converting enzyme inhibition.Journal of cardiac failure, , Volume: 4, Issue:3, 1998
Treatment with ramipril improves systolic function even in patients with mild systolic dysfunction and symptoms of heart failure after acute myocardial infarction.Clinical cardiology, , Volume: 21, Issue:11, 1998
Incidence and natural history of left ventricular thrombus following anterior wall acute myocardial infarction.The American journal of cardiology, , Aug-15, Volume: 80, Issue:4, 1997
[Effects of ramipril and spironolactone on ventricular remodeling after acute myocardial infarction: randomized and double-blind study].Revista medica de Chile, , Volume: 125, Issue:6, 1997
Angiotensin-converting enzyme inhibition limits dysfunction in adjacent noninfarcted regions during left ventricular remodeling.Journal of the American College of Cardiology, , Volume: 27, Issue:1, 1996
When a question has an answer: rationale for our early termination of the HEART Trial.The American journal of cardiology, , Jun-01, Volume: 75, Issue:16, 1995
ACE inhibitors after myocardial infarction.The British journal of clinical practice, , Volume: 49, Issue:4
Cutaneous vasculitis secondary to ramipril.Journal of drugs in dermatology : JDD, , Volume: 3, Issue:1
High Incidence of ACE/PAI-1 in Association to a Spectrum of Other Polymorphic Cardiovascular Genes Involving PBMCs Proinflammatory Cytokines in Hypertensive Hypercholesterolemic Patients: Reversibility with a Combination of ACE Inhibitor and Statin.PloS one, , Volume: 10, Issue:5, 2015
Impact of angiotensin-converting enzyme gene polymorphism on proteinuria and arterial hypertension.Collegium antropologicum, , Volume: 37, Issue:3, 2013
Circulating amylin in human essential hypertension: heritability and early increase in individuals at genetic risk.Journal of hypertension, , Volume: 18, Issue:11, 2000
Nephroprotection by long-term ACE inhibition with ramipril in spontaneously hypertensive stroke prone rats.Kidney international, , Volume: 54, Issue:6, 1998
Renal and vascular injury induced by exogenous angiotensin II is AT1 receptor-dependent.Nephron, , Volume: 87, Issue:1, 2001
Early induction of angiotensin I-converting enzyme in rat carotid artery after balloon injury.Hypertension (Dallas, Tex. : 1979), , Volume: 30, Issue:2 Pt 1, 1997
Kinins mediate the antiproliferative effect of ramipril in rat carotid artery.Biochemical and biophysical research communications, , Jan-15, Volume: 182, Issue:1, 1992
QGC606: A Best-in-Class Orally Active Centrally Acting Aminopeptidase A Inhibitor Prodrug for Treating Heart Failure Following Myocardial Infarction.The Canadian journal of cardiology, , Volume: 38, Issue:6, 2022
Impact of renin-angiotensin system inhibitors on clinical outcomes and ventricular remodelling after transcatheter aortic valve implantation: rationale and design of the RASTAVI randomised multicentre study.BMJ open, , 02-13, Volume: 8, Issue:2, 2018
Ramipril attenuates left ventricular remodeling by regulating the expression of activin A-follistatin in a rat model of heart failure.Scientific reports, , 09-19, Volume: 6, 2016
Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.Basic research in cardiology, , Volume: 109, Issue:4, 2014
Tenascin-C as predictor of left ventricular remodeling and mortality in patients with dilated cardiomyopathy.Journal of investigative medicine : the official publication of the American Federation for Clinical Research, , Volume: 61, Issue:4, 2013
A comparison between imidapril and ramipril on attenuation of ventricular remodeling after myocardial infarction.Journal of cardiovascular pharmacology, , Volume: 59, Issue:4, 2012
Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes.Diabetologia, , Volume: 55, Issue:5, 2012
Impact of nephron number dosing on cardiorenal damage and effects of ACE inhibition.American journal of hypertension, , Volume: 24, Issue:4, 2011
Spontaneous resolution of severe mitral regurgitation in a patient with a flail mitral valve.Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography, , Volume: 23, Issue:12, 2010
A proteomic study of the effects of ramipril on post-infarction left ventricular remodelling in the rabbit.European journal of heart failure, , Volume: 10, Issue:8, 2008
[Beneficial effects of Hartil on cardiovascular remodeling process in elderly and old patients with isolated systolic arterial hypertension].Georgian medical news, , Issue:154, 2008
Long-term but not short-term p38 mitogen-activated protein kinase inhibition improves cardiac function and reduces cardiac remodeling post-myocardial infarction.The Journal of pharmacology and experimental therapeutics, , Volume: 325, Issue:3, 2008
Left ventricular eccentric remodeling and matrix loss are mediated by bradykinin and precede cardiomyocyte elongation in rats with volume overload.Journal of the American College of Cardiology, , Feb-20, Volume: 49, Issue:7, 2007
Effects of purified herbal extract of Salvia miltiorrhiza on ischemic rat myocardium after acute myocardial infarction.Life sciences, , Apr-29, Volume: 76, Issue:24, 2005
[Effects of losartan, ramipril and their combination on left ventricular remodeling and function in spontaneous hypertensive rats].Zhonghua yi xue za zhi, , Nov-30, Volume: 85, Issue:45, 2005
Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients.The Journal of international medical research, , Volume: 33 Suppl 1, 2005
Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure.Journal of cardiac failure, , Volume: 10, Issue:1, 2004
Angina pectoris prior to myocardial infarction protects against subsequent left ventricular remodeling.Journal of the American College of Cardiology, , May-05, Volume: 43, Issue:9, 2004
Ischemic preconditioning in coronary heart disease: a therapeutic golden fleece?Journal of the American College of Cardiology, , May-05, Volume: 43, Issue:9, 2004
Comparison of cardioprotective effects of mibefradil and ramipril in stroke-prone spontaneously hypertensive rats.Acta pharmacologica Sinica, , Volume: 25, Issue:6, 2004
Adding angiotensin II type 1 receptor blockade to angiotensin-converting enzyme inhibition limits myocyte remodeling after myocardial infarction.Journal of cardiac failure, , Volume: 9, Issue:3, 2003
Effects of diuretic treatment on cardiac and circulating RAS in chronic heart failure post-myocardial infarction in rats.European journal of heart failure, , Volume: 5, Issue:3, 2003
Mechanisms of myocardial remodeling: ramiprilat blocks the expressional upregulation of protein kinase C-epsilon in the surviving myocardium early after infarction.Journal of cardiovascular pharmacology, , Volume: 41, Issue:5, 2003
Aldosterone receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure.Cardiovascular research, , Jun-01, Volume: 58, Issue:3, 2003
A prospective evaluation of the angiotensin-converting enzyme D/I polymorphism and left ventricular remodeling in the 'Healing and Early Afterload Reducing Therapy' study.Clinical genetics, , Volume: 61, Issue:1, 2002
Effect of ramipril and furosemide treatment on interstitial remodeling in post-infarction heart failure rat hearts.Journal of molecular and cellular cardiology, , Volume: 34, Issue:2, 2002
Combined angiotensin converting enzyme inhibition and angiotensin AT(1) receptor blockade up-regulates myocardial AT(2) receptors in remodeled myocardium post-infarction.Cardiovascular research, , Volume: 51, Issue:1, 2001
Combined angiotensin II receptor antagonism and angiotensin-converting enzyme inhibition further attenuates postinfarction left ventricular remodeling.Circulation, , Jun-12, Volume: 103, Issue:23, 2001
Regional wall stress predicts ventricular remodeling after anteroseptal myocardial infarction in the Healing and Early Afterload Reducing Trial (HEART): an echocardiography-based structural analysis.American heart journal, , Volume: 141, Issue:2, 2001
Changes in vasoconstrictive hormones, natriuretic peptides, and left ventricular remodeling soon after anterior myocardial infarction.American heart journal, , Volume: 142, Issue:6, 2001
Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B(2) kinin receptor gene knockout mice.Circulation research, , May-25, Volume: 88, Issue:10, 2001
Effects of ACE inhibitor, AT1 antagonist, and combined treatment in mice with heart failure.Journal of cardiovascular pharmacology, , Volume: 36, Issue:4, 2000
Beta-blockade improves adjacent regional sympathetic innervation during postinfarction remodeling.The American journal of physiology, , Volume: 277, Issue:4, 1999
Effects of ramipril on cardiac gene transcription levels of angiotensin II receptors after myocardial infarction.Zhongguo yao li xue bao = Acta pharmacologica Sinica, , Volume: 20, Issue:6, 1999
Functional impact of an increase in ventricular mass after myocardial damage and its attenuation by converting enzyme inhibition.Journal of cardiac failure, , Volume: 4, Issue:3, 1998
Modeling the cost effectiveness and budgetary impact of Polypills for secondary prevention of cardiovascular disease in the United States.American heart journal, , Volume: 214, 2019
Twenty-and-a-half syndrome: a case report.Journal of medical case reports, , Feb-15, Volume: 13, Issue:1, 2019
Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk.European heart journal, , 07-01, Volume: 40, Issue:25, 2019
Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.European heart journal, , 09-01, Volume: 39, Issue:33, 2018
Target Blood Pressure in Patients with Diabetes: Asian Perspective.Yonsei medical journal, , Volume: 57, Issue:6, 2016
Systolic blood pressure target levels: evidence for benefits in stroke.Hypertension (Dallas, Tex. : 1979), , Volume: 65, Issue:1, 2015
Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease.Hypertension (Dallas, Tex. : 1979), , Volume: 65, Issue:1, 2015
Childhood polyarteritis nodosa presenting as stroke and arterial hypertension.BMJ case reports, , Oct-29, Volume: 2014, 2014
The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.European journal of preventive cardiology, , Volume: 21, Issue:3, 2014
Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtoleranJournal of hypertension, , Volume: 30, Issue:5, 2012
A polypill for all? Critical review of the polypill literature for primary prevention of cardiovascular disease and stroke.The Annals of pharmacotherapy, , Volume: 46, Issue:5, 2012
Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in CombinatioCirculation, , Aug-21, Volume: 126, Issue:8, 2012
The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study.Journal of medical economics, , Volume: 14, Issue:6, 2011
Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET).Circulation, , Oct-18, Volume: 124, Issue:16, 2011
Prevention and intervention studies with telmisartan, ramipril and their combination in different rat stroke models.PloS one, , Volume: 6, Issue:8, 2011
Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.Circulation, , Mar-15, Volume: 123, Issue:10, 2011
Impact of ACE inhibitors on mortality and morbidity in patients with AMI: Does tissue selectivity matter?Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 14, Issue:1, 2011
Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET/TRANSCEND research programme.Diabetes research and clinical practice, , Volume: 83, Issue:3, 2009
The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial.Journal of cardiovascular electrophysiology, , Volume: 20, Issue:7, 2009
Preventing stroke: the PRoFESS, ONTARGET, and TRANSCEND trial programs.Journal of hypertension. Supplement : official journal of the International Society of Hypertension, , Volume: 27, Issue:5, 2009
ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?Blood pressure, , Volume: 18, Issue:1-2, 2009
Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats.Journal of hypertension, , Volume: 26, Issue:3, 2008
Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?Cerebrovascular diseases (Basel, Switzerland), , Volume: 26, Issue:5, 2008
[HOPE study].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 64 Suppl 6, 2006
Synergistic protective effects of erythropoietin and olmesartan on ischemic stroke survival and post-stroke memory dysfunctions in the gerbil.Journal of hypertension, , Volume: 24, Issue:11, 2006
Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study)*.Journal of hypertension, , Volume: 24, Issue:3, 2006
[Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].Italian heart journal : official journal of the Italian Federation of Cardiology, , Volume: 6 Suppl 7, 2005
The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences.Scandinavian journal of clinical and laboratory investigation. Supplementum, , Volume: 240, 2005
Impact of cigarette smoking in high-risk patients participating in a clinical trial. A substudy from the Heart Outcomes Prevention Evaluation (HOPE) trial.European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology, , Volume: 12, Issue:1, 2005
[Experiences with the realisation of the innovative study designs using the example of the HOPE study -- concerning the contribution in DMW Supplement 2/2005].Deutsche medizinische Wochenschrift (1946), , Nov-25, Volume: 130, Issue:47, 2005
Protection against stroke and dementia: an update on the latest clinical trial evidence.Current hypertension reports, , Volume: 6, Issue:4, 2004
The PROGRESS trial three years later: HOPE trial may shed some light.BMJ (Clinical research ed.), , Dec-11, Volume: 329, Issue:7479, 2004
[Can coronary risks be further reduced?].Presse medicale (Paris, France : 1983), , Sep-25, Volume: 33, Issue:16, 2004
Blood pressure drugs may help prevent stroke.Mayo Clinic health letter (English ed.), , Volume: 21, Issue:1, 2003
Angiotensin-converting enzyme inhibitors and stroke prevention: what about the influence of atrial fibrillation and antithrombotic therapy?Stroke, , Volume: 34, Issue:11, 2003
Best bang for the buck?Current hypertension reports, , Volume: 5, Issue:1, 2003
Stroke prevention: indapamide, a forgotten option?Stroke, , Volume: 34, Issue:9, 2003
Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study.Circulation, , Feb-25, Volume: 107, Issue:7, 2003
Should all patients with coronary disease receive angiotensin-converting-enzyme inhibitors?Lancet (London, England), , Sep-06, Volume: 362, Issue:9386, 2003
Preventing stroke with ramipril--authors' reply.BMJ (Clinical research ed.), , Jan-04, Volume: 326, Issue:7379, 2003
Angiotensin-converting enzyme inhibitors for stroke prevention: is there HOPE for PROGRESS After LIFE?Stroke, , Volume: 34, Issue:2, 2003
Converting enzyme inhibitor or AT1-receptor blocker for decreasing long-term mortality in patients with stroke history and renal dysfunction?Stroke, , Volume: 34, Issue:1, 2003
[Therapy of hypertension. Lasting organ protection moves into the foreground].MMW Fortschritte der Medizin, , Nov-20, Volume: 145, Issue:47, 2003
Economic impact of ramipril on hospitalization of high-risk cardiovascular patients.The Annals of pharmacotherapy, , Volume: 37, Issue:3, 2003
Effect of long-term therapy with ramipril in high-risk women.Journal of the American College of Cardiology, , Aug-21, Volume: 40, Issue:4, 2002
Preventing stroke with ramipril. Benefits were considerably overstated.BMJ (Clinical research ed.), , Aug-24, Volume: 325, Issue:7361, 2002
Preventing stroke with ramipril. Results should have been presented in ways that help practising clinicians.BMJ (Clinical research ed.), , Aug-24, Volume: 325, Issue:7361, 2002
Blood pressure drug helps prevent stroke.Health news (Waltham, Mass.), , Volume: 8, Issue:5, 2002
"Preemptive strike" heart medications. A.C.E. inhibitors gain new ground as multi-purpose cardiac drugs.Heart advisor, , Volume: 5, Issue:2, 2002
Use of ramipril in preventing stroke: double blind randomised trial.BMJ (Clinical research ed.), , Mar-23, Volume: 324, Issue:7339, 2002
Preventing stroke.BMJ (Clinical research ed.), , Mar-23, Volume: 324, Issue:7339, 2002
Preventing stroke with ramipril. Superiority of particular class of antihypertensive agent remains to be shown.BMJ (Clinical research ed.), , Aug-24, Volume: 325, Issue:7361, 2002
Preventing stroke with ramipril. Presentation of data is misleading.BMJ (Clinical research ed.), , Aug-24, Volume: 325, Issue:7361, 2002
The Heart Outcomes Prevention Evaluation study: angiotensin-converting enzyme inhibitors: are their benefits a class effect or do individual agents differ?Current opinion in nephrology and hypertension, , Volume: 10, Issue:5, 2001
What are 'tissue ACE inhibitors,' and should they be used instead of other ACE inhibitors?Cleveland Clinic journal of medicine, , Volume: 68, Issue:3, 2001
Diabetes and the HOPE study: implications for macrovascular and microvascular disease.International journal of clinical practice. Supplement, , Issue:117, 2001
[Achieving vascular protection. ACE inhibitor lowers not only blood pressure].MMW Fortschritte der Medizin, , Sep-06, Volume: 143, Issue:35-36, 2001
[Symposium "Emerging Approaches to Cardiovascular Diseases: Detailed results and implications of the HOPE Study". Atlanta, 10. November 1999].Der Internist, , Volume: 41, Issue:1, 2000
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.The New England journal of medicine, , 01-20, Volume: 342, Issue:3, 2000
ACE inhibition in cardiovascular disease.The New England journal of medicine, , Jan-20, Volume: 342, Issue:3, 2000
Don't keep that ACE (inhibitor) up your sleeve! Is ramipril effective for secondary prevention of cardiovascular disease and stroke?Canadian family physician Medecin de famille canadien, , Volume: 46, 2000
Ramipril study suggests drug may benefit broad group of patients.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Dec-15, Volume: 56, Issue:24, 1999
A safe new dose of heart protection. Study shows drug can prevent attacks, strokes.U.S. news & world report, , Nov-22, Volume: 127, Issue:20, 1999
[ACE inhibitor even prevents diabetes. Sensational HOPE Study].MMW Fortschritte der Medizin, , Sep-30, Volume: 141, Issue:39, 1999
Study at up to 700 sites will build on landmark HOPE trial.Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners, , Volume: 12, Issue:2
[Prevention of stroke: should high risk patients be treated with angiotensin II converting enzyme inhibitors without regard to their blood pressure levels? ].Lijecnicki vjesnik, , Volume: 125, Issue:1-2
ONTARGET programme of cardio- and vascular protection - first results are imminent.Cardiovascular journal of Africa, , Volume: 19, Issue:1
New uses for old drug: reducing risk of heart attacks and strokes.FDA consumer, , Volume: 35, Issue:1
Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly mild to moderate essential hypertensive patients with or without metabolic syndrome: a pooled post hoc analysis of two comparative trials.Drugs & aging, , Volume: 29, Issue:12, 2012
Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation.Journal of cardiovascular pharmacology and therapeutics, , Volume: 17, Issue:1, 2012
Kidney function in metabolic syndrome may be improved with Pycnogenol®.Panminerva medica, , Volume: 52, Issue:2 Suppl 1, 2010
Phosphodiesterase 5 inhibition improves beta-cell function in metabolic syndrome.Diabetes care, , Volume: 32, Issue:5, 2009
A new dawn in cardiovascular protection: total cardiovascular risk: rigorous treatment of risk factors. Introduction.Nature clinical practice. Cardiovascular medicine, , Volume: 5 Suppl 1, 2008
Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome.Nephrology (Carlton, Vic.), , Volume: 12, Issue:2, 2007
[In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension].MMW Fortschritte der Medizin, , Jun-29, Volume: 148, Issue:26, 2006
[Hypertension and diabetic nephropathy, a dangerous duo].Medizinische Klinik (Munich, Germany : 1983), , Nov-15, Volume: 100, Issue:11, 2005
Pregnancy outcome following exposure to orlistat, ramipril, glimepiride in a woman with metabolic syndrome.Saudi medical journal, , Volume: 26, Issue:3, 2005
Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE?Current medical research and opinion, , Volume: 20, Issue:3, 2004
Effects of ramipril therapy on some components of insulin resistance syndrome in patients with essential hypertension.Medicinski pregled, , Volume: 55, Issue:7-8
[Clinical effectiveness of metformin and ramipril combination in complex therapy of patients with metabolic syndrome].Likars'ka sprava, , Issue:1
[Efficacy of complex therapy with metformin and ramipril combination for patients with metabolic syndrome].Likars'ka sprava, , Issue:7-8
Does diabetes prevention translate into reduced long-term vascular complications of diabetes?Diabetologia, , Volume: 62, Issue:8, 2019
The mini-mental state examination, clinical factors, and motor vehicle crash risk.Journal of the American Geriatrics Society, , Volume: 62, Issue:8, 2014
Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtoleranJournal of hypertension, , Volume: 30, Issue:5, 2012
Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?Journal of hypertension, , Volume: 30, Issue:4, 2012
Combination delapril/manidipine as antihypertensive therapy in high-risk patients.Clinical drug investigation, , Volume: 31, Issue:7, 2011
The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study.Journal of medical economics, , Volume: 14, Issue:6, 2011
Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study.Journal of diabetes science and technology, , Jul-01, Volume: 5, Issue:4, 2011
Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.Clinical science (London, England : 1979), , Oct-26, Volume: 118, Issue:3, 2009
Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).The American journal of cardiology, , Dec-01, Volume: 104, Issue:11, 2009
Blockade of sensory abnormalities and kinin B(1) receptor expression by N-acetyl-L-cysteine and ramipril in a rat model of insulin resistance.European journal of pharmacology, , Jul-28, Volume: 589, Issue:1-3, 2008
[The use of angiotensin converting enzyme inhibitors in patients after myocardial infarction].Kardiologiia, , Volume: 48, Issue:11, 2008
[ONTARGET: similar protection of telmisartan and ramipril and lack of benefit of combined therapy in patients at high risk for vascular events].Revue medicale de Liege, , Volume: 63, Issue:4, 2008
Both ramipril and telmisartan reverse indices of early diabetic cardiomyopathy: a comparative study.European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology, , Volume: 8, Issue:6, 2007
Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk.Circulation, , Mar-20, Volume: 115, Issue:11, 2007
Investigation of the effect of a countywide protected learning time scheme on prescribing rates of ramipril: interrupted time series study.Family practice, , Volume: 24, Issue:1, 2007
Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 8, Issue:4, 2007
The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences.Scandinavian journal of clinical and laboratory investigation. Supplementum, , Volume: 240, 2005
Cardiovascular risk in patients with mild renal insufficiency: implications for the use of ACE inhibitors.Presse medicale (Paris, France : 1983), , Oct-22, Volume: 34, Issue:18, 2005
Simvastatin combined with ramipril treatment in hypercholesterolemic patients.Hypertension (Dallas, Tex. : 1979), , Volume: 44, Issue:2, 2004
[Vascular patient with high infarction risk. Does the AT-1 blocker protect as well as an ACE inhibitor?].MMW Fortschritte der Medizin, , Dec-18, Volume: 145, Issue:51-52, 2003
More than just hype.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , Jun-24, Volume: 168, Issue:13, 2003
Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.The Canadian journal of cardiology, , Volume: 18 Suppl A, 2002
Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.Annals of internal medicine, , Apr-17, Volume: 134, Issue:8, 2001
What is the relevance of the HOPE study in general practice?International journal of clinical practice, , Volume: 55, Issue:7, 2001
Ask the doctor. Recently, I read that the ACE inhibitor ramipril is very good at preventing heart problems, particularly in people with diabetes. I'm diabetic, and for years I have been on a different ACE inhibitor (lisinopril). Should I be taking ramipriHarvard heart letter : from Harvard Medical School, , Volume: 11, Issue:8, 2001
Why were the results of the Heart Outcomes Prevention Evaluation (HOPE) trial so astounding?The Canadian journal of cardiology, , Volume: 17 Suppl A, 2001
Summaries for patients. Trial of a drug to decrease the risk for heart disease in patients with mild kidney failure.Annals of internal medicine, , Apr-17, Volume: 134, Issue:8, 2001
Determinants of elevated urinary albumin in the 4,937 type 2 diabetic subjects recruited for the DIABHYCAR Study in Western Europe and North Africa.Diabetes care, , Volume: 23 Suppl 2, 2000
The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not.Cleveland Clinic journal of medicine, , Volume: 67, Issue:4, 2000
[Clinical study of the month. The HOPE study, a two-by-two factorial clinical trial with contrasted results].Revue medicale de Liege, , Volume: 55, Issue:2, 2000
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.Lancet (London, England), , Jan-22, Volume: 355, Issue:9200, 2000
ACE inhibition in cardiovascular disease.The New England journal of medicine, , Jan-20, Volume: 342, Issue:3, 2000
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.The New England journal of medicine, , 01-20, Volume: 342, Issue:3, 2000
The HOPE study and diabetes. Heart Outcomes Prevention Evaluation.Lancet (London, England), , Apr-01, Volume: 355, Issue:9210, 2000
The HOPE study and diabetes. Heart Outcomes Prevention Evaluation.Lancet (London, England), , Apr-01, Volume: 355, Issue:9210, 2000
The HOPE study and diabetes. Heart Outcomes Prevention Evaluation.Lancet (London, England), , Apr-01, Volume: 355, Issue:9210, 2000
HOPE for diabetes in the new millennium. Heart Outcomes Prevention Evaluation.Diabetes, obesity & metabolism, , Volume: 2, Issue:1, 2000
The HOPE study and diabetes. Heart Outcomes Prevention Evaluation.Lancet (London, England), , Apr-01, Volume: 355, Issue:9210, 2000
[Info-Congress. The HOPE Study: Demonstration of the cardiovascular protection of ramipril, an ACE-inhibitor].Revue medicale de Liege, , Volume: 54, Issue:10, 1999
Ramipril. An updated review of its therapeutic use in essential hypertension and heart failure.Drugs, , Volume: 49, Issue:3, 1995
Assessment of the efficacy, tolerance, and safety of ramipril in diabetic patients with mild-to-moderate hypertension: a retrospective analysis.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Effects of Direct Renin Blockade on Renal & Systemic Hemodynamics and on RAAS Activity, in Weight Excess and Hypertension: A Randomized Clinical Trial.PloS one, , Volume: 12, Issue:1, 2017
Ramipril/amlodipine single pill - effectiveness, tolerance and patient satisfaction with antihypertensive therapy in relation to nutritional status.Pharmacological reports : PR, , Volume: 66, Issue:6, 2014
ACE inhibition is renoprotective among obese patients with proteinuria.Journal of the American Society of Nephrology : JASN, , Volume: 22, Issue:6, 2011
Does diabetes prevention translate into reduced long-term vascular complications of diabetes?Diabetologia, , Volume: 62, Issue:8, 2019
Telmisartan, ramipril and their combination improve endothelial function in different tissues in a murine model of cholesterol-induced atherosclerosis.British journal of pharmacology, , Volume: 163, Issue:4, 2011
Immobilization stress induces endothelial dysfunction by oxidative stress via the activation of the angiotensin II/its type I receptor pathway.Atherosclerosis, , Volume: 213, Issue:1, 2010
Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients.Renal failure, , Volume: 32, Issue:8, 2010
Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).The American journal of cardiology, , Dec-01, Volume: 104, Issue:11, 2009
Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?Nature clinical practice. Cardiovascular medicine, , Volume: 5, Issue:9, 2008
Letter by Popa and Netea regarding article, "Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis".Circulation, , Nov-04, Volume: 118, Issue:19, 2008
Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis.Circulation, , Apr-29, Volume: 117, Issue:17, 2008
Captopril inhibits the oxidative modification of apolipoprotein B-100 caused by myeloperoxydase in a comparative in vitro assay of angiotensin converting enzyme inhibitors.European journal of pharmacology, , May-10, Volume: 537, Issue:1-3, 2006
Ramipril in the treatment of vascular diseases.Expert opinion on pharmacotherapy, , Volume: 6, Issue:11, 2005
Combined effects of HMG-CoA-reductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis.Atherosclerosis, , Volume: 182, Issue:1, 2005
[Effects of angiotensin receptor blocker and angiotensin-coverting enzyme inhibitor on vascular endothelial function in type 2 diabetic patients with atherosclerosis: a comparative study].Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA, , Volume: 25, Issue:8, 2005
[Direct antiatherosclerotic therapy: possible approaches, results of clinical trials].Patologicheskaia fiziologiia i eksperimental'naia terapiia, , Issue:4
Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3-/- Mice.Journal of the American Society of Nephrology : JASN, , 09-01, Volume: 34, Issue:9, 2023
mTORC Pathway Activation and Effect of Sirolimus on Native Kidney Antiphospholipid Syndrome Nephropathy: A Case Report.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 76, Issue:2, 2020
Effects of Sevelamer Carbonate in Patients With CKD and Proteinuria: The ANSWER Randomized Trial.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 74, Issue:3, 2019
Low-dose hydralazine prevents fibrosis in a murine model of acute kidney injury-to-chronic kidney disease progression.Kidney international, , Volume: 91, Issue:1, 2017
Effects of Ramipril and Telmisartan on Plasma Concentrations of Low Molecular Weight and Protein Thiols and Carotid Intima Media Thickness in Patients with Chronic Kidney Disease.Disease markers, , Volume: 2016, 2016
The Association of Losartan and Ramipril Therapy With Kidney and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: A Chinese Nation-Wide Cohort Study in Taiwan.Medicine, , Volume: 94, Issue:48, 2015
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.Hypertension (Dallas, Tex. : 1979), , Volume: 61, Issue:1, 2013
Activation of Rac-1 and RhoA contributes to podocyte injury in chronic kidney disease.PloS one, , Volume: 8, Issue:11, 2013
Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus.JAMA internal medicine, , Oct-14, Volume: 173, Issue:18, 2013
Moving dietary management of diabetes forward.JAMA internal medicine, , Oct-14, Volume: 173, Issue:18, 2013
A comparison of the antihypertensive and anti-inflammatory effects of aliskiren and ramipril add-on therapy in peritoneal dialysis patients--a pilot open label study.Kidney & blood pressure research, , Volume: 36, Issue:1, 2012
Phosphate may promote CKD progression and attenuate renoprotective effect of ACE inhibition.Journal of the American Society of Nephrology : JASN, , Volume: 22, Issue:10, 2011
Phosphate REINs in the renoprotective benefit of ACE inhibition.Journal of the American Society of Nephrology : JASN, , Volume: 22, Issue:10, 2011
Strict blood-pressure control and progression of renal failure in children.The New England journal of medicine, , Oct-22, Volume: 361, Issue:17, 2009
Blood-pressure control and delay in progression of kidney disease in children.The New England journal of medicine, , Oct-22, Volume: 361, Issue:17, 2009
Projecting the potential cost-effectiveness of dapagliflozin for chronic kidney disease in Kuwait.Journal of medical economics, , Volume: 26, Issue:1
Adverse cardiac effects of exogenous angiotensin 1-7 in rats with subtotal nephrectomy are prevented by ACE inhibition.PloS one, , Volume: 12, Issue:2, 2017
Is administration of preoperative angiotensin-converting enzyme inhibitors important for renal protection after cardiac surgery?Renal failure, , Volume: 35, Issue:5, 2013
Angiotensin-(1-7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy.Clinical science (London, England : 1979), , Volume: 120, Issue:8, 2011
ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?Blood pressure, , Volume: 18, Issue:1-2, 2009
Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial.Journal of hypertension, , Volume: 25, Issue:10, 2007
Renal failure following bowel cleansing with a sodium phosphate purgative.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 20, Issue:7, 2005
Ramipril/felodipine extended-release fixed-dose combination: a review of its use in the management of essential hypertension.Drugs, , Volume: 65, Issue:13, 2005
Cardiovascular risk in patients with mild renal insufficiency: implications for the use of ACE inhibitors.Presse medicale (Paris, France : 1983), , Oct-22, Volume: 34, Issue:18, 2005
Ramipril in the treatment of vascular diseases.Expert opinion on pharmacotherapy, , Volume: 6, Issue:11, 2005
Transforming growth factor beta1 and additional renoprotective effect of combination ACE inhibitor and angiotensin II receptor blocker in hypertensive subjects with minor renal abnormalities: a 24-week randomized controlled trial.Journal of hypertension, , Volume: 23, Issue:3, 2005
ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: the African American Study of Kidney Disease and Hypertension (AASK) trial.Kidney international. Supplement, , Issue:83, 2003
Cardiomyocyte loss in experimental renal failure: prevention by ramipril.Kidney international, , Volume: 63, Issue:5, 2003
Ramipril for the prevention and treatment of cardiovascular disease.The Annals of pharmacotherapy, , Volume: 37, Issue:3, 2003
Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome.Kidney international, , Volume: 63, Issue:2, 2003
Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 42, Issue:5, 2003
[Improved protection of heart and kidneys in the hypertensive patient. ACE inhibitor and AT1 blocker combined?].MMW Fortschritte der Medizin, , Jun-05, Volume: 145, Issue:23, 2003
Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study.Journal of the American Society of Nephrology : JASN, , Volume: 14, Issue:3, 2003
Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes.The Medical journal of Australia, , Mar-18, Volume: 176, Issue:6, 2002
Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial.Annals of internal medicine, , Apr-17, Volume: 134, Issue:8, 2001
The kidney in cardiovascular disease.Annals of internal medicine, , Apr-17, Volume: 134, Issue:8, 2001
ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy.Journal of the American Society of Nephrology : JASN, , Volume: 12, Issue:12, 2001
Summaries for patients. Trial of a drug to decrease the risk for heart disease in patients with mild kidney failure.Annals of internal medicine, , Apr-17, Volume: 134, Issue:8, 2001
Comparative effects of ramipril and nitrendipine on albuminuria in hypertensive patients with non-insulin-dependent diabetes mellitus and impaired renal function.Journal of human hypertension, , Volume: 9, Issue:2, 1995
Clinical pharmacokinetics of ramipril.Clinical pharmacokinetics, , Volume: 26, Issue:1, 1994
Ramipril prevents the detrimental sequels of chronic NO synthase inhibition in rats: hypertension, cardiac hypertrophy and renal insufficiency.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 350, Issue:6, 1994
Renal insufficiency predicts cardiovascular disease in high-risk individuals: the benefit of ramipril in the HOPE study. Heart Outcomes and Prevention Evaluation.Journal of clinical hypertension (Greenwich, Conn.), , Volume: 3, Issue:4
Blacks with hypertension, renal insufficiency, and baseline proteinuria benefit more from ACE inhibition than from calcium channel blockade.Journal of clinical hypertension (Greenwich, Conn.), , Volume: 3, Issue:5
Pharmacokinetic and pharmacodynamic parameters of ramipril and ramiprilat in healthy dogs and dogs with reduced glomerular filtration rate.Journal of veterinary internal medicine, , Volume: 20, Issue:3
The N-AcetylCysteine and RAMipril in Takotsubo Syndrome Trial (NACRAM): Rationale and design of a randomised controlled trial of sequential N-Acetylcysteine and ramipril for the management of Takotsubo Syndrome.Contemporary clinical trials, , Volume: 90, 2020
Conceivable utility of the electrocardiogram in the N-acetylcysteine and RAMipril in takotsubo syndrome trial (NACRAM).Contemporary clinical trials, , Volume: 88, 2020
Reversible stress cardiomyopathy in Guillain-Barré syndrome: a case report.Journal of medical case reports, , May-20, Volume: 13, Issue:1, 2019
Takotsubo-like syndrome triggered by fludrocortisone overdose for Addison's disease: a case report.Journal of medical case reports, , Oct-12, Volume: 10, Issue:1, 2016
Rituximab-induced Takotsubo syndrome: more cardiotoxic than it appears?BMJ case reports, , Mar-02, Volume: 2015, 2015
Takotsubo cardiomyopathy after an emotional outburst.The Ceylon medical journal, , Volume: 60, Issue:3, 2015
Tako-tsubo cardiomyopathy observed in a patient with sepsis and transient hyperthyroidism.Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace, , Volume: 72, Issue:1, 2009
A logistic regression model based on inpatient health records to predict drug-induced liver injury caused by ramipril-An angiotensin-converting enzyme inhibitor.PloS one, , Volume: 17, Issue:8, 2022
Angiotensin-converting enzyme inhibitor prevents oxidative stress, inflammation, and fibrosis in carbon tetrachloride-treated rat liver.Toxicology mechanisms and methods, , Volume: 26, Issue:1, 2016
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.Drug discovery today, , Volume: 21, Issue:4, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Ramipril-induced liver injury: case report and review of the literature.American journal of hypertension, , Volume: 26, Issue:9, 2013
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).PLoS computational biology, , Volume: 7, Issue:12, 2011
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.Chemical research in toxicology, , Volume: 23, Issue:1, 2010
[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
Medicine-Induced Acute Kidney Injury Findings from Spontaneous Reporting Systems, Sequence Symmetry Analysis and a Case-Control Study with a Focus on Medicines Used in Primary Care.Drug safety, , Volume: 45, Issue:11, 2022
Ramipril blunts glycerol-induced acute renal failure in rats through its antiapoptosis, anti-inflammatory, antioxidant, and renin-inhibiting properties.Journal of basic and clinical physiology and pharmacology, , Nov-06, Volume: 32, Issue:3, 2020
Low-dose hydralazine prevents fibrosis in a murine model of acute kidney injury-to-chronic kidney disease progression.Kidney international, , Volume: 91, Issue:1, 2017
MicroRNAs mediate the cardioprotective effect of angiotensin-converting enzyme inhibition in acute kidney injury.American journal of physiology. Renal physiology, , Dec-01, Volume: 309, Issue:11, 2015
Obesity and oxidative stress predict AKI after cardiac surgery.Journal of the American Society of Nephrology : JASN, , Volume: 23, Issue:7, 2012
Unexpected hospitalisation side effects in an elderly man.Internal and emergency medicine, , Volume: 6, Issue:2, 2011
[Acute renal insufficiency after flurbiprofen treatment in a patient treated with angiotensin converting enzyme inhibitor].La Revue de medecine interne, , Volume: 29, Issue:7, 2008
Minimal change disease in association with fire coral (Millepora species) exposure.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 47, Issue:1, 2006
[A patient with severe hyperkalaemia -- an emergency after RALES].Deutsche medizinische Wochenschrift (1946), , Sep-09, Volume: 130, Issue:36, 2005
Renal failure following bowel cleansing with a sodium phosphate purgative.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 20, Issue:7, 2005
Ramipril pretreatment worsened renal injury and survival despite a reduction in renal inflammation in experimentally induced sepsis in mice.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 21, Issue:2
Ileostomy and ramipril-induced acute renal failure and shock.Heart & lung : the journal of critical care, , Volume: 36, Issue:4
Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk.European heart journal, , 07-01, Volume: 40, Issue:25, 2019
Novel method to assess arterial insufficiency in rodent hind limb.The Journal of surgical research, , Volume: 201, Issue:1, 2016
Ramipril improves walking times and quality of life in patients with stable intermittent claudication.Evidence-based medicine, , Volume: 19, Issue:1, 2014
PURLs: ramipril for claudication?The Journal of family practice, , Volume: 62, Issue:10, 2013
ACP Journal Club. Ramipril improved walking times and QOL in peripheral artery disease and intermittent claudication.Annals of internal medicine, , Jun-18, Volume: 158, Issue:12, 2013
Ramipril for treatment of intermittent claudication.VASA. Zeitschrift fur Gefasskrankheiten, , Volume: 42, Issue:4, 2013
Medications for improving walking performance in peripheral artery disease: still miles to go.JAMA, , Feb-06, Volume: 309, Issue:5, 2013
[Not Available].MMW Fortschritte der Medizin, , May-29, Volume: 155, Issue:10, 2013
Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial.JAMA, , Feb-06, Volume: 309, Issue:5, 2013
Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. Journal of the American Medical Association 2013; 309: 453-460.Vascular medicine (London, England), , Volume: 18, Issue:4, 2013
Exploring consumer opinions on the presentation of side-effects information in Australian Consumer Medicine Information leaflets.Health expectations : an international journal of public participation in health care and health policy, , Volume: 19, Issue:3, 2016
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.Toxicological sciences : an official journal of the Society of Toxicology, , Volume: 136, Issue:1, 2013
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).PLoS computational biology, , Volume: 7, Issue:12, 2011
Safety and tolerability of ramipril 10 mg in patients at high risk of cardiovascular events: an observational study.Journal of the Indian Medical Association, , Volume: 106, Issue:7, 2008
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.Current drug discovery technologies, , Volume: 1, Issue:4, 2004
[Drug-induced liver injury; fourteenth updated edition of the bibliographic database of liver injuries and related drugs].Gastroenterologie clinique et biologique, , Volume: 28, Issue:8-9
Anthracycline-induced cardiotoxicity prevention with angiotensin-converting enzyme inhibitor ramipril in women with low-risk breast cancer: results of a prospective randomized study.Kardiologia polska, , 02-25, Volume: 78, Issue:2, 2020
SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab.Medical oncology (Northwood, London, England), , Volume: 34, Issue:5, 2017
Effect of ethanolic extract of Cyperus rotundus L. against isoprenaline induced cardiotoxicity.Indian journal of experimental biology, , Volume: 54, Issue:10, 2016
Effects of ramipril and darbepoetin on electromechanical activity of the heart in doxorubicin-induced cardiotoxicity.International journal of cardiology, , May-15, Volume: 173, Issue:3, 2014
Ramipril for the Treatment of COVID-19: RAMIC, a Randomized, Double-Blind, Placebo-Controlled Clinical Trial.Advances in therapy, , Volume: 40, Issue:11, 2023
RAMIC: Design of a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of ramipril in patients with COVID-19.Contemporary clinical trials, , Volume: 103, 2021
Lung and Kidney ACE2 and TMPRSS2 in Renin-Angiotensin System Blocker-Treated Comorbid Diabetic Mice Mimicking Host Factors That Have Been Linked to Severe COVID-19.Diabetes, , Volume: 70, Issue:3, 2021
Impact of the COVID-19 pandemic on the management of chronic heart failure.Reviews in cardiovascular medicine, , 06-30, Volume: 22, Issue:2, 2021
ACE inhibitor-related angioedema in a COVID-19 patient-a plausible contribution of the viral infection?European journal of clinical pharmacology, , Volume: 77, Issue:6, 2021
Effect of ramipril on kidney, lung and heart ACE2 in a diabetic mice model.Molecular and cellular endocrinology, , 06-01, Volume: 529, 2021
Renin-Angiotensin System Blockade in COVID-19: Good, Bad, or Indifferent?Journal of the American College of Cardiology, , 07-21, Volume: 76, Issue:3, 2020
Ramipril in High-Risk Patients With COVID-19.Journal of the American College of Cardiology, , 07-21, Volume: 76, Issue:3, 2020
ACE Inhibitors and Angiotensin II Receptor Blockers May Have Different Impact on Prognosis of COVID-19.Journal of the American College of Cardiology, , 10-27, Volume: 76, Issue:17, 2020
Caution in diagnosing angioedema as anaphylaxis.BMJ case reports, , Sep-04, Volume: 12, Issue:9, 2019
Basophil activation test, skin prick test, and anaphylaxis after drug hypersensitivity.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, , Volume: 116, Issue:5, 2016
Ramipril and metoprolol intake aggravate human and murine anaphylaxis: evidence for direct mast cell priming.The Journal of allergy and clinical immunology, , Volume: 135, Issue:2, 2015
[Anaphylactoid reaction in hemodyalisis: converting enzyme inhibitors interaction with no PAN 69 membrane].Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, , Volume: 27, Issue:3, 2007
Effects of ramipril on serum monocyte chemoattractant protein 1, interleukin-18, and interleukin-10 in elderly patients with acute coronary syndrome.Heart and vessels, , Volume: 25, Issue:2, 2010
Effect of ramipril on postrevascularization prevalence of angina and quality of life.International journal of cardiology, , Volume: 95, Issue:2-3, 2004
Cardiac angiotensin is upregulated in the hearts of unstable angina patients.Circulation research, , Jun-25, Volume: 94, Issue:12, 2004
Angina pectoris prior to myocardial infarction protects against subsequent left ventricular remodeling.Journal of the American College of Cardiology, , May-05, Volume: 43, Issue:9, 2004
Ischemic preconditioning in coronary heart disease: a therapeutic golden fleece?Journal of the American College of Cardiology, , May-05, Volume: 43, Issue:9, 2004
Simvastatin combined with ramipril treatment in hypercholesterolemic patients.Hypertension (Dallas, Tex. : 1979), , Volume: 44, Issue:2, 2004
Extended follow-up of patients randomly assigned in the Angiotensin-converting enzyme inhibition Post-Revascularization Study (APRES).American heart journal, , Volume: 148, Issue:3, 2004
Cardiac angiotensin II participates in coronary microvessel inflammation of unstable angina and strengthens the immunomediated component.Circulation research, , Jun-25, Volume: 94, Issue:12, 2004
["Using chance, despite high NNT"].MMW Fortschritte der Medizin, , Sep-18, Volume: 145, Issue:38, 2003
Beneficial effects of ramipril on left ventricular end-diastolic and end-systolic volume indexes after uncomplicated invasive revascularization are associated with a reduction in cardiac events in patients with moderately impaired left ventricular functioJournal of the American College of Cardiology, , Volume: 37, Issue:5, 2001
The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES).Journal of the American College of Cardiology, , Mar-15, Volume: 35, Issue:4, 2000
The Angiotensin Converting Enzyme Inhibition Post Revascularization Study (APRES). Effects of ramipril in patients with reduced left ventricular function. Rationale, design, methods, baseline characteristics and first-year experience.Scandinavian cardiovascular journal : SCJ, , Volume: 32, Issue:4, 1998
Cardiac angiotensin II participates in coronary microvessel inflammation of unstable angina and strengthens the immunomediated component.Circulation research, , Jun-25, Volume: 94, Issue:12, 2004
Cardiac angiotensin is upregulated in the hearts of unstable angina patients.Circulation research, , Jun-25, Volume: 94, Issue:12, 2004
Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study.Circulation, , Jul-31, Volume: 104, Issue:5, 2001
ACE inhibitors: new hope for old drugs?South Dakota journal of medicine, , Volume: 53, Issue:8, 2000
ACE inhibitor-related angioedema in a COVID-19 patient-a plausible contribution of the viral infection?European journal of clinical pharmacology, , Volume: 77, Issue:6, 2021
Caution in diagnosing angioedema as anaphylaxis.BMJ case reports, , Sep-04, Volume: 12, Issue:9, 2019
Angioedema Two Weeks After the Initial Administration of an ACE Inhibitor.Deutsches Arzteblatt international, , 03-02, Volume: 115, Issue:9, 2018
Fatal outcome of late-onset angiotensin-converting enzyme inhibitor induced angioedema: A case report.Medicine, , Volume: 97, Issue:31, 2018
A transient ischemic attack mimic.Acta neurologica Belgica, , Volume: 117, Issue:4, 2017
Potential Biomarkers for the Diagnosis of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema.ORL; journal for oto-rhino-laryngology and its related specialties, , Volume: 79, Issue:1-2, 2017
Drug-Induced Inhibition of Angiotensin Converting Enzyme and Dipeptidyl Peptidase 4 Results in Nearly Therapy Resistant Bradykinin Induced Angioedema: A Case Report.The American journal of case reports, , May-25, Volume: 18, 2017
Intestinal Angioedema in a Palliative Care Setting.The American journal of medicine, , Volume: 129, Issue:11, 2016
Using a bradykinin blocker in ACE inhibitor-associated angioedema in the emergency department.BMJ case reports, , Jan-31, Volume: 2013, 2013
Genetic variants associated with angiotensin-converting enzyme inhibitor-associated angioedema.Pharmacogenetics and genomics, , Volume: 23, Issue:9, 2013
Pharmacogenetic markers for antihypertensive drug-related adverse reactions.Pharmacogenomics, , Volume: 14, Issue:15, 2013
Fresh frozen plasma in the treatment of ACE inhibitor-induced angioedema.BMJ case reports, , Aug-24, Volume: 2012, 2012
Icatibant and ACE inhibitor angioedema.BMJ case reports, , Aug-30, Volume: 2012, 2012
[Dental care with local anesthesia: should the patient first discontinue ACE inhibitors?].MMW Fortschritte der Medizin, , Mar-03, Volume: 153, Issue:9, 2011
Imaging findings in angiotensin-converting enzyme inhibitor induced angioedema.Emergency medicine journal : EMJ, , Volume: 28, Issue:7, 2011
Telmisartan, ramipril, or both in patients at high risk of vascular events.The New England journal of medicine, , Jul-24, Volume: 359, Issue:4, 2008
Telmisartan, ramipril, or both in patients at high risk for vascular events.The New England journal of medicine, , Apr-10, Volume: 358, Issue:15, 2008
[Choroidal effusion after uncomplicated cataract surgery].Klinische Monatsblatter fur Augenheilkunde, , Volume: 225, Issue:6, 2008
[ Therapy of patients at high risk for vascular events: telmisartan, ramipril or a combination? ].Der Internist, , Volume: 49, Issue:9, 2008
[Fasciitis with eosinophilia: a possible causal role of angiotensin converting enzyme inhibitor].Revue neurologique, , Volume: 163, Issue:2, 2007
Acute upper airway obstruction from acquired angioedema.Emergency medicine Australasia : EMA, , Volume: 19, Issue:1, 2007
Fresh frozen plasma in the treatment of resistant angiotensin-converting enzyme inhibitor angioedema.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, , Volume: 92, Issue:5, 2004
[Tongue angioedema associated with angiotensin-converting enzyme inhibitor (diagnosis, differential diagnosis, treatment)].Medicina (Kaunas, Lithuania), , Volume: 39, Issue:6, 2003
Delayed diagnosis of angiotensin-converting enzyme (ACE) inhibitor induced angioedema and urticaria.Clinical and experimental dermatology, , Volume: 28, Issue:3, 2003
Severe angioedema induced by angiotensin converting enzyme inhibitors: role of precipitating factors.The Journal of dermatology, , Volume: 29, Issue:6, 2002
Angioedema caused by ramipril.The Annals of pharmacotherapy, , Volume: 29, Issue:4, 1995
The African American Study of Kidney Disease and Hypertension (AASK) trial: what more have we learned?Journal of clinical hypertension (Greenwich, Conn.), , Volume: 5, Issue:2
[Bradykinin mediated angioedema with ACE inhibitor in combination with immunosupressive agents].Therapie, , Volume: 69, Issue:2
Summaries for patients. Preventing worsening kidney function in patients receiving peritoneal dialysis.Annals of internal medicine, , Jul-15, Volume: 139, Issue:2, 2003
Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study.Annals of internal medicine, , Jul-15, Volume: 139, Issue:2, 2003
Effects of ramipril on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young normotensive subjects with successfully repaired coarctation of aorta: a randomized cross-over study.Journal of the American College of Cardiology, , Feb-19, Volume: 51, Issue:7, 2008
Effect of ACE inhibitor on DOCA-salt- and aortic coarctation-induced hypertension in mice: do kinin B2 receptors play a role?Hypertension (Dallas, Tex. : 1979), , Volume: 33, Issue:1 Pt 2, 1999
Nitric oxide and the depressor response to angiotensin blockade in hypertension.Hypertension (Dallas, Tex. : 1979), , Volume: 27, Issue:1, 1996
Role of kinins and nitric oxide in the antihypertrophic effect of ramipril.Hypertension (Dallas, Tex. : 1979), , Volume: 23, Issue:6 Pt 2, 1994
Impact of renin-angiotensin system inhibitors on clinical outcomes and ventricular remodelling after transcatheter aortic valve implantation: rationale and design of the RASTAVI randomised multicentre study.BMJ open, , 02-13, Volume: 8, Issue:2, 2018
A prospective, double-blind, randomized controlled trial of the angiotensin-converting enzyme inhibitor Ramipril In Aortic Stenosis (RIAS trial).European heart journal. Cardiovascular Imaging, , Volume: 16, Issue:8, 2015
ACE inhibitors in aortic stenosis: no fear just hope.European heart journal. Cardiovascular Imaging, , Volume: 16, Issue:8, 2015
Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations.British journal of pharmacology, , Volume: 162, Issue:3, 2011
Dual renin-angiotensin system blockade for patients with prosthesis-patient mismatch.The Annals of thoracic surgery, , Volume: 90, Issue:6, 2010
Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function.Journal of investigative medicine : the official publication of the American Federation for Clinical Research, , Volume: 52, Issue:3, 2004
Effect of angiotensin converting enzyme inhibition on pressure-induced left ventricular hypertrophy in rats.Circulation research, , Volume: 69, Issue:3, 1991
Influence of ramiprilat and losartan on ischemia reperfusion injury in rat hearts.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 13, Issue:1, 2012
[Cardioprotection of ramipril and BQ-123 against myocardial ischemia/reperfusion injury in vivo in rats].Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology, , Volume: 25, Issue:4, 2009
Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction.Circulation, , Sep-14, Volume: 110, Issue:11, 2004
Cardioprotective effects of the aminopeptidase P inhibitor apstatin: studies on ischemia/reperfusion injury in the isolated rat heart.Journal of cardiovascular pharmacology, , Volume: 34, Issue:4, 1999
Postinfarction survival and inducibility of ventricular arrhythmias in the spontaneously hypertensive rat : effects of ramipril and hydralazine.Circulation, , Nov-10, Volume: 98, Issue:19, 1998
[The efficacy of treatment with the angiotensin-converting enzyme inhibitor ramipril in patients with congestive heart failure of rheumatic etiology].Terapevticheskii arkhiv, , Volume: 68, Issue:2, 1996
Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats.Hypertension (Dallas, Tex. : 1979), , Volume: 27, Issue:1, 1996
Attenuation of reperfusion arrhythmias by selective inhibition of angiotensin-converting enzyme/kininase II in the ischemic zone: mediated by endogenous bradykinin?Journal of cardiovascular pharmacology, , Volume: 27, Issue:3, 1996
ACE-inhibition induces NO-formation in cultured bovine endothelial cells and protects isolated ischemic rat hearts.Journal of molecular and cellular cardiology, , Volume: 24, Issue:8, 1992
Local inhibition of bradykinin degradation in ischemic hearts.Journal of cardiovascular pharmacology, , Volume: 15 Suppl 6, 1990
Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril.Journal of the American College of Cardiology, , Volume: 36, Issue:2, 2000
Early induction of angiotensin I-converting enzyme in rat carotid artery after balloon injury.Hypertension (Dallas, Tex. : 1979), , Volume: 30, Issue:2 Pt 1, 1997
Appraisal of anti-inflammatory and immunomodulatory potential of ramipril against Freund's adjuvant-provoked arthritic rat model.Inflammopharmacology, , Volume: 31, Issue:6, 2023
Ramipril and haloperidol as promising approaches in managing rheumatoid arthritis in rats.European journal of pharmacology, , Oct-15, Volume: 765, 2015
Response to 'Ramipril attenuates lipid peroxidation and cardiac fibrosis in an experimental model of rheumatoid arthritis'.Arthritis research & therapy, , Apr-03, Volume: 15, Issue:2, 2013
Response to 'Ramipril attenuates lipid peroxidation and cardiac fibrosis in an experimental model of rheumatoid arthritis' - authors' reply.Arthritis research & therapy, , Apr-03, Volume: 15, Issue:2, 2013
Ramipril attenuates lipid peroxidation and cardiac fibrosis in an experimental model of rheumatoid arthritis.Arthritis research & therapy, , Oct-18, Volume: 14, Issue:5, 2012
Influence of the new angiotensin converting enzyme inhibitor ramipril on several models of acute inflammation and the adjuvant arthritis in the rat.Arzneimittel-Forschung, , Volume: 36, Issue:11, 1986
Ramipril and haloperidol as promising approaches in managing rheumatoid arthritis in rats.European journal of pharmacology, , Oct-15, Volume: 765, 2015
Response to 'Ramipril attenuates lipid peroxidation and cardiac fibrosis in an experimental model of rheumatoid arthritis' - authors' reply.Arthritis research & therapy, , Apr-03, Volume: 15, Issue:2, 2013
Response to 'Ramipril attenuates lipid peroxidation and cardiac fibrosis in an experimental model of rheumatoid arthritis'.Arthritis research & therapy, , Apr-03, Volume: 15, Issue:2, 2013
Ramipril attenuates lipid peroxidation and cardiac fibrosis in an experimental model of rheumatoid arthritis.Arthritis research & therapy, , Oct-18, Volume: 14, Issue:5, 2012
Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis.Circulation, , Apr-29, Volume: 117, Issue:17, 2008
Letter by Popa and Netea regarding article, "Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis".Circulation, , Nov-04, Volume: 118, Issue:19, 2008
Ramipril-induced generalized pustular psoriasis: case report and literature review.American journal of therapeutics, , Volume: 17, Issue:1
Factors that favor the occurrence of cough in patients treated with ramipril--a pharmacoepidemiological study.Medical science monitor : international medical journal of experimental and clinical research, , Volume: 18, Issue:9, 2012
Dyspnoea, asthma, and bronchospasm in relation to treatment with angiotensin converting enzyme inhibitors.BMJ (Clinical research ed.), , Jan-01, Volume: 308, Issue:6920, 1994
The effect of an angiotensin converting enzyme inhibitor, ramipril, on bronchial responses to inhaled histamine and bradykinin in asthmatic subjects.British journal of clinical pharmacology, , Volume: 23, Issue:1, 1987
Prevention of Atrial Fibrillation After Atrial Flutter Ablation With Ramipril (from the PREFACE Study).The American journal of cardiology, , 01-01, Volume: 162, 2022
Risk of renal dysfunction in an elderly patient with chronic heart failure.Medizinische Monatsschrift fur Pharmazeuten, , Volume: 39, Issue:10, 2016
Precardiac surgery angiotensin-converting enzymes and mineralocorticoid blockers do not trump atrial fibrillation but possibly acute kidney injury: the value of a negative randomized study.Critical care medicine, , Volume: 40, Issue:10, 2012
Prediction and prevention of atrial fibrillation in patients with high blood pressure or history of hypertension.Journal of hypertension, , Volume: 30, Issue:5, 2012
Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtoleranJournal of hypertension, , Volume: 30, Issue:5, 2012
Angiotensin-converting enzyme inhibition or mineralocorticoid receptor blockade do not affect prevalence of atrial fibrillation in patients undergoing cardiac surgery.Critical care medicine, , Volume: 40, Issue:10, 2012
Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation.Journal of cardiovascular pharmacology and therapeutics, , Volume: 17, Issue:1, 2012
[Role of ACE-inhibitors in preventing atrial fibrillation relapses in normotensive patients].Recenti progressi in medicina, , Volume: 100, Issue:11, 2009
Prevention of recurrent lone atrial fibrillation by the angiotensin-II converting enzyme inhibitor ramipril in normotensive patients.Journal of the American College of Cardiology, , Jan-06, Volume: 53, Issue:1, 2009
Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation.American journal of hypertension, , Volume: 21, Issue:9, 2008
Effect of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on the frequency of post-cardiothoracic surgery atrial fibrillation.The Annals of pharmacotherapy, , Volume: 41, Issue:3, 2007
Impact of ramipril on the incidence of atrial fibrillation: results of the Heart Outcomes Prevention Evaluation study.American heart journal, , Volume: 154, Issue:3, 2007
Angiotensin-converting enzyme inhibitors and stroke prevention: what about the influence of atrial fibrillation and antithrombotic therapy?Stroke, , Volume: 34, Issue:11, 2003
[Arrhythmogenic dilated cardiomyopathy].Medicina (Kaunas, Lithuania), , Volume: 39, Issue:7, 2003
Management of heart failure.Current cardiology reports, , Volume: 2, Issue:3, 2000
[Inappropriate antidiuretic hormone secretion syndrome associated with ramipril treatment].Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, , Volume: 34, Issue:3
Ramipril reduces incidence and prolongates latency time of radiation-induced rat myelopathy after photon and carbon ion irradiation.Journal of radiation research, , Sep-08, Volume: 61, Issue:5, 2020
Effect of telmisartan vs. ramipril on 'dipping' status and blood pressure variability: pooled analysis of the PRISMA studies.Hypertension research : official journal of the Japanese Society of Hypertension, , Volume: 37, Issue:2, 2014
Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects.American journal of physiology. Renal physiology, , Mar-15, Volume: 304, Issue:6, 2013
Chronic administration of the angiotensin-converting enzyme inhibitor, ramipril, prevents fractionated whole-brain irradiation-induced perirhinal cortex-dependent cognitive impairment.Radiation research, , Volume: 178, Issue:1, 2012
Renal outcome in equipotent antihypertensive treatment with telmisartan, ramipril and in combination in SHR-SP rats.Clinical laboratory, , Volume: 58, Issue:7-8, 2012
Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients.Hypertension research : official journal of the Japanese Society of Hypertension, , Volume: 34, Issue:1, 2011
Blockade of sensory abnormalities and kinin B(1) receptor expression by N-acetyl-L-cysteine and ramipril in a rat model of insulin resistance.European journal of pharmacology, , Jul-28, Volume: 589, Issue:1-3, 2008
Atrial natriuretic peptide prevents diabetes-induced endothelial dysfunction.Life sciences, , Apr-09, Volume: 82, Issue:15-16, 2008
Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction.American journal of physiology. Heart and circulatory physiology, , Volume: 294, Issue:4, 2008
Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.Circulation, , Apr-17, Volume: 115, Issue:15, 2007
Effects of angiotensin II on connexin 43 of VSMCs in arteriosclerosis.Journal of Zhejiang University. Science. B, , Volume: 7, Issue:8, 2006
Insulin-sensitizing and cardiovascular effects of the sodium-hydrogen exchange inhibitor, cariporide, in the JCR: LA-cp rat and db/db mouse.Journal of cardiovascular pharmacology, , Volume: 46, Issue:6, 2005
[Case report: hypertension after stroke].Wiener medizinische Wochenschrift (1946), , Volume: 154 Spec No 1, Issue:1, 2004
Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats.Biochemical and biophysical research communications, , Mar-26, Volume: 316, Issue:1, 2004
Vasopeptidase inhibition improves insulin sensitivity and endothelial function in the JCR:LA-cp rat.Journal of cardiovascular pharmacology, , Volume: 44, Issue:2, 2004
Effect of chronic treatment with the vasopeptidase inhibitor AVE 7688 and ramipril on endothelial function in atherogenic diet rabbits.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 4, Issue:3, 2003
Comparative effects of the dual ACE-NEP inhibitor MDL-100,240 and ramipril on hypertension and cardiovascular disease in endogenous angiotensin II-dependent hypertension.American journal of hypertension, , Volume: 15, Issue:2 Pt 1, 2002
Regression of ventricular and vascular hypertrophy: are there differences between structurally different angiotensin-converting enzyme inhibitors?Journal of hypertension, , Volume: 20, Issue:12, 2002
Dual ACE and NEP inhibitor MDL-100,240 prevents and regresses severe angiotensin II-dependent hypertension partially through bradykinin type 2 receptor.Journal of hypertension, , Volume: 20, Issue:7, 2002
Effects of angiotensin-converting enzyme inhibitor and angiotensin type 1 receptor antagonist in deoxycorticosterone acetate-salt hypertensive mice lacking Ren-2 gene.Hypertension (Dallas, Tex. : 1979), , Volume: 37, Issue:3, 2001
Ramipril and aminoguanidine restore renal lysosomal processing in streptozotocin diabetic rats.Diabetologia, , Volume: 44, Issue:2, 2001
Renal and vascular injury induced by exogenous angiotensin II is AT1 receptor-dependent.Nephron, , Volume: 87, Issue:1, 2001
Effect of ramipril on cardiovascular events in high-risk patients.The New England journal of medicine, , Jul-06, Volume: 343, Issue:1, 2000
Impaired nitric oxide modulation of myocardial oxygen consumption in genetically cardiomyopathic hamsters.Journal of molecular and cellular cardiology, , Volume: 32, Issue:12, 2000
The effect of urapidil and ramipril on hyperglycemia in streptozotocin diabetic rats.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 361, Issue:1, 2000
Late treatment with ramipril increases survival in old spontaneously hypertensive rats.Hypertension (Dallas, Tex. : 1979), , Volume: 34, Issue:2, 1999
Angiotensin converting enzyme inhibition reduces the expression of transforming growth factor-beta1 and type IV collagen in diabetic vasculopathy.Journal of hypertension, , Volume: 16, Issue:11, 1998
Effects of chronic ramipril treatment in streptozotocin-induced diabetic rats.Indian journal of physiology and pharmacology, , Volume: 41, Issue:4, 1997
Arterial responses to bradykinin after ramipril therapy in experimental hypertension.Pharmacology & toxicology, , Volume: 81, Issue:4, 1997
Interactions of the kallikrein-kinin and renin-angiotensin systems in experimental diabetes.Diabetes, , Volume: 46, Issue:1, 1997
Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production.Circulation, , Jun-01, Volume: 93, Issue:11, 1996
Resetting blood pressure in spontaneously hypertensive rats. The role of bradykinin.Hypertension (Dallas, Tex. : 1979), , Volume: 25, Issue:2, 1995
Attenuation of genetic hypertension after short-term vasopressin V1A receptor antagonism.Hypertension (Dallas, Tex. : 1979), , Volume: 26, Issue:5, 1995
Role of angiotensin in pressure overload-induced hypertrophy in rats: effects of angiotensin-converting enzyme inhibitors, an AT1 receptor antagonist, and surgical reversal.Journal of cardiovascular pharmacology, , Volume: 23, Issue:2, 1994
Effect of ramipril, an inhibitor of angiotensin converting enzyme, on the response of rat thoracic aorta to injury with a balloon catheter.Journal of cardiovascular pharmacology, , Volume: 18, Issue:2, 1991
Loop diuretics combined with an ACE inhibitor for treatment of hypertension: a study with furosemide, piretanide, and ramipril in spontaneously hypertensive rats.Journal of cardiovascular pharmacology, , Volume: 13 Suppl 3, 1989
Global and regional hemodynamic effects of ramipril in congestive heart failure.Journal of cardiovascular pharmacology, , Volume: 14, Issue:5, 1989
Ramipril reduces albuminuria in diabetic rats fed a high protein diet.Clinical and experimental pharmacology & physiology, , Volume: 16, Issue:8, 1989
Diabetic vascular hypertrophy and albuminuria: effect of angiotensin converting enzyme inhibition.Journal of diabetes and its complications, , Volume: 9, Issue:4
An open-label, noncomparative, multicenter study of ramipril in the treatment of patients with mild-to-moderate hypertension.Clinical therapeutics, , Volume: 18, Issue:6
Angiotensin-Converting Enzyme Inhibitor Reduces Radiation-Induced Periprosthetic Capsular Fibrosis.The Journal of surgical research, , Volume: 263, 2021
Anthracycline-induced cardiotoxicity prevention with angiotensin-converting enzyme inhibitor ramipril in women with low-risk breast cancer: results of a prospective randomized study.Kardiologia polska, , 02-25, Volume: 78, Issue:2, 2020
SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab.Medical oncology (Northwood, London, England), , Volume: 34, Issue:5, 2017
Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy.Lancet (London, England), , Feb-03, Volume: 347, Issue:8997, 1996
The prognostic significance of a history of systemic hypertension in patients randomised to either placebo or ramipril following acute myocardial infarction: evidence from the AIRE study. Acute Infarction Ramipril Efficacy.Journal of human hypertension, , Volume: 13, Issue:8, 1999
Amlodipine promotes kinin-mediated nitric oxide production in coronary microvessels of failing human hearts.The American journal of cardiology, , Aug-19, Volume: 84, Issue:4A, 1999
Structure and in vitro function of human subcutaneous small arteries in mild heart failure.The American journal of physiology, , Volume: 274, Issue:5, 1998
Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy.Lancet (London, England), , May-24, Volume: 349, Issue:9064, 1997
Absence of effect on exercise capacity of 12-weeks treatment with ramipril in patients with moderate congestive heart failure. Ramipril Study Group.European heart journal, , Volume: 15, Issue:12, 1994
Successful heart failure therapy in mitochondrial disorder with noncompaction cardiomyopathy.The international journal of cardiovascular imaging, , Volume: 22, Issue:3-4
Tenascin-C as predictor of left ventricular remodeling and mortality in patients with dilated cardiomyopathy.Journal of investigative medicine : the official publication of the American Federation for Clinical Research, , Volume: 61, Issue:4, 2013
Role of echocardiography in assessing the mechanism and effect of ramipril on functional mitral regurgitation in dilated cardiomyopathy.Echocardiography (Mount Kisco, N.Y.), , Volume: 22, Issue:4, 2005
[Arrhythmogenic dilated cardiomyopathy].Medicina (Kaunas, Lithuania), , Volume: 39, Issue:7, 2003
[Competitive sports and dilated cardiomyopathy: the case of a 32-year-old soccer player with ventricular tachycardia].Deutsche medizinische Wochenschrift (1946), , Jan-24, Volume: 128, Issue:4, 2003
Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.The Journal of pharmacology and experimental therapeutics, , Volume: 295, Issue:2, 2000
Treatment with angiotensin-converting-enzyme inhibitor for epirubicin-induced dilated cardiomyopathy.Lancet (London, England), , Feb-03, Volume: 347, Issue:8997, 1996
Quantitative assessment of daily physical activity levels in patients with chronic heart failure by measuring energy expenditure--effects of converting enzyme inhibitor therapy.Japanese circulation journal, , Volume: 59, Issue:10, 1995
[The use of ramipril in treating patients with chronic heart failure].Terapevticheskii arkhiv, , Volume: 67, Issue:5, 1995
Reversible dilated cardiomyopathy in a patient with Cushing's syndrome.Congestive heart failure (Greenwich, Conn.), , Volume: 16, Issue:2
A transient ischemic attack mimic.Acta neurologica Belgica, , Volume: 117, Issue:4, 2017
Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone).Journal of the American College of Cardiology, , Jun-02, Volume: 53, Issue:22, 2009
From the HOPE to the ONTARGET and the TRANSCEND studies: challenges in improving prognosis.The American journal of cardiology, , Jan-24, Volume: 89, Issue:2A, 2002
Effect of ramipril and vitamin E on atherosclerosis.Circulation, , Jan-15, Volume: 105, Issue:2, 2002
Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE).Circulation, , Feb-20, Volume: 103, Issue:7, 2001
ACE inhibitor inhibits atherosclerosis.Harvard heart letter : from Harvard Medical School, , Volume: 11, Issue:9, 2001
Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril.Journal of the American College of Cardiology, , Volume: 36, Issue:2, 2000
Study design and baseline characteristics of the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E: SECURE.The American journal of cardiology, , Oct-15, Volume: 78, Issue:8, 1996
Twenty-and-a-half syndrome: a case report.Journal of medical case reports, , Feb-15, Volume: 13, Issue:1, 2019
Churg-Strauss syndrome with endocardial injury, clot formation in heart's chambers, and neurological complications.Kardiologia polska, , Volume: 74, Issue:11, 2016
Reduced cerebrovascular remodeling and functional impairment in spontaneously hypertensive rats following combined treatment with suboptimal doses of telmisartan and ramipril: is less really more?Journal of hypertension, , Volume: 28, Issue:7, 2010
Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats.Journal of hypertension, , Volume: 26, Issue:3, 2008
Ramipril protects from free radical induced white matter damage in chronic hypoperfusion in the rat.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, , Volume: 15, Issue:2, 2008
Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients.Cerebrovascular diseases extra, , Volume: 10, Issue:3, 2020
Nephroprotection by long-term ACE inhibition with ramipril in spontaneously hypertensive stroke prone rats.Kidney international, , Volume: 54, Issue:6, 1998
Replacement of salt by a novel potassium- and magnesium-enriched salt alternative improves the cardiovascular effects of ramipril.British journal of pharmacology, , Volume: 111, Issue:4, 1994
Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin.Hypertension (Dallas, Tex. : 1979), , Volume: 23, Issue:4, 1994
Effect of ramipril on alpha-adrenoceptor-mediated oscillatory contractions in tail artery of hypertensive rats.European journal of pharmacology, , Oct-05, Volume: 242, Issue:3, 1993
Impact of the COVID-19 pandemic on the management of chronic heart failure.Reviews in cardiovascular medicine, , 06-30, Volume: 22, Issue:2, 2021
Dysglycemia and Cognitive Dysfunction and Ill Health in People With High CV Risk: Results From the ONTARGET/TRANSCEND Studies.The Journal of clinical endocrinology and metabolism, , Volume: 100, Issue:7, 2015
Effect of zofenopril and ramipril on cardiovascular mortality in patients with chronic heart failure.The American journal of cardiology, , Jul-01, Volume: 112, Issue:1, 2013
REIN on obesity, proteinuria and CKD.Journal of the American Society of Nephrology : JASN, , Volume: 22, Issue:6, 2011
ACE inhibition is renoprotective among obese patients with proteinuria.Journal of the American Society of Nephrology : JASN, , Volume: 22, Issue:6, 2011
Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway?Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 25, Issue:10, 2010
ONTARGET should not be over interpreted.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 25, Issue:1, 2010
Is therapy of people with chronic kidney disease ONTARGET?Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 25, Issue:1, 2010
Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 25, Issue:7, 2010
The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial.Journal of cardiovascular electrophysiology, , Volume: 20, Issue:7, 2009
Ramipril protects from free radical induced white matter damage in chronic hypoperfusion in the rat.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, , Volume: 15, Issue:2, 2008
Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure.European journal of heart failure, , Volume: 9, Issue:11, 2007
[ACE inhibitor therapy until end of life?].Deutsche medizinische Wochenschrift (1946), , Oct-29, Volume: 129, Issue:44, 2004
Improvement in endothelial progenitor cells from peripheral blood by ramipril therapy in patients with stable coronary artery disease.Cardiovascular drugs and therapy, , Volume: 18, Issue:3, 2004
Ramipril in the treatment of hypertension and proteinuria in children with chronic kidney diseases.American journal of hypertension, , Volume: 17, Issue:5 Pt 1, 2004
Effects of diuretic treatment on cardiac and circulating RAS in chronic heart failure post-myocardial infarction in rats.European journal of heart failure, , Volume: 5, Issue:3, 2003
Aspirin alters arterial function in patients with chronic heart failure treated with ACE inhibitors: a dose-mediated deleterious effect.European journal of heart failure, , Volume: 5, Issue:3, 2003
Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies.Kidney international, , Volume: 59, Issue:1, 2001
Effects of ACE inhibitor, AT1 antagonist, and combined treatment in mice with heart failure.Journal of cardiovascular pharmacology, , Volume: 36, Issue:4, 2000
Pretreatment blood pressure reliably predicts progression of chronic nephropathies. GISEN Group.Kidney international, , Volume: 58, Issue:5, 2000
Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen)Journal of the American Society of Nephrology : JASN, , Volume: 11, Issue:1, 2000
Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 35, Issue:6, 2000
In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. Investigators of the GISEN Group. Gruppo Italiano Studi Epidemiologici in Nefrologia.Journal of the American Society of Nephrology : JASN, , Volume: 10, Issue:5, 1999
[Ramipril treatment of heart failure in disseminated forms of pulmonary tuberculosis].Problemy tuberkuleza, , Issue:2, 1999
[Efficiency of ramipril treatment in patients with chronic obstructive bronchitis complicated by chronic cor pulmonale].Problemy tuberkuleza, , Issue:6, 1999
[Renal hemodynamics and proteinuria in chronic glomerulonephritis treated with beta-receptor blockers or ace inhibitors].Deutsche medizinische Wochenschrift (1946), , Aug-01, Volume: 122, Issue:31-32, 1997
Randomized controlled trial of ACE-inhibitors and beta-blockers with and without vasodilating activity in chronic glomerulonephritis.International journal of clinical pharmacology and therapeutics, , Volume: 34, Issue:11, 1996
Meta-analysis of morbidity and mortality in five exercise capacity trials evaluating ramipril in chronic congestive cardiac failure.The American journal of cardiology, , Jun-01, Volume: 77, Issue:14, 1996
[The use of ramipril in treating patients with chronic heart failure].Terapevticheskii arkhiv, , Volume: 67, Issue:5, 1995
A comparison of the efficacy and safety of ramipril and digoxin added to maintenance diuretic treatment in patients with chronic heart failure.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Influence of ramipril on renal function in patients with chronic congestive heart failure.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Acute hemodynamic, hormonal and electrolyte effects of ramipril in severe congestive heart failure.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Acute hemodynamic and hormonal effects of ramipril in chronic congestive heart failure and comparison with captopril.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Acute effects of the new angiotensin converting enzyme inhibitor ramipril on hemodynamics and carotid sinus baroreflex activity in congestive heart failure.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Dysglycemia and Cognitive Dysfunction and Ill Health in People With High CV Risk: Results From the ONTARGET/TRANSCEND Studies.The Journal of clinical endocrinology and metabolism, , Volume: 100, Issue:7, 2015
Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk.Hypertension (Dallas, Tex. : 1979), , Volume: 65, Issue:3, 2015
Chronic administration of the angiotensin-converting enzyme inhibitor, ramipril, prevents fractionated whole-brain irradiation-induced perirhinal cortex-dependent cognitive impairment.Radiation research, , Volume: 178, Issue:1, 2012
Renin-angiotensin system blockade and cognitive function in patients at high risk of cardiovascular disease: analysis of data from the ONTARGET and TRANSCEND studies.The Lancet. Neurology, , Volume: 10, Issue:1, 2011
Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET/TRANSCEND research programme.Diabetes research and clinical practice, , Volume: 83, Issue:3, 2009
Effect of ramipril therapy on cognitive functions in cases of mild to moderate essential hypertension.Indian journal of physiology and pharmacology, , Volume: 51, Issue:1
[Usefulness of capsule endoscopy in obscure gastrointestinal bleeding].Gastroenterologia y hepatologia, , Volume: 38, Issue:10, 2015
Ameliorative potential of angiotensin-converting enzyme inhibitor (ramipril) on chronic constriction injury of sciatic nerve induced neuropathic pain in mice.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 16, Issue:1, 2015
Right ventricular hypertrophy and apoptosis after pulmonary artery banding: regulation of PKC isozymes.Cardiovascular research, , Sep-01, Volume: 59, Issue:3, 2003
ACE inhibition decreases postoperative mortality in rats with left ventricular hypertrophy and myocardial infarction.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 18, Issue:5, 1996
Influence of ramipril on right ventricular hypertrophy induced by pulmonary artery stenosis in rats.Journal of cardiovascular pharmacology, , Volume: 16, Issue:3, 1990
Target Blood Pressure in Patients with Diabetes: Asian Perspective.Yonsei medical journal, , Volume: 57, Issue:6, 2016
Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease.Hypertension (Dallas, Tex. : 1979), , Volume: 65, Issue:1, 2015
Systolic blood pressure target levels: evidence for benefits in stroke.Hypertension (Dallas, Tex. : 1979), , Volume: 65, Issue:1, 2015
Angiotensin II impairs endothelial progenitor cell number and function in vitro and in vivo: implications for vascular regeneration.Hypertension (Dallas, Tex. : 1979), , Volume: 58, Issue:3, 2011
Effect of angiotensin-converting enzyme inhibition on C-reactive protein levels: the ramipril C-reactive pRotein randomized evaluation (4R) trial results.The Canadian journal of cardiology, , Volume: 25, Issue:7, 2009
Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes.Current atherosclerosis reports, , Volume: 10, Issue:2, 2008
Inflammatory activation during coronary artery surgery and its dose-dependent modulation by statin/ACE-inhibitor combination.Arteriosclerosis, thrombosis, and vascular biology, , Volume: 27, Issue:12, 2007
Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study.Circulation, , Jul-18, Volume: 114, Issue:3, 2006
Differential antiplatelet effects of angiotensin converting enzyme inhibitors: comparison of ex vivo platelet aggregation in cardiovascular patients with ramipril, captopril and enalapril.Clinical research in cardiology : official journal of the German Cardiac Society, , Volume: 95, Issue:4, 2006
Lack of effect on coronary atherosclerotic disease biomarkers with modest dosing of an angiotensin-converting enzyme inhibitor, angiotensin II type-1 receptor blocker, and the combination.Coronary artery disease, , Volume: 17, Issue:5, 2006
Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis.Zeitschrift fur Kardiologie, , Volume: 94, Issue:5, 2005
Do all patients with coronary artery disease benefit from angiotensin converting enzyme inhibitors?Journal of cardiovascular pharmacology and therapeutics, , Volume: 10, Issue:4, 2005
Vascular effects of simvastatin combined with ramipril in hypercholesterolemic patients with coronary artery disease, compared with simvastatin alone: a randomized, double-blind, placebo-controlled, crossover study.Atherosclerosis, , Volume: 177, Issue:1, 2004
Modulating atherosclerosis through inhibition or blockade of angiotensin.Clinical cardiology, , Volume: 26, Issue:7, 2003
[The status of atherosclerosis prevention in Austria].Wiener medizinische Wochenschrift (1946), , Volume: 153, Issue:15-16, 2003
[Preventing cardiovascular diseases. Discovering the optimal approach].MMW Fortschritte der Medizin, , Oct-11, Volume: 143, Issue:41, 2001
Study design and baseline characteristics of the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E: SECURE.The American journal of cardiology, , Oct-15, Volume: 78, Issue:8, 1996
[ACE inhibition and atherosclerosis in the animal model].Zeitschrift fur Kardiologie, , Volume: 83 Suppl 4, 1994
ACE inhibition, atherosclerosis and myocardial infarction--the AIRE Study in practice. Acute Infarction Ramipril Efficacy Study.European heart journal, , Volume: 15 Suppl B, 1994
Do ACE inhibitors have a real role in coronary artery disease?Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners, , Volume: 14, Issue:3
[Combination drug improves adherence].MMW Fortschritte der Medizin, , Apr-28, Volume: 158, Issue:8, 2016
[Polypill for secondary coronary heart disease prevention].MMW Fortschritte der Medizin, , Dec-14, Volume: 157, Issue:21-22, 2015
Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril.Postgraduate medicine, , Volume: 125, Issue:4, 2013
The common -866G>A variant in the promoter of UCP2 is associated with decreased risk of coronary artery disease in type 2 diabetic men.Diabetes, , Volume: 57, Issue:4, 2008
Noninvasive pulse waveform analysis in clinical trials: similarity of two methods for calculating aortic systolic pressure.American journal of hypertension, , Volume: 20, Issue:8, 2007
Influence of the angiotensin converting enzyme inhibitor ramipril on high-sensitivity C-reactive protein (hs-CRP) in patients with documented atherosclerosis.Zeitschrift fur Kardiologie, , Volume: 94, Issue:5, 2005
[Preventive therapy with ACE inhibitors for coronary patients].Orvosi hetilap, , Feb-29, Volume: 145, Issue:9, 2004
Ischemic preconditioning in coronary heart disease: a therapeutic golden fleece?Journal of the American College of Cardiology, , May-05, Volume: 43, Issue:9, 2004
Improvement in endothelial progenitor cells from peripheral blood by ramipril therapy in patients with stable coronary artery disease.Cardiovascular drugs and therapy, , Volume: 18, Issue:3, 2004
Combine EUROPA and HOPE.Lancet (London, England), , Dec-06, Volume: 362, Issue:9399, 2003
Should all patients with coronary disease receive angiotensin-converting-enzyme inhibitors?Lancet (London, England), , Sep-06, Volume: 362, Issue:9386, 2003
The EUROPA trial.Lancet (London, England), , Dec-06, Volume: 362, Issue:9399, 2003
["Using chance, despite high NNT"].MMW Fortschritte der Medizin, , Sep-18, Volume: 145, Issue:38, 2003
Vitamins, antioxidants and endothelial function in coronary artery disease.Cardiovascular drugs and therapy, , Volume: 16, Issue:5, 2002
[New indications. ACE inhibitor is now included in coronary heart disease therapy].MMW Fortschritte der Medizin, , May-02, Volume: 144, Issue:18, 2002
An ACE inhibitor to coronary patients: ramipril reduces mortality according to HOPE trial.Prescrire international, , Volume: 10, Issue:52, 2001
Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase.Circulation, , Feb-13, Volume: 103, Issue:6, 2001
Management of asymptomatic left ventricular dysfunction.Cleveland Clinic journal of medicine, , Volume: 68, Issue:3, 2001
[Endothelium and endogenous fibrinolysis].Zeitschrift fur Kardiologie, , Volume: 89, Issue:3, 2000
Management of heart failure.Current cardiology reports, , Volume: 2, Issue:3, 2000
Identifying patients at risk for coronary heart disease: implications from trials of lipid-lowering drug therapy.QJM : monthly journal of the Association of Physicians, , Volume: 93, Issue:9, 2000
Hidden benefits of ACE inhibitors.Harvard heart letter : from Harvard Medical School, , Volume: 10, Issue:6, 2000
Randomized, placebo-controlled trial of the angiotensin-converting enzyme inhibitor, ramipril, in patients with coronary or other occlusive arterial disease. PART-2 Collaborative Research Group. Prevention of Atherosclerosis with Ramipril.Journal of the American College of Cardiology, , Volume: 36, Issue:2, 2000
ACE inhibition with ramipril improves left ventricular function at rest and post exercise in patients with stable ischaemic heart disease and preserved left ventricular systolic function.European heart journal, , Volume: 20, Issue:22, 1999
Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure:the effects of ramipril, nifedipine and moxonidine.Journal of the American Society of Nephrology : JASN, , Volume: 7, Issue:5, 1996
Effect of angiotensin converting enzyme inhibitors on cardiac noradrenaline release.European heart journal, , Volume: 12 Suppl F, 1991
[ACE inhibition: mechanisms of "cardioprotection" in acute myocardial ischemia].Klinische Wochenschrift, , Volume: 69 Suppl 24, 1991
[Are the radical scavenging properties of ACE inhibitors with sulfhydryl groups in therapeutically effective concentrations of quantitative significance?].Klinische Wochenschrift, , Volume: 69 Suppl 24, 1991
Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: relationship between cardiac ACE inhibition and cardioprotection.The Journal of pharmacology and experimental therapeutics, , Volume: 257, Issue:3, 1991
[Acute effects of the angiotensin converting enzyme inhibitor ramipril in patients with coronary heart disease].Medizinische Klinik (Munich, Germany : 1983), , Feb-15, Volume: 85, Issue:2, 1990
Local inhibition of bradykinin degradation in ischemic hearts.Journal of cardiovascular pharmacology, , Volume: 15 Suppl 6, 1990
Ramiprilat attenuates the local release of noradrenaline in the ischemic myocardium.European journal of pharmacology, , Jul-18, Volume: 166, Issue:2, 1989
[Pharmacologic modification of the converting enzyme--local and systemic effects on the heart and blood vessels].Zeitschrift fur Kardiologie, , Volume: 77 Suppl 3, 1988
Beneficial effects of the converting enzyme inhibitor, ramipril, in ischemic rat hearts.Journal of cardiovascular pharmacology, , Volume: 8 Suppl 10, 1986
Cardiovascular effects of the converting enzyme inhibitor ramipril (HOE 498) in anesthetized dogs with acute ischemic left ventricular failure.Clinical and experimental hypertension. Part A, Theory and practice, , Volume: 8, Issue:6, 1986
Urticarial vasculitis from simvastatin: what is the alternative drug?Dermatitis : contact, atopic, occupational, drug, , Volume: 21, Issue:4
Reduction of reperfusion arrhythmias in the ischemic isolated rat heart by angiotensin converting enzyme inhibitors: a comparison of captopril, enalapril, and HOE 498.Journal of cardiovascular pharmacology, , Volume: 8, Issue:4
Ileostomy and ramipril-induced acute renal failure and shock.Heart & lung : the journal of critical care, , Volume: 36, Issue:4
Long-term antiplatelet therapy with the polypill after stenting: More information is necessary.International journal of cardiology, , Mar-15, Volume: 207, 2016
[A 60-year-old man with heart failure, dry cough and elevated INR values].Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, , Aug-14, Volume: 128, Issue:15, 2008
Ramiprilate inhibits functional matrix metalloproteinase activity in Crohn's disease fistulas.Basic & clinical pharmacology & toxicology, , Volume: 109, Issue:3, 2011
Incidence, severity, and etiology of drug-induced acute pancreatitis.Digestive diseases and sciences, , Volume: 55, Issue:10, 2010
Dysglycemia and Cognitive Dysfunction and Ill Health in People With High CV Risk: Results From the ONTARGET/TRANSCEND Studies.The Journal of clinical endocrinology and metabolism, , Volume: 100, Issue:7, 2015
The mini-mental state examination, clinical factors, and motor vehicle crash risk.Journal of the American Geriatrics Society, , Volume: 62, Issue:8, 2014
Protection against stroke and dementia: an update on the latest clinical trial evidence.Current hypertension reports, , Volume: 6, Issue:4, 2004
[Evaluation of efficacy and safety of hypertension treatment with original angiotensin-converting enzyme inhibitors: the comparison of original and generic formulations].Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, , Volume: 34, Issue:201, 2013
[Fasciitis with eosinophilia: a possible causal role of angiotensin converting enzyme inhibitor].Revue neurologique, , Volume: 163, Issue:2, 2007
Lichenoid and granulomatous stomatitis: an entity or a non-specific inflammatory process?Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, , Volume: 35, Issue:5, 2006
Delayed diagnosis of angiotensin-converting enzyme (ACE) inhibitor induced angioedema and urticaria.Clinical and experimental dermatology, , Volume: 28, Issue:3, 2003
Stevens-Johnson Syndrome associated with ramipril.International journal of dermatology, , Volume: 42, Issue:7, 2003
Occupational UVA-induced allergic photodermatitis in a welder due to hydrochlorothiazide and ramipril.Contact dermatitis, , Volume: 43, Issue:4, 2000
Ramipril-induced superficial pemphigus.The British journal of dermatology, , Volume: 135, Issue:4, 1996
Ramipril-induced generalized pustular psoriasis: case report and literature review.American journal of therapeutics, , Volume: 17, Issue:1
Cutaneous vasculitis secondary to ramipril.Journal of drugs in dermatology : JDD, , Volume: 3, Issue:1
Ramipril-induced drug reaction with eosinophilia and systemic symptoms (DRESS).European journal of dermatology : EJD, , Volume: 21, Issue:4
The membrane-associated protein 17 (MAP17) is up-regulated in response to empagliflozin on top of RAS blockade in experimental diabetic nephropathy.Clinical science (London, England : 1979), , 01-13, Volume: 137, Issue:1, 2023
Inhibition of Lysine 63 Ubiquitination Prevents the Progression of Renal Fibrosis in Diabetic DBA/2J Mice.International journal of molecular sciences, , May-14, Volume: 22, Issue:10, 2021
Investigating the beneficial effect of aliskiren in attenuating neuropathic pain in diabetic Sprague-Dawley rats.Endocrinology, diabetes & metabolism, , Volume: 4, Issue:2, 2021
Effect of ramipril on kidney, lung and heart ACE2 in a diabetic mice model.Molecular and cellular endocrinology, , 06-01, Volume: 529, 2021
Lung and Kidney ACE2 and TMPRSS2 in Renin-Angiotensin System Blocker-Treated Comorbid Diabetic Mice Mimicking Host Factors That Have Been Linked to Severe COVID-19.Diabetes, , Volume: 70, Issue:3, 2021
Antidepressant effect in diabetes-associated depression: A novel potential of RAAS inhibition.Psychoneuroendocrinology, , Volume: 118, 2020
Ramipril and resveratrol co-treatment attenuates RhoA/ROCK pathway-regulated early-stage diabetic nephropathy-associated glomerulosclerosis in streptozotocin-induced diabetic rats.Environmental toxicology, , Volume: 34, Issue:7, 2019
RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.The Journal of physiology, , Volume: 597, Issue:1, 2019
Combination of ramipril and rutin alleviate alloxan induced diabetic nephropathy targeting multiple stress pathways in vivo.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 108, 2018
Apigenin ameliorates streptozotocin-induced diabetic nephropathy in rats via MAPK-NF-κB-TNF-α and TGF-β1-MAPK-fibronectin pathways.American journal of physiology. Renal physiology, , Aug-01, Volume: 313, Issue:2, 2017
Levosimendan suppresses oxidative injury, apoptotic signaling and mitochondrial degeneration in streptozotocin-induced diabetic cardiomyopathy.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 38, Issue:1, 2016
Naringin Reduces Hyperglycemia-Induced Cardiac Fibrosis by Relieving Oxidative Stress.PloS one, , Volume: 11, Issue:3, 2016
Type 2 diabetes-induced cardiovascular complications: comparative evaluation of spironolactone, atenolol, metoprolol, ramipril and perindopril.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 36, Issue:5, 2014
Ramipril protects the endothelium from high glucose-induced dysfunction through CaMKKβ/AMPK and heme oxygenase-1 activation.The Journal of pharmacology and experimental therapeutics, , Volume: 350, Issue:1, 2014
Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters.American journal of physiology. Renal physiology, , Volume: 299, Issue:6, 2010
Preservation of kidney function with combined inhibition of NADPH oxidase and angiotensin-converting enzyme in diabetic nephropathy.American journal of nephrology, , Volume: 32, Issue:1, 2010
Effect of ramipril alone compared to ramipril with eplerenone on diabetic nephropathy in streptozocin-induced diabetic rats.Pharmacology, , Volume: 86, Issue:2, 2010
[Study on ultrastructure of cardioprotection of ramipril against ischemia/reperfusion injury in diabetic rats].Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology, , Volume: 25, Issue:4, 2009
Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.Clinical science (London, England : 1979), , Oct-26, Volume: 118, Issue:3, 2009
Reduced cortical renal GLUT1 expression induced by angiotensin-converting enzyme inhibition in diabetic spontaneously hypertensive rats.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, , Volume: 41, Issue:11, 2008
[Effects of ramipril and simvastatin on the oxidative stress of diabetic rats].Arquivos brasileiros de endocrinologia e metabologia, , Volume: 52, Issue:7, 2008
Atrial natriuretic peptide prevents diabetes-induced endothelial dysfunction.Life sciences, , Apr-09, Volume: 82, Issue:15-16, 2008
Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy?Endocrinology, , Volume: 148, Issue:2, 2007
Vasopeptidase inhibition attenuates proteinuria and podocyte injury in Zucker diabetic fatty rats.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 375, Issue:2, 2007
Chronic endothelin-A receptor antagonism is as protective as angiotensin converting enzyme inhibition against cardiac dysfunction in diabetic rats.British journal of pharmacology, , Volume: 151, Issue:8, 2007
Role of angiotensin II in retinal leukostasis in the diabetic rat.Experimental eye research, , Volume: 83, Issue:5, 2006
Identification of angiotensin converting enzyme 2 in the rodent retina.Current eye research, , Volume: 29, Issue:6, 2004
Reduced tubular cation transport in diabetes: prevented by ACE inhibition.Kidney international, , Volume: 63, Issue:6, 2003
Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.International immunopharmacology, , Volume: 3, Issue:3, 2003
Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy.Hypertension (Dallas, Tex. : 1979), , Volume: 41, Issue:3, 2003
Ramipril prevents microtubular changes in proximal tubules from streptozotocin diabetic rats.Nephrology (Carlton, Vic.), , Volume: 8, Issue:4, 2003
Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy.Diabetes, , Volume: 51, Issue:11, 2002
Impaired angiotensin II regulation of renal C-type natriuretic peptide mRNA expression in experimental diabetes mellitus.Cardiovascular research, , Aug-15, Volume: 51, Issue:3, 2001
Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade.Diabetologia, , Volume: 44, Issue:7, 2001
Aminoguanidine and ramipril prevent diabetes-induced increases in protein kinase C activity in glomeruli, retina and mesenteric artery.Clinical science (London, England : 1979), , Volume: 100, Issue:3, 2001
Ramipril and aminoguanidine restore renal lysosomal processing in streptozotocin diabetic rats.Diabetologia, , Volume: 44, Issue:2, 2001
Prevention of albuminuria by aminoguanidine or ramipril in streptozotocin-induced diabetic rats is associated with the normalization of glomerular protein kinase C.Diabetes, , Volume: 49, Issue:1, 2000
The effect of urapidil and ramipril on hyperglycemia in streptozotocin diabetic rats.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 361, Issue:1, 2000
Angiotensin converting enzyme inhibition reduces retinal overexpression of vascular endothelial growth factor and hyperpermeability in experimental diabetes.Diabetologia, , Volume: 43, Issue:11, 2000
Upregulation of osteopontin expression in renal cortex of streptozotocin-induced diabetic rats is mediated by bradykinin.Diabetes, , Volume: 47, Issue:9, 1998
Angiotensin converting enzyme inhibition and calcium antagonism attenuate streptozotocin-diabetes-associated mesenteric vascular hypertrophy independently of their hypotensive action.Journal of hypertension, , Volume: 16, Issue:6, 1998
Angiotensin converting enzyme inhibition reduces the expression of transforming growth factor-beta1 and type IV collagen in diabetic vasculopathy.Journal of hypertension, , Volume: 16, Issue:11, 1998
Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition.Diabetes, , Volume: 47, Issue:3, 1998
Interactions of the kallikrein-kinin and renin-angiotensin systems in experimental diabetes.Diabetes, , Volume: 46, Issue:1, 1997
Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies.Diabetes, , Volume: 46, Issue:10, 1997
Effects of chronic ramipril treatment in streptozotocin-induced diabetic rats.Indian journal of physiology and pharmacology, , Volume: 41, Issue:4, 1997
[Bioenergetics of liver mitochondria after administration of ramipril in experimental diabetes mellitus].Bratislavske lekarske listy, , Volume: 98, Issue:12, 1997
Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade.American journal of hypertension, , Volume: 9, Issue:9, 1996
Acute renal hemodynamic effects of ACE inhibition in diabetic hyperfiltration: role of kinins.The American journal of physiology, , Volume: 268, Issue:4 Pt 2, 1995
Ramipril prevents hypersensitivity to phenylephrine in aorta from streptozotocin-induced diabetic rats.Diabetologia, , Volume: 37, Issue:7, 1994
Dose-response differences in the ability of ramipril to improve retention in diabetic mice.European journal of pharmacology, , Aug-24, Volume: 240, Issue:2-3, 1993
Salt blocks the renal benefits of ramipril in diabetic hypertensive rats.Hypertension (Dallas, Tex. : 1979), , Volume: 17, Issue:4, 1991
High salt diet ameliorates effects of angiotensin converting enzyme inhibition in spontaneously hypertensive streptozotocin diabetic rats.Clinical and experimental pharmacology & physiology, , Volume: 17, Issue:3, 1990
Ramipril reduces albuminuria in diabetic rats fed a high protein diet.Clinical and experimental pharmacology & physiology, , Volume: 16, Issue:8, 1989
Diabetic vascular hypertrophy and albuminuria: effect of angiotensin converting enzyme inhibition.Journal of diabetes and its complications, , Volume: 9, Issue:4
Apigenin ameliorates streptozotocin-induced diabetic nephropathy in rats via MAPK-NF-κB-TNF-α and TGF-β1-MAPK-fibronectin pathways.American journal of physiology. Renal physiology, , Aug-01, Volume: 313, Issue:2, 2017
A pilot study on the effect of telmisartan & ramipril on 24 h blood pressure profile & dipping pattern in type 1 diabetes patients with nephropathy.The Indian journal of medical research, , Volume: 134, Issue:5, 2011
Anti-albuminuric efficacy of a combination of angiotensin converting enzyme inhibitor & angiotensin receptor blocker in type 1 DM with nephropathy.The Indian journal of medical research, , Volume: 132, 2010
Atrial natriuretic peptide prevents diabetes-induced endothelial dysfunction.Life sciences, , Apr-09, Volume: 82, Issue:15-16, 2008
[Hypertension and diabetic nephropathy, a dangerous duo].Medizinische Klinik (Munich, Germany : 1983), , Nov-15, Volume: 100, Issue:11, 2005
Modulation of the renal response to ACE inhibition by ACE insertion/deletion polymorphism during hyperglycemia in normotensive, normoalbuminuric type 1 diabetic patients.Diabetes, , Volume: 54, Issue:10, 2005
Effects of ACE inhibition and AT1-receptor blockade on haemodynamic responses to L-arginine in Type 1 diabetes.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 5, Issue:1, 2004
[Chronopharmacological approaches to the therapeutic prophylaxis of chronic cardiac insufficiency in type I diabetes mellitus].Vestnik Rossiiskoi akademii meditsinskikh nauk, , Issue:4, 2003
Reduction of ACE activity is insufficient to decrease microalbuminuria in normotensive patients with type 1 diabetes.Diabetes care, , Volume: 24, Issue:5, 2001
[Prediction, screening and treatment of renal complications of diabetes].La Revue du praticien, , Oct-15, Volume: 51, Issue:16, 2001
Low-dose ramipril reduces microalbuminuria in type 1 diabetic patients without hypertension: results of a randomized controlled trial.Diabetes care, , Volume: 23, Issue:12, 2000
Studies examining risk reduction in subjects with multiple metabolic and cardiovascular risk factors.Current hypertension reports, , Volume: 2, Issue:2, 2000
[Best antihypotensive agents for the treatment of type 2 diabetes. Ramipril, the first choice, in combination with felodipin is a sensible treatment plan].Der Internist, , Volume: 40, Issue:7, 1999
Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 34, Issue:5, 1999
Influence of ramipril on the course of plasma thrombomodulin in patients with diabetes mellitus.VASA. Zeitschrift fur Gefasskrankheiten, , Volume: 28, Issue:3, 1999
Microcirculation in hyperglycemic patients with IDDM without diabetic complications--effect of low-dose angiotensin-converting enzyme inhibition.Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, , Volume: 106, Issue:1, 1998
Short-term treatment with ramipril normalizes renal haemodynamics and the natriuretic response to a sodium load in type 1 diabetic patients with early nephropathy.Acta diabetologica, , Volume: 34, Issue:1, 1997
EUCLID study.Lancet (London, England), , Oct-11, Volume: 350, Issue:9084, 1997
Reversible hyperkalemia at the initiation of ACE inhibitors in a young diabetic patient with latent hyporeninemic hypoaldosteronism.Diabetes care, , Volume: 19, Issue:7, 1996
Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes PrevenDiabetes care, , Volume: 19, Issue:11, 1996
The study of the effect of intensity of blood pressure management on the progression of type 1 diabetic nephropathy: study design and baseline patient characteristics. Collaborative Study Group.Journal of the American Society of Nephrology : JASN, , Volume: 5, Issue:10, 1995
Small doses of ramipril to reduce microalbuminuria in diabetic patients with incipient nephropathy independently of blood pressure changes.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
[Dissociation of hypotensive and renal hemodynamic effects of an angiotensin converting enzyme inhibitor in insulin-dependent diabetic patients with incipient nephropathy].Archives des maladies du coeur et des vaisseaux, , Volume: 84, Issue:3, 1991
The effect of ramipril therapy on cytokines and parameters of incipient diabetic nephropathy in patients with type 1 diabetes mellitus.The Journal of international medical research, , Volume: 35, Issue:3
Double-blind, placebo-controlled study of ramipril in diabetics with mild to moderate hypertension.Clinical therapeutics, , Volume: 15, Issue:1
Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3-/- Mice.Journal of the American Society of Nephrology : JASN, , 09-01, Volume: 34, Issue:9, 2023
Enhanced Cardiorenal Protective Effects of Combining SGLT2 Inhibition, Endothelin Receptor Antagonism and RAS Blockade in Type 2 Diabetic Mice.International journal of molecular sciences, , Oct-24, Volume: 23, Issue:21, 2022
DPP4 (Dipeptidyl Peptidase-4) Inhibition Increases Catecholamines Without Increasing Blood Pressure During Sustained ACE (Angiotensin-Converting Enzyme) Inhibitor Treatment.Hypertension (Dallas, Tex. : 1979), , Volume: 79, Issue:4, 2022
A Prospective Single-Blind Randomized Trial of Ramipril, Eplerenone and Their Combination in Type 2 Diabetic Nephropathy.Cardiorenal medicine, , Volume: 10, Issue:6, 2020
Does diabetes prevention translate into reduced long-term vascular complications of diabetes?Diabetologia, , Volume: 62, Issue:8, 2019
Benefits of Fixed Dose Combination of Ramipril/Amlodipine in Hypertensive Diabetic Patients: A Subgroup Analysis of RAMONA Trial.Chinese medical journal, , May-20, Volume: 129, Issue:10, 2016
Target Blood Pressure in Patients with Diabetes: Asian Perspective.Yonsei medical journal, , Volume: 57, Issue:6, 2016
Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 16, Issue:4, 2015
[The role of ramipril in the therapy of diabetic nephropathy].Orvosi hetilap, , Feb-16, Volume: 155, Issue:7, 2014
Type 2 diabetes-induced cardiovascular complications: comparative evaluation of spironolactone, atenolol, metoprolol, ramipril and perindopril.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 36, Issue:5, 2014
Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy.American journal of nephrology, , Volume: 40, Issue:3, 2014
Recent clinical trials.Journal of the American Society of Hypertension : JASH, , Volume: 8, Issue:10, 2014
Effects of a long-term treatment with aliskiren or ramipril on structural alterations of subcutaneous small-resistance arteries of diabetic hypertensive patients.Hypertension (Dallas, Tex. : 1979), , Volume: 64, Issue:4, 2014
Acute regulation of pancreatic islet microcirculation and glycaemia by telmisartan and ramipril: discordant effects between normal and type 2 diabetic rats.Clinical science (London, England : 1979), , Volume: 125, Issue:9, 2013
Moving dietary management of diabetes forward.JAMA internal medicine, , Oct-14, Volume: 173, Issue:18, 2013
Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria.Expert opinion on pharmacotherapy, , Volume: 14, Issue:4, 2013
Diet and kidney disease in high-risk individuals with type 2 diabetes mellitus.JAMA internal medicine, , Oct-14, Volume: 173, Issue:18, 2013
Effect of imidapril versus ramipril on urinary albumin excretion in hypertensive patients with type 2 diabetes and microalbuminuria.Expert opinion on pharmacotherapy, , Volume: 14, Issue:18, 2013
Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes.Diabetologia, , Volume: 55, Issue:5, 2012
Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study.Cardiovascular diabetology, , Jan-09, Volume: 11, 2012
Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy.Expert opinion on pharmacotherapy, , Volume: 13, Issue:8, 2012
Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).Journal of the American College of Cardiology, , Jan-03, Volume: 59, Issue:1, 2012
Incidence of diabetes following ramipril or rosiglitazone withdrawal.Diabetes care, , Volume: 34, Issue:6, 2011
Angiotensin converting enzyme inhibitor or angiotensin II receptor blocker for the prevention of type 2 diabetes mellitus?Diabetes research and clinical practice, , Volume: 90, Issue:2, 2010
Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.Diabetic medicine : a journal of the British Diabetic Association, , Volume: 27, Issue:11, 2010
Effect of Rosiglitazone and Ramipril on {beta}-cell function in people with impaired glucose tolerance or impaired fasting glucose: the DREAM trial.Diabetes care, , Volume: 33, Issue:3, 2010
Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.Diabetes care, , Volume: 33, Issue:10, 2010
Role of renin-angiotensin system blockade in patients with diabetes mellitus.The American journal of cardiology, , Sep-15, Volume: 104, Issue:6, 2009
Normal pregnancy and healthy child after continued exposure to gliclazide and ramipril during pregnancy.The Annals of pharmacotherapy, , Volume: 43, Issue:1, 2009
[The study of effects of ramipril and amlodipine combination in patients with arterial hypertension and type 2 diabetes mellitus].Kardiologiia, , Volume: 49, Issue:5, 2009
Renal vascular endothelial function in hypertensive patients with type 2 diabetes mellitus.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 53, Issue:2, 2009
Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria.Clinical journal of the American Society of Nephrology : CJASN, , Volume: 4, Issue:3, 2009
Effects of telmisartan and ramipril on adiponectin and blood pressure in patients with type 2 diabetes.American journal of hypertension, , Volume: 21, Issue:12, 2008
[The effectiveness in type 2 diabetes prevention: a forced landing to reality].Medicina clinica, , Mar-08, Volume: 130, Issue:8, 2008
Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular events, and Ramipril (DIABHYCAR), Diabete dDiabetes care, , Volume: 31, Issue:10, 2008
First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation.Cardiovascular diabetology, , Jul-24, Volume: 7, 2008
Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms.Diabetes care, , Volume: 31, Issue:1, 2008
Dysglycemia and a history of reproductive risk factors.Diabetes care, , Volume: 31, Issue:8, 2008
The ADVANCE trial.Lancet (London, England), , Jan-05, Volume: 371, Issue:9606, 2008
The common -866G>A variant in the promoter of UCP2 is associated with decreased risk of coronary artery disease in type 2 diabetic men.Diabetes, , Volume: 57, Issue:4, 2008
[Parameters of vasomotor function of endothelium and elasticity of arterial wall during therapy with angiotensin converting enzyme inhibitor ramiprilin patients with type 2 diabetes mellitus].Kardiologiia, , Volume: 48, Issue:11, 2008
Ramipril improves oxidative stress-related vascular endothelial dysfunction in db/db mice.The journal of physiological sciences : JPS, , Volume: 58, Issue:6, 2008
[Acute renal insufficiency after flurbiprofen treatment in a patient treated with angiotensin converting enzyme inhibitor].La Revue de medecine interne, , Volume: 29, Issue:7, 2008
Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1+2 in patients with type 2 diabetes.Atherosclerosis, , Volume: 194, Issue:1, 2007
Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled study.European journal of clinical pharmacology, , Volume: 63, Issue:8, 2007
Estimating the cost effectiveness of ramipril used for specific clinical indications: comparing the outcomes in four clinical trials with a common economic model.American journal of cardiovascular drugs : drugs, devices, and other interventions, , Volume: 7, Issue:6, 2007
Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes.Diabetes care, , Volume: 30, Issue:6, 2007
The therapeutic effects of angiotensin-converting enzyme inhibitors in severe non-proliferative diabetic retinopathy.Korean journal of ophthalmology : KJO, , Volume: 21, Issue:1, 2007
DREAM and ADOPT: rosiglitazone does what it says on the packet.Diabetic medicine : a journal of the British Diabetic Association, , Volume: 24, Issue:2, 2007
Diabetes prevention: still no effective drugs.Prescrire international, , Volume: 16, Issue:92, 2007
Beneficial effects of ramipril on myocardial diastolic function in patients with type 2 diabetes mellitus, normal LV systolic function and without coronary artery disease: a prospective study using tissue Doppler.Diabetes & vascular disease research, , Volume: 4, Issue:4, 2007
[Three studies in type 2 diabetes: DREAM the wash-out results].Annales d'endocrinologie, , Volume: 68 Suppl 1, 2007
Trials that matter: rosiglitazone, ramipril, and the prevention of type 2 diabetes.Annals of internal medicine, , Mar-20, Volume: 146, Issue:6, 2007
[Influence of diabetes incidence by ramipril and rosiglitazone: DREAM study (diabetes reduction assessment with ramipril and rosiglitazone medication)].Der Internist, , Volume: 48, Issue:10, 2007
Diabetes prevention between RAAS inhibition and PPAR-gamma stimulation: the diabetes reduction assessment with ramipril and rosiglitazone medication (DREAM) trial.Journal of the cardiometabolic syndrome, ,Spring, Volume: 2, Issue:2, 2007
Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 21, Issue:3, 2006
Urinary TGF-beta1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy.Diabetes research and clinical practice, , Volume: 72, Issue:3, 2006
Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease.Archives of internal medicine, , Apr-10, Volume: 166, Issue:7, 2006
[DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease].Revue medicale de Liege, , Volume: 61, Issue:10, 2006
[Effects and mechanism of ShenQi compound recipe on inflammation maker in GK rats].Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials, , Volume: 29, Issue:3, 2006
[In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension].MMW Fortschritte der Medizin, , Jun-29, Volume: 148, Issue:26, 2006
[Experiences of the DREAM trial].Orvosi hetilap, , Dec-31, Volume: 147, Issue:52, 2006
[Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].Italian heart journal : official journal of the Italian Federation of Cardiology, , Volume: 6 Suppl 7, 2005
Ramipril in the treatment of vascular diseases.Expert opinion on pharmacotherapy, , Volume: 6, Issue:11, 2005
[Effects of angiotensin receptor blocker and angiotensin-coverting enzyme inhibitor on vascular endothelial function in type 2 diabetic patients with atherosclerosis: a comparative study].Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA, , Volume: 25, Issue:8, 2005
Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes.Hypertension (Dallas, Tex. : 1979), , Volume: 45, Issue:6, 2005
Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition.Diabetologia, , Volume: 48, Issue:8, 2005
[Association between angiotensin converting enzyme I/D polymorphism and high-sensitivity C-reactive protein in type 2 diabetic patients with atherosclerosis treated with ramipril].Di 1 jun yi da xue xue bao = Academic journal of the first medical college of PLA, , Volume: 25, Issue:6, 2005
[Hypertension and diabetic nephropathy, a dangerous duo].Medizinische Klinik (Munich, Germany : 1983), , Nov-15, Volume: 100, Issue:11, 2005
Comparison of the effects of ramipril versus telmisartan in reducing serum levels of high-sensitivity C-reactive protein and oxidized low-density lipoprotein cholesterol in patients with type 2 diabetes mellitus.The American journal of cardiology, , Jun-01, Volume: 95, Issue:11, 2005
Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats.Biochemical and biophysical research communications, , Mar-26, Volume: 316, Issue:1, 2004
Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).BMJ (Clinical research ed.), , Feb-28, Volume: 328, Issue:7438, 2004
Losartan-ramipril combination treatment.The Journal of the Association of Physicians of India, , Volume: 52, 2004
Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme.Expert opinion on pharmacotherapy, , Volume: 5, Issue:5, 2004
The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy.Journal of clinical hypertension (Greenwich, Conn.), , Volume: 6, Issue:8, 2004
Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina).Diabetes, nutrition & metabolism, , Volume: 17, Issue:5, 2004
Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty rats.Cardiovascular research, , Nov-01, Volume: 60, Issue:2, 2003
[Corner points of antihypertensive therapy in prediabetic state. Success with a combination].MMW Fortschritte der Medizin, , Jul-10, Volume: 145, Issue:27-28, 2003
Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 42, Issue:5, 2003
Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease.Archives of biochemistry and biophysics, , Nov-01, Volume: 419, Issue:1, 2003
More than just hype.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , Jun-24, Volume: 168, Issue:13, 2003
Long-term treatment with ramipril attenuates renal osteopontin expression in diabetic rats.Kidney international, , Volume: 63, Issue:2, 2003
Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study.Diabetes care, , Volume: 26, Issue:3, 2003
[Dangerous duo: hypertension and pre-diabetes--the underestimated risk].MMW Fortschritte der Medizin, , Jan-23, Volume: 145, Issue:3-4, 2003
[Primary prevention of diabetes mellitus by pharmacological intervention].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 60 Suppl 9, 2002
[ACE inhibitors for diabetic patients. passed the test on the heart and kidneys].MMW Fortschritte der Medizin, , Oct-31, Volume: 144, Issue:44, 2002
[Therapy of hypertension with ACE inhibitors. One third fewer cases of diabetes].MMW Fortschritte der Medizin, , Mar-07, Volume: 144, Issue:10, 2002
Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes.The Medical journal of Australia, , Mar-18, Volume: 176, Issue:6, 2002
HOPE for patients with Type 2 diabetes: an application of the findings of the MICRO-HOPE substudy in a British hospital diabetes clinic.Diabetic medicine : a journal of the British Diabetic Association, , Volume: 18, Issue:8, 2001
[Diabetic nephropathy. Smoking also damages the kidney].MMW Fortschritte der Medizin, , Aug-23, Volume: 143, Issue:33-34, 2001
[Prediction, screening and treatment of renal complications of diabetes].La Revue du praticien, , Oct-15, Volume: 51, Issue:16, 2001
[Type 2 diabetes and cardiovascular risk: lessons from therapeutic trials].La Revue du praticien, , Oct-15, Volume: 51, Issue:16, 2001
The non-insulin-dependent diabetes, hypertension, microalbuminuria or proteinuria, cardiovascular events, and ramipril (DIABHYCAR) study: design, organization, and patient recruitment. DIABHYCAR Study Group.Controlled clinical trials, , Volume: 21, Issue:4, 2000
HOPE for all people with diabetes? Heart Outcomes Prevention Evaluation.Diabetic medicine : a journal of the British Diabetic Association, , Volume: 17 Suppl 2, 2000
[Endothelium and endogenous fibrinolysis].Zeitschrift fur Kardiologie, , Volume: 89, Issue:3, 2000
ACE inhibitors: new hope for old drugs?South Dakota journal of medicine, , Volume: 53, Issue:8, 2000
Effect of ramipril on cardiovascular events in high-risk patients.The New England journal of medicine, , Jul-06, Volume: 343, Issue:1, 2000
Determinants of elevated urinary albumin in the 4,937 type 2 diabetic subjects recruited for the DIABHYCAR Study in Western Europe and North Africa.Diabetes care, , Volume: 23 Suppl 2, 2000
The HOPE study and diabetes. Heart Outcomes Prevention Evaluation.Lancet (London, England), , Apr-01, Volume: 355, Issue:9210, 2000
[ACE inhibitor even prevents diabetes. Sensational HOPE Study].MMW Fortschritte der Medizin, , Sep-30, Volume: 141, Issue:39, 1999
[Best antihypotensive agents for the treatment of type 2 diabetes. Ramipril, the first choice, in combination with felodipin is a sensible treatment plan].Der Internist, , Volume: 40, Issue:7, 1999
Influence of ramipril on the course of plasma thrombomodulin in patients with diabetes mellitus.VASA. Zeitschrift fur Gefasskrankheiten, , Volume: 28, Issue:3, 1999
Beneficial impact of ramipril on left ventricular hypertrophy in normotensive nonalbuminuric NIDDM patients.Diabetes care, , Volume: 22, Issue:1, 1999
Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function.Journal of human hypertension, , Volume: 13, Issue:1, 1999
Beneficial impact of ramipril on left ventricular hypertrophy in normotensive nonalbuminuric NIDDM patients.Diabetes care, , Volume: 21, Issue:5, 1998
Impediment of the progressions of microalbuminuria and hyperlipidemia in normotensive type 2 diabetes by low-dose ramipril.Journal of the Medical Association of Thailand = Chotmaihet thangphaet, , Volume: 81, Issue:9, 1998
[The effect of ramipril on metabolic, renal and cardiac function in hypertension and type II diabetes mellitus].Vnitrni lekarstvi, , Volume: 44, Issue:6, 1998
Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria.Diabetologia, , Volume: 39, Issue:12, 1996
Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes PrevenDiabetes care, , Volume: 19, Issue:11, 1996
The DIAB-HYCAR Study.Diabetologia, , Volume: 39, Issue:12, 1996
Comparative effects of ramipril and nitrendipine on albuminuria in hypertensive patients with non-insulin-dependent diabetes mellitus and impaired renal function.Journal of human hypertension, , Volume: 9, Issue:2, 1995
Comparison of ramipril and nitrendipine.Journal of human hypertension, , Volume: 9, Issue:11, 1995
Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group.American journal of hypertension, , Volume: 8, Issue:9, 1995
[The nephroprotective effect of ramipril. Effect on blood pressure and metabolic control in insulin-treated patients with type-2 diabetes mellitus].Fortschritte der Medizin, , Jan-30, Volume: 112, Issue:3, 1994
Metabolic effects of ramipril treatment in hypertensive subjects with non-insulin-dependent diabetes mellitus.Arzneimittel-Forschung, , Volume: 40, Issue:4, 1990
[Inappropriate antidiuretic hormone secretion syndrome associated with ramipril treatment].Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, , Volume: 34, Issue:3
Double-blind, placebo-controlled study of ramipril in diabetics with mild to moderate hypertension.Clinical therapeutics, , Volume: 15, Issue:1
[Clinical effectiveness of metformin and ramipril combination in complex therapy of patients with metabolic syndrome].Likars'ka sprava, , Issue:1
[Efficacy of complex therapy with metformin and ramipril combination for patients with metabolic syndrome].Likars'ka sprava, , Issue:7-8
[The metabolic effects of isradipine, ramipril, Ednit and beta-adrenoblockers in patients with non-insulin-dependent diabetes mellitus and arterial hypertension].Eksperimental'naia i klinicheskaia farmakologiia, , Volume: 62, Issue:2
Projecting the potential cost-effectiveness of dapagliflozin for chronic kidney disease in Kuwait.Journal of medical economics, , Volume: 26, Issue:1
Aliskiren versus ramipril in hypertension.Therapeutic advances in cardiovascular disease, , Volume: 4, Issue:3, 2010
Glucose intolerance and diabetes as risk factors for cognitive impairment in people at high cardiovascular risk: results from the ONTARGET/TRANSCEND research programme.Diabetes research and clinical practice, , Volume: 83, Issue:3, 2009
Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms.Diabetes care, , Volume: 31, Issue:1, 2008
Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes.Current atherosclerosis reports, , Volume: 10, Issue:2, 2008
Atrial natriuretic peptide prevents diabetes-induced endothelial dysfunction.Life sciences, , Apr-09, Volume: 82, Issue:15-16, 2008
The common -866G>A variant in the promoter of UCP2 is associated with decreased risk of coronary artery disease in type 2 diabetic men.Diabetes, , Volume: 57, Issue:4, 2008
Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular events, and Ramipril (DIABHYCAR), Diabete dDiabetes care, , Volume: 31, Issue:10, 2008
Ramipril improves oxidative stress-related vascular endothelial dysfunction in db/db mice.The journal of physiological sciences : JPS, , Volume: 58, Issue:6, 2008
Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes.Diabetes care, , Volume: 30, Issue:6, 2007
Effect of rosiglitazone/ramipril on preclinical vasculopathy in newly diagnosed, untreated diabetes and IGT patients: 1-year randomised, double-blind, placebo-controlled study.European journal of clinical pharmacology, , Volume: 63, Issue:8, 2007
The question of whether diabetes and its cardiovascular risks can be prevented: a realistic DREAM?Blood pressure, , Volume: 15, Issue:5, 2006
The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non-diabetic participants in the HOPE study: a prospective epidemiological analysis.Diabetologia, , Volume: 48, Issue:9, 2005
Evaluation of efficacy and tolerability of Losartan and Ramipril combination in the management of hypertensive patients with associated diabetes mellitus in India (LORD Trial).The Journal of the Association of Physicians of India, , Volume: 52, 2004
Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.Diabetologia, , Volume: 47, Issue:9, 2004
Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).BMJ (Clinical research ed.), , Feb-28, Volume: 328, Issue:7438, 2004
Cost-effectiveness of ramipril in patients at high risk for cardiovascular events: a Swiss perspective.Swiss medical weekly, , Jul-10, Volume: 134, Issue:27-28, 2004
[Dangerous duo: hypertension and pre-diabetes--the underestimated risk].MMW Fortschritte der Medizin, , Jan-23, Volume: 145, Issue:3-4, 2003
Use of angiotensin-converting enzyme inhibitors after coronary artery bypass grafting in patients with diabetes mellitus.The American journal of cardiology, , Jul-01, Volume: 92, Issue:1, 2003
Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease.Archives of biochemistry and biophysics, , Nov-01, Volume: 419, Issue:1, 2003
[Standpoint on the use of angiotensin receptor blockers in the treatment of hypertension].Harefuah, , Volume: 142, Issue:4, 2003
Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.The Canadian journal of cardiology, , Volume: 18 Suppl A, 2002
Diabetes and the HOPE study: implications for macrovascular and microvascular disease.International journal of clinical practice. Supplement, , Issue:117, 2001
Why were the results of the Heart Outcomes Prevention Evaluation (HOPE) trial so astounding?The Canadian journal of cardiology, , Volume: 17 Suppl A, 2001
[Atherosclerosis. High dosage ACE inhibitor keeps event rate under control].MMW Fortschritte der Medizin, , Mar-29, Volume: 143, Issue:13, 2001
The renin angiotensin system and cardiovascular disease: hope or hype?Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 1, Issue:2, 2000
The HOPE study and diabetes. Heart Outcomes Prevention Evaluation.Lancet (London, England), , Apr-01, Volume: 355, Issue:9210, 2000
HOPE for all people with diabetes? Heart Outcomes Prevention Evaluation.Diabetic medicine : a journal of the British Diabetic Association, , Volume: 17 Suppl 2, 2000
The HOPE Study (Heart Outcomes Prevention Evaluation).Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 1, Issue:1, 2000
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.Lancet (London, England), , Jan-22, Volume: 355, Issue:9200, 2000
Angiotensin converting enzyme inhibition reduces the expression of transforming growth factor-beta1 and type IV collagen in diabetic vasculopathy.Journal of hypertension, , Volume: 16, Issue:11, 1998
Microcirculation in hyperglycemic patients with IDDM without diabetic complications--effect of low-dose angiotensin-converting enzyme inhibition.Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, , Volume: 106, Issue:1, 1998
Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes PrevenDiabetes care, , Volume: 19, Issue:11, 1996
Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE.Diabetes/metabolism research and reviews, , Volume: 18 Suppl 3
[Ramipril and new therapeutic possibilities for ACE-inhibitors].La Clinica terapeutica, , Volume: 151, Issue:4
Clinical and economic benefits of ramipril: an Australian analysis of the HOPE study.Internal medicine journal, , Volume: 33, Issue:9-10
Achieving blood preSsure goals sTudy in uncontrolled hypeRtensive pAtients treated with a fixed-dose combination of ramipriL/hydrochlorothiazide: the ASTRAL study.Cardiovascular journal of Africa, , Volume: 22, Issue:2
The membrane-associated protein 17 (MAP17) is up-regulated in response to empagliflozin on top of RAS blockade in experimental diabetic nephropathy.Clinical science (London, England : 1979), , 01-13, Volume: 137, Issue:1, 2023
Inhibition of Lysine 63 Ubiquitination Prevents the Progression of Renal Fibrosis in Diabetic DBA/2J Mice.International journal of molecular sciences, , May-14, Volume: 22, Issue:10, 2021
A Prospective Single-Blind Randomized Trial of Ramipril, Eplerenone and Their Combination in Type 2 Diabetic Nephropathy.Cardiorenal medicine, , Volume: 10, Issue:6, 2020
RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.The Journal of physiology, , Volume: 597, Issue:1, 2019
Ramipril can alleviate the accumulation of renal mesangial matrix in rats with diabetic nephropathy by inhibiting insulin-like growth factor-1.Acta cirurgica brasileira, , 02-14, Volume: 34, Issue:1, 2019
Ramipril and resveratrol co-treatment attenuates RhoA/ROCK pathway-regulated early-stage diabetic nephropathy-associated glomerulosclerosis in streptozotocin-induced diabetic rats.Environmental toxicology, , Volume: 34, Issue:7, 2019
Combination of ramipril and rutin alleviate alloxan induced diabetic nephropathy targeting multiple stress pathways in vivo.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, , Volume: 108, 2018
The superoxide dismutase mimetic tempol blunts diabetes-induced upregulation of NADPH oxidase and endoplasmic reticulum stress in a rat model of diabetic nephropathy.European journal of pharmacology, , Jul-15, Volume: 807, 2017
Apigenin ameliorates streptozotocin-induced diabetic nephropathy in rats via MAPK-NF-κB-TNF-α and TGF-β1-MAPK-fibronectin pathways.American journal of physiology. Renal physiology, , Aug-01, Volume: 313, Issue:2, 2017
Targeted mitochondrial therapy using MitoQ shows equivalent renoprotection to angiotensin converting enzyme inhibition but no combined synergy in diabetes.Scientific reports, , 11-09, Volume: 7, Issue:1, 2017
Discovery and Preclinical Characterization of 6-Chloro-5-[4-(1-hydroxycyclobutyl)phenyl]-1H-indole-3-carboxylic Acid (PF-06409577), a Direct Activator of Adenosine Monophosphate-activated Protein Kinase (AMPK), for the Potential Treatment of Diabetic NephJournal of medicinal chemistry, , 09-08, Volume: 59, Issue:17, 2016
[The role of ramipril in the therapy of diabetic nephropathy].Orvosi hetilap, , Feb-16, Volume: 155, Issue:7, 2014
Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy.American journal of nephrology, , Volume: 40, Issue:3, 2014
Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects.American journal of physiology. Renal physiology, , Mar-15, Volume: 304, Issue:6, 2013
Renal antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.American journal of nephrology, , Volume: 37, Issue:1, 2013
A pilot study on the effect of telmisartan & ramipril on 24 h blood pressure profile & dipping pattern in type 1 diabetes patients with nephropathy.The Indian journal of medical research, , Volume: 134, Issue:5, 2011
Reduced proteinuria using ramipril in diabetic CKD stage 1 decreases circulating cell death receptor activators concurrently with ADMA. A novel pathophysiological pathway?Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 25, Issue:10, 2010
Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy.Nephrology (Carlton, Vic.), , Volume: 15, Issue:2, 2010
Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease.Current diabetes reports, , Volume: 10, Issue:4, 2010
Preservation of kidney function with combined inhibition of NADPH oxidase and angiotensin-converting enzyme in diabetic nephropathy.American journal of nephrology, , Volume: 32, Issue:1, 2010
Effect of ramipril alone compared to ramipril with eplerenone on diabetic nephropathy in streptozocin-induced diabetic rats.Pharmacology, , Volume: 86, Issue:2, 2010
Anti-albuminuric efficacy of a combination of angiotensin converting enzyme inhibitor & angiotensin receptor blocker in type 1 DM with nephropathy.The Indian journal of medical research, , Volume: 132, 2010
Inhibition of chymase protects against diabetes-induced oxidative stress and renal dysfunction in hamsters.American journal of physiology. Renal physiology, , Volume: 299, Issue:6, 2010
Renal protection in diabetes: lessons from ONTARGET.Cardiovascular diabetology, , Oct-01, Volume: 9, 2010
Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria.Clinical journal of the American Society of Nephrology : CJASN, , Volume: 4, Issue:3, 2009
Inhibition of renin angiotensin system decreases renal protein oxidative damage in diabetic rats.Biochemical and biophysical research communications, , Apr-11, Volume: 368, Issue:3, 2008
Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular events, and Ramipril (DIABHYCAR), Diabete dDiabetes care, , Volume: 31, Issue:10, 2008
Urinary TGF-beta1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy.Diabetes research and clinical practice, , Volume: 72, Issue:3, 2006
Effect of low-dose dual blockade of renin-angiotensin system on urinary TGF-beta in type 2 diabetic patients with advanced kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 21, Issue:3, 2006
Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease.Archives of internal medicine, , Apr-10, Volume: 166, Issue:7, 2006
An update of irbesartan and renin-angiotensin system blockade in diabetic nephropathy.Expert opinion on pharmacotherapy, , Volume: 6, Issue:9, 2005
Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition.Diabetologia, , Volume: 48, Issue:8, 2005
Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy.Journal of the American Society of Nephrology : JASN, , Volume: 16, Issue:8, 2005
[Hypertension and diabetic nephropathy, a dangerous duo].Medizinische Klinik (Munich, Germany : 1983), , Nov-15, Volume: 100, Issue:11, 2005
Effects of low dose ramipril on cardiovascular and renal outcomes in patients with type 2 diabetes and raised excretion of urinary albumin: randomised, double blind, placebo controlled trial (the DIABHYCAR study).BMJ (Clinical research ed.), , Feb-28, Volume: 328, Issue:7438, 2004
Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina).Diabetes, nutrition & metabolism, , Volume: 17, Issue:5, 2004
The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.Clinical nephrology, , Volume: 60, Issue:5, 2003
Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.International immunopharmacology, , Volume: 3, Issue:3, 2003
Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products.Journal of human hypertension, , Volume: 17, Issue:4, 2003
Ramipril prevents microtubular changes in proximal tubules from streptozotocin diabetic rats.Nephrology (Carlton, Vic.), , Volume: 8, Issue:4, 2003
Reduced tubular cation transport in diabetes: prevented by ACE inhibition.Kidney international, , Volume: 63, Issue:6, 2003
Development of renal disease in people at high cardiovascular risk: results of the HOPE randomized study.Journal of the American Society of Nephrology : JASN, , Volume: 14, Issue:3, 2003
[Hypertension and prediabetes. "Don't trust anybody over 130/80"].MMW Fortschritte der Medizin, , Mar-27, Volume: 145, Issue:13, 2003
Evolving concepts in advanced glycation, diabetic nephropathy, and diabetic vascular disease.Archives of biochemistry and biophysics, , Nov-01, Volume: 419, Issue:1, 2003
Progression of renal insufficiency in type 2 diabetes with and without microalbuminuria: results of the Heart Outcomes and Prevention Evaluation (HOPE) randomized study.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 42, Issue:5, 2003
Long-term treatment with ramipril attenuates renal osteopontin expression in diabetic rats.Kidney international, , Volume: 63, Issue:2, 2003
Characterization of renal angiotensin-converting enzyme 2 in diabetic nephropathy.Hypertension (Dallas, Tex. : 1979), , Volume: 41, Issue:3, 2003
Vasopeptidase inhibition prevents nephropathy in Zucker diabetic fatty rats.Cardiovascular research, , Nov-01, Volume: 60, Issue:2, 2003
Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy.Diabetes, , Volume: 51, Issue:11, 2002
Angiotensin blockade in type 2 diabetes: what the new evidence tells us about renal and cardiac complications.The Canadian journal of cardiology, , Volume: 18 Suppl A, 2002
Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes.The Medical journal of Australia, , Mar-18, Volume: 176, Issue:6, 2002
Using ACE inhibitors appropriately.American family physician, , Aug-01, Volume: 66, Issue:3, 2002
[Prediction, screening and treatment of renal complications of diabetes].La Revue du praticien, , Oct-15, Volume: 51, Issue:16, 2001
Diabetes and the HOPE study: implications for macrovascular and microvascular disease.International journal of clinical practice. Supplement, , Issue:117, 2001
Prevention, protection, and the intrarenal renin-angiotensin systems.Seminars in nephrology, , Volume: 21, Issue:6, 2001
[Diabetic nephropathy. Smoking also damages the kidney].MMW Fortschritte der Medizin, , Aug-23, Volume: 143, Issue:33-34, 2001
Ramipril and aminoguanidine restore renal lysosomal processing in streptozotocin diabetic rats.Diabetologia, , Volume: 44, Issue:2, 2001
HOPE for all people with diabetes? Heart Outcomes Prevention Evaluation.Diabetic medicine : a journal of the British Diabetic Association, , Volume: 17 Suppl 2, 2000
Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 35, Issue:6, 2000
The HOPE study and diabetes. Heart Outcomes Prevention Evaluation.Lancet (London, England), , Apr-01, Volume: 355, Issue:9210, 2000
The HOPE study and diabetes. Heart Outcomes Prevention Evaluation.Lancet (London, England), , Apr-01, Volume: 355, Issue:9210, 2000
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.Lancet (London, England), , Jan-22, Volume: 355, Issue:9200, 2000
HOPE and extension of the indications for ACE inhibitors? Heart Outcomes Prevention Evaluation.Lancet (London, England), , Jan-22, Volume: 355, Issue:9200, 2000
Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 34, Issue:5, 1999
Influence of ramipril on the course of plasma thrombomodulin in patients with diabetes mellitus.VASA. Zeitschrift fur Gefasskrankheiten, , Volume: 28, Issue:3, 1999
Upregulation of osteopontin expression in renal cortex of streptozotocin-induced diabetic rats is mediated by bradykinin.Diabetes, , Volume: 47, Issue:9, 1998
Expression of transforming growth factor-beta1 and type IV collagen in the renal tubulointerstitium in experimental diabetes: effects of ACE inhibition.Diabetes, , Volume: 47, Issue:3, 1998
Role of angiotensin II and bradykinin in experimental diabetic nephropathy. Functional and structural studies.Diabetes, , Volume: 46, Issue:10, 1997
Stabilization of glomerular filtration rate over 2 years in patients with diabetic nephropathy under intensified therapy regimens. Diabetes Treatment and Teaching Programmes Working Group.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 12, Issue:9, 1997
Short-term treatment with ramipril normalizes renal haemodynamics and the natriuretic response to a sodium load in type 1 diabetic patients with early nephropathy.Acta diabetologica, , Volume: 34, Issue:1, 1997
EUCLID study.Lancet (London, England), , Oct-11, Volume: 350, Issue:9084, 1997
[The effectiveness of ramipril in the treatment of diabetic nephropathy in normotensive children and adolescents].Klinicheskaia meditsina, , Volume: 75, Issue:12, 1997
The DIAB-HYCAR Study.Diabetologia, , Volume: 39, Issue:12, 1996
Renal and metabolic effects of 1-year treatment with ramipril or atenolol in NIDDM patients with microalbuminuria.Diabetologia, , Volume: 39, Issue:12, 1996
Rationale and design of a large study to evaluate the renal and cardiovascular effects of an ACE inhibitor and vitamin E in high-risk patients with diabetes. The MICRO-HOPE Study. Microalbuminuria, cardiovascular, and renal outcomes. Heart Outcomes PrevenDiabetes care, , Volume: 19, Issue:11, 1996
The study of the effect of intensity of blood pressure management on the progression of type 1 diabetic nephropathy: study design and baseline patient characteristics. Collaborative Study Group.Journal of the American Society of Nephrology : JASN, , Volume: 5, Issue:10, 1995
[The nephroprotective effect of ramipril. Effect on blood pressure and metabolic control in insulin-treated patients with type-2 diabetes mellitus].Fortschritte der Medizin, , Jan-30, Volume: 112, Issue:3, 1994
[Dissociation of hypotensive and renal hemodynamic effects of an angiotensin converting enzyme inhibitor in insulin-dependent diabetic patients with incipient nephropathy].Archives des maladies du coeur et des vaisseaux, , Volume: 84, Issue:3, 1991
Salt blocks the renal benefits of ramipril in diabetic hypertensive rats.Hypertension (Dallas, Tex. : 1979), , Volume: 17, Issue:4, 1991
Small doses of ramipril to reduce microalbuminuria in diabetic patients with incipient nephropathy independently of blood pressure changes.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Reduction of cardiovascular events and microvascular complications in diabetes with ACE inhibitor treatment: HOPE and MICRO-HOPE.Diabetes/metabolism research and reviews, , Volume: 18 Suppl 3
Diabetic vascular hypertrophy and albuminuria: effect of angiotensin converting enzyme inhibition.Journal of diabetes and its complications, , Volume: 9, Issue:4
The effect of ramipril therapy on cytokines and parameters of incipient diabetic nephropathy in patients with type 1 diabetes mellitus.The Journal of international medical research, , Volume: 35, Issue:3
[Ramipril and new therapeutic possibilities for ACE-inhibitors].La Clinica terapeutica, , Volume: 151, Issue:4
A retrospective study of the effects of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in diabetic nephropathy.Indian journal of pharmacology, , Volume: 47, Issue:2
ACE-inhibitors and progression of chronic renal insufficiency: a contribution of Italian clinical research.Journal of nephrology, , Volume: 11, Issue:3
Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency.Journal of nephrology, , Volume: 15, Issue:4
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.Proceedings of the National Academy of Sciences of the United States of America, , 12-08, Volume: 117, Issue:49, 2020
Antidepressant effect in diabetes-associated depression: A novel potential of RAAS inhibition.Psychoneuroendocrinology, , Volume: 118, 2020
Ramipril blunts glycerol-induced acute renal failure in rats through its antiapoptosis, anti-inflammatory, antioxidant, and renin-inhibiting properties.Journal of basic and clinical physiology and pharmacology, , Nov-06, Volume: 32, Issue:3, 2020
Angiotensin converting enzyme and neprilysin inhibition alter pain response in dexhamethasone-induced hypertensive rats.Pharmacological reports : PR, , Volume: 71, Issue:2, 2019
Comparison of Efficacy between Ramipril and Carvedilol on Limiting the Expansion of Abdominal Aortic Aneurysm in Mouse Model.Journal of cardiovascular pharmacology and therapeutics, , Volume: 24, Issue:2, 2019
Mitigation of radiation myelopathy and reduction of microglial infiltration by Ramipril, ACE inhibitor.Spinal cord, , Volume: 56, Issue:8, 2018
Low-dose hydralazine prevents fibrosis in a murine model of acute kidney injury-to-chronic kidney disease progression.Kidney international, , Volume: 91, Issue:1, 2017
Targeted mitochondrial therapy using MitoQ shows equivalent renoprotection to angiotensin converting enzyme inhibition but no combined synergy in diabetes.Scientific reports, , 11-09, Volume: 7, Issue:1, 2017
The superoxide dismutase mimetic tempol blunts diabetes-induced upregulation of NADPH oxidase and endoplasmic reticulum stress in a rat model of diabetic nephropathy.European journal of pharmacology, , Jul-15, Volume: 807, 2017
Acute Bradykinin Receptor Blockade During Hemorrhagic Shock in Mice Prevents the Worsening Hypotensive Effect of Angiotensin-Converting Enzyme Inhibitor.Critical care medicine, , Volume: 44, Issue:9, 2016
Effect of ethanolic extract of Cyperus rotundus L. against isoprenaline induced cardiotoxicity.Indian journal of experimental biology, , Volume: 54, Issue:10, 2016
Ramipril attenuates left ventricular remodeling by regulating the expression of activin A-follistatin in a rat model of heart failure.Scientific reports, , 09-19, Volume: 6, 2016
MicroRNAs mediate the cardioprotective effect of angiotensin-converting enzyme inhibition in acute kidney injury.American journal of physiology. Renal physiology, , Dec-01, Volume: 309, Issue:11, 2015
Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading.Clinical and experimental nephrology, , Volume: 18, Issue:4, 2014
Antifibrotic, nephroprotective effects of paricalcitol versus calcitriol on top of ACE-inhibitor therapy in the COL4A3 knockout mouse model for progressive renal fibrosis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 29, Issue:5, 2014
Type 2 diabetes-induced cardiovascular complications: comparative evaluation of spironolactone, atenolol, metoprolol, ramipril and perindopril.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 36, Issue:5, 2014
Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.Basic research in cardiology, , Volume: 109, Issue:4, 2014
Etoricoxib attenuates effect of antihypertensives in a rodent model of DOCA-salt induced hypertension.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 35, Issue:8, 2013
Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects.American journal of physiology. Renal physiology, , Mar-15, Volume: 304, Issue:6, 2013
Simvastatin enhances the antihypertensive effect of ramipril in hypertensive hypercholesterolemic animals and patients. Possible role of nitric oxide, oxidative stress, and high sensitivity C-reactive protein.Fundamental & clinical pharmacology, , Volume: 26, Issue:6, 2012
Effect of ramipril on the regulation of the expression of connexins 40 and 43 in a rabbit model of arterial balloon injury.Molecular medicine reports, , Volume: 6, Issue:3, 2012
Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes.Diabetologia, , Volume: 55, Issue:5, 2012
Ramipril attenuates lipid peroxidation and cardiac fibrosis in an experimental model of rheumatoid arthritis.Arthritis research & therapy, , Oct-18, Volume: 14, Issue:5, 2012
Effect of ramipril on the electrophysiological characteristics of ventricular myocardium after myocardial infarction in rabbits.Journal of cardiovascular medicine (Hagerstown, Md.), , Volume: 13, Issue:5, 2012
A comparison between imidapril and ramipril on attenuation of ventricular remodeling after myocardial infarction.Journal of cardiovascular pharmacology, , Volume: 59, Issue:4, 2012
Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations.British journal of pharmacology, , Volume: 162, Issue:3, 2011
Angiotensin-(1-7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy.Clinical science (London, England : 1979), , Volume: 120, Issue:8, 2011
Ramipril-like activity of Spondias mombin linn against no-flow ischemia and isoproterenol-induced cardiotoxicity in rat heart.Cardiovascular toxicology, , Volume: 10, Issue:4, 2010
The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice.Experimental physiology, , Volume: 94, Issue:3, 2009
ACE inhibition promotes upregulation of endothelial progenitor cells and neoangiogenesis in cardiac pressure overload.Cardiovascular research, , Jul-01, Volume: 83, Issue:1, 2009
Candesartan but not ramipril pretreatment improves outcome after stroke and stimulates neurotrophin BNDF/TrkB system in rats.Journal of hypertension, , Volume: 26, Issue:3, 2008
Blockade of sensory abnormalities and kinin B(1) receptor expression by N-acetyl-L-cysteine and ramipril in a rat model of insulin resistance.European journal of pharmacology, , Jul-28, Volume: 589, Issue:1-3, 2008
Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction.American journal of physiology. Heart and circulatory physiology, , Volume: 294, Issue:4, 2008
Ramipril improves oxidative stress-related vascular endothelial dysfunction in db/db mice.The journal of physiological sciences : JPS, , Volume: 58, Issue:6, 2008
Ramipril protects from free radical induced white matter damage in chronic hypoperfusion in the rat.Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia, , Volume: 15, Issue:2, 2008
A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity.Journal of hypertension, , Volume: 25, Issue:1, 2007
Effects of ACE inhibition and beta-blockade on plasminogen activator inhibitor-1 and transforming growth factor-beta1 in carotid glomus and autonomic ganglia in hypertensive rats.American journal of hypertension, , Volume: 20, Issue:3, 2007
Left ventricular eccentric remodeling and matrix loss are mediated by bradykinin and precede cardiomyocyte elongation in rats with volume overload.Journal of the American College of Cardiology, , Feb-20, Volume: 49, Issue:7, 2007
Synergistic protective effects of erythropoietin and olmesartan on ischemic stroke survival and post-stroke memory dysfunctions in the gerbil.Journal of hypertension, , Volume: 24, Issue:11, 2006
Differential effects of olmesartan and ramipril on inflammatory response after myocardial infarction in rats.Blood pressure, , Volume: 15, Issue:2, 2006
ACE inhibition reduces activity of the plasminogen/plasmin and MMP systems in the brain of spontaneous hypertensive stroke-prone rats.Neuroscience letters, , Mar-16, Volume: 376, Issue:3, 2005
Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses.Journal of the American Society of Nephrology : JASN, , Volume: 16 Suppl 1, 2005
Ramipril prevents extracellular matrix accumulation in cerebral microvessels.Neurological research, , Volume: 27, Issue:5, 2005
Combined effects of HMG-CoA-reductase inhibition and renin-angiotensin system blockade on experimental atherosclerosis.Atherosclerosis, , Volume: 182, Issue:1, 2005
Cardioprotective activity of alcoholic extract of Tinospora cordifolia in ischemia-reperfusion induced myocardial infarction in rats.Biological & pharmaceutical bulletin, , Volume: 28, Issue:12, 2005
Vasopeptidase inhibition improves insulin sensitivity and endothelial function in the JCR:LA-cp rat.Journal of cardiovascular pharmacology, , Volume: 44, Issue:2, 2004
Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure.Journal of cardiac failure, , Volume: 10, Issue:1, 2004
Bradykinin and matrix metalloproteinases are involved the structural alterations of rat small resistance arteries with inhibition of ACE and NEP.Journal of hypertension, , Volume: 22, Issue:4, 2004
Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 19, Issue:7, 2004
Effect of chronic treatment with the vasopeptidase inhibitor AVE 7688 and ramipril on endothelial function in atherogenic diet rabbits.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 4, Issue:3, 2003
Differential effects of saralasin and ramiprilat, the inhibitors of renin-angiotensin system, on cerulein-induced acute pancreatitis.Regulatory peptides, , Mar-28, Volume: 111, Issue:1-3, 2003
[Fast and strong lowering of pressure. The newest sartan has passed the practice test].MMW Fortschritte der Medizin, , Oct-30, Volume: 145, Issue:44, 2003
Renoprotection: clues from knockout models of rare diseases.Kidney international, , Volume: 63, Issue:2, 2003
Cardiomyocyte loss in experimental renal failure: prevention by ramipril.Kidney international, , Volume: 63, Issue:5, 2003
Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome.Kidney international, , Volume: 63, Issue:2, 2003
Effects of diuretic treatment on cardiac and circulating RAS in chronic heart failure post-myocardial infarction in rats.European journal of heart failure, , Volume: 5, Issue:3, 2003
Activity and functional significance of the renal kallikrein-kinin-system in polycystic kidney disease of the rat.Kidney international, , Volume: 61, Issue:6, 2002
Ramipril administration to atherosclerotic mice reduces oxidized low-density lipoprotein uptake by their macrophages and blocks the progression of atherosclerosis.Atherosclerosis, , Volume: 161, Issue:1, 2002
Inhibition of angiotensin-converting enzyme reduces susceptibility of hypertrophied rat myocardium to ventricular fibrillation.Circulation journal : official journal of the Japanese Circulation Society, , Volume: 66, Issue:11, 2002
Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy.Diabetes, , Volume: 51, Issue:11, 2002
Dual ACE and NEP inhibitor MDL-100,240 prevents and regresses severe angiotensin II-dependent hypertension partially through bradykinin type 2 receptor.Journal of hypertension, , Volume: 20, Issue:7, 2002
Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B(2) kinin receptor gene knockout mice.Circulation research, , May-25, Volume: 88, Issue:10, 2001
Combined angiotensin II receptor antagonism and angiotensin-converting enzyme inhibition further attenuates postinfarction left ventricular remodeling.Circulation, , Jun-12, Volume: 103, Issue:23, 2001
Podocyte foot process broadening in experimental diabetic nephropathy: amelioration with renin-angiotensin blockade.Diabetologia, , Volume: 44, Issue:7, 2001
Cardioprotective effects of ramipril and losartan in right ventricular pressure overload in the rabbit: importance of kinins and influence on angiotensin II type 1 receptor signaling pathway.Circulation, , Aug-21, Volume: 104, Issue:8, 2001
Osteopontin expression in progressive renal injury in remnant kidney: role of angiotensin II.Kidney international, , Volume: 58, Issue:4, 2000
Interaction between the renin-angiotensin system and insulin-like growth factor I in aorto-caval fistula-induced cardiac hypertrophy in rats.Acta physiologica Scandinavica, , Volume: 165, Issue:2, 1999
Development of heart failure following isoproterenol administration in the rat: role of the renin-angiotensin system.Cardiovascular research, , Volume: 37, Issue:1, 1998
Functional impact of an increase in ventricular mass after myocardial damage and its attenuation by converting enzyme inhibition.Journal of cardiac failure, , Volume: 4, Issue:3, 1998
Effect of ramiprilat or captopril on myocardial infarct size: assessment in canine models of ischemia alone and ischemia with reperfusion.Pharmacology, , Volume: 57, Issue:1, 1998
Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.The Journal of clinical investigation, , Apr-15, Volume: 99, Issue:8, 1997
Arterial responses to bradykinin after ramipril therapy in experimental hypertension.Pharmacology & toxicology, , Volume: 81, Issue:4, 1997
Possible protective effects of kinins and converting enzyme inhibitors in cardiovascular tissues.Immunopharmacology, , Volume: 36, Issue:2-3, 1997
Ramiprilat attenuates hypoxia/reoxygenation injury to cardiac myocytes via a bradykinin-dependent mechanism.European journal of pharmacology, , Jun-13, Volume: 306, Issue:1-3, 1996
Experimental evidence for effects of ramipril on cardiac and vascular hypertrophy beyond blood pressure reduction.Archives des maladies du coeur et des vaisseaux, , Volume: 88 Spec No 2, 1995
[Cardioprotective effects by ramipril after ischemia and reperfusion in animal experiment studies].Zeitschrift fur Kardiologie, , Volume: 83 Suppl 4, 1994
[ACE inhibition and atherosclerosis in the animal model].Zeitschrift fur Kardiologie, , Volume: 83 Suppl 4, 1994
Control of renin gene expression in 2 kidney-1 clip rats.Kidney international, , Volume: 46, Issue:6, 1994
Angiotensin-converting enzyme inhibition during development alters calcium regulation in adult hypertensive rats.The Journal of pharmacology and experimental therapeutics, , Volume: 267, Issue:3, 1993
Development and modulation of experimental right ventricular hypertrophy in rats.Journal of cardiovascular pharmacology, , Volume: 20 Suppl 1, 1992
Role of bradykinin in chronic antihypertensive actions of ramipril in different hypertension models.Journal of cardiovascular pharmacology, , Volume: 20 Suppl 9, 1992
Influence of the new angiotensin converting enzyme inhibitor ramipril on several models of acute inflammation and the adjuvant arthritis in the rat.Arzneimittel-Forschung, , Volume: 36, Issue:11, 1986
Modulation of hemodynamics, endogenous antioxidant enzymes, and pathophysiological changes by Angiotensin-converting enzyme inhibitors in pressure-overload rats.Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese, , Volume: 52, Issue:3
Pharmacokinetic and pharmacodynamic parameters of ramipril and ramiprilat in healthy dogs and dogs with reduced glomerular filtration rate.Journal of veterinary internal medicine, , Volume: 20, Issue:3
The role of angiotensin converting enzyme and nitric oxide in the enhanced systemic depressor responses to bradykinin in pregnant rats.Clinical and experimental pharmacology & physiology, , Volume: 22, Issue:6-7
Renal medulla and bradykinin during the development of hypertension in SHR.Clinical and experimental pharmacology & physiology, , Volume: 22, Issue:6-7
Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial.Journal of veterinary internal medicine, , Volume: 34, Issue:6, 2020
Effects of ramipril on renal function during progressive overpacing-induced heart failure in dogs.American journal of veterinary research, , Volume: 67, Issue:7, 2006
Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease.The Journal of small animal practice, , Volume: 46, Issue:3, 2005
[The effectiveness and tolerance of ramipril in comparison to captopril for heart failure in dogs].DTW. Deutsche tierarztliche Wochenschrift, , Volume: 103, Issue:5, 1996
Comparative Efficacy of Antihypertensive Drugs in Dogs: A Systematic Review.Topics in companion animal medicine, , Volume: 50
Pharmacokinetic and pharmacodynamic parameters of ramipril and ramiprilat in healthy dogs and dogs with reduced glomerular filtration rate.Journal of veterinary internal medicine, , Volume: 20, Issue:3
Basophil activation test, skin prick test, and anaphylaxis after drug hypersensitivity.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, , Volume: 116, Issue:5, 2016
[Successful use of C1 esterase inhibitor in capillary leak syndrome].Der Anaesthesist, , Volume: 61, Issue:11, 2012
Lichenoid and granulomatous stomatitis: an entity or a non-specific inflammatory process?Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology, , Volume: 35, Issue:5, 2006
Ramipril-induced drug reaction with eosinophilia and systemic symptoms (DRESS).European journal of dermatology : EJD, , Volume: 21, Issue:4
Variation at the NFATC2 locus increases the risk of thiazolidinedione-induced edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) study.Diabetes care, , Volume: 33, Issue:10, 2010
An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.Clinical therapeutics, , Volume: 30, Issue:9, 2008
Minimal change disease in association with fire coral (Millepora species) exposure.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 47, Issue:1, 2006
Differential effects of saralasin and ramiprilat, the inhibitors of renin-angiotensin system, on cerulein-induced acute pancreatitis.Regulatory peptides, , Mar-28, Volume: 111, Issue:1-3, 2003
Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes.Diabetologia, , Volume: 55, Issue:5, 2012
Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure:the effects of ramipril, nifedipine and moxonidine.Journal of the American Society of Nephrology : JASN, , Volume: 7, Issue:5, 1996
Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats.British journal of pharmacology, , Volume: 107, Issue:4, 1992
[Fasciitis with eosinophilia: a possible causal role of angiotensin converting enzyme inhibitor].Revue neurologique, , Volume: 163, Issue:2, 2007
Angiotensin-converting enzyme inhibitors and diarrhea.Journal of clinical gastroenterology, , Volume: 35, Issue:1, 2002
Ramipril-induced drug reaction with eosinophilia and systemic symptoms (DRESS).European journal of dermatology : EJD, , Volume: 21, Issue:4
Effect of pharmacological heart failure drugs and gene therapy on Danon's cardiomyopathy.Biochemical pharmacology, , Volume: 215, 2023
Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3-/- Mice.Journal of the American Society of Nephrology : JASN, , 09-01, Volume: 34, Issue:9, 2023
QGC606: A Best-in-Class Orally Active Centrally Acting Aminopeptidase A Inhibitor Prodrug for Treating Heart Failure Following Myocardial Infarction.The Canadian journal of cardiology, , Volume: 38, Issue:6, 2022
Inhibition of Lysine 63 Ubiquitination Prevents the Progression of Renal Fibrosis in Diabetic DBA/2J Mice.International journal of molecular sciences, , May-14, Volume: 22, Issue:10, 2021
Angiotensin-Converting Enzyme Inhibitor Reduces Radiation-Induced Periprosthetic Capsular Fibrosis.The Journal of surgical research, , Volume: 263, 2021
Randomised controlled trial into the role of ramipril in fibrosis reduction in rheumatic heart disease: the RamiRHeD trial protocol.BMJ open, , 09-13, Volume: 11, Issue:9, 2021
RAAS inhibitors directly reduce diabetes-induced renal fibrosis via growth factor inhibition.The Journal of physiology, , Volume: 597, Issue:1, 2019
The superoxide dismutase mimetic tempol blunts diabetes-induced upregulation of NADPH oxidase and endoplasmic reticulum stress in a rat model of diabetic nephropathy.European journal of pharmacology, , Jul-15, Volume: 807, 2017
Low-dose hydralazine prevents fibrosis in a murine model of acute kidney injury-to-chronic kidney disease progression.Kidney international, , Volume: 91, Issue:1, 2017
Apigenin ameliorates streptozotocin-induced diabetic nephropathy in rats via MAPK-NF-κB-TNF-α and TGF-β1-MAPK-fibronectin pathways.American journal of physiology. Renal physiology, , Aug-01, Volume: 313, Issue:2, 2017
Ramipril attenuates left ventricular remodeling by regulating the expression of activin A-follistatin in a rat model of heart failure.Scientific reports, , 09-19, Volume: 6, 2016
MicroRNAs mediate the cardioprotective effect of angiotensin-converting enzyme inhibition in acute kidney injury.American journal of physiology. Renal physiology, , Dec-01, Volume: 309, Issue:11, 2015
Antifibrotic, nephroprotective effects of paricalcitol versus calcitriol on top of ACE-inhibitor therapy in the COL4A3 knockout mouse model for progressive renal fibrosis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 29, Issue:5, 2014
Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.Basic research in cardiology, , Volume: 109, Issue:4, 2014
Ramipril and telmisartan exhibit differential effects in cardiac pressure overload-induced hypertrophy without an additional benefit of the combination of both drugs.Journal of cardiovascular pharmacology and therapeutics, , Volume: 18, Issue:1, 2013
A comparison between imidapril and ramipril on attenuation of ventricular remodeling after myocardial infarction.Journal of cardiovascular pharmacology, , Volume: 59, Issue:4, 2012
Ramipril attenuates lipid peroxidation and cardiac fibrosis in an experimental model of rheumatoid arthritis.Arthritis research & therapy, , Oct-18, Volume: 14, Issue:5, 2012
Impact of nephron number dosing on cardiorenal damage and effects of ACE inhibition.American journal of hypertension, , Volume: 24, Issue:4, 2011
The cardiac renin-angiotensin system is responsible for high-salt diet-induced left ventricular hypertrophy in mice.European journal of heart failure, , Volume: 12, Issue:11, 2010
Hypertension-mediated albuminuria is associated with reduced lysosomal activity in the kidney and the heart.American journal of nephrology, , Volume: 29, Issue:5, 2009
Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.Clinical science (London, England : 1979), , Oct-26, Volume: 118, Issue:3, 2009
Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction.American journal of physiology. Heart and circulatory physiology, , Volume: 294, Issue:4, 2008
Chronic endothelin-A receptor antagonism is as protective as angiotensin converting enzyme inhibition against cardiac dysfunction in diabetic rats.British journal of pharmacology, , Volume: 151, Issue:8, 2007
High glucose increases extracellular matrix production in pancreatic stellate cells by activating the renin-angiotensin system.Journal of cellular biochemistry, , May-15, Volume: 98, Issue:2, 2006
The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension.Journal of hypertension, , Volume: 24, Issue:7, 2006
Vasopeptidase inhibition prevents target organ damage and improves survival in spontaneously hypertensive rats.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 7, Issue:3, 2006
Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats.Biochemical and biophysical research communications, , Mar-26, Volume: 316, Issue:1, 2004
Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 19, Issue:7, 2004
Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome.Kidney international, , Volume: 63, Issue:2, 2003
Raised blood pressure, not renin-angiotensin systems, causes cardiac fibrosis in TGR m(Ren2)27 rats.Cardiovascular research, , Volume: 47, Issue:1, 2000
Effect of long-term ACE inhibition on myocardial tissue in hypertensive stroke-prone rats.Journal of molecular and cellular cardiology, , Volume: 31, Issue:8, 1999
Postinfarction survival and inducibility of ventricular arrhythmias in the spontaneously hypertensive rat : effects of ramipril and hydralazine.Circulation, , Nov-10, Volume: 98, Issue:19, 1998
Extracellular matrix deposition in hypertensive hearts antifibrotic effects of ramipril.European heart journal, , Volume: 16 Suppl C, 1995
Myocardial interstitial fibrosis in experimental uremia--implications for cardiac compliance.Kidney international, , Volume: 33, Issue:4, 1988
Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis.Molecular and cellular biochemistry, , Volume: 147, Issue:1-2
The effect of ramipril on left ventricular mass, myocardial fibrosis, diastolic function, and plasma neurohormones in Maine Coon cats with familial hypertrophic cardiomyopathy without heart failure.Journal of veterinary internal medicine, , Volume: 20, Issue:5
Comparison of higher dose of losartan treatment with losartan plus carvedilol and losartan plus ramipril in patients with glomerulonephritis and proteinuria.Renal failure, , Volume: 29, Issue:2, 2007
Maximal suppression of renin-angiotensin system in nonproliferative glomerulonephritis.Kidney international, , Volume: 63, Issue:6, 2003
Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products.Journal of human hypertension, , Volume: 17, Issue:4, 2003
Acute and long-term effects of ACE inhibition on renal haemodynamics in glomerular and interstitial nephropathies.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 3, Issue:1, 2002
[Renal hemodynamics and proteinuria in chronic glomerulonephritis treated with beta-receptor blockers or ace inhibitors].Deutsche medizinische Wochenschrift (1946), , Aug-01, Volume: 122, Issue:31-32, 1997
A comparison of the effect of ramipril, felodipine and placebo on glomerular filtration rate, albuminuria, blood pressure and vasoactive hormones in chronic glomerulonephritis. A randomized, prospective, double-blind, placebo-controlled study over two yeaScandinavian journal of clinical and laboratory investigation, , Volume: 57, Issue:8, 1997
Angiotensin-converting enzyme inhibition in experimental in-situ immune complex glomerulonephritis: influence on renal function, proteinuria, and morphology.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 11, Issue:1, 1996
Randomized controlled trial of ACE-inhibitors and beta-blockers with and without vasodilating activity in chronic glomerulonephritis.International journal of clinical pharmacology and therapeutics, , Volume: 34, Issue:11, 1996
Treatment of idiopathic glomerulonephritis in the elderly. Personal data.Contributions to nephrology, , Volume: 105, 1993
[Effect of the angiotensin-converting enzyme inhibitor ramipril on proteinuria, blood pressure and kidney function in histologically confirmed glomerulonephritis with nephrotic syndrome].Zeitschrift fur Kardiologie, , Volume: 77 Suppl 3, 1988
Successful Use of Aliskiren in a Case of IgA- Mesangial Glomerulonephritis Unresponsive to Conventional Therapies.Reviews on recent clinical trials, , Volume: 14, Issue:1, 2019
Treatment of early immunoglobulin A nephropathy by angiotensin-converting enzyme inhibitor.The American journal of medicine, , Volume: 126, Issue:2, 2013
Glomerular disease: ACEIs with or without corticosteroids in IgA nephropathy?Nature reviews. Nephrology, , Volume: 6, Issue:5, 2010
Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 24, Issue:1, 2009
Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 24, Issue:12, 2009
Can young adult patients with proteinuric IgA nephropathy perform physical exercise?American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 44, Issue:2, 2004
The effects of dual blockade of the renin-angiotensin system on urinary protein and transforming growth factor-beta excretion in 2 groups of patients with IgA and diabetic nephropathy.Clinical nephrology, , Volume: 60, Issue:5, 2003
ACE inhibitors and angiotensin II receptor blockers in IgA nephropathy with mild proteinuria: the ACEARB study.Journal of nephrology, , Volume: 19, Issue:4
Prospective randomized controlled multicenter trial on steroids plus ramipril in proteinuric IgA nephropathy.Journal of nephrology, , Volume: 14, Issue:4
Ramipril and resveratrol co-treatment attenuates RhoA/ROCK pathway-regulated early-stage diabetic nephropathy-associated glomerulosclerosis in streptozotocin-induced diabetic rats.Environmental toxicology, , Volume: 34, Issue:7, 2019
Marfan syndrome and focal segmental glomerulosclerosis: a novel association.Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, , Volume: 21, Issue:4, 2010
Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation.Transplant international : official journal of the European Society for Organ Transplantation, , Volume: 22, Issue:11, 2009
Collapsing glomerulopathy coexisting with membranous glomerulonephritis in native kidney biopsies: a report of 3 HIV-negative patients.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 42, Issue:3, 2003
Pharmacological and nutritional treatment for McArdle disease (Glycogen Storage Disease type V).The Cochrane database of systematic reviews, , Nov-12, Issue:11, 2014
Randomized, placebo-controlled, double-blind pilot trial of ramipril in McArdle's disease.Muscle & nerve, , Volume: 37, Issue:3, 2008
[Evaluation of efficacy and safety of hypertension treatment with original angiotensin-converting enzyme inhibitors: the comparison of original and generic formulations].Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, , Volume: 34, Issue:201, 2013
Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.Journal of clinical pharmacology, , Volume: 48, Issue:1, 2008
Comparison of the Efficacy and Safety of Sacubitril/Valsartan versus Ramipril in Patients With ST-Segment Elevation Myocardial Infarction.The American journal of cardiology, , 03-15, Volume: 143, 2021
Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study.Circulation, , Jul-18, Volume: 114, Issue:3, 2006
Extended follow-up of patients randomly assigned in the Angiotensin-converting enzyme inhibition Post-Revascularization Study (APRES).American heart journal, , Volume: 148, Issue:3, 2004
Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme.Expert opinion on pharmacotherapy, , Volume: 5, Issue:5, 2004
Combine EUROPA and HOPE.Lancet (London, England), , Dec-06, Volume: 362, Issue:9399, 2003
Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study.Circulation, , Feb-25, Volume: 107, Issue:7, 2003
Why were the results of the Heart Outcomes Prevention Evaluation (HOPE) trial so astounding?The Canadian journal of cardiology, , Volume: 17 Suppl A, 2001
Should you take an ACE inhibitor?The Johns Hopkins medical letter health after 50, , Volume: 12, Issue:1, 2000
Incidence and natural history of left ventricular thrombus following anterior wall acute myocardial infarction.The American journal of cardiology, , Aug-15, Volume: 80, Issue:4, 1997
Effects of ACE inhibitor therapy on quality of life in patients with heart failure.Pharmacotherapy, , Volume: 18, Issue:6
Effect of pharmacological heart failure drugs and gene therapy on Danon's cardiomyopathy.Biochemical pharmacology, , Volume: 215, 2023
Adverse cardiac effects of exogenous angiotensin 1-7 in rats with subtotal nephrectomy are prevented by ACE inhibition.PloS one, , Volume: 12, Issue:2, 2017
MicroRNAs mediate the cardioprotective effect of angiotensin-converting enzyme inhibition in acute kidney injury.American journal of physiology. Renal physiology, , Dec-01, Volume: 309, Issue:11, 2015
Ramipril and telmisartan exhibit differential effects in cardiac pressure overload-induced hypertrophy without an additional benefit of the combination of both drugs.Journal of cardiovascular pharmacology and therapeutics, , Volume: 18, Issue:1, 2013
Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes.Diabetologia, , Volume: 55, Issue:5, 2012
Hypertension augments cardiac Toll-like receptor 4 expression and activity.Hypertension research : official journal of the Japanese Society of Hypertension, , Volume: 34, Issue:5, 2011
Angiotensin-(1-7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy.Clinical science (London, England : 1979), , Volume: 120, Issue:8, 2011
Hypertension-mediated albuminuria is associated with reduced lysosomal activity in the kidney and the heart.American journal of nephrology, , Volume: 29, Issue:5, 2009
Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction.American journal of physiology. Heart and circulatory physiology, , Volume: 294, Issue:4, 2008
[Involvement of angiotensin II in pathogenesis of hypertension and target organ damage].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 62 Suppl 3, 2004
Inhibition of angiotensin-converting enzyme reduces susceptibility of hypertrophied rat myocardium to ventricular fibrillation.Circulation journal : official journal of the Japanese Circulation Society, , Volume: 66, Issue:11, 2002
Acute antihypertrophic actions of bradykinin in the rat heart: importance of cyclic GMP.Hypertension (Dallas, Tex. : 1979), , Volume: 40, Issue:4, 2002
Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study.Annals of internal medicine, , Mar-20, Volume: 134, Issue:6, 2001
Low-dose ramipril treatment improves relaxation and calcium cycling after established cardiac hypertrophy.American journal of physiology. Heart and circulatory physiology, , Volume: 280, Issue:3, 2001
Effects of ACE inhibition and bradykinin antagonism on cardiovascular changes in uremic rats.Kidney international, , Volume: 58, Issue:1, 2000
Combined treatment with ramipril and metoprolol prevents changes in the creatine kinase isoenzyme system and improves hemodynamic function in rat hearts after myocardial infarction.Cardiovascular drugs and therapy, , Volume: 14, Issue:6, 2000
Late treatment with ramipril increases survival in old spontaneously hypertensive rats.Hypertension (Dallas, Tex. : 1979), , Volume: 34, Issue:2, 1999
Interaction between the renin-angiotensin system and insulin-like growth factor I in aorto-caval fistula-induced cardiac hypertrophy in rats.Acta physiologica Scandinavica, , Volume: 165, Issue:2, 1999
The effect of non-antihypertensive doses of angiotensin converting enzyme inhibitor on myocardial necrosis and hypertrophy in young rats with renovascular hypertension.International journal of experimental pathology, , Volume: 80, Issue:2, 1999
Sub-antihypertensive doses of ramipril normalize sarcoplasmic reticulum calcium ATPase expression and function following cardiac hypertrophy in rats.Journal of molecular and cellular cardiology, , Volume: 30, Issue:12, 1998
Effects of endothelin receptor antagonism and angiotensin-converting enzyme inhibition on cardiac and renal remodeling in the rat.Journal of cardiovascular pharmacology, , Volume: 31 Suppl 1, 1998
Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade.American journal of hypertension, , Volume: 9, Issue:9, 1996
Role of angiotensin in pressure overload-induced hypertrophy in rats: effects of angiotensin-converting enzyme inhibitors, an AT1 receptor antagonist, and surgical reversal.Journal of cardiovascular pharmacology, , Volume: 23, Issue:2, 1994
Role of kinins and nitric oxide in the antihypertrophic effect of ramipril.Hypertension (Dallas, Tex. : 1979), , Volume: 23, Issue:6 Pt 2, 1994
Ramipril prevents the detrimental sequels of chronic NO synthase inhibition in rats: hypertension, cardiac hypertrophy and renal insufficiency.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 350, Issue:6, 1994
A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril.British journal of pharmacology, , Volume: 105, Issue:4, 1992
Development and modulation of experimental right ventricular hypertrophy in rats.Journal of cardiovascular pharmacology, , Volume: 20 Suppl 1, 1992
Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats.British journal of pharmacology, , Volume: 107, Issue:4, 1992
Role of angiotensin II receptor antagonism and converting enzyme inhibition in the progression and regression of cardiac hypertrophy in rats.Journal of hypertension. Supplement : official journal of the International Society of Hypertension, , Volume: 9, Issue:6, 1991
Effect of angiotensin converting enzyme inhibition on pressure-induced left ventricular hypertrophy in rats.Circulation research, , Volume: 69, Issue:3, 1991
Influence of ramipril on right ventricular hypertrophy induced by pulmonary artery stenosis in rats.Journal of cardiovascular pharmacology, , Volume: 16, Issue:3, 1990
Regression of left ventricular hypertrophy under ramipril treatment investigated by nuclear magnetic resonance imaging.Journal of cardiovascular pharmacology, , Volume: 13 Suppl 3, 1989
The renin-angiotensin system and ramipril, a new converting enzyme inhibitor.Journal of cardiovascular pharmacology, , Volume: 14 Suppl 4, 1989
Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats.Clinical and experimental hypertension. Part A, Theory and practice, , Volume: 11, Issue:7, 1989
[Pharmacologic modification of the converting enzyme--local and systemic effects on the heart and blood vessels].Zeitschrift fur Kardiologie, , Volume: 77 Suppl 3, 1988
Use of nuclear magnetic resonance imaging to show regression of hypertrophy with ramipril treatment.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Effect of chronic high- and low-dose ACE inhibitor treatment on cardiac and vascular hypertrophy and vascular function in spontaneously hypertensive rats.Experimental nephrology, , Volume: 2, Issue:2
Modulation of hemodynamics, endogenous antioxidant enzymes, and pathophysiological changes by Angiotensin-converting enzyme inhibitors in pressure-overload rats.Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese, , Volume: 52, Issue:3
Effect of pharmacological heart failure drugs and gene therapy on Danon's cardiomyopathy.Biochemical pharmacology, , Volume: 215, 2023
Comparative Efficacy of Levosimendan, Ramipril, and Sacubitril/ Valsartan in Isoproterenol-induced Experimental Heart Failure: A Hemodynamic and Molecular Approach.Current molecular pharmacology, , Volume: 16, Issue:6, 2023
Angiotensin Receptor-Neprilysin Inhibitor in Acute Myocardial Infarction.The Journal of the Association of Physicians of India, , Volume: 70, Issue:4, 2022
Angiotensin-converting enzyme inhibitors, angiotensin-II-receptor antagonists and angiotensin-receptor blocker/neprilysin inhibitor utilization in heart failure patients: Sub-analysis of a nation-wide population-based study in the Czech Republic.Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, , Volume: 166, Issue:3, 2022
The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial.Circulation, , 12-06, Volume: 146, Issue:23, 2022
Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial.European journal of heart failure, , Volume: 24, Issue:10, 2022
QGC606: A Best-in-Class Orally Active Centrally Acting Aminopeptidase A Inhibitor Prodrug for Treating Heart Failure Following Myocardial Infarction.The Canadian journal of cardiology, , Volume: 38, Issue:6, 2022
Impact of Sacubitril/Valsartan Versus Ramipril on Total Heart Failure Events in the PARADISE-MI Trial.Circulation, , 01-04, Volume: 145, Issue:1, 2022
Efficacy of Sacubitril-Valsartan in Patients With Reduced Left Ventricular Ejection Fraction.The American journal of cardiology, , 08-15, Volume: 153, 2021
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.The New England journal of medicine, , 11-11, Volume: 385, Issue:20, 2021
Long-term survival benefit of ramipril in patients with acute myocardial infarction complicated by heart failure.Heart (British Cardiac Society), , Volume: 107, Issue:5, 2021
Comparison of the Efficacy and Safety of Sacubitril/Valsartan versus Ramipril in Patients With ST-Segment Elevation Myocardial Infarction.The American journal of cardiology, , 03-15, Volume: 143, 2021
Impact of the COVID-19 pandemic on the management of chronic heart failure.Reviews in cardiovascular medicine, , 06-30, Volume: 22, Issue:2, 2021
Impact of different angiotensin-converting inhibitors on outcomes of post-myocardial infarction patients.Wiadomosci lekarskie (Warsaw, Poland : 1960), , Volume: 73, Issue:3, 2020
Long-term clinical outcomes with use of an angiotensin-converting enzyme inhibitor early after heart transplantation.American heart journal, , Volume: 222, 2020
Efficacy of adding ramipril (VAsotop) to the combination of furosemide (Lasix) and pimobendan (VEtmedin) in dogs with mitral valve degeneration: The VALVE trial.Journal of veterinary internal medicine, , Volume: 34, Issue:6, 2020
Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk.European heart journal, , 07-01, Volume: 40, Issue:25, 2019
Expectoration of bronchial casts in association with Ramipril treatment.Cardiology in the young, , Volume: 29, Issue:12, 2019
Effects of neprilysin-renin inhibition in comparison with neprilysin-angiotensin inhibition on the neurohumoral changes in rats with heart failure.BMC pharmacology & toxicology, , 05-03, Volume: 20, Issue:1, 2019
Efficacy and Safety of Zofenopril Versus Ramipril in the Treatment of Myocardial Infarction and Heart Failure: A Review of the Published and Unpublished Data of the Randomized Double-Blind SMILE-4 Study.Advances in therapy, , Volume: 35, Issue:5, 2018
Angioedema Two Weeks After the Initial Administration of an ACE Inhibitor.Deutsches Arzteblatt international, , 03-02, Volume: 115, Issue:9, 2018
Comparative effectiveness of enalapril, lisinopril, and ramipril in the treatment of patients with chronic heart failure: a propensity score-matched cohort study.European heart journal. Cardiovascular pharmacotherapy, , 04-01, Volume: 4, Issue:2, 2018
Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.European heart journal, , 09-01, Volume: 39, Issue:33, 2018
Takotsubo-like syndrome triggered by fludrocortisone overdose for Addison's disease: a case report.Journal of medical case reports, , Oct-12, Volume: 10, Issue:1, 2016
Risk of renal dysfunction in an elderly patient with chronic heart failure.Medizinische Monatsschrift fur Pharmazeuten, , Volume: 39, Issue:10, 2016
Angiotensin converting enzyme inhibitors for heart failure with reduced ejection fraction or left ventricular dysfunction: A complementary network meta-analyses.International journal of cardiology, , Jul-01, Volume: 214, 2016
Ramipril and Losartan Exert a Similar Long-Term Effect upon Markers of Heart Failure, Endogenous Fibrinolysis, and Platelet Aggregation in Survivors of ST-Elevation Myocardial Infarction: A Single Centre Randomized Trial.BioMed research international, , Volume: 2016, 2016
Ramipril attenuates left ventricular remodeling by regulating the expression of activin A-follistatin in a rat model of heart failure.Scientific reports, , 09-19, Volume: 6, 2016
A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors.British journal of clinical pharmacology, , Volume: 80, Issue:4, 2015
Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.Basic research in cardiology, , Volume: 109, Issue:4, 2014
The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.European journal of preventive cardiology, , Volume: 21, Issue:3, 2014
Effect of zofenopril and ramipril on cardiovascular mortality in patients with chronic heart failure.The American journal of cardiology, , Jul-01, Volume: 112, Issue:1, 2013
Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril.Postgraduate medicine, , Volume: 125, Issue:4, 2013
Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European studClinical cardiology, , Volume: 35, Issue:7, 2012
Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.Circulation, , Mar-15, Volume: 123, Issue:10, 2011
Telmisartan for the management of patients at high cardiovascular risk.Current medical research and opinion, , Volume: 27, Issue:8, 2011
Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data.Chinese medical journal, , Volume: 124, Issue:12, 2011
The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study.Journal of medical economics, , Volume: 14, Issue:6, 2011
Impact of ACE inhibitors on mortality and morbidity in patients with AMI: Does tissue selectivity matter?Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 14, Issue:1, 2011
New data on ONTARGET: more confusion?Journal of clinical hypertension (Greenwich, Conn.), , Volume: 12, Issue:3, 2010
[Renal effect of treatment for heart failure].Ugeskrift for laeger, , Feb-23, Volume: 171, Issue:9, 2009
The peroxisome proliferator-activated receptor-alpha (PPAR-alpha) agonist, AVE8134, attenuates the progression of heart failure and increases survival in rats.Acta pharmacologica Sinica, , Volume: 30, Issue:7, 2009
The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial.Journal of cardiovascular electrophysiology, , Volume: 20, Issue:7, 2009
[A 60-year-old man with heart failure, dry cough and elevated INR values].Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, , Aug-14, Volume: 128, Issue:15, 2008
Comparative effectiveness of angiotensin-converting-enzyme inhibitors: is an ACE always an ace?CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , May-06, Volume: 178, Issue:10, 2008
Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , May-06, Volume: 178, Issue:10, 2008
[The use of angiotensin converting enzyme inhibitors in patients after myocardial infarction].Kardiologiia, , Volume: 48, Issue:11, 2008
Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk.Circulation, , Mar-20, Volume: 115, Issue:11, 2007
Left ventricular eccentric remodeling and matrix loss are mediated by bradykinin and precede cardiomyocyte elongation in rats with volume overload.Journal of the American College of Cardiology, , Feb-20, Volume: 49, Issue:7, 2007
Estimating the cost effectiveness of ramipril used for specific clinical indications: comparing the outcomes in four clinical trials with a common economic model.American journal of cardiovascular drugs : drugs, devices, and other interventions, , Volume: 7, Issue:6, 2007
Neurohumoral effects of the new orally active renin inhibitor, aliskiren, in chronic heart failure.European journal of heart failure, , Volume: 9, Issue:11, 2007
Effects of ramipril on renal function during progressive overpacing-induced heart failure in dogs.American journal of veterinary research, , Volume: 67, Issue:7, 2006
Lipid peroxidation is not increased in heart failure patients on modern pharmacological therapy.International journal of cardiology, , Oct-10, Volume: 112, Issue:3, 2006
Practical recommendations for the use of ACE inhibitors, beta-blockers, aldosterone antagonists and angiotensin receptor blockers in heart failure: putting guidelines into practice.European journal of heart failure, , Volume: 7, Issue:5, 2005
The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences.Scandinavian journal of clinical and laboratory investigation. Supplementum, , Volume: 240, 2005
[A patient with severe hyperkalaemia -- an emergency after RALES].Deutsche medizinische Wochenschrift (1946), , Sep-09, Volume: 130, Issue:36, 2005
Ramipril in the treatment of vascular diseases.Expert opinion on pharmacotherapy, , Volume: 6, Issue:11, 2005
Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease.The Journal of small animal practice, , Volume: 46, Issue:3, 2005
[Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].Italian heart journal : official journal of the Italian Federation of Cardiology, , Volume: 6 Suppl 7, 2005
Effects of combined inhibition of the Na+-H+ exchanger and angiotensin-converting enzyme in rats with congestive heart failure after myocardial infarction.British journal of pharmacology, , Volume: 146, Issue:5, 2005
Combined effects of ramipril and angiotensin II receptor blocker TCV116 on rat congestive heart failure after myocardial infarction.Chinese medical journal, , Jan-20, Volume: 118, Issue:2, 2005
Comparison of angiotensin-converting enzyme inhibitors in the treatment of congestive heart failure.The American journal of cardiology, , Jan-15, Volume: 95, Issue:2, 2005
Inhibition of angiotensin-converting enzyme and phosphodiesterase type 5 improves endothelial function in heart failure.Clinical science (London, England : 1979), , Volume: 108, Issue:4, 2005
Extended follow-up of patients randomly assigned in the Angiotensin-converting enzyme inhibition Post-Revascularization Study (APRES).American heart journal, , Volume: 148, Issue:3, 2004
Dual inhibition of ACE and NEP provides greater cardioprotection in mice with heart failure.Journal of cardiac failure, , Volume: 10, Issue:1, 2004
[ACE inhibitor therapy until end of life?].Deutsche medizinische Wochenschrift (1946), , Oct-29, Volume: 129, Issue:44, 2004
Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study.Diabetes care, , Volume: 26, Issue:3, 2003
Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study.Circulation, , Mar-11, Volume: 107, Issue:9, 2003
Economic impact of ramipril on hospitalization of high-risk cardiovascular patients.The Annals of pharmacotherapy, , Volume: 37, Issue:3, 2003
[Chronopharmacological approaches to the therapeutic prophylaxis of chronic cardiac insufficiency in type I diabetes mellitus].Vestnik Rossiiskoi akademii meditsinskikh nauk, , Issue:4, 2003
Aldosterone receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure.Cardiovascular research, , Jun-01, Volume: 58, Issue:3, 2003
Effects of diuretic treatment on cardiac and circulating RAS in chronic heart failure post-myocardial infarction in rats.European journal of heart failure, , Volume: 5, Issue:3, 2003
Aspirin alters arterial function in patients with chronic heart failure treated with ACE inhibitors: a dose-mediated deleterious effect.European journal of heart failure, , Volume: 5, Issue:3, 2003
Ramipril improves nitric oxide availability in hypertensive rats with failing hearts after myocardial infarction.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 4, Issue:3, 2003
[Added organ protection at little cost. Double savings with ACE inhibitors].MMW Fortschritte der Medizin, , Nov-27, Volume: 145, Issue:48, 2003
[New possibilities in clinical use of angiotensin II receptor inhibitors].Orvosi hetilap, , Dec-07, Volume: 144, Issue:49, 2003
[Therapy of hypertension. Lasting organ protection moves into the foreground].MMW Fortschritte der Medizin, , Nov-20, Volume: 145, Issue:47, 2003
Effect of ramipril and furosemide treatment on interstitial remodeling in post-infarction heart failure rat hearts.Journal of molecular and cellular cardiology, , Volume: 34, Issue:2, 2002
"Preemptive strike" heart medications. A.C.E. inhibitors gain new ground as multi-purpose cardiac drugs.Heart advisor, , Volume: 5, Issue:2, 2002
Cost-effectiveness of the treatment of heart failure with ramipril: a Spanish analysis of the AIRE study.European journal of heart failure, , Volume: 4, Issue:4, 2002
Using ACE inhibitors appropriately.American family physician, , Aug-01, Volume: 66, Issue:3, 2002
Haemorheological and endothelial-dependent alterations in heart failure after ACE inhibitor, calcium antagonist and beta blocker.Clinical hemorheology and microcirculation, , Volume: 27, Issue:3-4, 2002
Management of asymptomatic left ventricular dysfunction.Cleveland Clinic journal of medicine, , Volume: 68, Issue:3, 2001
Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril.Circulation, , Oct-02, Volume: 104, Issue:14, 2001
Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B(2) kinin receptor gene knockout mice.Circulation research, , May-25, Volume: 88, Issue:10, 2001
[Activity of the renin-angiotensin-aldosterone system and its impact on the effectiveness of treatment of chronic heart failure in patients with pulmonary tuberculosis].Problemy tuberkuleza, , Issue:5, 2001
Modulation of renal oxygen consumption by nitric oxide is impaired after development of congestive heart failure in dogs.Journal of cardiovascular pharmacology, , Volume: 37, Issue:3, 2001
Beneficial effects of ramipril on left ventricular end-diastolic and end-systolic volume indexes after uncomplicated invasive revascularization are associated with a reduction in cardiac events in patients with moderately impaired left ventricular functioJournal of the American College of Cardiology, , Volume: 37, Issue:5, 2001
Simvastatin reverses impaired regulation of renal oxygen consumption in congestive heart failure.American journal of physiology. Renal physiology, , Volume: 281, Issue:5, 2001
The HOPE study: comparison with other trials of secondary prevention.European heart journal, , Volume: 22, Issue:15, 2001
What are 'tissue ACE inhibitors,' and should they be used instead of other ACE inhibitors?Cleveland Clinic journal of medicine, , Volume: 68, Issue:3, 2001
[Effects of angiotensin-converting enzyme inhibitors and cosaar on quality of life of patients with pulmonary tuberculosis and chronic heart failure].Problemy tuberkuleza, , Issue:8, 2001
[Results of the RALES trial: good news for patients with heart failure and ... for health administrations].Medicina clinica, , Apr-15, Volume: 114, Issue:14, 2000
The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES).Journal of the American College of Cardiology, , Mar-15, Volume: 35, Issue:4, 2000
Management of heart failure.Current cardiology reports, , Volume: 2, Issue:3, 2000
ACE inhibitor dosage at the time of listing predicts survival.The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, , Volume: 19, Issue:2, 2000
Effects of ACE inhibitor, AT1 antagonist, and combined treatment in mice with heart failure.Journal of cardiovascular pharmacology, , Volume: 36, Issue:4, 2000
Ramipril.International journal of clinical practice, , Volume: 54, Issue:4, 2000
Epidemiology and pathophysiology of heart failure.Current cardiology reports, , Volume: 2, Issue:3, 2000
Synergy of amlodipine and angiotensin-converting enzyme inhibitors in regulating myocardial oxygen consumption in normal canine and failing human hearts.The American journal of cardiology, , Jun-17, Volume: 83, Issue:12A, 1999
Angiotensin inhibition and atrial natriuretic peptide release after acute volume expansion in rats with aortocaval shunt.Cardiovascular research, , Volume: 42, Issue:3, 1999
ACE inhibition improves cardiac NE uptake and attenuates sympathetic nerve terminal abnormalities in heart failure.The American journal of physiology, , Volume: 277, Issue:4, 1999
[Ramipril treatment of heart failure in disseminated forms of pulmonary tuberculosis].Problemy tuberkuleza, , Issue:2, 1999
beta blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: evidence from the AIRE study.Heart (British Cardiac Society), , Volume: 81, Issue:1, 1999
Ramipril reduces QT dispersion in patients with acute myocardial infarction and heart failure.The American journal of cardiology, , Mar-15, Volume: 83, Issue:6, 1999
Kinin-mediated coronary nitric oxide production contributes to the therapeutic action of angiotensin-converting enzyme and neutral endopeptidase inhibitors and amlodipine in the treatment in heart failure.The Journal of pharmacology and experimental therapeutics, , Volume: 288, Issue:2, 1999
Effect of angiotensin-converting enzyme inhibition on protein kinase C and SR proteins in heart failure.The American journal of physiology, , Volume: 276, Issue:1, 1999
Treatment with ramipril improves systolic function even in patients with mild systolic dysfunction and symptoms of heart failure after acute myocardial infarction.Clinical cardiology, , Volume: 21, Issue:11, 1998
Development of heart failure following isoproterenol administration in the rat: role of the renin-angiotensin system.Cardiovascular research, , Volume: 37, Issue:1, 1998
Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance.PharmacoEconomics, , Volume: 14, Issue:6, 1998
Effects of chronic AVP V2R blockade in congestive heart failure in sheep. Comparison with chronic ACE inhibition.Advances in experimental medicine and biology, , Volume: 449, 1998
AIRE Extension (AIREX) Study.Lancet (London, England), , Aug-02, Volume: 350, Issue:9074, 1997
Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy.Lancet (London, England), , May-24, Volume: 349, Issue:9064, 1997
ACE inhibitors in heart failure: effect on mode of death.European heart journal, , Volume: 18, Issue:1, 1997
Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators.European heart journal, , Volume: 18, Issue:1, 1997
Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.The Journal of clinical investigation, , Apr-15, Volume: 99, Issue:8, 1997
Effect of ramipril on heart rate variability in digitalis-treated patients with chronic heart failure.Cardiovascular drugs and therapy, , Volume: 11, Issue:4, 1997
Cost effectiveness in the treatment of heart failure with ramipril. A Swedish substudy of the AIRE study. Acute Infarction Ramipril Efficacy.PharmacoEconomics, , Volume: 12, Issue:2 Pt 2, 1997
Possible protective effects of kinins and converting enzyme inhibitors in cardiovascular tissues.Immunopharmacology, , Volume: 36, Issue:2-3, 1997
Meta-analysis of morbidity and mortality in five exercise capacity trials evaluating ramipril in chronic congestive cardiac failure.The American journal of cardiology, , Jun-01, Volume: 77, Issue:14, 1996
[The effectiveness and tolerance of ramipril in comparison to captopril for heart failure in dogs].DTW. Deutsche tierarztliche Wochenschrift, , Volume: 103, Issue:5, 1996
Mega-trials: is meta-analysis an alternative?European journal of clinical pharmacology, , Volume: 49 Suppl 1, 1996
Angiotensin-converting enzyme inhibition, autonomic activity, and hemodynamics in patients with heart failure who perform isometric exercise.American heart journal, , Volume: 131, Issue:5, 1996
[The efficacy of treatment with the angiotensin-converting enzyme inhibitor ramipril in patients with congestive heart failure of rheumatic etiology].Terapevticheskii arkhiv, , Volume: 68, Issue:2, 1996
Neurohormonal activation in patients with acute myocardial infarction or chronic congestive heart failure. With special reference to treatment with angiotensin converting enzyme inhibitors.Blood pressure. Supplement, , Volume: 1, 1995
Effects of 12 weeks of ramipril treatment on the quality of life in patients with moderate congestive heart failure: results of a placebo-controlled trial. Ramipril Study Group.Cardiovascular drugs and therapy, , Volume: 9, Issue:4, 1995
Ramipril. An updated review of its therapeutic use in essential hypertension and heart failure.Drugs, , Volume: 49, Issue:3, 1995
[The use of ramipril in treating patients with chronic heart failure].Terapevticheskii arkhiv, , Volume: 67, Issue:5, 1995
Quantitative assessment of daily physical activity levels in patients with chronic heart failure by measuring energy expenditure--effects of converting enzyme inhibitor therapy.Japanese circulation journal, , Volume: 59, Issue:10, 1995
Inhibition of ACE/Kininase-II after myocardial infarction--addendum.Cardiovascular research, , Volume: 28, Issue:2, 1994
Clinical pharmacokinetics of ramipril.Clinical pharmacokinetics, , Volume: 26, Issue:1, 1994
ACE inhibition, atherosclerosis and myocardial infarction--the AIRE Study in practice. Acute Infarction Ramipril Efficacy Study.European heart journal, , Volume: 15 Suppl B, 1994
Effects of ramipril on the neurohormonal response to exercise in patients with mild or moderate congestive heart failure.European heart journal, , Volume: 15, Issue:2, 1994
Exercise testing in heart failure. A critical review.Drugs, , Volume: 47 Suppl 4, 1994
Influence of angiotensin converting enzyme inhibition on relation of atrial natriuretic peptide concentration to atrial pressure in heart failure.British heart journal, , Volume: 72, Issue:6, 1994
ACE-inhibitor therapy after myocardial infarction--a new treatment strategy.Zeitschrift fur Kardiologie, , Volume: 83 Suppl 4, 1994
[Reduction of infarct size and remodeling after ramipril].Zeitschrift fur Kardiologie, , Volume: 83 Suppl 4, 1994
Neurohormonal activation in patients with mild or moderately severe congestive heart failure and effects of ramipril. The Ramipril Trial Study Group.British heart journal, , Volume: 72, Issue:5, 1994
Absence of effect on exercise capacity of 12-weeks treatment with ramipril in patients with moderate congestive heart failure. Ramipril Study Group.European heart journal, , Volume: 15, Issue:12, 1994
Response of plasma neuropeptide Y and noradrenaline to dynamic exercise and ramipril treatment in patients with congestive heart failure.Clinical physiology (Oxford, England), , Volume: 14, Issue:2, 1994
Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.Lancet (London, England), , Oct-02, Volume: 342, Issue:8875, 1993
Multiple-dose pharmacokinetics of ramipril in patients with chronic congestive heart failure.Journal of cardiovascular pharmacology, , Volume: 22 Suppl 9, 1993
Validation of primary and secondary outcomes and classification of mode of death among patients with clinical evidence of heart failure after a myocardial infarction: a report from the Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.Journal of cardiovascular pharmacology, , Volume: 22 Suppl 9, 1993
Acute haemodynamic effects and pharmacokinetics of ramipril in patients with heart failure. A placebo controlled three-dose study.European journal of clinical pharmacology, , Volume: 45, Issue:3, 1993
ACE inhibitors: review of four new agents.American family physician, , Volume: 48, Issue:5, 1993
Influence of ramipril on plasma atrial natriuretic peptide, antidiuretic hormone, angiotensin II and aldosterone in patients with chronic congestive heart failure.Clinical physiology and biochemistry, , Volume: 9, Issue:3, 1992
Ramipril: a review of the new ACE inhibitor.The Journal of the Arkansas Medical Society, , Volume: 88, Issue:9, 1992
Influence of ramipril on renal function in patients with chronic congestive heart failure.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
A comparison of the efficacy and safety of ramipril and digoxin added to maintenance diuretic treatment in patients with chronic heart failure.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Three new ACE inhibitors for hypertension.The Medical letter on drugs and therapeutics, , Sep-06, Volume: 33, Issue:852, 1991
[Acute effects of the angiotensin converting enzyme inhibitor ramipril in patients with coronary heart disease].Medizinische Klinik (Munich, Germany : 1983), , Feb-15, Volume: 85, Issue:2, 1990
Pharmacokinetic and pharmacodynamic properties of ramipril in patients with congestive heart failure (NYHA III-IV).Journal of cardiovascular pharmacology, , Volume: 13 Suppl 3, 1989
Global and regional hemodynamic effects of ramipril in congestive heart failure.Journal of cardiovascular pharmacology, , Volume: 14, Issue:5, 1989
Acute and chronic effects of ramipril and captopril in congestive heart failure.International journal of cardiology, , Volume: 23, Issue:1, 1989
Atrial natriuretic peptide levels in congestive heart failure in man before and during converting enzyme inhibition.Clinical and experimental pharmacology & physiology, , Volume: 16, Issue:5, 1989
[Pharmacologic modification of the converting enzyme--local and systemic effects on the heart and blood vessels].Zeitschrift fur Kardiologie, , Volume: 77 Suppl 3, 1988
Ramipril and captopril in patients with heart failure: effects on hemodynamics and vasoconstrictor systems.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Acute effects of the new angiotensin converting enzyme inhibitor ramipril on hemodynamics and carotid sinus baroreflex activity in congestive heart failure.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Acute hemodynamic, hormonal and electrolyte effects of ramipril in severe congestive heart failure.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Acute hemodynamic and hormonal effects of ramipril in chronic congestive heart failure and comparison with captopril.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Clinical pharmacology of ramipril.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Ramipril: review of pharmacology.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
ACE inhibitors after myocardial infarction.The British journal of clinical practice, , Volume: 49, Issue:4
Achieving blood preSsure goals sTudy in uncontrolled hypeRtensive pAtients treated with a fixed-dose combination of ramipriL/hydrochlorothiazide: the ASTRAL study.Cardiovascular journal of Africa, , Volume: 22, Issue:2
[Therapeutic perspectives: association of ACE inhibitors and angiotensin receptor blockers].La Clinica terapeutica, , Volume: 152, Issue:2
Role of ACE I/D gene polymorphisms on the effect of ramipril in inflammatory response and myocardial injury in patients undergoing coronary artery bypass grafts.European journal of clinical pharmacology, , Volume: 70, Issue:12, 2014
Functional impact of an increase in ventricular mass after myocardial damage and its attenuation by converting enzyme inhibition.Journal of cardiac failure, , Volume: 4, Issue:3, 1998
Bradykinin antagonism inhibits the antigrowth effect of converting enzyme inhibition in the dog myocardium after discrete transmural myocardial necrosis.Circulation, , Apr-01, Volume: 91, Issue:7, 1995
Does this case hold the answer to one of the worse types of pain in medicine--that of loin pain haematuria syndrome (LPHS).BMJ case reports, , Apr-26, Volume: 2015, 2015
Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 24, Issue:1, 2009
Can young adult patients with proteinuric IgA nephropathy perform physical exercise?American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 44, Issue:2, 2004
Primary Aldosteronism: The Next Decade.Hypertension (Dallas, Tex. : 1979), , Volume: 76, Issue:2, 2020
Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives.American journal of hypertension, , Volume: 18, Issue:1, 2005
High Incidence of ACE/PAI-1 in Association to a Spectrum of Other Polymorphic Cardiovascular Genes Involving PBMCs Proinflammatory Cytokines in Hypertensive Hypercholesterolemic Patients: Reversibility with a Combination of ACE Inhibitor and Statin.PloS one, , Volume: 10, Issue:5, 2015
Simvastatin enhances the antihypertensive effect of ramipril in hypertensive hypercholesterolemic animals and patients. Possible role of nitric oxide, oxidative stress, and high sensitivity C-reactive protein.Fundamental & clinical pharmacology, , Volume: 26, Issue:6, 2012
Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.Circulation. Cardiovascular quality and outcomes, , Jul-01, Volume: 5, Issue:4, 2012
Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1+2 in patients with type 2 diabetes.Atherosclerosis, , Volume: 194, Issue:1, 2007
Vascular effects of simvastatin combined with ramipril in hypercholesterolemic patients with coronary artery disease, compared with simvastatin alone: a randomized, double-blind, placebo-controlled, crossover study.Atherosclerosis, , Volume: 177, Issue:1, 2004
Simvastatin combined with ramipril treatment in hypercholesterolemic patients.Hypertension (Dallas, Tex. : 1979), , Volume: 44, Issue:2, 2004
Effect of chronic treatment with the vasopeptidase inhibitor AVE 7688 and ramipril on endothelial function in atherogenic diet rabbits.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 4, Issue:3, 2003
[Type 2 diabetes and cardiovascular risk: lessons from therapeutic trials].La Revue du praticien, , Oct-15, Volume: 51, Issue:16, 2001
Effects of hypercholesterolemia on the contractions to angiotensin II in the isolated aorta and iliac artery of the rabbit: role of arachidonic acid metabolites.Journal of cardiovascular pharmacology, , Volume: 30, Issue:1, 1997
Coenzyme Q10 attenuates diastolic dysfunction, cardiomyocyte hypertrophy and cardiac fibrosis in the db/db mouse model of type 2 diabetes.Diabetologia, , Volume: 55, Issue:5, 2012
Effects of ethnicity on diabetes incidence and prevention: results of the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) trial.Diabetic medicine : a journal of the British Diabetic Association, , Volume: 27, Issue:11, 2010
Effect of ramipril and of rosiglitazone on carotid intima-media thickness in people with impaired glucose tolerance or impaired fasting glucose: STARR (STudy of Atherosclerosis with Ramipril and Rosiglitazone).Journal of the American College of Cardiology, , Jun-02, Volume: 53, Issue:22, 2009
Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes.Current atherosclerosis reports, , Volume: 10, Issue:2, 2008
The new clinical trials with thiazolidinediones--DREAM, ADOPT, and CHICAGO: promises fulfilled?Current opinion in lipidology, , Volume: 18, Issue:4, 2007
[Three studies in type 2 diabetes: DREAM the wash-out results].Annales d'endocrinologie, , Volume: 68 Suppl 1, 2007
Glucose levels predict hospitalization for congestive heart failure in patients at high cardiovascular risk.Circulation, , Mar-20, Volume: 115, Issue:11, 2007
[DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular desease].Revue medicale de Liege, , Volume: 61, Issue:10, 2006
Modulation of the renal response to ACE inhibition by ACE insertion/deletion polymorphism during hyperglycemia in normotensive, normoalbuminuric type 1 diabetic patients.Diabetes, , Volume: 54, Issue:10, 2005
The effect of urapidil and ramipril on hyperglycemia in streptozotocin diabetic rats.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 361, Issue:1, 2000
Microcirculation in hyperglycemic patients with IDDM without diabetic complications--effect of low-dose angiotensin-converting enzyme inhibition.Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, , Volume: 106, Issue:1, 1998
Interactions of the kallikrein-kinin and renin-angiotensin systems in experimental diabetes.Diabetes, , Volume: 46, Issue:1, 1997
Effect of short-term ACE inhibitor treatment on peripheral insulin sensitivity in obese insulin-resistant subjects.Diabetologia, , Volume: 49, Issue:12, 2006
Contribution of bradykinin to the beneficial effects of ramipril in the fructose-fed rat.Journal of cardiovascular pharmacology, , Volume: 31, Issue:4, 1998
Significance of exaggerated natriuresis after angiotensin AT1 receptor blockade or angiotensin- converting enzyme inhibition in obese Zucker rats.Clinical and experimental pharmacology & physiology, , Volume: 28, Issue:5-6
Effects of Ramipril on Biomarkers of Endothelial Dysfunction and Inflammation in Hypertensive Children on Maintenance Hemodialysis: the SEARCH Randomized Placebo-Controlled Trial.Hypertension (Dallas, Tex. : 1979), , Volume: 79, Issue:8, 2022
Runner's new diet, his collapse, and his ECG: when a rapid ECG diagnosis can save the day.Canadian family physician Medecin de famille canadien, , Volume: 60, Issue:4, 2014
The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.European journal of preventive cardiology, , Volume: 21, Issue:3, 2014
Ramipril and risk of hyperkalemia in chronic hemodialysis patients.Collegium antropologicum, , Volume: 35, Issue:2, 2011
Dual renin-angiotensin-aldosterone system blockade for diabetic kidney disease.Current diabetes reports, , Volume: 10, Issue:4, 2010
Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE study.Clinical nephrology, , Volume: 63, Issue:3, 2005
[A patient with severe hyperkalaemia -- an emergency after RALES].Deutsche medizinische Wochenschrift (1946), , Sep-09, Volume: 130, Issue:36, 2005
Reversible hyperkalemia at the initiation of ACE inhibitors in a young diabetic patient with latent hyporeninemic hypoaldosteronism.Diabetes care, , Volume: 19, Issue:7, 1996
Pharmacokinetic interaction study with ramipril and digoxin in healthy volunteers.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Comparative effect of Ocimum sanctum, Commiphora mukul, folic acid and ramipril on lipid peroxidation in experimentally-induced hyperlipidemia.Indian journal of experimental biology, , Volume: 48, Issue:3, 2010
Impediment of the progressions of microalbuminuria and hyperlipidemia in normotensive type 2 diabetes by low-dose ramipril.Journal of the Medical Association of Thailand = Chotmaihet thangphaet, , Volume: 81, Issue:9, 1998
Contribution of bradykinin to the beneficial effects of ramipril in the fructose-fed rat.Journal of cardiovascular pharmacology, , Volume: 31, Issue:4, 1998
Ramipril prevents impaired endothelium-dependent relaxation in arteries from rabbits fed an atherogenic diet.Atherosclerosis, , Volume: 100, Issue:2, 1993
Effects of Ramipril on Biomarkers of Endothelial Dysfunction and Inflammation in Hypertensive Children on Maintenance Hemodialysis: the SEARCH Randomized Placebo-Controlled Trial.Hypertension (Dallas, Tex. : 1979), , Volume: 79, Issue:8, 2022
INDICATORS OF ENDOTHELIAL DYSFUNCTION, MARKERS OF INFLAMMATION AND LIPID METABOLISM IN PATIENTS WITH HYPERTENSION WITH THE ADMINISTRATION OF QUERCETIN.Wiadomosci lekarskie (Warsaw, Poland : 1960), , Volume: 75, Issue:7, 2022
Heat-based transdermal delivery of a ramipril loaded cream for treating hypertension.Nanoscale, , Sep-02, Volume: 14, Issue:34, 2022
Study of possible sex features of ramipril and candesartan treatment under experimental arterial hypertension in rats.Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti, ,Summer, Volume: 71, Issue:3, 2022
Angiotensin converting enzyme inhibitor potentiates the hypoglycaemic effect of NG-nitro-L-arginine methyl ester (L-NAME) in rats.Archives of physiology and biochemistry, , Volume: 128, Issue:6, 2022
Primary Aldosteronism: The Next Decade.Hypertension (Dallas, Tex. : 1979), , Volume: 76, Issue:2, 2020
ACE-inhibitor/calcium antagonist combination: is this the first-choice therapy in arterial hypertension?Minerva medica, , Volume: 110, Issue:6, 2019
The interrelation of endothelial function and microvascular reactivity in different vascular beds, and risk assessment in hypertension: results from the Doxazosin-ramipril study.Heart and vessels, , Volume: 34, Issue:3, 2019
Angiotensin converting enzyme and neprilysin inhibition alter pain response in dexhamethasone-induced hypertensive rats.Pharmacological reports : PR, , Volume: 71, Issue:2, 2019
Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk.European heart journal, , 07-01, Volume: 40, Issue:25, 2019
[Effects of Ramipril on the expression of connexin 43 in cerebral arteries of spontaneously hypertensive rats].Sheng li xue bao : [Acta physiologica Sinica], , Jun-25, Volume: 71, Issue:3, 2019
The effects of single and combined application of ramipril and losartan on renal structure and function in hypertensive rats.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 40, Issue:7, 2018
Effects of Angiotensin-Converting Enzyme Inhibition and Alpha 1-Adrenergic Receptor Blockade on Inflammation and Hemostasis in Human Hypertension.Journal of cardiovascular pharmacology, , Volume: 71, Issue:4, 2018
Fixed-dose vs free-dose combinations for the management of hypertension-An analysis of 81Â 958 patients.Journal of clinical hypertension (Greenwich, Conn.), , Volume: 20, Issue:4, 2018
Antihypertensive drug use in resistant and nonresistant hypertension and in controlled and uncontrolled resistant hypertension.Journal of hypertension, , Volume: 36, Issue:7, 2018
PATHOMORPHOLOGY OF THE MYOCARDIUM, KIDNEY AND LIVER IN SPONTANEOUSLY HYPERTENSIVE RATS TREATED WITH SHORT AND LONG-TERM USE RAMIPRIL AND CANDESARTAN.Georgian medical news, , Issue:276, 2018
Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.European heart journal, , 09-01, Volume: 39, Issue:33, 2018
The effect of nebivolol and ramipril on selected biochemical parameters, arterial stiffness, and circadian profile of blood pressure in young men with primary hypertension: A 12-week prospective randomized, open-label study trial.Medicine, , Volume: 97, Issue:30, 2018
Fatal outcome of late-onset angiotensin-converting enzyme inhibitor induced angioedema: A case report.Medicine, , Volume: 97, Issue:31, 2018
How to Treat Hypertension in Venlafaxine-Medicated Patients-Pharmacokinetic Considerations in Prescribing Amlodipine and Ramipril.Journal of clinical psychopharmacology, , Volume: 38, Issue:5, 2018
Hypertension Treatment Effects on Orthostatic Hypotension and Its Relationship With Cardiovascular Disease.Hypertension (Dallas, Tex. : 1979), , Volume: 72, Issue:4, 2018
Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.Lancet (London, England), , Jun-03, Volume: 389, Issue:10085, 2017
Short-term changes of serum potassium concentration induced by physical exercise in patient with arterial hypertension treated with angiotensin-converting enzyme inhibitor alone or in combination with statin.Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, , Volume: 68, Issue:1, 2017
Relative and Combined Prognostic Importance of On-Treatment Mean and Visit-to-Visit Blood Pressure Variability in ONTARGET and TRANSCEND Patients.Hypertension (Dallas, Tex. : 1979), , Volume: 70, Issue:5, 2017
[One year adherence of ramipril versus ramipril/amlodipine fixed dose combination therapy in hypertension].Orvosi hetilap, , Volume: 158, Issue:42, 2017
The effects of alpha 1-adrenoceptor blockade and angiotensin converting enzyme inhibition on central and brachial blood pressure and vascular reactivity: the doxazosin-ramipril study.Heart and vessels, , Volume: 32, Issue:6, 2017
Effects of Direct Renin Blockade on Renal & Systemic Hemodynamics and on RAAS Activity, in Weight Excess and Hypertension: A Randomized Clinical Trial.PloS one, , Volume: 12, Issue:1, 2017
Adverse cardiac effects of exogenous angiotensin 1-7 in rats with subtotal nephrectomy are prevented by ACE inhibition.PloS one, , Volume: 12, Issue:2, 2017
Potential Biomarkers for the Diagnosis of Angiotensin-Converting Enzyme Inhibitor-Induced Angioedema.ORL; journal for oto-rhino-laryngology and its related specialties, , Volume: 79, Issue:1-2, 2017
Clinical efficacy of African traditional medicines in hypertension: A randomized controlled trial with Combretum micranthum and Hibiscus sabdariffa.Journal of human hypertension, , Volume: 32, Issue:1, 2017
Risk of renal dysfunction in an elderly patient with chronic heart failure.Medizinische Monatsschrift fur Pharmazeuten, , Volume: 39, Issue:10, 2016
[Ramipril plus amlodipine and lisinopril plus amlodipine fixed dose combinations and patient's adherence].Orvosi hetilap, , Jan-03, Volume: 157, Issue:1, 2016
Benefits of Fixed Dose Combination of Ramipril/Amlodipine in Hypertensive Diabetic Patients: A Subgroup Analysis of RAMONA Trial.Chinese medical journal, , May-20, Volume: 129, Issue:10, 2016
Ramipril + amlodipine and ramipril + hydrochlorothiazide fixed-dose combinations in relation to patient adherence.The Journal of international medical research, , Volume: 44, Issue:5, 2016
Target Blood Pressure in Patients with Diabetes: Asian Perspective.Yonsei medical journal, , Volume: 57, Issue:6, 2016
[Comparative Assessment of Effects of Free and Fixed Combinations of Hypotensive Drugs on Quality of Life of Patients With Arterial Hypertension of High and Very High Risk].Kardiologiia, , Volume: 56, Issue:3, 2016
Combination therapy with aliskiren versus ramipril or losartan added to conventional therapy in patients with type 2 diabetes mellitus, uncontrolled hypertension and microalbuminuria.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 16, Issue:4, 2015
Single-pill combination therapy in the initial treatment of marked hypertension: a propensity-matched analysis.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 37, Issue:5, 2015
Systolic blood pressure variation and mean heart rate is associated with cognitive dysfunction in patients with high cardiovascular risk.Hypertension (Dallas, Tex. : 1979), , Volume: 65, Issue:3, 2015
High Incidence of ACE/PAI-1 in Association to a Spectrum of Other Polymorphic Cardiovascular Genes Involving PBMCs Proinflammatory Cytokines in Hypertensive Hypercholesterolemic Patients: Reversibility with a Combination of ACE Inhibitor and Statin.PloS one, , Volume: 10, Issue:5, 2015
[Usefulness of capsule endoscopy in obscure gastrointestinal bleeding].Gastroenterologia y hepatologia, , Volume: 38, Issue:10, 2015
Patients With Newly Diagnosed Hypertension Treated With the Renin Angiotensin Receptor Blocker Azilsartan Medoxomil vs Angiotensin-Converting Enzyme Inhibitors: The Prospective EARLY Registry.Journal of clinical hypertension (Greenwich, Conn.), , Volume: 17, Issue:12, 2015
Association of the ADRB2 (rs2053044) polymorphism and angiotensin-converting enzyme-inhibitor blood pressure response in the African American Study of Kidney Disease and Hypertension.Pharmacogenetics and genomics, , Volume: 25, Issue:9, 2015
Olmesartan vs ramipril in the treatment of hypertension and associated clinical conditions in the elderly: a reanalysis of two large double-blind, randomized studies at the light of the most recent blood pressure targets recommended by guidelines.Clinical interventions in aging, , Volume: 10, 2015
The Association of Losartan and Ramipril Therapy With Kidney and Cardiovascular Outcomes in Patients With Chronic Kidney Disease: A Chinese Nation-Wide Cohort Study in Taiwan.Medicine, , Volume: 94, Issue:48, 2015
The renin-angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril in clinical trials versus routine practice: insights from the prospective EARLY registry.Trials, , Dec-19, Volume: 16, 2015
[A 93-year-old patient with hypertensive crises and renal failure due to bilateral renal artery stenosis].MMW Fortschritte der Medizin, , Nov-05, Volume: 157, Issue:19, 2015
Greater efficacy of aldosterone blockade and diuretic reinforcement vs. dual renin-angiotensin blockade for left ventricular mass regression in patients with resistant hypertension.Journal of hypertension, , Volume: 32, Issue:10, 2014
Effect of telmisartan vs. ramipril on 'dipping' status and blood pressure variability: pooled analysis of the PRISMA studies.Hypertension research : official journal of the Japanese Society of Hypertension, , Volume: 37, Issue:2, 2014
Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading.Clinical and experimental nephrology, , Volume: 18, Issue:4, 2014
The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.European journal of preventive cardiology, , Volume: 21, Issue:3, 2014
Olmesartan vs. ramipril in elderly hypertensive patients: review of data from two published randomized, double-blind studies.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, , Volume: 21, Issue:1, 2014
The effect of aliskiren versus ramipril-based treatment on the Ambulatory Arterial Stiffness Index in hypertensive patients.International angiology : a journal of the International Union of Angiology, , Volume: 33, Issue:1, 2014
[The role of ramipril in the therapy of diabetic nephropathy].Orvosi hetilap, , Feb-16, Volume: 155, Issue:7, 2014
Effects of a long-term treatment with aliskiren or ramipril on structural alterations of subcutaneous small-resistance arteries of diabetic hypertensive patients.Hypertension (Dallas, Tex. : 1979), , Volume: 64, Issue:4, 2014
Effects of aliskiren- and ramipril-based treatment on central aortic blood pressure in elderly with systolic hypertension: a substudy of AGELESS.Vascular health and risk management, , Volume: 10, 2014
Childhood polyarteritis nodosa presenting as stroke and arterial hypertension.BMJ case reports, , Oct-29, Volume: 2014, 2014
Constitutive activation of the renin-angiotensin system reduces visceral fat and improves glucose tolerance in mice.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 15, Issue:4, 2014
[Medication adherence with the fixed combination of ramipril and amlodipine].Orvosi hetilap, , Nov-23, Volume: 155, Issue:47, 2014
Recent clinical trials.Journal of the American Society of Hypertension : JASH, , Volume: 8, Issue:10, 2014
Ramipril/amlodipine single pill - effectiveness, tolerance and patient satisfaction with antihypertensive therapy in relation to nutritional status.Pharmacological reports : PR, , Volume: 66, Issue:6, 2014
[The influence of combined therapy with calcium antagonist and angiotensin-converting enzyme inhibitor on the circadian profile of arterial pressure in patients with arterial hypertension in the Far North].Klinicheskaia meditsina, , Volume: 92, Issue:10, 2014
Time course of antiproteinuric effect of aliskiren in arterial hypertension associated with type 2 diabetes and microalbuminuria.Expert opinion on pharmacotherapy, , Volume: 14, Issue:4, 2013
Suits you? A qualitative study exploring preferences regarding the tailoring of consumer medicines information.The International journal of pharmacy practice, , Volume: 21, Issue:4, 2013
Response to nondipping and cardiovascular risk after morning renin–angiotensin blockade.Hypertension (Dallas, Tex. : 1979), , Volume: 61, Issue:2, 2013
[Telangiectasia during amlodipine therapy].Annales de dermatologie et de venereologie, , Volume: 140, Issue:3, 2013
Etoricoxib attenuates effect of antihypertensives in a rodent model of DOCA-salt induced hypertension.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 35, Issue:8, 2013
Antihypertensive efficacy of the angiotensin receptor blocker azilsartan medoxomil compared with the angiotensin-converting enzyme inhibitor ramipril.Journal of human hypertension, , Volume: 27, Issue:8, 2013
Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a retrospective analysis in hypertensive patients of the SMILE-4 study.Journal of hypertension, , Volume: 31, Issue:6, 2013
Effect of aliskiren on arterial stiffness, compared with ramipril in patients with mild to moderate essential hypertension.Chinese medical journal, , Volume: 126, Issue:7, 2013
Efficacy and safety of two ramipril and hydrochlorothiazide fixed-dose combination formulations in adults with stage 1 or stage 2 arterial hypertension evaluated by using ABPM.Clinical therapeutics, , Volume: 35, Issue:5, 2013
Long-term control of ambulatory hypertension in children: improving with time but still not achieving new blood pressure goals.American journal of hypertension, , Volume: 26, Issue:7, 2013
Hypertension is difficult to control in children, too.American journal of hypertension, , Volume: 26, Issue:7, 2013
[Evaluation of efficacy and safety of hypertension treatment with original angiotensin-converting enzyme inhibitors: the comparison of original and generic formulations].Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, , Volume: 34, Issue:201, 2013
Ramipril-induced liver injury: case report and review of the literature.American journal of hypertension, , Volume: 26, Issue:9, 2013
Drugs for treating hypertension.Nursing, , Volume: 43, Issue:8, 2013
Effect of naproxen and acetaminophen on blood pressure lowering by ramipril, valsartan and aliskiren in hypertensive patients.Expert opinion on pharmacotherapy, , Volume: 14, Issue:14, 2013
Assessment of arterial stiffness: combine the pieces of the puzzle.Chinese medical journal, , Volume: 126, Issue:15, 2013
Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril.Postgraduate medicine, , Volume: 125, Issue:4, 2013
Ramipril and hydrochlorothiazide treatment of hypertensive urgency in the ED.The American journal of emergency medicine, , Volume: 31, Issue:10, 2013
Medication adherence in hypertensive patients of different cardiovascular risk treated in primary health care.Przeglad lekarski, , Volume: 70, Issue:6, 2013
[Effect of RAAS antagonist on the expression of gap junction cx43 in myocardium of spontaneously hypertensive rat].Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition, , Volume: 44, Issue:4, 2013
[Advantages of ramipril/amlodipin fixed combination therapy. When should we use it?].Orvosi hetilap, , Oct-20, Volume: 154, Issue:42, 2013
Nonpharmacologic treatment is an indispensable part of antihypertensive therapy in all hypertensive children.American journal of hypertension, , Volume: 26, Issue:12, 2013
Effect of imidapril versus ramipril on urinary albumin excretion in hypertensive patients with type 2 diabetes and microalbuminuria.Expert opinion on pharmacotherapy, , Volume: 14, Issue:18, 2013
Impact of angiotensin-converting enzyme gene polymorphism on proteinuria and arterial hypertension.Collegium antropologicum, , Volume: 37, Issue:3, 2013
[Possibilities of rational combination antihypertensive therapy: results of HEMERA international clinical trial].Terapevticheskii arkhiv, , Volume: 85, Issue:10, 2013
Thrombin activatable fibrinolysis inhibitor (TAFI) levels in hypertensive patients and a comparison of the effects of amlodipine and ramipril on TAFI levels.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 35, Issue:2, 2013
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.Hypertension (Dallas, Tex. : 1979), , Volume: 61, Issue:1, 2013
Long-term treatment with ramipril favourably modifies the haemostatic response to acute submaximal exercise in hypertensives.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 14, Issue:4, 2013
Nondipping and cardiovascular risk after morning renin-angiotensin blockade.Hypertension (Dallas, Tex. : 1979), , Volume: 61, Issue:2, 2013
Treatment of early immunoglobulin A nephropathy by angiotensin-converting enzyme inhibitor.The American journal of medicine, , Volume: 126, Issue:2, 2013
Effect of telmisartan and ramipril on atrial fibrillation recurrence and severity in hypertensive patients with metabolic syndrome and recurrent symptomatic paroxysmal and persistent atrial fibrillation.Journal of cardiovascular pharmacology and therapeutics, , Volume: 17, Issue:1, 2012
Renin-angiotensin-aldosterone system blockade is safe and effective in elderly hypertensive patients with and without impaired renal function.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, , Volume: 19, Issue:4, 2012
Antihypertensive efficacy of olmesartan medoxomil and ramipril in elderly patients with mild to moderate hypertension grouped according to renal function status : a retrospective analysis.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension, , Volume: 19, Issue:4, 2012
Effects of valsartan or ramipril addition to amlodipine/hydrochlorothiazide combination on left ventricular mass in diabetic hypertensive patients with left ventricular hypertrophy.Expert opinion on pharmacotherapy, , Volume: 13, Issue:8, 2012
Twenty-four hour and early morning blood pressure control of olmesartan vs. ramipril in elderly hypertensive patients: pooled individual data analysis of two randomized, double-blind, parallel-group studies.Journal of hypertension, , Volume: 30, Issue:7, 2012
Cardiovascular and systemic microvascular effects of anti-vascular endothelial growth factor therapy for cancer.Journal of the American College of Cardiology, , Aug-14, Volume: 60, Issue:7, 2012
Sequential nephron blockade versus sequential renin-angiotensin system blockade in resistant hypertension: a prospective, randomized, open blinded endpoint study.Journal of hypertension, , Volume: 30, Issue:8, 2012
A comparison of the antihypertensive and anti-inflammatory effects of aliskiren and ramipril add-on therapy in peritoneal dialysis patients--a pilot open label study.Kidney & blood pressure research, , Volume: 36, Issue:1, 2012
Additional drug treatment in resistant hypertension: need for randomized studies.Journal of hypertension, , Volume: 30, Issue:8, 2012
Comparison of risk factor reduction and tolerability of a full-dose polypill (with potassium) versus low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases: the Second Indian Polycap Study (TIPS-2) investigators.Circulation. Cardiovascular quality and outcomes, , Jul-01, Volume: 5, Issue:4, 2012
Ambulatory blood pressure values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET).Hypertension (Dallas, Tex. : 1979), , Volume: 60, Issue:6, 2012
Antihypertensive and laxative effects by pharmacological inhibition of sodium-proton-exchanger subtype 3-mediated sodium absorption in the gut.Hypertension (Dallas, Tex. : 1979), , Volume: 60, Issue:6, 2012
[Dual blockade of the renin-angiotensin system in hypertensive treatment: yes].Deutsche medizinische Wochenschrift (1946), , Volume: 137, Issue:48, 2012
Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly mild to moderate essential hypertensive patients with or without metabolic syndrome: a pooled post hoc analysis of two comparative trials.Drugs & aging, , Volume: 29, Issue:12, 2012
Effect of aliskiren treatment on endothelium-dependent vasodilation and aortic stiffness in essential hypertensive patients.European heart journal, , Volume: 33, Issue:12, 2012
Inhibition of the renin-angiotensin-aldosterone system: is there room for dual blockade in the cardiorenal continuum?Journal of hypertension, , Volume: 30, Issue:4, 2012
Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study.Cardiovascular diabetology, , Jan-09, Volume: 11, 2012
Chronic kidney disease: cardiac and renal angiotensin-converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition.Experimental physiology, , Volume: 97, Issue:4, 2012
Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).Journal of the American College of Cardiology, , Jan-03, Volume: 59, Issue:1, 2012
Finding a place for aliskiren in the wide spectrum of blood pressure lowering agents.Hypertension research : official journal of the Japanese Society of Hypertension, , Volume: 35, Issue:1, 2012
Simvastatin enhances the antihypertensive effect of ramipril in hypertensive hypercholesterolemic animals and patients. Possible role of nitric oxide, oxidative stress, and high sensitivity C-reactive protein.Fundamental & clinical pharmacology, , Volume: 26, Issue:6, 2012
Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension.Hypertension research : official journal of the Japanese Society of Hypertension, , Volume: 35, Issue:1, 2012
[Dental care with local anesthesia: should the patient first discontinue ACE inhibitors?].MMW Fortschritte der Medizin, , Mar-03, Volume: 153, Issue:9, 2011
Combination delapril/manidipine as antihypertensive therapy in high-risk patients.Clinical drug investigation, , Volume: 31, Issue:7, 2011
Mixed messages on blood pressure goals.Hypertension (Dallas, Tex. : 1979), , Volume: 57, Issue:6, 2011
Limitations of analyses based on achieved blood pressure: lessons from the African American study of kidney disease and hypertension trial.Hypertension (Dallas, Tex. : 1979), , Volume: 57, Issue:6, 2011
[Prevention of hypertension by drugs and immunization against angiotensin II].Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine, , Feb-10, Volume: 100, Issue:2, 2011
Hypertension augments cardiac Toll-like receptor 4 expression and activity.Hypertension research : official journal of the Japanese Society of Hypertension, , Volume: 34, Issue:5, 2011
Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesartan and ramipril.International journal of clinical practice, , Volume: 65, Issue:2, 2011
Different actions of losartan and ramipril on adipose tissue activity and vascular remodeling biomarkers in hypertensive patients.Hypertension research : official journal of the Japanese Society of Hypertension, , Volume: 34, Issue:1, 2011
Stimulation of cardiac apoptosis in ovariectomized hypertensive rats: potential role of the renin-angiotensin system.Journal of hypertension, , Volume: 29, Issue:2, 2011
Angiotensin-(1-7) infusion is associated with increased blood pressure and adverse cardiac remodelling in rats with subtotal nephrectomy.Clinical science (London, England : 1979), , Volume: 120, Issue:8, 2011
Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension.Blood pressure. Supplement, , Volume: 1, 2011
Impact of nephron number dosing on cardiorenal damage and effects of ACE inhibition.American journal of hypertension, , Volume: 24, Issue:4, 2011
[High blood pressure in the morning].MMW Fortschritte der Medizin, , Dec-08, Volume: 153, Issue:49-50, 2011
Effect of ramipril therapy on abnormal left atrial appendage function.The Journal of international medical research, , Volume: 39, Issue:6, 2011
Comparison between nebivolol and ramipril in patients with hypertension and left ventricular hypertrophy: a randomized open blinded end-point (PROBE) trial.European review for medical and pharmacological sciences, , Volume: 15, Issue:12, 2011
New clinical concepts after the ONTARGET trial.Expert review of cardiovascular therapy, , Volume: 9, Issue:6, 2011
Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study.Journal of hypertension, , Volume: 28, Issue:11, 2010
A comparison of the effects of ramipril and losartan on blood pressure control and left ventricle hypertrophy in patients with autosomal dominant polycystic kidney disease.Renal failure, , Volume: 32, Issue:8, 2010
Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients.Renal failure, , Volume: 32, Issue:8, 2010
Effects of suboptimal doses of the AT1 receptor blocker, telmisartan, with the angiotensin-converting enzyme inhibitor, ramipril, on cerebral arterioles in spontaneously hypertensive rat.Journal of hypertension, , Volume: 28, Issue:7, 2010
Reduced cerebrovascular remodeling and functional impairment in spontaneously hypertensive rats following combined treatment with suboptimal doses of telmisartan and ramipril: is less really more?Journal of hypertension, , Volume: 28, Issue:7, 2010
New standards in hypertension and cardiovascular risk management: focus on telmisartan.Vascular health and risk management, , Mar-24, Volume: 6, 2010
New data on ONTARGET: more confusion?Journal of clinical hypertension (Greenwich, Conn.), , Volume: 12, Issue:3, 2010
Aliskiren versus ramipril in hypertension.Therapeutic advances in cardiovascular disease, , Volume: 4, Issue:3, 2010
ACE inhibition reduces infarction in normotensive but not hypertensive rats: correlation with cortical ACE activity.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism, , Volume: 30, Issue:8, 2010
Comparative efficacy of aliskiren monotherapy and ramipril monotherapy in patients with stage 2 systolic hypertension: subgroup analysis of a double-blind, active comparator trial.Cardiovascular therapeutics, , Volume: 28, Issue:6, 2010
Images in cardiovascular medicine. Wide-field scanning laser ophthalmoscope imaging and angiography of central retinal vein occlusion.Circulation, , Mar-30, Volume: 121, Issue:12, 2010
[An experience with the use of direct renin inhibitor aliskiren in a patient with obesity and arterial hypertension].Kardiologiia, , Volume: 50, Issue:2, 2010
Kidney flow and function in hypertension: protective effects of pycnogenol in hypertensive participants--a controlled study.Journal of cardiovascular pharmacology and therapeutics, , Volume: 15, Issue:1, 2010
Aliskiren for geriatric lowering of systolic hypertension: a randomized controlled trial.Journal of human hypertension, , Volume: 24, Issue:9, 2010
Choosing an angiotensin-receptor blocker: blood pressure lowering, cardiovascular protection or both?Future cardiology, , Volume: 6, Issue:1, 2010
Reduction in renal ACE2 expression in subtotal nephrectomy in rats is ameliorated with ACE inhibition.Clinical science (London, England : 1979), , Volume: 118, Issue:4, 2010
Ramipril in the treatment of proteinuria in children after renal transplantation.Pediatric transplantation, , Volume: 14, Issue:2, 2010
Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.Journal of human hypertension, , Volume: 24, Issue:2, 2010
Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs.International journal of cardiology, , Apr-01, Volume: 140, Issue:1, 2010
[Role of ACE-inhibitors in preventing atrial fibrillation relapses in normotensive patients].Recenti progressi in medicina, , Volume: 100, Issue:11, 2009
Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).The American journal of cardiology, , Dec-01, Volume: 104, Issue:11, 2009
Blood-pressure control and delay in progression of kidney disease in children.The New England journal of medicine, , Oct-22, Volume: 361, Issue:17, 2009
Strict blood-pressure control and progression of renal failure in children.The New England journal of medicine, , Oct-22, Volume: 361, Issue:17, 2009
Severe paradoxical hypertension with angiotensin-converting enzyme inhibitors: an unusual feature of renal artery stenosis.Hypertension (Dallas, Tex. : 1979), , Volume: 54, Issue:3, 2009
Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 10, Issue:3, 2009
Achieving blood pressure goals: should angiotensin II receptor blockers become first-line treatment in hypertension?Journal of hypertension. Supplement : official journal of the International Society of Hypertension, , Volume: 27, Issue:5, 2009
Cardiovascular protection: a breakthrough for high-risk patients?Journal of hypertension. Supplement : official journal of the International Society of Hypertension, , Volume: 27, Issue:5, 2009
Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor.Journal of hypertension. Supplement : official journal of the International Society of Hypertension, , Volume: 27, Issue:5, 2009
Introduction: Reducing cardiovascular risk: ONTARGET--a new standard in cardiovascular protection.Journal of hypertension. Supplement : official journal of the International Society of Hypertension, , Volume: 27, Issue:5, 2009
Effect of angiotensin-converting enzyme inhibition on C-reactive protein levels: the ramipril C-reactive pRotein randomized evaluation (4R) trial results.The Canadian journal of cardiology, , Volume: 25, Issue:7, 2009
Aliskiren monotherapy results in the greatest and the least blood pressure lowering in patients with high- and low-baseline PRA levels, respectively.American journal of hypertension, , Volume: 22, Issue:9, 2009
Efficacy and tolerability of two formulations of ramipril in Korean adults with mild to moderate essential hypertension: an 8-week, multicenter, prospective, randomized, open-label, parallel-group noninferiority trial.Clinical therapeutics, , Volume: 31, Issue:5, 2009
CORD: COmparsion of Recommended Doses of ACE inhibitors and angiotensin II receptor blockers.Vnitrni lekarstvi, , Volume: 55, Issue:5, 2009
Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study.Journal of hypertension, , Volume: 27, Issue:7, 2009
[The study of effects of ramipril and amlodipine combination in patients with arterial hypertension and type 2 diabetes mellitus].Kardiologiia, , Volume: 49, Issue:5, 2009
Chronotherapy with the angiotensin-converting enzyme inhibitor ramipril in essential hypertension: improved blood pressure control with bedtime dosing.Hypertension (Dallas, Tex. : 1979), , Volume: 54, Issue:1, 2009
Does it matter when drugs are taken?Hypertension (Dallas, Tex. : 1979), , Volume: 54, Issue:1, 2009
Recent advances in cardiovascular risk reduction: implications of ONTARGET.Clinical cornerstone, , Volume: 9 Suppl 3, 2009
ACE inhibition promotes upregulation of endothelial progenitor cells and neoangiogenesis in cardiac pressure overload.Cardiovascular research, , Jul-01, Volume: 83, Issue:1, 2009
[The ONTARGET trial].Giornale italiano di cardiologia (2006), , Volume: 10, Issue:2, 2009
Conjugated linoleic acid supplementation enhances antihypertensive effect of ramipril in Chinese patients with obesity-related hypertension.American journal of hypertension, , Volume: 22, Issue:6, 2009
Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials.Journal of human hypertension, , Volume: 23, Issue:9, 2009
ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?Blood pressure, , Volume: 18, Issue:1-2, 2009
Normal pregnancy and healthy child after continued exposure to gliclazide and ramipril during pregnancy.The Annals of pharmacotherapy, , Volume: 43, Issue:1, 2009
Renal vascular endothelial function in hypertensive patients with type 2 diabetes mellitus.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 53, Issue:2, 2009
Hypertension-mediated albuminuria is associated with reduced lysosomal activity in the kidney and the heart.American journal of nephrology, , Volume: 29, Issue:5, 2009
Telmisartan versus angiotension-converting enzyme inhibitors in the treatment of hypertension: a meta-analysis of randomized controlled trials.Journal of human hypertension, , Volume: 23, Issue:5, 2009
The PHARAO study: prevention of hypertension with the angiotensin-converting enzyme inhibitor ramipril in patients with high-normal blood pressure: a prospective, randomized, controlled prevention trial of the German Hypertension League.Journal of hypertension, , Volume: 26, Issue:7, 2008
Blockade of sensory abnormalities and kinin B(1) receptor expression by N-acetyl-L-cysteine and ramipril in a rat model of insulin resistance.European journal of pharmacology, , Jul-28, Volume: 589, Issue:1-3, 2008
A stunning day in hypertension research - Results of ONTARGET, ACCOMPLISH and HYVET.Blood pressure, , Volume: 17, Issue:2, 2008
Combination of amlodipine 10 mg and valsartan 160 mg lowers blood pressure in patients with hypertension not controlled by an ACE inhibitor/CCB combination.Blood pressure. Supplement, , Volume: 2, 2008
[Parameters of vasomotor function of endothelium and elasticity of arterial wall during therapy with angiotensin converting enzyme inhibitor ramiprilin patients with type 2 diabetes mellitus].Kardiologiia, , Volume: 48, Issue:11, 2008
[Treatment of patients at high cardiovascular risk: confirmation and surprising results of the ONTARGET-Study].Praxis, , May-14, Volume: 97, Issue:10, 2008
Comparative effects of N-acetyl-L-cysteine and ramipril on arterial hypertension, insulin resistance, and oxidative stress in chronically glucose-fed rats.Canadian journal of physiology and pharmacology, , Volume: 86, Issue:11, 2008
Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives.Journal of hypertension, , Volume: 26, Issue:12, 2008
Safety and tolerability of ramipril 10 mg in patients at high risk of cardiovascular events: an observational study.Journal of the Indian Medical Association, , Volume: 106, Issue:7, 2008
Can aliskiren reduce the incidence of cough caused by ramipril?Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 9, Issue:3, 2008
Telmisartan and stroke reduction in the ONTARGET trial: benefit beyond blood pressure lowering?Cerebrovascular diseases (Basel, Switzerland), , Volume: 26, Issue:5, 2008
The smoothness of blood pressure control of ramipril in essential hypertensive Thai patients evaluation by 24-hour ambulatory blood pressure monitoring.Journal of the Medical Association of Thailand = Chotmaihet thangphaet, , Volume: 91, Issue:9, 2008
An 18-week, prospective, randomized, double-blind, multicenter study of amlodipine/ramipril combination versus amlodipine monotherapy in the treatment of hypertension: the assessment of combination therapy of amlodipine/ramipril (ATAR) study.Clinical therapeutics, , Volume: 30, Issue:9, 2008
Prognostic value of the insertion/deletion polymorphism of the ACE gene in type 2 diabetic subjects: results from the Non-Insulin-Dependent Diabetes, Hypertension, Microalbuminuria or Proteinuria, Cardiovascular events, and Ramipril (DIABHYCAR), Diabete dDiabetes care, , Volume: 31, Issue:10, 2008
Evaluation of fixed dose combination (FDC) of telmisartan+ramipril usage in patients with micro-albuminuria and persistent hypertension: A TRIUMPH study.Journal of the Indian Medical Association, , Volume: 106, Issue:3, 2008
[Choroidal effusion after uncomplicated cataract surgery].Klinische Monatsblatter fur Augenheilkunde, , Volume: 225, Issue:6, 2008
Utility of semiautomatic clinic and 24-h ambulatory blood pressure measurements to evaluate combination therapy: the Ramipril-Hydrochlorothiazide Hypertension trial.Journal of human hypertension, , Volume: 22, Issue:8, 2008
Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans.Archives of internal medicine, , Apr-28, Volume: 168, Issue:8, 2008
[Beneficial effects of Hartil on cardiovascular remodeling process in elderly and old patients with isolated systolic arterial hypertension].Georgian medical news, , Issue:154, 2008
Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial.Journal of hypertension, , Volume: 26, Issue:3, 2008
Effects of a Rho kinase inhibitor on pressure overload induced cardiac hypertrophy and associated diastolic dysfunction.American journal of physiology. Heart and circulatory physiology, , Volume: 294, Issue:4, 2008
Effects of dual blockade of Renin-Angiotensin system on concentric left ventricular hypertrophy in essential hypertension: a randomized, controlled pilot study.American journal of hypertension, , Volume: 21, Issue:2, 2008
Renal and cardiac effects of antihypertensive treatment with ramipril versus metoprolol in autosomal dominant polycystic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 23, Issue:2, 2008
Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 23, Issue:2, 2008
ONTARGET: questions asked, questions answered.Journal of clinical hypertension (Greenwich, Conn.), , Volume: 10, Issue:6, 2008
[Therapy of hypertension with expanded outlook. Constant pressure decline and organ protection].MMW Fortschritte der Medizin, , Dec-06, Volume: 149, Issue:49-50, 2007
Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 8, Issue:4, 2007
Clinical trial update: focus on the ONTARGET study.Vascular health and risk management, , Volume: 3, Issue:6, 2007
Angiotensin-converting enzyme gene polymorphism predicts the time-course of blood pressure response to angiotensin converting enzyme inhibition in the AASK trial.Journal of hypertension, , Volume: 25, Issue:10, 2007
Regression of left-ventricular hypertrophy in children and adolescents with hypertension during ramipril monotherapy.American journal of hypertension, , Volume: 20, Issue:9, 2007
Differential effects of ramipril on ambulatory blood pressure in African Americans and Caucasians.American journal of hypertension, , Volume: 20, Issue:8, 2007
Treatment of microalbuminuria in hypertensive subjects with elevated cardiovascular risk: results of the IMPROVE trial.Kidney international, , Volume: 72, Issue:7, 2007
Rationale for double renin-angiotensin-aldosterone system blockade.The American journal of cardiology, , Aug-06, Volume: 100, Issue:3A, 2007
The effect of telmisartan and ramipril on early morning blood pressure surge: a pooled analysis of two randomized clinical trials.Blood pressure monitoring, , Volume: 12, Issue:3, 2007
Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients.European heart journal, , Volume: 28, Issue:12, 2007
Optimal treatment of obesity-related hypertension: the Hypertension-Obesity-Sibutramine (HOS) study.Circulation, , Apr-17, Volume: 115, Issue:15, 2007
Effect of sulfhydryl and non-sulfhydryl angiotensin-converting enzyme inhibitors on endothelial function in essential hypertensive patients.American journal of hypertension, , Volume: 20, Issue:4, 2007
Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome.Nephrology (Carlton, Vic.), , Volume: 12, Issue:2, 2007
[Fasciitis with eosinophilia: a possible causal role of angiotensin converting enzyme inhibitor].Revue neurologique, , Volume: 163, Issue:2, 2007
Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes.Diabetes care, , Volume: 30, Issue:6, 2007
Effects of ACE inhibition and beta-blockade on plasminogen activator inhibitor-1 and transforming growth factor-beta1 in carotid glomus and autonomic ganglia in hypertensive rats.American journal of hypertension, , Volume: 20, Issue:3, 2007
Effect of dual blockade of renin-angiotensin system on TGFbeta1 and left ventricular structure and function in hypertensive patients.Journal of human hypertension, , Volume: 21, Issue:4, 2007
Effect of ramipril on the incidence of diabetes.The New England journal of medicine, , Feb-01, Volume: 356, Issue:5, 2007
Effect of ramipril on the incidence of diabetes.The New England journal of medicine, , Feb-01, Volume: 356, Issue:5, 2007
Ramipril dose-dependently increases nitric oxide availability in the radial artery of essential hypertension patients.Journal of hypertension, , Volume: 25, Issue:2, 2007
Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.Hypertension (Dallas, Tex. : 1979), , Volume: 49, Issue:2, 2007
A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity.Journal of hypertension, , Volume: 25, Issue:1, 2007
Lichen planus pemphigoides associated with ramipril.International journal of dermatology, , Volume: 45, Issue:12, 2006
Vasopeptidase inhibition prevents target organ damage and improves survival in spontaneously hypertensive rats.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 7, Issue:3, 2006
Redefining the ACE-inhibitor dose-response relationship: substantial blood pressure lowering after massive doses.European journal of clinical pharmacology, , Volume: 62, Issue:12, 2006
Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.International journal of clinical practice, , Volume: 60, Issue:11, 2006
Antihypertensive agents have different ability to modulate arterial pressure and heart rate variability in 2K1C rats.American journal of hypertension, , Volume: 19, Issue:10, 2006
Lessons from the African-American Study of Kidney Disease and Hypertension: an update.Current hypertension reports, , Volume: 8, Issue:5, 2006
Different pathomechanisms of essential and obesity-associated hypertension in adolescents.Pediatric nephrology (Berlin, Germany), , Volume: 21, Issue:10, 2006
[In the framework of the 72nd Annual Meeting of the DKG (German CardiologySociety) in Mannheim presented: Ontarget-the until now largest study program on cardiovascular prevention in patients with hypertension].MMW Fortschritte der Medizin, , Jun-29, Volume: 148, Issue:26, 2006
Oxidative stress: a potentially important new marker in renal transplantation.The Journal of pediatrics, , Volume: 149, Issue:1, 2006
The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension.Journal of hypertension, , Volume: 24, Issue:7, 2006
Quality of life in the African American Study of Kidney Disease and Hypertension: effects of blood pressure management.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 47, Issue:6, 2006
Differential antiplatelet effects of angiotensin converting enzyme inhibitors: comparison of ex vivo platelet aggregation in cardiovascular patients with ramipril, captopril and enalapril.Clinical research in cardiology : official journal of the German Cardiac Society, , Volume: 95, Issue:4, 2006
Initiation of hypertension treatment with a fixed-dose combination or its monocomponents -- does it really matter?International journal of clinical practice, , Volume: 60, Issue:3, 2006
Microalbuminuria and tubular proteinuria as risk predictors of cardiovascular morbidity and mortality in essential hypertension: final results of a prospective long-term study (MARPLE Study)*.Journal of hypertension, , Volume: 24, Issue:3, 2006
Smart damping modulation of carotid wall energetics in human hypertension: effects of angiotensin-converting enzyme inhibition.Hypertension (Dallas, Tex. : 1979), , Volume: 47, Issue:3, 2006
A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring.American journal of hypertension, , Volume: 19, Issue:1, 2006
Urinary TGF-beta1 reduction related to a decrease of systolic blood pressure in patients with type 2 diabetes and clinical diabetic nephropathy.Diabetes research and clinical practice, , Volume: 72, Issue:3, 2006
The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I).Journal of hypertension, , Volume: 24, Issue:1, 2006
Ramipril in the treatment of vascular diseases.Expert opinion on pharmacotherapy, , Volume: 6, Issue:11, 2005
[A patient with severe hyperkalaemia -- an emergency after RALES].Deutsche medizinische Wochenschrift (1946), , Sep-09, Volume: 130, Issue:36, 2005
Ramipril/felodipine extended-release fixed-dose combination: a review of its use in the management of essential hypertension.Drugs, , Volume: 65, Issue:13, 2005
An update of irbesartan and renin-angiotensin system blockade in diabetic nephropathy.Expert opinion on pharmacotherapy, , Volume: 6, Issue:9, 2005
The comparative effects of telmisartan and ramipril on P-wave dispersion in hypertensive patients: a randomized clinical study.Clinical cardiology, , Volume: 28, Issue:6, 2005
Ramipril prevents extracellular matrix accumulation in cerebral microvessels.Neurological research, , Volume: 27, Issue:5, 2005
[Experiences with the realisation of innovative study designs using the example of the HOPE-study].Deutsche medizinische Wochenschrift (1946), , Jul-08, Volume: 130 Suppl 2, 2005
Ramipril induced polyserositis with pericardial tamponade and pleural effusion.International journal of cardiology, , Jul-10, Volume: 102, Issue:2, 2005
Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses.Journal of the American Society of Nephrology : JASN, , Volume: 16 Suppl 1, 2005
Blood pressure control, drug therapy, and kidney disease.Hypertension (Dallas, Tex. : 1979), , Volume: 46, Issue:1, 2005
Effect of the renin-angiotensin system or calcium channel blockade on the circadian variation of heart rate variability, blood pressure and circulating catecholamines in hypertensive patients.Journal of hypertension, , Volume: 23, Issue:6, 2005
[Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].Italian heart journal : official journal of the Italian Federation of Cardiology, , Volume: 6 Suppl 7, 2005
The ONTARGET/TRANSCEND Trial Programme: baseline data.Acta diabetologica, , Volume: 42 Suppl 1, 2005
[Effects of losartan, ramipril and their combination on left ventricular remodeling and function in spontaneous hypertensive rats].Zhonghua yi xue za zhi, , Nov-30, Volume: 85, Issue:45, 2005
[Hypertension and diabetic nephropathy, a dangerous duo].Medizinische Klinik (Munich, Germany : 1983), , Nov-15, Volume: 100, Issue:11, 2005
The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.Archives of internal medicine, , Apr-25, Volume: 165, Issue:8, 2005
Effects of circadian rhythms, posture, and medication on renin-aldosterone interrelations in essential hypertensives.American journal of hypertension, , Volume: 18, Issue:1, 2005
[Experiences with the realisation of the innovative study designs using the example of the HOPE study -- concerning the contribution in DMW Supplement 2/2005].Deutsche medizinische Wochenschrift (1946), , Nov-25, Volume: 130, Issue:47, 2005
Renoprotective effect of early inhibition of the renin-angiotensin system in renal transplant recipients.Transplantation proceedings, , Volume: 37, Issue:2, 2005
Benefits from angiotensin-converting enzyme inhibitor 'beyond blood pressure lowering': beyond blood pressure or beyond the brachial artery?Journal of hypertension, , Volume: 23, Issue:3, 2005
Cardiovascular risk in patients with mild renal insufficiency: implications for the use of ACE inhibitors.Presse medicale (Paris, France : 1983), , Oct-22, Volume: 34, Issue:18, 2005
Comparative effects of the angiotensin II receptor blocker, telmisartan, and the angiotensin-converting enzyme inhibitor, ramipril, on cerebrovascular structure in spontaneously hypertensive rats.Journal of hypertension, , Volume: 23, Issue:5, 2005
Ventricular and vascular remodelling effects of the angiotensin II receptor blocker telmisartan and/or the angiotensin-converting enzyme inhibitor ramipril in hypertensive patients.The Journal of international medical research, , Volume: 33 Suppl 1, 2005
ACE inhibition reduces activity of the plasminogen/plasmin and MMP systems in the brain of spontaneous hypertensive stroke-prone rats.Neuroscience letters, , Mar-16, Volume: 376, Issue:3, 2005
Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme.Expert opinion on pharmacotherapy, , Volume: 5, Issue:5, 2004
[Involvement of angiotensin II in pathogenesis of hypertension and target organ damage].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 62 Suppl 3, 2004
[Hypertensive nephrosclerosis].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 62 Suppl 3, 2004
Simvastatin combined with ramipril treatment in hypercholesterolemic patients.Hypertension (Dallas, Tex. : 1979), , Volume: 44, Issue:2, 2004
Fresh frozen plasma in the treatment of resistant angiotensin-converting enzyme inhibitor angioedema.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology, , Volume: 92, Issue:5, 2004
Ramipril: clinical and economic benefits.Internal medicine journal, , Volume: 34, Issue:7, 2004
The JNC 7 approach compared to conventional treatment in diabetic patients with hypertension: a double-blind trial of initial monotherapy vs. combination therapy.Journal of clinical hypertension (Greenwich, Conn.), , Volume: 6, Issue:8, 2004
[Case report: hypertension after stroke].Wiener medizinische Wochenschrift (1946), , Volume: 154 Spec No 1, Issue:1, 2004
Effects of graded-release diltiazem versus ramipril, dosed at bedtime, on early morning blood pressure, heart rate, and the rate-pressure product.American heart journal, , Volume: 148, Issue:4, 2004
Acute pancreatitis due to ramipril therapy.Postgraduate medical journal, , Volume: 80, Issue:948, 2004
A comparison of the efficacy and duration of action of telmisartan, amlodipine and ramipril in patients with confirmed ambulatory hypertension.Blood pressure monitoring, , Volume: 9, Issue:5, 2004
[ACE inhibitor therapy until end of life?].Deutsche medizinische Wochenschrift (1946), , Oct-29, Volume: 129, Issue:44, 2004
The PROGRESS trial three years later: HOPE trial may shed some light.BMJ (Clinical research ed.), , Dec-11, Volume: 329, Issue:7479, 2004
Evaluation of efficacy and tolerability of Losartan and Ramipril combination in the management of hypertensive patients with associated diabetes mellitus in India (LORD Trial).The Journal of the Association of Physicians of India, , Volume: 52, 2004
Timing of drug treatment is crucial.BMJ (Clinical research ed.), , Jan-17, Volume: 328, Issue:7432, 2004
Losartan-ramipril combination treatment.The Journal of the Association of Physicians of India, , Volume: 52, 2004
An unusual cause of exertional leg pain.Current sports medicine reports, , Volume: 3, Issue:2, 2004
Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE?Current medical research and opinion, , Volume: 20, Issue:3, 2004
Combined blockade of AT1-receptors and ACE synergistically potentiates antihypertensive effects in SHR.Journal of hypertension, , Volume: 22, Issue:3, 2004
Effect of lercanidipine compared with ramipril on albumin excretion rate in hypertensive Type 2 diabetic patients with microalbuminuria: DIAL study (diabete, ipertensione, albuminuria, lercanidipina).Diabetes, nutrition & metabolism, , Volume: 17, Issue:5, 2004
Ramipril in the treatment of hypertension and proteinuria in children with chronic kidney diseases.American journal of hypertension, , Volume: 17, Issue:5 Pt 1, 2004
Bradykinin and matrix metalloproteinases are involved the structural alterations of rat small resistance arteries with inhibition of ACE and NEP.Journal of hypertension, , Volume: 22, Issue:4, 2004
Best bang for the buck?Current hypertension reports, , Volume: 5, Issue:1, 2003
The effect of ramipril on albumin excretion in diabetes and hypertension: the role of increased lysosomal activity and decreased transforming growth factor-beta expression.Journal of hypertension, , Volume: 21, Issue:2, 2003
Angiotensin-converting enzyme inhibitors for stroke prevention: is there HOPE for PROGRESS After LIFE?Stroke, , Volume: 34, Issue:2, 2003
[Dangerous duo: hypertension and pre-diabetes--the underestimated risk].MMW Fortschritte der Medizin, , Jan-23, Volume: 145, Issue:3-4, 2003
Antihypertensive drugs and renal protection.JAMA, , Mar-05, Volume: 289, Issue:9, 2003
More hype than HOPE.Hypertension (Dallas, Tex. : 1979), , Volume: 41, Issue:4, 2003
Parallel renal and extremity blood supply abnormalities in nonmodulation: responses to ACE inhibition.Hypertension (Dallas, Tex. : 1979), , Volume: 41, Issue:4, 2003
[Standpoint on the use of angiotensin receptor blockers in the treatment of hypertension].Harefuah, , Volume: 142, Issue:4, 2003
[Improved protection of heart and kidneys in the hypertensive patient. ACE inhibitor and AT1 blocker combined?].MMW Fortschritte der Medizin, , Jun-05, Volume: 145, Issue:23, 2003
[Relationship between regression of hypertensive left ventricular hypertrophy and improvement of coronary flow reserve].Zhonghua yi xue za zhi, , Apr-25, Volume: 83, Issue:8, 2003
[Ramipril in elderly patients with mild and moderate hypertension. Clinical efficacy, effect on cerebral blood flow and intellectual functioning].Kardiologiia, , Volume: 43, Issue:6, 2003
[Comparative assessment of antihypertensive effects of angiotensin-converting enzyme inhibitors ramipril and captopril in patients with hypertension in ambulatory settings].Kardiologiia, , Volume: 43, Issue:3, 2003
Conundrum of the HOPE study: time of taking ramipril may account for lack of relation between blood pressure and outcome.BMJ (Clinical research ed.), , Sep-20, Volume: 327, Issue:7416, 2003
[Corner points of antihypertensive therapy in prediabetic state. Success with a combination].MMW Fortschritte der Medizin, , Jul-10, Volume: 145, Issue:27-28, 2003
Ramipril improves nitric oxide availability in hypertensive rats with failing hearts after myocardial infarction.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 4, Issue:3, 2003
Recommendations for the management of special populations: racial and ethnic populations.American journal of hypertension, , Volume: 16, Issue:11 Pt 2, 2003
[Fast and strong lowering of pressure. The newest sartan has passed the practice test].MMW Fortschritte der Medizin, , Oct-30, Volume: 145, Issue:44, 2003
[Added organ protection at little cost. Double savings with ACE inhibitors].MMW Fortschritte der Medizin, , Nov-27, Volume: 145, Issue:48, 2003
[Therapy of hypertension. Cost conscious prevention of complications].MMW Fortschritte der Medizin, , Nov-20, Volume: 145, Issue:47, 2003
[Health care too costly? Saving more than 10 million euros in 2 months!].MMW Fortschritte der Medizin, , Nov-20, Volume: 145, Issue:47, 2003
[Therapy of hypertension. Lasting organ protection moves into the foreground].MMW Fortschritte der Medizin, , Nov-20, Volume: 145, Issue:47, 2003
[Hypertension and prediabetes. "Don't trust anybody over 130/80"].MMW Fortschritte der Medizin, , Mar-27, Volume: 145, Issue:13, 2003
Ramipril improves hemodynamic recovery but not microvascular response to ischemia in spontaneously hypertensive rats.American journal of hypertension, , Volume: 15, Issue:5, 2002
Effect of ramipril versus amlodipine on renal outcomes in hypertensive nephrosclerosis.Current hypertension reports, , Volume: 4, Issue:3, 2002
Renal protection by angiotensin II receptor antagonists in patients with type 2 diabetes.The Medical journal of Australia, , Mar-18, Volume: 176, Issue:6, 2002
[The plasma levels of proinsulin and true insulin and the effects of ramipril in hypertension].Zhonghua nei ke za zhi, , Volume: 41, Issue:2, 2002
[Therapy of hypertension with ACE inhibitors. One third fewer cases of diabetes].MMW Fortschritte der Medizin, , Mar-07, Volume: 144, Issue:10, 2002
Comparative effects of the dual ACE-NEP inhibitor MDL-100,240 and ramipril on hypertension and cardiovascular disease in endogenous angiotensin II-dependent hypertension.American journal of hypertension, , Volume: 15, Issue:2 Pt 1, 2002
The 24-hour blood pressure pattern: does it have implications for morbidity and mortality?The American journal of cardiology, , Jan-24, Volume: 89, Issue:2A, 2002
Severe angioedema induced by angiotensin converting enzyme inhibitors: role of precipitating factors.The Journal of dermatology, , Volume: 29, Issue:6, 2002
Dual ACE and NEP inhibitor MDL-100,240 prevents and regresses severe angiotensin II-dependent hypertension partially through bradykinin type 2 receptor.Journal of hypertension, , Volume: 20, Issue:7, 2002
Long-term angiotensin-converting enzyme inhibition with ramipril reduces thrombin generation in human hypertension.Clinical science (London, England : 1979), , Volume: 103, Issue:2, 2002
Using ACE inhibitors appropriately.American family physician, , Aug-01, Volume: 66, Issue:3, 2002
Oxidative stress in kidney transplant patients with calcineurin inhibitor-induced hypertension: effect of ramipril.Journal of cardiovascular pharmacology, , Volume: 40, Issue:4, 2002
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.JAMA, , Nov-20, Volume: 288, Issue:19, 2002
ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time.Hypertension (Dallas, Tex. : 1979), , Volume: 40, Issue:6, 2002
[Assessment of acute blood pressure variability during a stress test].Annales de cardiologie et d'angeiologie, , Volume: 51, Issue:2, 2002
[Type 2 diabetes and cardiovascular risk: lessons from therapeutic trials].La Revue du praticien, , Oct-15, Volume: 51, Issue:16, 2001
[Prediction, screening and treatment of renal complications of diabetes].La Revue du praticien, , Oct-15, Volume: 51, Issue:16, 2001
Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy.Hypertension (Dallas, Tex. : 1979), , Dec-01, Volume: 38, Issue:6, 2001
Mechanical vs intrinsic components in the improvement of brachial arterial compliance. Comparison of the effects of atenolol versus ramipril in hypertensive patients.Medicina, , Volume: 61, Issue:5 Pt 1, 2001
[Achieving vascular protection. ACE inhibitor lowers not only blood pressure].MMW Fortschritte der Medizin, , Sep-06, Volume: 143, Issue:35-36, 2001
Clinical trials report. The effect of Ramipril versus Amlodipine on renal outcomes in hypertension nephrosclerosis.Current hypertension reports, , Volume: 3, Issue:5, 2001
Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance.PharmacoEconomics, , Volume: 19, Issue:5 Pt 1, 2001
Right atrial function in hypertensive patients: effects of antihypertensive therapy.Journal of human hypertension, , Volume: 15, Issue:7, 2001
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.JAMA, , Jun-06, Volume: 285, Issue:21, 2001
Hypertensive African Americans with kidney disease should seek advice from doctor about blood pressure medication.Ethnicity & disease, ,Winter, Volume: 11, Issue:1, 2001
Management of asymptomatic left ventricular dysfunction.Cleveland Clinic journal of medicine, , Volume: 68, Issue:3, 2001
Effects of angiotensin-converting enzyme inhibitor and angiotensin type 1 receptor antagonist in deoxycorticosterone acetate-salt hypertensive mice lacking Ren-2 gene.Hypertension (Dallas, Tex. : 1979), , Volume: 37, Issue:3, 2001
The renin angiotensin system and cardiovascular disease: hope or hype?Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 1, Issue:2, 2000
Improvement in midwall myocardial shortening with regression of left ventricular hypertrophy.Hypertension (Dallas, Tex. : 1979), , Volume: 36, Issue:5, 2000
Circulating amylin in human essential hypertension: heritability and early increase in individuals at genetic risk.Journal of hypertension, , Volume: 18, Issue:11, 2000
Treatment of arterial hypertension in the elderly with diltiazem vs ramipril.Minerva cardioangiologica, , Volume: 48, Issue:6, 2000
Rationale for angiotensin II receptor blockers in patients with low-renin hypertension.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 36, Issue:3 Suppl 1, 2000
[Protein markers in evaluation of nephroprotective effects of antihypertensive drugs in patients with arterial hypertension].Klinicheskaia laboratornaia diagnostika, , Issue:7, 2000
Angiotensin-converting enzyme inhibitors in antihypertensive therapy.Current hypertension reports, , Volume: 2, Issue:2, 2000
Studies examining risk reduction in subjects with multiple metabolic and cardiovascular risk factors.Current hypertension reports, , Volume: 2, Issue:2, 2000
HOPE gives reason for hope. Heart Outcomes Prevention Evaluation.Current hypertension reports, , Volume: 2, Issue:1, 2000
[PHARAO Study of the Hypertension League. Can development of hypertension be prevented with drugs?].MMW Fortschritte der Medizin, , Jul-20, Volume: 142, Issue:28-29, 2000
Practice vs ambulatory blood pressure measurement under treatment with ramipril (PLUR Study): a randomised, prospective long-term study to evaluate the benefits of ABPM in patients on antihypertensive treatment.Journal of human hypertension, , Volume: 14, Issue:7, 2000
Ramipril.International journal of clinical practice, , Volume: 54, Issue:4, 2000
Renal protection: progression, regression, remission from nephropathy beyond blood pressure control.International journal of clinical practice. Supplement, , Issue:110, 2000
Raised blood pressure, not renin-angiotensin systems, causes cardiac fibrosis in TGR m(Ren2)27 rats.Cardiovascular research, , Volume: 47, Issue:1, 2000
Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 35, Issue:6, 2000
The HOPE study and diabetes. Heart Outcomes Prevention Evaluation.Lancet (London, England), , Apr-01, Volume: 355, Issue:9210, 2000
The HOPE study and diabetes. Heart Outcomes Prevention Evaluation.Lancet (London, England), , Apr-01, Volume: 355, Issue:9210, 2000
The HOPE study and diabetes. Heart Outcomes Prevention Evaluation.Lancet (London, England), , Apr-01, Volume: 355, Issue:9210, 2000
The HOPE study and diabetes. Heart Outcomes Prevention Evaluation.Lancet (London, England), , Apr-01, Volume: 355, Issue:9210, 2000
The HOPE study and diabetes. Heart Outcomes Prevention Evaluation.Lancet (London, England), , Apr-01, Volume: 355, Issue:9210, 2000
[Effects of angiotensin-converting enzyme (ACE) inhibitors on water-salt homeostasis in hypertensive patients living in Far North].Klinicheskaia meditsina, , Volume: 78, Issue:3, 2000
The HOPE study. Ramipril lowered cardiovascular risk, but vitamin E did not.Cleveland Clinic journal of medicine, , Volume: 67, Issue:4, 2000
Increased apoptosis in the heart of genetic hypertension, associated with increased fibroblasts.Cardiovascular research, , Volume: 45, Issue:3, 2000
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.Lancet (London, England), , Jan-22, Volume: 355, Issue:9200, 2000
The relationship between apoptosis and spontaneous hypertension.Chinese medical journal, , Volume: 112, Issue:6, 1999
[Ambulatory long-term blood pressure determination improves therapy of hypertension].MMW Fortschritte der Medizin, , Jul-22, Volume: 141, Issue:28-29, 1999
Prostacyclin: its pathogenic role in essential hypertension and the class effect of ACE inhibitors on prostaglandin metabolism.Blood pressure, , Volume: 8, Issue:5-6, 1999
Antihypertensive efficacy and tolerability of once-daily sustained-release diltiazem alone and in combination with ramipril in hypertension.The Journal of the Association of Physicians of India, , Volume: 47, Issue:10, 1999
[Time-dependent effects of ramipril in patients with hypertension of 2 stage].Klinicheskaia meditsina, , Volume: 77, Issue:10, 1999
The influence of long-term ACE inhibitor treatment on circulatory responses to stress in human hypertension.American journal of hypertension, , Volume: 12, Issue:12 Pt 1-2, 1999
Antihypertensive profiles with ascending dose combinations of ramipril and felodipine ER.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 21, Issue:8, 1999
The prognostic significance of a history of systemic hypertension in patients randomised to either placebo or ramipril following acute myocardial infarction: evidence from the AIRE study. Acute Infarction Ramipril Efficacy.Journal of human hypertension, , Volume: 13, Issue:8, 1999
Late treatment with ramipril increases survival in old spontaneously hypertensive rats.Hypertension (Dallas, Tex. : 1979), , Volume: 34, Issue:2, 1999
Effect of long-term ACE inhibition on myocardial tissue in hypertensive stroke-prone rats.Journal of molecular and cellular cardiology, , Volume: 31, Issue:8, 1999
Long-term effects of angiotensin-converting enzyme inhibition on renal medullary neutral lipid in spontaneously hypertensive rats.Hypertension (Dallas, Tex. : 1979), , Volume: 33, Issue:5, 1999
The effects of ramipril on sympathetic nervous system function in older patients with hypertension.Clinical pharmacology and therapeutics, , Volume: 65, Issue:4, 1999
Effect of ACE inhibitor on DOCA-salt- and aortic coarctation-induced hypertension in mice: do kinin B2 receptors play a role?Hypertension (Dallas, Tex. : 1979), , Volume: 33, Issue:1 Pt 2, 1999
Long-term effects of ramipril and nitrendipine on albuminuria in hypertensive patients with type II diabetes and impaired renal function.Journal of human hypertension, , Volume: 13, Issue:1, 1999
Reciprocal role of the AT1 receptor in modulating renal and neuronal AT1 mRNA expression.Journal of the American Society of Nephrology : JASN, , Volume: 10 Suppl 11, 1999
[Investigation of inhibitory effect of ramipril on apoptosis in spontaneously hypertensive rats].Hua xi yi ke da xue xue bao = Journal of West China University of Medical Sciences = Huaxi yike daxue xuebao, , Volume: 30, Issue:1, 1999
[Improvement in diastolic function in hypertensive patients with left ventricular hypertrophy with inhibitors of the angiotensin converting enzyme].Revista clinica espanola, , Volume: 198, Issue:1, 1998
Efficacy of ramipril in therapy-resistant hypertension.Current medical research and opinion, , Volume: 14, Issue:2, 1998
Effects of Ramipril and Isradipin on hemorheological profiles in patients with arterial hypertension.Clinical hemorheology and microcirculation, , Volume: 18, Issue:2-3, 1998
Angiotensin converting enzyme inhibitors and cough--a north Indian study.The Journal of the Association of Physicians of India, , Volume: 46, Issue:5, 1998
Differential responses of the heart and vasculature to chronic blood pressure reduction in essential hypertension.Clinical pharmacology and therapeutics, , Volume: 64, Issue:1, 1998
Differential effects of angiotensin converting enzyme inhibition and diuretic therapy on reductions in ambulatory blood pressure, left ventricular mass, and vascular hypertrophy.American journal of hypertension, , Volume: 11, Issue:4 Pt 1, 1998
Vagal cardiac activity in essential hypertension: the effects of metoprolol and ramipril.American journal of hypertension, , Volume: 11, Issue:6 Pt 1, 1998
Response of serum total renin to ramipril and metoprolol in hypertensive patients.Scandinavian journal of clinical and laboratory investigation, , Volume: 58, Issue:8, 1998
Influence of dietary salts on the cardiovascular effects of low-dose combination of ramipril and felodipine in spontaneously hypertensive rats.British journal of pharmacology, , Volume: 123, Issue:2, 1998
[Ramipril effects on 24 hour profile of blood pressure in patients with mild and moderate hypertension].Terapevticheskii arkhiv, , Volume: 70, Issue:9, 1998
[The effect of ramipril on metabolic, renal and cardiac function in hypertension and type II diabetes mellitus].Vnitrni lekarstvi, , Volume: 44, Issue:6, 1998
[Ramipril in the treatment of moderate to moderately severe hypertension. A multicenter open study].Vnitrni lekarstvi, , Volume: 44, Issue:6, 1998
The arterial length-densities under preventive angiotensin-converting-enzyme inhibiting treatment in the myocardium of spontaneously hypertensive rats.Basic research in cardiology, , Volume: 93, Issue:1, 1998
Inhibition of tissue angiotensin converting enzyme activity prevents malignant hypertension in TGR(mREN2)27.Journal of hypertension, , Volume: 16, Issue:5, 1998
Contribution of bradykinin to the beneficial effects of ramipril in the fructose-fed rat.Journal of cardiovascular pharmacology, , Volume: 31, Issue:4, 1998
L-type calcium channels modulate the regression of left ventricular hypertrophy after ace-inhibition in genetic hypertension.Pharmacological research, , Volume: 38, Issue:4, 1998
Regulation of extracellular matrix proteins in pressure-overload cardiac hypertrophy: effects of angiotensin converting enzyme inhibition.Journal of hypertension, , Volume: 16, Issue:9, 1998
Cardiovascular kinin-generating capability in hypertensive fructose-fed rats.Journal of hypertension, , Volume: 16, Issue:9, 1998
Accelerated cholesteryl ester transfer in patients with essential hypertension and the effect of ramipril treatment.Atherosclerosis, , Volume: 140, Issue:1, 1998
Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke-prone spontaneously hypertensive rats.Hypertension (Dallas, Tex. : 1979), , Volume: 29, Issue:1 Pt 2, 1997
Ramipril therapy improves arterial dilation in experimental hypertension.Cardiovascular research, , Volume: 33, Issue:1, 1997
Modulation of genetic hypertension by short-term AVP V1A or V2 receptor antagonism in young SHR.The American journal of physiology, , Volume: 272, Issue:2 Pt 2, 1997
Impaired renal haemodynamic response to amino acid infusion in essential hypertension during angiotensin converting enzyme inhibitor treatment.Journal of hypertension, , Volume: 15, Issue:5, 1997
Cardiovascular effects of a low-dose combination of ramipril and felodipine in spontaneously hypertensive rats.British journal of pharmacology, , Volume: 121, Issue:3, 1997
[A decrease in left ventricular hypertrophy and the dynamics of the parameters of circadian BP monitoring under the influence of ramipril in patients with essential arterial hypertension].Terapevticheskii arkhiv, , Volume: 69, Issue:4, 1997
ACE inhibition reduces left ventricular mass independent of pressure without affecting coronary flow and flow reserve in spontaneously hypertensive rats.The American journal of the medical sciences, , Volume: 314, Issue:1, 1997
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)Lancet (London, England), , Jun-28, Volume: 349, Issue:9069, 1997
Effects of ramipril on the hormone concentrations in serum of hypertensive patients.European journal of clinical chemistry and clinical biochemistry : journal of the Forum of European Clinical Chemistry Societies, , Volume: 35, Issue:6, 1997
Possible protective effects of kinins and converting enzyme inhibitors in cardiovascular tissues.Immunopharmacology, , Volume: 36, Issue:2-3, 1997
Is ramipril anti-arrhythmic?Australian family physician, , Volume: 26, Issue:8, 1997
Secreted protein acidic and rich in cysteine expression after subtotal nephrectomy and blockade of the renin-angiotensin system.Journal of the American Society of Nephrology : JASN, , Volume: 8, Issue:9, 1997
[Clinical effectiveness of and tolerance to ramipril in the treatment of essential arterial hypertension phase 1 and 2. Results of a multicenter study].Revista medica de Chile, , Volume: 125, Issue:1, 1997
Arterial responses to bradykinin after ramipril therapy in experimental hypertension.Pharmacology & toxicology, , Volume: 81, Issue:4, 1997
Effects of chronic ramipril treatment in streptozotocin-induced diabetic rats.Indian journal of physiology and pharmacology, , Volume: 41, Issue:4, 1997
Angiotensin-converting enzyme inhibition alters nitric oxide and superoxide release in normotensive and hypertensive rats.Hypertension (Dallas, Tex. : 1979), , Volume: 30, Issue:5, 1997
Influence of age and dietary sodium on the cardiovascular and renal effects of ramipril in spontaneously hypertensive rats.Methods and findings in experimental and clinical pharmacology, , Volume: 19, Issue:5, 1997
EUCLID study.Lancet (London, England), , Oct-11, Volume: 350, Issue:9084, 1997
Sustained diurnal blood pressure reduction in SHR with ramipril assessed by telemetric monitoring.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 19, Issue:8, 1997
Nitric oxide and the depressor response to angiotensin blockade in hypertension.Hypertension (Dallas, Tex. : 1979), , Volume: 27, Issue:1, 1996
Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production.Circulation, , Jun-01, Volume: 93, Issue:11, 1996
Kinetics, safety, and efficacy of ramipril after long-term administration in hemodialyzed patients.Journal of cardiovascular pharmacology, , Volume: 27, Issue:2, 1996
Regulation of ANG II receptor in hypertension: role of ANG II.The American journal of physiology, , Volume: 271, Issue:1 Pt 2, 1996
ACE inhibition decreases postoperative mortality in rats with left ventricular hypertrophy and myocardial infarction.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 18, Issue:5, 1996
Vascular hypertrophy and albumin permeability in a rat model combining hypertension and diabetes mellitus. Effects of calcium antagonism, angiotensin converting enzyme inhibition, and angiotensin II-AT1-receptor blockade.American journal of hypertension, , Volume: 9, Issue:9, 1996
Monitoring antihypertensive therapy through blood pressure measurements taken casually, at rest, during exercise, and under outpatient conditions.Zeitschrift fur Kardiologie, , Volume: 85 Suppl 3, 1996
Left ventricular hypertrophy and QT dispersion in hypertension.Hypertension (Dallas, Tex. : 1979), , Volume: 28, Issue:5, 1996
Therapeutic, but not low-dose, angiotensin-converting enzyme inhibition causes regression of cardiovascular changes in spontaneously hypertensive rats.Journal of cardiovascular pharmacology, , Volume: 27, Issue:3, 1996
Vascular and cardiac protection by ramipril in spontaneously hypertensive rats: prevention versus regression study.British journal of clinical practice. Supplement, , Volume: 84, 1996
Ramipril and felodipine: a comparison of the efficacy and safety of monotherapy versus combination therapy.Current medical research and opinion, , Volume: 13, Issue:8, 1996
[Antihypertensive effect of ramipril. Ambultory monitoring of arterial blood pressure in mild to moderate hypertension].Recenti progressi in medicina, , Volume: 87, Issue:9, 1996
The DIAB-HYCAR Study.Diabetologia, , Volume: 39, Issue:12, 1996
[A comparison of the effect of Capoten (captopril) and ramipril on the circadian profile of the arterial pressure and peripheral hemodynamics in patients with hypertension combined with diabetes mellitus].Terapevticheskii arkhiv, , Volume: 68, Issue:5, 1996
Interruption of prolonged ramipril treatment in hypertensive patients: effects on the renin-angiotensin system.Fundamental & clinical pharmacology, , Volume: 10, Issue:5, 1996
[New therapeutic principle in the management of hypertension].Der Internist, , Volume: 37, Issue:4 Suppl Ne, 1996
Ramipril-induced regression of left ventricular hypertrophy in treated hypertensive individuals. HYCAR Study Group.Hypertension (Dallas, Tex. : 1979), , Volume: 25, Issue:1, 1995
Resetting blood pressure in spontaneously hypertensive rats. The role of bradykinin.Hypertension (Dallas, Tex. : 1979), , Volume: 25, Issue:2, 1995
Differential effects of chronic oral antihypertensive therapies on systemic arterial circulation and ventricular energetics in African-American patients.Circulation, , Feb-15, Volume: 91, Issue:4, 1995
Long-term effects of brief antihypertensive treatment on systolic blood pressure and vascular reactivity in young genetically hypertensive rats.Cardiovascular drugs and therapy, , Volume: 9, Issue:3, 1995
Effect of low-dose ramipril on microalbuminuria in normotensive or mild hypertensive non-insulin-dependent diabetic patients. North-East Italy Microalbuminuria Study Group.American journal of hypertension, , Volume: 8, Issue:9, 1995
[Effects of bisoprolol and ramipril on short-term variability of systolic blood pressure during mental stress test: spectrum analysis].Archives des maladies du coeur et des vaisseaux, , Volume: 88, Issue:8, 1995
Comparison of ramipril and nitrendipine.Journal of human hypertension, , Volume: 9, Issue:11, 1995
Ramipril decreases chlorthalidone-induced loss of magnesium and potassium in hypertensive patients.Journal of clinical pharmacology, , Volume: 35, Issue:12, 1995
European postmarketing surveillance of ramipril in hypertension. 1. Feasibility and study cohort.European journal of clinical pharmacology, , Volume: 49, Issue:1-2, 1995
Angioedema caused by ramipril.The Annals of pharmacotherapy, , Volume: 29, Issue:4, 1995
ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group.Journal of hypertension, , Volume: 13, Issue:11, 1995
The effects of antihypertensive therapy on carotid vascular structure in man.Cardiovascular research, , Volume: 30, Issue:1, 1995
Extracellular matrix deposition in hypertensive hearts antifibrotic effects of ramipril.European heart journal, , Volume: 16 Suppl C, 1995
Double-blind comparison of antihypertensive treatment with ramipril and piretanide, given alone or in combination.Journal of cardiovascular pharmacology, , Volume: 26, Issue:1, 1995
Attenuation of genetic hypertension after short-term vasopressin V1A receptor antagonism.Hypertension (Dallas, Tex. : 1979), , Volume: 26, Issue:5, 1995
Myalgia and arthralgia associated with enalapril and ramipril.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Jan-15, Volume: 52, Issue:2, 1995
Nitric oxide and prostaglandins in the prolonged effects of losartan and ramipril in hypertension.Hypertension (Dallas, Tex. : 1979), , Volume: 26, Issue:2, 1995
Comparative effects of ramipril and nitrendipine on albuminuria in hypertensive patients with non-insulin-dependent diabetes mellitus and impaired renal function.Journal of human hypertension, , Volume: 9, Issue:2, 1995
Effects of intensified blood-pressure reduction on renal function and albumin excretion in primary hypertension. Addition of felodipine or ramipril to long-term treatment with beta-blockade.American journal of hypertension, , Volume: 8, Issue:2, 1995
Ramipril. An updated review of its therapeutic use in essential hypertension and heart failure.Drugs, , Volume: 49, Issue:3, 1995
Ramipril vs captopril in mild to moderate hypertension.The Journal of the Association of Physicians of India, , Volume: 42, Issue:2, 1994
Does lipophilicity of angiotensin converting enzyme inhibitors selectively influence autonomic neural function in human hypertension?Journal of hypertension, , Volume: 12, Issue:11, 1994
[A comparison of the efficacy of cilazapril and ramipril in treating arterial hypertension patients (a randomized study)].Terapevticheskii arkhiv, , Volume: 66, Issue:12, 1994
Study of the efficacy and safety of the combination ramipril 2.5 mg plus hydrochlorothiazide 12.5 mg in patients with mild-to-moderate hypertension. ATHES Study Group.International journal of clinical pharmacology research, , Volume: 14, Issue:1, 1994
Heterogeneity of the arterial tree in essential hypertension: a noninvasive study of the terminal aorta and the common carotid artery.Journal of human hypertension, , Volume: 8, Issue:7, 1994
Amlodipine versus ramipril in the treatment of mild to moderate hypertension: evaluation by 24-hour ambulatory blood pressure monitoring.Cardiology, , Volume: 85, Issue:1, 1994
Clinical pharmacokinetics of ramipril.Clinical pharmacokinetics, , Volume: 26, Issue:1, 1994
[The nephroprotective effect of ramipril. Effect on blood pressure and metabolic control in insulin-treated patients with type-2 diabetes mellitus].Fortschritte der Medizin, , Jan-30, Volume: 112, Issue:3, 1994
Angiotensin-converting enzyme inhibition improves cardiac function. Role of bradykinin.Hypertension (Dallas, Tex. : 1979), , Volume: 23, Issue:4, 1994
Remission of high blood pressure reverses arterial potassium channel alterations.Hypertension (Dallas, Tex. : 1979), , Volume: 23, Issue:6 Pt 2, 1994
Role of kinins and nitric oxide in the antihypertrophic effect of ramipril.Hypertension (Dallas, Tex. : 1979), , Volume: 23, Issue:6 Pt 2, 1994
Effects of ramipril on contractile oscillations in arteries from genetically hypertensive rats.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 16, Issue:6, 1994
Ramipril prevents the detrimental sequels of chronic NO synthase inhibition in rats: hypertension, cardiac hypertrophy and renal insufficiency.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 350, Issue:6, 1994
[Study report: Hypertension therapy with organ protection. Piretanid and Ramipril: advantages with fixed combination].Fortschritte der Medizin. Supplement : die Kongressinformation fur die Praxis, , Volume: 164, 1994
[Ramipril in the treatment of hypertension. The pharmacodynamic validation of its efficacy in the therapy of initial cardiac and renal involvement].Terapevticheskii arkhiv, , Volume: 65, Issue:4, 1993
ACE inhibitors: review of four new agents.American family physician, , Volume: 48, Issue:5, 1993
Long-term low-dose angiotensin converting enzyme inhibitor treatment increases vascular cyclic guanosine 3',5'-monophosphate.Hypertension (Dallas, Tex. : 1979), , Volume: 22, Issue:5, 1993
[Ramipril, a new antagonist of angiotensin converting enzyme].Arquivos brasileiros de cardiologia, , Volume: 60, Issue:2, 1993
Usefulness of piretanide plus ramipril for systemic hypertension: a multicenter trial.The American journal of cardiology, , Sep-15, Volume: 72, Issue:9, 1993
Effect of ramipril on alpha-adrenoceptor-mediated oscillatory contractions in tail artery of hypertensive rats.European journal of pharmacology, , Oct-05, Volume: 242, Issue:3, 1993
Short report: ramipril and hydrochlorothiazide combination therapy in hypertension: a clinical trial of factorial design. The East Germany Collaborative Trial Group.Journal of hypertension, , Volume: 11, Issue:2, 1993
Vascular remodeling in systemic hypertension.The American journal of cardiology, , Jun-24, Volume: 71, Issue:17, 1993
Combination of ramipril and hydrochlorothiazide in the treatment of mild to moderate hypertension--Part 2: An open long-term study of efficacy and safety.Clinical cardiology, , Volume: 16, Issue:1, 1993
Angiotensin-converting enzyme inhibition during development alters calcium regulation in adult hypertensive rats.The Journal of pharmacology and experimental therapeutics, , Volume: 267, Issue:3, 1993
[New possibilities for preparations suppressing the activity of the angiotensin-converting enzyme].Terapevticheskii arkhiv, , Volume: 64, Issue:9, 1992
Combination of ramipril and hydrochlorothiazide in the treatment of mild to moderate hypertension: Part 1--A double-blind, comparative, multicenter study in nonresponders to ramipril monotherapy.Clinical cardiology, , Volume: 15, Issue:12, 1992
[Monotherapy with the ACE-inhibitor ramipril or the calcium antagonist nitrendipine in essential hypertension].Schweizerische medizinische Wochenschrift, , Oct-03, Volume: 122, Issue:40, 1992
[Long-term blood pressure measurement for evaluating the first dose response of captopril and ramipril in patients with a stimulated renin system].Zeitschrift fur Kardiologie, , Volume: 81 Suppl 2, 1992
Ramipril prevents left ventricular hypertrophy with myocardial fibrosis without blood pressure reduction: a one year study in rats.British journal of pharmacology, , Volume: 107, Issue:4, 1992
Effect of early onset angiotensin converting enzyme inhibition on myocardial capillaries.Hypertension (Dallas, Tex. : 1979), , Volume: 20, Issue:4, 1992
A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril.British journal of pharmacology, , Volume: 105, Issue:4, 1992
The French multicentre study of ramipril in ambulatory patients with mild-to-moderate hypertension.Clinical physiology and biochemistry, , Volume: 9, Issue:3, 1992
The analysis of a multiple-dose, combination-drug clinical trial using response surface methodology.Journal of biopharmaceutical statistics, , Volume: 2, Issue:1, 1992
Role of bradykinin in chronic antihypertensive actions of ramipril in different hypertension models.Journal of cardiovascular pharmacology, , Volume: 20 Suppl 9, 1992
Changes in peripheral sympathetic outflow of pithed spontaneously hypertensive rats after bradykinin and DesArg-bradykinin infusions: influence of converting-enzyme inhibition.Journal of cardiovascular pharmacology, , Volume: 20 Suppl 9, 1992
Kinins, nitric oxide, and the hypotensive effect of captopril and ramiprilat in hypertension.Hypertension (Dallas, Tex. : 1979), , Volume: 19, Issue:2, 1992
Ramipril: a review of the new ACE inhibitor.The Journal of the Arkansas Medical Society, , Volume: 88, Issue:9, 1992
Role of angiotensin II receptor antagonism and converting enzyme inhibition in the progression and regression of cardiac hypertrophy in rats.Journal of hypertension. Supplement : official journal of the International Society of Hypertension, , Volume: 9, Issue:6, 1991
Long lasting arterial effects of the ACE inhibitor ramipril.Journal of human hypertension, , Volume: 5, Issue:5, 1991
24-hour blood pressure profiles in hypertensive patients administered ramipril or placebo once daily: magnitude and duration of antihypertensive effects. Ramipril Multicenter Study Group.Clinical cardiology, , Volume: 14, Issue:9, 1991
More ACE inhibitors--quinapril, perindopril & ramipril.Drug and therapeutics bulletin, , Apr-15, Volume: 29, Issue:8, 1991
The influence of ramipril on blood pressure, ACE-activity, sperm density and motility of spontaneously hypertensive rats during puberty.Die Pharmazie, , Volume: 46, Issue:5, 1991
Three new ACE inhibitors for hypertension.The Medical letter on drugs and therapeutics, , Sep-06, Volume: 33, Issue:852, 1991
Salt blocks the renal benefits of ramipril in diabetic hypertensive rats.Hypertension (Dallas, Tex. : 1979), , Volume: 17, Issue:4, 1991
Efficacy and safety of ramipril in combination with hydrochlorothiazide: results of a long-term study.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Assessment of the efficacy, tolerance, and safety of ramipril in diabetic patients with mild-to-moderate hypertension: a retrospective analysis.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
The effects of ramipril on glucose tolerance, insulin secretion, and insulin sensitivity in patients with hypertension.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Comparison of ramipril against atenolol in controlling mild-to-moderate hypertension.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Effects of ramipril on arterial hemodynamics.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Efficacy and safety of a new angiotensin-converting enzyme inhibitor, ramipril, vs. enalapril in essential hypertension: a multicenter trial.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Comparison of response rates to the angiotensin-converting enzyme inhibitor ramipril in mild-to-moderate hypertension in a double-blind, parallel-group study and an open single-blind study.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Tolerability of ramipril in a multicenter study of mild-to-moderate hypertension in general practice.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Antihypertensive efficacy, tolerance, and safety of long-term treatment with ramipril in patients with mild-to-moderate essential hypertension.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Antihypertensive efficacy, tolerance, and safety of ramipril in young vs. old patients: a retrospective study.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
The effect of ramipril on ambulatory blood pressure: a multicenter trial.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Dose-response relationship of ramipril in patients with mild-to-moderate hypertension.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
The pharmacokinetics of ramipril in a group of ten elderly patients with essential hypertension.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Effect of angiotensin-converting enzyme inhibition on human tissue renin.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Age-related variations in tissue angiotensin converting enzyme activities: comparison between spontaneously hypertensive and Wistar-Kyoto rats.Journal of hypertension, , Volume: 8, Issue:8, 1990
The measurement of intrarenal plasma flow distribution in essential hypertension. The effect of angiotensin-converting enzyme inhibition.Contributions to nephrology, , Volume: 79, 1990
In vivo concentrations of kinins and angiotensins.Hormone and metabolic research. Supplement series, , Volume: 22, 1990
[The French ambulatory multicenter trial of Triatec: conclusions of the trial].La Revue du praticien, , Jun-21, Volume: 40, Issue:18 Suppl, 1990
[Ambulatory multicenter study of Triatec (ramipril). Observations concerning the lessons of the trial for the realization of future trials and for the management of hypertensive patients].La Revue du praticien, , Jun-21, Volume: 40, Issue:18 Suppl, 1990
[Tolerance to Triatec in monotherapy and in combination with Lasilix in a French multicenter study].La Revue du praticien, , Jun-21, Volume: 40, Issue:18 Suppl, 1990
[French multicenter study of Triatec (ramipril) in ambulatory patients: methodology and trial structure].La Revue du praticien, , Jun-21, Volume: 40, Issue:18 Suppl, 1990
[Efficacy of Triatec in monotherapy and in combination with Lasilix in a French multicenter study].La Revue du praticien, , Jun-21, Volume: 40, Issue:18 Suppl, 1990
Metabolic effects of ramipril treatment in hypertensive subjects with non-insulin-dependent diabetes mellitus.Arzneimittel-Forschung, , Volume: 40, Issue:4, 1990
[Immunological effects of captopril and ramipril in patients with hypertension].Klinicheskaia meditsina, , Volume: 68, Issue:2, 1990
Role of the kidney in primary hypertension: a renal transplantation study in rats.The American journal of physiology, , Volume: 258, Issue:3 Pt 2, 1990
The effect of ramipril, a new angiotensin-converting enzyme inhibitor on cortical nephron flow and effective renal plasma flow in patients with essential hypertension.Nephron, , Volume: 54, Issue:1, 1990
Cardiovascular and renal effects of ramipril.Lancet (London, England), , Apr-15, Volume: 1, Issue:8642, 1989
Comparisons in vitro, ex vivo, and in vivo of the actions of seven structurally diverse inhibitors of angiotensin converting enzyme (ACE).British journal of clinical pharmacology, , Volume: 28 Suppl 2, 1989
Change in cough reflex after treatment with enalapril and ramipril.BMJ (Clinical research ed.), , Jul-01, Volume: 299, Issue:6690, 1989
Significance of kallikrein-kinin and renin-angiotensin systems in the hypotensive mechanism of angiotensin-I converting enzyme inhibitors in essential hypertensives.Advances in experimental medicine and biology, , Volume: 247A, 1989
Converting enzyme inhibition specifically prevents the development and induces regression of cardiac hypertrophy in rats.Clinical and experimental hypertension. Part A, Theory and practice, , Volume: 11, Issue:7, 1989
The renin-angiotensin system and ramipril, a new converting enzyme inhibitor.Journal of cardiovascular pharmacology, , Volume: 14 Suppl 4, 1989
An open multicenter study to assess the long-term efficacy, tolerance, and safety of the oral angiotensin converting enzyme inhibitor ramipril in patients with mild to moderate essential hypertension.Journal of cardiovascular pharmacology, , Volume: 13 Suppl 3, 1989
Role of kallikrein-kinin system in the hypotensive mechanisms of converting enzyme inhibitors in essential hypertension.Journal of cardiovascular pharmacology, , Volume: 13 Suppl 3, 1989
Loop diuretics combined with an ACE inhibitor for treatment of hypertension: a study with furosemide, piretanide, and ramipril in spontaneously hypertensive rats.Journal of cardiovascular pharmacology, , Volume: 13 Suppl 3, 1989
Renin-angiotensin and vasopressin in the development of salt-induced hypertension.Journal of hypertension, , Volume: 6, Issue:12, 1988
Amelioration of systemic hypertension by converting enzyme inhibition in the renal ablation model.American journal of hypertension, , Volume: 1, Issue:2, 1988
First dose response and 24-hour antihypertensive efficacy of the new once-daily angiotensin converting enzyme inhibitor, ramipril.The American journal of cardiology, , Aug-01, Volume: 62, Issue:4, 1988
Myocardial interstitial fibrosis in experimental uremia--implications for cardiac compliance.Kidney international, , Volume: 33, Issue:4, 1988
[Interaction of chronic inhibition of the angiotensin-converting enzyme and the sympathetic system: effect of added sodium chloride load].Zeitschrift fur Kardiologie, , Volume: 77 Suppl 3, 1988
A multi-centre comparative study between ramipril and enalapril in patients with mild to moderate essential hypertension.Current medical research and opinion, , Volume: 11, Issue:2, 1988
[Pharmacologic modification of the converting enzyme--local and systemic effects on the heart and blood vessels].Zeitschrift fur Kardiologie, , Volume: 77 Suppl 3, 1988
Use of nuclear magnetic resonance imaging to show regression of hypertrophy with ramipril treatment.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Blood pressure response of nephrectomized subjects and patients with essential hypertension to ramipril: indirect evidence that inhibition of tissue angiotensin converting enzyme is important.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Effect of ramipril, a new angiotensin converting enzyme inhibitor, on diurnal variations of blood pressure in essential hypertension.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Short- and long-term effects of ramipril in hypertension.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Effect of ramipril on 24-hour variability of blood pressure and heart rate in essential hypertension.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Ramipril: review of pharmacology.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Clinical pharmacology of ramipril.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Combined treatment of severe essential hypertension with the new angiotensin converting enzyme inhibitor ramipril.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Efficacy and safety of ramipril (HOE 498) in the treatment of hypertension: dose finding study.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Dose-response relation of the angiotensin converting enzyme inhibitor ramipril in mild to moderate essential hypertension.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
A double-blind study to compare the efficacy, tolerance and safety of two doses of the angiotensin converting enzyme inhibitor ramipril with placebo.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Comparative double-blind study of ramipril and captopril in mild to moderate essential hypertension.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Efficacy, tolerance and hormonal effects of a new oral angiotensin converting enzyme inhibitor, ramipril (HOE 498), in mild to moderate primary hypertension.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
[Influence of acute administration of ramipril on the excretion of uric acid].Archives des maladies du coeur et des vaisseaux, , Volume: 80, Issue:6, 1987
Pharmacokinetics of a single dose of ramipril in patients with renal dysfunction: comparison with essential hypertension.Journal of cardiovascular pharmacology, , Volume: 10 Suppl 7, 1987
Interference with the autonomic nervous system by the converting enzyme inhibitor ramipril in conscious spontaneously hypertensive rats.Journal of cardiovascular pharmacology, , Volume: 10 Suppl 7, 1987
Levels of brain angiotensin in the spontaneously hypertensive rat and treatment with ramiprilat.Journal of hypertension. Supplement : official journal of the International Society of Hypertension, , Volume: 4, Issue:6, 1986
Effect of converting enzyme inhibitors on hypertensive large arteries in humans.Journal of hypertension. Supplement : official journal of the International Society of Hypertension, , Volume: 4, Issue:5, 1986
Humoral and blood pressure effects of the angiotensin converting enzyme inhibitor ramipril in essential hypertension.Arzneimittel-Forschung, , Volume: 36, Issue:11, 1986
[Antihypertensive action and inhibition of tissue conversion enzyme by ramipril, perindopril and enalapril in the spontaneously hypertensive rat (SHRSP)].Archives des maladies du coeur et des vaisseaux, , Volume: 79, Issue:6, 1986
Antihypertensive action and inhibition of tissue converting enzyme (CE) by three prodrug CE inhibitors, enalapril, ramipril and perindopril in stroke-prone spontaneously hypertensive rats.Journal of hypertension. Supplement : official journal of the International Society of Hypertension, , Volume: 4, Issue:3, 1986
Studies on the antihypertensive effect of single doses of the angiotensin converting enzyme inhibitor ramipril (HOE 498) in man.European journal of clinical pharmacology, , Volume: 30, Issue:5, 1986
Effects of the new angiotensin-converting enzyme inhibitor, ramipril, in patients with essential hypertension.Klinische Wochenschrift, , Jun-16, Volume: 64, Issue:12, 1986
Vascular angiotensin conversion in humans.Journal of cardiovascular pharmacology, , Volume: 8 Suppl 10, 1986
Disappearance of captopril-induced taste disturbance after substitution with angiotensin-converting-enzyme inhibitor HOE 498.Lancet (London, England), , Mar-02, Volume: 1, Issue:8427, 1985
Effects of the new oral angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498) in essential hypertension.Arzneimittel-Forschung, , Volume: 34, Issue:10B, 1984
2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498): antihypertensive action and persistent inhibition of tissue converting enzyme activity in spontaneously hypertensive rats.Arzneimittel-Forschung, , Volume: 34, Issue:10B, 1984
Modulation of hemodynamics, endogenous antioxidant enzymes, and pathophysiological changes by Angiotensin-converting enzyme inhibitors in pressure-overload rats.Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese, , Volume: 52, Issue:3
Comparative Efficacy of Antihypertensive Drugs in Dogs: A Systematic Review.Topics in companion animal medicine, , Volume: 50
Achieving blood preSsure goals sTudy in uncontrolled hypeRtensive pAtients treated with a fixed-dose combination of ramipriL/hydrochlorothiazide: the ASTRAL study.Cardiovascular journal of Africa, , Volume: 22, Issue:2
Beta blockers & left ventricular hypertrophy regression.Indian heart journal, , Volume: 62, Issue:2
Blacks with hypertension, renal insufficiency, and baseline proteinuria benefit more from ACE inhibition than from calcium channel blockade.Journal of clinical hypertension (Greenwich, Conn.), , Volume: 3, Issue:5
Large prospective study of ramipril in patients with hypertension. CARE Investigators.Clinical therapeutics, , Volume: 15, Issue:5
Comparison of ramipril and enalapril in patients with essential hypertension.Pharmacotherapy, , Volume: 13, Issue:3
Lessons learned with ambulatory blood pressure monitoring: a focus on ramipril.Clinical therapeutics, , Volume: 15, Issue:3
The African American Study of Kidney Disease and Hypertension (AASK): new findings.Journal of clinical hypertension (Greenwich, Conn.), , Volume: 3, Issue:4
Double-blind, placebo-controlled study of ramipril in diabetics with mild to moderate hypertension.Clinical therapeutics, , Volume: 15, Issue:1
[Therapeutic perspectives: association of ACE inhibitors and angiotensin receptor blockers].La Clinica terapeutica, , Volume: 152, Issue:2
[Severe hypoglycemia secondary to angiotensin-converting-enzyme inhibitors in the absence of diabetes mellitus. Report of a case].Gaceta medica de Mexico, , Volume: 137, Issue:3
Renal medulla and bradykinin during the development of hypertension in SHR.Clinical and experimental pharmacology & physiology, , Volume: 22, Issue:6-7
The role of angiotensin converting enzyme and nitric oxide in the enhanced systemic depressor responses to bradykinin in pregnant rats.Clinical and experimental pharmacology & physiology, , Volume: 22, Issue:6-7
Urticarial vasculitis from simvastatin: what is the alternative drug?Dermatitis : contact, atopic, occupational, drug, , Volume: 21, Issue:4
[Fixed combinations of antihypertensive medications--new opportunity in treatment of hypertension].Lijecnicki vjesnik, , Volume: 132, Issue:3-4
[Inappropriate antidiuretic hormone secretion syndrome associated with ramipril treatment].Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria, , Volume: 34, Issue:3
An open-label, noncomparative, multicenter study of ramipril in the treatment of patients with mild-to-moderate hypertension.Clinical therapeutics, , Volume: 18, Issue:6
Need for new hypertension guidelines for high-risk patients.Cardiovascular journal of Africa, , Volume: 20, Issue:4
Ramipril-induced generalized pustular psoriasis: case report and literature review.American journal of therapeutics, , Volume: 17, Issue:1
[Bradykinin mediated angioedema with ACE inhibitor in combination with immunosupressive agents].Therapie, , Volume: 69, Issue:2
Rheological changes in hypertensive patients treated with ramipril.Clinical hemorheology and microcirculation, , Volume: 17, Issue:1
[New studies on hypertension of great significance to clinical practice. Also very old persons benefit from blood pressure reduction].Lakartidningen, , Volume: 105, Issue:19
From Tritace to Tri-Plen - the South African journey.Cardiovascular journal of Africa, , Volume: 20, Issue:1
Correlation of renin angiotensin system (RAS) candidate gene polymorphisms with response to Ramipril in patients with essential hypertension.Journal of postgraduate medicine, , Volume: 61, Issue:1
Renin-angiotensin-aldosterone system (RAAS) block revisited.The National medical journal of India, , Volume: 21, Issue:4
Establishing correlation between genetics and nonresponse.Journal of postgraduate medicine, , Volume: 61, Issue:2
[Is it feasible to improve the duration and the efficiency of Ramipril anti-proteinuric response?].Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, , Volume: 32, Issue:1
Renal tissue angiotensins during converting enzyme inhibition in the spontaneously hypertensive rat.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 19, Issue:5-6
Safety and tolerability of ramipril 10 mg in patients at high risk of cardiovascular events: an observational study.Indian heart journal, , Volume: 60, Issue:3
Ramipril: the better angiotensin-converting enzyme inhibitor?Indian heart journal, , Volume: 60, Issue:3
Authors' reply.Journal of postgraduate medicine, , Volume: 61, Issue:2
FIXED DOSE COMBINATIONS WITH SELECTIVE BETA-BLOCKERS: QUANTITATIVE DETERMINATION IN BIOLOGICAL FLUIDS.Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi, , Volume: 119, Issue:2
[The metabolic effects of isradipine, ramipril, Ednit and beta-adrenoblockers in patients with non-insulin-dependent diabetes mellitus and arterial hypertension].Eksperimental'naia i klinicheskaia farmakologiia, , Volume: 62, Issue:2
Effect of atenolol and ramipril on regression of left ventricular hypertrophy: comparative echocardiographic assessment.Advances in therapy, , Volume: 12, Issue:2
Effect of acute and long-term administration of ramipril on circadian rhythm of blood pressure in essential hypertension.Advances in therapy, , Volume: 12, Issue:1
Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with the two different compounds, Hoe498 and MK421, in spontaneously hypertensive rats.Journal of cardiovascular pharmacology, , Volume: 6, Issue:5
[spACE, the last frontier? Renin inhibition in hypertension].Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, , Volume: 25, Issue:3
Loss of captopril-bound Fe by end-stage renal failure patients during hemodialysis.Journal of nephrology, , Volume: 17, Issue:1
Tolerability of 10 mg of ramipril in normotensive Indian patients.The National medical journal of India, , Volume: 15, Issue:4
Effect of ramipril therapy on cognitive functions in cases of mild to moderate essential hypertension.Indian journal of physiology and pharmacology, , Volume: 51, Issue:1
Effects of ramipril therapy on some components of insulin resistance syndrome in patients with essential hypertension.Medicinski pregled, , Volume: 55, Issue:7-8
Ileostomy and ramipril-induced acute renal failure and shock.Heart & lung : the journal of critical care, , Volume: 36, Issue:4
True versus immunoreactive angiotensin II in human plasma.Hypertension (Dallas, Tex. : 1979), , Volume: 7, Issue:3 Pt 2
The African American Study of Kidney Disease and Hypertension (AASK) trial: what more have we learned?Journal of clinical hypertension (Greenwich, Conn.), , Volume: 5, Issue:2
Persistent tissue converting enzyme inhibition following chronic treatment with Hoe498 and MK421 in spontaneously hypertensive rats.Journal of cardiovascular pharmacology, , Volume: 7, Issue:1
[Effect of ramipril on the glucose/insulin coefficient and the ventricular mass index in patients with light to moderate arterial hypertension].Archivos de cardiologia de Mexico, , Volume: 73, Issue:1
Antihypertensive action of the converting enzyme inhibitor perindopril (S9490-3) in spontaneously hypertensive rats: comparison with enalapril (MK421) and ramipril (Hoe498).Journal of cardiovascular pharmacology, , Volume: 8, Issue:2
Preliminary experiences with HOE 498, a novel long-acting converting enzyme inhibitor, in hypertensive patients.Journal of cardiovascular pharmacology, , Volume: 7, Issue:6
Ramipril and methyldopa compared in patients with mild to moderate hypertension.Clinical therapeutics, , Volume: 12, Issue:5
Ambulatory 24-h blood pressure monitoring in essential hypertensives treated with the angiotensin-converting enzyme inhibitor ramipril.The Journal of international medical research, , Volume: 19, Issue:1
ARBs for cardiovascular and renal protection in high-risk patients.Cardiovascular journal of Africa, , Volume: 22, Issue:4
Renal protection in diabetes: lessons from ONTARGET.Cardiovascular diabetology, , Oct-01, Volume: 9, 2010
Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation.Transplant international : official journal of the European Society for Organ Transplantation, , Volume: 22, Issue:11, 2009
Effects of telmisartan and ramipril on adiponectin and blood pressure in patients with type 2 diabetes.American journal of hypertension, , Volume: 21, Issue:12, 2008
Influence of angiotensin converting enzyme inhibitor treatment on cardiac autonomic modulation in patients receiving haemodialysis.Nephrology (Carlton, Vic.), , Volume: 11, Issue:6, 2006
Differing effects of antihypertensive drugs on the incidence of diabetes mellitus among patients with hypertensive kidney disease.Archives of internal medicine, , Apr-10, Volume: 166, Issue:7, 2006
Vasopeptidase inhibition normalizes blood pressure and restores endothelial function in renovascular hypertension.Kidney & blood pressure research, , Volume: 29, Issue:6, 2006
Vasopeptidase inhibition prevents target organ damage and improves survival in spontaneously hypertensive rats.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 7, Issue:3, 2006
Transforming growth factor beta1 and additional renoprotective effect of combination ACE inhibitor and angiotensin II receptor blocker in hypertensive subjects with minor renal abnormalities: a 24-week randomized controlled trial.Journal of hypertension, , Volume: 23, Issue:3, 2005
Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 45, Issue:5, 2005
[Involvement of angiotensin II in pathogenesis of hypertension and target organ damage].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 62 Suppl 3, 2004
Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure.Kidney international, , Volume: 66, Issue:2, 2004
Antifibrotic, nephroprotective potential of ACE inhibitor vs AT1 antagonist in a murine model of renal fibrosis.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 19, Issue:7, 2004
Angiotensin II-dependent increased expression of Na+-glucose cotransporter in hypertension.American journal of physiology. Renal physiology, , Volume: 286, Issue:1, 2004
Development of congestive heart failure in type 2 diabetic patients with microalbuminuria or proteinuria: observations from the DIABHYCAR (type 2 DIABetes, Hypertension, CArdiovascular Events and Ramipril) study.Diabetes care, , Volume: 26, Issue:3, 2003
Initial findings of the AASK: African Americans with hypertensive kidney disease benefit from an ACE inhibitor.Cleveland Clinic journal of medicine, , Volume: 70, Issue:4, 2003
Kinins are involved in the antiproteinuric effect of angiotensin-converting enzyme inhibition in experimental diabetic nephropathy.International immunopharmacology, , Volume: 3, Issue:3, 2003
ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: the African American Study of Kidney Disease and Hypertension (AASK) trial.Kidney international. Supplement, , Issue:83, 2003
Ramipril treatment in a patient with glycogen storage disease I non-A.Journal of inherited metabolic disease, , Volume: 25, Issue:6, 2002
Acute and long-term effects of ACE inhibition on renal haemodynamics in glomerular and interstitial nephropathies.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 3, Issue:1, 2002
What is the best treatment for slowing the progression to end-stage renal disease (ESRD) in African Americans with hypertensive nephropathy?The Journal of family practice, , Volume: 50, Issue:9, 2001
Regulation of renin gene expression in kidneys of eNOS- and nNOS-deficient mice.Pflugers Archiv : European journal of physiology, , Volume: 439, Issue:5, 2000
Effect of ramipril on ambulatory blood pressure and albuminuria in renal hypertension.Pediatric nephrology (Berlin, Germany), , Volume: 15, Issue:1-2, 2000
Effects of ACE inhibition and bradykinin antagonism on cardiovascular changes in uremic rats.Kidney international, , Volume: 58, Issue:1, 2000
Haemodynamic mechanisms of corticotropin (ACTH)-induced hypertension in the rat.Journal of hypertension, , Volume: 17, Issue:12 Pt 1, 1999
Effect of intensive blood pressure control on the course of type 1 diabetic nephropathy. Collaborative Study Group.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 34, Issue:5, 1999
Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.Lancet (London, England), , Jul-31, Volume: 354, Issue:9176, 1999
[Hemodynamic mechanisms of lupus nephritis progression].Terapevticheskii arkhiv, , Volume: 70, Issue:6, 1998
[Renal tissue angiotensins during converting enzyme inhibition of angiotensin I in spontaneously hypertensive rat].Archives des maladies du coeur et des vaisseaux, , Volume: 90, Issue:8, 1997
Long- versus short-term effects of two different ACE inhibitors on renal haemodynamics: preliminary results from an ongoing trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 10 Suppl 6, 1995
Ramipril: a review of the new ACE inhibitor.The Journal of the Arkansas Medical Society, , Volume: 88, Issue:9, 1992
Role of bradykinin in chronic antihypertensive actions of ramipril in different hypertension models.Journal of cardiovascular pharmacology, , Volume: 20 Suppl 9, 1992
Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency.European journal of clinical pharmacology, , Volume: 37, Issue:3, 1989
Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure.Journal of cardiovascular pharmacology, , Volume: 13 Suppl 3, 1989
Steady-state kinetics of ramipril in renal failure.Journal of cardiovascular pharmacology, , Volume: 13 Suppl 3, 1989
[Effect of the angiotensin-converting enzyme inhibitor ramipril on proteinuria, blood pressure and kidney function in histologically confirmed glomerulonephritis with nephrotic syndrome].Zeitschrift fur Kardiologie, , Volume: 77 Suppl 3, 1988
[Variability of cardiac rhythm in patients with a symptomatic renal hypertension and effect of ramipril on its changes].Likars'ka sprava, , Issue:1-2
[A 93-year-old patient with hypertensive crises and renal failure due to bilateral renal artery stenosis].MMW Fortschritte der Medizin, , Nov-05, Volume: 157, Issue:19, 2015
Alterations in myocardial collagen content affect rat papillary muscle function.American journal of physiology. Heart and circulatory physiology, , Volume: 279, Issue:4, 2000
The effect of non-antihypertensive doses of angiotensin converting enzyme inhibitor on myocardial necrosis and hypertrophy in young rats with renovascular hypertension.International journal of experimental pathology, , Volume: 80, Issue:2, 1999
Effect of ACE inhibitor on DOCA-salt- and aortic coarctation-induced hypertension in mice: do kinin B2 receptors play a role?Hypertension (Dallas, Tex. : 1979), , Volume: 33, Issue:1 Pt 2, 1999
Experimental evidence for effects of ramipril on cardiac and vascular hypertrophy beyond blood pressure reduction.Archives des maladies du coeur et des vaisseaux, , Volume: 88 Spec No 2, 1995
Plasma renin activity and changes in tissue angiotensin converting enzyme.Journal of hypertension, , Volume: 12, Issue:5, 1994
Interrelation between renin mRNA levels, renin secretion, and blood pressure in two-kidney, one clip rats.Hypertension (Dallas, Tex. : 1979), , Volume: 24, Issue:2, 1994
Control of renin gene expression in 2 kidney-1 clip rats.Kidney international, , Volume: 46, Issue:6, 1994
Chronic kinin receptor blockade attenuates the antihypertensive effect of ramipril.Hypertension (Dallas, Tex. : 1979), , Volume: 20, Issue:1, 1992
Kinin contribution to chronic antihypertensive actions of ACE-inhibitors in hypertensive rats.Agents and actions. Supplements, , Volume: 38 ( Pt 2), 1992
[Inhibition of the enzyme of conversion and cardioprotection: role of bradykinins].Diabete & metabolisme, , Volume: 18, Issue:2 Pt 2, 1992
Role of vascular angiotensin converting enzyme in hypertension.Journal of hypertension. Supplement : official journal of the International Society of Hypertension, , Volume: 6, Issue:3, 1988
Ramipril for hypertension secondary to renal artery stenosis. Changes in blood pressure, the renin-angiotensin system and total and divided renal function.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
Cardiovascular and antihypertensive activities of the novel non-sulfhydryl converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).Arzneimittel-Forschung, , Volume: 34, Issue:10B, 1984
[Takayasu arteritis with aortic coarctation and multiple stenosis of aortic branches].Recenti progressi in medicina, , Volume: 101, Issue:7-8
The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.European journal of preventive cardiology, , Volume: 21, Issue:3, 2014
Serum potassium, cardiovascular risk, and effects of an ACE inhibitor: results of the HOPE study.Clinical nephrology, , Volume: 63, Issue:3, 2005
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.The New England journal of medicine, , 11-11, Volume: 385, Issue:20, 2021
Achieved blood pressure and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.Lancet (London, England), , Jun-03, Volume: 389, Issue:10085, 2017
Acute Bradykinin Receptor Blockade During Hemorrhagic Shock in Mice Prevents the Worsening Hypotensive Effect of Angiotensin-Converting Enzyme Inhibitor.Critical care medicine, , Volume: 44, Issue:9, 2016
Target Blood Pressure in Patients with Diabetes: Asian Perspective.Yonsei medical journal, , Volume: 57, Issue:6, 2016
[Evaluation of efficacy and safety of hypertension treatment with original angiotensin-converting enzyme inhibitors: the comparison of original and generic formulations].Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, , Volume: 34, Issue:201, 2013
Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).Journal of the American College of Cardiology, , Jan-03, Volume: 59, Issue:1, 2012
Prophylactic vasopressin in patients receiving the angiotensin-converting enzyme inhibitor ramipril undergoing coronary artery bypass graft surgery.Journal of cardiothoracic and vascular anesthesia, , Volume: 24, Issue:2, 2010
[ Therapy of patients at high risk for vascular events: telmisartan, ramipril or a combination? ].Der Internist, , Volume: 49, Issue:9, 2008
Telmisartan, ramipril, or both in patients at high risk of vascular events.The New England journal of medicine, , Jul-24, Volume: 359, Issue:4, 2008
Ramipril prior to thrombolysis attenuates the early increase of PAI-1 in patients with acute myocardial infarction.Thrombosis and haemostasis, , Volume: 88, Issue:2, 2002
Induction of functional bradykinin b(1)-receptors in normotensive rats and mice under chronic Angiotensin-converting enzyme inhibitor treatment.Circulation, , Feb-05, Volume: 105, Issue:5, 2002
Telmisartan, ramipril and their combination improve endothelial function in different tissues in a murine model of cholesterol-induced atherosclerosis.British journal of pharmacology, , Volume: 163, Issue:4, 2011
Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtolerCirculation, , Mar-30, Volume: 121, Issue:12, 2010
Sexual function, satisfaction, and association of erectile dysfunction with cardiovascular disease and risk factors in cardiovascular high-risk patients: substudy of the ONgoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/TelmAmerican heart journal, , Volume: 154, Issue:1, 2007
INDICATORS OF ENDOTHELIAL DYSFUNCTION, MARKERS OF INFLAMMATION AND LIPID METABOLISM IN PATIENTS WITH HYPERTENSION WITH THE ADMINISTRATION OF QUERCETIN.Wiadomosci lekarskie (Warsaw, Poland : 1960), , Volume: 75, Issue:7, 2022
Effects of Ramipril on Biomarkers of Endothelial Dysfunction and Inflammation in Hypertensive Children on Maintenance Hemodialysis: the SEARCH Randomized Placebo-Controlled Trial.Hypertension (Dallas, Tex. : 1979), , Volume: 79, Issue:8, 2022
Mitigation of radiation myelopathy and reduction of microglial infiltration by Ramipril, ACE inhibitor.Spinal cord, , Volume: 56, Issue:8, 2018
Effects of Angiotensin-Converting Enzyme Inhibition and Alpha 1-Adrenergic Receptor Blockade on Inflammation and Hemostasis in Human Hypertension.Journal of cardiovascular pharmacology, , Volume: 71, Issue:4, 2018
Angiotensin-converting enzyme inhibitor prevents oxidative stress, inflammation, and fibrosis in carbon tetrachloride-treated rat liver.Toxicology mechanisms and methods, , Volume: 26, Issue:1, 2016
ACE inhibitors potently reduce vascular inflammation, results of an open proof-of-concept study in the abdominal aortic aneurysm.PloS one, , Volume: 9, Issue:12, 2014
Comparative effects of angiotensin receptor blockade and ACE inhibition on the fibrinolytic and inflammatory responses to cardiopulmonary bypass.Clinical pharmacology and therapeutics, , Volume: 91, Issue:6, 2012
The crossroad of RAAS modulation, inflammation, and oxidative stress in dialysis patients: light at the end of the tunnel?Journal of the American Society of Nephrology : JASN, , Volume: 23, Issue:2, 2012
Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis.Journal of the American Society of Nephrology : JASN, , Volume: 23, Issue:2, 2012
Effect of pioglitazone and ramipril on biomarkers of low-grade inflammation and vascular function in nondiabetic patients with increased cardiovascular risk and an activated inflammation: results from the PIOace study.Journal of diabetes science and technology, , Jul-01, Volume: 5, Issue:4, 2011
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.Current protocols in cytometry, , Volume: Chapter 13, 2010
Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy.Nephrology (Carlton, Vic.), , Volume: 15, Issue:2, 2010
Effect of angiotensin-converting enzyme inhibition on C-reactive protein levels: the ramipril C-reactive pRotein randomized evaluation (4R) trial results.The Canadian journal of cardiology, , Volume: 25, Issue:7, 2009
Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms.Diabetes care, , Volume: 31, Issue:1, 2008
Inflammatory activation during coronary artery surgery and its dose-dependent modulation by statin/ACE-inhibitor combination.Arteriosclerosis, thrombosis, and vascular biology, , Volume: 27, Issue:12, 2007
Lack of effect on coronary atherosclerotic disease biomarkers with modest dosing of an angiotensin-converting enzyme inhibitor, angiotensin II type-1 receptor blocker, and the combination.Coronary artery disease, , Volume: 17, Issue:5, 2006
Differential effects of olmesartan and ramipril on inflammatory response after myocardial infarction in rats.Blood pressure, , Volume: 15, Issue:2, 2006
Effects of an angiotensin-converting enzyme inhibitor (ramipril) on inflammatory markers in secondary prevention patients: RAICES Study.Coronary artery disease, , Volume: 16, Issue:7, 2005
The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences.Scandinavian journal of clinical and laboratory investigation. Supplementum, , Volume: 240, 2005
[Can coronary risks be further reduced?].Presse medicale (Paris, France : 1983), , Sep-25, Volume: 33, Issue:16, 2004
Different proinflammatory profile of three ACE inhibitors: cilazapril, enalaprilat, and ramiprilat.The American journal of medicine, , Apr-23, Volume: 94, Issue:4A, 1993
Influence of the new angiotensin converting enzyme inhibitor ramipril on several models of acute inflammation and the adjuvant arthritis in the rat.Arzneimittel-Forschung, , Volume: 36, Issue:11, 1986
The effect of ramipril therapy on cytokines and parameters of incipient diabetic nephropathy in patients with type 1 diabetes mellitus.The Journal of international medical research, , Volume: 35, Issue:3
Ramipril pretreatment worsened renal injury and survival despite a reduction in renal inflammation in experimentally induced sepsis in mice.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 21, Issue:2
Protective effect of losartan and ramipril against stress induced insulin resistance and related complications: Anti-inflammatory mechanisms.European journal of pharmacology, , Apr-15, Volume: 801, 2017
Ramipril protects the endothelium from high glucose-induced dysfunction through CaMKKβ/AMPK and heme oxygenase-1 activation.The Journal of pharmacology and experimental therapeutics, , Volume: 350, Issue:1, 2014
Effect of renin-angiotensin-aldosterone system (RAAS) blockade on visfatin levels in diabetic nephropathy.Nephrology (Carlton, Vic.), , Volume: 15, Issue:2, 2010
Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes.Current atherosclerosis reports, , Volume: 10, Issue:2, 2008
Telmisartan improves insulin resistance in high renin nonmodulating salt-sensitive hypertensives.Journal of hypertension, , Volume: 26, Issue:12, 2008
Blockade of sensory abnormalities and kinin B(1) receptor expression by N-acetyl-L-cysteine and ramipril in a rat model of insulin resistance.European journal of pharmacology, , Jul-28, Volume: 589, Issue:1-3, 2008
Comparative effects of N-acetyl-L-cysteine and ramipril on arterial hypertension, insulin resistance, and oxidative stress in chronically glucose-fed rats.Canadian journal of physiology and pharmacology, , Volume: 86, Issue:11, 2008
Effect of ramipril on the incidence of diabetes.The New England journal of medicine, , Feb-01, Volume: 356, Issue:5, 2007
Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan.Blood purification, , Volume: 25, Issue:4, 2007
Effect of antihypertensive agents on plasma adiponectin levels in hypertensive patients with metabolic syndrome.Nephrology (Carlton, Vic.), , Volume: 12, Issue:2, 2007
Effect of short-term ACE inhibitor treatment on peripheral insulin sensitivity in obese insulin-resistant subjects.Diabetologia, , Volume: 49, Issue:12, 2006
[Experiences of the DREAM trial].Orvosi hetilap, , Dec-31, Volume: 147, Issue:52, 2006
Vascular and metabolic effects of combined therapy with ramipril and simvastatin in patients with type 2 diabetes.Hypertension (Dallas, Tex. : 1979), , Volume: 45, Issue:6, 2005
Insulin-sensitizing and cardiovascular effects of the sodium-hydrogen exchange inhibitor, cariporide, in the JCR: LA-cp rat and db/db mouse.Journal of cardiovascular pharmacology, , Volume: 46, Issue:6, 2005
Vasopeptidase inhibition improves insulin sensitivity and endothelial function in the JCR:LA-cp rat.Journal of cardiovascular pharmacology, , Volume: 44, Issue:2, 2004
[Involvement of angiotensin II in pathogenesis of hypertension and target organ damage].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 62 Suppl 3, 2004
Ramipril treatment suppresses islet fibrosis in Otsuka Long-Evans Tokushima fatty rats.Biochemical and biophysical research communications, , Mar-26, Volume: 316, Issue:1, 2004
Selective imidazoline agonist moxonidine plus the ACE inhibitor ramipril in hypertensive patients with impaired insulin sensitivity: partners in a successful MARRIAGE?Current medical research and opinion, , Volume: 20, Issue:3, 2004
Vasopeptidase inhibitor omapatrilat induces profound insulin sensitization and increases myocardial glucose uptake in Zucker fatty rats: Studies comparing a vasopeptidase inhibitor, angiotensin-converting enzyme inhibitor, and angiotensin II type I receptCirculation, , Apr-15, Volume: 107, Issue:14, 2003
[Hypertension and prediabetes. "Don't trust anybody over 130/80"].MMW Fortschritte der Medizin, , Mar-27, Volume: 145, Issue:13, 2003
ACE inhibition versus angiotensin type 1 receptor antagonism: differential effects on PAI-1 over time.Hypertension (Dallas, Tex. : 1979), , Volume: 40, Issue:6, 2002
Circulating amylin in human essential hypertension: heritability and early increase in individuals at genetic risk.Journal of hypertension, , Volume: 18, Issue:11, 2000
Ramipril increases the protein level of skeletal muscle IRS-1 and alters protein tyrosine phosphatase activity in spontaneously hypertensive rats.Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 362, Issue:1, 2000
[The effect of ramipril on metabolic, renal and cardiac function in hypertension and type II diabetes mellitus].Vnitrni lekarstvi, , Volume: 44, Issue:6, 1998
Effect of ramipril on insulin sensitivity in obese patients. Time-course study of glucose infusion rate during euglycaemic hyperinsulinaemic clamp.Diabetes & metabolism, , Volume: 22, Issue:3, 1996
Effects of ramipril therapy on some components of insulin resistance syndrome in patients with essential hypertension.Medicinski pregled, , Volume: 55, Issue:7-8
[Severe hypoglycemia secondary to angiotensin-converting-enzyme inhibitors in the absence of diabetes mellitus. Report of a case].Gaceta medica de Mexico, , Volume: 137, Issue:3
Effects of Ramipril on Biomarkers of Endothelial Dysfunction and Inflammation in Hypertensive Children on Maintenance Hemodialysis: the SEARCH Randomized Placebo-Controlled Trial.Hypertension (Dallas, Tex. : 1979), , Volume: 79, Issue:8, 2022
Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension.The Cochrane database of systematic reviews, , 10-22, Volume: 10, 2020
The win ratio approach did not alter study conclusions and may mitigate concerns regarding unequal composite end points in kidney transplant trials.Journal of clinical epidemiology, , Volume: 98, 2018
Angiotensin receptor blocker vs ACE inhibitor effects on HDL functionality in patients on maintenance hemodialysis.Nutrition, metabolism, and cardiovascular diseases : NMCD, , Volume: 28, Issue:6, 2018
Risk of renal dysfunction in an elderly patient with chronic heart failure.Medizinische Monatsschrift fur Pharmazeuten, , Volume: 39, Issue:10, 2016
Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial.The lancet. Diabetes & endocrinology, , Volume: 4, Issue:4, 2016
Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, , Volume: 15, Issue:12, 2015
Angiotensin Converting Enzyme Inhibitor Dialyzability and Outcomes in Older Patients Receiving Hemodialysis.Blood purification, , Volume: 40, Issue:3, 2015
Angiotensin converting enzyme inhibition increases ADMA concentration in patients on maintenance hemodialysis--a randomized cross-over study.BMC nephrology, , Oct-22, Volume: 16, 2015
Ramipril lowers plasma FGF-23 in patients with diabetic nephropathy.American journal of nephrology, , Volume: 40, Issue:3, 2014
Sodium intake, ACE inhibition, and progression to ESRD.Journal of the American Society of Nephrology : JASN, , Volume: 23, Issue:1, 2012
Comparative effects of angiotensin-converting enzyme inhibition and angiotensin-receptor blockade on inflammation during hemodialysis.Journal of the American Society of Nephrology : JASN, , Volume: 23, Issue:2, 2012
Sodium intake, ACE inhibition, and progression to ESRD.Journal of the American Society of Nephrology : JASN, , Volume: 23, Issue:1, 2012
Chronic kidney disease: cardiac and renal angiotensin-converting enzyme (ACE) 2 expression in rats after subtotal nephrectomy and the effect of ACE inhibition.Experimental physiology, , Volume: 97, Issue:4, 2012
ACE inhibition is renoprotective among obese patients with proteinuria.Journal of the American Society of Nephrology : JASN, , Volume: 22, Issue:6, 2011
Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.Circulation, , Mar-15, Volume: 123, Issue:10, 2011
REIN on obesity, proteinuria and CKD.Journal of the American Society of Nephrology : JASN, , Volume: 22, Issue:6, 2011
Impact of amlodipine or ramipril treatment on left ventricular mass and carotid intima-media thickness in nondiabetic hemodialysis patients.Renal failure, , Volume: 32, Issue:8, 2010
Strict blood-pressure control and progression of renal failure in children.The New England journal of medicine, , Oct-22, Volume: 361, Issue:17, 2009
Combined treatment with renin-angiotensin system blockers and polyunsaturated fatty acids in proteinuric IgA nephropathy: a randomized controlled trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 24, Issue:1, 2009
Severe paradoxical hypertension with angiotensin-converting enzyme inhibitors: an unusual feature of renal artery stenosis.Hypertension (Dallas, Tex. : 1979), , Volume: 54, Issue:3, 2009
[Clinical study on Shen Shuai Fang in treating chronic renal failure].Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials, , Volume: 31, Issue:5, 2008
Renin-angiotensin blockade and kidney disease.Lancet (London, England), , Aug-16, Volume: 372, Issue:9638, 2008
Long-term effects of renin-angiotensin system-blocking therapy and a low blood pressure goal on progression of hypertensive chronic kidney disease in African Americans.Archives of internal medicine, , Apr-28, Volume: 168, Issue:8, 2008
The Canadian ACE-inhibitor trial to improve renal outcomes and patient survival in kidney transplantation--study design.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 23, Issue:1, 2008
Improving proteinuria, endothelial functions and asymmetric dimethylarginine levels in chronic kidney disease: ramipril versus valsartan.Blood purification, , Volume: 25, Issue:4, 2007
Lessons from the African-American Study of Kidney Disease and Hypertension: an update.Current hypertension reports, , Volume: 8, Issue:5, 2006
Influence of angiotensin converting enzyme inhibitor treatment on cardiac autonomic modulation in patients receiving haemodialysis.Nephrology (Carlton, Vic.), , Volume: 11, Issue:6, 2006
Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents.Journal of the American Society of Nephrology : JASN, , Volume: 16, Issue:2, 2005
Angiotensin-converting enzyme inhibition and renal protection in nondiabetic patients: the data of the meta-analyses.Journal of the American Society of Nephrology : JASN, , Volume: 16 Suppl 1, 2005
Blood pressure control, drug therapy, and kidney disease.Hypertension (Dallas, Tex. : 1979), , Volume: 46, Issue:1, 2005
An update of irbesartan and renin-angiotensin system blockade in diabetic nephropathy.Expert opinion on pharmacotherapy, , Volume: 6, Issue:9, 2005
The relationship between magnitude of proteinuria reduction and risk of end-stage renal disease: results of the African American study of kidney disease and hypertension.Archives of internal medicine, , Apr-25, Volume: 165, Issue:8, 2005
Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 45, Issue:5, 2005
[Renoprotective effect of ramipril in children with chronic renal failure--the experience of one centre].Srpski arhiv za celokupno lekarstvo, , Volume: 132 Suppl 1, 2004
Antihypertensive and antiproteinuric efficacy of ramipril in children with chronic renal failure.Kidney international, , Volume: 66, Issue:2, 2004
Summaries for patients. Preventing worsening kidney function in patients receiving peritoneal dialysis.Annals of internal medicine, , Jul-15, Volume: 139, Issue:2, 2003
Antihypertensive drugs and renal protection.JAMA, , Mar-05, Volume: 289, Issue:9, 2003
Retarding progression of chronic renal disease: the neglected issue of residual proteinuria.Kidney international, , Volume: 63, Issue:6, 2003
Effects of an angiotensin-converting enzyme inhibitor on residual renal function in patients receiving peritoneal dialysis. A randomized, controlled study.Annals of internal medicine, , Jul-15, Volume: 139, Issue:2, 2003
Acute and long-term effects of ACE inhibition on renal haemodynamics in glomerular and interstitial nephropathies.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 3, Issue:1, 2002
Cardiovascular risk in patients with early renal insufficiency: implications for the use of ACE inhibitors.American journal of cardiovascular drugs : drugs, devices, and other interventions, , Volume: 2, Issue:3, 2002
Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial.JAMA, , Nov-20, Volume: 288, Issue:19, 2002
Effect of high dose ramipril with or without indomethacin on glomerular selectivity.Kidney international, , Volume: 62, Issue:3, 2002
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.JAMA, , Jun-06, Volume: 285, Issue:21, 2001
Ramipril prolongs life and is cost effective in chronic proteinuric nephropathies.Kidney international, , Volume: 59, Issue:1, 2001
ACE inhibitors to prevent end-stage renal disease: when to start and why possibly never to stop: a post hoc analysis of the REIN trial results. Ramipril Efficacy in Nephropathy.Journal of the American Society of Nephrology : JASN, , Volume: 12, Issue:12, 2001
What is the best treatment for slowing the progression to end-stage renal disease (ESRD) in African Americans with hypertensive nephropathy?The Journal of family practice, , Volume: 50, Issue:9, 2001
Can ACE inhibitor therapy prevent end-stage renal failure?The Medical journal of Australia, , Sep-03, Volume: 175, Issue:5, 2001
Clinical trials report. The effect of Ramipril versus Amlodipine on renal outcomes in hypertension nephrosclerosis.Current hypertension reports, , Volume: 3, Issue:5, 2001
Pretreatment blood pressure reliably predicts progression of chronic nephropathies. GISEN Group.Kidney international, , Volume: 58, Issue:5, 2000
Chronic proteinuric nephropathies. II. Outcomes and response to treatment in a prospective cohort of 352 patients: differences between women and men in relation to the ACE gene polymorphism. Gruppo Italiano di Studi Epidemologici in Nefrologia (Gisen)Journal of the American Society of Nephrology : JASN, , Volume: 11, Issue:1, 2000
Chronic proteinuric nephropathies: outcomes and response to treatment in a prospective cohort of 352 patients with different patterns of renal injury.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 35, Issue:6, 2000
[Further evidence for the renoprotective effect of ACE inhibitors: ramipril protects against the progression of chronic renal insufficiency in non-diabetic nephropathy with nephrotic proteinuria].Schweizerische medizinische Wochenschrift, , Apr-01, Volume: 130, Issue:13, 2000
Effects of ACE inhibition and bradykinin antagonism on cardiovascular changes in uremic rats.Kidney international, , Volume: 58, Issue:1, 2000
Renal protection: progression, regression, remission from nephropathy beyond blood pressure control.International journal of clinical practice. Supplement, , Issue:110, 2000
Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria.Lancet (London, England), , Jul-31, Volume: 354, Issue:9176, 1999
Non-diabetic nephropathies and ACE inhibition.Lancet (London, England), , Nov-27, Volume: 354, Issue:9193, 1999
Renoprotective therapy: titration against urinary protein excretion.Lancet (London, England), , Jul-31, Volume: 354, Issue:9176, 1999
A subdepressor low dose of ramipril lowers urinary protein excretion without increasing plasma potassium.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 33, Issue:3, 1999
Role of kinins in the renoprotective effect of angiotensin-converting enzyme inhibitors in experimental chronic renal failure.Kidney & blood pressure research, , Volume: 21, Issue:5, 1998
Urinary protein excretion rate is the best independent predictor of ESRF in non-diabetic proteinuric chronic nephropathies. "Gruppo Italiano di Studi Epidemiologici in Nefrologia" (GISEN).Kidney international, , Volume: 53, Issue:5, 1998
The renoprotective effect of angiotensin-converting enzyme inhibitors in experimental chronic renal failure is not dependent on enhanced kinin activity.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 13, Issue:1, 1998
Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy in Nephropathy.Lancet (London, England), , Oct-17, Volume: 352, Issue:9136, 1998
Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)Lancet (London, England), , Jun-28, Volume: 349, Issue:9069, 1997
ACE-inhibitors: panacea for progressive renal disease.Lancet (London, England), , Jun-28, Volume: 349, Issue:9069, 1997
Effect of ramipril, nifedipine, and moxonidine on glomerular morphology and podocyte structure in experimental renal failure.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 11, Issue:6, 1996
Arteriolar wall thickening, capillary rarefaction and interstitial fibrosis in the heart of rats with renal failure:the effects of ramipril, nifedipine and moxonidine.Journal of the American Society of Nephrology : JASN, , Volume: 7, Issue:5, 1996
Long- versus short-term effects of two different ACE inhibitors on renal haemodynamics: preliminary results from an ongoing trial.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 10 Suppl 6, 1995
Steady-state kinetics of ramipril in renal failure.Journal of cardiovascular pharmacology, , Volume: 13 Suppl 3, 1989
Therapeutic efficacy and tolerance of ramipril in hypertensive patients with renal failure.Journal of cardiovascular pharmacology, , Volume: 13 Suppl 3, 1989
Pharmacokinetics and pharmacodynamics of ramipril in renal failure.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
REIN follow-up trial. Ramipril Efficacy in Nephropathy.Lancet (London, England), , Volume: 352, Issue:9145
REIN follow-up trial. Ramipril Efficacy in Nephropathy.Lancet (London, England), , Volume: 352, Issue:9145
Inhibitors of the renin-angiotensin system reduce the rate of GFR decline and end-stage renal disease in patients with severe renal insufficiency.Journal of nephrology, , Volume: 15, Issue:4
Renoprotective therapy: is it blood pressure or albuminuria that matters?Lancet (London, England), , Volume: 365, Issue:9463
Loss of captopril-bound Fe by end-stage renal failure patients during hemodialysis.Journal of nephrology, , Volume: 17, Issue:1
ACE-inhibitors and progression of chronic renal insufficiency: a contribution of Italian clinical research.Journal of nephrology, , Volume: 11, Issue:3
Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial.Lancet (London, England), , Volume: 365, Issue:9463
Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products.Journal of human hypertension, , Volume: 17, Issue:4, 2003
Activity and functional significance of the renal kallikrein-kinin-system in polycystic kidney disease of the rat.Kidney international, , Volume: 61, Issue:6, 2002
Ramipril in non-diabetic renal failure (REIN study). Ramipril Efficiency in Nephropathy study.Lancet (London, England), , Sep-06, Volume: 350, Issue:9079, 1997
Effects of renin-angiotensin system inhibitors on fibrosis in patients with alcoholic chronic pancreatitis.Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, , Volume: 67, Issue:1, 2016
Angiotensin-converting enzyme inhibitor prevents oxidative stress, inflammation, and fibrosis in carbon tetrachloride-treated rat liver.Toxicology mechanisms and methods, , Volume: 26, Issue:1, 2016
Angiotensin-converting enzyme inhibition in cirrhotic patients--pharmacokinetics of ramipril.Acta medica Austriaca, , Volume: 24, Issue:1, 1997
Centrally acting ACE inhibitor (cACEi) and angiotensin receptor blocker (cARB) use and cognitive dysfunction in patients with SLE.Lupus science & medicine, , Volume: 10, Issue:2, 2023
Ramipril Improves Endothelial Function and Increases the Number of Endothelial Progenitor Cells in Patients With Systemic Lupus Erythematosus.Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, , Oct-01, Volume: 28, Issue:7, 2022
IgA vasculitis (formerly Henoch-Schönlein purpura) in an adult with systemic lupus erythematosus.BMJ case reports, , Sep-09, Volume: 2015, 2015
Barriers to a trial of atherosclerosis prevention in systemic lupus erythematosus.Arthritis and rheumatism, , Oct-15, Volume: 53, Issue:5, 2005
Spontaneous resolution of severe mitral regurgitation in a patient with a flail mitral valve.Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography, , Volume: 23, Issue:12, 2010
Minimal change disease in association with fire coral (Millepora species) exposure.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 47, Issue:1, 2006
Role of echocardiography in assessing the mechanism and effect of ramipril on functional mitral regurgitation in dilated cardiomyopathy.Echocardiography (Mount Kisco, N.Y.), , Volume: 22, Issue:4, 2005
Effects of angiotensin-converting enzyme inhibition on mitral regurgitation severity, left ventricular size, and functional capacity.American heart journal, , Volume: 150, Issue:5, 2005
Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease.The Journal of small animal practice, , Volume: 46, Issue:3, 2005
Effect of ramipril on mitral regurgitation secondary to mitral valve prolapse.The American journal of cardiology, , Sep-01, Volume: 80, Issue:5, 1997
Randomised controlled trial into the role of ramipril in fibrosis reduction in rheumatic heart disease: the RamiRHeD trial protocol.BMJ open, , 09-13, Volume: 11, Issue:9, 2021
Cardiac angiotensin II participates in coronary microvessel inflammation of unstable angina and strengthens the immunomediated component.Circulation research, , Jun-25, Volume: 94, Issue:12, 2004
Ramipril restores PPARβ/δ and PPARγ expressions and reduces cardiac NADPH oxidase but fails to restore cardiac function and accompanied myosin heavy chain ratio shift in severe anthracycline-induced cardiomyopathy in rat.European journal of pharmacology, , Nov-15, Volume: 791, 2016
[Postpartum cardiomyopathy].Deutsche medizinische Wochenschrift (1946), , Volume: 136, Issue:22, 2011
Prevention of myocardial fibrosis by N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.Clinical science (London, England : 1979), , Oct-26, Volume: 118, Issue:3, 2009
[Renal effect of treatment for heart failure].Ugeskrift for laeger, , Feb-23, Volume: 171, Issue:9, 2009
Both ramipril and telmisartan reverse indices of early diabetic cardiomyopathy: a comparative study.European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology, , Volume: 8, Issue:6, 2007
Impaired nitric oxide modulation of myocardial oxygen consumption in genetically cardiomyopathic hamsters.Journal of molecular and cellular cardiology, , Volume: 32, Issue:12, 2000
Myocardial interstitial fibrosis in experimental uremia--implications for cardiac compliance.Kidney international, , Volume: 33, Issue:4, 1988
Comparative Efficacy of Levosimendan, Ramipril, and Sacubitril/ Valsartan in Isoproterenol-induced Experimental Heart Failure: A Hemodynamic and Molecular Approach.Current molecular pharmacology, , Volume: 16, Issue:6, 2023
Firibastat Versus Ramipril After Acute Mechanical Reperfusion of Anterior Myocardial Infarction: A Phase 2 Study.American journal of cardiovascular drugs : drugs, devices, and other interventions, , Volume: 23, Issue:2, 2023
QGC606: A Best-in-Class Orally Active Centrally Acting Aminopeptidase A Inhibitor Prodrug for Treating Heart Failure Following Myocardial Infarction.The Canadian journal of cardiology, , Volume: 38, Issue:6, 2022
Angiotensin Receptor-Neprilysin Inhibitor in Acute Myocardial Infarction.The Journal of the Association of Physicians of India, , Volume: 70, Issue:4, 2022
Polypill Strategy in Secondary Cardiovascular Prevention.The New England journal of medicine, , 09-15, Volume: 387, Issue:11, 2022
Sacubitril/valsartan versus ramipril for patients with acute myocardial infarction: win-ratio analysis of the PARADISE-MI trial.European journal of heart failure, , Volume: 24, Issue:10, 2022
The Effects of Angiotensin Receptor-Neprilysin Inhibition on Major Coronary Events in Patients With Acute Myocardial Infarction: Insights From the PARADISE-MI Trial.Circulation, , 12-06, Volume: 146, Issue:23, 2022
Angiotensin Receptor-Neprilysin Inhibition in Acute Myocardial Infarction.The New England journal of medicine, , 11-11, Volume: 385, Issue:20, 2021
ACE inhibitor-related angioedema in a COVID-19 patient-a plausible contribution of the viral infection?European journal of clinical pharmacology, , Volume: 77, Issue:6, 2021
Comparison of the Efficacy and Safety of Sacubitril/Valsartan versus Ramipril in Patients With ST-Segment Elevation Myocardial Infarction.The American journal of cardiology, , 03-15, Volume: 143, 2021
Long-term survival benefit of ramipril in patients with acute myocardial infarction complicated by heart failure.Heart (British Cardiac Society), , Volume: 107, Issue:5, 2021
Efficacy of Sacubitril-Valsartan in Patients With Reduced Left Ventricular Ejection Fraction.The American journal of cardiology, , 08-15, Volume: 153, 2021
Impact of different angiotensin-converting inhibitors on outcomes of post-myocardial infarction patients.Wiadomosci lekarskie (Warsaw, Poland : 1960), , Volume: 73, Issue:3, 2020
Renin inhibitors versus angiotensin converting enzyme (ACE) inhibitors for primary hypertension.The Cochrane database of systematic reviews, , 10-22, Volume: 10, 2020
Cardiovascular outcomes and achieved blood pressure in patients with and without diabetes at high cardiovascular risk.European heart journal, , 07-01, Volume: 40, Issue:25, 2019
Efficacy and Safety of Zofenopril Versus Ramipril in the Treatment of Myocardial Infarction and Heart Failure: A Review of the Published and Unpublished Data of the Randomized Double-Blind SMILE-4 Study.Advances in therapy, , Volume: 35, Issue:5, 2018
Effects of the concomitant administration of xanthine oxidase inhibitors with zofenopril or other ACE-inhibitors in post-myocardial infarction patients: a meta-analysis of individual data of four randomized, double-blind, prospective studies.BMC cardiovascular disorders, , 06-05, Volume: 18, Issue:1, 2018
Achieved diastolic blood pressure and pulse pressure at target systolic blood pressure (120-140 mmHg) and cardiovascular outcomes in high-risk patients: results from ONTARGET and TRANSCEND trials.European heart journal, , 09-01, Volume: 39, Issue:33, 2018
Early Treatment With Zofenopril and Ramipril in Combination With Acetyl Salicylic Acid in Patients With Left Ventricular Systolic Dysfunction After Acute Myocardial Infarction: Results of a 5-Year Follow-up of Patients of the SMILE-4 Study.Journal of cardiovascular pharmacology, , Volume: 69, Issue:5, 2017
Zofenopril and ramipril in patients with left ventricular systolic dysfunction after acute myocardial infarction: A propensity analysis of the Survival of Myocardial Infarction Long-term Evaluation (SMILE) 4 study.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 17, Issue:4, 2016
Ramipril attenuates left ventricular remodeling by regulating the expression of activin A-follistatin in a rat model of heart failure.Scientific reports, , 09-19, Volume: 6, 2016
Zofenopril Protects Against Myocardial Ischemia-Reperfusion Injury by Increasing Nitric Oxide and Hydrogen Sulfide Bioavailability.Journal of the American Heart Association, , 07-05, Volume: 5, Issue:7, 2016
Ramipril and Losartan Exert a Similar Long-Term Effect upon Markers of Heart Failure, Endogenous Fibrinolysis, and Platelet Aggregation in Survivors of ST-Elevation Myocardial Infarction: A Single Centre Randomized Trial.BioMed research international, , Volume: 2016, 2016
Risk of renal dysfunction in an elderly patient with chronic heart failure.Medizinische Monatsschrift fur Pharmazeuten, , Volume: 39, Issue:10, 2016
Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction: A Retrospective Analysis of the SMILE-4 Randomized, Double-Blind Study in Diabetic Patients.Cardiovascular therapeutics, , Volume: 34, Issue:2, 2016
Effect of ethanolic extract of Cyperus rotundus L. against isoprenaline induced cardiotoxicity.Indian journal of experimental biology, , Volume: 54, Issue:10, 2016
A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors.British journal of clinical pharmacology, , Volume: 80, Issue:4, 2015
Systolic and diastolic blood pressure changes in relation with myocardial infarction and stroke in patients with coronary artery disease.Hypertension (Dallas, Tex. : 1979), , Volume: 65, Issue:1, 2015
Systolic blood pressure target levels: evidence for benefits in stroke.Hypertension (Dallas, Tex. : 1979), , Volume: 65, Issue:1, 2015
The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.European journal of preventive cardiology, , Volume: 21, Issue:3, 2014
Soluble guanylyl cyclase activation improves progressive cardiac remodeling and failure after myocardial infarction. Cardioprotection over ACE inhibition.Basic research in cardiology, , Volume: 109, Issue:4, 2014
Not all angiotensin-converting enzyme inhibitors are equal: focus on ramipril and perindopril.Postgraduate medicine, , Volume: 125, Issue:4, 2013
Zofenopril and ramipril and acetylsalicylic acid in postmyocardial infarction patients with left ventricular systolic dysfunction: a retrospective analysis in hypertensive patients of the SMILE-4 study.Journal of hypertension, , Volume: 31, Issue:6, 2013
Effects of nonpersistence with medication on outcomes in high-risk patients with cardiovascular disease.American heart journal, , Volume: 166, Issue:2, 2013
A comparison between imidapril and ramipril on attenuation of ventricular remodeling after myocardial infarction.Journal of cardiovascular pharmacology, , Volume: 59, Issue:4, 2012
Influence of ramiprilat and losartan on ischemia reperfusion injury in rat hearts.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 13, Issue:1, 2012
Effect of ramipril on the electrophysiological characteristics of ventricular myocardium after myocardial infarction in rabbits.Journal of cardiovascular medicine (Hagerstown, Md.), , Volume: 13, Issue:5, 2012
Impact of sex on cardiovascular outcome in patients at high cardiovascular risk: analysis of the Telmisartan Randomized Assessment Study in ACE-Intolerant Subjects With Cardiovascular Disease (TRANSCEND) and the Ongoing Telmisartan Alone and in CombinatioCirculation, , Aug-21, Volume: 126, Issue:8, 2012
Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions.Clinical science (London, England : 1979), , Volume: 123, Issue:11, 2012
Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European studClinical cardiology, , Volume: 35, Issue:7, 2012
Comparing effects of lacidipine, ramipril, and valsartan against experimentally induced myocardial infarcted rats.Cardiovascular toxicology, , Volume: 12, Issue:2, 2012
The cost implications of the use of telmisartan or ramipril in patients at high risk for vascular events: the ONTARGET study.Journal of medical economics, , Volume: 14, Issue:6, 2011
Telmisartan for the management of patients at high cardiovascular risk.Current medical research and opinion, , Volume: 27, Issue:8, 2011
Cardiovascular and renal outcomes with telmisartan, ramipril, or both in people at high renal risk: results from the ONTARGET and TRANSCEND studies.Circulation, , Mar-15, Volume: 123, Issue:10, 2011
Impact of ACE inhibitors on mortality and morbidity in patients with AMI: Does tissue selectivity matter?Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research, , Volume: 14, Issue:1, 2011
[Efficacy of ramipril, carvedilol, and trimetazidine MR in improvement of quality of life of patients after myocardial infarction].Kardiologiia, , Volume: 50, Issue:12, 2010
Age-related short-term effect of ramipril on N-terminal pro-brain natriuretic peptide and markers of hemostasis in patients after acute myocardial infarction.Wiener klinische Wochenschrift, , Volume: 122 Suppl 2, 2010
Ramipril-like activity of Spondias mombin linn against no-flow ischemia and isoproterenol-induced cardiotoxicity in rat heart.Cardiovascular toxicology, , Volume: 10, Issue:4, 2010
The kinin B1 receptor contributes to the cardioprotective effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in mice.Experimental physiology, , Volume: 94, Issue:3, 2009
Investigation of effects of Lacidipine, Ramipril and Valsartan on DNA damage and oxidative stress occurred in acute and chronic periods following isoproterenol-induced myocardial infarct in rats.Molecular and cellular biochemistry, , Volume: 328, Issue:1-2, 2009
The prognostic significance of bundle branch block in high-risk chronic stable vascular disease patients: a report from the HOPE trial.Journal of cardiovascular electrophysiology, , Volume: 20, Issue:7, 2009
[Investigation of converting enzyme inhibitors in patients, survivors of myocardial infarction].Kardiologiia, , Volume: 48, Issue:7, 2008
[The use of angiotensin converting enzyme inhibitors in patients after myocardial infarction].Kardiologiia, , Volume: 48, Issue:11, 2008
Attenuation of left ventricular dysfunction by an ACE inhibitor after myocardial infarction in a kininogen-deficient rat model.Biological chemistry, , Volume: 389, Issue:6, 2008
A proteomic study of the effects of ramipril on post-infarction left ventricular remodelling in the rabbit.European journal of heart failure, , Volume: 10, Issue:8, 2008
Long-term but not short-term p38 mitogen-activated protein kinase inhibition improves cardiac function and reduces cardiac remodeling post-myocardial infarction.The Journal of pharmacology and experimental therapeutics, , Volume: 325, Issue:3, 2008
Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes.Current atherosclerosis reports, , Volume: 10, Issue:2, 2008
Chronic angiotensin II receptor blockade induces cardioprotection during ischemia by increased PKC-epsilon expression in the mouse heart.Journal of cardiovascular pharmacology, , Volume: 49, Issue:1, 2007
Redefining the ACE-inhibitor dose-response relationship: substantial blood pressure lowering after massive doses.European journal of clinical pharmacology, , Volume: 62, Issue:12, 2006
Impact of ramipril on the circadian periodicity of acute myocardial infarction.The American journal of cardiology, , Sep-15, Volume: 98, Issue:6, 2006
Comparative impact of multiple biomarkers and N-Terminal pro-brain natriuretic peptide in the context of conventional risk factors for the prediction of recurrent cardiovascular events in the Heart Outcomes Prevention Evaluation (HOPE) Study.Circulation, , Jul-18, Volume: 114, Issue:3, 2006
Is ramipril really better than other angiotensin-converting enzyme inhibitors after acute myocardial infarction?The American journal of cardiology, , Jul-01, Volume: 98, Issue:1, 2006
Differential effects of olmesartan and ramipril on inflammatory response after myocardial infarction in rats.Blood pressure, , Volume: 15, Issue:2, 2006
Lipid peroxidation is not increased in heart failure patients on modern pharmacological therapy.International journal of cardiology, , Oct-10, Volume: 112, Issue:3, 2006
The HOPE (Heart Outcomes Prevention Evaluation) Study and its consequences.Scandinavian journal of clinical and laboratory investigation. Supplementum, , Volume: 240, 2005
[Experiences with the realisation of innovative study designs using the example of the HOPE-study].Deutsche medizinische Wochenschrift (1946), , Jul-08, Volume: 130 Suppl 2, 2005
Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia.FASEB journal : official publication of the Federation of American Societies for Experimental Biology, , Volume: 19, Issue:9, 2005
Combined effects of ramipril and angiotensin II receptor blocker TCV116 on rat congestive heart failure after myocardial infarction.Chinese medical journal, , Jan-20, Volume: 118, Issue:2, 2005
Myocardial infarction increases ACE2 expression in rat and humans.European heart journal, , Volume: 26, Issue:4, 2005
Impact of cigarette smoking in high-risk patients participating in a clinical trial. A substudy from the Heart Outcomes Prevention Evaluation (HOPE) trial.European journal of cardiovascular prevention and rehabilitation : official journal of the European Society of Cardiology, Working Groups on Epidemiology & Prevention and Cardiac Rehabilitation and Exercise Physiology, , Volume: 12, Issue:1, 2005
Effects of purified herbal extract of Salvia miltiorrhiza on ischemic rat myocardium after acute myocardial infarction.Life sciences, , Apr-29, Volume: 76, Issue:24, 2005
[Olmesartan after experimental myocardial infarct compared with ramipril: organ protective effect].Krankenpflege Journal, , Volume: 43, Issue:4-6, 2005
Effects of combined inhibition of the Na+-H+ exchanger and angiotensin-converting enzyme in rats with congestive heart failure after myocardial infarction.British journal of pharmacology, , Volume: 146, Issue:5, 2005
[Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].Italian heart journal : official journal of the Italian Federation of Cardiology, , Volume: 6 Suppl 7, 2005
Cardioprotective activity of alcoholic extract of Tinospora cordifolia in ischemia-reperfusion induced myocardial infarction in rats.Biological & pharmaceutical bulletin, , Volume: 28, Issue:12, 2005
[Experiences with the realisation of the innovative study designs using the example of the HOPE study -- concerning the contribution in DMW Supplement 2/2005].Deutsche medizinische Wochenschrift (1946), , Nov-25, Volume: 130, Issue:47, 2005
Extended follow-up of patients randomly assigned in the Angiotensin-converting enzyme inhibition Post-Revascularization Study (APRES).American heart journal, , Volume: 148, Issue:3, 2004
[Can coronary risks be further reduced?].Presse medicale (Paris, France : 1983), , Sep-25, Volume: 33, Issue:16, 2004
Comparison of cardioprotective effects of mibefradil and ramipril in stroke-prone spontaneously hypertensive rats.Acta pharmacologica Sinica, , Volume: 25, Issue:6, 2004
The problem of underdosing of angiotensin-converting enzyme inhibitors is markedly overrated: results from a study of patients discharged from hospital after an acute myocardial infarction.European journal of clinical pharmacology, , Volume: 60, Issue:3, 2004
[Preventive therapy with ACE inhibitors for coronary patients].Orvosi hetilap, , Feb-29, Volume: 145, Issue:9, 2004
Angina pectoris prior to myocardial infarction protects against subsequent left ventricular remodeling.Journal of the American College of Cardiology, , May-05, Volume: 43, Issue:9, 2004
Ischemic preconditioning in coronary heart disease: a therapeutic golden fleece?Journal of the American College of Cardiology, , May-05, Volume: 43, Issue:9, 2004
Randomized, double-blind, placebo-controlled long-term study of isosorbide-5-mononitrate therapy in patients with left ventricular dysfunction after acute myocardial infarction.American heart journal, , Volume: 145, Issue:1, 2003
Cost implications of the use of ramipril in high-risk patients based on the Heart Outcomes Prevention Evaluation (HOPE) study.Circulation, , Feb-25, Volume: 107, Issue:7, 2003
Prevention of Heart Failure in Patients in the Heart Outcomes Prevention Evaluation (HOPE) Study.Circulation, , Mar-11, Volume: 107, Issue:9, 2003
Economic impact of ramipril on hospitalization of high-risk cardiovascular patients.The Annals of pharmacotherapy, , Volume: 37, Issue:3, 2003
Mechanisms of myocardial remodeling: ramiprilat blocks the expressional upregulation of protein kinase C-epsilon in the surviving myocardium early after infarction.Journal of cardiovascular pharmacology, , Volume: 41, Issue:5, 2003
Aldosterone receptor blockade improves left ventricular remodeling and increases ventricular fibrillation threshold in experimental heart failure.Cardiovascular research, , Jun-01, Volume: 58, Issue:3, 2003
Effects of diuretic treatment on cardiac and circulating RAS in chronic heart failure post-myocardial infarction in rats.European journal of heart failure, , Volume: 5, Issue:3, 2003
Adding angiotensin II type 1 receptor blockade to angiotensin-converting enzyme inhibition limits myocyte remodeling after myocardial infarction.Journal of cardiac failure, , Volume: 9, Issue:3, 2003
Comparison of cardioprotective effects using ramipril and DanShen for the treatment of acute myocardial infarction in rats.Life sciences, , Aug-01, Volume: 73, Issue:11, 2003
Should all patients with coronary disease receive angiotensin-converting-enzyme inhibitors?Lancet (London, England), , Sep-06, Volume: 362, Issue:9386, 2003
Infarct size limiting effect of apstatin alone and in combination with enalapril, lisinopril and ramipril in rats with experimental myocardial infarction.Pharmacological research, , Volume: 48, Issue:6, 2003
Ramipril improves nitric oxide availability in hypertensive rats with failing hearts after myocardial infarction.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 4, Issue:3, 2003
[Ramipril after myocardial infarct. Long lasting cardiovascular protective action].MMW Fortschritte der Medizin, , Sep-25, Volume: 145, Issue:39, 2003
[Fast and strong lowering of pressure. The newest sartan has passed the practice test].MMW Fortschritte der Medizin, , Oct-30, Volume: 145, Issue:44, 2003
[Therapy of hypertension. Lasting organ protection moves into the foreground].MMW Fortschritte der Medizin, , Nov-20, Volume: 145, Issue:47, 2003
[Vascular patient with high infarction risk. Does the AT-1 blocker protect as well as an ACE inhibitor?].MMW Fortschritte der Medizin, , Dec-18, Volume: 145, Issue:51-52, 2003
The angiotensin-converting enzyme gene I/D polymorphism and heart rate variability following acute myocardial infarction.Clinical autonomic research : official journal of the Clinical Autonomic Research Society, , Volume: 12, Issue:2, 2002
A prospective evaluation of the angiotensin-converting enzyme D/I polymorphism and left ventricular remodeling in the 'Healing and Early Afterload Reducing Therapy' study.Clinical genetics, , Volume: 61, Issue:1, 2002
Effect of ramipril and furosemide treatment on interstitial remodeling in post-infarction heart failure rat hearts.Journal of molecular and cellular cardiology, , Volume: 34, Issue:2, 2002
Ramipril prior to thrombolysis attenuates the early increase of PAI-1 in patients with acute myocardial infarction.Thrombosis and haemostasis, , Volume: 88, Issue:2, 2002
Effect of long-term therapy with ramipril in high-risk women.Journal of the American College of Cardiology, , Aug-21, Volume: 40, Issue:4, 2002
[Dangerous plaque often symptom-free. ACE inhibitors prevent rupture].MMW Fortschritte der Medizin, , Aug-22, Volume: 144, Issue:33-34, 2002
Impact of ramipril versus other angiotensin-converting enzyme inhibitors on outcome of unselected patients with ST-elevation acute myocardial infarction.The American journal of cardiology, , Nov-15, Volume: 90, Issue:10, 2002
Using ACE inhibitors appropriately.American family physician, , Aug-01, Volume: 66, Issue:3, 2002
Cost-effectiveness of the treatment of heart failure with ramipril: a Spanish analysis of the AIRE study.European journal of heart failure, , Volume: 4, Issue:4, 2002
"Preemptive strike" heart medications. A.C.E. inhibitors gain new ground as multi-purpose cardiac drugs.Heart advisor, , Volume: 5, Issue:2, 2002
The Heart Outcomes Prevention Evaluation study: angiotensin-converting enzyme inhibitors: are their benefits a class effect or do individual agents differ?Current opinion in nephrology and hypertension, , Volume: 10, Issue:5, 2001
Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study.Circulation, , Jul-31, Volume: 104, Issue:5, 2001
Combined angiotensin II receptor antagonism and angiotensin-converting enzyme inhibition further attenuates postinfarction left ventricular remodeling.Circulation, , Jun-12, Volume: 103, Issue:23, 2001
Combined angiotensin converting enzyme inhibition and angiotensin AT(1) receptor blockade up-regulates myocardial AT(2) receptors in remodeled myocardium post-infarction.Cardiovascular research, , Volume: 51, Issue:1, 2001
Diminished cardioprotective response to inhibition of angiotensin-converting enzyme and angiotensin II type 1 receptor in B(2) kinin receptor gene knockout mice.Circulation research, , May-25, Volume: 88, Issue:10, 2001
[Atherosclerosis. High dosage ACE inhibitor keeps event rate under control].MMW Fortschritte der Medizin, , Mar-29, Volume: 143, Issue:13, 2001
Management of asymptomatic left ventricular dysfunction.Cleveland Clinic journal of medicine, , Volume: 68, Issue:3, 2001
What are 'tissue ACE inhibitors,' and should they be used instead of other ACE inhibitors?Cleveland Clinic journal of medicine, , Volume: 68, Issue:3, 2001
[ACE inhibition in patients with myocardial infarct and ventricular dysfunction: inappropriate application of therapy standards in patient samples].Zeitschrift fur Kardiologie, , Volume: 90, Issue:2, 2001
Recovery of ventricular function after myocardial infarction in the reperfusion era: the healing and early afterload reducing therapy study.Annals of internal medicine, , Mar-20, Volume: 134, Issue:6, 2001
Changes in vasoconstrictive hormones, natriuretic peptides, and left ventricular remodeling soon after anterior myocardial infarction.American heart journal, , Volume: 142, Issue:6, 2001
Diabetes and the HOPE study: implications for macrovascular and microvascular disease.International journal of clinical practice. Supplement, , Issue:117, 2001
[Achieving vascular protection. ACE inhibitor lowers not only blood pressure].MMW Fortschritte der Medizin, , Sep-06, Volume: 143, Issue:35-36, 2001
Regional wall stress predicts ventricular remodeling after anteroseptal myocardial infarction in the Healing and Early Afterload Reducing Trial (HEART): an echocardiography-based structural analysis.American heart journal, , Volume: 141, Issue:2, 2001
Apstatin, a selective inhibitor of aminopeptidase P, reduces myocardial infarct size by a kinin-dependent pathway.British journal of pharmacology, , Volume: 134, Issue:2, 2001
Inhibitors of bradykinin-inactivating enzymes decrease myocardial ischemia/reperfusion injury following 3 and 7 days of reperfusion.The Journal of pharmacology and experimental therapeutics, , Volume: 298, Issue:3, 2001
Enhanced reduction of myocardial infarct size by combined ACE inhibition and AT(1)-receptor antagonism.British journal of pharmacology, , Volume: 131, Issue:1, 2000
Hidden benefits of ACE inhibitors.Harvard heart letter : from Harvard Medical School, , Volume: 10, Issue:6, 2000
Effects of ACE inhibitor, AT1 antagonist, and combined treatment in mice with heart failure.Journal of cardiovascular pharmacology, , Volume: 36, Issue:4, 2000
ACE inhibitors: new hope for old drugs?South Dakota journal of medicine, , Volume: 53, Issue:8, 2000
Combined treatment with ramipril and metoprolol prevents changes in the creatine kinase isoenzyme system and improves hemodynamic function in rat hearts after myocardial infarction.Cardiovascular drugs and therapy, , Volume: 14, Issue:6, 2000
Ramipril.International journal of clinical practice, , Volume: 54, Issue:4, 2000
Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.The New England journal of medicine, , 01-20, Volume: 342, Issue:3, 2000
ACE inhibition in cardiovascular disease.The New England journal of medicine, , Jan-20, Volume: 342, Issue:3, 2000
[How should ACE inhibitors be used in myocardial infarction?].Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke, , Nov-20, Volume: 120, Issue:28, 2000
Effects of metoprolol and ramipril on action potentials after myocardial infarction in rats.European journal of pharmacology, , Feb-04, Volume: 388, Issue:3, 2000
[Symposium "Emerging Approaches to Cardiovascular Diseases: Detailed results and implications of the HOPE Study". Atlanta, 10. November 1999].Der Internist, , Volume: 41, Issue:1, 2000
The Angiotensin-converting Enzyme Inhibition Post Revascularization Study (APRES).Journal of the American College of Cardiology, , Mar-15, Volume: 35, Issue:4, 2000
HOPE for all people with diabetes? Heart Outcomes Prevention Evaluation.Diabetic medicine : a journal of the British Diabetic Association, , Volume: 17 Suppl 2, 2000
Angiotensin-converting enzyme inhibitors in antihypertensive therapy.Current hypertension reports, , Volume: 2, Issue:2, 2000
Ramipril reduces QT dispersion in patients with acute myocardial infarction and heart failure.The American journal of cardiology, , Mar-15, Volume: 83, Issue:6, 1999
beta blocker treatment and other prognostic variables in patients with clinical evidence of heart failure after acute myocardial infarction: evidence from the AIRE study.Heart (British Cardiac Society), , Volume: 81, Issue:1, 1999
[ACE inhibitor even prevents diabetes. Sensational HOPE Study].MMW Fortschritte der Medizin, , Sep-30, Volume: 141, Issue:39, 1999
The prognostic significance of a history of systemic hypertension in patients randomised to either placebo or ramipril following acute myocardial infarction: evidence from the AIRE study. Acute Infarction Ramipril Efficacy.Journal of human hypertension, , Volume: 13, Issue:8, 1999
Beta-blockade improves adjacent regional sympathetic innervation during postinfarction remodeling.The American journal of physiology, , Volume: 277, Issue:4, 1999
Ramipril study suggests drug may benefit broad group of patients.American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, , Dec-15, Volume: 56, Issue:24, 1999
A safe new dose of heart protection. Study shows drug can prevent attacks, strokes.U.S. news & world report, , Nov-22, Volume: 127, Issue:20, 1999
Effects of ramipril on cardiac gene transcription levels of angiotensin II receptors after myocardial infarction.Zhongguo yao li xue bao = Acta pharmacologica Sinica, , Volume: 20, Issue:6, 1999
Postinfarction survival and inducibility of ventricular arrhythmias in the spontaneously hypertensive rat : effects of ramipril and hydralazine.Circulation, , Nov-10, Volume: 98, Issue:19, 1998
Treatment with ramipril improves systolic function even in patients with mild systolic dysfunction and symptoms of heart failure after acute myocardial infarction.Clinical cardiology, , Volume: 21, Issue:11, 1998
Bradykinin and the therapeutic actions of angiotensin-converting enzyme inhibitors.The American journal of cardiology, , Nov-19, Volume: 82, Issue:10A, 1998
Cost-effectiveness analysis of ramipril in heart failure after myocardial infarction. Economic evaluation of the Acute Infarction Ramipril Efficacy (AIRE) study for Germany from the perspective of Statutory Health Insurance.PharmacoEconomics, , Volume: 14, Issue:6, 1998
Changes in left ventricular mass and volumes in patients receiving angiotensin-converting enzyme inhibitor therapy for left ventricular dysfunction after Q-wave myocardial infarction.American heart journal, , Volume: 136, Issue:2, 1998
Effect of ramiprilat or captopril on myocardial infarct size: assessment in canine models of ischemia alone and ischemia with reperfusion.Pharmacology, , Volume: 57, Issue:1, 1998
Effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotensin II type 2 receptors.The Journal of clinical investigation, , Apr-15, Volume: 99, Issue:8, 1997
[Effects of ramipril and spironolactone on ventricular remodeling after acute myocardial infarction: randomized and double-blind study].Revista medica de Chile, , Volume: 125, Issue:6, 1997
Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators.European heart journal, , Volume: 18, Issue:1, 1997
ACE inhibitors in heart failure: effect on mode of death.European heart journal, , Volume: 18, Issue:1, 1997
Incidence and natural history of left ventricular thrombus following anterior wall acute myocardial infarction.The American journal of cardiology, , Aug-15, Volume: 80, Issue:4, 1997
AIRE Extension (AIREX) Study.Lancet (London, England), , Aug-02, Volume: 350, Issue:9074, 1997
Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators.Circulation, , Jul-15, Volume: 96, Issue:2, 1997
Angiotensin-converting enzyme inhibitor therapy affects left ventricular mass in patients with ejection fraction > 40% after acute myocardial infarction.Journal of the American College of Cardiology, , Volume: 29, Issue:1, 1997
Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial.Circulation, , Jun-17, Volume: 95, Issue:12, 1997
Follow-up study of patients randomly allocated ramipril or placebo for heart failure after acute myocardial infarction: AIRE Extension (AIREX) Study. Acute Infarction Ramipril Efficacy.Lancet (London, England), , May-24, Volume: 349, Issue:9064, 1997
Angiotensin-converting enzyme inhibition limits dysfunction in adjacent noninfarcted regions during left ventricular remodeling.Journal of the American College of Cardiology, , Volume: 27, Issue:1, 1996
Effect of ramipril and losartan on collagen expression in right and left heart after myocardial infarction.Molecular and cellular biochemistry, , Dec-06, Volume: 165, Issue:1, 1996
ACE inhibition decreases postoperative mortality in rats with left ventricular hypertrophy and myocardial infarction.Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 18, Issue:5, 1996
Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats.Hypertension (Dallas, Tex. : 1979), , Volume: 27, Issue:1, 1996
How ACE inhibitors reduce death from myocardial infarction: hypotheses from the AIRE study. Acute Infarction Ramipril Efficacy study.British journal of clinical practice. Supplement, , Volume: 84, 1996
The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors.The Annals of thoracic surgery, , Volume: 60, Issue:3, 1995
Neurohormonal activation in patients with acute myocardial infarction or chronic congestive heart failure. With special reference to treatment with angiotensin converting enzyme inhibitors.Blood pressure. Supplement, , Volume: 1, 1995
Quantitative assessment of daily physical activity levels in patients with chronic heart failure by measuring energy expenditure--effects of converting enzyme inhibitor therapy.Japanese circulation journal, , Volume: 59, Issue:10, 1995
When a question has an answer: rationale for our early termination of the HEART Trial.The American journal of cardiology, , Jun-01, Volume: 75, Issue:16, 1995
Ramipril. An updated review of its therapeutic use in essential hypertension and heart failure.Drugs, , Volume: 49, Issue:3, 1995
[Reduction of infarct size and remodeling after ramipril].Zeitschrift fur Kardiologie, , Volume: 83 Suppl 4, 1994
ACE-inhibitor therapy after myocardial infarction--a new treatment strategy.Zeitschrift fur Kardiologie, , Volume: 83 Suppl 4, 1994
ACE inhibition, atherosclerosis and myocardial infarction--the AIRE Study in practice. Acute Infarction Ramipril Efficacy Study.European heart journal, , Volume: 15 Suppl B, 1994
Inhibition of ACE/Kininase-II after myocardial infarction--addendum.Cardiovascular research, , Volume: 28, Issue:2, 1994
[Angiotensin converting enzyme inhibitors during acute phase of myocardial infarct].Giornale italiano di cardiologia, , Volume: 24, Issue:1, 1994
Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition.European journal of pharmacology, , Apr-06, Volume: 234, Issue:2-3, 1993
Reduction of myocardial infarct size in rabbits by ramiprilat: reversal by the bradykinin antagonist HOE 140.Journal of cardiovascular pharmacology, , Volume: 21, Issue:6, 1993
Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.Lancet (London, England), , Oct-02, Volume: 342, Issue:8875, 1993
Do angiotensin converting enzyme inhibitors limit myocardial infarct size?Clinical and experimental pharmacology & physiology, , Volume: 20, Issue:6, 1993
Validation of primary and secondary outcomes and classification of mode of death among patients with clinical evidence of heart failure after a myocardial infarction: a report from the Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.Journal of cardiovascular pharmacology, , Volume: 22 Suppl 9, 1993
Acronyms and myocardial infarction studies.Clinical cardiology, , Volume: 15, Issue:4, 1992
The possible role of bradykinin in the antiischemic activity of ACE-inhibitors.Agents and actions. Supplements, , Volume: 38 ( Pt 3), 1992
Development and modulation of experimental right ventricular hypertrophy in rats.Journal of cardiovascular pharmacology, , Volume: 20 Suppl 1, 1992
The Acute Infarction Ramipril Efficacy (AIRE) Study: rationale, design, organization, and outcome definitions.Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2, 1991
Reduction of infarct size by local angiotensin-converting enzyme inhibition is abolished by a bradykinin antagonist.European journal of pharmacology, , Jul-03, Volume: 182, Issue:2, 1990
ACE inhibitors after myocardial infarction.Lancet (London, England), , Volume: 2, Issue:8678-8679
Study at up to 700 sites will build on landmark HOPE trial.Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners, , Volume: 12, Issue:2
ACE inhibitors after myocardial infarction.The British journal of clinical practice, , Volume: 49, Issue:4
A randomized trial comparing the effect of ramipril and losartan in survivors of ST-elevation myocardial infarction.The Journal of international medical research, , Volume: 37, Issue:5
[Ramipril and new therapeutic possibilities for ACE-inhibitors].La Clinica terapeutica, , Volume: 151, Issue:4
[Effect of the angiotensin-converting enzyme inhibitor ramipril on the processes of lipid peroxidation on the status of the endogenous antioxidant system in patients with myocardial infarction].Patologicheskaia fiziologiia i eksperimental'naia terapiia, , Issue:4
Early administration of ramipril in acute myocardial infarction: neurohormonal and hemodynamic effects and tolerability.Cardiology, , Volume: 88, Issue:6
Angiotensin converting enzyme inhibitors in acute myocardial infarction.Indian heart journal, , Volume: 46, Issue:4
New uses for old drug: reducing risk of heart attacks and strokes.FDA consumer, , Volume: 35, Issue:1
Multicap to improve adherence after acute coronary syndromes: results of a randomized controlled clinical trial.Therapeutic advances in cardiovascular disease, , Volume: 14
Zofenopril versus ramipril in the early phase of acute myocardial infarction with systolic dysfunction: A retrospective study.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 21, Issue:3
Do ACE inhibitors have a real role in coronary artery disease?Cardiovascular journal of South Africa : official journal for Southern Africa Cardiac Society [and] South African Society of Cardiac Practitioners, , Volume: 14, Issue:3
Expectoration of bronchial casts in association with Ramipril treatment.Cardiology in the young, , Volume: 29, Issue:12, 2019
Myocarditis and pericarditis in the course of colitis ulcerosa.Kardiologia polska, , Volume: 72, Issue:4, 2014
A young patient with heart failure: picture quiz question.Acute medicine, , Volume: 11, Issue:1, 2012
[Improvement of left ventricular function during combined carvedilol, ramipril and spironolactone therapy after myocarditis in patient treated earlier by chemotherapy due to Hodgkin's lymphoma - 3-years follow-up].Kardiologia polska, , Volume: 68, Issue:7, 2010
A case of acute myocarditis caused by pandemic (H1N1) 2009 influenza virus.Journal of the Formosan Medical Association = Taiwan yi zhi, , Volume: 109, Issue:11, 2010
Cardiovascular and systemic microvascular effects of anti-vascular endothelial growth factor therapy for cancer.Journal of the American College of Cardiology, , Aug-14, Volume: 60, Issue:7, 2012
Meta-analysis of randomized controlled trials on effect of angiotensin-converting enzyme inhibitors on cancer risk.The American journal of cardiology, , Jul-15, Volume: 108, Issue:2, 2011
Effect of the multitargeted receptor tyrosine kinase inhibitor, ABT-869 [N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N'-(2-fluoro-5-methylphenyl)urea], on blood pressure in conscious rats and mice: reversal with antihypertensive agents and effect on tumor growtThe Journal of pharmacology and experimental therapeutics, , Volume: 329, Issue:3, 2009
Ramipril prevents extracellular matrix accumulation in cerebral microvessels.Neurological research, , Volume: 27, Issue:5, 2005
The arterial length-densities under preventive angiotensin-converting-enzyme inhibiting treatment in the myocardium of spontaneously hypertensive rats.Basic research in cardiology, , Volume: 93, Issue:1, 1998
Blockade of bradykinin B2 receptors prevents the increase in capillary density induced by chronic angiotensin-converting enzyme inhibitor treatment in stroke-prone spontaneously hypertensive rats.Hypertension (Dallas, Tex. : 1979), , Volume: 29, Issue:1 Pt 2, 1997
Local administration of ramiprilat is less effective than oral ramipril in preventing restenosis after balloon angioplasty in an animal model.Journal of vascular and interventional radiology : JVIR, , Volume: 10, Issue:10
Finerenone Added to RAS/SGLT2 Blockade for CKD in Alport Syndrome. Results of a Randomized Controlled Trial with Col4a3-/- Mice.Journal of the American Society of Nephrology : JASN, , 09-01, Volume: 34, Issue:9, 2023
Long-term ACE inhibition in Alport syndrome: are the benefits worth the risks?Kidney international, , Volume: 97, Issue:6, 2020
A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndrome.Kidney international, , Volume: 97, Issue:6, 2020
Challenges for academic investigator-initiated pediatric trials for rare diseases.Clinical therapeutics, , Feb-01, Volume: 36, Issue:2, 2014
Renoprotection: clues from knockout models of rare diseases.Kidney international, , Volume: 63, Issue:2, 2003
Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome.Kidney international, , Volume: 63, Issue:2, 2003
Interstitial nephritis and autoimmune pancreatitis: a case report.International urology and nephrology, , Volume: 44, Issue:1, 2012
Effects of ramipril in nondiabetic nephropathy: improved parameters of oxidatives stress and potential modulation of advanced glycation end products.Journal of human hypertension, , Volume: 17, Issue:4, 2003
Long-term treatment with ramipril attenuates renal osteopontin expression in diabetic rats.Kidney international, , Volume: 63, Issue:2, 2003
Acute and long-term effects of ACE inhibition on renal haemodynamics in glomerular and interstitial nephropathies.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 3, Issue:1, 2002
Osteopontin expression in progressive renal injury in remnant kidney: role of angiotensin II.Kidney international, , Volume: 58, Issue:4, 2000
Renal antifibrotic effect of N-acetyl-seryl-aspartyl-lysyl-proline in diabetic rats.American journal of nephrology, , Volume: 37, Issue:1, 2013
Quality of life in the African American Study of Kidney Disease and Hypertension: effects of blood pressure management.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 47, Issue:6, 2006
Lessons from the African-American Study of Kidney Disease and Hypertension: an update.Current hypertension reports, , Volume: 8, Issue:5, 2006
Cardiovascular risk in patients with mild renal insufficiency: implications for the use of ACE inhibitors.Presse medicale (Paris, France : 1983), , Oct-22, Volume: 34, Issue:18, 2005
[Hypertensive nephrosclerosis].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 62 Suppl 3, 2004
ACE inhibition is effective and renoprotective in hypertensive nephrosclerosis: the African American Study of Kidney Disease and Hypertension (AASK) trial.Kidney international. Supplement, , Issue:83, 2003
Effect of ramipril versus amlodipine on renal outcomes in hypertensive nephrosclerosis.Current hypertension reports, , Volume: 4, Issue:3, 2002
Clinical trials report. The effect of Ramipril versus Amlodipine on renal outcomes in hypertension nephrosclerosis.Current hypertension reports, , Volume: 3, Issue:5, 2001
Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.JAMA, , Jun-06, Volume: 285, Issue:21, 2001
[Choroidal effusion after uncomplicated cataract surgery].Klinische Monatsblatter fur Augenheilkunde, , Volume: 225, Issue:6, 2008
Minimal change disease in association with fire coral (Millepora species) exposure.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 47, Issue:1, 2006
Cost effectiveness of ramipril in patients with non-diabetic nephropathy and hypertension: economic evaluation of Ramipril Efficacy in Nephropathy (REIN) Study for Germany from the perspective of statutory health insurance.PharmacoEconomics, , Volume: 19, Issue:5 Pt 1, 2001
Angiotensin converting enzyme and neprilysin inhibition alter pain response in dexhamethasone-induced hypertensive rats.Pharmacological reports : PR, , Volume: 71, Issue:2, 2019
Rhabdomyolysis-induced compartment syndrome secondary to atorvastatin and strenuous exercise.BMJ case reports, , Mar-16, Volume: 2017, 2017
Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial.JAMA, , Feb-06, Volume: 309, Issue:5, 2013
An unusual cause of exertional leg pain.Current sports medicine reports, , Volume: 3, Issue:2, 2004
From the Food and Drug Administration.JAMA, , Dec-06, Volume: 284, Issue:21, 2000
Modulation of pain perception by ramipril and losartan in human volunteers.Indian journal of physiology and pharmacology, , Volume: 52, Issue:1
Interstitial nephritis and autoimmune pancreatitis: a case report.International urology and nephrology, , Volume: 44, Issue:1, 2012
Incidence, severity, and etiology of drug-induced acute pancreatitis.Digestive diseases and sciences, , Volume: 55, Issue:10, 2010
High glucose increases extracellular matrix production in pancreatic stellate cells by activating the renin-angiotensin system.Journal of cellular biochemistry, , May-15, Volume: 98, Issue:2, 2006
Acute pancreatitis due to ramipril therapy.Postgraduate medical journal, , Volume: 80, Issue:948, 2004
Differential effects of saralasin and ramiprilat, the inhibitors of renin-angiotensin system, on cerulein-induced acute pancreatitis.Regulatory peptides, , Mar-28, Volume: 111, Issue:1-3, 2003
Fulminant pancreatitis associated with ramipril therapy.Pancreas, , Volume: 27, Issue:3, 2003
Losartan versus ramipril in the treatment of postrenal transplant erythrocytosis.Transplantation proceedings, , Volume: 30, Issue:5, 1998
Long term effects of ACE inhibitors on the erythrocytosis in renal transplant recipients.The International journal of artificial organs, , Volume: 18, Issue:1, 1995
Ramipril in post-renal transplant erythrocytosis.Journal of nephrology, , Volume: 20, Issue:1
Ramipril and left ventricular diastolic function in stable patients with pulmonary regurgitation after repair of tetralogy of Fallot.International journal of cardiology, , Dec-01, Volume: 272, 2018
The win ratio approach did not alter study conclusions and may mitigate concerns regarding unequal composite end points in kidney transplant trials.Journal of clinical epidemiology, , Volume: 98, 2018
Rhabdomyolysis-induced compartment syndrome secondary to atorvastatin and strenuous exercise.BMJ case reports, , Mar-16, Volume: 2017, 2017
Ramipril versus placebo in kidney transplant patients with proteinuria: a multicentre, double-blind, randomised controlled trial.The lancet. Diabetes & endocrinology, , Volume: 4, Issue:4, 2016
Effect of Ramipril on Urinary Protein Excretion in Maintenance Renal Transplant Patients Converted to Sirolimus.American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons, , Volume: 15, Issue:12, 2015
Is administration of preoperative angiotensin-converting enzyme inhibitors important for renal protection after cardiac surgery?Renal failure, , Volume: 35, Issue:5, 2013
Obesity and oxidative stress predict AKI after cardiac surgery.Journal of the American Society of Nephrology : JASN, , Volume: 23, Issue:7, 2012
Comparative effects of angiotensin receptor blockade and ACE inhibition on the fibrinolytic and inflammatory responses to cardiopulmonary bypass.Clinical pharmacology and therapeutics, , Volume: 91, Issue:6, 2012
[Choroidal effusion after uncomplicated cataract surgery].Klinische Monatsblatter fur Augenheilkunde, , Volume: 225, Issue:6, 2008
Effect of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on the frequency of post-cardiothoracic surgery atrial fibrillation.The Annals of pharmacotherapy, , Volume: 41, Issue:3, 2007
Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 45, Issue:5, 2005
Effect of ramipril on postrevascularization prevalence of angina and quality of life.International journal of cardiology, , Volume: 95, Issue:2-3, 2004
Beneficial effects of ramipril on left ventricular end-diastolic and end-systolic volume indexes after uncomplicated invasive revascularization are associated with a reduction in cardiac events in patients with moderately impaired left ventricular functioJournal of the American College of Cardiology, , Volume: 37, Issue:5, 2001
Losartan versus ramipril in the treatment of postrenal transplant erythrocytosis.Transplantation proceedings, , Volume: 30, Issue:5, 1998
The Angiotensin Converting Enzyme Inhibition Post Revascularization Study (APRES). Effects of ramipril in patients with reduced left ventricular function. Rationale, design, methods, baseline characteristics and first-year experience.Scandinavian cardiovascular journal : SCJ, , Volume: 32, Issue:4, 1998
Ileostomy and ramipril-induced acute renal failure and shock.Heart & lung : the journal of critical care, , Volume: 36, Issue:4
Ramipril-based versus diuretic-based antihypertensive primary treatment in patients with pre-diabetes (ADaPT) study.Cardiovascular diabetology, , Jan-09, Volume: 11, 2012
First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation.Cardiovascular diabetology, , Jul-24, Volume: 7, 2008
Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes.Current atherosclerosis reports, , Volume: 10, Issue:2, 2008
Diabetes prevention between RAAS inhibition and PPAR-gamma stimulation: the diabetes reduction assessment with ramipril and rosiglitazone medication (DREAM) trial.Journal of the cardiometabolic syndrome, ,Spring, Volume: 2, Issue:2, 2007
DREAM study and its impact on India.The Journal of the Association of Physicians of India, , Volume: 54, 2006
[Corner points of antihypertensive therapy in prediabetic state. Success with a combination].MMW Fortschritte der Medizin, , Jul-10, Volume: 145, Issue:27-28, 2003
[Hypertension and prediabetes. "Don't trust anybody over 130/80"].MMW Fortschritte der Medizin, , Mar-27, Volume: 145, Issue:13, 2003
[Dangerous duo: hypertension and pre-diabetes--the underestimated risk].MMW Fortschritte der Medizin, , Jan-23, Volume: 145, Issue:3-4, 2003
Dysglycemia and a history of reproductive risk factors.Diabetes care, , Volume: 31, Issue:8, 2008
Pregnancy outcome following exposure to orlistat, ramipril, glimepiride in a woman with metabolic syndrome.Saudi medical journal, , Volume: 26, Issue:3, 2005
[A patient with severe hyperkalaemia -- an emergency after RALES].Deutsche medizinische Wochenschrift (1946), , Sep-09, Volume: 130, Issue:36, 2005
From the Food and Drug Administration.JAMA, , Dec-06, Volume: 284, Issue:21, 2000
[Hartil effects on structural-functional condition of the heart in patients with chronic cor pulmonale].Terapevticheskii arkhiv, , Volume: 80, Issue:9, 2008
[Effects of angiotensin-converting enzyme inhibitors and cosaar on quality of life of patients with pulmonary tuberculosis and chronic heart failure].Problemy tuberkuleza, , Issue:8, 2001
[Ramipril treatment of heart failure in disseminated forms of pulmonary tuberculosis].Problemy tuberkuleza, , Issue:2, 1999
[Efficiency of ramipril treatment in patients with chronic obstructive bronchitis complicated by chronic cor pulmonale].Problemy tuberkuleza, , Issue:6, 1999
Ramipril for left ventricular diastolic function in patients with pulmonary regurgitation after repair of tetralogy of Fallot.International journal of cardiology, , 03-01, Volume: 278, 2019
Ramipril for left ventricular diastolic function in patients with pulmonary regurgitation after repair of tetralogy of Fallot.International journal of cardiology, , 03-01, Volume: 278, 2019
Renin-angiotensin-aldosterone system blockade in patients with repaired tetralogy of Fallot: When and how.International journal of cardiology, , 12-01, Volume: 272, 2018
Ramipril and left ventricular diastolic function in stable patients with pulmonary regurgitation after repair of tetralogy of Fallot.International journal of cardiology, , Dec-01, Volume: 272, 2018
Randomised trial of ramipril in repaired tetralogy of Fallot and pulmonary regurgitation: the APPROPRIATE study (Ace inhibitors for Potential PRevention Of the deleterious effects of Pulmonary Regurgitation In Adults with repaired TEtralogy of Fallot).International journal of cardiology, , Feb-09, Volume: 154, Issue:3, 2012
Assessment of a guideline-based heart substructures delineation in left-sided breast cancer patients undergoing adjuvant radiotherapy : Quality assessment within a randomized phase III trial testing a cardioprotective treatment strategy (SAFE-2014).Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], , Volume: 195, Issue:1, 2019
Late normal tissue response in the rat spinal cord after carbon ion irradiation.Radiation oncology (London, England), , Jan-11, Volume: 13, Issue:1, 2018
Differential expression of Homer1a in the hippocampus and cortex likely plays a role in radiation-induced brain injury.Radiation research, , Volume: 181, Issue:1, 2014
Mitigation of experimental radiation nephropathy by renin-equivalent doses of angiotensin converting enzyme inhibitors.International journal of radiation biology, , Volume: 90, Issue:9, 2014
Angiotensin-Converting Enzyme Inhibitor Reduces Radiation-Induced Periprosthetic Capsular Fibrosis.The Journal of surgical research, , Volume: 263, 2021
A Comparison of Ramipril and Bevacizumab to Mitigate Radiation-Induced Brain Necrosis: An Experimental Study.World neurosurgery, , Volume: 144, 2020
Mitigation of radiation myelopathy and reduction of microglial infiltration by Ramipril, ACE inhibitor.Spinal cord, , Volume: 56, Issue:8, 2018
Chronic administration of the angiotensin-converting enzyme inhibitor, ramipril, prevents fractionated whole-brain irradiation-induced perirhinal cortex-dependent cognitive impairment.Radiation research, , Volume: 178, Issue:1, 2012
Combined atorvastatin and ramipril mitigate radiation-induced impairment of dentate gyrus neurogenesis.Journal of neuro-oncology, , Volume: 101, Issue:3, 2011
Ramipril mitigates radiation-induced impairment of neurogenesis in the rat dentate gyrus.Radiation oncology (London, England), , Feb-01, Volume: 5, 2010
Mitigation of radiation-induced optic neuropathy in rats by ACE inhibitor ramipril: importance of ramipril dose and treatment time.Journal of neuro-oncology, , Volume: 82, Issue:2, 2007
Modification of radiation injury by ramipril, inhibitor of angiotensin-converting enzyme, on optic neuropathy in the rat.Radiation research, , Volume: 161, Issue:2, 2004
Prevention of Atrial Fibrillation After Atrial Flutter Ablation With Ramipril (from the PREFACE Study).The American journal of cardiology, , 01-01, Volume: 162, 2022
Use of the Cardiovascular Polypill in Secondary Prevention of Cerebrovascular Disease: A Real-Life Tertiary Hospital Cohort Study of 104 Patients.Cerebrovascular diseases extra, , Volume: 10, Issue:3, 2020
A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors.British journal of clinical pharmacology, , Volume: 80, Issue:4, 2015
Does this case hold the answer to one of the worse types of pain in medicine--that of loin pain haematuria syndrome (LPHS).BMJ case reports, , Apr-26, Volume: 2015, 2015
Differential levels of circulating progenitor cells in acute coronary syndrome patients with a first event versus patients with recurring events.International journal of cardiology, , May-19, Volume: 149, Issue:1, 2011
Effect of a triple blockade of the renin-angiotensin-system in recurrent focal segmental glomerulosclerosis after kidney transplantation.Transplant international : official journal of the European Society for Organ Transplantation, , Volume: 22, Issue:11, 2009
Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation.American journal of hypertension, , Volume: 21, Issue:9, 2008
Late recurrence of scleroderma renal crisis in a renal transplant recipient despite angiotensin II blockade.American journal of kidney diseases : the official journal of the National Kidney Foundation, , Volume: 45, Issue:5, 2005
[Achieving vascular protection. ACE inhibitor lowers not only blood pressure].MMW Fortschritte der Medizin, , Sep-06, Volume: 143, Issue:35-36, 2001
Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators.European heart journal, , Volume: 18, Issue:1, 1997
Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial.Circulation, , Jun-17, Volume: 95, Issue:12, 1997
ACE inhibition, atherosclerosis and myocardial infarction--the AIRE Study in practice. Acute Infarction Ramipril Efficacy Study.European heart journal, , Volume: 15 Suppl B, 1994
[A 93-year-old patient with hypertensive crises and renal failure due to bilateral renal artery stenosis].MMW Fortschritte der Medizin, , Nov-05, Volume: 157, Issue:19, 2015
Severe paradoxical hypertension with angiotensin-converting enzyme inhibitors: an unusual feature of renal artery stenosis.Hypertension (Dallas, Tex. : 1979), , Volume: 54, Issue:3, 2009
Manipulation of the renin angiotensin system in peripheral arterial disease.European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, , Volume: 28, Issue:6, 2004
Ramipril for hypertension secondary to renal artery stenosis. Changes in blood pressure, the renin-angiotensin system and total and divided renal function.The American journal of cardiology, , Apr-24, Volume: 59, Issue:10, 1987
[Takayasu arteritis with aortic coarctation and multiple stenosis of aortic branches].Recenti progressi in medicina, , Volume: 101, Issue:7-8
Randomised controlled trial into the role of ramipril in fibrosis reduction in rheumatic heart disease: the RamiRHeD trial protocol.BMJ open, , 09-13, Volume: 11, Issue:9, 2021
[The efficacy of treatment with the angiotensin-converting enzyme inhibitor ramipril in patients with congestive heart failure of rheumatic etiology].Terapevticheskii arkhiv, , Volume: 68, Issue:2, 1996
[The use of ramipril in treating patients with chronic heart failure].Terapevticheskii arkhiv, , Volume: 67, Issue:5, 1995
Twenty-and-a-half syndrome: a case report.Journal of medical case reports, , Feb-15, Volume: 13, Issue:1, 2019
Does this case hold the answer to one of the worse types of pain in medicine--that of loin pain haematuria syndrome (LPHS).BMJ case reports, , Apr-26, Volume: 2015, 2015
Renin-angiotensin system blockade is effective in reducing proteinuria of patients with progressive nephropathy caused by MYH9 mutations (Fechtner-Epstein syndrome).Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 23, Issue:8, 2008
Drug-induced Evans syndrome.Annals of internal medicine, , Feb-15, Volume: 128, Issue:4, 1998
Ramipril-induced drug reaction with eosinophilia and systemic symptoms (DRESS).European journal of dermatology : EJD, , Volume: 21, Issue:4
Ramipril for left ventricular diastolic function in patients with pulmonary regurgitation after repair of tetralogy of Fallot.International journal of cardiology, , 03-01, Volume: 278, 2019
Ramipril for left ventricular diastolic function in patients with pulmonary regurgitation after repair of tetralogy of Fallot.International journal of cardiology, , 03-01, Volume: 278, 2019
Renin-angiotensin-aldosterone system blockade in patients with repaired tetralogy of Fallot: When and how.International journal of cardiology, , 12-01, Volume: 272, 2018
Ramipril and left ventricular diastolic function in stable patients with pulmonary regurgitation after repair of tetralogy of Fallot.International journal of cardiology, , Dec-01, Volume: 272, 2018
Randomised trial of ramipril in repaired tetralogy of Fallot and pulmonary regurgitation: the APPROPRIATE study (Ace inhibitors for Potential PRevention Of the deleterious effects of Pulmonary Regurgitation In Adults with repaired TEtralogy of Fallot).International journal of cardiology, , Feb-09, Volume: 154, Issue:3, 2012
Renin-angiotensin system blockade is effective in reducing proteinuria of patients with progressive nephropathy caused by MYH9 mutations (Fechtner-Epstein syndrome).Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 23, Issue:8, 2008
A Forgotten Cause of Thrombocytopenia in Post Renal Transplant Setting.Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, , Volume: 31, Issue:5
Churg-Strauss syndrome with endocardial injury, clot formation in heart's chambers, and neurological complications.Kardiologia polska, , Volume: 74, Issue:11, 2016
Incidence and natural history of left ventricular thrombus following anterior wall acute myocardial infarction.The American journal of cardiology, , Aug-15, Volume: 80, Issue:4, 1997
Letter by Popa and Netea regarding article, "Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis".Circulation, , Nov-04, Volume: 118, Issue:19, 2008
Angiotensin-converting enzyme inhibition improves vascular function in rheumatoid arthritis.Circulation, , Apr-29, Volume: 117, Issue:17, 2008
Propylthiouracil-induced vasculitis associated with ANCA: a case report.Renal failure, , Volume: 29, Issue:2, 2007
Cardiac angiotensin II participates in coronary microvessel inflammation of unstable angina and strengthens the immunomediated component.Circulation research, , Jun-25, Volume: 94, Issue:12, 2004
Low-dose hydralazine prevents fibrosis in a murine model of acute kidney injury-to-chronic kidney disease progression.Kidney international, , Volume: 91, Issue:1, 2017
Inhibition of angiotensin-converting enzyme reduces rat liver reperfusion injury via bradykinin-2-receptor.The Journal of surgical research, , Volume: 134, Issue:2, 2006
Cardioprotective effects of the aminopeptidase P inhibitor apstatin: studies on ischemia/reperfusion injury in the isolated rat heart.Journal of cardiovascular pharmacology, , Volume: 34, Issue:4, 1999
Ramipril-induced delayed myocardial protection against free radical injury involves bradykinin B2 receptor-NO pathway and protein synthesis.British journal of pharmacology, , Volume: 125, Issue:3, 1998
Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats.Hypertension (Dallas, Tex. : 1979), , Volume: 27, Issue:1, 1996
Bradykinin accounts for improved postischemic function and decreased glutathione release of guinea pig heart treated with the angiotensin-converting enzyme inhibitor ramiprilat.Journal of cardiovascular pharmacology, , Volume: 23, Issue:4, 1994
Zofenopril Protects Against Myocardial Ischemia-Reperfusion Injury by Increasing Nitric Oxide and Hydrogen Sulfide Bioavailability.Journal of the American Heart Association, , 07-05, Volume: 5, Issue:7, 2016
Expressional profile of cardiac uncoupling protein-2 following myocardial ischemia reperfusion in losartan- and ramiprilat-treated rats.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 15, Issue:3, 2014
Influence of ramiprilat and losartan on ischemia reperfusion injury in rat hearts.Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 13, Issue:1, 2012
[Cardioprotection of ramipril and BQ-123 against myocardial ischemia/reperfusion injury in vivo in rats].Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology, , Volume: 25, Issue:4, 2009
[Study on ultrastructure of cardioprotection of ramipril against ischemia/reperfusion injury in diabetic rats].Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology, , Volume: 25, Issue:4, 2009
Chronic endothelin-A receptor antagonism is as protective as angiotensin converting enzyme inhibition against cardiac dysfunction in diabetic rats.British journal of pharmacology, , Volume: 151, Issue:8, 2007
Role of tissue kallikrein in the cardioprotective effects of ischemic and pharmacological preconditioning in myocardial ischemia.FASEB journal : official publication of the Federation of American Societies for Experimental Biology, , Volume: 19, Issue:9, 2005
Cardioprotective activity of alcoholic extract of Tinospora cordifolia in ischemia-reperfusion induced myocardial infarction in rats.Biological & pharmaceutical bulletin, , Volume: 28, Issue:12, 2005
Infarct size limiting effect of apstatin alone and in combination with enalapril, lisinopril and ramipril in rats with experimental myocardial infarction.Pharmacological research, , Volume: 48, Issue:6, 2003
Inhibition of angiotensin-converting enzyme reduces susceptibility of hypertrophied rat myocardium to ventricular fibrillation.Circulation journal : official journal of the Japanese Circulation Society, , Volume: 66, Issue:11, 2002
Inhibitors of bradykinin-inactivating enzymes decrease myocardial ischemia/reperfusion injury following 3 and 7 days of reperfusion.The Journal of pharmacology and experimental therapeutics, , Volume: 298, Issue:3, 2001
Effect of ramiprilat or captopril on myocardial infarct size: assessment in canine models of ischemia alone and ischemia with reperfusion.Pharmacology, , Volume: 57, Issue:1, 1998
Ramiprilat attenuates hypoxia/reoxygenation injury to cardiac myocytes via a bradykinin-dependent mechanism.European journal of pharmacology, , Jun-13, Volume: 306, Issue:1-3, 1996
Attenuation of reperfusion arrhythmias by selective inhibition of angiotensin-converting enzyme/kininase II in the ischemic zone: mediated by endogenous bradykinin?Journal of cardiovascular pharmacology, , Volume: 27, Issue:3, 1996
The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors.The Annals of thoracic surgery, , Volume: 60, Issue:3, 1995
[Cardioprotective effects by ramipril after ischemia and reperfusion in animal experiment studies].Zeitschrift fur Kardiologie, , Volume: 83 Suppl 4, 1994
ACE-inhibition induces NO-formation in cultured bovine endothelial cells and protects isolated ischemic rat hearts.Journal of molecular and cellular cardiology, , Volume: 24, Issue:8, 1992
[ACE inhibition: mechanisms of "cardioprotection" in acute myocardial ischemia].Klinische Wochenschrift, , Volume: 69 Suppl 24, 1991
[Are the radical scavenging properties of ACE inhibitors with sulfhydryl groups in therapeutically effective concentrations of quantitative significance?].Klinische Wochenschrift, , Volume: 69 Suppl 24, 1991
Local inhibition of bradykinin degradation in ischemic hearts.Journal of cardiovascular pharmacology, , Volume: 15 Suppl 6, 1990
Effects of endothelin on isolated ischaemic rat hearts during ramiprilat, bradykinin and indomethacin perfusion.Journal of hypertension. Supplement : official journal of the International Society of Hypertension, , Volume: 7, Issue:6, 1989
Prostacyclin-mediated cardioprotection of captopril and ramiprilate against lipid peroxidation in rat.Progress in clinical and biological research, , Volume: 301, 1989
Local inhibition of angiotensin II formation and bradykinin degradation in isolated hearts.Clinical and experimental hypertension. Part A, Theory and practice, , Volume: 10, Issue:6, 1988
[A 93-year-old patient with hypertensive crises and renal failure due to bilateral renal artery stenosis].MMW Fortschritte der Medizin, , Nov-05, Volume: 157, Issue:19, 2015
Prevention and noninvasive management of coronary atherosclerosis in patients with diabetes.Current atherosclerosis reports, , Volume: 10, Issue:2, 2008
[Corner points of antihypertensive therapy in prediabetic state. Success with a combination].MMW Fortschritte der Medizin, , Jul-10, Volume: 145, Issue:27-28, 2003
Studies examining risk reduction in subjects with multiple metabolic and cardiovascular risk factors.Current hypertension reports, , Volume: 2, Issue:2, 2000
Renin-angiotensin system inhibitors reduce the progression of mesangioproliferative glomerulonephritis: 10 year follow-up.European journal of internal medicine, , Volume: 22, Issue:6, 2011
Treatment of idiopathic glomerulonephritis in the elderly. Personal data.Contributions to nephrology, , Volume: 105, 1993
Essential mixed cryoglobulinemia type II.Clinical and experimental rheumatology, , Volume: 24, Issue:3
[Telmisartan, ramipril, or both in patients at high risk for vascular events. Results of the ONTARGET trial].Kardiologiia, , Volume: 48, Issue:5, 2008
Effect of ramipril on renal function in patients with intermittent claudication.Vascular health and risk management, , Volume: 4, Issue:2, 2008
Reduced arterial stiffness may contribute to angiotensin-converting enzyme inhibitor induced improvements in walking time in peripheral arterial disease patients.Journal of hypertension, , Volume: 26, Issue:5, 2008
Summaries for patients. Ramipril improves walking ability in patients with peripheral arterial disease.Annals of internal medicine, , May-02, Volume: 144, Issue:9, 2006
Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial.Annals of internal medicine, , May-02, Volume: 144, Issue:9, 2006
Effects of ramipril on arterial stiffness.Hypertension (Dallas, Tex. : 1979), , Volume: 46, Issue:4, 2005
Ramipril reduces large-artery stiffness in peripheral arterial disease and promotes elastogenic remodeling in cell culture.Hypertension (Dallas, Tex. : 1979), , Volume: 45, Issue:6, 2005
Manipulation of the renin angiotensin system in peripheral arterial disease.European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, , Volume: 28, Issue:6, 2004
Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease.European heart journal, , Volume: 25, Issue:1, 2004
Comparative effects of ramipril on ambulatory and office blood pressures: a HOPE Substudy.Hypertension (Dallas, Tex. : 1979), , Dec-01, Volume: 38, Issue:6, 2001
Dysglycemia and a history of reproductive risk factors.Diabetes care, , Volume: 31, Issue:8, 2008
Rationale, design and recruitment characteristics of a large, simple international trial of diabetes prevention: the DREAM trial.Diabetologia, , Volume: 47, Issue:9, 2004
[HOPE study].Nihon rinsho. Japanese journal of clinical medicine, , Volume: 64 Suppl 6, 2006
Influence of angiotensin converting enzyme inhibitor treatment on cardiac autonomic modulation in patients receiving haemodialysis.Nephrology (Carlton, Vic.), , Volume: 11, Issue:6, 2006
Effect of ramipril in reducing sudden deaths and nonfatal cardiac arrests in high-risk individuals without heart failure or left ventricular dysfunction.Circulation, , Sep-14, Volume: 110, Issue:11, 2004
[Preventive therapy with ACE inhibitors for coronary patients].Orvosi hetilap, , Feb-29, Volume: 145, Issue:9, 2004
[Symposium "Emerging Approaches to Cardiovascular Diseases: Detailed results and implications of the HOPE Study". Atlanta, 10. November 1999].Der Internist, , Volume: 41, Issue:1, 2000
The prognostic significance of a history of systemic hypertension in patients randomised to either placebo or ramipril following acute myocardial infarction: evidence from the AIRE study. Acute Infarction Ramipril Efficacy.Journal of human hypertension, , Volume: 13, Issue:8, 1999
ACE inhibitors in heart failure: effect on mode of death.European heart journal, , Volume: 18, Issue:1, 1997
Effect of ramipril on morbidity and mode of death among survivors of acute myocardial infarction with clinical evidence of heart failure. A report from the AIRE Study Investigators.European heart journal, , Volume: 18, Issue:1, 1997
Inhibition of ACE/Kininase-II after myocardial infarction--addendum.Cardiovascular research, , Volume: 28, Issue:2, 1994
Rapamycin for treatment of type I autosomal dominant polycystic kidney disease (RAPYD-study): a randomized, controlled study.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 27, Issue:9, 2012
A comparison of the effects of ramipril and losartan on blood pressure control and left ventricle hypertrophy in patients with autosomal dominant polycystic kidney disease.Renal failure, , Volume: 32, Issue:8, 2010
Renal and cardiac effects of antihypertensive treatment with ramipril vs metoprolol in autosomal dominant polycystic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 23, Issue:2, 2008
Renal and cardiac effects of antihypertensive treatment with ramipril versus metoprolol in autosomal dominant polycystic kidney disease.Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 23, Issue:2, 2008
Activity and functional significance of the renal kallikrein-kinin-system in polycystic kidney disease of the rat.Kidney international, , Volume: 61, Issue:6, 2002
[Gallop in the Routineergometrie: Only Chore or Diagnostic Challenge?]Deutsche medizinische Wochenschrift (1946), , Volume: 143, Issue:3, 2018
Effect of ramipril on the electrophysiological characteristics of ventricular myocardium after myocardial infarction in rabbits.Journal of cardiovascular medicine (Hagerstown, Md.), , Volume: 13, Issue:5, 2012
[Competitive sports and dilated cardiomyopathy: the case of a 32-year-old soccer player with ventricular tachycardia].Deutsche medizinische Wochenschrift (1946), , Jan-24, Volume: 128, Issue:4, 2003
Reciprocal regulation of NO signaling and TXNIP expression in humans: impact of aging and ramipril therapy.International journal of cardiology, , Oct-12, Volume: 168, Issue:5, 2013
Reverse evidence based medicine.The Pan African medical journal, , Volume: 16, 2013
Ramipril-like activity of Spondias mombin linn against no-flow ischemia and isoproterenol-induced cardiotoxicity in rat heart.Cardiovascular toxicology, , Volume: 10, Issue:4, 2010
ONTARGET, TRANSCEND and PROFESS--clarifying, confusing or misleading?Blood pressure, , Volume: 18, Issue:1-2, 2009
Clinical practice guides.Clinical cardiology, , Volume: 32, Issue:4, 2009
Chronic angiotensin II receptor blockade induces cardioprotection during ischemia by increased PKC-epsilon expression in the mouse heart.Journal of cardiovascular pharmacology, , Volume: 49, Issue:1, 2007
[Angiotensin converting enzyme inhibitors in patients with ischemic heart disease: in all cases or in high risk of complications].Kardiologiia, , Volume: 45, Issue:9, 2005
Effects of purified herbal extract of Salvia miltiorrhiza on ischemic rat myocardium after acute myocardial infarction.Life sciences, , Apr-29, Volume: 76, Issue:24, 2005
The cardioprotective effect of dual metallopeptidase inhibition: respective roles of endogenous kinins and natriuretic peptides.Canadian journal of physiology and pharmacology, , Volume: 83, Issue:2, 2005
[Ischemic heart disease with low risk of vascular complications -- a novel indication for angiotensin converting enzyme inhibitors (results of EUROPA trial)].Kardiologiia, , Volume: 44, Issue:3, 2004
Effect of ACE-inhibitor ramiprilat and AT1-receptor antagonist candesartan on cardiac norepinephrine release: comparison between ischemic and nonischemic conditions.Journal of cardiovascular pharmacology, , Volume: 40, Issue:4, 2002
Effects of ramipril on coronary events in high-risk persons: results of the Heart Outcomes Prevention Evaluation Study.Circulation, , Jul-31, Volume: 104, Issue:5, 2001
ACE inhibitor reduces cardiovascular events by 22%.Indian journal of medical sciences, , Volume: 54, Issue:3, 2000
Protective effect of omapatrilat, a vasopeptidase inhibitor, on the metabolism of bradykinin in normal and failing human hearts.The Journal of pharmacology and experimental therapeutics, , Volume: 295, Issue:2, 2000
Ramiprilat prevents the development of acute coronary endothelial dysfunction in the dog.Basic research in cardiology, , Volume: 94, Issue:4, 1999
Functional impact of an increase in ventricular mass after myocardial damage and its attenuation by converting enzyme inhibition.Journal of cardiac failure, , Volume: 4, Issue:3, 1998
Effect of ramiprilat or captopril on myocardial infarct size: assessment in canine models of ischemia alone and ischemia with reperfusion.Pharmacology, , Volume: 57, Issue:1, 1998
Paracrine systems in the cardioprotective effect of angiotensin-converting enzyme inhibitors on myocardial ischemia/reperfusion injury in rats.Hypertension (Dallas, Tex. : 1979), , Volume: 27, Issue:1, 1996
Attenuation of reperfusion arrhythmias by selective inhibition of angiotensin-converting enzyme/kininase II in the ischemic zone: mediated by endogenous bradykinin?Journal of cardiovascular pharmacology, , Volume: 27, Issue:3, 1996
Nitric oxide mitigates leukocyte adhesion and vascular leak after myocardial ischemia.Journal of molecular and cellular cardiology, , Volume: 28, Issue:3, 1996
[A comparison of the effect of Capoten (captopril) and ramipril on the circadian profile of the arterial pressure and peripheral hemodynamics in patients with hypertension combined with diabetes mellitus].Terapevticheskii arkhiv, , Volume: 68, Issue:5, 1996
The role of bradykinin and nitric oxide in the cardioprotective action of ACE inhibitors.The Annals of thoracic surgery, , Volume: 60, Issue:3, 1995
Influence of angiotensin converting enzyme inhibition on relation of atrial natriuretic peptide concentration to atrial pressure in heart failure.British heart journal, , Volume: 72, Issue:6, 1994
Cardioprotective actions of bradykinin in myocardial ischemia and left ventricular hypertrophy.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, , Volume: 27, Issue:8, 1994
Inhibition of nitric oxide synthase prevents myocardial protection by ramiprilat.The Journal of pharmacology and experimental therapeutics, , Volume: 270, Issue:3, 1994
Ramiprilat increases bradykinin outflow from isolated hearts of rat.British journal of pharmacology, , Volume: 108, Issue:2, 1993
Reduction of myocardial infarct size by ramiprilat is independent of angiotensin II synthesis inhibition.European journal of pharmacology, , Apr-06, Volume: 234, Issue:2-3, 1993
Cardioprotection by ramiprilat in isolated rabbit hearts.European journal of pharmacology, , Sep-14, Volume: 241, Issue:2-3, 1993
Contribution of bradykinin to the cardiovascular effects of ramipril.Journal of cardiovascular pharmacology, , Volume: 22 Suppl 9, 1993
ACE-inhibition induces NO-formation in cultured bovine endothelial cells and protects isolated ischemic rat hearts.Journal of molecular and cellular cardiology, , Volume: 24, Issue:8, 1992
The possible role of bradykinin in the antiischemic activity of ACE-inhibitors.Agents and actions. Supplements, , Volume: 38 ( Pt 3), 1992
Safety/Toxicity (41)
| Article | Year |
|---|
Comparison of the Efficacy and Safety of Sacubitril/Valsartan versus Ramipril in Patients With ST-Segment Elevation Myocardial Infarction.
The American journal of cardiology, , 03-15, Volume: 143 | 2021 |
A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndrome.
Kidney international, , Volume: 97, Issue:6 | 2020 |
Anthracycline-induced cardiotoxicity prevention with angiotensin-converting enzyme inhibitor ramipril in women with low-risk breast cancer: results of a prospective randomized study.
Kardiologia polska, , 02-25, Volume: 78, Issue:2 | 2020 |
Side Effects of Frequently Used Antihypertensive Drugs on Wound Healing in vitro.
Skin pharmacology and physiology, , Volume: 32, Issue:3 | 2019 |
Assessment of a guideline-based heart substructures delineation in left-sided breast cancer patients undergoing adjuvant radiotherapy : Quality assessment within a randomized phase III trial testing a cardioprotective treatment strategy (SAFE-2014).
Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al], , Volume: 195, Issue:1 | 2019 |
Effect of ethanolic extract of Cyperus rotundus L. against isoprenaline induced cardiotoxicity.
Indian journal of experimental biology, , Volume: 54, Issue:10 | 2016 |
Quantification of Hydrochlorothiazide and Ramipril/Ramiprilate in Blood Serum and Cerebrospinal Fluid: A Pharmacokinetic Assessment of Central Nervous System Adverse Effects.
Pharmacology, , Volume: 102, Issue:3-4 | 2018 |
Efficacy and Safety of Zofenopril Versus Ramipril in the Treatment of Myocardial Infarction and Heart Failure: A Review of the Published and Unpublished Data of the Randomized Double-Blind SMILE-4 Study.
Advances in therapy, , Volume: 35, Issue:5 | 2018 |
SAFE trial: an ongoing randomized clinical study to assess the role of cardiotoxicity prevention in breast cancer patients treated with anthracyclines with or without trastuzumab.
Medical oncology (Northwood, London, England), , Volume: 34, Issue:5 | 2017 |
[Evaluation of efficacy and safety of hypertension treatment with original angiotensin-converting enzyme inhibitors: the comparison of original and generic formulations].
Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, , Volume: 34, Issue:201 | 2013 |
Efficacy and safety of two ramipril and hydrochlorothiazide fixed-dose combination formulations in adults with stage 1 or stage 2 arterial hypertension evaluated by using ABPM.
Clinical therapeutics, , Volume: 35, Issue:5 | 2013 |
Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly mild to moderate essential hypertensive patients with or without metabolic syndrome: a pooled post hoc analysis of two comparative trials.
Drugs & aging, , Volume: 29, Issue:12 | 2012 |
Analogs of bardoxolone methyl worsen diabetic nephropathy in rats with additional adverse effects.
American journal of physiology. Renal physiology, , Mar-15, Volume: 304, Issue:6 | 2013 |
The safe introduction of angiotensin-converting enzyme inhibitor in renal allograft recipients.
Transplantation proceedings, , Volume: 44, Issue:7 | 2012 |
Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).
PLoS computational biology, , Volume: 7, Issue:12 | 2011 |
Efficacy and safety of aliskiren, a direct renin inhibitor, compared with ramipril in Asian patients with mild to moderate hypertension.
Hypertension research : official journal of the Japanese Society of Hypertension, , Volume: 35, Issue:1 | 2012 |
Neuroprotective effect of ACE inhibitors in glutamate - induced neurotoxicity: rat neuron culture study.
Turkish neurosurgery, , Volume: 21, Issue:3 | 2011 |
Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension.
Blood pressure. Supplement, , Volume: 1 | 2011 |
Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study.
Journal of hypertension, , Volume: 28, Issue:11 | 2010 |
Safety and tolerability of ramipril 10 mg in patients at high risk of cardiovascular events: an observational study.
Indian heart journal, , Volume: 60, Issue:3 | |
Safety and tolerability of ramipril 10 mg in patients at high risk of cardiovascular events: an observational study.
Journal of the Indian Medical Association, , Volume: 106, Issue:7 | 2008 |
Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial.
Journal of hypertension, , Volume: 26, Issue:3 | 2008 |
Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension.
Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 8, Issue:4 | 2007 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Current drug discovery technologies, , Volume: 1, Issue:4 | 2004 |
The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I).
Journal of hypertension, , Volume: 24, Issue:1 | 2006 |
Efficacy and safet of pimobendan in canine heart failure caused by myxomatous mitral valve disease.
The Journal of small animal practice, , Volume: 46, Issue:3 | 2005 |
Ramipril-induced agranulocytosis confirmed by a lymphocyte cytotoxicity test.
The American journal of the medical sciences, , Volume: 329, Issue:1 | 2005 |
Ramipril and felodipine: a comparison of the efficacy and safety of monotherapy versus combination therapy.
Current medical research and opinion, , Volume: 13, Issue:8 | 1996 |
Kinetics, safety, and efficacy of ramipril after long-term administration in hemodialyzed patients.
Journal of cardiovascular pharmacology, , Volume: 27, Issue:2 | 1996 |
Study of the efficacy and safety of the combination ramipril 2.5 mg plus hydrochlorothiazide 12.5 mg in patients with mild-to-moderate hypertension. ATHES Study Group.
International journal of clinical pharmacology research, , Volume: 14, Issue:1 | 1994 |
Attenuation of cyclosporine A-induced vascular toxicity by ramipril.
Journal of cardiovascular pharmacology, , Volume: 24, Issue:1 | 1994 |
Efficacy and safety of ramipril (HOE 498) in the treatment of hypertension: dose finding study.
The American journal of cardiology, , Apr-24, Volume: 59, Issue:10 | 1987 |
A double-blind study to compare the efficacy, tolerance and safety of two doses of the angiotensin converting enzyme inhibitor ramipril with placebo.
The American journal of cardiology, , Apr-24, Volume: 59, Issue:10 | 1987 |
Acute, subchronic and chronic toxicity of the new angiotensin converting enzyme inhibitor ramipril.
Arzneimittel-Forschung, , Volume: 38, Issue:1 | 1988 |
An open multicenter study to assess the long-term efficacy, tolerance, and safety of the oral angiotensin converting enzyme inhibitor ramipril in patients with mild to moderate essential hypertension.
Journal of cardiovascular pharmacology, , Volume: 13 Suppl 3 | 1989 |
A comparison of the efficacy and safety of ramipril and digoxin added to maintenance diuretic treatment in patients with chronic heart failure.
Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2 | 1991 |
Efficacy and safety of ramipril in combination with hydrochlorothiazide: results of a long-term study.
Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2 | 1991 |
Assessment of the efficacy, tolerance, and safety of ramipril in diabetic patients with mild-to-moderate hypertension: a retrospective analysis.
Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2 | 1991 |
Efficacy and safety of a new angiotensin-converting enzyme inhibitor, ramipril, vs. enalapril in essential hypertension: a multicenter trial.
Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2 | 1991 |
Antihypertensive efficacy, tolerance, and safety of long-term treatment with ramipril in patients with mild-to-moderate essential hypertension.
Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2 | 1991 |
Antihypertensive efficacy, tolerance, and safety of ramipril in young vs. old patients: a retrospective study.
Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2 | 1991 |
Long-term Use (20)
| Article | Year |
|---|
[Chronic use of the unfixed combination of ACE-inhibitors and beta-blockers in Italy from 2013 to 2019 through the healthcare administrative data.]
Recenti progressi in medicina, , Volume: 112, Issue:10 | 2021 |
PATHOMORPHOLOGY OF THE MYOCARDIUM, KIDNEY AND LIVER IN SPONTANEOUSLY HYPERTENSIVE RATS TREATED WITH SHORT AND LONG-TERM USE RAMIPRIL AND CANDESARTAN.
Georgian medical news, , Issue:276 | 2018 |
Chronic administration of the angiotensin-converting enzyme inhibitor, ramipril, prevents fractionated whole-brain irradiation-induced perirhinal cortex-dependent cognitive impairment.
Radiation research, , Volume: 178, Issue:1 | 2012 |
Investigation of the effects of the chronic administration of some antihypertensive drugs on enzymatic and non-enzymatic oxidant/antioxidant parameters in rat ovarian tissue.
Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology, , Volume: 27, Issue:11 | 2011 |
Combined atorvastatin and ramipril mitigate radiation-induced impairment of dentate gyrus neurogenesis.
Journal of neuro-oncology, , Volume: 101, Issue:3 | 2011 |
[Hartil effects on structural-functional condition of the heart in patients with chronic cor pulmonale].
Terapevticheskii arkhiv, , Volume: 80, Issue:9 | 2008 |
[Renoprotective effect of ramipril in children with chronic renal failure--the experience of one centre].
Srpski arhiv za celokupno lekarstvo, , Volume: 132 Suppl 1 | 2004 |
Prospective randomized controlled multicenter trial on steroids plus ramipril in proteinuric IgA nephropathy.
Journal of nephrology, , Volume: 14, Issue:4 | |
Effect of acute and long-term administration of ramipril on circadian rhythm of blood pressure in essential hypertension.
Advances in therapy, , Volume: 12, Issue:1 | |
Effects of ramipril on plasma fibrinolytic balance in patients with acute anterior myocardial infarction. HEART Study Investigators.
Circulation, , Jul-15, Volume: 96, Issue:2 | 1997 |
The inhibition of angiotensin converting enzyme attenuates the effects of chronic hypoxia on pulmonary blood vessels in the rat.
Physiological research, , Volume: 45, Issue:3 | 1996 |
Kinetics, safety, and efficacy of ramipril after long-term administration in hemodialyzed patients.
Journal of cardiovascular pharmacology, , Volume: 27, Issue:2 | 1996 |
Chronic kinin blockade and effect of ramipril in renal adaptation to sodium restriction.
Hypertension (Dallas, Tex. : 1979), , Volume: 27, Issue:1 | 1996 |
Nitric oxide and the depressor response to angiotensin blockade in hypertension.
Hypertension (Dallas, Tex. : 1979), , Volume: 27, Issue:1 | 1996 |
Quantitative assessment of daily physical activity levels in patients with chronic heart failure by measuring energy expenditure--effects of converting enzyme inhibitor therapy.
Japanese circulation journal, , Volume: 59, Issue:10 | 1995 |
Angiotensin converting enzyme inhibitors, left ventricular hypertrophy and fibrosis.
Molecular and cellular biochemistry, , Volume: 147, Issue:1-2 | |
Efficacy, tolerance and hormonal effects of a new oral angiotensin converting enzyme inhibitor, ramipril (HOE 498), in mild to moderate primary hypertension.
The American journal of cardiology, , Apr-24, Volume: 59, Issue:10 | 1987 |
Role of kallikrein-kinin system in the hypotensive mechanisms of converting enzyme inhibitors in essential hypertension.
Journal of cardiovascular pharmacology, , Volume: 13 Suppl 3 | 1989 |
Long lasting arterial effects of the ACE inhibitor ramipril.
Journal of human hypertension, , Volume: 5, Issue:5 | 1991 |
Effects of ramipril on arterial hemodynamics.
Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2 | 1991 |
Pharmacokinetics (46)
| Article | Year |
|---|
Pharmacodynamic study of the cardiovascular polypill. Is there any interaction among the monocomponents?
Revista espanola de cardiologia (English ed.), , Volume: 74, Issue:1 | 2021 |
How to Treat Hypertension in Venlafaxine-Medicated Patients-Pharmacokinetic Considerations in Prescribing Amlodipine and Ramipril.
Journal of clinical psychopharmacology, , Volume: 38, Issue:5 | 2018 |
Quantification of Hydrochlorothiazide and Ramipril/Ramiprilate in Blood Serum and Cerebrospinal Fluid: A Pharmacokinetic Assessment of Central Nervous System Adverse Effects.
Pharmacology, , Volume: 102, Issue:3-4 | 2018 |
Pharmacokinetics and pharmacodynamics of ramipril and ramiprilat after intravenous and oral doses of ramipril in healthy horses.
Veterinary journal (London, England : 1997), , Volume: 208 | 2016 |
Effect of contrasted sodium diets on the pharmacokinetics and pharmacodynamic effects of renin-angiotensin system blockers.
Hypertension (Dallas, Tex. : 1979), , Volume: 61, Issue:6 | 2013 |
Rosuvastatin combined with ramipril significantly reduced atheroma volume by anti-inflammatory mechanism: comparative analysis with rosuvastatin alone by intravascular ultrasound.
International journal of cardiology, , Jul-12, Volume: 158, Issue:2 | 2012 |
Simultaneous determination of atorvastatin, amlodipine, ramipril and benazepril in human plasma by LC-MS/MS and its application to a human pharmacokinetic study.
Biomedical chromatography : BMC, , Volume: 25, Issue:4 | 2011 |
Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug-drug interaction studies.
Journal of clinical pharmacology, , Volume: 51, Issue:4 | 2011 |
Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).
The American journal of cardiology, , Dec-01, Volume: 104, Issue:11 | 2009 |
Pharmacokinetics and pharmacodynamics of ramipril and ramiprilat in healthy cats.
Journal of veterinary pharmacology and therapeutics, , Volume: 31, Issue:4 | 2008 |
Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
Journal of clinical pharmacology, , Volume: 48, Issue:1 | 2008 |
Left ventricular eccentric remodeling and matrix loss are mediated by bradykinin and precede cardiomyocyte elongation in rats with volume overload.
Journal of the American College of Cardiology, , Feb-20, Volume: 49, Issue:7 | 2007 |
Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
International journal of clinical practice, , Volume: 60, Issue:11 | 2006 |
Pharmacokinetic and pharmacodynamic parameters of ramipril and ramiprilat in healthy dogs and dogs with reduced glomerular filtration rate.
Journal of veterinary internal medicine, , Volume: 20, Issue:3 | |
Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans.
Clinical pharmacology and therapeutics, , Volume: 79, Issue:1 | 2006 |
Human physiologically based pharmacokinetic model for ACE inhibitors: ramipril and ramiprilat.
BMC clinical pharmacology, , Jan-06, Volume: 6 | 2006 |
High-performance liquid chromatography-mass spectrometric analysis of ramipril and its active metabolite ramiprilat in human serum: application to a pharmacokinetic study in the Chinese volunteers.
Journal of pharmaceutical and biomedical analysis, , Feb-13, Volume: 40, Issue:2 | 2006 |
Renal accumulation and clearance of advanced glycation end-products in type 2 diabetic nephropathy: effect of angiotensin-converting enzyme and vasopeptidase inhibition.
Diabetologia, , Volume: 48, Issue:8 | 2005 |
Beneficial effects of ramipril on left ventricular end-diastolic and end-systolic volume indexes after uncomplicated invasive revascularization are associated with a reduction in cardiac events in patients with moderately impaired left ventricular functio
Journal of the American College of Cardiology, , Volume: 37, Issue:5 | 2001 |
Effects of icatibant on the ramipril-induced decreased in renal lithium clearance in the rat.
Naunyn-Schmiedeberg's archives of pharmacology, , Volume: 363, Issue:3 | 2001 |
Angiotensin inhibition and atrial natriuretic peptide release after acute volume expansion in rats with aortocaval shunt.
Cardiovascular research, , Volume: 42, Issue:3 | 1999 |
Increased renal endothelin formation is associated with sodium retention and increased free water clearance.
The American journal of physiology, , Volume: 275, Issue:3 | 1998 |
Changes in left ventricular mass and volumes in patients receiving angiotensin-converting enzyme inhibitor therapy for left ventricular dysfunction after Q-wave myocardial infarction.
American heart journal, , Volume: 136, Issue:2 | 1998 |
Comparison of some pharmacokinetic parameters of 5 angiotensin-converting enzyme inhibitors in normal beagles.
Journal of veterinary internal medicine, , Volume: 12, Issue:2 | |
Selective induction of the creatine kinase-B gene in chronic volume overload hypertrophy is not affected by ACE-inhibitor therapy.
Journal of molecular and cellular cardiology, , Volume: 29, Issue:10 | 1997 |
Angiotensin-converting enzyme inhibition in cirrhotic patients--pharmacokinetics of ramipril.
Acta medica Austriaca, , Volume: 24, Issue:1 | 1997 |
Tight binding of ramiprilat to ACE: consequences for pharmacokinetic and pharmacodynamic measurements.
International journal of clinical pharmacology and therapeutics, , Volume: 33, Issue:12 | 1995 |
The pharmacokinetic and pharmacodynamic interactions of ramipril with propranolol.
European journal of clinical pharmacology, , Volume: 45, Issue:3 | 1993 |
Clinical pharmacokinetics of ramipril.
Clinical pharmacokinetics, , Volume: 26, Issue:1 | 1994 |
[Ramipril in the treatment of hypertension. The pharmacodynamic validation of its efficacy in the therapy of initial cardiac and renal involvement].
Terapevticheskii arkhiv, , Volume: 65, Issue:4 | 1993 |
Pharmacokinetics and pharmacodynamics of ramipril and piretanide administered alone and in combination.
European journal of clinical pharmacology, , Volume: 46, Issue:6 | 1994 |
Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril.
European journal of clinical pharmacology, , Volume: 47, Issue:6 | 1995 |
Pharmacokinetics, metabolism and biliary and urinary excretion of oral ramipril in man.
Current medical research and opinion, , Volume: 13, Issue:5 | 1995 |
Multiple-dose pharmacokinetics of ramipril in patients with chronic congestive heart failure.
Journal of cardiovascular pharmacology, , Volume: 22 Suppl 9 | 1993 |
Pharmacokinetics and pharmacodynamics of a novel orally active angiotensin converting enzyme inhibitor (HOE 498) in healthy subjects.
European journal of clinical pharmacology, , Volume: 27, Issue:5 | 1984 |
Influence of renal function on the pharmacokinetics of ramipril (HOE 498).
The American journal of cardiology, , Apr-24, Volume: 59, Issue:10 | 1987 |
Pharmacokinetics and pharmacodynamics of ramipril in renal failure.
The American journal of cardiology, , Apr-24, Volume: 59, Issue:10 | 1987 |
Pharmacokinetics, converting enzyme inhibition and peripheral arterial hemodynamics of ramipril in healthy volunteers.
The American journal of cardiology, , Apr-24, Volume: 59, Issue:10 | 1987 |
Pharmacokinetics of ramipril in the elderly.
The American journal of cardiology, , Apr-24, Volume: 59, Issue:10 | 1987 |
Pharmacokinetics and effects on the renin-angiotensin system of ramipril in elderly patients.
The American journal of cardiology, , Apr-24, Volume: 59, Issue:10 | 1987 |
Pharmacokinetics of ramipril in hypertensive patients with renal insufficiency.
European journal of clinical pharmacology, , Volume: 37, Issue:3 | 1989 |
Pharmacokinetics of a single dose of ramipril in patients with renal dysfunction: comparison with essential hypertension.
Journal of cardiovascular pharmacology, , Volume: 10 Suppl 7 | 1987 |
Pharmacokinetic and pharmacodynamic properties of ramipril in patients with congestive heart failure (NYHA III-IV).
Journal of cardiovascular pharmacology, , Volume: 13 Suppl 3 | 1989 |
Pharmacodynamic effects of a single 10-mg dose of the angiotensin converting enzyme inhibitor ramipril in patients with impaired renal function.
Journal of cardiovascular pharmacology, , Volume: 13 Suppl 3 | 1989 |
The pharmacokinetics of ramipril in a group of ten elderly patients with essential hypertension.
Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2 | 1991 |
A study of the acute pharmacodynamic interaction of ramipril and felodipine in normotensive subjects.
British journal of clinical pharmacology, , Volume: 31, Issue:2 | 1991 |
Onset of Action (2)
Bioavailability (20)
| Article | Year |
|---|
Formulation and In Vitro Evaluation of a Ramipril Entrapped in a Microsponge-based Drug-delivery System.
International journal of pharmaceutical compounding, , Volume: 27, Issue:4 | |
Heat-based transdermal delivery of a ramipril loaded cream for treating hypertension.
Nanoscale, , Sep-02, Volume: 14, Issue:34 | 2022 |
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Molecular pharmacology, , Volume: 96, Issue:5 | 2019 |
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
The Journal of biological chemistry, , 11-15, Volume: 294, Issue:46 | 2019 |
Zofenopril Protects Against Myocardial Ischemia-Reperfusion Injury by Increasing Nitric Oxide and Hydrogen Sulfide Bioavailability.
Journal of the American Heart Association, , 07-05, Volume: 5, Issue:7 | 2016 |
Pharmacokinetics and pharmacodynamics of ramipril and ramiprilat after intravenous and oral doses of ramipril in healthy horses.
Veterinary journal (London, England : 1997), , Volume: 208 | 2016 |
Simvastatin enhances the antihypertensive effect of ramipril in hypertensive hypercholesterolemic animals and patients. Possible role of nitric oxide, oxidative stress, and high sensitivity C-reactive protein.
Fundamental & clinical pharmacology, , Volume: 26, Issue:6 | 2012 |
Prediction of drug intestinal absorption by new linear and non-linear QSPR.
European journal of medicinal chemistry, , Volume: 46, Issue:1 | 2011 |
Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers.
American journal of cardiovascular drugs : drugs, devices, and other interventions, , Volume: 10, Issue:2 | 2010 |
Bioequivalence study of two tablet formulations of ramipril in healthy volunteers.
Arzneimittel-Forschung, , Volume: 59, Issue:8 | 2009 |
Ramipril improves oxidative stress-related vascular endothelial dysfunction in db/db mice.
The journal of physiological sciences : JPS, , Volume: 58, Issue:6 | 2008 |
Development and bioavailability assessment of ramipril nanoemulsion formulation.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, , Volume: 66, Issue:2 | 2007 |
Comparative bioavailability of two ramipril formulations after single-dose administration in healthy volunteers.
International journal of clinical pharmacology and therapeutics, , Volume: 44, Issue:2 | 2006 |
Effect of chronic treatment with the vasopeptidase inhibitor AVE 7688 and ramipril on endothelial function in atherogenic diet rabbits.
Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 4, Issue:3 | 2003 |
Ramipril improves nitric oxide availability in hypertensive rats with failing hearts after myocardial infarction.
Journal of the renin-angiotensin-aldosterone system : JRAAS, , Volume: 4, Issue:3 | 2003 |
Comparative effect of ace inhibition and angiotensin II type 1 receptor antagonism on bioavailability of nitric oxide in patients with coronary artery disease: role of superoxide dismutase.
Circulation, , Feb-13, Volume: 103, Issue:6 | 2001 |
Central nervous and systemic kinetics of ramipril and ramiprilat in the conscious dog.
The Journal of pharmacology and experimental therapeutics, , Volume: 266, Issue:1 | 1993 |
Pharmacokinetics, pharmacodynamics and bioavailability of the ACE inhibitor ramipril.
European journal of clinical pharmacology, , Volume: 47, Issue:6 | 1995 |
Pharmacological properties of the new orally active angiotensin converting enzyme inhibitor 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl] -(1S,3S,5S)-2-azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).
Arzneimittel-Forschung, , Volume: 34, Issue:10B | 1984 |
Synthesis of a highly active angiotensin converting enzyme inhibitor: 2-[N-[(S)-1-ethoxycarbonyl-3-phenylpropyl]-L-alanyl]-(1S,3S,5S)-2- azabicyclo[3.3.0]octane-3-carboxylic acid (Hoe 498).
Arzneimittel-Forschung, , Volume: 34, Issue:10B | 1984 |
Dosage (145)
| Article | Year |
|---|
Formulation and In Vitro Evaluation of a Ramipril Entrapped in a Microsponge-based Drug-delivery System.
International journal of pharmaceutical compounding, , Volume: 27, Issue:4 | |
In silico and in vitro screening for carcinogenic potential of angiotensin-converting enzyme inhibitors and their degradation impurities.
Toxicology and applied pharmacology, , 06-15, Volume: 469 | 2023 |
Differential effects of RYGB surgery and best medical treatment for obesity-diabetes on intestinal and islet adaptations in obese-diabetic ZDSD rats.
PloS one, , Volume: 17, Issue:9 | 2022 |
[Chronic use of the unfixed combination of ACE-inhibitors and beta-blockers in Italy from 2013 to 2019 through the healthcare administrative data.]
Recenti progressi in medicina, , Volume: 112, Issue:10 | 2021 |
Impact of the COVID-19 pandemic on the management of chronic heart failure.
Reviews in cardiovascular medicine, , 06-30, Volume: 22, Issue:2 | 2021 |
Mechanistic Considerations About an Unexpected Ramipril Drug-Drug Interaction in the Development of a Triple Fixed-Dose Combination Product Containing Ramipril, Amlodipine, and Atorvastatin.
Clinical pharmacology in drug development, , Volume: 10, Issue:11 | 2021 |
Smart UV spectrophotometric methods based on simple mathematical filtration for the simultaneous determination of celecoxib and ramipril in their pharmaceutical mixtures with amlodipine: A comparative statistical study.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, , Jan-05, Volume: 244 | 2021 |
Ramipril reduces incidence and prolongates latency time of radiation-induced rat myelopathy after photon and carbon ion irradiation.
Journal of radiation research, , Sep-08, Volume: 61, Issue:5 | 2020 |
Valvejet Technology for the Production of a Personalised Fixed Dose Combination of Ramipril and Glimepiride: an Investigative Study on the Stability of Ramipril.
Pharmaceutical research, , Jul-27, Volume: 35, Issue:9 | 2018 |
Late normal tissue response in the rat spinal cord after carbon ion irradiation.
Radiation oncology (London, England), , Jan-11, Volume: 13, Issue:1 | 2018 |
Takotsubo-like syndrome triggered by fludrocortisone overdose for Addison's disease: a case report.
Journal of medical case reports, , Oct-12, Volume: 10, Issue:1 | 2016 |
Zofenopril Protects Against Myocardial Ischemia-Reperfusion Injury by Increasing Nitric Oxide and Hydrogen Sulfide Bioavailability.
Journal of the American Heart Association, , 07-05, Volume: 5, Issue:7 | 2016 |
How to improve duration and efficiency of the antiproteinuric response to Ramipril: RamiPROT-a prospective cohort study.
Journal of nephrology, , Volume: 30, Issue:1 | 2017 |
3D printing of five-in-one dose combination polypill with defined immediate and sustained release profiles.
Journal of controlled release : official journal of the Controlled Release Society, , Nov-10, Volume: 217 | 2015 |
Development and validation of TLC-densitometric method for simultaneous determination of two binary antihypertensive mixtures containing felodipine in fixed dose combinations.
Biomedical chromatography : BMC, , Volume: 30, Issue:2 | 2016 |
Statistical optimization and in-vitro evaluation of hollow microcapsules of an anti-hypertensive agent.
Acta poloniae pharmaceutica, , Volume: 71, Issue:1 | |
Utility of 4-chloro-7-nitrobenzofurazan (NBD-CI) for the Spectrophotometric and spectrofluorometric determination of several antihistamine and antihypertensive drugs.
Journal of AOAC International, , Volume: 96, Issue:5 | |
Medication adherence in hypertensive patients of different cardiovascular risk treated in primary health care.
Przeglad lekarski, , Volume: 70, Issue:6 | 2013 |
Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers.
Clinical therapeutics, , Volume: 35, Issue:3 | 2013 |
A trial of 2 strategies to reduce nocturnal blood pressure in blacks with chronic kidney disease.
Hypertension (Dallas, Tex. : 1979), , Volume: 61, Issue:1 | 2013 |
Twenty-four hour and early morning blood pressure control of olmesartan vs. ramipril in elderly hypertensive patients: pooled individual data analysis of two randomized, double-blind, parallel-group studies.
Journal of hypertension, , Volume: 30, Issue:7 | 2012 |
A comparison between imidapril and ramipril on attenuation of ventricular remodeling after myocardial infarction.
Journal of cardiovascular pharmacology, , Volume: 59, Issue:4 | 2012 |
[Ten years after publishing results from The Heart Outcomes Prevention Evaluation Study--HOPE: implications on treatment with angiotensin converting enzyme inhibitors in clinical practice].
Lijecnicki vjesnik, , Volume: 133, Issue:1-2 | |
Development of a capillary electrophoresis method for the assay of ramipril and its impurities: an issue of cis-trans isomerization.
Journal of chromatography. A, , May-06, Volume: 1218, Issue:18 | 2011 |
Impact of prolonged antihypertensive duration of action on predicted clinical outcomes in imperfectly adherent patients: comparison of aliskiren, irbesartan and ramipril.
International journal of clinical practice, , Volume: 65, Issue:2 | 2011 |
A novel analytical approach for reducing the consumption of organic solvents in the charge transfer-based spectrophotometric analysis: application in the analysis of certain antihypertensive drugs.
Acta pharmaceutica (Zagreb, Croatia), , Volume: 60, Issue:4 | 2010 |
Simultaneous determination of atorvastatin calcium and ramipril in capsule dosage forms by high-performance liquid chromatography and high-performance thin layer chromatography.
Journal of AOAC International, , Volume: 93, Issue:5 | |
Stimulation of cardiac apoptosis in ovariectomized hypertensive rats: potential role of the renin-angiotensin system.
Journal of hypertension, , Volume: 29, Issue:2 | 2011 |
Antihypertensive efficacy and safety of olmesartan and ramipril in elderly patients with mild to moderate systolic and diastolic essential hypertension.
Blood pressure. Supplement, , Volume: 1 | 2011 |
From evidence to rationale: cardiovascular protection by angiotensin II receptor blockers compared with angiotensin-converting enzyme inhibitors.
Cardiology, , Volume: 117, Issue:3 | 2010 |
Impact of nephron number dosing on cardiorenal damage and effects of ACE inhibition.
American journal of hypertension, , Volume: 24, Issue:4 | 2011 |
Antihypertensive efficacy and safety of olmesartan medoxomil and ramipril in elderly patients with mild to moderate essential hypertension: the ESPORT study.
Journal of hypertension, , Volume: 28, Issue:11 | 2010 |
New standards in hypertension and cardiovascular risk management: focus on telmisartan.
Vascular health and risk management, , Mar-24, Volume: 6 | 2010 |
Diuretic uptitration with half dose combined ACEI + ARB better decreases proteinuria than combined ACEI + ARB uptitration.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association, , Volume: 25, Issue:7 | 2010 |
Bioequivalence study of two tablet formulations of ramipril in healthy volunteers.
Arzneimittel-Forschung, , Volume: 59, Issue:8 | 2009 |
Achieving blood pressure goals: should angiotensin II receptor blockers become first-line treatment in hypertension?
Journal of hypertension. Supplement : official journal of the International Society of Hypertension, , Volume: 27, Issue:5 | 2009 |
Maintenance of blood-pressure-lowering effect following a missed dose of aliskiren, irbesartan or ramipril: results of a randomized, double-blind study.
Journal of human hypertension, , Volume: 24, Issue:2 | 2010 |
Chronotherapy with the angiotensin-converting enzyme inhibitor ramipril in essential hypertension: improved blood pressure control with bedtime dosing.
Hypertension (Dallas, Tex. : 1979), , Volume: 54, Issue:1 | 2009 |
[Renal effect of treatment for heart failure].
Ugeskrift for laeger, , Feb-23, Volume: 171, Issue:9 | 2009 |
Antihypertensive efficacy of telmisartan vs ramipril over the 24-h dosing period, including the critical early morning hours: a pooled analysis of the PRISMA I and II randomized trials.
Journal of human hypertension, , Volume: 23, Issue:9 | 2009 |
[Effects of ramipril and simvastatin on the oxidative stress of diabetic rats].
Arquivos brasileiros de endocrinologia e metabologia, , Volume: 52, Issue:7 | 2008 |
Spectrophotometric and atomic absorption determination of ramipril, enalapril maleate and fosinopril through ternary complex formation with molybdenum (V)-thiocyanate (Mo(V)-SCN).
Chemical & pharmaceutical bulletin, , Volume: 56, Issue:11 | 2008 |
Pharmacokinetics and pharmacodynamics of ramipril and ramiprilat in healthy cats.
Journal of veterinary pharmacology and therapeutics, , Volume: 31, Issue:4 | 2008 |
Simultaneous estimation of atorvastatin and ramipril by RP-HPLC and spectroscopy.
Pakistan journal of pharmaceutical sciences, , Volume: 21, Issue:3 | 2008 |
Effect of different angiotensin-converting-enzyme inhibitors on mortality among elderly patients with congestive heart failure.
CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, , May-06, Volume: 178, Issue:10 | 2008 |
Vildagliptin, a novel dipeptidyl peptidase IV inhibitor, has no pharmacokinetic interactions with the antihypertensive agents amlodipine, valsartan, and ramipril in healthy subjects.
Journal of clinical pharmacology, , Volume: 48, Issue:1 | 2008 |
Noninvasive pulse waveform analysis in clinical trials: similarity of two methods for calculating aortic systolic pressure.
American journal of hypertension, , Volume: 20, Issue:8 | 2007 |
Assessment of single versus twice daily dosing of ramipril by ambulatory blood pressure monitoring in patients similar to those included in the HOPE study.
Journal of human hypertension, , Volume: 21, Issue:7 | 2007 |
Ramipril in post-renal transplant erythrocytosis.
Journal of nephrology, , Volume: 20, Issue:1 | |
Ramipril dose-dependently increases nitric oxide availability in the radial artery of essential hypertension patients.
Journal of hypertension, , Volume: 25, Issue:2 | 2007 |
A vaccine for hypertension based on virus-like particles: preclinical efficacy and phase I safety and immunogenicity.
Journal of hypertension, , Volume: 25, Issue:1 | 2007 |
Development and bioavailability assessment of ramipril nanoemulsion formulation.
European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V, , Volume: 66, Issue:2 | 2007 |
Redefining the ACE-inhibitor dose-response relationship: substantial blood pressure lowering after massive doses.
European journal of clinical pharmacology, , Volume: 62, Issue:12 | 2006 |
Lack of pharmacokinetic interactions of aliskiren, a novel direct renin inhibitor for the treatment of hypertension, with the antihypertensives amlodipine, valsartan, hydrochlorothiazide (HCTZ) and ramipril in healthy volunteers.
International journal of clinical practice, , Volume: 60, Issue:11 | 2006 |
Investigation of the effect of a countywide protected learning time scheme on prescribing rates of ramipril: interrupted time series study.
Family practice, , Volume: 24, Issue:1 | 2007 |
Spectrophotometric and spectrofluorimetric methods for the determination of ramipril in its pure and dosage form.
Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy, , Volume: 66, Issue:3 | 2007 |
[Effects and mechanism of ShenQi compound recipe on inflammation maker in GK rats].
Zhong yao cai = Zhongyaocai = Journal of Chinese medicinal materials, , Volume: 29, Issue:3 | 2006 |
Lack of effect on coronary atherosclerotic disease biomarkers with modest dosing of an angiotensin-converting enzyme inhibitor, angiotensin II type-1 receptor blocker, and the combination.
Coronary artery disease, , Volume: 17, Issue:5 | 2006 |
Pharmacokinetic and pharmacodynamic parameters of ramipril and ramiprilat in healthy dogs and dogs with reduced glomerular filtration rate.
Journal of veterinary internal medicine, , Volume: 20, Issue:3 | |
A multicenter, 14-week study of telmisartan and ramipril in patients with mild-to-moderate hypertension using ambulatory blood pressure monitoring.
American journal of hypertension, , Volume: 19, Issue:1 | 2006 |
Pharmacokinetics and pharmacodynamics of the vasopeptidase inhibitor AVE7688 in humans.
Clinical pharmacology and therapeutics, , Volume: 79, Issue:1 | 2006 |
The prospective, randomized investigation of the safety and efficacy of telmisartan versus ramipril using ambulatory blood pressure monitoring (PRISMA I).
Journal of hypertension, , Volume: 24, Issue:1 | 2006 |
Ramipril in the treatment of vascular diseases.
Expert opinion on pharmacotherapy, , Volume: 6, Issue:11 | 2005 |
The HOPE TIPS: the HOPE study translated into practices.
Cardiovascular drugs and therapy, , Volume: 19, Issue:3 | 2005 |
Ramipril/felodipine extended-release fixed-dose combination: a review of its use in the management of essential hypertension.
Drugs, , Volume: 65, Issue:13 | 2005 |
Combined effects of ramipril and angiotensin II receptor blocker TCV116 on rat congestive heart failure after myocardial infarction.
Chinese medical journal, , Jan-20, Volume: 118, Issue:2 | 2005 |
Diuretic and enhanced sodium restriction results in improved antiproteinuric response to RAS blocking agents.
Journal of the American Society of Nephrology : JASN, , Volume: 16, Issue:2 | 2005 |
[Renoprotective effect of ramipril in children with chronic renal failure--the experience of one centre].
Srpski arhiv za celokupno lekarstvo, , Volume: 132 Suppl 1 | 2004 |
Effects of graded-release diltiazem versus ramipril, dosed at bedtime, on early morning blood pressure, heart rate, and the rate-pressure product.
American heart journal, , Volume: 148, Issue:4 | 2004 |
Combined blockade of AT1-receptors and ACE synergistically potentiates antihypertensive effects in SHR.
Journal of hypertension, , Volume: 22, Issue:3 | 2004 |
The problem of underdosing of angiotensin-converting enzyme inhibitors is markedly overrated: results from a study of patients discharged from hospital after an acute myocardial infarction.
European journal of clinical pharmacology, , Volume: 60, Issue:3 | 2004 |
[Ramipril in elderly patients with mild and moderate hypertension. Clinical efficacy, effect on cerebral blood flow and intellectual functioning].
Kardiologiia, , Volume: 43, Issue:6 | 2003 |
Spectrophotometric and AAS determination of ramipril and enalapril through ternary complex formation.
Journal of pharmaceutical and biomedical analysis, , Apr-15, Volume: 28, Issue:2 | 2002 |
Comparative effects of the dual ACE-NEP inhibitor MDL-100,240 and ramipril on hypertension and cardiovascular disease in endogenous angiotensin II-dependent hypertension.
American journal of hypertension, , Volume: 15, Issue:2 Pt 1 | 2002 |
The 24-hour blood pressure pattern: does it have implications for morbidity and mortality?
The American journal of cardiology, , Jan-24, Volume: 89, Issue:2A | 2002 |
Use of 7-fluoro-4-nitrobenzo-2-oxo-1,3-diazole (NBD-F) for the determination of ramipril in tablets and spiked human plasma.
Farmaco (Societa chimica italiana : 1989), , Volume: 56, Issue:4 | 2001 |
[ACE inhibition in patients with myocardial infarct and ventricular dysfunction: inappropriate application of therapy standards in patient samples].
Zeitschrift fur Kardiologie, , Volume: 90, Issue:2 | 2001 |
Voltammetric determination of benazepril and ramipril in dosage forms and biological fluids through nitrosation.
Journal of AOAC International, , Volume: 84, Issue:1 | |
A stability-indicating LC method for the simultaneous determination of ramipril and hydrochlorothiazide in dosage forms.
Journal of pharmaceutical and biomedical analysis, , Volume: 24, Issue:3 | 2001 |
The voltammetric study and determination of ramipril in dosage forms and biological fluids.
Farmaco (Societa chimica italiana : 1989), , Volume: 55, Issue:3 | 2000 |
ACE inhibitor dosage at the time of listing predicts survival.
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, , Volume: 19, Issue:2 | 2000 |
Potentiation of the vascular response to kinins by inhibition of myocardial kininases.
Hypertension (Dallas, Tex. : 1979), , Volume: 35, Issue:1 Pt 1 | 2000 |
Attenuation of atherosclerosis in apolipoprotein E-deficient mice by ramipril is dissociated from its antihypertensive effect and from potentiation of bradykinin.
Journal of cardiovascular pharmacology, , Volume: 35, Issue:1 | 2000 |
Antihypertensive profiles with ascending dose combinations of ramipril and felodipine ER.
Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 21, Issue:8 | 1999 |
Absence of nitrate tolerance after long-term treatment with ramipril: an endothelium-dependent mechanism.
Journal of cardiovascular pharmacology, , Volume: 34, Issue:4 | 1999 |
Spectrophotometric and atomic absorption spectrometric determination of ramipril and perindopril through ternary complex formation with eosin and Cu(II).
Journal of pharmaceutical and biomedical analysis, , Volume: 18, Issue:6 | 1999 |
Comparison of some pharmacokinetic parameters of 5 angiotensin-converting enzyme inhibitors in normal beagles.
Journal of veterinary internal medicine, , Volume: 12, Issue:2 | |
Development of heart failure following isoproterenol administration in the rat: role of the renin-angiotensin system.
Cardiovascular research, , Volume: 37, Issue:1 | 1998 |
The arterial length-densities under preventive angiotensin-converting-enzyme inhibiting treatment in the myocardium of spontaneously hypertensive rats.
Basic research in cardiology, , Volume: 93, Issue:1 | 1998 |
Sustained diurnal blood pressure reduction in SHR with ramipril assessed by telemetric monitoring.
Clinical and experimental hypertension (New York, N.Y. : 1993), , Volume: 19, Issue:8 | 1997 |
Angiotensin-converting enzyme inhibition alters nitric oxide and superoxide release in normotensive and hypertensive rats.
Hypertension (Dallas, Tex. : 1979), , Volume: 30, Issue:5 | 1997 |
Aspirin does not prevent the attenuation of myocardial stunning by the ACE inhibitor ramiprilat.
Journal of molecular and cellular cardiology, , Volume: 28, Issue:3 | 1996 |
Ramipril and felodipine: a comparison of the efficacy and safety of monotherapy versus combination therapy.
Current medical research and opinion, , Volume: 13, Issue:8 | 1996 |
Efficacy of ramipril versus enalapril in patients with mild to moderate essential hypertension.
The British journal of clinical practice, , Volume: 50, Issue:6 | 1996 |
[The effectiveness and tolerance of ramipril in comparison to captopril for heart failure in dogs].
DTW. Deutsche tierarztliche Wochenschrift, , Volume: 103, Issue:5 | 1996 |
Tight binding of ramiprilat to ACE: consequences for pharmacokinetic and pharmacodynamic measurements.
International journal of clinical pharmacology and therapeutics, , Volume: 33, Issue:12 | 1995 |
The CARE Study: a postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators.
Clinical therapeutics, , Volume: 18, Issue:4 | |
Evidence for load-dependent and load-independent determinants of cardiac natriuretic peptide production.
Circulation, , Jun-01, Volume: 93, Issue:11 | 1996 |
Short report: ramipril and hydrochlorothiazide combination therapy in hypertension: a clinical trial of factorial design. The East Germany Collaborative Trial Group.
Journal of hypertension, , Volume: 11, Issue:2 | 1993 |
Central nervous and systemic kinetics of ramipril and ramiprilat in the conscious dog.
The Journal of pharmacology and experimental therapeutics, , Volume: 266, Issue:1 | 1993 |
Interactions (28)
| Article | Year |
|---|
Mechanistic Considerations About an Unexpected Ramipril Drug-Drug Interaction in the Development of a Triple Fixed-Dose Combination Product Containing Ramipril, Amlodipine, and Atorvastatin.
Clinical pharmacology in drug development, , Volume: 10, Issue:11 | 2021 |
Short-term changes of serum potassium concentration induced by physical exercise in patient with arterial hypertension treated with angiotensin-converting enzyme inhibitor alone or in combination with statin.
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society, , Volume: 68, Issue:1 | 2017 |
A population-based study of the drug interaction between clopidogrel and angiotensin converting enzyme inhibitors.
British journal of clinical pharmacology, , Volume: 80, Issue:4 | 2015 |
[Bradykinin mediated angioedema with ACE inhibitor in combination with immunosupressive agents].
Therapie, , Volume: 69, Issue:2 | |
Lack of clinically relevant drug-drug interaction between empagliflozin, a sodium glucose cotransporter 2 inhibitor, and verapamil, ramipril, or digoxin in healthy volunteers.
Clinical therapeutics, , Volume: 35, Issue:3 | 2013 |
Ambulatory blood pressure values in the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial (ONTARGET).
Hypertension (Dallas, Tex. : 1979), , Volume: 60, Issue:6 | 2012 |
Comparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European stud
Clinical cardiology, , Volume: 35, Issue:7 | 2012 |
Blood pressure and other determinants of new-onset atrial fibrillation in patients at high cardiovascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial/Telmisartan Randomized AssessmeNt Study in ACE iNtoleran
Journal of hypertension, , Volume: 30, Issue:5 | 2012 |
Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial).
Journal of the American College of Cardiology, , Jan-03, Volume: 59, Issue:1 | 2012 |
Blood pressure targets recommended by guidelines and incidence of cardiovascular and renal events in the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET).
Circulation, , Oct-18, Volume: 124, Issue:16 | 2011 |
Rosuvastatin combined with ramipril significantly reduced atheroma volume by anti-inflammatory mechanism: comparative analysis with rosuvastatin alone by intravascular ultrasound.
International journal of cardiology, , Jul-12, Volume: 158, Issue:2 | 2012 |
Effects of commonly administered agents and genetics on nebivolol pharmacokinetics: drug-drug interaction studies.
Journal of clinical pharmacology, , Volume: 51, Issue:4 | 2011 |
Preservation of bioavailability of ingredients and lack of drug-drug interactions in a novel five-ingredient polypill (polycap): a five-arm phase I crossover trial in healthy volunteers.
American journal of cardiovascular drugs : drugs, devices, and other interventions, , Volume: 10, Issue:2 | 2010 |
Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial [ONTARGET]).
The American journal of cardiology, , Dec-01, Volume: 104, Issue:11 | 2009 |
Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination With Ramipril Global End Point Trial and the Telmisartan Randomized Assessment
Circulation, , Oct-06, Volume: 120, Issue:14 | 2009 |
Prognostic value of blood pressure in patients with high vascular risk in the Ongoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial study.
Journal of hypertension, , Volume: 27, Issue:7 | 2009 |
Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET): implications for reduced cardiovascular risk.
Preventive cardiology, ,Winter, Volume: 12, Issue:1 | 2009 |
Aliskiren reduces blood pressure and suppresses plasma renin activity in combination with a thiazide diuretic, an angiotensin-converting enzyme inhibitor, or an angiotensin receptor blocker.
Hypertension (Dallas, Tex. : 1979), , Volume: 49, Issue:2 | 2007 |
Vascular effects of simvastatin combined with ramipril in hypercholesterolemic patients with coronary artery disease, compared with simvastatin alone: a randomized, double-blind, placebo-controlled, crossover study.
Atherosclerosis, , Volume: 177, Issue:1 | 2004 |
Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmi
American heart journal, , Volume: 148, Issue:1 | 2004 |
Simvastatin combined with ramipril treatment in hypercholesterolemic patients.
Hypertension (Dallas, Tex. : 1979), , Volume: 44, Issue:2 | 2004 |
Challenges in improving prognosis and therapy: the Ongoing Telmisartan Alone and in Combination with Ramipril Global End point Trial programme.
Expert opinion on pharmacotherapy, , Volume: 5, Issue:5 | 2004 |
Infarct size limiting effect of apstatin alone and in combination with enalapril, lisinopril and ramipril in rats with experimental myocardial infarction.
Pharmacological research, , Volume: 48, Issue:6 | 2003 |
The ongoing telmisartan alone and in combination with ramipril global endpoint trial program.
The American journal of cardiology, , May-22, Volume: 91, Issue:10A | 2003 |
Antihypertensive efficacy and tolerability of once-daily sustained-release diltiazem alone and in combination with ramipril in hypertension.
The Journal of the Association of Physicians of India, , Volume: 47, Issue:10 | 1999 |
Loop diuretics combined with an ACE inhibitor for treatment of hypertension: a study with furosemide, piretanide, and ramipril in spontaneously hypertensive rats.
Journal of cardiovascular pharmacology, , Volume: 13 Suppl 3 | 1989 |
[Tolerance to Triatec in monotherapy and in combination with Lasilix in a French multicenter study].
La Revue du praticien, , Jun-21, Volume: 40, Issue:18 Suppl | 1990 |
Efficacy and safety of ramipril in combination with hydrochlorothiazide: results of a long-term study.
Journal of cardiovascular pharmacology, , Volume: 18 Suppl 2 | 1991 |